<SEC-DOCUMENT>0001062993-26-004230.txt : 20260812
<SEC-HEADER>0001062993-26-004230.hdr.sgml : 20260812
<ACCEPTANCE-DATETIME>20260812171949
ACCESSION NUMBER:		0001062993-26-004230
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20260630
FILED AS OF DATE:		20260812
DATE AS OF CHANGE:		20260812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Medicus Pharma Ltd.
		CENTRAL INDEX KEY:			0001997296
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				981778211
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42408
		FILM NUMBER:		261268824

	BUSINESS ADDRESS:	
		STREET 1:		300 CONSHOHOCKEN STATE RD.
		STREET 2:		SUITE 200
		CITY:			W. CONSHOHOCKEN
		STATE:			PA
		ZIP:			19428
		BUSINESS PHONE:		610-540-7515

	MAIL ADDRESS:	
		STREET 1:		300 CONSHOHOCKEN STATE RD.
		STREET 2:		SUITE 200
		CITY:			W. CONSHOHOCKEN
		STATE:			PA
		ZIP:			19428
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--INTEGIX by Ez-XBRL-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:country="http://xbrl.sec.gov/country/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2026" xmlns:exch="http://xbrl.sec.gov/exch/2026" xmlns:naics="http://xbrl.sec.gov/naics/2026" xmlns:sic="http://xbrl.sec.gov/sic/2026" xmlns:stpr="http://xbrl.sec.gov/stpr/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:inmd="http://abc.com/20261231" xmlns:ecd="http://xbrl.sec.gov/ecd/2026" xmlns:srt-types="http://fasb.org/srt-types/2026" xmlns:currency="http://xbrl.sec.gov/currency/2026" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:cyd="http://xbrl.sec.gov/cyd/2026" xmlns:cyd-af="http://xbrl.sec.gov/cyd-af/2026" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2026" xmlns:mdcx="http://www.medicuspharma.com/20260630"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><title>Medicus Pharma Ltd.: Form 10-Q - Filed by newsfilecorp.com</title></head><body style="font-size:10pt;font-family:Times New Roman, Times, serif;">
        <div style="display:none">
        <ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20260101to20260630" id="F20250325062249593_0">0001997296</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20260101to20260630" id="F20250325062249593_1">false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="C_20260101to20260630" id="F20250325062249593_2">Q2</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="C_20260101to20260630" id="Fdei_CurrentFiscalYearEndDate20260509003700566">--12-31</ix:nonNumeric></ix:hidden>
<ix:references>
        <link:schemaRef xlink:type="simple" xlink:href="mdcx-20260630.xsd"/>
        </ix:references><ix:resources><xbrli:context id="C_20260101to20260630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20250630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260131_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mdcx:RbxCapitalLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20231018to20231018_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mdcx:RbxCapitalLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-10-18</xbrli:startDate>
        <xbrli:endDate>2023-10-18</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mdcx:RbxCapitalLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20250630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mdcx:RbxCapitalLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250401to20250630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mdcx:RbxCapitalLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mdcx:RbxCapitalLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mdcx:RbxCapitalLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260401to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mdcx:RbxCapitalLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-04-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260401to20260630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:SkinjectIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ClinicalManufacturingAndRegulatoryActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-04-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250401to20250630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:SkinjectIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ClinicalManufacturingAndRegulatoryActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:SkinjectIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ClinicalManufacturingAndRegulatoryActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20250630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:SkinjectIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ClinicalManufacturingAndRegulatoryActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20250630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:SkinjectIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ProfessionalServicesAndIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:SkinjectIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ProfessionalServicesAndIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250401to20250630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:SkinjectIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ProfessionalServicesAndIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260401to20260630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:SkinjectIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ProfessionalServicesAndIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-04-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20250630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:TeverelixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ClinicalManufacturingAndRegulatoryActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:TeverelixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ClinicalManufacturingAndRegulatoryActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250401to20250630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:TeverelixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ClinicalManufacturingAndRegulatoryActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260401to20260630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:TeverelixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ClinicalManufacturingAndRegulatoryActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-04-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20250630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:TeverelixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ProfessionalServicesAndIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:TeverelixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ProfessionalServicesAndIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250401to20250630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:TeverelixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ProfessionalServicesAndIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260401to20260630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:TeverelixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ProfessionalServicesAndIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-04-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250401to20250630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260401to20260630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-04-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapDebtInstrumentAxis_mdcxNoteBMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_mdcxBusinessCombinationConsiderationTransferredEquityInterestTypeAxis_usgaapCommonStockMember_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="mdcx:BusinessCombinationConsiderationTransferredEquityInterestTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdcx:AntevLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdcx:ContingentConsiderationPhasesOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdcx:AntevLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdcx:ContingentConsiderationPhasesOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_mdcxBusinessCombinationConsiderationTransferredEquityInterestTypeAxis_usgaapCommonStockMember_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="mdcx:BusinessCombinationConsiderationTransferredEquityInterestTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdcx:AntevLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdcx:ContingentConsiderationPhasesTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdcx:AntevLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdcx:ContingentConsiderationPhasesTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_srtRangeAxis_srtMaximumMember_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesThreeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdcx:AntevLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdcx:ContingentConsiderationPhasesThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesThreeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdcx:AntevLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdcx:ContingentConsiderationPhasesThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_srtRangeAxis_srtMaximumMember_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesFourMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdcx:AntevLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdcx:ContingentConsiderationPhasesFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesFourMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdcx:AntevLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdcx:ContingentConsiderationPhasesFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdcx:AntevLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260331"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SharesIssuedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20250331"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20250331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SharesIssuedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SharesIssuedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SharesIssuedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260331"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SharesIssuedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250331"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SharesIssuedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-04-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-04-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-04-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-04-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260401to20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SharesIssuedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-04-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-04-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SharesIssuedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250401to20250630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SharesIssuedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SharesIssuedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260810"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-08-10</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250901to20250917_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mdcx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-17</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250917_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mdcx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-09-17</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260331_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:DebentureContinuityOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:DebentureContinuityOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mdcx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:DebentureContinuityOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260501to20260527_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mdcx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-05-01</xbrli:startDate>
        <xbrli:endDate>2026-05-27</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260501to20260527_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-05-01</xbrli:startDate>
        <xbrli:endDate>2026-05-27</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-05-27</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260501to20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-05-01</xbrli:startDate>
        <xbrli:endDate>2026-05-27</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260501to20260527_usgaapDebtInstrumentAxis_mdcxNoteBMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-05-01</xbrli:startDate>
        <xbrli:endDate>2026-05-27</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteBMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-05-27</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_usgaapDebtInstrumentAxis_mdcxNoteBMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapDebtInstrumentAxis_mdcxNoteBMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260331_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:DebentureContinuityOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260401to20260630_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:DebentureContinuityOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-04-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteBMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-05-27</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260527_srtRangeAxis_srtMaximumMember_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-05-27</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260501to20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-05-01</xbrli:startDate>
        <xbrli:endDate>2026-05-27</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20240101to20241231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260330to20260330_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mdcx:IndividualsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-03-30</xbrli:startDate>
        <xbrli:endDate>2026-03-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260601to20260603_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mdcx:IndividualsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-06-01</xbrli:startDate>
        <xbrli:endDate>2026-06-03</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250310to20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mdcx:RegulationAOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-03-10</xbrli:startDate>
        <xbrli:endDate>2025-03-10</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mdcx:RegulationAOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-03-10</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_mdcxMeasurementInputValuationDateSharePriceMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mdcx:RegulationAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">mdcx:MeasurementInputValuationDateSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-03-10</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExercisePriceMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mdcx:RegulationAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-03-10</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mdcx:RegulationAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-03-10</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mdcx:RegulationAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-03-10</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mdcx:RegulationAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-03-10</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mdcx:RegulationAOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250210to20250210_usgaapSubsidiarySaleOfStockAxis_mdcxStandbyEquityPurchaseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mdcx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-02-10</xbrli:startDate>
        <xbrli:endDate>2025-02-10</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantsIssuedAsPartOfIpoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:WarrantsIssuedAsPartOfIpoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxRegulationAWarrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:RegulationAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantWithExpiryDateJune302030WarrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:WarrantWithExpiryDateJune302030WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantsIssuedAsPartOfIpoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:WarrantsIssuedAsPartOfIpoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapStatementEquityComponentsAxis_mdcxRegulationAWarrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:RegulationAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantWithExpiryDateJune302030WarrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:WarrantWithExpiryDateJune302030WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxSeriesCAndDWarrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SeriesCAndDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapStatementEquityComponentsAxis_mdcxSeriesCAndDWarrantsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SeriesCAndDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_mdcxStandbyEquityPurchaseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mdcx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapFinancialInstrumentAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_usgaapFinancialInstrumentAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mdcx:RegulationAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-03-10</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20251231_usgaapFinancialInstrumentAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251231_usgaapFinancialInstrumentAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20251229_usgaapSubsidiarySaleOfStockAxis_mdcxAtmAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mdcx:AtmAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2025-12-29</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_mdcxAtmAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mdcx:AtmAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mdcx:RegulationAOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260630_usgaapSubsidiarySaleOfStockAxis_mdcxStandbyEquityPurchaseAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mdcx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2026-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mdcxStockOptionsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mdcx:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260101to20260630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mdcxDebenturesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mdcx:DebenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20250630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mdcxStockOptionsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mdcx:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20250630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20250101to20250630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mdcxDebenturesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mdcx:DebenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20260701to20260731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001997296</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2026-07-01</xbrli:startDate>
        <xbrli:endDate>2026-07-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:unit id="CAD_Per_share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="Percent"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Percentage"><xbrli:measure>mdcx:Percentage</xbrli:measure></xbrli:unit>
<xbrli:unit id="Segment"><xbrli:measure>mdcx:Segment</xbrli:measure></xbrli:unit>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_PER_SHARE"><xbrli:measure>mdcx:USD_PER_SHARE</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_Per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="Year"><xbrli:measure>mdcx:Year</xbrli:measure></xbrli:unit>
</ix:resources></ix:header></div><div>
  <hr style="height:3px;color:#000000;background-color:#000000;width:100%"/>
  <p><span id="page_1"><!-- anchor --></span></p>
  <p style="margin-bottom:0pt;text-align:center;margin-top:10pt"><span style="font-size:18pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>UNITED STATES</strong></span><br/><span><strong>SECURITIES AND EXCHANGE COMMISSION</strong></span></span></span></p>
  <p style="margin-top:0pt;text-align:center;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Washington, D.C. 20549</span></span></p>
  <p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:18pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>FORM <ix:nonNumeric id="Fxbrl_20220623095332635" name="dei:DocumentType" contextRef="C_20260101to20260630">10-Q</ix:nonNumeric></strong></span></span></span></p>
  <p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(MARK ONE)</span></span></p>
  <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220623112859151" name="dei:DocumentQuarterlyReport" contextRef="C_20260101to20260630" format="ixt:fixed-true">&#9746;</ix:nonNumeric>&#160;<strong>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</strong></span></span></p>
  <p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the quarterly period ended <span style="text-decoration:underline"><strong><ix:nonNumeric id="Fxbrl_20260322150144982" name="dei:DocumentPeriodEndDate" contextRef="C_20260101to20260630" format="ixt:date-monthname-day-year-en">June 30, <ix:nonNumeric id="Fxbrl_20260322150212142" name="dei:DocumentFiscalYearFocus" contextRef="C_20260101to20260630">2026</ix:nonNumeric></ix:nonNumeric></strong></span></span></span></p>
  <p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>OR</strong></span></span></p>
  <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220623095400766" name="dei:DocumentTransitionReport" contextRef="C_20260101to20260630" format="ixt:fixed-false">&#9744;</ix:nonNumeric>&#160;<strong>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</strong></span></span></p>
  <p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the transition period from <span style="text-decoration:underline">_____</span> to <span style="text-decoration:underline">_____</span></span></span></p>
  <p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Commission file number: <span style="text-decoration:underline"><strong><ix:nonNumeric id="Fxbrl_20260810151922184" name="dei:EntityFileNumber" contextRef="C_20260101to20260630">001-42408</ix:nonNumeric></strong></span></span></span></p>
  <p style="margin-bottom:0pt;text-align:center;margin-top:10pt"><span style="font-size:18pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline"><strong><ix:nonNumeric id="Fxbrl_20260509004231725" name="dei:EntityRegistrantName" contextRef="C_20260101to20260630">MEDICUS PHARMA LTD.</ix:nonNumeric></strong></span></span></span></p>
  <p style="margin-top:0pt;text-align:center;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Exact Name of Registrant as Specified in Its Charter)</span></span></p>
  <table cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-size:10pt;width:100%">

      <tr>
        <td style="width:50%;padding-right:0.5pt;padding-left:0.5pt;vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonNumeric id="Fxbrl_20220623095428081" name="dei:EntityIncorporationStateCountryCode" contextRef="C_20260101to20260630" format="ixt-sec:edgarprovcountryen">Ontario</ix:nonNumeric>, Canada </strong></span></span></td>
        <td style="width:50%;padding-right:0.5pt;padding-left:0.5pt;vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonNumeric id="Fxbrl_20220623095437970" name="dei:EntityTaxIdentificationNumber" contextRef="C_20260101to20260630">98-1778211</ix:nonNumeric> </strong></span></span></td>
      </tr>
      <tr>
        <td style="width:50%;padding-right:0.5pt;padding-left:0.5pt;vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(State or other jurisdiction of<br/>incorporation or organization)</span></span></td>
        <td style="width:50%;padding-right:0.5pt;padding-left:0.5pt;vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(I.R.S. Employer<br/>Identification No.)</span></span></td>
      </tr>
      <tr>
        <td style="width:50%;padding-right:0.5pt;padding-left:0.5pt;vertical-align:bottom;text-align:center">&#160;</td>
        <td style="width:50%;padding-right:0.5pt;padding-left:0.5pt;vertical-align:bottom;text-align:center">&#160;</td>
      </tr>
      <tr>
        <td style="width:50%;padding-right:0.5pt;padding-left:0.5pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonNumeric id="Fxbrl_20220623095455172" name="dei:EntityAddressAddressLine1" contextRef="C_20260101to20260630">300 Conshohocken State Rd</ix:nonNumeric>., <ix:nonNumeric id="Fxbrl_20260509004320494" name="dei:EntityAddressAddressLine2" contextRef="C_20260101to20260630">Suite 200</ix:nonNumeric> </strong><br/><strong><ix:nonNumeric id="Fxbrl_20220623095509997" name="dei:EntityAddressCityOrTown" contextRef="C_20260101to20260630">W. Conshohocken</ix:nonNumeric>, <ix:nonNumeric id="Fxbrl_20220623095521671" name="dei:EntityAddressStateOrProvince" contextRef="C_20260101to20260630">PA</ix:nonNumeric> </strong></span></span></td>
        <td style="width:50%;padding-right:0.5pt;padding-left:0.5pt;vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonNumeric id="Fxbrl_20220623095535888" name="dei:EntityAddressPostalZipCode" contextRef="C_20260101to20260630">19428</ix:nonNumeric> </strong></span></span></td>
      </tr>
      <tr>
        <td style="width:50%;padding-right:0.5pt;padding-left:0.5pt;vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Address of principal executive offices)</span></span></td>
        <td style="width:50%;padding-right:0.5pt;padding-left:0.5pt;vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Zip Code)</span></span></td>
      </tr>

  </table>
  <p style="margin-bottom:0pt;text-align:center;margin-top:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline"><strong>(<ix:nonNumeric id="Fxbrl_20220623095546673" name="dei:CityAreaCode" contextRef="C_20260101to20260630">610</ix:nonNumeric>) <ix:nonNumeric id="Fxbrl_20220623095555746" name="dei:LocalPhoneNumber" contextRef="C_20260101to20260630">636-0184</ix:nonNumeric></strong></span></span></span></p>
  <p style="margin-top:0pt;text-align:center;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Registrant's telephone number, including area code)</span></span></p>
  <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Securities registered pursuant to Section 12(b) of the Act:</span></span></p>
  <table cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-size:10pt;width:100%">

      <tr>
        <td style="width:33%;padding-right:0.5pt;padding-left:0.5pt;vertical-align:top;text-align:center;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Title of each class</strong></span></span></td>
        <td style="width:33%;padding-right:0.5pt;padding-left:0.5pt;vertical-align:top;text-align:center;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Trading Symbol(s)</strong></span></span></td>
        <td style="width:33%;padding-right:0.5pt;padding-left:0.5pt;vertical-align:top;text-align:center;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Name of each exchange on which registered</strong></span></span></td>
      </tr>
      <tr>
        <td style="width:33%;padding-right:0.5pt;padding-left:0.5pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonNumeric id="Fxbrl_20220623095613676" name="dei:Security12gTitle" contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">Common shares, no par value</ix:nonNumeric> </strong></span></span></td>
        <td style="width:33%;padding-right:0.5pt;padding-left:0.5pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonNumeric id="Fxbrl_20230318022908173" name="dei:TradingSymbol" contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">MDCX</ix:nonNumeric></strong></span></span></td>
        <td style="width:33%;padding-right:0.5pt;padding-left:0.5pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>The <ix:nonNumeric id="Fxbrl_20250325151346309" name="dei:SecurityExchangeName" contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market</strong></span></span></td>
      </tr>
      <tr>
        <td style="width:33%;padding-right:0.5pt;padding-left:0.5pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonNumeric id="Fxbrl_20260511105600664" name="dei:Security12gTitle" contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapWarrantMember">Warrants</ix:nonNumeric>, each exercisable for one common </strong><br/><strong>share at an exercise price of $4.64 per share</strong></span></span></td>
        <td style="width:33%;padding-right:0.5pt;padding-left:0.5pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonNumeric id="Fxbrl_20260511103901103" name="dei:TradingSymbol" contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapWarrantMember">MDCXW</ix:nonNumeric> </strong></span></span></td>
        <td style="width:33%;padding-right:0.5pt;padding-left:0.5pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>The <ix:nonNumeric id="Fxbrl_20260511103912746" name="dei:SecurityExchangeName" contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapWarrantMember" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market</strong></span></span></td>
      </tr>

  </table>
  <p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></span></p>
  <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220623113244591" name="dei:EntityCurrentReportingStatus" contextRef="C_20260101to20260630">Yes</ix:nonNumeric> &#9746; No &#9744;</span></span></p>
  <hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/>
  <p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_2"><!-- anchor --></span></span></span></p>
  <p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></span></p>
  <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220623095718179" name="dei:EntityInteractiveDataCurrent" contextRef="C_20260101to20260630">Yes</ix:nonNumeric> &#9746; No &#9744;</span></span></p>
  <p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer", "smaller reporting company", and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></span></p>
  <table cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-size:10pt;width:100%">

      <tr>
        <td style="margin-top:0pt;margin-bottom:0pt;width:40%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Large accelerated filer</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9744;</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;width:40%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accelerated filer</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9744;</span></span></td>
      </tr>
      <tr>
        <td style="margin-top:0pt;margin-bottom:0pt;width:40%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220623095732300" name="dei:EntityFilerCategory" contextRef="C_20260101to20260630" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9746;</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;width:40%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Smaller reporting company</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220623095745301" name="dei:EntitySmallBusiness" contextRef="C_20260101to20260630" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span></span></td>
      </tr>
      <tr>
        <td style="margin-top:0pt;margin-bottom:0pt;width:40%">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;width:10%">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;width:40%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Emerging growth company</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20220623095754631" name="dei:EntityEmergingGrowthCompany" contextRef="C_20260101to20260630" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span></span></td>
      </tr>

  </table>
  <p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></span></p>
  <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Yes &#9744; No <ix:nonNumeric id="Fxbrl_20220623113153809" name="dei:EntityExTransitionPeriod" contextRef="C_20260101to20260630" format="ixt:fixed-false">&#9746;</ix:nonNumeric></span></span></p>
  <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></span></p>
  <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Yes &#9744; No <ix:nonNumeric id="Fxbrl_20220623095809952" name="dei:EntityShellCompany" contextRef="C_20260101to20260630" format="ixt:fixed-false">&#9746;</ix:nonNumeric></span></span></p>
  <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of August 10, 2026, there were <ix:nonFraction id="Fxbrl_20260810192557303" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_20260810" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">63,180,610</ix:nonFraction> common shares, no par value, issued and outstanding.</span></span></p>
  <hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/>
  <p><span id="page_3"><!-- anchor --></span></p>
<p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>MEDICUS PHARMA LTD.</strong></span></span></p><p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2026</strong></span></span></p><p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>TABLE OF CONTENTS</strong></span></span></p><table style="border-collapse:collapse;font-size:10pt;width:100%"><tr><td style="width:90%;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_5">PART I - FINANCIAL INFORMATION</a></span></span></td><td style="width:10%;text-align:right;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_5">2</a></span></span></td></tr><tr><td style="width:90%">&#160;</td><td style="width:10%;text-align:right">&#160;</td></tr><tr><td style="width:90%;padding-left:35pt;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_5">Item 1. Interim Financial Statements</a></span></span></td><td style="width:10%;text-align:right;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_5">2</a></span></span></td></tr><tr><td style="width:90%;padding-left:35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_23">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></span></td><td style="width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_23">11</a></span></span></td></tr><tr><td style="width:90%;padding-left:35pt;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_33">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></span></td><td style="width:10%;text-align:right;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_33">21</a></span></span></td></tr><tr><td style="width:90%;padding-left:35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_33">Item 4. CONTROLS AND PROCEDURES</a></span></span></td><td style="width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_33">21</a></span></span></td></tr><tr><td style="width:90%;padding-left:35pt;background-color:#eeeeee">&#160;</td><td style="width:10%;text-align:right;background-color:#eeeeee">&#160;</td></tr><tr><td style="width:90%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_33">PART II - OTHER INFORMATION</a></span></span></td><td style="width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_33">21</a></span></span></td></tr><tr><td style="width:90%;background-color:#eeeeee">&#160;</td><td style="width:10%;text-align:right;background-color:#eeeeee">&#160;</td></tr><tr><td style="width:90%;padding-left:35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_33">Item 1. Legal Proceedings</a></span></span></td><td style="width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_33">21</a></span></span></td></tr><tr><td style="width:90%;padding-left:35pt;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_33">Item 1A. Risk Factors</a></span></span></td><td style="width:10%;text-align:right;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_33">21</a></span></span></td></tr><tr><td style="width:90%;padding-left:35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_34">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></span></td><td style="width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_34">22</a></span></span></td></tr><tr><td style="width:90%;padding-left:35pt;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_34">Item 3. Defaults Upon Senior Securities</a></span></span></td><td style="width:10%;text-align:right;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_34">22</a></span></span></td></tr><tr><td style="width:90%;padding-left:35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_34">Item 4. Mine Safety Disclosures</a></span></span></td><td style="width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_34">22</a></span></span></td></tr><tr><td style="width:90%;padding-left:35pt;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_34">Item 5. Other Information</a></span></span></td><td style="width:10%;text-align:right;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_34">22</a></span></span></td></tr><tr><td style="width:90%;padding-left:35pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_35">Item 6. Exhibits</a></span></span></td><td style="width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_35">23</a></span></span></td></tr><tr><td style="width:90%;padding-left:35pt;background-color:#eeeeee">&#160;</td><td style="width:10%;text-align:right;background-color:#eeeeee">&#160;</td></tr><tr><td style="width:90%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_37">SIGNATURES</a></span></span></td><td style="width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#page_37">25</a></span></span></td></tr></table><p style="margin-top:0pt;margin-bottom:0pt">&#160;</p><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/><p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_4"><!-- anchor --></span></span></span></p><p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</strong></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">This Quarterly Report on Form 10-Q (this "Quarterly Report") contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as well as forward-looking information within the meaning of applicable Canadian securities laws, that involve substantial risks and uncertainties. All statements, other than statements of historical facts contained in this Quarterly Report regarding our strategy, future operations, future financial position, projected costs, prospects, plans, and objectives of management are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would," or the negative of such terms and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are based on assumptions and expectations that may not be realized and are inherently subject to risks, uncertainties, and other factors, many of which cannot be predicted with accuracy and some of which might not even be anticipated.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The forward-looking statements in this Quarterly Report include, among other things, statements about:</span></span></p><ul style="padding-left:0pt;list-style-type:disc"><li style="margin-left:45.6pt;padding-left:8.4pt;text-align:justify"><p style="margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">our financial results, including our ability to continue as a going concern, generate earnings and achieve and sustain profitability, which may vary significantly from forecasts and from period to period&#894;</span></span></p></li><li style="margin-left:45.6pt;padding-left:8.4pt;text-align:justify"><p style="margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the progress, timing and completion of our research, development and preclinical studies and clinical trials for our products and product candidates, and any progress or developments regarding the regulatory approvals sought and process related thereto&#894;</span></span></p></li><li style="margin-left:45.6pt;padding-left:8.4pt;text-align:justify"><p style="margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">our ability to successfully integrate Antev Limited into our business and operations, successfully develop Teverelix trifluoroacetate and realize the benefits currently anticipated from the Antev transaction&#894;</span></span></p></li><li style="margin-left:45.6pt;padding-left:8.4pt;text-align:justify"><p style="margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">our ability to market, commercialize, achieve market acceptance for and sell our products and product candidates and the potential market opportunities related thereto&#894;</span></span></p></li><li style="margin-left:45.6pt;padding-left:8.4pt;text-align:justify"><p style="margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">our ability to develop, manage and maintain our direct sales and marketing organizations&#894;</span></span></p></li><li style="margin-left:45.6pt;padding-left:8.4pt;text-align:justify"><p style="margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing&#894;</span></span></p></li><li style="margin-left:45.6pt;padding-left:8.4pt;text-align:justify"><p style="margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">market risks regarding consolidation in the healthcare, pharmaceutical and biotech/life sciences industry&#894;</span></span></p></li><li style="margin-left:45.6pt;padding-left:8.4pt;text-align:justify"><p style="margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third party payors for procedures using our products significantly declines&#894;</span></span></p></li><li style="margin-left:45.6pt;padding-left:8.4pt;text-align:justify"><p style="margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">our ability to adequately protect our intellectual property and operate our business without infringing upon the intellectual property rights of others&#894;</span></span></p></li><li style="margin-left:45.6pt;padding-left:8.4pt;text-align:justify"><p style="margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the market price of our securities may be volatile and fluctuate substantially, which could cause the value of your investment to decline and may impact our ability to comply with the continued listing requirements of the Nasdaq Capital Market;</span></span></p></li><li style="margin-left:45.6pt;padding-left:8.4pt;text-align:justify"><p style="margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the fact that product quality issues or product defects may harm our business&#894;</span></span></p></li></ul><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/><p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_5"><!-- anchor --></span></span></span></p><ul style="padding-left:0pt;list-style-type:disc"><li style="margin-left:45.6pt;padding-left:8.4pt;text-align:justify"><p style="margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">any product liability claims&#894; and</span></span></p></li><li style="margin-left:45.6pt;padding-left:8.4pt;text-align:justify"><p style="margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the regulatory, legal and certain operating risks that our operations subject us to.</span></span></p></li></ul><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The forward-looking statements contained in this Quarterly Report are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading "Risk Factors" in Part I, Item 1A in our Annual Report on Form 10-K, as amended, originally filed with the United States Securities and Exchange Commission (the "SEC") on March 25, 2026 (the "2025 Annual Report") and in Part II, Item 1A of this Quarterly Report. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.</span></span></p>
  <p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>PART I - FINANCIAL INFORMATION</strong></span></span></p>
  <p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Item 1. Interim Financial Statements</strong></span></span></p>
  <p style="margin-top:10pt;margin-bottom:10pt;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>MEDICUS PHARMA LTD.<br/>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS<br/>(EXPRESSED IN UNITED STATES DOLLARS EXCEPT NUMBER OF SHARES)&#160;</strong></span></span></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

      <tr>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30, 2026</strong></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>December 31, 2025</strong></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap">&#160;</td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Assets</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Current assets</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:3pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160; Cash and cash equivalents</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20250324185207196" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">15,174,128</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250324185220671" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">8,705,218</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:3pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160; Prepaid expenses and other current assets</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20250324185211363" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">1,807,461</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250324185228349" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">1,086,121</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:3pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160; Deferred financing costs</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:12%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321102225490_xbrl_20250324185211363" name="us-gaap:DeferredCostsCurrent" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:12%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321102225490_xbrl_20250324185228349" name="us-gaap:DeferredCostsCurrent" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">99,305</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total current assets</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:12%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20250324185213621" name="us-gaap:AssetsCurrent" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">16,981,589</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:12%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250324185230475" name="us-gaap:AssetsCurrent" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">9,890,644</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)">Restricted cash</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(255, 255, 255)"><strong><ix:nonFraction id="Fxbrl_20260812112738426_xbrl_20260321102225490_xbrl_20250324185211363" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">10,017,412</ix:nonFraction></strong></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(255, 255, 255)"><ix:nonFraction id="Fxbrl_20260812112738426_xbrl_20260321102225490_xbrl_20250324185228349" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease right-of-use assets</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:12%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20250324185215866" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">117,184</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:12%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250324185232983" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">170,733</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total assets</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;width:12%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20250324185217711" name="us-gaap:Assets" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">27,116,185</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;width:12%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250324185235659" name="us-gaap:Assets" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">10,061,377</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;width:12%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;width:12%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Liabilities and Shareholders' (deficit) equity</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Current liabilities</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:3pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160; Accounts payable</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20250324185546605" name="us-gaap:AccountsPayableCurrent" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">6,734,310</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250324185621737" name="us-gaap:AccountsPayableCurrent" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">3,435,297</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:3pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160; Accrued expenses and other current liabilities</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20250324185548578" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">308,007</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250324185623692" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">995,290</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:3pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160; Related party payable</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20250325140138511" name="mdcx:RelatedPartyPayableCurrent" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">161,846</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250325140141152" name="mdcx:RelatedPartyPayableCurrent" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">116,476</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:3pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160; Operating lease liability, current</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20250324185833660" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">137,330</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250324185632506" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">145,456</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:3pt;background-color:rgb(230, 239, 255)">
          <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160; Debentures and secured promissory notes, current</p>
        </td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(230, 239, 255)"><strong><ix:nonFraction id="Fxbrl_20260812113042661_xbrl_20250324185833660" name="us-gaap:SecuredDebtCurrent" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">3,500,000</ix:nonFraction></strong></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid rgb(0, 0, 0);background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(230, 239, 255)"><ix:nonFraction id="Fxbrl_20260812113042661_xbrl_20250324185632506" name="us-gaap:SecuredDebtCurrent" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">5,245,543</ix:nonFraction></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total current liabilities</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:12%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20250324185556041" name="us-gaap:LiabilitiesCurrent" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">10,841,493</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:12%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250324185635725" name="us-gaap:LiabilitiesCurrent" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">9,938,062</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Debentures and secured promissory notes, non-current</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260810095620851_xbrl_20250325140138511" name="us-gaap:SecuredLongTermDebt" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">17,982,542</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810095620851_xbrl_20250325140141152" name="us-gaap:SecuredLongTermDebt" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loan payable</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321102232034_xbrl_20250324185211363" name="us-gaap:LongTermLoansPayable" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">17,114</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321102232034_xbrl_20250324185228349" name="us-gaap:LongTermLoansPayable" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">25,865</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease liability, non-current</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:12%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20250324185558941" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:12%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250324185638603" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">60,139</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total liabilities</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:12%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20250324185601168" name="us-gaap:Liabilities" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">28,841,149</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:12%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250324185643822" name="us-gaap:Liabilities" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">10,024,066</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;width:12%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;width:12%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Commitments and contingencies (Note 9)</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;width:12%;text-align:right;background-color:rgb(255, 255, 255)"><ix:nonFraction id="Fxbrl_20260810094937290" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20260630" unitRef="USD" xsi:nil="true"></ix:nonFraction></td>
        <td style="vertical-align:bottom;width:2%;text-align:left;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;width:12%;text-align:right;background-color:rgb(255, 255, 255)"><ix:nonFraction id="Fxbrl_20260810094942483" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20251231" unitRef="USD" xsi:nil="true"></ix:nonFraction></td>
        <td style="vertical-align:bottom;width:2%;text-align:left;background-color:rgb(255, 255, 255)">&#160;</td>
      </tr>

  </table>
  <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
  <hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/>
  <p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_6"><!-- anchor --></span></span></span></p>
  <div style="margin-top:15pt">
    <table border="0" cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

        <tr style="background-color:rgb(230, 239, 255)">
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:69.6145%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Shareholders' (deficit) equity </strong></span></span></td>
          <td style="vertical-align:bottom;text-align:right;width:1.02041%;background-color:rgb(230, 239, 255)">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:12.0181%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
          <td style="vertical-align:bottom;text-align:right;width:2.04082%;background-color:rgb(230, 239, 255)">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:1.02041%;background-color:rgb(230, 239, 255)">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:12.3583%;background-color:rgb(230, 239, 255)">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:2.04082%;background-color:rgb(230, 239, 255)">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:69.6145%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Common shares, <ix:nonFraction id="Fxbrl_20250325175853688" name="us-gaap:CommonStockNoParValue" contextRef="C_20251231" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="Fxbrl_20250324194312776" name="us-gaap:CommonStockNoParValue" contextRef="C_20260630" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> par value; unlimited shares authorized; <ix:nonFraction id="Fxbrl_20250324195143853" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20260630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20250324195131376" name="us-gaap:CommonStockSharesIssued" contextRef="C_20260630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20250324195110360" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20260630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">60,168,044</ix:nonFraction></ix:nonFraction></ix:nonFraction> and <ix:nonFraction id="Fxbrl_20250325153820533" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20251231" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20250325153757310" name="us-gaap:CommonStockSharesIssued" contextRef="C_20251231" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20250325153750820" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20251231" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">25,176,303</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June 30, 2026, and December 31, 2025, respectively</span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1.02041%;background-color:rgb(255, 255, 255)">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:12.0181%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20250324185603778" name="us-gaap:CommonStockValue" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">74,298,513</ix:nonFraction></strong></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:2.04082%;background-color:rgb(255, 255, 255)">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1.02041%;background-color:rgb(255, 255, 255)">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:12.3583%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250324185645813" name="us-gaap:CommonStockValue" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">57,076,175</ix:nonFraction></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:2.04082%;background-color:rgb(255, 255, 255)">&#160;</td>
        </tr>
        <tr style="background-color:rgb(230, 239, 255)">
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:69.6145%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Common shares to be issued</span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1.02041%;background-color:rgb(230, 239, 255)">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:12.0181%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321102237428_xbrl_20250324185211363" name="mdcx:CommonSharesToBeIssued" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:2.04082%;background-color:rgb(230, 239, 255)">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1.02041%;background-color:rgb(230, 239, 255)">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:12.3583%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321102237428_xbrl_20250324185228349" name="mdcx:CommonSharesToBeIssued" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">313,934</ix:nonFraction></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:2.04082%;background-color:rgb(230, 239, 255)">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:69.6145%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional paid-in capital</span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1.02041%;background-color:rgb(255, 255, 255)">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:12.0181%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20250324185606115" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">8,884,707</ix:nonFraction></strong></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:2.04082%;background-color:rgb(255, 255, 255)">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1.02041%;background-color:rgb(255, 255, 255)">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:12.3583%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250324185648279" name="us-gaap:AdditionalPaidInCapital" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">6,879,575</ix:nonFraction></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:2.04082%;background-color:rgb(255, 255, 255)">&#160;</td>
        </tr>
        <tr style="background-color:rgb(230, 239, 255)">
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:69.6145%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated other comprehensive income</span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1.02041%;background-color:rgb(230, 239, 255)">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:12.0181%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321102239953_xbrl_20250324185211363" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">61,095</ix:nonFraction></strong></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:2.04082%;background-color:rgb(230, 239, 255)">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1.02041%;background-color:rgb(230, 239, 255)">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:12.3583%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321102239953_xbrl_20250324185228349" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">10,880</ix:nonFraction></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:2.04082%;background-color:rgb(230, 239, 255)">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:69.6145%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated deficit</span></span></td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1.02041%;background-color:rgb(255, 255, 255)">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:12.0181%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20250324185608476" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">85,007,966</ix:nonFraction></strong></span></span></td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2.04082%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1.02041%;background-color:rgb(255, 255, 255)">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:12.3583%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250324185657379" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">64,348,118</ix:nonFraction></span></span></td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2.04082%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
        <tr style="background-color:rgb(230, 239, 255)">
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:69.6145%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total shareholders' (deficit) equity attributable to Medicus Pharma Ltd.</strong></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1.02041%;background-color:rgb(230, 239, 255)">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:12.0181%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20260321102243202_xbrl_20250324185211363" name="us-gaap:StockholdersEquity" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">1,763,651</ix:nonFraction></strong></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2.04082%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1.02041%;background-color:rgb(230, 239, 255)">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:12.3583%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260321102243202_xbrl_20250324185228349" name="us-gaap:StockholdersEquity" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">67,554</ix:nonFraction></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2.04082%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:69.6145%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-controlling interests</span></span></td>
          <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:1.02041%;background-color:rgb(255, 255, 255)">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:12.0181%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321102246836_xbrl_20250324185211363" name="us-gaap:MinorityInterest" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">38,687</ix:nonFraction></strong></span></span></td>
          <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2.04082%;background-color:rgb(255, 255, 255)">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:1.02041%;background-color:rgb(255, 255, 255)">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:12.3583%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321102246836_xbrl_20250324185228349" name="us-gaap:MinorityInterest" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">104,865</ix:nonFraction></span></span></td>
          <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2.04082%;background-color:rgb(255, 255, 255)">&#160;</td>
        </tr>
        <tr style="background-color:rgb(230, 239, 255)">
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:69.6145%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total shareholders' (deficit) equity</strong></span></span></td>
          <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:1.02041%;background-color:rgb(230, 239, 255)">&#160;</td>
          <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:12.0181%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20250324185610766" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">1,724,964</ix:nonFraction></strong></span></span></td>
          <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2.04082%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
          <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:1.02041%;background-color:rgb(230, 239, 255)">&#160;</td>
          <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:12.3583%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250324185659593" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">37,311</ix:nonFraction></span></span></td>
          <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2.04082%;background-color:rgb(230, 239, 255)">&#160;</td>
        </tr>
        <tr style="background-color:rgb(255, 255, 255)">
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:69.6145%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total liabilities and shareholders' (deficit) equity </strong></span></span></td>
          <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:1.02041%;background-color:rgb(255, 255, 255)">&#160;</td>
          <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:12.0181%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20250324185613231" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">27,116,185</ix:nonFraction></strong></span></span></td>
          <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2.04082%;background-color:rgb(255, 255, 255)">&#160;</td>
          <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:1.02041%;background-color:rgb(255, 255, 255)">&#160;</td>
          <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:12.3583%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250324185702202" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">10,061,377</ix:nonFraction></span></span></td>
          <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2.04082%;background-color:rgb(255, 255, 255)">&#160;</td>
        </tr>

    </table>
  </div>
  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>
  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></span></p>
  <hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/>
  <p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_7"><!-- anchor --></span></span></span></p>

  <p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>MEDICUS PHARMA LTD.</strong><br/><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND<br/>COMPREHENSIVE LOSS </strong><br/><strong>(EXPRESSED IN UNITED STATES DOLLARS, EXCEPT NUMBER OF SHARES)</strong></span></span></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

      <tr>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
        <td colspan="5" style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Three months ended June 30,</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap">&#160;</td>
        <td colspan="7" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Six months ended June 30,</strong></span></span></td>
      </tr>
      <tr>
        <td style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2026</strong></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2025</strong></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2026</strong></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2025</strong></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Operating expenses:</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative</span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321104758134_xbrl_20250808233309120" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">6,571,097</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321104758134_xbrl_20250808233317465" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">4,576,524</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260810101807932" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">12,463,781</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810101810031" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">7,696,584</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321104758137_xbrl_20250808233332815" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">4,907,692</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321104758137_xbrl_20250808233340505" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">1,439,564</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260810101814690" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">7,612,085</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810101816498" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">3,445,778</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total operating expenses</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321104758139_xbrl_20250808233347755" name="us-gaap:OperatingExpenses" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">11,478,789</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321104758139_xbrl_20250808233357158" name="us-gaap:OperatingExpenses" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">6,016,088</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260810101820769" name="us-gaap:OperatingExpenses" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">20,075,866</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810101822204" name="us-gaap:OperatingExpenses" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">11,142,362</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Loss from operations</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20260321104758140_xbrl_20250808233405500" name="us-gaap:OperatingIncomeLoss" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">11,478,789</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260321104758140_xbrl_20250808233409898" name="us-gaap:OperatingIncomeLoss" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">6,016,088</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20260810101831139" name="us-gaap:OperatingIncomeLoss" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">20,075,866</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260810101833313" name="us-gaap:OperatingIncomeLoss" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">11,142,362</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Other income (expense)</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:bottom;padding-left:5pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Finance income</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509005722018_xbrl_20260321104758148_xbrl_20250808233430989" name="us-gaap:InvestmentIncomeNet" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260509005722018_xbrl_20260321104758148_xbrl_20250808233437947" name="us-gaap:InvestmentIncomeNet" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">40,004</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260810101839161" name="us-gaap:InvestmentIncomeNet" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810101841731" name="us-gaap:InvestmentIncomeNet" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">63,870</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest (expense)</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20260509005723514_xbrl_20260321104758148_xbrl_20250808233430989" name="us-gaap:InterestExpense" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">205,638</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260509005723514_xbrl_20260321104758148_xbrl_20250808233437947" name="us-gaap:InterestExpense" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20260810101846864" name="us-gaap:InterestExpense" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">523,789</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810101849602" name="us-gaap:InterestExpense" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="vertical-align:bottom;padding-left:5pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss on SEPA (as defined below) settlements</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509005725117_xbrl_20260321104758148_xbrl_20250808233430989" name="mdcx:GainLossOnSettlements" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260509005725117_xbrl_20260321104758148_xbrl_20250808233437947" name="mdcx:GainLossOnSettlements" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20260810101854475" name="mdcx:GainLossOnSettlements" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">127,083</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810101857403" name="mdcx:GainLossOnSettlements" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="vertical-align:bottom;padding-left:5pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in fair value of debentures</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260810102250180_xbrl_20260509005725117_xbrl_20260321104758148_xbrl_20250808233430989" name="mdcx:ChangeInFairValueOfDebentures" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260810102250180_xbrl_20260509005725117_xbrl_20260321104758148_xbrl_20250808233437947" name="mdcx:ChangeInFairValueOfDebentures" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">200,000</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260810102250180_xbrl_20260810101854475" name="mdcx:ChangeInFairValueOfDebentures" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260810102250180_xbrl_20260810101857403" name="mdcx:ChangeInFairValueOfDebentures" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">200,000</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total other income (expense)</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20260321104758148_xbrl_20250808233430989" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">205,638</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260321104758148_xbrl_20250808233437947" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">159,996</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20260810101906321" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">650,872</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260810101909713" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">136,130</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Net loss for the period</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;border-bottom:2.25pt double rgb(0, 0, 0);background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20260321104819527_xbrl_20251114150504281" name="us-gaap:ProfitLoss" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">11,684,427</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;border-bottom:2.25pt double rgb(0, 0, 0);background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;border-bottom:2.25pt double rgb(0, 0, 0);background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260321104819527_xbrl_20251105161449089_xbrl_20250808233357158" name="us-gaap:ProfitLoss" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">6,176,084</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;border-bottom:2.25pt double rgb(0, 0, 0);background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;border-bottom:2.25pt double rgb(0, 0, 0);background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;border-bottom:2.25pt double rgb(0, 0, 0);background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20260810101914674" name="us-gaap:ProfitLoss" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">20,726,738</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;border-bottom:2.25pt double rgb(0, 0, 0);background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;border-bottom:2.25pt double rgb(0, 0, 0);background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;border-bottom:2.25pt double rgb(0, 0, 0);background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260810101917011" name="us-gaap:ProfitLoss" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">11,278,492</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;border-bottom:2.25pt double rgb(0, 0, 0);background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign currency translation adjustment</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321104758151_xbrl_20251105161451073_xbrl_20250808233347755" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">255,177</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810101935010" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260810101937186" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">50,928</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810101941218" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Comprehensive loss for the period attributable to common shareholders</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><strong>(<ix:nonFraction id="Fxbrl_20260810101949188" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">11,429,250</ix:nonFraction></strong></strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260810101951874" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">6,176,084</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20260321104837020_xbrl_20251105161452905_xbrl_20250808233347755" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">20,675,810</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260321104837020_xbrl_20251105161452905_xbrl_20250808233357158" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">11,278,492</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Net loss attributable to</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Common shareholders of the Company</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20260321104758153_xbrl_20251105162318707_xbrl_20251105161452905_xbrl_20250808233347755" name="us-gaap:NetIncomeLoss" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">11,617,705</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260321104758153_xbrl_20251105162318707_xbrl_20251105161452905_xbrl_20250808233357158" name="us-gaap:NetIncomeLoss" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">6,176,084</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20260810101956771" name="us-gaap:NetIncomeLoss" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">20,659,848</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260810101959210" name="us-gaap:NetIncomeLoss" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">11,278,492</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-controlling interests</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20260321104758154_xbrl_20251105162320777_xbrl_20251105161452905_xbrl_20250808233347755" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">66,722</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321104758154_xbrl_20251105162320777_xbrl_20251105161452905_xbrl_20250808233357158" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20260810102004458" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">66,890</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810102006776" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Comprehensive loss attributable to</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Common shareholders of the Company</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20260321104758156_xbrl_20251105162323034_xbrl_20251105161452905_xbrl_20250808233347755" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">11,438,822</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260321104758156_xbrl_20251105162323034_xbrl_20251105161452905_xbrl_20250808233357158" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">6,176,084</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20260810102012212" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">20,676,523</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260810102014931" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">11,278,492</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-controlling interests</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321104758157_xbrl_20251105162325523_xbrl_20251105161452905_xbrl_20250808233347755" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">3,572</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321104758157_xbrl_20251105162325523_xbrl_20251105161452905_xbrl_20250808233357158" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260810102020219" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">713</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810102028394" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss per share attributable to common shareholders - basic and diluted</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20260321190555378" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20260401to20260630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fxbrl_20260321104758160_xbrl_20250808233500804" name="us-gaap:EarningsPerShareBasic" contextRef="C_20260401to20260630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.21</ix:nonFraction></ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;border-bottom:2.25pt double rgb(0, 0, 0);background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260321215446573" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20250401to20250630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fxbrl_20260321215440862" name="us-gaap:EarningsPerShareBasic" contextRef="C_20250401to20250630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.43</ix:nonFraction></ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><strong>(<ix:nonFraction id="Fxbrl_s_20260810102038529" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20260101to20260630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fxbrl_20260810102038529" name="us-gaap:EarningsPerShareBasic" contextRef="C_20260101to20260630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.43</ix:nonFraction></ix:nonFraction></strong></strong></span></span></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_s_20260810102042460" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20250101to20250630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fxbrl_20260810102042460" name="us-gaap:EarningsPerShareBasic" contextRef="C_20250101to20250630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.81</ix:nonFraction></ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;border-bottom:2.25pt double rgb(0, 0, 0);background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
      </tr>
      <tr style="background-color:rgb(230, 239, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(230, 239, 255)">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
      </tr>
      <tr style="background-color:rgb(255, 255, 255)">
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of common shares outstanding - basic and diluted</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321190632072" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20260401to20260630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20260321104758162_xbrl_20250808233514249" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20260401to20260630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">55,055,225</ix:nonFraction></ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;border-bottom:2.25pt double rgb(0, 0, 0);background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321190643627" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20250401to20250630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20260321104758162_xbrl_20250808233518944" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20250401to20250630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">14,284,261</ix:nonFraction></ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><strong><ix:nonFraction id="Fxbrl_s_20260810102048145" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20260101to20260630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20260810102048146" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20260101to20260630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">47,566,945</ix:nonFraction></ix:nonFraction></strong></strong></span></span></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_s_20260810102050362" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20250101to20250630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20260810102050362" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20250101to20250630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">13,853,305</ix:nonFraction></ix:nonFraction></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;border-bottom:2.25pt double rgb(0, 0, 0);width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
      </tr>

  </table>
  <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></span></p>
  <hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/>
  <p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_8"><!-- anchor --></span></span></span></p>

  <p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>MEDICUS PHARMA LTD.</strong><br/><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS'<br/>( DEFICIT) EQUITY</strong><br/><strong>(EXPRESSED IN UNITED STATES DOLLARS, EXCEPT NUMBER OF SHARES)</strong></span></span></p>
  <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:8pt;border-color:#000000">

      <tr>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
        <td colspan="4" style="vertical-align:bottom;text-align:right;white-space:nowrap"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Common shares</strong></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;width:1%">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
        <td colspan="4" style="vertical-align:bottom;text-align:right;white-space:nowrap"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Shares to be<br/>issued</strong></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;white-space:nowrap"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Additional</strong><br/><strong>paid-in<br/>capital</strong></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;width:1%">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Accumulated</strong><br/><strong>deficit</strong></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;white-space:nowrap"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Accumulated</strong><br/><strong>Other</strong><br/><strong>Comprehensive</strong><br/><strong>Income</strong></span></span></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:right;white-space:nowrap;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;white-space:nowrap"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Non-</strong><br/><strong>Controlling</strong><br/><strong>Interest </strong></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:right;white-space:nowrap;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;white-space:nowrap"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Total</strong></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:right;white-space:nowrap;width:1%">&#160;</td>
      </tr>
      <tr>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
        <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>#</strong></span></span></span></span></td>
        <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
        <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
        <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
        <td colspan="1" style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="1" style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>#</strong></span></span></span></span></td>
        <td colspan="1" style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
        <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
        <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
        <td colspan="1" style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td colspan="2" style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
        <td colspan="1" style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
        <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
        <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
        <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$ </strong></span></span></span></span></td>
        <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
        <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$ </strong></span></span></span></span></td>
        <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
        <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
        <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
      </tr>
      <tr>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Balance as of December 31, 2025</strong></span></span></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260321120838609_xbrl_20250325144928519" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20251231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">25,176,303</ix:nonFraction></strong></span></span></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260321120838609_xbrl_20250325144956857" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20251231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">57,076,175</ix:nonFraction></strong></span></span></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260321120838609_xbrl_20251106045621903" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20251231_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">205,980</ix:nonFraction></strong></span></span></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260321124601612" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20251231_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">313,934</ix:nonFraction></strong></span></span></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260321120838609_xbrl_20250325145111663" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20251231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">6,879,575</ix:nonFraction></strong></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>(<ix:nonFraction id="Fxbrl_20260321120838609_xbrl_20250325145117272" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20251231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">64,348,118</ix:nonFraction></strong></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>)</strong></span></span></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260321124608991" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20251231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">10,880</ix:nonFraction></strong></span></span></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260321124625180" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20251231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">104,865</ix:nonFraction></strong></span></span></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260321120838609_xbrl_20250325145121928" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">37,311</ix:nonFraction></strong></span></span></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
      </tr>
      <tr>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Issuance of common shares in connection with SEPA</span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121109065_xbrl_20250503161758184_xbrl_20250503134537353_xbrl_20250325144928519" name="mdcx:StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">5,336,780</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121109065_xbrl_20250503161758184_xbrl_20250503134537353_xbrl_20250325144956857" name="mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">4,229,823</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121109065_xbrl_20251106045713574" name="mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121109065_xbrl_20250503161758184_xbrl_20250503134537353_xbrl_20250325145111663" name="mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121109065_xbrl_20250503161758184_xbrl_20250503134537353_xbrl_20250325145117272" name="mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121109065_xbrl_20251106045954378" name="mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121109065_xbrl_20251106045957744" name="mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121109065_xbrl_20250503161758184_xbrl_20250503134537353_xbrl_20250325145121928" name="mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" contextRef="C_20260101to20260331" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">4,229,823</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
      </tr>
      <tr>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Issuance of common shares in connection with ATM, net of issuance cost</span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321124124958_xbrl_20250325144928519" name="mdcx:StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">9,482,380</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321124124958_xbrl_20250325144956857" name="mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">5,808,013</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321124124958_xbrl_20260321124030010" name="mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321124124958_xbrl_20250325145111663" name="mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321124124958_xbrl_20250325145117272" name="mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321124124958_xbrl_20260321124004517" name="mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321124124958_xbrl_20260321124008252" name="mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321124124958_xbrl_20250325145121928" name="mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost" contextRef="C_20260101to20260331" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">5,808,013</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
      </tr>
      <tr>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Stock-based compensation</span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321125311378" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321125314259" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250325151831513_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145111663" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">599,306</ix:nonFraction></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321125316410" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321125318666" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321125321097" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250325151831513_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145121928" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20260101to20260331" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">599,306</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
      </tr>
      <tr>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net loss for the period</span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321125420345" name="us-gaap:ProfitLoss" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321125425147" name="us-gaap:ProfitLoss" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321125428162" name="us-gaap:ProfitLoss" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20260321121442929_xbrl_20251106050849745_xbrl_20251106050116126" name="us-gaap:ProfitLoss" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">9,042,143</ix:nonFraction></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321125431787" name="us-gaap:ProfitLoss" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20260321121442929_xbrl_20251106050849745_xbrl_20251106050100818" name="us-gaap:ProfitLoss" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">168</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20260321121442929_xbrl_20251106050849745_xbrl_20250325151300282_xbrl_20250325151118378_xbrl_20250325145121928" name="us-gaap:ProfitLoss" contextRef="C_20260101to20260331" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">9,042,311</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
      </tr>
      <tr>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other comprehensive loss for the period</span></span></span></span></td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121508234_xbrl_20251106054755749" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20251106045811216" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145111663" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145117272" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20251106050023393" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">201,390</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20251106050032310" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">2,859</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145121928" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="C_20260101to20260331" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">204,249</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
      </tr>
      <tr>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Balance as of March 31, 2026</strong></span></span></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192029694" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">39,995,463</ix:nonFraction></strong></span></span></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192035816" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">67,114,012</ix:nonFraction></strong></span></span></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050516320" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20260331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">205,980</ix:nonFraction></strong></span></span></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050456969" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20260331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">313,934</ix:nonFraction></strong></span></span></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192041478" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20260331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">7,478,881</ix:nonFraction></strong></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>(<ix:nonFraction id="Fxbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192047365" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20260331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">73,390,261</ix:nonFraction></strong></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>)</strong></span></span></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>(<ix:nonFraction id="Fxbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050501329" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20260331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">190,510</ix:nonFraction></strong></span></span></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>)</strong></span></span></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050504953" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20260331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">101,838</ix:nonFraction></strong></span></span></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192053814" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20260331" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">1,427,894</ix:nonFraction></strong></span></span></span></span></td>
        <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
      </tr>
      <tr>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Issuance of common shares in connection with ATM, net of issuance cost</span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113640894_xbrl_20260321124124958_xbrl_20250325144928519" name="mdcx:StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">18,766,601</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113640894_xbrl_20260321124124958_xbrl_20250325144956857" name="mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">6,492,497</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113640894_xbrl_20260321124124958_xbrl_20260321124030010" name="mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113640894_xbrl_20260321124124958_xbrl_20250325145111663" name="mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113640894_xbrl_20260321124124958_xbrl_20250325145117272" name="mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113640894_xbrl_20260321124124958_xbrl_20260321124004517" name="mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113640894_xbrl_20260321124124958_xbrl_20260321124008252" name="mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113640894_xbrl_20260321124124958_xbrl_20250325145121928" name="mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">6,492,497</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
      </tr>
      <tr>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Issuance of common shares in connection with non-cash compensation for services rendered</span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810120415332_xbrl_20260810113640894_xbrl_20260321124124958_xbrl_20250325144928519" name="mdcx:StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">1,200,000</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810120415332_xbrl_20260810113640894_xbrl_20260321124124958_xbrl_20250325144956857" name="mdcx:StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">378,070</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810120415332_xbrl_20260810113640894_xbrl_20260321124124958_xbrl_20260321124030010" name="mdcx:StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810120415332_xbrl_20260810113640894_xbrl_20260321124124958_xbrl_20250325145111663" name="mdcx:StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810120415332_xbrl_20260810113640894_xbrl_20260321124124958_xbrl_20250325145117272" name="mdcx:StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810120415332_xbrl_20260810113640894_xbrl_20260321124124958_xbrl_20260321124004517" name="mdcx:StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810120415332_xbrl_20260810113640894_xbrl_20260321124124958_xbrl_20260321124008252" name="mdcx:StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810120415332_xbrl_20260810113640894_xbrl_20260321124124958_xbrl_20250325145121928" name="mdcx:StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">378,070</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
      </tr>
      <tr>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Issuance of common shares for asset acquisition</span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114458150_xbrl_20260321120838609_xbrl_20250325144928519" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">205,980</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114458150_xbrl_20260321120838609_xbrl_20250325144956857" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">313,934</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20260810114458150_xbrl_20260321120838609_xbrl_20251106045621903" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">205,980</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20260810114458150_xbrl_20260321124601612" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">313,934</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114458150_xbrl_20260321120838609_xbrl_20250325145111663" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114458150_xbrl_20260321120838609_xbrl_20250325145117272" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114458150_xbrl_20260321124608991" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114458150_xbrl_20260321124625180" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114458150_xbrl_20260321120838609_xbrl_20250325145121928" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
      </tr>
      <tr>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Stock-based compensation</span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113723460_xbrl_20260321125311378" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113723460_xbrl_20260321125314259" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113723460_xbrl_20250325151831513_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145111663" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">1,405,826</ix:nonFraction></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td colspan="1" style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113723460_xbrl_20260321125316410" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td colspan="1" style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113723460_xbrl_20260321125318666" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113723460_xbrl_20260321125321097" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:8%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113723460_xbrl_20250325151831513_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145121928" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">1,405,826</ix:nonFraction></span></span></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
      </tr>

  </table>
  <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
  <hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/>
  <p><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span id="page_9"><!-- anchor --></span></span></span></span></span></p>
  <div style="margin-top:17pt">
    <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:8pt;border-color:#000000">

        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:9.97732%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td colspan="4" style="vertical-align:bottom;text-align:right;white-space:nowrap;width:17.8934%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Common shares</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td colspan="4" style="vertical-align:bottom;text-align:right;white-space:nowrap;width:18.1202%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Shares to be<br/>issued</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;white-space:nowrap;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Additional</strong><br/><strong>paid-in<br/>capital</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:right;white-space:nowrap;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;white-space:nowrap;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Accumulated</strong><br/><strong>deficit</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;white-space:nowrap;width:8.16327%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Accumulated</strong><br/><strong>Other</strong><br/><strong>Comprehensive</strong><br/><strong>Income</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;white-space:nowrap;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Non-</strong><br/><strong>Controlling</strong><br/><strong>Interest </strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;white-space:nowrap;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Total</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:9.97732%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>#</strong></span></span></span></span></td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:1.02041%">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>#</strong></span></span></span></span></td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:1.02041%">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:8.16327%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$ </strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$ </strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:9.97732%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net loss for the period</span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114127151_xbrl_20260321125420345" name="us-gaap:ProfitLoss" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114127151_xbrl_20260321125425147" name="us-gaap:ProfitLoss" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114127151_xbrl_20260321125428162" name="us-gaap:ProfitLoss" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20260810114127151_xbrl_20260321121442929_xbrl_20251106050849745_xbrl_20251106050116126" name="us-gaap:ProfitLoss" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">11,617,705</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:8.16327%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114127151_xbrl_20260321125431787" name="us-gaap:ProfitLoss" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20260810114127151_xbrl_20260321121442929_xbrl_20251106050849745_xbrl_20251106050100818" name="us-gaap:ProfitLoss" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">66,722</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20260810114127151_xbrl_20260321121442929_xbrl_20251106050849745_xbrl_20250325151300282_xbrl_20250325151118378_xbrl_20250325145121928" name="us-gaap:ProfitLoss" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">11,684,427</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;width:9.97732%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other comprehensive loss for the period</span></span></span></span></td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114039868_xbrl_20260321121508234_xbrl_20251106054755749" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114039868_xbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20251106045811216" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114039868_xbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145111663" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114039868_xbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145117272" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:8.16327%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114039868_xbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20251106050023393" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">251,605</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114039868_xbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20251106050032310" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">3,572</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114039868_xbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145121928" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">255,177</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:9.97732%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Balance as of June 30, 2026</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260810114640487_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192029694" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">60,168,044</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260810114640487_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192035816" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">74,298,513</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260810114640487_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050516320" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="Share" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260810114640487_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050456969" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260810114640487_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192041478" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">8,884,707</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>(<ix:nonFraction id="Fxbrl_20260810114640487_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192047365" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">85,007,966</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>)</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.16327%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260810114640487_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050501329" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">61,095</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260810114640487_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050504953" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20260630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">38,687</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>(<ix:nonFraction id="Fxbrl_20260810114640487_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192053814" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">1,724,964</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>)</strong></span></span></span></span></td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;width:9.97732%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.16327%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:9.97732%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.16327%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;width:9.97732%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Balance as of December 31, 2024</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20250325144928519" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">11,816,721</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20250325144956857" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">30,518,195</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20251106045621903" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20241231_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260321124030010" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20241231_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20250325145111663" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">1,520,412</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>(<ix:nonFraction id="Fxbrl_20250325145117272" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">28,903,903</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>)</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.16327%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260321124004517" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260321124008252" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20250325145121928" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20241231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">3,134,704</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:9.97732%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Issuance of common shares and warrants in connection with Regulation A, net of issuance costs of $<ix:nonFraction id="Fxbrl_20260321130439346" name="mdcx:IssuanceCostsInConnectionWithRegulationA" contextRef="C_20250101to20250331" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">483,020</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321153117197" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,490,000</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321153042823" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">2,076,507</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121049666_xbrl_20251106045701376" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121049666_xbrl_20250503134537353_xbrl_20250325145111663" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">1,612,474</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121049666_xbrl_20250503134537353_xbrl_20250325145117272" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.16327%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121049666_xbrl_20251106045934567" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121049666_xbrl_20251106045941896" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121049666_xbrl_20250503134537353_xbrl_20250325145121928" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20250101to20250331" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">3,688,981</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
        </tr>

    </table>
  </div>
  <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
  <hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/>
  <p><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span id="page_10"><!-- anchor --></span></span></span></span></span></p>
  <div style="margin-top:17pt">
    <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:8pt;border-color:#000000">

        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:9.97732%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td colspan="4" style="vertical-align:bottom;text-align:right;white-space:nowrap;width:17.8934%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Common shares</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td colspan="4" style="vertical-align:bottom;text-align:right;white-space:nowrap;width:18.1202%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Shares to be<br/>issued</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;white-space:nowrap;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Additional</strong><br/><strong>paid-in<br/>capital</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;white-space:nowrap;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Accumulated</strong><br/><strong>deficit</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;white-space:nowrap;width:8.16327%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Accumulated</strong><br/><strong>Other</strong><br/><strong>Comprehensive</strong><br/><strong>Income</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;white-space:nowrap;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Non-</strong><br/><strong>Controlling</strong><br/><strong>Interest </strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;white-space:nowrap;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Total</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:9.97732%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>#</strong></span></span></span></span></td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:1.02041%">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>#</strong></span></span></span></span></td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:1%">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:1.02041%">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:8.16327%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$ </strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$ </strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
          <td style="border-bottom:0.75pt solid #000000;text-align:right;vertical-align:bottom;white-space:nowrap;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;white-space:nowrap">&#160;</td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;width:9.97732%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Issuance of common shares in connection with SEPA offering costs</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260509011751740_xbrl_20260321121109065_xbrl_20250503161758184_xbrl_20250503134537353_xbrl_20250325144928519" name="mdcx:StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">105,840</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260509011751740_xbrl_20260321121109065_xbrl_20250503161758184_xbrl_20250503134537353_xbrl_20250325144956857" name="mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">300,000</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260509011751740_xbrl_20260321121109065_xbrl_20251106045713574" name="mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260509011751740_xbrl_20260321121109065_xbrl_20250503161758184_xbrl_20250503134537353_xbrl_20250325145111663" name="mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260509011751740_xbrl_20260321121109065_xbrl_20250503161758184_xbrl_20250503134537353_xbrl_20250325145117272" name="mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.16327%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260509011751740_xbrl_20260321121109065_xbrl_20251106045954378" name="mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260509011751740_xbrl_20260321121109065_xbrl_20251106045957744" name="mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260509011751740_xbrl_20260321121109065_xbrl_20250503161758184_xbrl_20250503134537353_xbrl_20250325145121928" name="mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" contextRef="C_20250101to20250331" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">300,000</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:9.97732%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Issuance of common shares upon exercise of stock warrants</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325144928519" name="mdcx:StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325144956857" name="mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">14,000</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121249955_xbrl_20251106050608804_xbrl_20251106045740351" name="mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325145111663" name="mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325145117272" name="mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.16327%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121249955_xbrl_20251106050608804_xbrl_20251106050011572" name="mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321121249955_xbrl_20251106050608804_xbrl_20251106050014802" name="mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325145121928" name="mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants" contextRef="C_20250101to20250331" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">14,000</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;width:9.97732%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Stock-based compensation</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321120741328_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325144956857" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321120741328_xbrl_20251106045811216" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321120741328_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145111663" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">112,277</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321120741328_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145117272" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.16327%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321120741328_xbrl_20251106050023393" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321120741328_xbrl_20251106050032310" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321120741328_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145121928" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20250101to20250331" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">112,277</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:9.97732%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net loss and comprehensive loss for the period</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321120759983_xbrl_20250325151300282_xbrl_20250325151118378_xbrl_20250325144956857" name="us-gaap:ProfitLoss" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321120759983_xbrl_20251106045822777" name="us-gaap:ProfitLoss" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321120759983_xbrl_20250325151300282_xbrl_20250325151118378_xbrl_20250325145111663" name="us-gaap:ProfitLoss" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20260321120759983_xbrl_20250325151300282_xbrl_20250325151118378_xbrl_20250325145117272" name="us-gaap:ProfitLoss" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">5,102,408</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.16327%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321120759983_xbrl_20251106050116126" name="us-gaap:ProfitLoss" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260321120759983_xbrl_20251106050100818" name="us-gaap:ProfitLoss" contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20260321120759983_xbrl_20250325151300282_xbrl_20250325151118378_xbrl_20250325145121928" name="us-gaap:ProfitLoss" contextRef="C_20250101to20250331" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">5,102,408</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;width:9.97732%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Balance as of March 31, 2025</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192035816" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">13,417,561</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050516320" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">32,908,702</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050456969" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20250331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="Share" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192041478" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20250331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192047365" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20250331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">3,245,163</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>(<ix:nonFraction id="Fxbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050501329" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20250331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">34,006,311</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>)</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.16327%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050504953" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20250331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192053814" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20250331" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">2,147,554</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align:bottom;width:9.97732%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Issuance of common shares in connection with equity financing, net of offering<br/>costs of $<ix:nonFraction id="Fxbrl_20260810120551437" name="mdcx:IssuanceCostsInConnectionWithEquityFinancing" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">809,606</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114904191_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325144928519" name="mdcx:StockIssuedDuringPeriodSharesConnectionWithEquityFinancing" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">2,260,000</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114904191_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325144956857" name="mdcx:StockIssuedDuringPeriodValueConnectionWithEquityFinancing" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">3,961,899</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114904191_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20251106045740351" name="mdcx:StockIssuedDuringPeriodValueConnectionWithEquityFinancing" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114904191_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325145111663" name="mdcx:StockIssuedDuringPeriodValueConnectionWithEquityFinancing" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">2,234,495</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114904191_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325145117272" name="mdcx:StockIssuedDuringPeriodValueConnectionWithEquityFinancing" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.16327%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114904191_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20251106050011572" name="mdcx:StockIssuedDuringPeriodValueConnectionWithEquityFinancing" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114904191_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20251106050014802" name="mdcx:StockIssuedDuringPeriodValueConnectionWithEquityFinancing" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810114904191_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325145121928" name="mdcx:StockIssuedDuringPeriodValueConnectionWithEquityFinancing" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">6,196,394</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;width:9.97732%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Issuance of common shares upon exercise of stock warrants</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113942846_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325144928519" name="mdcx:StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">258,705</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113942846_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325144956857" name="mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">963,398</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113942846_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20251106045740351" name="mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113942846_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325145111663" name="mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113942846_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325145117272" name="mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.16327%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113942846_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20251106050011572" name="mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113942846_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20251106050014802" name="mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113942846_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325145121928" name="mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">963,398</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:9.97732%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Stock-based compensation</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113917847_xbrl_20260321120741328_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325144956857" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113917847_xbrl_20260321120741328_xbrl_20251106045811216" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113917847_xbrl_20260321120741328_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145111663" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">117,448</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113917847_xbrl_20260321120741328_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145117272" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.16327%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113917847_xbrl_20260321120741328_xbrl_20251106050023393" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113917847_xbrl_20260321120741328_xbrl_20251106050032310" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113917847_xbrl_20260321120741328_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145121928" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">117,448</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;width:9.97732%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net loss and comprehensive loss for the period</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113848230_xbrl_20260321120759983_xbrl_20250325151300282_xbrl_20250325151118378_xbrl_20250325144956857" name="us-gaap:ProfitLoss" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113848230_xbrl_20260321120759983_xbrl_20251106045822777" name="us-gaap:ProfitLoss" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113848230_xbrl_20260321120759983_xbrl_20250325151300282_xbrl_20250325151118378_xbrl_20250325145111663" name="us-gaap:ProfitLoss" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20260810113848230_xbrl_20260321120759983_xbrl_20250325151300282_xbrl_20250325151118378_xbrl_20250325145117272" name="us-gaap:ProfitLoss" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">6,176,084</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.16327%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113848230_xbrl_20260321120759983_xbrl_20251106050116126" name="us-gaap:ProfitLoss" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20260810113848230_xbrl_20260321120759983_xbrl_20251106050100818" name="us-gaap:ProfitLoss" contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20260810113848230_xbrl_20260321120759983_xbrl_20250325151300282_xbrl_20250325151118378_xbrl_20250325145121928" name="us-gaap:ProfitLoss" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">6,176,084</ix:nonFraction></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:9.97732%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Balance as of June 30, 2025</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260810113755227_xbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192035816" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">15,936,266</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:7.93651%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260810113755227_xbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050516320" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">37,833,999</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260810113755227_xbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050456969" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20250630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="Share" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1.02041%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260810113755227_xbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192041478" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20250630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260810113755227_xbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192047365" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">5,597,106</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>(<ix:nonFraction id="Fxbrl_20260810113755227_xbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050501329" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">40,182,395</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>)</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.16327%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260810113755227_xbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050504953" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#160;</strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;width:8.04989%"><span style="font-size:8pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260810113755227_xbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192053814" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">3,248,710</ix:nonFraction></strong></span></span></span></span></td>
          <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
        </tr>

    </table>
  </div>
  <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></span></p>
  <hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/>
  <p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_11"><!-- anchor --></span></span></span></p>

  <p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>MEDICUS PHARMA LTD.</strong><br/><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</strong><br/><strong>(EXPRESSED IN UNITED STATES DOLLARS)</strong></span></span></p>
  <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

      <tr>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;width:489px">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;border-bottom:0.75pt solid rgb(0, 0, 0);width:5px">&#160;</td>
        <td colspan="5" style="vertical-align:bottom;text-align:center;white-space:nowrap;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Six months ended June 30,</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:right;white-space:nowrap;border-bottom:0.75pt solid #000000">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;width:489px">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;width:5px">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2026</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2025</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255);width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Cash flows from operating activities</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255);width:5px">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;background-color:#e6efff;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;background-color:#e6efff;text-align:right">&#160;</td>
        <td style="vertical-align:bottom;background-color:#e6efff;text-align:right">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss for the period</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td>
        <td colspan="2" style="vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20260321111840933_xbrl_20250325115322380" name="us-gaap:ProfitLoss" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">20,726,738</ix:nonFraction></strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
        <td style="vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260321111840933_xbrl_20250325115328019" name="us-gaap:ProfitLoss" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">11,278,492</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
      </tr>
      <tr>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255);width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Adjustments to reconcile net loss to net cash used in operating activities:</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="vertical-align:bottom;padding-left:5.65pt;width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock-based compensation expense</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321111737911_xbrl_20250325130311306" name="us-gaap:ShareBasedCompensation" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">2,005,132</ix:nonFraction></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321111737911_xbrl_20250325130455375" name="us-gaap:ShareBasedCompensation" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">229,725</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="vertical-align:bottom;padding-left:5.65pt;background-color:rgb(230, 239, 255);width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-cash interest expense</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321111737920_xbrl_20250809010611002_xbrl_20250325130317063" name="us-gaap:PaidInKindInterest" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">480,594</ix:nonFraction></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321111737920_xbrl_20250809010611002_xbrl_20250325130501370" name="us-gaap:PaidInKindInterest" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="vertical-align:bottom;padding-left:5.65pt;width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in operating lease right-of-use assets</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321111737912_xbrl_20250325130317063" name="mdcx:IncreaseDecreaseInOperatingLeaseRightofuseAssets" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">53,549</ix:nonFraction></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321111737912_xbrl_20250325130501370" name="mdcx:IncreaseDecreaseInOperatingLeaseRightofuseAssets" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">47,572</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="vertical-align:bottom;padding-left:5.65pt;background-color:rgb(230, 239, 255);width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss on SEPA settlements</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321111737922_xbrl_20251105165758290_xbrl_20250325130311306" name="mdcx:GainLossOnSettlements" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">127,083</ix:nonFraction></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321111737922_xbrl_20251105165758290_xbrl_20250325130455375" name="mdcx:GainLossOnSettlements" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="vertical-align:bottom;padding-left:5.65pt;width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in fair value of debentures and secured promissory notes</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810105602017_xbrl_20260321111737922_xbrl_20251105165758290_xbrl_20250325130311306" name="mdcx:ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810105602017_xbrl_20260321111737922_xbrl_20251105165758290_xbrl_20250325130455375" name="mdcx:ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="vertical-align:bottom;padding-left:5.65pt;background-color:rgb(230, 239, 255);width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost to issue debentures and secured promissory notes</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810105604189_xbrl_20260321111737922_xbrl_20251105165758290_xbrl_20250325130311306" name="mdcx:CostsToIssueDebenturesAndSecuredPromissoryNotes" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810105604189_xbrl_20260321111737922_xbrl_20251105165758290_xbrl_20250325130455375" name="mdcx:CostsToIssueDebenturesAndSecuredPromissoryNotes" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">111,725</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="vertical-align:bottom;padding-left:5.65pt;width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of common shares in connection with non-cash compensation for services rendered</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810105606137_xbrl_20260321111737922_xbrl_20251105165758290_xbrl_20250325130311306" name="mdcx:IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">378,070</ix:nonFraction></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810105606137_xbrl_20260321111737922_xbrl_20251105165758290_xbrl_20250325130455375" name="mdcx:IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255);width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes in operating assets and liabilities:</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="vertical-align:bottom;padding-left:5.65pt;width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid expenses</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260321111737926_xbrl_20250325115752505" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">707,316</ix:nonFraction></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260321111737926_xbrl_20250325115849101" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">113,201</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
      </tr>
      <tr>
        <td colspan="2" style="vertical-align:bottom;padding-left:5.65pt;background-color:rgb(230, 239, 255);width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accounts payable</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321111737929_xbrl_20250325115755346" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">3,147,801</ix:nonFraction></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321111737929_xbrl_20250325115851240" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">404,670</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="vertical-align:bottom;padding-left:5.65pt;width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued expenses and other current&#160; liabilities</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260321111737931_xbrl_20250325115757810" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">680,071</ix:nonFraction></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321111737931_xbrl_20250325115859128" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">1,065,475</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="vertical-align:bottom;padding-left:5.65pt;background-color:rgb(230, 239, 255);width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease liability</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260321111737933_xbrl_20250325115800060" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">76,605</ix:nonFraction></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260321111737933_xbrl_20250325115901950" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">56,113</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
      </tr>
      <tr>
        <td colspan="2" style="vertical-align:bottom;padding-left:5.65pt;width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Related party payable</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321111737935_xbrl_20250325115803074" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">45,370</ix:nonFraction></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260321111737935_xbrl_20250325115857197" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">21,186</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
      </tr>
      <tr>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255);width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Net cash used in operating activities</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px;background-color:rgb(230, 239, 255);border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20260321111737937_xbrl_20250325115805768" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">15,953,129</ix:nonFraction></strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;background-color:#e6efff;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20260321111737937_xbrl_20250325115904539" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">9,409,825</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
      </tr>
      <tr>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:489px">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:2.25pt double #000000;text-align:right;width:12%">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double #000000;text-align:right;width:12%">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double #000000;text-align:left;width:2%">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255);width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Cash flows from financing activities</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="vertical-align:bottom;padding-left:5.65pt;width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net proceeds from issuance of common shares and warrants</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321113859805_xbrl_20260321112041265_xbrl_20251105165804188_xbrl_20250325130311306" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321113859805_xbrl_20260321112041265_xbrl_20251105165804188_xbrl_20250325130455375" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">9,790,015</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="vertical-align:bottom;padding-left:5.65pt;background-color:rgb(230, 239, 255);width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from issuance of debentures and secured promissory notes</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810111159411_xbrl_20260321113859805_xbrl_20260321112041265_xbrl_20251105165804188_xbrl_20250325130311306" name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">22,000,000</ix:nonFraction></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810111159411_xbrl_20260321113859805_xbrl_20260321112041265_xbrl_20251105165804188_xbrl_20250325130455375" name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">4,500,000</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="vertical-align:bottom;padding-left:5.65pt;width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from exercise of warrants</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260810111201315_xbrl_20260321113859805_xbrl_20260321112041265_xbrl_20251105165804188_xbrl_20250325130311306" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810111201315_xbrl_20260321113859805_xbrl_20260321112041265_xbrl_20251105165804188_xbrl_20250325130455375" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">977,398</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="vertical-align:bottom;padding-left:5.65pt;background-color:rgb(230, 239, 255);width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost to issue debentures and secured promissory notes</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260810111203246_xbrl_20260321113859805_xbrl_20260321112041265_xbrl_20251105165804188_xbrl_20250325130311306" name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">615,000</ix:nonFraction></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260810111203246_xbrl_20260321113859805_xbrl_20260321112041265_xbrl_20251105165804188_xbrl_20250325130455375" name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">54,582</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
      </tr>
      <tr>
        <td colspan="2" style="vertical-align:bottom;padding-left:5.65pt;width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash paid for financing costs in connection with SEPA</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509015909416_xbrl_20260321112129228_xbrl_20251105183204922_xbrl_20251105165804188_xbrl_20250325130311306" name="us-gaap:PaymentsOfFinancingCosts" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260509015909416_xbrl_20260321112129228_xbrl_20251105183204922_xbrl_20251105165804188_xbrl_20250325130455375" name="us-gaap:PaymentsOfFinancingCosts" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">297,783</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
      </tr>
      <tr>
        <td colspan="2" style="vertical-align:bottom;padding-left:5.65pt;background-color:rgb(230, 239, 255);width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Repayment of debentures and secured promissory notes</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260321112059420_xbrl_20251105165808130_xbrl_20250325130311306" name="us-gaap:RepaymentsOfDebt" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">5,532,613</ix:nonFraction></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321112059420_xbrl_20251105165808130_xbrl_20250325130455375" name="us-gaap:RepaymentsOfDebt" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from issuance of common shares under SEPA</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321112129228_xbrl_20251105183204922_xbrl_20251105165804188_xbrl_20250325130311306" name="mdcx:ProceedsFromIssuanceOfSharesUnderSettlements" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">4,102,740</ix:nonFraction></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321112129228_xbrl_20251105183204922_xbrl_20251105165804188_xbrl_20250325130455375" name="mdcx:ProceedsFromIssuanceOfSharesUnderSettlements" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255);width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from issuance of common shares under ATM, net of issuance costs</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260509015831576_xbrl_20260321112129228_xbrl_20251105183204922_xbrl_20251105165804188_xbrl_20250325130311306" name="mdcx:ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">12,399,815</ix:nonFraction></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509015831576_xbrl_20260321112129228_xbrl_20251105183204922_xbrl_20251105165804188_xbrl_20250325130455375" name="mdcx:ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Net cash provided by financing activities</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px;border-top:2.25pt double rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321111737953_xbrl_20250325115820829" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">32,354,942</ix:nonFraction></strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321111737953_xbrl_20250325115921653" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">14,915,048</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255);width:489px">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:2.25pt double #000000;text-align:right;width:12%;background-color:#e6efff">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double #000000;text-align:right;width:12%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign currency effect on cash and cash equivalents</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px;border-bottom:2.25pt double rgb(0, 0, 0)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:12%;border-bottom:2.25pt double #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321111737961_xbrl_20251105165823133_xbrl_20250325130311306" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">84,509</ix:nonFraction></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%;border-bottom:2.25pt double #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;border-bottom:2.25pt double #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
        <td style="vertical-align:bottom;text-align:right;width:12%;border-bottom:2.25pt double #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321111737961_xbrl_20251105165823133_xbrl_20250325130455375" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;border-bottom:2.25pt double #000000">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255);width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Net increase in cash and cash equivalents and restricted cash during the period</strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px;background-color:rgb(230, 239, 255)">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;border-top:2.25pt double #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321112144595_xbrl_20251105165823133_xbrl_20250325130311306" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">16,486,322</ix:nonFraction></strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
        <td style="vertical-align:bottom;border-top:2.25pt double #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321112144595_xbrl_20251105165823133_xbrl_20250325130455375" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">5,505,223</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;border-top:2.25pt double #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
      </tr>
      <tr>
        <td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:489px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents and restricted cash, beginning of the period</span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:5px;border-bottom:2.25pt double #000000">&#160;</td>
        <td colspan="2" style="vertical-align:bottom;text-align:right;width:12%;border-bottom:2.25pt double #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321112149025_xbrl_20250325115828192" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">8,705,218</ix:nonFraction></strong></span></span></td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:2%;border-bottom:2.25pt double #000000">&#160;</td>
        <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;text-align:left;width:1%;border-bottom:2.25pt double #000000">&#160;</td>
        <td style="vertical-align:bottom;text-align:right;width:12%;border-bottom:2.25pt double #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321112149025_xbrl_20250325115927259" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20241231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">4,164,323</ix:nonFraction></span></span></td>
        <td style="vertical-align:bottom;text-align:left;width:2%;border-bottom:2.25pt double #000000">&#160;</td>
      </tr>

  </table>
  <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
  <hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/>
  <p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span></span></span></span></p>
  <div style="margin-top:15pt">
    <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Cash and cash equivalents and restricted cash, end of the period</strong></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321112202767_xbrl_20250325115830759" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">25,191,540</ix:nonFraction></strong></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:12%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321112202767_xbrl_20250325115931676" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">9,669,546</ix:nonFraction></strong></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Supplemental information </strong></span></span></td>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash paid for interest</span></span></td>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td>
          <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321113925782_xbrl_20260321112224885_xbrl_20251107154602864" name="us-gaap:InterestPaidNet" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">330,626</ix:nonFraction></strong></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321113925782_xbrl_20260321112224885_xbrl_20251107154609823" name="us-gaap:InterestPaidNet" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></span></span></td>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred issuance costs on issued shares related to SEPA agreement</span></span></td>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td>
          <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321112336068_xbrl_20251105190829309_xbrl_20250326124516894" name="mdcx:DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321112336068_xbrl_20251105190829309_xbrl_20250326124531877" name="mdcx:DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">300,000</ix:nonFraction></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
        </tr>
        <tr>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance costs included in accounts payable</span></span></td>
          <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td>
          <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260321112303177_xbrl_20250326124516894" name="mdcx:IssuanceCostsIncludedInAccountsPayable" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
          <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321112303177_xbrl_20250326124531877" name="mdcx:IssuanceCostsIncludedInAccountsPayable" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">271,618</ix:nonFraction></span></span></td>
          <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
        </tr>

    </table>
  </div>
  <p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></span></p>
  <hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/>
  <p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_13"><!-- anchor --></span></span></span></p>

  <p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>MEDICUS PHARMA LTD.</strong><br/><strong>NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong><br/><strong>(EXPRESSED IN UNITED STATES DOLLARS, EXCEPT SHARE AMOUNTS)</strong></span></span></p>
  <ix:nonNumeric id="Fxbrl_20250323190950558" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="C_20260101to20260630" escape="true">
    <p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1. Description of business</strong></span></span></p>
    <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Medicus Pharma Ltd. (the "Company"), formerly Interactive Capital Partners Corporation, is a clinical stage, multi-strategy, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets.</span></span></p>
    <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is a public limited company originally incorporated pursuant to the provisions of the <i>Business Corporations Act</i> (Ontario) on April 30, 2008, as a private company named Interactive Capital Partners Corporation, with nominal assets and liabilities. The Company's registered office is located at 100 King Street West, Suite 3400, One First Canadian Place, Toronto, Ontario, Canada, and its head office is located at 300 Conshohocken State Rd., Suite 200, W. Conshohocken, PA.</span></span></p>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20250323220925857" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20260101to20260630" escape="true">
    <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2. Summary of significant accounting policies </strong></span></span></p>
    <ix:nonNumeric id="Fxbrl_20250323221121886" name="mdcx:BasisOfPresentationAndConsolidationPolicyTextBlock" contextRef="C_20260101to20260630" escape="true">
      <div>
        <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Basis of presentation and consolidation</strong></span></span></p>
        <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying unaudited condensed consolidated financial statements included herein have been prepared in conformity with generally accepted accounting principles in the United States ("GAAP") and under the rules and regulations of the United States Securities and Exchange Commission ("SEC") for interim reporting. The accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, that are necessary to present fairly the Company's financial position, results of operations, and cash flows. The condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosures of the Company normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC's rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto for the year ended December 31, 2025, included in the Company's Annual Report on Form 10-K, as amended, originally filed with the SEC on March 25, 2026 (the "2025 Annual Report"). These condensed consolidated financial statements include the financial statements of the Company and its subsidiaries, SkinJect, Inc., Medicus Pharma Inc., Antev Limited ("Antev") and MDCX Holdings, LLC. All intercompany balances and transactions have been eliminated on consolidation. Non-controlling interest in the consolidated financial statements represents the portion of Antev not 100% owned by the Company. The functional currency of the Company and its three wholly-owned subsidiaries, SkinJect, Inc., Medicus Pharma Inc. and MDCX Holdings, LLC. is the United States dollar (USD). The functional currency of the Company's other subsidiary, Antev is Pound Sterling (GBP).</span></span></p>
      </div>
    </ix:nonNumeric>
    <ix:nonNumeric id="Fxbrl_20260321123839001" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="C_20260101to20260630" escape="true">
      <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Foreign operations remeasurement and translation</strong></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions, and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates, are generally recognized in the condensed consolidated statements of operations and comprehensive loss. The results and financial position of foreign operation which has functional currency different from presentation currency are translated into the presentation currency as follows: assets and liabilities are translated at the closing rate at the date of that statement of financial position, income and expenses are translated at average exchange rates, and all resulting translated exchange differences are recognized in a separate component of other comprehensive loss within the condensed consolidated statement of changes in shareholders equity.</span></span></p>
    </ix:nonNumeric>
    <ix:nonNumeric id="Fxbrl_20250323221204705" name="us-gaap:UseOfEstimates" contextRef="C_20260101to20260630" escape="true">
      <div>
        <div>
          <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Use of estimates</strong></span></span></p>
        </div>
        <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of these condensed consolidated financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements, and the reported amounts of income and expenses during the reporting period. Such estimates include the valuation of stock-based awards, the incremental borrowing rate used to discount the Company's operating lease liabilities, fair value of the Company's debentures and secured promissory notes and warrants, and valuation allowance on deferred tax assets, all of which are management's best estimates. Estimates are based on historical experience, where applicable, and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. By their nature, these estimates are subject to measurement uncertainty and the effect on the financial statements of changes in estimates in future years could be significant. Management believes that the estimates utilized in preparing the financial statements are reasonable, however, actual results could differ from those estimates.</span></span></p>
      </div>
    </ix:nonNumeric>
    <p style="margin:0pt">&#160;</p>
    <div><ix:exclude>
      <div>
        <div><div><div style="text-align:center"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1</span></span></span></div></div></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%;margin-bottom:10pt;margin-top:10pt"/>
      </div>
    </ix:exclude></div>
    <ix:nonNumeric id="Fxbrl_20250323221856028" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_20260101to20260630" escape="true">
      <div>
        <div>
          <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Operating segments</strong></span></span></p>
        </div>
        <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating segments are identified as components of an entity about which separate discrete financial information is available for evaluation by the chief operating decision-maker ("CODM") in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in <ix:nonFraction id="Fxbrl_20260509005724318" name="us-gaap:NumberOfOperatingSegments" contextRef="C_20260101to20260630" unitRef="Segment" scale="0" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction> operating segment.</span></span></p>
      </div>
    </ix:nonNumeric>
    <ix:nonNumeric id="Fxbrl_20250323221934096" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_20260101to20260630" escape="true">
      <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Recently issued accounting pronouncements </strong></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2024, the FASB issued ASU 2024-03 "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures" to provide greater transparency about the components of specific expense categories in the income statements. The effective dates of ASU 2024-03 were subsequently clarified by ASU 2025-01. ASU 2025-01 is effective for our annual period beginning January 1, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting the amendment on the Company's financial statements.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">There were no other significant updates to the recently issued accounting standards which may be applicable to the Company. Although there are several other new accounting pronouncements issued or proposed by the FASB, the Company does not believe any of those accounting pronouncements have had or will have a material impact on its financial position or operating results.</span></span></p>
    </ix:nonNumeric>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20260321100201840" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" contextRef="C_20260101to20260630" escape="true">
    <div>
      <p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>3.</strong>&#160;<strong>Balance sheet components</strong></span></span></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Prepaid expenses include the following:</span></span></span></span></p>
      <ix:nonNumeric id="Fxbrl_20260321100214534" name="mdcx:ScheduleOfPrepaidExpensesTableTextBlock" contextRef="C_20260101to20260630" escape="true">
        <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>June 30, 2026</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>December 31, 2025</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Insurance</span></span></span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250323225637621" name="us-gaap:PrepaidInsurance" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">109,405</ix:nonFraction></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250323225919745" name="us-gaap:PrepaidInsurance" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">345,084</ix:nonFraction></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Contract research organizations</span></span></span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250323225802395" name="mdcx:PrepaidContractResearch" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">390,000</ix:nonFraction></span></span></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250323225934485" name="mdcx:PrepaidContractResearch" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">410,000</ix:nonFraction></span></span></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Professional services</span></span></span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250323225820626" name="mdcx:PrepaidProfessionalServices" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">330,400</ix:nonFraction></span></span></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250323225941575" name="mdcx:PrepaidProfessionalServices" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">300,033</ix:nonFraction></span></span></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Prepaid services</span></span></span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250323225833496" name="mdcx:PrepaidServices" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">977,656</ix:nonFraction></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250323230008285" name="mdcx:PrepaidServices" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">31,004</ix:nonFraction></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt">&#160;</td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20250323225900903" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">1,807,461</ix:nonFraction></strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20260810183443310" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">1,086,121</ix:nonFraction></strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>

        </table>
      </ix:nonNumeric>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued expenses and other current liabilities include the following:</span></span></span></span></p>
      <ix:nonNumeric id="Fxbrl_20250323225619934" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_20260101to20260630" escape="true">
        <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>June 30, 2026</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>December 31, 2025</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued legal fees</span></span></span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250323230109336" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">110,976</ix:nonFraction></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250323230126130" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">352,864</ix:nonFraction></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued compensation and benefits</span></span></span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250323230147827" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">195,082</ix:nonFraction></span></span></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250323230259340" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">300,181</ix:nonFraction></span></span></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued other</span></span></span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250323230240468" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">1,949</ix:nonFraction></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20250323230316942" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">342,245</ix:nonFraction></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt">&#160;</td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20250323230225428" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">308,007</ix:nonFraction></strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:2%">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><ix:nonFraction id="Fxbrl_20250323230326696" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">995,290</ix:nonFraction></strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:2%">&#160;</td>
            </tr>

        </table>
      </ix:nonNumeric>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
  <div>
    <div><div><div style="text-align:center"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">2</span></span></span></div></div></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%;margin-bottom:10pt;margin-top:10pt"/>
  </div>

  <ix:nonNumeric id="Fxbrl_20260509010341744" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_20260101to20260630" escape="true">
    <div>
      <p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>4. Leases</strong></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2026, the Company had one operating lease for its corporate office that commenced in 2024, for which the Company recorded a right-of-use asset and lease liability as of the commencement date. The Company's lease does not contain a purchase option. Where the Company's lease contains an option to extend the lease term, the extended lease term is only included in the measurement of the lease when it is reasonably certain to remain in the lease beyond the non-cancellable term. The Company's lease also contains variable lease costs, which pertain to common area maintenance and other operating charges, that are expensed as incurred.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance sheet information related to the Company's lease is presented below:</span></span></p>
      <ix:nonNumeric id="Fxbrl_20250323230512381" name="mdcx:LesseeOperatingLeasesDisclosureTableTextBlock" contextRef="C_20260101to20260630" escape="true">
        <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

            <tr>
              <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Six Months Ended </strong><br/><strong>June 30, 2026</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Year Ended </strong><br/><strong>December 31,2025</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Operating lease</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease right-of-use assets</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321100722615" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">117,184</ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250323231135654" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">170,733</ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease liabilities - current</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321100728265" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">137,330</ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250323231148017" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">145,456</ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease liabilities - non-current</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321100734695" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250323231214952" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">60,139</ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>

        </table>
      </ix:nonNumeric>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other information related to leases is presented below:</span></span></p>
      <ix:nonNumeric id="Fxbrl_20250323230540980" name="us-gaap:LeaseCostTableTextBlock" contextRef="C_20260101to20260630" escape="true">
        <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

            <tr>
              <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap">&#160;</td>
              <td colspan="4" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Six months ended June 30,</strong></span></span></span></span></td>
              <td colspan="1" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2026</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2025</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease cost</span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease cost</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321100521993" name="us-gaap:OperatingLeaseExpense" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">61,889</ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250323231231585" name="us-gaap:OperatingLeaseExpense" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">61,889</ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other information</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating cash flows used in operating leases</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260321100533032" name="us-gaap:OperatingLeasePayments" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">76,952</ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250323231246011" name="us-gaap:OperatingLeasePayments" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">70,080</ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">)</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Remaining lease term (in years)</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20260321100538623" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="C_20260630" format="ixt-sec:duryear">1.00</ix:nonNumeric></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20250323231302002" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="C_20250630" format="ixt-sec:duryear">1.92</ix:nonNumeric></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Discount rate</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321100546455" name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="C_20260630" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction>%</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250323231338153" name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="C_20250630" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction>%</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>

        </table>
      </ix:nonNumeric>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2026, the annual future minimum lease payments of the Company's operating lease liabilities were as follows:</span></span></p>
      <ix:nonNumeric id="Fxbrl_20250323230555241" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_20260101to20260630" escape="true">
        <div>
          <table cellpadding="0" cellspacing="0" style="width:50%;border-collapse:collapse;font-size:10pt;border-color:#000000">

              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#231f20">2026</span></span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#231f20"><ix:nonFraction id="Fxbrl_20250323231412976" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">74,348</ix:nonFraction></span></span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2027</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#231f20"><ix:nonFraction id="Fxbrl_20250323232600160" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">74,348</ix:nonFraction></span></span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#231f20">Total future minimum lease payments, undiscounted</span></span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250323232614195" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">148,696</ix:nonFraction></span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value discount</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20250323232634471" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">11,366</ix:nonFraction></span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total lease liability</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20250323232646916" name="us-gaap:OperatingLeaseLiability" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">137,330</ix:nonFraction></strong></span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000">&#160;</td>
              </tr>

          </table>
        </div>
      </ix:nonNumeric>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20260509013512151" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_20260101to20260630" escape="true">
    <div>
      <p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>5. Share capital</strong></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Authorized</i></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has authorized an unlimited number of common shares participating, voting and without nominal or par value. Each holder of common shares is entitled to one vote for each share owned on all matters voted upon by shareholders.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Regulation A Offering</i></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On March 10, 2025, the Company closed a Tier II Regulation A offering for gross proceeds of $<ix:nonFraction id="F20260321072134998_15" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="C_20250310to20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">4,172,000</ix:nonFraction>. The Company issued <ix:nonFraction id="F20260321072134999_16" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_20250310to20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,490,000</ix:nonFraction> units at a price of $<ix:nonFraction id="F20260321072134999_17" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.80</ix:nonFraction> per unit. Each unit consisted of one common share of the Company and one warrant to purchase one common share of the Company (each a "Regulation A Warrant"). The Regulation A Warrants have an exercise price of $<ix:nonFraction id="F20260321072135000_18" name="mdcx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20250310to20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.80</ix:nonFraction> per share and will expire <ix:nonNumeric id="Fxbrl_20260323102539545" name="mdcx:StockPurchaseWarrantsTerm" contextRef="C_20250310to20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember" format="ixt-sec:duryear">5</ix:nonNumeric> years from the date of issuance on March 10, 2030. The Company incurred total issuance costs of $<ix:nonFraction id="F20260321072135000_20" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20250310to20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">483,020</ix:nonFraction>, including legal fees and placement fees directly related to the issuance. The issuance costs incurred were recognized as a reduction in equity and allocated based on the relative fair values of the Regulation A Warrants and common shares on a standalone basis. The fair value of the common shares was based on the Company's share price on the day of issuance of $<ix:nonFraction id="F20260321072135001_21" name="mdcx:FairValuePerShare" contextRef="C_20250310to20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">3.40</ix:nonFraction> and the fair value of the Regulation A Warrants was $<ix:nonFraction id="F20260321072135001_22" name="mdcx:FairValuePerWarrant" contextRef="C_20250310to20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.63</ix:nonFraction> per warrant. The Regulation A Warrants were recognized in additional paid-in capital as they met the criteria for equity classification.</span></span></p>
      <div><ix:exclude>
        <div><div><div style="text-align:center"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">3</span></span></span></div></div></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%;margin-bottom:10pt;margin-top:10pt"/>
        <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_12"><!-- anchor --></span></span></span></p>
      </ix:exclude></div>
      <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company's Regulation A Warrants are not actively traded and are therefore classified as Level 3 within the fair value hierarchy. The fair value of these warrants is estimated using a Black-Scholes option pricing model. The valuation incorporates significant unobservable inputs and management judgment.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2026, <ix:nonFraction id="F20260321072135005_33" name="mdcx:NumberOfWarrantsExercised" contextRef="C_20260630_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">133,800</ix:nonFraction> of the <ix:nonFraction id="F20260321072135005_34" name="mdcx:NumberOfCommonShareWarrantsOutstandingGrantsInPeriod" contextRef="C_20250310to20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">1,490,000</ix:nonFraction> Regulation A Warrants have been exercised for cash for proceeds to the Company of $<ix:nonFraction id="Fxbrl_20260809151738991" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">374,640</ix:nonFraction>. No Regulation A Warrants were exercised during the six months ended June 30, 2026.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the Regulation A Warrants were estimated using the Black-Scholes model with the following assumptions:</span></span></p>
      <ix:nonNumeric id="F20260321072135028_76" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" contextRef="C_20260101to20260630" escape="true">
        <div>
          <table cellpadding="0" cellspacing="0" style="width:50%;border-collapse:collapse;font-size:10pt;border-color:#000000;margin-left:auto;margin-right:auto">

              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Issue Date</strong><br/><strong>March 10,<br/>2025</strong></span></span></span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuation date share price</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20260321072135002_24" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_mdcxMeasurementInputValuationDateSharePriceMember" unitRef="USD_PER_SHARE" scale="0" decimals="2" format="ixt:num-dot-decimal">3.40</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise price</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20260321072135003_26" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExercisePriceMember" unitRef="USD_PER_SHARE" scale="0" decimals="2" format="ixt:num-dot-decimal">2.80</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20260321072135003_28" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember" unitRef="Percentage" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20260321072135004_30" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" unitRef="Percentage" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.98</ix:nonFraction>%</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected warrant life</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20260321072135037_99" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember" unitRef="Year" scale="0" decimals="0" format="ixt:num-dot-decimal">5</ix:nonFraction>.00 years</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20260321072135005_32" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember" unitRef="Percentage" scale="0" decimals="2" format="ixt:num-dot-decimal">97.81</ix:nonFraction>%</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>

          </table>
        </div>
      </ix:nonNumeric>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrant activity as below:</span></span></p>
      <ix:nonNumeric id="Fxbrl_20260809151418948" name="mdcx:ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock" contextRef="C_20260101to20260630" escape="true">
        <div>
          <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Number of </strong><br/><strong>common share </strong><br/><strong>warrants </strong><br/><strong>outstanding</strong></span></span></span></span></td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Weighted<br/>average exercise<br/>price $</strong></span></span></span></span></td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Weighted average<br/>remaining life<br/>(years)</strong></span></span></span></span></td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding as at December 31, 2025</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321163632269_20260321072135029_78" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_20251231_usgaapFinancialInstrumentAxis_usgaapWarrantMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">7,281,795</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321163632269_20260321072135030_81" name="mdcx:WeightedAverageExercisePriceOfWarrant" contextRef="C_20251231_usgaapFinancialInstrumentAxis_usgaapWarrantMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.70</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20260321163632269_20260321072135030_80" name="mdcx:WeightedAverageRemainingContractualTermOfWarrant" contextRef="C_20250101to20251231_usgaapFinancialInstrumentAxis_usgaapWarrantMember" format="ixt-sec:duryear">4.90</ix:nonNumeric></span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants granted</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20260321072135031_84" name="mdcx:NumberOfCommonShareWarrantsOutstandingGrantsInPeriod" contextRef="C_20260101to20260630_usgaapFinancialInstrumentAxis_usgaapWarrantMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20260321072135034_92" name="mdcx:WeightedAverageExercisePriceWarrantGranted" contextRef="C_20260101to20260630_usgaapFinancialInstrumentAxis_usgaapWarrantMember" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants exercised</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321164432396_20260321072135032_86" name="mdcx:NumberOfCommonShareWarrantsOutstandingExerciseInPeriod" contextRef="C_20260101to20260630_usgaapFinancialInstrumentAxis_usgaapWarrantMember" unitRef="Share" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260321164432396_20260321072135035_94" name="mdcx:WeightedAverageExercisePriceWarrantExercise" contextRef="C_20260101to20260630_usgaapFinancialInstrumentAxis_usgaapWarrantMember" unitRef="USD_Per_Share" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total Warrants outstanding as at June 30, 2026</strong></span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:10%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="F20260321072135031_83" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_20260630_usgaapFinancialInstrumentAxis_usgaapWarrantMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">7,281,795</ix:nonFraction></strong></span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:10%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509013754603" name="mdcx:WeightedAverageExercisePriceOfWarrant" contextRef="C_20260630_usgaapFinancialInstrumentAxis_usgaapWarrantMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.70</ix:nonFraction></strong></span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:10%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonNumeric id="Fxbrl_20260509013801382" name="mdcx:WeightedAverageRemainingContractualTermOfWarrant" contextRef="C_20260101to20260630_usgaapFinancialInstrumentAxis_usgaapWarrantMember" format="ixt-sec:duryear">4.41</ix:nonNumeric></strong></span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>

          </table>
        </div>
      </ix:nonNumeric>
      <p style="margin:0pt">&#160;</p>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">The number of warrants outstanding as at the six months ended June 30, 2026:</p>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>
      <ix:nonNumeric id="F20260321072135011_50" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" contextRef="C_20260101to20260630" escape="true">
        <div>
          <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt">

              <tr>
                <td style="width:20%;vertical-align:top;border-bottom:0.75pt solid #000000;text-align:center;padding-left:5pt;padding-right:5pt;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
                <td colspan="4" style="padding-right:5pt;padding-left:5pt;vertical-align:top;border-bottom:0.75pt solid #000000;text-align:center;width:80%;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Warrants outstanding</strong></span></span></span></span></td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;border-bottom:0.75pt solid #000000;white-space:nowrap;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;border-bottom:0.75pt solid #000000;white-space:nowrap;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Expiry date</strong></span></span></span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Exercise price</strong></span></span></span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Number outstanding</strong></span></span></span></span></td>
                <td style="width:20%;vertical-align:top;border-bottom:0.75pt solid #000000;text-align:right;padding-left:5pt;padding-right:5pt;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Number<br/>exercisable </strong></span></span></span></span></td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants issued as part of the IPO</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20260321072135012_51" name="mdcx:ClassOfWarrantOrRightExpiryDate" contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantsIssuedAsPartOfIpoMember">November 15, 2029</ix:nonNumeric></span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$ <ix:nonFraction id="F20260321072135013_55" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantsIssuedAsPartOfIpoMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">4.64</ix:nonFraction></span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20260321072135013_54" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantsIssuedAsPartOfIpoMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">985,595</ix:nonFraction></span></span></td>
                <td style="width:20%;vertical-align:top;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:right;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260324062626887" name="mdcx:ClassOfWarrantOrRightExercisable" contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantsIssuedAsPartOfIpoMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">985,595</ix:nonFraction></span></span></td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Regulation A Warrants</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20260321072135012_52" name="mdcx:ClassOfWarrantOrRightExpiryDate" contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxRegulationAWarrantsMember">March 10, 2030</ix:nonNumeric></span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$ <ix:nonFraction id="F20260321072135014_57" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20260630_usgaapStatementEquityComponentsAxis_mdcxRegulationAWarrantsMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.80</ix:nonFraction></span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20260321072135014_56" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_20260630_usgaapStatementEquityComponentsAxis_mdcxRegulationAWarrantsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">16,200</ix:nonFraction></span></span></td>
                <td style="width:20%;vertical-align:top;text-align:right;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260324062633517" name="mdcx:ClassOfWarrantOrRightExercisable" contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxRegulationAWarrantsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">16,200</ix:nonFraction></span></span></td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30, 2030 Warrants</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20260321072135013_53" name="mdcx:ClassOfWarrantOrRightExpiryDate" contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantWithExpiryDateJune302030WarrantsMember">June 2, 2030</ix:nonNumeric></span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;background-color:#e6efff;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$ <ix:nonFraction id="F20260321072135015_59" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantWithExpiryDateJune302030WarrantsMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">3.10</ix:nonFraction></span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;background-color:#e6efff;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20260321072135014_58" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantWithExpiryDateJune302030WarrantsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">2,260,000</ix:nonFraction></span></span></td>
                <td style="width:20%;vertical-align:top;background-color:#e6efff;text-align:right;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260324062639233" name="mdcx:ClassOfWarrantOrRightExercisable" contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantWithExpiryDateJune302030WarrantsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">2,260,000</ix:nonFraction></span></span></td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Series C and D Warrants</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20260321072135015_60" name="mdcx:ClassOfWarrantOrRightExpiryDate" contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxSeriesCAndDWarrantsMember">June 5, 2031</ix:nonNumeric></span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$ <ix:nonFraction id="Fxbrl_20251105153503197_20260321072135015_59" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20260630_usgaapStatementEquityComponentsAxis_mdcxSeriesCAndDWarrantsMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.00</ix:nonFraction></span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20251105153503197_20260321072135014_58" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_20260630_usgaapStatementEquityComponentsAxis_mdcxSeriesCAndDWarrantsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">4,020,000</ix:nonFraction></span></span></td>
                <td style="width:20%;vertical-align:top;text-align:right;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260324062645731" name="mdcx:ClassOfWarrantOrRightExercisable" contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxSeriesCAndDWarrantsMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">4,020,000</ix:nonFraction></span></span></td>
              </tr>

          </table>
        </div>
      </ix:nonNumeric>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Standby Equity Purchase Agreement </i></span></span></p>
      <div><ix:exclude>
        <div><div><div style="text-align:center"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">4</span></span></span></div></div></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%;margin-bottom:10pt;margin-top:10pt"/>
      </ix:exclude></div>
      <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On February 10, 2025, the Company also announced that it had entered into a standby equity purchase agreement (the "SEPA") with YA II PN, Ltd. ("Yorkville"). Pursuant to the SEPA and subject to the satisfaction of certain conditions, Yorkville has committed to purchase the Company's common shares in increments up to an aggregate gross sales price of $<ix:nonFraction id="F20260321072135009_44" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20250210to20250210_usgaapSubsidiarySaleOfStockAxis_mdcxStandbyEquityPurchaseAgreementMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">15,000,000</ix:nonFraction> during the 36 months following the date of the SEPA (such shares, the "Shares"). The Shares will be sold at the Company's option pursuant to the SEPA at <ix:nonFraction id="F20260321072135010_45" name="mdcx:SharePriceAsPercentageOfMarketPrice" contextRef="C_20250210to20250210_usgaapSubsidiarySaleOfStockAxis_mdcxStandbyEquityPurchaseAgreementMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">97</ix:nonFraction>% of the Market Price (as defined pursuant to the SEPA) and purchases are subject to certain limitations set forth in the SEPA. For the six months ended June 30, 2026, the Company issued <ix:nonFraction id="F20260321072135026_71" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_mdcxStandbyEquityPurchaseAgreementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">5,336,780</ix:nonFraction> common shares pursuant to the SEPA at market prices for gross proceeds of $<ix:nonFraction id="F20260321072135026_70" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_mdcxStandbyEquityPurchaseAgreementMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">4,229,823</ix:nonFraction> and net proceeds of&#160; $<ix:nonFraction id="F20260321072135026_69" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_mdcxStandbyEquityPurchaseAgreementMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">4,102,740</ix:nonFraction>. During the six months ended June 30, 2026, $<ix:nonFraction id="Fxbrl_20260809154820152" name="mdcx:ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures" contextRef="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_mdcxStandbyEquityPurchaseAgreementMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">3,223,980</ix:nonFraction> of the gross proceeds received under the SEPA were held back to partially repay the Company's Yorkville debenture and related interest obligations. As at June 30, 2026 the Company has $<ix:nonFraction id="Fxbrl_20260809155228524" name="mdcx:AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement" contextRef="C_20260630_usgaapSubsidiarySaleOfStockAxis_mdcxStandbyEquityPurchaseAgreementMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">2,489,206</ix:nonFraction> available to exercise in relation to the SEPA.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 29, 2025, the Company entered into an equity distribution agreement (the "ATM Agreement") with Maxim Group LLC and Yorkville Securities LLC ("Yorkville Securities" and together with Maxim Group LLC, the "Agents") to create an at-the-market equity program (the "ATM"). Under the ATM Agreement, the Company may offer and sell its common shares from time to time through the Agents. The Company agreed to pay the Agents a commission equal to <ix:nonFraction id="Fxbrl_20260321182936616" name="mdcx:EquityDistributionAgreementCommissionRate" contextRef="C_20251229_usgaapSubsidiarySaleOfStockAxis_mdcxAtmAgreementMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction>% of the gross sales from the sales of the shares pursuant to the ATM Agreement. For the six months ended June 30, 2026, the Company has issued <ix:nonFraction id="Fxbrl_20260509014444569" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_mdcxAtmAgreementMember" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">28,248,981</ix:nonFraction> common shares as part of the program. The gross proceeds from the issuance were $<ix:nonFraction id="Fxbrl_20260509014515926" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_mdcxAtmAgreementMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">12,868,181</ix:nonFraction>.</span></span></p>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20260509021028221" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_20260101to20260630" escape="true">
    <div>
      <p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>6.</strong>&#160;<strong>Stock-based compensation </strong></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">At June 30, 2026, the Company had in place a stock option plan for employee, non-employee directors, and consultants of the Company (the "Plan"). The Plan provides both for the direct award or sale of shares and for the grant of options to purchase shares. Under the plan, the total number of shares available for options cannot exceed <ix:nonFraction id="Fxbrl_20250325182814380" name="mdcx:LimitOfOptionsAsPercentageOfSharesOutstanding" contextRef="C_20260101to20260630" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction>% of the Company's issued and outstanding common shares at the time of any grant. The Company is authorized to issue options to employees, non-employee directors and consultants under the plan.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On March 30, 2026, the Company issued <ix:nonFraction id="Fxbrl_20260509022608290" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20260330to20260330_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">975,000</ix:nonFraction> stock options to directors, officers, and employees of the Company. The options are exercisable at $<ix:nonFraction id="Fxbrl_20260509022617981" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20260330to20260330_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.50</ix:nonFraction> per share, expire <ix:nonNumeric id="Fxbrl_20260509022622751" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_20260330to20260330_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric> from the grant date, and vest quarterly over a <ix:nonNumeric id="Fxbrl_20260509022627134" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20260330to20260330_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember" format="ixt-sec:durwordsen">one-year</ix:nonNumeric> period. On June 3, 2026, the Company issued an additional <ix:nonFraction id="Fxbrl_20260809160528164" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20260601to20260603_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">2,075,000</ix:nonFraction> stock options to directors, officers, and employees of the Company. The options are exercisable at $<ix:nonFraction id="Fxbrl_20260809160554428" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20260601to20260603_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.36</ix:nonFraction> per share, expire <ix:nonNumeric id="Fxbrl_20260809160601051" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_20260601to20260603_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric> from the grant date, and vest quarterly over a <ix:nonNumeric id="Fxbrl_20260809160608532" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20260601to20260603_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember" format="ixt-sec:durwordsen">one-year</ix:nonNumeric> period. During the three months ended June 30, 2026, the Company accelerated the vesting of all options outstanding except the <ix:nonFraction id="Fxbrl_20260809160619082" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20260601to20260603_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">2,075,000</ix:nonFraction> options that were granted on June 3, 2026.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table summarizes option transactions for the Plan:</span></span></p>
      <ix:nonNumeric id="Fxbrl_20260509015400849" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_20260101to20260630" escape="true">
        <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-size:10pt;width:100%;border-color:#000000">

            <tr>
              <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Number of</strong><br/><strong>options</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Weighted</strong><br/><strong>average</strong><br/><strong>exercise price</strong><br/><strong>$</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Weighted</strong><br/><strong>average</strong><br/><strong>remaining</strong><br/><strong>contractual life</strong><br/><strong>(years)</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Aggregate</strong><br/><strong>intrinsic value</strong><br/><strong>$</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
            </tr>
            <tr style="background-color:rgb(230, 239, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding at December 31, 2024</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509021349807_xbrl_20260509014944168_xbrl_20250324181236791_xbrl_20250324180521687_12" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20241231" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">1,185,000</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509021349807_xbrl_20260509014944168_xbrl_20250324181236791_xbrl_20250324180521687_15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20241231" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.47</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonNumeric id="Fxbrl_20260509021349807_xbrl_20260509014944168_xbrl_20250324181437312" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20240101to20241231" format="ixt-sec:duryear">4.18</ix:nonNumeric></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509021349807_xbrl_20260509014944168_xbrl_20250324181236791_xbrl_20250324180521687_111" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_20241231" unitRef="USD" scale="0" decimals="2" format="ixt:num-dot-decimal">1.18</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260809160005135_xbrl_20260509015013472_xbrl_20250811142538631" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20250101to20250630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260809160005135_xbrl_20260509015013472_xbrl_20250811142601463" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20250101to20250630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.60</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonNumeric id="Fxbrl_20260809160005135_xbrl_20260509015013472_xbrl_20250811142608728" name="mdcx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" contextRef="C_20250101to20250630" format="ixt-sec:duryear">5.00</ix:nonNumeric></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(230, 239, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding at June 30, 2025</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509021353733_xbrl_20260509014944168_xbrl_20250324181236791_xbrl_20250324180521687_12" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20250630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">1,285,000</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509021353733_xbrl_20260509014944168_xbrl_20250324181236791_xbrl_20250324180521687_15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20250630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.56</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonNumeric id="Fxbrl_20260509021353733_xbrl_20260509014944168_xbrl_20250324181437312" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20250101to20250630" format="ixt-sec:duryear">3.79</ix:nonNumeric></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509021353733_xbrl_20260509014944168_xbrl_20250324181236791_xbrl_20250324180521687_111" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_20250630" unitRef="USD" scale="0" decimals="2" format="ixt:num-dot-decimal">1.43</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Exercisable at June 30, 2025</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509021407501_xbrl_20260509015056344_xbrl_20250324180521687_72" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20250630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">980,000</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509021407501_xbrl_20260509015056344_xbrl_20250324180521687_75" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_20250630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.25</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonNumeric id="Fxbrl_20260509021407501_xbrl_20260509015056344_xbrl_20250324180521687_78" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20250101to20250630" format="ixt-sec:duryear">4.01</ix:nonNumeric></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509021407501_xbrl_20260509015056344_xbrl_20250324180521687_711" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_20250630" unitRef="USD" scale="0" decimals="2" format="ixt:num-dot-decimal">1.74</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(230, 239, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Unvested at June 30, 2025</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509021414469_xbrl_20260509015104079_xbrl_20250324180521687_82" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="C_20250630" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">305,000</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509021414469_xbrl_20260509015104079_xbrl_20250325103832992" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_20250630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.56</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonNumeric id="Fxbrl_20260509021414469_xbrl_20260509015104079_xbrl_20250325105103101" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_20250101to20250630" format="ixt-sec:duryear">4.44</ix:nonNumeric></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509021414469_xbrl_20260509015104079_xbrl_20250325105245212" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="C_20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(230, 239, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding at December 31, 2025</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509014944168_xbrl_20250324181236791_xbrl_20250324180521687_12" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20251231" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">2,505,000</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509014944168_xbrl_20250324181236791_xbrl_20250324180521687_15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20251231" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.05</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonNumeric id="Fxbrl_20260509014944168_xbrl_20250324181437312" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20250101to20251231" format="ixt-sec:duryear">2.75</ix:nonNumeric></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509014944168_xbrl_20250324181236791_xbrl_20250324180521687_111" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:20pt;padding-right:5pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509015013472_xbrl_20250811142538631" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20260101to20260630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">3,050,000</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509015013472_xbrl_20250811142601463" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20260101to20260630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.40</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonNumeric id="Fxbrl_20260509015013472_xbrl_20250811142608728" name="mdcx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" contextRef="C_20260101to20260630" format="ixt-sec:duryear">4.87</ix:nonNumeric></strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(230, 239, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:20pt;padding-right:5pt;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(<ix:nonFraction id="Fxbrl_20251105132756851" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20260101to20260630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">45,000</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20251105132812260" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20260101to20260630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.79</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding at June 30, 2026</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509015049128_xbrl_20250324182436535_xbrl_20250324181236791_xbrl_20250324180521687_12" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20260630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">5,510,000</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509015049128_xbrl_20250324182436535_xbrl_20250324181236791_xbrl_20250324180521687_15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20260630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.14</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonNumeric id="Fxbrl_20260509015049128_xbrl_20250324182436535_xbrl_20250324181437312" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20260101to20260630" format="ixt-sec:duryear">4.32</ix:nonNumeric></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509015049128_xbrl_20250324182436535_xbrl_20250324181236791_xbrl_20250324180521687_111" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(230, 239, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Exercisable at June 30, 2026</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509015056344_xbrl_20250324180521687_72" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20260630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">3,435,000</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509015056344_xbrl_20250324180521687_75" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_20260630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.62</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonNumeric id="Fxbrl_20260509015056344_xbrl_20250324180521687_78" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20260101to20260630" format="ixt-sec:duryear">3.94</ix:nonNumeric></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509015056344_xbrl_20250324180521687_711" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Unvested at June 30, 2026</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509015104079_xbrl_20250324180521687_82" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="C_20260630" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal">2,075,000</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509015104079_xbrl_20250325103832992" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_20260630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.36</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonNumeric id="Fxbrl_20260509015104079_xbrl_20250325105103101" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_20260101to20260630" format="ixt-sec:duryear">4.93</ix:nonNumeric></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260509015104079_xbrl_20250325105245212" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>

        </table>
      </ix:nonNumeric>
      <p style="margin:0pt">&#160;</p>
      <div><ix:exclude>
        <div><div><div style="text-align:center"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5</span></span></span></div></div></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%;margin-bottom:10pt;margin-top:10pt"/>
      </ix:exclude></div>
      <p style="margin:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2026, there were $<ix:nonFraction id="Fxbrl_20250324203254745" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">419,075</ix:nonFraction> of unrecognized stock-based compensation cost related to share options outstanding, which is expected to be recognized over a weighted-average period of <ix:nonNumeric id="Fxbrl_20250325135300051" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_20260101to20260630" format="ixt-sec:duryear">0.93</ix:nonNumeric> years.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The weighted average grant date fair value of awards for options granted during the six months ended June 30, 2026, was $<ix:nonFraction id="Fxbrl_20250809015123536" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20260101to20260630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.24</ix:nonFraction>. The fair value of options granted was estimated using the Black-Scholes option pricing model, resulting in the following weighted average assumptions for the options granted:</span></span></p>
      <ix:nonNumeric id="Fxbrl_20260810163956578" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_20260101to20260630" escape="true">
        <div>
          <table cellpadding="0" cellspacing="0" style="width:90%;border-collapse:collapse;font-size:10pt;border-color:#000000">

              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>June 30, 2026</strong><br/><strong>Weighted-average</strong></span></span></span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise price</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260509015239492_xbrl_20250809064019026" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="C_20260630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.40</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share price</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260509015239492_xbrl_20250809064050283" name="us-gaap:SharePrice" contextRef="C_20260630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.37</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260509015239493_xbrl_20250809064053729" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20260101to20260630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20250809064056897" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20260101to20260630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.13</ix:nonFraction>%</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Estimated life (in years)</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20250809064112019" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20260101to20260630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">5</ix:nonNumeric></span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260509015239494_xbrl_20250809064109086" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20260101to20260630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">76.33</ix:nonFraction>%</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>

          </table>
        </div>
      </ix:nonNumeric>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>For the three and six months ended June 30, 2026, stock-based compensation expense was $<ix:nonFraction id="Fxbrl_20260812123047230" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">1,405,826</ix:nonFraction> and $<ix:nonFraction id="Fxbrl_20260812123101326" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">2,005,133</ix:nonFraction>, respectively. For the three and six months ended June 30, 2025, stock-based compensation expense was $<ix:nonFraction id="Fxbrl_20260812123120147" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">117,448</ix:nonFraction> and $<ix:nonFraction id="Fxbrl_20260812123126205" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">585,442</ix:nonFraction>, respectively. Stock-based compensation expense has been reported in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss within the line items &#8216;general and administrative&#8217; expenses</span></span>.</span></span></p>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20260509023016958" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_20260101to20260630" escape="true">
    <div>
      <div>
        <p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>7.</strong>&#160;<strong>Related party transactions</strong></span></span></p>
        <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 18, 2023, the Company signed an agreement with RBx Capital, LP ("RBx"), a family office controlled by the Company's Executive Chairman and CEO, that provides for certain managerial positions to be filled from within RBx. RBx is responsible for the payment and provision of all wages, bonuses, and benefits for these positions. In January 2026, reimbursable salaries paid to RBx pursuant to this agreement were increased to $<ix:nonFraction id="Fxbrl_20250324001152653" name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="C_20260101to20260131_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction> per month from $<ix:nonFraction id="Fxbrl_20250324001225834" name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="C_20231018to20231018_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction> per month. Reimbursable salaries paid to RBx were $<ix:nonFraction id="Fxbrl_20250324001249676" name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="C_20260101to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">750,000</ix:nonFraction> and $<ix:nonFraction id="Fxbrl_20250324001253364" name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="C_20250101to20250630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">600,000</ix:nonFraction> during the six months ended June 30, 2026 and 2025, respectively. Additional expenses of $<ix:nonFraction id="Fxbrl_20260812123840354" name="mdcx:RelatedPartyTransactionAdditionalExpenses" contextRef="C_20260401to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">455,486</ix:nonFraction> and $<ix:nonFraction id="Fxbrl_20250324001337661" name="mdcx:RelatedPartyTransactionAdditionalExpenses" contextRef="C_20250401to20250630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">64,046</ix:nonFraction> were incurred by RBx on behalf of the Company during the three months ended June 30, 2026 and 2025, respectively. Additional expenses of $<ix:nonFraction id="Fxbrl_20260812123553899" name="mdcx:RelatedPartyTransactionAdditionalExpenses" contextRef="C_20260101to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">898,983</ix:nonFraction> and $<ix:nonFraction id="Fxbrl_20260812123609030" name="mdcx:RelatedPartyTransactionAdditionalExpenses" contextRef="C_20250101to20250630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">104,911</ix:nonFraction> were incurred by RBx on behalf of the Company during the six months ended June 30, 2026 and 2025, respectively.&#160;The total amount of accounts payable to RBx was $<ix:nonFraction id="Fxbrl_20250324001421995" name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="C_20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">161,846</ix:nonFraction> and $<ix:nonFraction id="Fxbrl_20250324001437196" name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="C_20250630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">121,273</ix:nonFraction> as of June 30, 2026 and 2025, respectively.</span></span></p>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20260321105359264" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_20260101to20260630" escape="true">
    <p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>8.</strong>&#160;<strong>Fair value measurements</strong></span></span></p>
    <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accounting guidance for fair value establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></span></p>
    <p style="margin-left:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1: Observable inputs such as quoted prices in active markets;</span></span></p>
    <p style="margin-left:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly; and</span></span></p>
    <p style="margin-left:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 3: Unobservable inputs in which there is little or no market data, or which require the reporting entity to develop its own assumptions.</span></span></p>
    <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company's cash and cash equivalents and restricted cash are classified as Level 1. The fair value of the Company's cash and cash equivalents is determined based on market pricing that is both objective and publicly available. As of June 30, 2026 and December 31, 2025, the fair value of the Company's cash and cash equivalents and restricted cash were $<ix:nonFraction id="Fxbrl_20260321111218190" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">25,191,540</ix:nonFraction> and $<ix:nonFraction id="Fxbrl_20260321111227246" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_20251231" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">8,705,218</ix:nonFraction>, respectively. As of June 30, 2026 and December 31, 2025, the Company's cash equivalents are invested in money market funds.</span></span></p>
    <div><ix:exclude>
      <div style="margin-top:0pt;margin-bottom:0pt">
        <div><div><div style="text-align:center"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">6</span></span></span></div></div></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%;margin-bottom:10pt;margin-top:10pt"/>
      </div>
    </ix:exclude></div>
    <div style="margin-top:0pt;margin-bottom:0pt">
      <ix:nonNumeric id="Fxbrl_20260809161332878" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_20260101to20260630" escape="true">
        <div style="margin-top:0pt;margin-bottom:0pt">
          <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;width:100%;border-color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

              <tr style="margin-top:0pt;margin-bottom:0pt">
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">June 30, 2026</strong></span></span></span></p>
                </td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt">
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Level 1</strong></span></span></span></td>
                <td style="vertical-align:bottom;text-align:center;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Level 2</strong></span></span></span></td>
                <td style="vertical-align:bottom;text-align:center;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Level 3</strong></span></span></span></td>
                <td style="vertical-align:bottom;text-align:center;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Total</strong></span></span></span></td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">
                <td style="padding-right:5.4pt;padding-left:16.2pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Current assets:</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
                <td style="padding-right:5.4pt;padding-left:27pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Money market funds</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20260321112324586_20260321050257311_4" name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="C_20260630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">13,573,269</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20260321112324586_20260321050257311_5" name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="C_20260630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20260321112324586_20260321050257311_6" name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="C_20260630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20260321112324586_20260321050257312_7" name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="C_20260630_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">13,573,269</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">
                <td style="padding-right:5.4pt;padding-left:52.2pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Total assets measured at fair value</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20260321050257311_4" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_20260630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">13,573,269</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20260321050257311_5" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_20260630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20260321050257311_6" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_20260630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20260321050257312_7" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_20260630_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">13,573,269</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;text-align:right;width:10%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;width:1%;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);text-align:center;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">December 31, 2025</strong></span></span></span></td>
                <td style="vertical-align:bottom;width:2%;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Level 1</strong></span></span></span></td>
                <td style="vertical-align:bottom;width:2%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Level 2</strong></span></span></span></td>
                <td style="vertical-align:bottom;width:2%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Level 3</strong></span></span></span></td>
                <td style="vertical-align:bottom;width:2%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Total</strong></span></span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:2%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">
                <td style="padding-right:5.4pt;padding-left:16.2pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Current assets:</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
                <td style="padding-right:5.4pt;padding-left:27pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Cash and cash equivalents</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20260321112327479_20260321050257311_4" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20251231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">8,705,218</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20260321112327479_20260321050257311_5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20251231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20260321112327479_20260321050257311_6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20251231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20260321112327479_20260321050257312_7" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20251231_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">8,705,218</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">
                <td style="padding-right:5.4pt;padding-left:52.2pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Total assets measured at fair value</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20260321050257312_12" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_20251231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">8,705,218</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20260321050257312_13" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_20251231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20260321050257313_14" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_20251231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="F20260321050257313_15" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_20251231_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">8,705,218</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
              </tr>

          </table>
        </div>
      </ix:nonNumeric>
    </div>
    <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company did not reclassify any investments between levels in the fair value hierarchy during the periods presented.</span></span></p>
    <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The carrying value of the Company's secured promissory notes described in Note 12 below approximates the fair value since the financial instrument is short-term with a maturity date of November 27, 2027. As of June 30, 2026 and December 31, 2025, the carrying amounts of the Company's other financial instruments, which include cash and cash equivalents and restricted cash, accounts payable and accrued expenses approximate fair values because of their short-term maturities.</span></span></p>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20260321102720325" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_20260101to20260630" escape="true">
    <div>
      <div>
        <div>
          <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>9.</strong>&#160;<strong>Commitments and contingencies</strong></span></span></p>
          <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Commitments</i></span></span></p>
          <div>
            <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As part of the acquisition of Antev, the Company may be required to make future payments contingent on the achievement of specified milestones. These potential payments represent a commitment and may result in future cash outflows. As these milestones conditions are not considered probable, the Company has not recognized liability related to the contingent consideration.</span></span></p>
            <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to the terms of the Antev acquisition, the Company acquired <ix:nonFraction id="Fxbrl_20260812173234560" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">98.60</ix:nonFraction>% ownership in Antev, including all the assets and its In-Process Research and Development (IPR&amp;D) &#8211; Teverelix. There was additional contingent consideration based on the following development milestones of the IPR&amp;D:</span></span></p>
            <ix:nonNumeric id="Fxbrl_20260812152017209" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock" contextRef="C_20260101to20260630" escape="true">
              <table border="0" style="border-collapse:collapse" width="100%">

                  <tr style="background-color:rgb(230, 239, 255)">
                    <td style="vertical-align:top;padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Phases</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Contingent Consideration agreed for Antev shares acquired through issue of shares</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Contingent Consideration agreed for Antev shares acquired by cash payment</span></span></span></span></span></span></td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(i) Advanced Prostate Cancer - Phase 2 success or registration</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$<ix:nonFraction id="Fxbrl_20260812151036268" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="C_20260630_mdcxBusinessCombinationConsiderationTransferredEquityInterestTypeAxis_usgaapCommonStockMember_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesOneMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">2.00</ix:nonFraction> per common share issued</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$<ix:nonFraction id="Fxbrl_20260812151114782" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesOneMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">1.47</ix:nonFraction> per Antev share (pro rata interest in $<ix:nonFraction id="Fxbrl_20260812151133117" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="C_20260630_mdcxBusinessCombinationConsiderationTransferredEquityInterestTypeAxis_usgaapCommonStockMember_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesOneMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">5,333,200</ix:nonFraction>)</span></span></span></span></span></span></td>
                  </tr>
                  <tr style="background-color:rgb(230, 239, 255)">
                    <td style="padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(ii)Acute Urinary Retention Prevention - Phase 2 success or registration</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$<ix:nonFraction id="Fxbrl_20260812151240084" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="C_20260630_mdcxBusinessCombinationConsiderationTransferredEquityInterestTypeAxis_usgaapCommonStockMember_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesTwoMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">7.50</ix:nonFraction> per common share issued</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$<ix:nonFraction id="Fxbrl_20260812151306717" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesTwoMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">5.52</ix:nonFraction> per Antev share (pro rata interest in $<ix:nonFraction id="Fxbrl_20260812151323991" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesTwoMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">19,999,500</ix:nonFraction>)</span></span></span></span></span></span></td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(iii) FDA NDA approval - Hormone therapy for prostate cancer</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Up to $<ix:nonFraction id="Fxbrl_20260812151342260" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="C_20260630_srtRangeAxis_srtMaximumMember_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesThreeMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction> (subject to pro rata reduction)</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$<ix:nonFraction id="Fxbrl_20260812151537933" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesThreeMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">5.52</ix:nonFraction> per Antev share (pro rata interest in $<ix:nonFraction id="Fxbrl_20260812151558038" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesThreeMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction></span></span></span></span></span></span></td>
                  </tr>
                  <tr style="background-color:rgb(230, 239, 255)">
                    <td style="padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(iv) FDA NDA approval &#8211; AUR prevention</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Up to $<ix:nonFraction id="Fxbrl_20260812151629135" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="C_20260630_srtRangeAxis_srtMaximumMember_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesFourMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction> (subject to pro rata reduction)</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$<ix:nonFraction id="Fxbrl_20260812151703255" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesFourMember" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">5.52</ix:nonFraction> per Antev share (pro rata interest in $<ix:nonFraction id="Fxbrl_20260812151735397" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesFourMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction>)</span></span></span></span></span></span></td>
                  </tr>

              </table>
            </ix:nonNumeric>
          </div>
          <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2026, the Company had no other long-term commitments.</span></span></p>
          <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Contingencies </i></span></span></p>
          <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In the ordinary course of business, from time to time, the Company may be involved in various claims related to operations, rights, commercial, employment or other claims. Although such matters cannot be predicted with certainty, management does not consider the Company's exposure to such claims to be material to these consolidated financial statements.</span></span></p>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif;text-align:left;font-size:10pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20260509025046115" name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="C_20260101to20260630" escape="true">
    <div>
      <div>
        <p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>10.</strong>&#160;<strong>Segment reporting</strong></span></span></span></span></p>
        <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the CODM in deciding how to allocate resources to an individual segment and in assessing performance. The Company manages the business activities on a consolidated basis and operates as&#160;<ix:nonFraction id="Fxbrl_20260812173738166" name="us-gaap:NumberOfReportableSegments" contextRef="C_20260101to20260630" unitRef="Segment" scale="0" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction> reportable segment that constitutes all of the consolidated entity, which is the business of advancing the clinical development program of the Company&#8217;s product, while opportunistically identifying, evaluating, and acquiring accretive assets, properties or businesses. The Company&#8217;s CODM is its Chief Executive Officer. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM uses consolidated net loss to measure segment loss, allocate resources and assess performance. The significant segment expense categories (general and administrative and research and development) are consistent with those presented on the face of the statements of operations and comprehensive loss. Other segment items are interest (income) expenses which are consistent with those presented on the face of the statements of operations and comprehensive loss. Additionally, the CODM reviews cash forecast models to determine where the Company will invest in planned research and development activities.&#160;As the Company&#8217;s operations are comprised of a single reporting segment, the segment assets are reflected on the accompanying condensed consolidated balance sheet as Total Assets. Segment asset information is not used by the CODM to allocate resources.</span></span></span></span></span></span></p>
        <div>
          <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company's single reporting segment. A reconciliation to consolidated operating expenses as the Company&#8217;s single segment operating loss for the three and six months ended June 30, 2026 and 2025 is included in the table below:</span></span></span></p>
          <ix:nonNumeric id="Fxbrl_20260812165504668" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" contextRef="C_20260101to20260630" escape="true">
            <table cellpadding="0" cellspacing="0" style="font-size:10pt;border-collapse:collapse;width:100%;border-color:#000000">

                <tr>
                  <td style="vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="4" style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Three Months Ended June 30,</strong></span></span></span></td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="4" style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Six Months Ended June 30,</strong></span></span></span></td>
                  <td colspan="1" style="vertical-align:bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></td>
                  <td style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>2026</strong></span></span></span></td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>2025</strong></span></span></span></td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>2026</strong></span></span></span></td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>2025</strong></span></span></span></td>
                  <td colspan="1" style="vertical-align:bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Research and development expenses:</strong></span></span></span></td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>SkinJect</strong></span></span></span></td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-left:10pt;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Clinical, manufacturing and regulatory activities</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812163638895" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="C_20260401to20260630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">1,268,747</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812163817879" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="C_20250401to20250630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">1,011,362</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812163821574" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="C_20260101to20260630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">2,011,288</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812163826824" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="C_20250101to20250630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">2,453,931</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-left:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Professional services and intellectual property</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164137234_xbrl_20260812163638895" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="C_20260401to20260630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">96,653</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164137234_xbrl_20260812163817879" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="C_20250401to20250630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">71,561</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164137234_xbrl_20260812163821574" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="C_20260101to20260630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">145,227</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164137234_xbrl_20260812163826824" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="C_20250101to20250630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">116,678</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Teverelix</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-left:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Clinical, manufacturing and regulatory activities</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164139513_xbrl_20260812163638895" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="C_20260401to20260630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">2,927,793</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164139513_xbrl_20260812163817879" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="C_20250401to20250630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164139513_xbrl_20260812163821574" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="C_20260101to20260630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">3,850,023</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164139513_xbrl_20260812163826824" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="C_20250101to20250630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-left:10pt;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Professional services and intellectual property</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164141327_xbrl_20260812163638895" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="C_20260401to20260630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">46,169</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164141327_xbrl_20260812163817879" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="C_20250401to20250630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164141327_xbrl_20260812163821574" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="C_20260101to20260630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">78,341</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164141327_xbrl_20260812163826824" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" contextRef="C_20250101to20250630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Salaries and benefits</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164145506_xbrl_20260812163638895" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">568,329</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164145506_xbrl_20260812163817879" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">356,641</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164145506_xbrl_20260812163821574" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">1,527,207</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164145506_xbrl_20260812163826824" name="us-gaap:LaborAndRelatedExpense" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">875,169</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Total research and development expenses</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong><ix:nonFraction id="Fxbrl_20260812164147650_xbrl_20260812163638895" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">4,907,692</ix:nonFraction></strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong><ix:nonFraction id="Fxbrl_20260812164147650_xbrl_20260812163817879" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">1,439,564</ix:nonFraction></strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong><ix:nonFraction id="Fxbrl_20260812164147650_xbrl_20260812163821574" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">7,612,085</ix:nonFraction></strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong><ix:nonFraction id="Fxbrl_20260812164147650_xbrl_20260812163826824" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">3,445,778</ix:nonFraction></strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Total general and administrative expenses</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong><ix:nonFraction id="Fxbrl_20260812164149201_xbrl_20260812163638895" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">6,571,097</ix:nonFraction></strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong><ix:nonFraction id="Fxbrl_20260812164149201_xbrl_20260812163817879" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">4,576,524</ix:nonFraction></strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong><ix:nonFraction id="Fxbrl_20260812164149201_xbrl_20260812163821574" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">12,463,781</ix:nonFraction></strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong><ix:nonFraction id="Fxbrl_20260812164149201_xbrl_20260812163826824" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">7,696,584</ix:nonFraction></strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Total operating expenses</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong><ix:nonFraction id="Fxbrl_20260812164150832_xbrl_20260812163638895" name="us-gaap:OperatingExpenses" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">11,478,789</ix:nonFraction></strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong><ix:nonFraction id="Fxbrl_20260812164150832_xbrl_20260812163817879" name="us-gaap:OperatingExpenses" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">6,016,088</ix:nonFraction></strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong><ix:nonFraction id="Fxbrl_20260812164150832_xbrl_20260812163821574" name="us-gaap:OperatingExpenses" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">20,075,866</ix:nonFraction></strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong><ix:nonFraction id="Fxbrl_20260812164150832_xbrl_20260812163826824" name="us-gaap:OperatingExpenses" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">11,142,362</ix:nonFraction></strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Other income (expense):</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Finance income</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164152960_xbrl_20260812163638895" name="us-gaap:InvestmentIncomeNet" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164152960_xbrl_20260812163817879" name="us-gaap:InvestmentIncomeNet" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">40,004</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164152960_xbrl_20260812163821574" name="us-gaap:InvestmentIncomeNet" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164152960_xbrl_20260812163826824" name="us-gaap:InvestmentIncomeNet" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">63,870</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Interest income (expense)</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="Fxbrl_20260812164155160_xbrl_20260812163638895" name="us-gaap:InterestExpense" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">205,638</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164155160_xbrl_20260812163817879" name="us-gaap:InterestExpense" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="Fxbrl_20260812164155160_xbrl_20260812163821574" name="us-gaap:InterestExpense" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">523,789</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164155160_xbrl_20260812163826824" name="us-gaap:InterestExpense" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Loss on SEPA settlements</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164158430_xbrl_20260812163638895" name="mdcx:GainLossOnSettlements" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164158430_xbrl_20260812163817879" name="mdcx:GainLossOnSettlements" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="Fxbrl_20260812164158430_xbrl_20260812163821574" name="mdcx:GainLossOnSettlements" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">127,083</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164158430_xbrl_20260812163826824" name="mdcx:GainLossOnSettlements" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Change in fair value of debentures</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20260812164202863_xbrl_20260812163817879" name="mdcx:ChangeInFairValueOfDebentures" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="Fxbrl_20260812164202863_xbrl_20260812163821574" name="mdcx:ChangeInFairValueOfDebentures" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">200,000</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="Fxbrl_20260812164202863_xbrl_20260812163826824" name="mdcx:ChangeInFairValueOfDebentures" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">200,000</ix:nonFraction></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Total other income (expense)</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(<ix:nonFraction id="Fxbrl_20260812164205057_xbrl_20260812163638895" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">205,638</ix:nonFraction></strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(<ix:nonFraction id="Fxbrl_20260812164205057_xbrl_20260812163817879" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">159,996</ix:nonFraction></strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(<ix:nonFraction id="Fxbrl_20260812164205057_xbrl_20260812163821574" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">650,872</ix:nonFraction></strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(<ix:nonFraction id="Fxbrl_20260812164205057_xbrl_20260812163826824" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">136,130</ix:nonFraction></strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Net loss for the period</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(<ix:nonFraction id="Fxbrl_20260812164206802_xbrl_20260812163638895" name="us-gaap:ProfitLoss" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">11,684,427</ix:nonFraction></strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(<ix:nonFraction id="Fxbrl_20260812164206802_xbrl_20260812163817879" name="us-gaap:ProfitLoss" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">6,176,084</ix:nonFraction></strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(<ix:nonFraction id="Fxbrl_20260812164206802_xbrl_20260812163821574" name="us-gaap:ProfitLoss" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">20,726,738</ix:nonFraction></strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(<ix:nonFraction id="Fxbrl_20260812164206802_xbrl_20260812163826824" name="us-gaap:ProfitLoss" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">11,278,492</ix:nonFraction></strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="text-align:justify;margin-top:0pt;margin-bottom:0pt">&#160;</p>
  <div><div><div style="text-align:center"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">7</span></span></span></div></div></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%;margin-bottom:10pt;margin-top:10pt"/>

  <ix:nonNumeric id="Fxbrl_20260810114655501" name="us-gaap:LongTermDebtTextBlock" contextRef="C_20260101to20260630" escape="true">
    <div>
      <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>11. Debentures and Secured Promissory Notes</strong></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On September 17, 2025, the Company entered into a securities purchase agreement with Yorkville to issue a debenture with the principal amount of $<ix:nonFraction id="F20260321061347344_8" name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="C_20250901to20250917_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">8,000,000</ix:nonFraction> issued at a discount of $<ix:nonFraction id="Fxbrl_20260321160743159" name="mdcx:DebtIssuanceDiscount" contextRef="C_20250917_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">633,707</ix:nonFraction> for proceeds of approximately $<ix:nonFraction id="Fxbrl_20260321160819556" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="C_20250901to20250917_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">7,366,293</ix:nonFraction>. Interest accrued on the outstanding principal amount of the debenture at an annual rate of <ix:nonFraction id="F20260321061347344_10" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_20250917_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">8</ix:nonFraction>%, subject to a potential increase to <ix:nonFraction id="F20260321061347345_11" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="C_20250901to20250917_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">18</ix:nonFraction>% per annum upon the occurrence of certain events of default. The debenture had a maturity date of <ix:nonNumeric id="F20260321061347345_12" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_20250901to20250917_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember" format="ixt:date-monthname-day-year-en">September 17, 2026</ix:nonNumeric>, and was to be repaid using proceeds from the SEPA; however, on May 27, 2026, the Company used part of the proceeds from the issuance of the Secured Promissory Notes (as defined herein) to repay and extinguish the outstanding balance and accrued interest owing on the debenture.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The debenture was initially recorded at fair value, based on the discounted proceeds. Subsequently, the Company accounted for the debenture at amortized cost using the effective interest rate method, resulting in accretion expense of $<ix:nonFraction id="F20260321061347347_23" name="mdcx:ConvertibleDebtAccretionExpense" contextRef="C_20260101to20260630_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">374,712</ix:nonFraction> for the six months ended June 30, 2026. The effective interest rate calculated was <ix:nonFraction id="Fxbrl_20260321161504817" name="mdcx:EffectiveInterestRateOnDebt" contextRef="C_20260101to20260630_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">32.75</ix:nonFraction>% as of June 30, 2026. On May 27, 2026, the Company repaid the outstanding principal balance of $<ix:nonFraction id="Fxbrl_20260810103130553" name="us-gaap:RepaymentsOfDebt" contextRef="C_20260501to20260527_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">2,343,778</ix:nonFraction> related to the Yorkville debenture, together with accrued interest of $<ix:nonFraction id="Fxbrl_20260810103316307" name="mdcx:AccruedInterestRepaid" contextRef="C_20260501to20260527_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">135,664</ix:nonFraction>, using proceeds received from the issuance of the Secured Promissory Notes.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 27, 2026, the Company entered into a Note Purchase Agreement with Streeterville Capital, LLC ("Streeterville"), pursuant to which the Company issued two secured promissory notes with aggregate principal amounts of $<ix:nonFraction id="Fxbrl_20260810110719057" name="us-gaap:ProceedsFromNotesPayable" contextRef="C_20260501to20260527_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">22,864,225</ix:nonFraction>. The first promissory note ("Note A") was issued with a face value of $<ix:nonFraction id="Fxbrl_20260810110742939" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">12,864,225</ix:nonFraction> and a purchase price of $<ix:nonFraction id="Fxbrl_20260810110804602" name="us-gaap:ProceedsFromNotesPayable" contextRef="C_20260501to20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">12,000,000</ix:nonFraction>, resulting in an issue discount of $<ix:nonFraction id="Fxbrl_20260810110852840" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">864,225</ix:nonFraction>. The second promissory note ("Note B") was issued with a principal amount of $<ix:nonFraction id="Fxbrl_20260810110825087" name="us-gaap:ProceedsFromNotesPayable" contextRef="C_20260501to20260527_usgaapDebtInstrumentAxis_mdcxNoteBMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction>. Note A bears interest at <ix:nonFraction id="Fxbrl_20260810111030162" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.75</ix:nonFraction>% per annum compounded daily and Note B bears interest at <ix:nonFraction id="Fxbrl_20260810111022825" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteBMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="Percent" scale="-2" decimals="3" format="ixt:num-dot-decimal">5.0</ix:nonFraction>% per annum compounded daily. Both promissory notes mature on <ix:nonNumeric id="Fxbrl_20260810111132411" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_20260501to20260527_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" format="ixt:date-monthname-day-year-en">November 27, 2027</ix:nonNumeric>.</span></span></p>
      <div style="margin-top:0pt;margin-bottom:0pt"><ix:exclude>
        <div style="margin-top:0pt;margin-bottom:0pt">
          <div><div><div style="text-align:center"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">8</span></span></span></div></div></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%;margin-bottom:10pt;margin-top:10pt"/>
        </div>
      </ix:exclude></div>
      <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span id="page_21"><!-- anchor --></span></span></span></p>
      <p style="text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">The Secured Promissory Notes are secured by a first-ranking security interest over substantially all assets of the Company. Guarantees are provided by the Company's subsidiaries.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company evaluated the transaction under ASC 470-50, Debt Modifications and Extinguishments, and determined that the issuance of the Streeterville promissory notes and repayment of the Yorkville debenture should be accounted for as an extinguishment of debt. Accordingly, the carrying amount of the Yorkville debenture was derecognized upon settlement, and the newly issued promissory notes were recognized as new debt instruments.</span></span></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company initially recorded the Note A and Note B ("promissory notes") at fair value based on the proceeds received, net of directly attributable debt issuance costs. Subsequently, the Company accounts for the promissory notes at amortized cost using the effective interest method. Debt issuance costs are amortized over the contractual life of the respective promissory notes. The&#160;Company&#160;incurred $<ix:nonFraction id="Fxbrl_20260810111602099" name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="C_20260501to20260527_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">615,000</ix:nonFraction> in debt issuance cost related to the promissory notes.</span></span></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Note A permits the lender to require monthly redemptions beginning on the seventh month following the issuance, subject to the terms of the agreement. Beginning on the seventh month following the issuance date,&#160;the lender has the right to require monthly redemptions of up to $<ix:nonFraction id="Fxbrl_20260812143050726" name="mdcx:DebtInstrumentRedemptionLimitAmount" contextRef="C_20260527_srtRangeAxis_srtMaximumMember_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction> per month plus make-whole interest calculated as if the redeemed amount had remained outstanding until maturity. If the Company fails to satisfy a redemption notice within the required period, the outstanding balance is increased by <ix:nonFraction id="Fxbrl_20260812154444764" name="mdcx:DebtDefaultBalanceIncreasePercentage" contextRef="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction>% of the applicable redemption amount. In addition, beginning on the sixth month following the issuance date, both Note A and Note B permit the lender to require limited redemptions of up to <ix:nonFraction id="Fxbrl_20260812154510515" name="mdcx:DebtInstrumentVolumeBasedRedemptionPercentageLimit" contextRef="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of the cumulative daily dollar trading volume during specified redemption windows when the Company's common shares trade at least <ix:nonFraction id="Fxbrl_20260812154749211" name="mdcx:DebtInstrumentCovenantSharePriceThresholdPercentage" contextRef="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction>% above the defined Minimum Price per the agreement. Such limited redemptions are payable at <ix:nonFraction id="Fxbrl_20260812154846305" name="us-gaap:DebtInstrumentRedemptionPricePercentage" contextRef="C_20260501to20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">110</ix:nonFraction>% of the applicable redemption amount.</span></span></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Both Note A and Note B contain customary trigger event and event of default provisions, including payment defaults, insolvency events, delisting determinations and specified corporate transactions.&#160;&#160;<ix:nonNumeric id="Fxbrl_20260812114904600" name="us-gaap:DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault" contextRef="C_20260501to20260527_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember">Upon the occurrence of such trigger events, the lender may increase the outstanding balance by 5% for certain minor trigger events or 15% for certain major trigger events, as more fully described in Note A and Note B, subject to contractual limitations. Following an event of default, the lender may accelerate repayment and default interest may accrue at a rate of up to 18% per annum, subject to applicable law.</ix:nonNumeric></span></span></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As at June 30, 2026, the Company was in compliance with the terms and covenants of both notes.</span></span></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In connection with Note B, $<ix:nonFraction id="Fxbrl_20260812142123073" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteBMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> of the proceeds were deposited into a restricted deposit account maintained pursuant to a Deposit Account Control Agreement. The lender has control rights over the account upon the occurrence of specified trigger events and may direct the disposition of funds in the account. Under certain circumstances, amounts outstanding under Note B may be exchanged into additional Note A borrowings. Specifically, for each $<ix:nonFraction id="Fxbrl_20260812155856621" name="mdcx:DebtInstrumentExchangeThresholdAmount" contextRef="C_20260501to20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction> million of Note A principal repaid, up to $<ix:nonFraction id="Fxbrl_20260812155825869" name="mdcx:DebtInstrumentMaximumExchangeLimitAmount" contextRef="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteBMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction> million of the outstanding Note B balance may be exchanged into a new Note A advance, subject to the conditions set out in the financing agreements.</span></span></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company evaluated the embedded features contained within the promissory notes and concluded that certain features would require bifurcation under ASC 815; however, the fair value of such features was determined to be de minimis. Accordingly, no embedded derivative liability was recorded as of June 30, 2026.</span></span></p>
      <ix:nonNumeric id="Fxbrl_20260810174201949" name="us-gaap:ConvertibleDebtTableTextBlock" contextRef="C_20260101to20260630" escape="true">
        <div>
          <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Debenture issued on September 17, 2025:</span></span></td>
                <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30, 2026</strong></span></span></td>
                <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net balance as at December 31, 2025</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260509022016774" name="us-gaap:DebtCurrent" contextRef="C_20251231_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">5,245,543</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Repayment of new debenture</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20260321061347346_19" name="us-gaap:RepaymentsOfDebt" contextRef="C_20260101to20260331_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">3,180,084</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              </tr>
              <tr>
                <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest accretion</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20260321061347347_20" name="mdcx:ConvertibleDebtAccretionExpense" contextRef="C_20260101to20260331_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">374,712</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest payment</span></span></td>
                <td style="vertical-align:bottom;text-align:left;border-bottom:0.75pt solid #000000;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="F20260321061347347_21" name="mdcx:RepaymentsOfInterest" contextRef="C_20260101to20260331_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">96,393</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;text-align:left;border-bottom:0.75pt solid #000000;width:2%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              </tr>
              <tr>
                <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ending balance as of March 31, 2026</span></span></td>
                <td style="vertical-align:bottom;text-align:left;border-bottom:2.25pt double #000000;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                <td style="vertical-align:bottom;text-align:right;border-bottom:2.25pt double #000000;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810144141928" name="us-gaap:DebtCurrent" contextRef="C_20260331_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">2,343,778</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;text-align:left;border-bottom:2.25pt double #000000;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Repayment of Yorkville debenture</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260810144324362" name="us-gaap:RepaymentsOfDebt" contextRef="C_20260401to20260630_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">2,343,778</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              </tr>
              <tr>
                <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Ending balance as of June 30, 2026</strong></span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;border-bottom:2.25pt double #000000;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;border-bottom:2.25pt double #000000;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="F20260321061347347_22" name="us-gaap:DebtCurrent" contextRef="C_20260630_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember" unitRef="USD" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;border-bottom:2.25pt double #000000;width:2%;background-color:#e6efff">&#160;</td>
              </tr>

          </table>
        </div>
      </ix:nonNumeric>
      <div>
        <ix:nonNumeric id="Fxbrl_20260810174251326" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" contextRef="C_20260101to20260630" escape="true">
          <div>
            <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
            <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

                <tr>
                  <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Note A issued on May 27, 2026:</strong></span></span></td>
                  <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30, 2026</strong></span></span></td>
                  <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds of Note A</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810115824309" name="us-gaap:ProceedsFromNotesPayable" contextRef="C_20260101to20260630_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">12,864,225</ix:nonFraction></span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Discount on debt</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260810115904324" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="C_20260630_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">864,225</ix:nonFraction></span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Debt issuance costs</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260810115933474" name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="C_20260101to20260630_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">349,091</ix:nonFraction></span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest accretion</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810115955476" name="us-gaap:InterestExpenseDebt" contextRef="C_20260101to20260630_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">79,257</ix:nonFraction></span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Ending balance</strong></span></span></td>
                  <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;border-bottom:2.25pt double #000000;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                  <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;border-bottom:2.25pt double #000000;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810120017545" name="us-gaap:NotesPayable" contextRef="C_20260630_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">11,730,166</ix:nonFraction></span></span></td>
                  <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;border-bottom:2.25pt double #000000;width:2%;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Note B issued on May 27, 2026:</strong></span></span></td>
                  <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30, 2026</strong></span></span></td>
                  <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds of Note B</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810115850550" name="us-gaap:ProceedsFromNotesPayable" contextRef="C_20260101to20260630_usgaapDebtInstrumentAxis_mdcxNoteBMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Debt issuance costs</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260810115924469" name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="C_20260101to20260630_usgaapDebtInstrumentAxis_mdcxNoteBMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">265,909</ix:nonFraction></span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest accretion</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810120007773" name="us-gaap:InterestExpenseDebt" contextRef="C_20260101to20260630_usgaapDebtInstrumentAxis_mdcxNoteBMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">18,286</ix:nonFraction></span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Ending balance</strong></span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                  <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260810120033798" name="us-gaap:NotesPayable" contextRef="C_20260630_usgaapDebtInstrumentAxis_mdcxNoteBMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">9,752,376</ix:nonFraction></span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
                </tr>

            </table>
          </div>
        </ix:nonNumeric>
      </div>
      <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</p>
      <div><ix:exclude>
        <div><div><div style="text-align:center"><span style="width:34%;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">9</span></span></span></div></div></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%;margin-bottom:10pt;margin-top:10pt"/>
      </ix:exclude></div>
      <div style="margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">As of June 30, 2026, accrued interest of $<ix:nonFraction id="Fxbrl_20260810113217371" name="us-gaap:InterestPayableCurrent" contextRef="C_20260630_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">81,426</ix:nonFraction> related to the promissory notes was included in accounts payable on the condensed consolidated balance sheet, with the corresponding amount recognized in interest expense in the condensed consolidated statement of operations and comprehensive loss.</span></span></p>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20260810014026005" name="us-gaap:RestrictedAssetsDisclosureTextBlock" contextRef="C_20260101to20260630" escape="true">
    <div>
      <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>12. Restricted Cash</strong></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2026, cash of US$<ix:nonFraction id="Fxbrl_20260810014041940" name="us-gaap:RestrictedCashCurrent" contextRef="C_20260630_usgaapDebtInstrumentAxis_mdcxNoteBMember" unitRef="USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction> million was held in a restricted deposit account maintained by a subsidiary of the Company pursuant to the Deposit Account Control Agreement entered into in connection with the Note B financing. The funds are subject to a first-ranking security interest in favour of the lender and are not available for general corporate purposes except in accordance with the financing arrangements. Accordingly, the balance has been presented as restricted cash in the condensed interim consolidated statement of financial position.</span></span></p>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20260509031047316" name="mdcx:LiquidityTextBlock" contextRef="C_20260101to20260630" escape="true">
    <div>
      <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>13. Liquidity and Going Concern</strong></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. In addition to the ATM, SEPA and Debenture (as defined herein), management believes that the Company has access to additional capital resources through public and/or private equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, it is possible that the Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. Further, the terms of any financing may adversely affect the holdings or the rights of the Company's shareholders. If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays or entirely prevent the Company's continued efforts to progress its research and development program, pursue product portfolio expansion or commercialize its current or future products, each of which is critical to the realization of the Company's business plan and its future operations. This uncertainty, along with the Company's history of losses, indicates that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. The financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is subject to risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company's research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable.</span></span></p>
    </div>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20260812123257109" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_20260101to20260630" escape="true">
    <div>
      <p style="margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>14.</strong>&#160;<strong>Loss per share</strong></span></span></p>
      <p style="margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows:</span></span></p>
      <ix:nonNumeric id="Fxbrl_20260812123321374" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_20260101to20260630" escape="true">
        <table cellpadding="0" cellspacing="0" style="font-size:10pt;border-collapse:collapse;width:100%;border-color:#000000">

            <tr>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td colspan="4" style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Three Months Ended June 30,</strong></span></span></td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td colspan="4" style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Six Months Ended June 30,</strong></span></span></td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2026</strong></span></span></td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2025</strong></span></span></td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2026</strong></span></span></td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2025</strong></span></span></td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Net loss attributable to shareholders</strong></span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260812123408401" name="us-gaap:NetIncomeLoss" contextRef="C_20260401to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">11,617,705</ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260812123424680" name="us-gaap:NetIncomeLoss" contextRef="C_20250401to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">6,176,084</ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260812123436467" name="us-gaap:NetIncomeLoss" contextRef="C_20260101to20260630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">20,659,848</ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260812123614310" name="us-gaap:NetIncomeLoss" contextRef="C_20250101to20250630" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal" sign="-">11,278,492</ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
            </tr>
            <tr>
              <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Weighted average number of common shares outstanding </strong></span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260812123636698_xbrl_20260812123408401" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20260401to20260630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">55,055,225</ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260812123636698_xbrl_20260812123424680" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20250401to20250630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">14,284,261</ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260812123636698_xbrl_20260812123436467" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20260101to20260630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">47,566,945</ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260812123636698_xbrl_20260812123614310" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20250101to20250630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">13,853,305</ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Basic and diluted net loss per share attributable to shareholders</strong></span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260812124007459" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20260401to20260630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fxbrl_20260812123639038_xbrl_20260812123408401" name="us-gaap:EarningsPerShareBasic" contextRef="C_20260401to20260630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.21</ix:nonFraction></ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260812124022429" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20250401to20250630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fxbrl_20260812123639038_xbrl_20260812123424680" name="us-gaap:EarningsPerShareBasic" contextRef="C_20250401to20250630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.43</ix:nonFraction></ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260812124050854" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20260101to20260630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fxbrl_20260812123639038_xbrl_20260812123436467" name="us-gaap:EarningsPerShareBasic" contextRef="C_20260101to20260630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.43</ix:nonFraction></ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20260812124058038" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20250101to20250630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="Fxbrl_20260812123639038_xbrl_20260812123614310" name="us-gaap:EarningsPerShareBasic" contextRef="C_20250101to20250630" unitRef="USD_Per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal" sign="-">0.81</ix:nonFraction></ix:nonFraction></span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
            </tr>

        </table>
      </ix:nonNumeric>
      <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
      <p style="text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:10pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">The Company's potentially dilutive securities as of June 30, 2026 and 2025, include stock options, warrants, and debentures. The Company excluded the potential ordinary shares outstanding at each period end from the computation of diluted net loss per share attributable to ordinary shareholders for the period ended June 30, 2026 and 2025 because including them would have had an anti-dilutive effect.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:</span></span></p>
    </div>
    <ix:nonNumeric id="Fxbrl_20260812123332775" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_20260101to20260630" escape="true">
      <div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-size:10pt;border-collapse:collapse;width:100%;border-color:#000000">

                <tr>
                  <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
                  <td colspan="1" style="vertical-align:bottom">&#160;</td>
                  <td colspan="4" style="vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>For the Period Ended</strong></span></span></td>
                  <td colspan="1" style="vertical-align:bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30, 2026</strong></span></span></td>
                  <td style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30, 2025</strong></span></span></td>
                  <td style="vertical-align:bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock options</span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260812123410224" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20260101to20260630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mdcxStockOptionsMember" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">5,510,000</ix:nonFraction></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260812123540584" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20250101to20250630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mdcxStockOptionsMember" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">1,285,000</ix:nonFraction></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants</span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260812123457576" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20260101to20260630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">7,281,795</ix:nonFraction></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260812123557337" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20250101to20250630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">4,596,795</ix:nonFraction></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Debentures</span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260812123532496" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20260101to20260630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mdcxDebenturesMember" unitRef="Share" scale="0" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20260812123600848" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20250101to20250630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mdcxDebenturesMember" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260812123505336" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20260101to20260630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">12,791,795</ix:nonFraction></strong></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><ix:nonFraction id="Fxbrl_20260812123604792" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20250101to20250630" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">10,881,795</ix:nonFraction></strong></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                </tr>

            </table>
          </div>
        </div>
      </div>
    </ix:nonNumeric>
    <p style="text-align:justify;margin-top:0pt;margin-bottom:0pt">&#160;</p>
  </ix:nonNumeric>

  <ix:nonNumeric id="Fxbrl_20260810014241249" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_20260101to20260630" escape="true">
    <div>
      <p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>15.</strong>&#160;<strong>Subsequent events</strong></span></span></p>
      <div>
        <p style="margin-top:10pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Subsequent to the period ended June 30, 2026, the Company completed sales under its ATM pursuant to which it issued <ix:nonFraction id="Fxbrl_20260321152020250" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20260701to20260731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="Share" scale="0" decimals="0" format="ixt:num-dot-decimal">2,812,566</ix:nonFraction> common shares for gross proceeds of approximately $<ix:nonFraction id="Fxbrl_20260321143243804" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20260701to20260731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">840,471</ix:nonFraction> or approximately $<ix:nonFraction id="Fxbrl_20260321152044696" name="mdcx:ProceedsFromCommonSharesNetOfCommissionsPayableToAgents" contextRef="C_20260701to20260731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" unitRef="USD" scale="0" decimals="0" format="ixt:num-dot-decimal">815,257</ix:nonFraction> after incurring commissions payable to the Agents.</span></span></p>
      </div>
    </div>
  </ix:nonNumeric>
  <div>
    <p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10</span></span></p>
  </div>
  <hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/>
  <p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_23"><!-- anchor --></span></span></span></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</strong></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>This Item and other sections of this Quarterly Report contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. When reviewing the discussion below, you should keep in mind the substantial risks and uncertainties that impact our business. In particular, we encourage you to review the risks and uncertainties described in "Risk Factors" in Part I, Item 1A in the 2025 Annual Report and Part II, Item 1A of this Quarterly Report. These risks and uncertainties could cause actual results to differ materially from those projected or implied by our forward-looking statements contained in this Quarterly Report. These forward-looking statements are made as of the date of this Quarterly Report, and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. All amounts are expressed in United States dollars unless otherwise stated. This discussion should be read in conjunction with the Company's interim unaudited condensed consolidated financial statements for the three&#160; and six months ended June 30, 2026 and 2025.</i></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Company Overview</strong></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Medicus Pharma Ltd. (the "Company") is a clinical stage, multi-strategy, biotech/life sciences company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The Company looks into opportunities across all therapeutic areas where an unmet need exists for improved patient safety and efficacy. The Company is opportunistically exploring to expand its drug development pipeline through qualified and accretive acquisitions and partnerships.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has three wholly owned subsidiaries, Medicus Pharma Inc., a company incorporated in the state of Delaware on October 12, 2023, SkinJect, Inc. ("SkinJect"), a company incorporated in the state of Pennsylvania on March 3, 2015 and, for purposes of engaging in the Secured Promissory Notes (as defined below) transactions, MDCX Holdings, LLC, a limited liability company organized in the state of Utah on May 19, 2026.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company also has one non-wholly owned subsidiary, Antev Limited ("Antev"), a company formed in England and Wales, of which it owns 98.6% of the issued and outstanding shares.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SkinJect is focused on the development of a novel "innovation combination product", as an investigational new drug, using uniquely designed, patent protected dissolvable microneedle arrays ("C-MNA" or "P-MNA") and doxorubicin containing dissolvable microneedle arrays ("D-MNA") for the treatment of certain skin cancers. To that end, the Company licensed certain technology co-developed by the University of Pittsburgh and Carnegie Mellon University. The Company established and validated fabrication processes relative to the C-MNAs or P-MNAs and D-MNAs, completed pre-clinical testing and secured approval to proceed with clinical trials activity from the Food and Drug Administration ("FDA").</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has advanced SkinJect through a multi-stage clinical program. An initial Phase 1 dose-escalation study ("SKNJCT-001") established that the D-MNA patch was well tolerated with no dose-limiting toxicity in patients with basal cell carcinoma ("BCC"). The Company also initiated a study ("SKNJCT-002") to evaluate device penetration in healthy volunteers, but paused the study after enrolling seven of a planned 15 subjects due to variability in array application and ultimately closed the study without further enrollment - no adverse events were reported. The Company also conducted a Phase 2 study ("SKNJCT-003") which was a randomized, double-blinded, three arm study evaluating two dose levels of D-MNA compared with a device-only control (C-MNA or P-MNA) in patients with nodular type basal cell carcinoma ("nBCC"). The SKNJCT-003 study, conducted across sites in the United States and in Europe, reported topline results in March 2026 showing 73% clinical clearance and 40% histological clearance in the D-MNA arm compared to 38% clinical clearance in the device-only P-MNA arm in the 200-&#181;g patient cohort at Day 57 of the study. The Company provided further updates on the results of the SKNJCT-003 study in June 2026, showing 55% histological clearance and 64% clinical clearance in patients in the 200 ug cohort that were treated with SkinJect. The Company is conducting a separate Phase 2 study in the United Arab Emirates ("SKNJCT-004") and, in September 2025, gained FDA alignment to pursue the 505(b)(2) regulatory pathway to treat BCC using D-MNA.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is separately pursuing SkinJect as a treatment for Gorlin Syndrome (Nevoid Basal Cell Carcinoma Syndrome), a rare inherited genetic disorder associated with lifelong development of multiple basal cell carcinomas and recurrent skin cancers. In support of this program, the Company is pursuing a registrational Phase 2b study design ("SKNJCT-005") and filed applications for Orphan Drug Designation and Rare Pediatric Disease Designation.</span></span></p><div><p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11</span></span></p></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/><p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_24"><!-- anchor --></span></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In August 2025, the Company completed its acquisition of Antev, a UK-based clinical biotech company developing Teverelix, a next-generation gonadotropin-releasing hormone ("GnRH") antagonist, as a first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention ("AUR") episodes due to enlarged prostate. The Company has received FDA clearance to proceed with a Phase 2b dose-optimization study of Teverelix in men with advanced prostate cancer ("APC") and has submitted an optimized Phase 2 study design for the prevention of recurrent AUR in men with benign prostatic hyperplasia. The Company has also submitted an investigational new drug application to the United Arab Emirates ("UAE") Department of Health, Abu Dhabi ("DOH") for its planned PRECISION-E2 study, a first-of-its-kind, Phase 2a genomics-enabled clinical trial, that will evaluate Teverelix in women with symptomatic endometriosis in the UAE.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company continues to engage with the FDA and international regulators to advance these programs toward registrational development and to pursue further developmental opportunities.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Recent Developments</strong></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 6, 2026, the Company announced its submission of an optimized Phase 2 clinical study design to the FDA for Teverelix, for the prevention of recurrent AUR in men with benign prostatic hyperplasia as part of the Company's existing open investigational new drug for Teverelix.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 17, 2026, the Company announced its submission of an orphan drug designation application to the FDA for SkinJect for the treatment of BCC in patients with Gorlin Syndrome, a rare genetic disorder characterized by the development of multiple, recurrent skin cancers.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 21, 2026, the Company received written notice from the Listing Qualifications Department of Nasdaq, notifying the Company that the closing bid price for the common shares had been below $1.00 per share for the previous 30 consecutive business days, and that the Company is therefore not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with the Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until October 19, 2026, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the common shares must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-day period. The notice has no immediate effect on the listing or trading of the common shares on the Nasdaq Capital Market.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 6, 2026, the Company announced results from a pre-specified expanded dataset analysis demonstrating positive dose response from its Phase 2 SKNJCT-003 study evaluating safety and efficacy of D-MNA to treat nBCC of the skin, the most common type of skin cancer. This additional pre-specified analysis, builds upon the previously reported positive topline results, provides expanded biological, histologic, and safety insights that further strengthen SkinJect's therapeutic profile and future registrational discussions with the FDA. The expanded analysis showed clear and consistent dose response relationship across endpoints, demonstrating stronger separation between the 200ug cohort and control, particularly at Day 57. These additional findings are also consistent with prior Phase 1 clinical observations in the SKNJCT-001 study in March 2021, and interim analysis of SKNJCT-003 in March 2025, reinforcing reproducibility across studies.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 3, 2026, the Company announced its submission of Protocol SKNJCT-005 to the FDA under the Company's existing Investigational New Drug ("IND") application, for SkinJect into registrational development for patients with Gorlin Syndrome, also called Nevoid Basal Cell Carcinoma Syndrome, a rare inherited genetic disorder associated with lifelong development of multiple basal cell carcinomas and recurrent skin cancers, often resulting in repeated surgical procedures. The submitted protocol outlines a Phase 2b, open-label study designed to generate efficacy and safety data intended to support a future new drug application for SkinJect in Gorlin Syndrome.</span></span></p><div><p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12</span></span></p></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/><p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_25"><!-- anchor --></span></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 8, 2026, the Company announced its submission of a substantial modification application through the European Union Clinical Trials Information System supporting the planned Phase 2b study of Teverelix in APC. The planned Phase 2b study is designed to optimize dose selection and further characterize the pharmacokinetic, pharmacodynamic, efficacy and safety profile of Teverelix ahead of planned registrational development. Medicus has previously engaged extensively with the FDA regarding its APC development strategy, including future studies focused on patients with elevated cardiovascular risk.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 11, 2026, the Company announced its submission of an IND application to the DOH for PRECISION-E2, a first-of-its-kind, Phase 2a genomics-enabled clinical trial evaluating Teverelix in women with symptomatic endometriosis in the UAE. The PRECISION-E2 study is designed to combine clinical outcomes, hormonal biomarkers, pharmacokinetic and pharmacodynamic measurements, and genomic analyses to better understand treatment response variability in women suffering from endometriosis.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 15, 2026, the Company announced its submission of Rare Pediatric Disease Designation ("RPDD") request to the FDA for SkinJect, the Company's investigational D-MNA patch, for the treatment of BCC in patients with Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome. The RPDD submission was made pursuant to Section 529 of the Federal Food, Drug, and Cosmetic Act and follows the Company's previously announced Orphan Drug Designation ("ODD") application (DRU-2026-11578), and Registrational study design (SKNJCT-005) which remains under FDA review. The design of the Company's Gorlin Syndrome development program has been informed through engagement with clinical experts and the Gorlin Syndrome Alliance, a patient advocacy group focused on the needs and priorities of this unique patient population.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 24, 2026, the Company participated in the 2026 Bio International Conference in San Diego, California, where Dr. Faisal Mehmud, Chief Medical Officer of Medicus, delivered a company presentation highlighting clinical, regulatory and strategic advancements across the Company's development portfolio. The presentation included, among other updates, the updated positive decision-grade dataset from the Phase 2 SKNJCT-003 study, which demonstrated a clear dose-response relationship and clinically meaningful complete response rates (55% histological clearance and 64% clinical clearance) in patients in the 200 ug cohort that were treated with SkinJect.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On July 16, 2026, the Company announced it received written feedback from the FDA and central Institutional Review Board approval, with modifications, for its optimized Phase 2 clinical study of Teverelix in men following a first episode of AUR. The Company submitted the optimized protocol to the FDA on April 2, 2026, under its existing IND application for Teverelix. The redesigned study is expected to enroll approximately 126 patients across the United States and Europe, compared with approximately 390 patients contemplated under the Company's previously disclosed development plan, and is intended to generate an early pharmacodynamic signal while supporting dose optimization, route selection and future clinical development.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On July 27, 2026, the Company announced that the FDA completed its safety review of the Company's IND application for SKNJCT-005 and issued a "Study May Proceed" letter authorizing the initiation of the Company's NDA-enabling registrational Phase 2b clinical study evaluating SkinJect 200 mcg in patients with Gorlin Syndrome presenting with multiple BCCs.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On July 31, 2026, the Company announced that the UAE DOH has granted IND authorization for the Company's PRECISION-E2 Phase 2a clinical study evaluating Teverelix in women with moderate-to-severe symptomatic endometriosis.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 3, 2026, the Company announced the appointment of Faisal Mehmud, MD, MRCP, as chief executive officer of Antev, effective August 30, 2026. Dr. Mehmud will continue to serve as Chief Medical Officer of Medicus and Co-Chairman of Antev.</span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i><strong>Share Consolidation</strong></i></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 25, 2024, the Company's shareholders approved an amendment to the Company's articles of incorporation to provide for a share consolidation (the "Share Consolidation"), or reverse stock split, of the Company's issued and outstanding common shares at such a consolidation ratio to be determined by the Company's board of directors in its sole discretion, to permit the Company to satisfy all conditions and necessary regulatory approvals to list the common shares on a U.S. national securities exchange as the Company's board of directors may determine in its sole discretion. Our board of directors approved the Share Consolidation on October 15, 2024, and the Share Consolidation was completed by the Company on October 28, 2024, at the ratio of 1-for-2.</span></span></p><div><p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></p></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/><p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_26"><!-- anchor --></span></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">After the completion of the Share Consolidation, the number of the Company's issued and outstanding common shares decreased from 21,693,560 to 10,846,721. The par value of the Company's common shares remains unchanged at $0 per share after the Share Consolidation. The Share Consolidation was completed in preparation for a U.S. listing.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 3, 2026, at the Company's 2026 Annual General and Special Meeting of shareholders, the Company's shareholders approved a special resolution authorizing the Board, in its discretion, to effect a consolidation of the Company's common shares on the basis of a consolidation ratio to be determined by the Board, up to a maximum ratio of 50 pre-consolidation common shares for every one post-consolidation Common Share, if the Board determines such a consolidation is necessary or desirable, including, without limitation, for the purpose of meeting any applicable stock exchange or regulatory requirements. As of the date hereof, the Board has neither effected such share consolidation nor announced an intention to do so.</span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i><strong>Initial Public Offering</strong></i></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On November 14, 2024, the Company completed its initial public offering with the sale of 970,000 Units at the price of $4.125 per Unit, with each Unit (the "Unit") consisting of one common share and one warrant (the "Public Warrants" and with the Regulation A Warrants and the June 2030 Warrants, each as defined below, the "Warrants"). The Public Warrants expire five years from their date of issuance on November 15, 2029. In addition, the underwriters exercised an option to purchase 145,500 Public Warrants (the "Overallotment Warrants") at a price of $0.01 per warrant.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total gross proceeds from our initial public offering were $4.0 million, including the proceeds from the Overallotment Warrants. The Company incurred total issuance costs of $2.1 million, including underwriter fees, and legal and other professional fees incurred directly related to the issuance. No Public Warrants issued as part of our initial public offering were exercised during the three and six months ended June 30, 2026.</span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i><strong>Regulation A Offering</strong></i></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On March 10, 2025, the Company completed an offering (the "Regulation A Offering") of 1,490,000 units at $2.80 per unit pursuant to Tier II of Regulation A under the Securities Act, with each unit consisting of one common share and one warrant (each, a "Regulation A Warrant"). The Regulation A Warrants have an exercise price of $2.80 and expire on March 10, 2030. The aggregate gross proceeds to the Company from the Regulation A Offering were $4.2 million. No Regulation A Warrants were exercised during the three and six months ended June 30, 2026.</span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i><strong>Debentures</strong></i></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 2, 2025, the Company entered into a securities purchase agreement with YA II PN, Ltd. ("Yorkville"), under which the Company has issued and sold three debentures (the "Initial Debentures") to Yorkville in an aggregate principal amount totaling $5,000,000. The Initial Debentures were issued at a discounted price of 90% for proceeds to the Company of $4,500,000. Interest accrued on the outstanding principal amount of each Initial Debenture at an annual rate of 8%, subject to a potential increase to 18% per annum upon the occurrence of certain events of default. The Initial Debentures had a maturity date of February 2, 2026.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On September 17, 2025, the Company entered into a securities purchase agreement with Yorkville to issue a new debenture (the "Debenture") with the principal amount of $8,000,000 issued at a discount of $633,707 for proceeds of approximately $7,366,293. Interest accrued on the outstanding principal amount of the Debenture at an annual rate of 8%, subject to a potential increase to 18% per annum upon the occurrence of certain events of default. The Debenture had a maturity date of September 17, 2026 and was to be partially repaid using proceeds from the SEPA (as defined below). On May 27, 2026, the Company used part of the proceeds of its issuance of the Secured Promissory Notes to repay and extinguish the outstanding balance and accrued interest owing on the Debenture.</span></span></p><div><p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14</span></span></p></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/><p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_27"><!-- anchor --></span></span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i><strong>June 2025 Public Offering</strong></i></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 2, 2025, the Company closed a public offering with gross proceeds of $7.0 million (the "June 2025 Public Offering"). The Company issued 2,260,000 units at a price of $3.10 per unit. Each unit consisted of one common share of the Company and one warrant to purchase one common share (the "June 2030 Warrants"). The June 2030 Warrants have an exercise price of $3.10 per share and will expire on June 2, 2030. No June 2030 Warrants were exercised during the three and six months ended June 30, 2026.</span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i><strong>Warrant Inducement</strong></i></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On July 14, 2025, the Company entered into a warrant inducement agreement (the "Warrant Inducement Agreement") with an institutional investor, pursuant to which the investor agreed to exercise existing Regulation A Warrants to purchase up to 1,340,000 of the Company's common shares issued on March 10, 2025 and with an exercise price of $2.80 per common share, in consideration for receiving the 2,680,000 warrants (the "Series A and B Warrants") with an exercise price of $3.75. In accordance with the Warrant Inducement Agreement, the investor exercised its existing warrants for cash, for gross proceeds of $3.8 million to the Company.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 5, 2025, the Company entered into a warrant inducement agreement with an institutional investor (the "Second Warrant Inducement Agreement"), pursuant to which the investor agreed to exercise existing Series A and B Warrants to purchase up to 2,680,000 of the Company's common shares issued on July 14, 2025 with an amended exercise price of $1.92 per common share, in consideration for receiving 4,020,000 warrants (the "Series C and D Warrants") with an exercise price of $2.00. In accordance with the Second Warrant Inducement Agreement, the investor exercised its existing warrants for cash, for gross proceeds of approximately $5.1 million to the Company.</span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i><strong>At-The-Market Program</strong></i></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 29, 2025, we entered into an equity distribution agreement (the "Equity Distribution Agreement") with Maxim Group LLC and Yorkville Securities, LLC, an affiliate of Yorkville as agents (together, the "Agents"), whereby the Agents may sell up to $15.3 million of our common shares as part of an at-the-market program (the "ATM"). On April 23, 2026, the Company and the Agents entered into an amendment to the Equity Distribution Agreement, up-sizing the ATM program from $15.3 million to up to $50 million.</span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i><strong>Secured Promissory Notes</strong></i></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On May 27, 2026, the Company entered into and closed on a note purchase agreement with Streeterville Capital, LLC, providing for the issuance of two secured promissory notes: (i) a Secured Promissory Note A in the original principal amount of $12,864,225 carrying an 8.75% interest rate and a 6.7% original issue discount (the &#8220;Note A&#8221;) and (ii) a Secured Promissory Note B in the original principal amount of $10,000,000 carrying a 5% interest rate with no original issue discount (the &#8220;Note B&#8221; and together with the Note A, the &#8220;Secured Promissory Notes&#8221;). The Secured Promissory Notes will mature on November 27, 2027.</span></span></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Results of Operations</strong></span></span></p><div><div><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The following table outlines our statements of loss and comprehensive loss for the three and six months ended June 30, 2026 and 2025:</span></span></p><table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000"><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td colspan="1" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap">&#160;</td><td colspan="4" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Three months ended </strong><br/><strong>June 30,</strong></span></span></td><td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td colspan="1" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap">&#160;</td><td colspan="4" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Six months ended</strong><br/><strong>June 30,</strong></span></span></td><td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>2026</strong></span></span></td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>2025</strong></span></span></td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>2026</strong></span></span></td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>2025</strong></span></span></td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Change</strong></span></span></td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Change</strong></span></span></td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">General and administrative</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">6,571,097</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">4,576,524</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1,994,573</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">12,463,781</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">7,696,584</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">4,767,197</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Research and development</span></span></td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">4,907,692</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1,439,564</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">3,468,128</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">7,612,085</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">3,445,778</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">4,166,307</span></span></td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:2%;text-align:left">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Total operating expenses</strong></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">11,478,789</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">6,016,088</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5,462,701</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">20,075,866</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">11,142,362</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">8,933,504</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Loss from operations</strong></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(11,478,789</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(6,016,088</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(5,462,701</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(20,075,866</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(11,142,362</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(8,933,504</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Other income (expense)</strong>:</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Finance income</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">40,004</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(40,004</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">63,870</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(63,870</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Interest expense</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(205,638</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(205,638</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(523,789</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(523,789</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Loss on SEPA settlements</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(127,083</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(127,083</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Change in fair value of debentures and secured promissory notes</span></span></td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(200,000</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">200,000</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(200,000</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">200,000</span></span></td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:2%;text-align:left;background-color:#e6efff">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Total other income (expense)</strong></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(205,638</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(159,996</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(45,642</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(650,872</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(136,130</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(514,742</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Net loss for the period</strong></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(11,684,427</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(6,176,084</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(5,508,343</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(20,726,738</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(11,278,492</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(9,448,246</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Foreign currency translation adjustment</span></span></td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">255,177</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">255,177</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">50,928</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">50,928</span></span></td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:2%;text-align:left">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Comprehensive loss for the period</strong></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(11,429,250</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(6,176,084</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(5,253,166</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(20,675,810</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(11,278,492</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(9,397,318</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Net loss per common share (basic and diluted)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(0.21</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(0.43</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.22</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(0.43</span></span></td><td style="margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(0.81</span></span></td><td style="margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-bottom:0pt;vertical-align:bottom;width:8%;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.38</span></span></td><td style="margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left">&#160;</td></tr></table></div></div><p style="margin-top:0pt;margin-bottom:0pt">&#160;</p><div><p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15</span></span></p></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/><p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_28"><!-- anchor --></span></span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i><strong>General and administrative</strong></i></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative expenses increased by $1,994,573 or 43.6% for the three months ended June 30, 2026, compared to the three months ended June 30, 2025, and increased by $4,767,197 or 61.9% for the six months ended June 30, 2026, compared to the six months ended June 30, 2025. This increase was primarily due to an increase in consulting fees, salaries and wages with increased headcount at board and management level and fees, expenses related to business development and investor relations and stock-based compensation. General and administrative expenses primarily include professional fees, consulting fees, salaries, wages and benefits, general office, insurance, administration expenditures, costs related to business development and investor relations, public relations, market awareness, advocacy and stock-based compensation associated with maintaining investor relations, public relations, market awareness, advocacy, director and officer insurance and compliance with applicable securities law requirements. In addition, there are additional costs, recurring and non-recurring, associated with increased regulatory requirements following the Company's initial public offering, transition to U.S. domestic issuer status, multiple financing transactions and the Antev acquisition.</span></span></p><div><div><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i><strong>Research and development ("R&amp;D")</strong></i></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses consist of costs incurred to research and develop our product candidates and are expensed as incurred. We do not track total R&amp;D expense by program, therapeutic indication or product candidate, as our internal resources are shared across programs and our development priorities shift over time. We separately identify external costs that are directly attributable to the SkinJect and Teverelix programs, which primarily include costs related to clinical, manufacturing, and regulatory activities, as well as certain professional services and intellectual property costs. Internal personnel costs (salaries and benefits, including share-based compensation) are shared across programs, are not attributable to a single product candidate, and are presented as unallocated. Of the total research and development expense noted in the table below, the external, third-party costs that were directly attributable to our product candidates were as follows:</span></span></p><table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000"><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td><td colspan="7" style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Six months ended June 30, 2026</strong></span></span></td><td colspan="1" style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>($) - External R&amp;D costs</strong></span></span></td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>SkinJect</strong></span></span></td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Teverelix</strong></span></span></td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total</strong></span></span></td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Clinical, manufacturing and regulatory activities</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,011,288</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,850,023</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,861,311</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Professional services and intellectual property</span></span></td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">145,227</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">78,341</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">223,567</span></span></td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:2%;text-align:left">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total external costs directly attributable</strong></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2,156,515</strong></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>3,928,364</strong></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>6,084,879</strong></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Salaries and benefits</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,527,207</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total research and development expense (1)</strong></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>7,612,085</strong></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td></tr></table><p style="margin-top:0pt;margin-bottom:0pt">&#160;</p><div><p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">16</span></span></p></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/><p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_29"><!-- anchor --></span></span></span></p><table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000"><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td colspan="1" style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td><td colspan="4" style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Six months ended June 30,<br/>2025</strong></span></span></td><td colspan="1" style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>($) - External R&amp;D costs</strong></span></span></td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>SkinJect</strong></span></span></td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total</strong></span></span></td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Clinical, manufacturing and regulatory activities</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,453,931</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,453,931</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Professional services and intellectual property</span></span></td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:12%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">116,678</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:12%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">116,678</span></span></td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:2%;text-align:left">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total external costs directly attributable</strong></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2,570,609</strong></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2,570,609</strong></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Salaries and benefits</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:12%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:12%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">875,169</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total research and development expense (1)</strong></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>3,445,778</strong></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td></tr></table><table cellpadding="0" cellspacing="0" style="font-size:10pt;border-collapse:collapse;width:100%;border-color:#000000"><tr><td style="vertical-align:bottom">&#160;</td><td colspan="1" style="vertical-align:bottom">&#160;</td><td colspan="7" style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Three months ended June 30, 2026</strong></span></span></td><td colspan="1" style="vertical-align:bottom">&#160;</td></tr><tr><td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>($) &#8211; External R&amp;D costs</strong></span></span></td><td style="vertical-align:bottom">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>SkinJect</strong></span></span></td><td style="vertical-align:bottom;text-align:center">&#160;</td><td style="vertical-align:bottom;text-align:center">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Teverelix</strong></span></span></td><td style="vertical-align:bottom;text-align:center">&#160;</td><td style="vertical-align:bottom;text-align:center">&#160;</td><td style="vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total</strong></span></span></td><td style="vertical-align:bottom">&#160;</td></tr><tr><td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Clinical, manufacturing and regulatory activities</span></span></td><td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,268,747</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,927,793</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,196,540</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td></tr><tr><td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Professional services and intellectual property</span></span></td><td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">96,653</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">46,169</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">142,822</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td></tr><tr><td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total external costs directly attributable</strong></span></span></td><td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1,365,400</strong></span></span></p></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2,973,962</strong></span></span></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>4,339,362</strong></span></span></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td></tr><tr><td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Salaries and benefits</strong></span></span></td><td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">568,329</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td></tr><tr><td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total research and development expense (1)</strong></span></span></td><td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>4,907,692</strong></span></span></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td></tr></table><p style="margin-top:0pt;margin-bottom:0pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font-size:10pt;border-collapse:collapse;width:100%;border-color:#000000"><tr><td style="vertical-align:bottom">&#160;</td><td colspan="1" style="vertical-align:bottom">&#160;</td><td colspan="4" style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Three months ended June<br/>30, 2025</strong></span></span></td><td colspan="1" style="vertical-align:bottom">&#160;</td></tr><tr><td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>($) &#8211; External R&amp;D costs</strong></span></span></td><td style="vertical-align:bottom">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">SkinJect</span></span></td><td style="vertical-align:bottom;text-align:center">&#160;</td><td style="vertical-align:bottom;text-align:center">&#160;</td><td style="vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total</strong></span></span></td><td style="vertical-align:bottom">&#160;</td></tr><tr><td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Clinical, manufacturing and regulatory activities</span></span></td><td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,011,362</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,011,362</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td></tr><tr><td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Professional services and intellectual property</span></span></td><td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:12%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">71,561</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:12%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">71,561</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td></tr><tr><td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total external costs directly attributable</strong></span></span></td><td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1,082,923</strong></span></span></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1,082,923</strong></span></span></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td></tr><tr><td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Salaries and benefits</strong></span></span></td><td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:12%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:12%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">356,641</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td></tr><tr><td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total research and development expense (1)</strong></span></span></td><td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1,439,564</strong></span></span></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td></tr></table><p style="margin-left:40pt;text-indent:-20pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1)<span style="display:inline-block;width:8pt">&#160;</span>Total research and development expense reconciles to the amount reported on the Company's consolidated statements of operations for each period presented.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">R&amp;D expenses increased by $4,166,307 or 120.9% for the six months ended June 30, 2026, compared to the six months ended June 30, 2025. This increase is primarily due to the development of Teverelix, offset with a reduction in costs relating to SkinJect as we come to the end of its Phase 2 trials. We expect our R&amp;D expenses to increase going forward with the costs of two separate Phase 2 trials associated with Teverelix advancing.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The principal risks related to the Company's future performance are that the trials are unsuccessful, the Company does not receive FDA approval to proceed with the next stages of its multiple research and development tracks, or the Company is unsuccessful in obtaining future funding needed to continue its research and development tracks. These are customary risks for a development stage pharmaceutical Company and are less acute than for a Company with a less advanced product. Nevertheless, there can be no assurance that the Company will be able to complete its trials, that the trials will be successful, or that the product will ultimately reach commercialization.</span></span></p></div></div><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i><strong>Other income (expense)</strong></i></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other income (expense) for the three and six months ended June 30, 2026, was an expense of $205,638 and $650,872, respectively, compared to an expense of $159,996 and $136,130 for the three and six months ended June 30, 2025, respectively. Other income (expense) for the three and six months ended June 30, 2026 is primarily related to interest expense of $205,638 and $523,789, respectively, a loss on SEPA settlements of $nil and $127,083, respectively. Other income (expense) for the three and six months ended June 30, 2025 consisted primarily of finance income of $40,004 and $63,870, respectively, more than offset by a $200,000 change in the fair value of debentures recognized in each period.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Liquidity and Capital Resources</strong></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We are a clinical stage development company, and we currently do not earn any revenues from our drug development programs and are therefore considered to be in the R&amp;D stage. As required, the Company will continue to finance its operations through the sale of equity or pursue alternative funding sources available to the Company in the future. The continuation of our R&amp;D activities is dependent on our ability to obtain financing.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The financial statements and this Management's Discussion and Analysis of Financial Condition and Results of Operations (this "MD&amp;A") have been prepared on the basis of accounting principles applicable to a going concern, which assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations.</span></span></p><div><p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">17</span></span></p></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/><p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_30"><!-- anchor --></span></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. In addition to the ATM, SEPA and Secured Promissory Notes (as defined herein), management believes that the Company has access to additional capital resources through public and/or private equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, it is possible that the Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. Further, the terms of any financing may adversely affect the holdings or the rights of the Company's shareholders. If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays or entirely prevent the Company's continued efforts to progress its research and development program, pursue product portfolio expansion or commercialize its current or future products, each of which is critical to the realization of the Company's business plan and its future operations. This uncertainty, along with the Company's history of losses, indicates that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. The financial statements and this MD&amp;A do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is subject to risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company's research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2026, the Company had cash and cash equivalents of $15,174,128 and restricted cash of $10,017,412 compared to cash and cash equivalents of $8,705,218 and restricted cash of $nil as of December 31, 2025. During the six months ended June 30, 2026, the Company received $21,385,000 of net proceeds from the issuance of the Secured Promissory Notes, $12,399,815 of net proceeds from the issuance of common shares under the ATM and $4,102,740 of proceeds from the issuance of common shares under the SEPA. For the six months ended June 30, 2026, cash used in operating activities was $15,953,129 compared to $9,409,825 for the six months ended June 30, 2025. As of June 30, 2026, the Company had an accumulated deficit of $85,007,966 (December 31, 2025 &#8211; $64,348,118) and net loss of $11,684,427 and $20,726,738 for the three and six months ended June 30, 2026, respectively (June 30, 2025 - $6,176,084 and $11,278,492, respectively). The Company has a working capital of $6,140,096 as of June 30, 2026.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On March 10, 2025, the Company completed the Regulation A Offering of 1,490,000 units at $2.80 per unit. None of the 1,490,000 Regulation A Warrants have been exercised during the three and six months ended June 30, 2026.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On June 2, 2025, the Company closed its public offering with gross proceeds of $7.0 million. The Company issued 2,260,000 units at a price of $3.10 per unit. Each unit consisted of one common share of the Company and one June 2030 Warrant. The June 2030 Warrants have an exercise price of $3.10 per share and will expire June 2, 2030. As of June 30, 2026, no June 2030 Warrants have been exercised.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On July 14, 2025, the Company entered into the Warrant Inducement Agreement with an institutional investor, pursuant to which the investor agreed to exercise existing Regulation A Warrants to purchase up to 1,340,000 of the Company's common shares issued on March 10, 2025 and with an exercise price of $2.80 per common share, in consideration for receiving the 2,680,000 Series A and B Warrants with an exercise price of $3.75. In accordance with the Warrant Inducement Agreement, the investor exercised its existing warrants for cash, for gross proceeds of $3.8 million to the Company.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 5, 2025, the Company entered into The Second Warrant Inducement Agreement with an institutional investor, pursuant to which the investor agreed to exercise existing Series A and B Warrants to purchase up to 2,680,000 of the Company's common shares issued on July 14, 2025 with an amended exercise price of $1.92 per common share, in consideration for receiving 4,020,000 Series C and D Warrants with an exercise price of $2.00. In accordance with the Second Warrant Inducement Agreement, the investor exercised its existing warrants for cash, for gross proceeds of approximately $5.1 million to the Company.</span></span></p><div><p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">18</span></span></p></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/><p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_31"><!-- anchor --></span></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 29, 2025, the Company entered into the Equity Distribution Agreement with Maxim Group LLC and Yorkville Securities, LLC, an affiliate of Yorkville as agents, whereby the Agents may sell up to $15.3 million of our common shares as part of an at-the-market program. On April 23, 2026, the Company and the Agents entered into an amendment to the Equity Distribution Agreement, up-sizing the ATM program from $15.3 million to up to $50 million. As of June 30, 2026, the Company has issued 28,248,981 common shares as part of the program. The gross proceeds from the issuances were $12,868,181.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2026, no Public Warrants issued as part of the initial public offering have been exercised for cash for nil proceeds to the Company.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2026, the Company had issued 5,336,780 common shares at an aggregate market price of $4,229,823 for net proceeds of $4,102,740 under the SEPA.</span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i><strong>Standby Equity Purchase Agreement</strong></i></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company entered into a standby equity purchase agreement dated February 10, 2025 (the "SEPA") with Yorkville, an investment fund managed by Yorkville Advisors Global, LP. Pursuant to the SEPA, the Company has the option, at its sole discretion, to sell up to $15,000,000 of the Company's common shares to Yorkville at any time during the 36-months following the date of the SEPA.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Yorkville's obligation to purchase the common shares is subject to a number of conditions, including that the Company file a registration statement with the SEC registering the resale of the common shares issuable thereunder, and that the registration statement is declared effective by the SEC. Such current registration statement, as amended, was originally filed with the SEC on September 29, 2025 and declared effective by the SEC on November 14, 2025.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The issuance of common shares under the SEPA is subject to further limitations, including that the common shares beneficially owned by Yorkville and its affiliates at any one time will not exceed 4.99% of the then-outstanding common shares.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Common shares issued and sold to Yorkville under the SEPA will be priced at 97% of the market price (as defined in the SEPA) of the common shares during a specified three-day pricing period. The Company reserves the right to set a minimum acceptable price for the common share issuances.</span></span></p><div><div><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2026, the Company issued 5,336,780 common shares at market price of $4,229,823 for proceeds of $4,102,740. During the six months ended June 30, 2026, $3,223,980 of the gross proceeds were held back to partially repay the Company's outstanding debenture and interest to Yorkville, which was fully repaid and extinguished on May 27, 2026. As of June 30, 2026, the Company has capacity to issue up to approximately $2.5 million worth of common shares under the SEPA.</span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i><strong>Cash flows</strong></i></span></span></p><table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000"><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap">&#160;</td><td colspan="4" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Six months ended</strong><br/><strong>June 30,</strong></span></span></td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2026</strong></span></span></td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2025</strong></span></span></td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Change</strong></span></span></td><td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash used in operating activities</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(15,953,129</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(9,409,825</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6,543,304</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash provided by financing activities</span></span></td><td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">32,354,942</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14,915,048</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">17,439,894</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff;border-bottom:0.75pt solid #000000">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff;border-bottom:0.75pt solid #000000">&#160;</td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff;border-bottom:0.75pt solid #000000">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff;border-bottom:0.75pt solid #000000">&#160;</td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff;border-bottom:0.75pt solid #000000">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff;border-bottom:0.75pt solid #000000">&#160;</td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff;border-bottom:0.75pt solid #000000">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign currency effect on cash and cash equivalents</span></span></td><td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">84,509</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">84,509</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net change in cash and cash equivalents and restricted cash during the period</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">16,486,322</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,505,223</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,981,099</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents and restricted cash, beginning of period</span></span></td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,705,218</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,164,323</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left;background-color:#e6efff">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,540,895</span></span></td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:2%;text-align:left;background-color:#e6efff">&#160;</td></tr><tr><td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents and restricted cash, end of period</span></span></td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">25,191,540</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,669,546</span></span></td><td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:1%;text-align:left">&#160;</td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15,521,994</span></span></td><td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;width:2%;text-align:left">&#160;</td></tr></table></div></div><p style="margin-top:0pt;margin-bottom:0pt">&#160;</p><div><p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">19</span></span></p></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/><p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_32"><!-- anchor --></span></span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Cash flows used in operating activities</i></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash flows used in operating activities for the six months ended June 30, 2026, were $15,953,129 compared to cash flows used in operating activities of $9,409,825 for the six months ended June 30, 2025. The increase is primarily due to increased spending on research and development and general and administrative expenses.</span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Cash flows provided by financing activities</i></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash flows provided by financing activities for the six months ended June 30, 2026, were $32,354,942 compared to cash flows provided by financing activities of $14,915,048 for the six months ended June 30, 2025. The increase is primarily due to increased proceeds from the issuance of common shares in equity offerings and under the SEPA, during the six months ended June 30, 2026, compared to proceeds from the issuance of common shares and warrants, net of offering costs from the Regulation A Offering, during the six months ended June 30, 2025.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Contractual Obligations</strong></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have no significant contractual arrangements other than those noted in our financial statements.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Off-Balance Sheet Arrangements</strong></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2026, we have not entered into any off-balance sheet arrangements.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Critical Accounting Policies</strong></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">There have been no material changes to our critical accounting policies and estimates from the information provided in the MD&amp;A section in our Annual Report.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Updated share information</strong></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2026, we had 60,168,044 common shares issued and outstanding. In addition, there were 5,510,000 common shares issuable upon the exercise of outstanding stock options and 7,281,795 common shares issuable upon the exercise of warrants.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Recent Accounting Pronouncements</strong></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">See Note 2 to our consolidated financial statements.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Subsequent Events</strong></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On July 16, 2026, the Company announced it received written feedback from the FDA and central Institutional Review Board approval, with modifications, for its optimized Phase 2 clinical study of Teverelix in men following a first episode of AUR. The Company submitted the optimized protocol to the FDA on April 2, 2026, under its existing IND application for Teverelix. The redesigned study is expected to enroll approximately 126 patients across the United States and Europe, compared with approximately 390 patients contemplated under the Company's previously disclosed development plan, and is intended to generate an early pharmacodynamic signal while supporting dose optimization, route selection and future clinical development.</span></span></p><div><p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20</span></span></p></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/><p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_33"><!-- anchor --></span></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On July 27, 2026, the Company announced that the FDA completed its safety review of the Company's IND application for SKNJCT-005 and issued a "Study May Proceed" letter authorizing the initiation of the Company's NDA-enabling registrational Phase 2b clinical study evaluating SkinJect 200 mcg in patients with Gorlin Syndrome presenting with multiple BCCs.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On July 31, 2026, the Company announced that the UAE DOH has granted IND authorization for the Company's PRECISION-E2 Phase 2a clinical study evaluating Teverelix in women with moderate-to-severe symptomatic endometriosis.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 3, 2026, the Company announced the appointment of Faisal Mehmud, MD, MRCP, as chief executive officer of Antev, effective August 30, 2026. Dr. Mehmud will continue to serve as Chief Medical Officer of Medicus and Co-Chairman of Antev.</span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Item 3. Quantitative and Qualitative Disclosures About Market Risk</strong></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As a smaller reporting company, we are not required to provide the information required by this Item.</span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Item 4. CONTROLS AND PROCEDURES</strong></span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Evaluation of Disclosure Controls and Procedures</i></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Disclosure controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report, is recorded, processed, summarized, and reported within the time period specified in the SEC's rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our current chief executive officer and chief financial officer (our "Certifying Officers"), the effectiveness of our disclosure controls and procedures as of June 30, 2026, pursuant to Rule 13a-15(b) under the Exchange Act. Based upon that evaluation, our Certifying Officers concluded that, as of June 30, 2026, our disclosure controls and procedures were effective.</span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Changes in Internal Control over Financial Reporting</i></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">There were no changes in the Company's internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the quarter ended June 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></span></p><p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>PART II - OTHER INFORMATION</strong></span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Item 1. Legal Proceedings</strong></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">There is no material litigation, arbitration or governmental proceeding currently pending against us or any members of our management team in their capacity as such, and we and the members of our management team have not been subject to any such proceeding in the 12 months preceding the date hereof.</span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Item 1A. Risk Factors</strong></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Factors that could cause our actual results to differ materially from those in this Quarterly Report on Form 10-Q include the risk factors described in the 2025 Annual Report. Any of these risk factors could result in a significant or material adverse effect on the Company's business, financial condition and/or results of operations. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in the 2025 Annual Report.</span></span></p><div><p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">21</span></span></p></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/><p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_34"><!-- anchor --></span></span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</strong></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 15, 2026, the Company issued 500,000 common shares to an accredited investor under a strategic media agreement for advertising services to the Company. In addition, on April 22, 2026, the Company granted 250,000 Common Shares to certain accredited investors as compensation for services rendered to the Company. Such issuances and grants of common shares were made in reliance upon the exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act.</span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other than the aforementioned transactions, all other information required by Item 701 of Regulation S-K as to unregistered sales of equity securities of the Company during the period covered by this Quarterly Report has previously been included in Current Reports on Form 8-K filed with the SEC.</span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Item 3. Defaults Upon Senior Securities</strong></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">None.</span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Item 4. Mine Safety Disclosures</strong></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Not applicable.</span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Item 5. Other Information</strong></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">None.</span></span></p><div><p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">22</span></span></p></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/><p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_35"><!-- anchor --></span></span></span></p><p style="text-indent:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Item 6. Exhibits</strong></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.</span></span></p><table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt"><tr><td style="vertical-align:top;text-align:center;border-bottom:0.75pt solid #000000;width:8%;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>No.</strong></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;white-space:nowrap">&#160;</td><td style="width:90%;vertical-align:top;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Description of Exhibit</strong></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299324011392/exhibit3-1.htm">3.1</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top;background-color:#eeeeee">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299324011392/exhibit3-1.htm">Articles of Incorporation of Medicus Pharma Ltd. (incorporated by reference from Exhibit 3.1 to the Registrant's Registration Statement on Form F-1, filed with the SEC on May 29, 2024)</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299324011392/exhibit3-2.htm">3.2</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299324011392/exhibit3-2.htm">Articles of Amendment of Medicus Pharma Ltd., effective as of September 29, 2023 (incorporated by reference from Exhibit 3.2 to the Registrant's Registration Statement on Form F-1, filed with the SEC on May 29, 2024)</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299324018057/exhibit3-4.htm">3.3</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top;background-color:#eeeeee">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299324018057/exhibit3-4.htm">Articles of Amendment of Medicus Pharma Ltd., effective as of October 28, 2024 (incorporated by reference from Exhibit 3.4 to the Registrant's Registration Statement on Form F-1, filed with the SEC on October 29, 2024)</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299325014058/exhibit3-2.htm">3.4</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299325014058/exhibit3-2.htm">Articles of Amendment of Medicus Pharma Ltd., effective as of August 8, 2025 (incorporated by reference from Exhibit 3.2 to the Registrant's Quarterly Report on Form 10-Q, filed with the SEC on August 11, 2025)</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299325014058/exhibit3-1.htm">3.5</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top;background-color:#eeeeee">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299325014058/exhibit3-1.htm">Bylaws of Medicus Pharma Ltd., as in effect as of the date hereof (incorporated by reference from Exhibit 3.1 to the Registrant's Quarterly Report on Form 10-Q, filed with the SEC on August 11, 2025)</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299326002142/exhibit10-1.htm">10.1</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#0000ee">&#160;</span></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299326002142/exhibit10-1.htm">Amendment No. 1 to the Equity Distribution Agreement, dated April 23, 2026, among Medicus Pharma Ltd., Maxim Group LLC and Yorkville Securities, LLC (incorporated by reference from Exhibit 10.1 to the Registrant's Current Report on Form 8-K, filed with the SEC on April 24, 2026)</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299326002900/exhibit10-1.htm">10.2#</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top;background-color:#eeeeee">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299326002900/exhibit10-1.htm">Note Purchase Agreement dated May 27, 2026, by and between the Company and Streeterville Capital, LLC (incorporated by reference from Exhibit 10.1 to the Registrant's Current Report on Form 8-K, filed with the SEC on May 27, 2026)</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299326002900/exhibit10-2.htm">10.3</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299326002900/exhibit10-2.htm">Secured Promissory Note A-1 dated May 27, 2026, made by the Company in favor of Streeterville Capital, LLC (incorporated by reference from Exhibit 10.2 to the Registrant's Current Report on Form 8-K, filed with the SEC on May 27, 2026)</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299326002900/exhibit10-3.htm">10.4</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top;background-color:#eeeeee">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299326002900/exhibit10-3.htm">Secured Promissory Note B dated May 27, 2026, made by the Company in favor of Streeterville Capital, LLC (incorporated by reference from Exhibit 10.3 to the Registrant's Current Report on Form 8-K, filed with the SEC on May 27, 2026)</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299326002900/exhibit10-4.htm">10.5</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299326002900/exhibit10-4.htm">Security Agreement dated May 27, 2026, by and between the Company and Streeterville Capital, LLC (incorporated by reference from Exhibit 10.4 to the Registrant's Current Report on Form 8-K, filed with the SEC on May 27, 2026)</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299326002900/exhibit10-5.htm">10.6</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top;background-color:#eeeeee">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299326002900/exhibit10-5.htm">Security Agreement dated May 27, 2026, by and between Antev Limited and Streeterville Capital, LLC (incorporated by reference from Exhibit 10.5 to the Registrant's Current Report on Form 8-K, filed with the SEC on May 27, 2026)</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299326002900/exhibit10-6.htm">10.7</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299326002900/exhibit10-6.htm">Intellectual Property Security Agreement dated May 27, 2026, by and between Antev Limited and Streeterville Capital, LLC (incorporated by reference from Exhibit 10.6 to the Registrant's Current Report on Form 8-K, filed with the SEC on May 27, 2026)</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299326002900/exhibit10-7.htm">10.8</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top;background-color:#eeeeee">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="http://www.sec.gov/Archives/edgar/data/1997296/000106299326002900/exhibit10-7.htm">Guaranty dated May 27, 2026, made by SkinJect, Inc., Medicus Pharma, Inc., Antev Limited, and MDCX Holdings, LLC for the benefit of Streeterville Capital, LLC (incorporated by reference from Exhibit 10.7 to the Registrant's Current Report on Form 8-K, filed with the SEC on May 27, 2026)</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit31-1.htm">31.1*</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit31-1.htm">Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit31-2.htm">31.2*</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top;background-color:#eeeeee">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit31-2.htm">Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit32-1.htm">32.1**</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit32-1.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit32-2.htm">32.2**</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top;background-color:#eeeeee">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit32-2.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.INS*</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></span></td></tr></table><p style="margin-top:0pt;margin-bottom:0pt">&#160;</p><div><p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">23</span></span></p></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/><p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_36"><!-- anchor --></span></span></span></p><div style="margin-top:15pt"><table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt"><tr><td style="vertical-align:top;text-align:center;border-bottom:0.75pt solid #000000;width:8%;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>No.</strong></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;white-space:nowrap">&#160;</td><td style="width:90%;vertical-align:top;text-align:center;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Description of Exhibit</strong></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="mdcx-20260630.xsd">101.SCH*</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top;background-color:#eeeeee">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="mdcx-20260630.xsd">Inline XBRL Taxonomy Extension Schema Document</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="mdcx-20260630_cal.xml">101.CAL*</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="mdcx-20260630_cal.xml">Inline XBRL Taxonomy Extension Calculation Linkbase Document</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="mdcx-20260630_def.xml">101.DEF*</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top;background-color:#eeeeee">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="mdcx-20260630_def.xml">Inline XBRL Taxonomy Extension Definition Linkbase Document</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="mdcx-20260630_lab.xml">101.LAB*</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="mdcx-20260630_lab.xml">Inline XBRL Taxonomy Extension Label Linkbase Document</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="mdcx-20260630_pre.xml">101.PRE*</a></span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top;background-color:#eeeeee">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify;background-color:#eeeeee"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="mdcx-20260630_pre.xml">Inline XBRL Taxonomy Extension Presentation Linkbase Document</a></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">104</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify">&#160;</td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Filed herewith.</span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify">&#160;</td></tr><tr><td style="margin-bottom:0pt;width:8%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">**</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top">&#160;</td><td style="margin-bottom:0pt;width:90%;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Furnished herewith.</span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;text-align:justify;vertical-align:top">&#160;</td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:8%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">#</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:2%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:90%;text-align:justify;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Schedules and certain other private or confidential information (as indicated therein) have been omitted pursuant to Item 601(b)(2)(ii) of Regulation S-K. The Company hereby undertakes to furnish supplementally copies of any of the omitted schedules upon request by the SEC.</span></span></td></tr></table></div><p style="margin-top:0pt;margin-bottom:0pt">&#160;</p><div><p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">24</span></span></p></div><hr style="break-after:page;text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/><p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="page_37"><!-- anchor --></span></span></span></p><p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>SIGNATURES</strong></span></span></p><p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></span></p><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-size:10pt;width:100%"><tr><td style="margin-top:0pt;margin-bottom:0pt;width:30%;vertical-align:top">&#160;</td><td colspan="2" style="margin-top:0pt;margin-bottom:0pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>MEDICUS PHARMA LTD.</strong></span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:30%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:5%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:65%;vertical-align:top">&#160;</td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:30%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:5%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:65%;vertical-align:top">&#160;</td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:30%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Date: August 12, 2026</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:5%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">By:</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:65%;border-bottom:0.75pt solid #000000;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/ Raza Bokhari</span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:30%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:5%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Name:</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:65%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dr. Raza Bokhari</span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:30%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:5%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Title:</span></span></td><td style="width:65%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Executive Chairman and Chief Executive Officer<br/>(Principal Executive Officer)</span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:30%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:5%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:65%;vertical-align:top">&#160;</td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:30%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:5%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:65%;vertical-align:top">&#160;</td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:30%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Date: August 12, 2026</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:5%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">By:</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:65%;border-bottom:0.75pt solid #000000;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/ Carolyn Bonner</span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:30%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:5%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Name:</span></span></td><td style="margin-top:0pt;margin-bottom:0pt;width:65%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Carolyn Bonner</span></span></td></tr><tr><td style="margin-top:0pt;margin-bottom:0pt;width:30%;vertical-align:top">&#160;</td><td style="margin-top:0pt;margin-bottom:0pt;width:5%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Title:</span></span></td><td style="width:65%;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">President and Chief Financial Officer<br/>(Principal Financial and Accounting Officer)</span></span></td></tr></table><p style="margin-top:0pt;margin-bottom:0pt">&#160;</p><div><p style="text-align:center;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">25</span></span></p></div><hr style="text-align:center;height:5px;color:#000000;background-color:#000000;width:100%"/></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>

<head>
    <title>Medicus Pharma Ltd.: Exhibit 31.1 - Filed by newsfilecorp.com</title>
</head>

<body style="font-size:10pt; font-family:'Times New Roman';">
    <hr width="100%" size="3" color="black" noshade="noshade"><a name="page_1"></a>
    <p style="text-align: right; margin-top: 10pt; margin-bottom: 10pt;"><b>Exhibit 31.1</b></p>
    <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><b>CERTIFICATION OF CHIEF EXECUTIVE OFFICER</b><br><b>PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</b><br><b>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p>
    <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">I, Dr. Raza Bokhari, certify that:</p>
    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">1.<font style="width: 10.5pt; text-indent: 0pt; display: inline-block;">&#160;</font>I have reviewed this quarterly report on Form 10-Q of Medicus Pharma Ltd&#894;</p>
    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.<font style="width: 10.5pt; text-indent: 0pt; display: inline-block;">&#160;</font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#894;</p>
    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">3.<font style="width: 10.5pt; text-indent: 0pt; display: inline-block;">&#160;</font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#894;</p>
    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">4.<font style="width: 10.5pt; text-indent: 0pt; display: inline-block;">&#160;</font>The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p>
    <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">a)<font style="width: 10.23pt; text-indent: 0pt; display: inline-block;">&#160;</font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#894;</p>
    <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">b)<font style="width: 9.67pt; text-indent: 0pt; display: inline-block;">&#160;</font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
    <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">c)<font style="width: 10.23pt; text-indent: 0pt; display: inline-block;">&#160;</font>Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#894; and</p>
    <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">d)<font style="width: 9.67pt; text-indent: 0pt; display: inline-block;">&#160;</font>Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#894; and</p>
    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">5.<font style="width: 10.5pt; text-indent: 0pt; display: inline-block;">&#160;</font>The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p>
    <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">a)<font style="width: 10.23pt; text-indent: 0pt; display: inline-block;">&#160;</font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#894; and</p>
    <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">b)<font style="width: 9.67pt; text-indent: 0pt; display: inline-block;">&#160;</font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p>
    <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">Date: August 12, 2026</p>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000;">/s/ Raza Bokhari</td>
        </tr>
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt;">Dr. Raza Bokhari</td>
        </tr>
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt;">Executive Chairman and Chief Executive Officer</td>
        </tr>
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt;">(Principal Executive Officer)</td>
        </tr>
    </table>
    <br>
    <hr width="100%" size="5" color="black" noshade="noshade">
</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>

<head>
    <title>Medicus Pharma Ltd.: Exhibit 31.2 - Filed by newsfilecorp.com</title>
</head>

<body style="font-size:10pt; font-family:'Times New Roman';">
    <hr width="100%" size="3" color="black" noshade="noshade"><a name="page_1"></a>
    <p style="text-align: right; margin-top: 10pt; margin-bottom: 10pt;"><b>Exhibit 31.2</b></p>
    <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><b>CERTIFICATION OF CHIEF FINANCIAL OFFICER</b><br><b>PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</b><br><b>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p>
    <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">I, Carolyn Bonner, certify that:</p>
    <p style="margin-left: 36pt; text-indent: -36pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">1.<font style="display: inline-block; width: 10.5pt;">&#160;</font>I have reviewed this quarterly report on Form 10-Q of Medicus Pharma Ltd&#894;</p>
    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.<font style="width: 10.5pt; text-indent: 0pt; display: inline-block;">&#160;</font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#894;</p>
    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">3.<font style="width: 10.5pt; text-indent: 0pt; display: inline-block;">&#160;</font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#894;</p>
    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">4.<font style="width: 10.5pt; text-indent: 0pt; display: inline-block;">&#160;</font>The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p>
    <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">a)<font style="width: 10.23pt; text-indent: 0pt; display: inline-block;">&#160;</font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#894;</p>
    <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">b)<font style="width: 9.67pt; text-indent: 0pt; display: inline-block;">&#160;</font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#894;</p>
    <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">c)<font style="width: 10.23pt; text-indent: 0pt; display: inline-block;">&#160;</font>Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#894; and</p>
    <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">d)<font style="width: 9.67pt; text-indent: 0pt; display: inline-block;">&#160;</font>Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#894; and</p>
    <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">5.<font style="width: 10.5pt; text-indent: 0pt; display: inline-block;">&#160;</font>The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p>
    <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">a)<font style="width: 10.23pt; text-indent: 0pt; display: inline-block;">&#160;</font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#894; and</p>
    <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">b)<font style="width: 9.67pt; text-indent: 0pt; display: inline-block;">&#160;</font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p>
    <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">Date: August 12, 2026</p>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000;">/s/ Carolyn Bonner</td>
        </tr>
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt;">Carolyn Bonner</td>
        </tr>
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt;">President and Chief Financial Officer</td>
        </tr>
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt;">(Principal Financial and Accounting Officer)</td>
        </tr>
    </table>
    <br>
    <hr width="100%" size="5" color="black" noshade="noshade">
</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>

<head>
    <title>Medicus Pharma Ltd.: Exhibit 32.1 - Filed by newsfilecorp.com</title>
</head>

<body style="font-size:10pt; font-family:'Times New Roman';">
    <hr width="100%" size="3" color="black" noshade="noshade"><a name="page_1"></a>
    <p style="text-align: right; margin-top: 10pt; margin-bottom: 10pt;"><b>Exhibit 32.1</b></p>
    <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><b>CERTIFICATION PURSUANT TO</b><br><b>18 U.S.C. SECTION 1350</b><br><b>AS ADOPTED PURSUANT TO</b><br><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>
    <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">In connection with the Quarterly Report of Medicus Pharma Ltd. (the "Company") on Form 10-Q for the quarterly period ended June 30, 2026, as filed with the Securities and Exchange Commission (the "Report"), I, Raza Bokhari, Executive Chairman and Chief Executive Officer, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</p>
    <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">1.<font style="width: 10.5pt; text-indent: 0pt; display: inline-block;">&#160;</font>The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#894; and</p>
    <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.<font style="width: 10.5pt; text-indent: 0pt; display: inline-block;">&#160;</font>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
    <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">Dated: August 12, 2026</p>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid #000000;">/s/ Raza Bokhari</td>
        </tr>
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt;">Dr. Raza Bokhari</td>
        </tr>
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt;">Executive Chairman and Chief Executive Officer</td>
        </tr>
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt;">(Principal Executive Officer)</td>
        </tr>
    </table>
    <br>
    <hr width="100%" size="5" color="black" noshade="noshade">
</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>

<head>
    <title>Medicus Pharma Ltd.: Exhibit 32.2 - Filed by newsfilecorp.com</title>
</head>

<body style="font-size:10pt; font-family:'Times New Roman';">
    <hr width="100%" size="3" color="black" noshade="noshade"><a name="page_1"></a>
    <p style="text-align: right; margin-top: 10pt; margin-bottom: 10pt;"><b>Exhibit 32.2</b></p>
    <p style="text-align: center; margin-top: 10pt; margin-bottom: 10pt;"><b>CERTIFICATION PURSUANT TO</b><br><b>18 U.S.C. SECTION 1350</b><br><b>AS ADOPTED PURSUANT TO</b><br><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>
    <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">In connection with the Quarterly Report of Medicus Pharma Ltd. (the "Company") on Form 10-Q for the quarterly period ended June 30, 2026, as filed with the Securities and Exchange Commission (the "Report"), I, Carolyn Bonner, President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</p>
    <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">1.<font style="width: 10.5pt; text-indent: 0pt; display: inline-block;">&#160;</font>The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#894; and</p>
    <p style="margin-left: 36pt; text-indent: -18pt; text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">2.<font style="width: 10.5pt; text-indent: 0pt; display: inline-block;">&#160;</font>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
    <p style="text-align: justify; margin-top: 10pt; margin-bottom: 10pt;">Dated: August 12, 2026</p>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 0.75pt solid rgb(0, 0, 0);">/s/ Carolyn Bonner</td>
        </tr>
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt;">Carolyn Bonner</td>
        </tr>
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt;">President and Chief Financial Officer</td>
        </tr>
        <tr>
            <td style="margin-top: 0pt; margin-bottom: 0pt;">(Principal Financial and Accounting Officer)</td>
        </tr>
    </table>
    <br>
    <hr width="100%" size="5" color="black" noshade="noshade">
</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>mdcx-20260630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:mdcx="http://www.medicuspharma.com/20260630" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:country="http://xbrl.sec.gov/country/2026" xmlns:currency="http://xbrl.sec.gov/currency/2026" xmlns:exch="http://xbrl.sec.gov/exch/2026" xmlns:naics="http://xbrl.sec.gov/naics/2026" xmlns:sic="http://xbrl.sec.gov/sic/2026" xmlns:stpr="http://xbrl.sec.gov/stpr/2026" xmlns:us-types="http://fasb.org/us-types/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:srt-types="http://fasb.org/srt-types/2026" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2026" targetNamespace="http://www.medicuspharma.com/20260630" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2026" schemaLocation="https://xbrl.sec.gov/dei/2026/dei-2026.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2026" schemaLocation="https://xbrl.sec.gov/country/2026/country-2026.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2026" schemaLocation="https://xbrl.sec.gov/currency/2026/currency-2026.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2026" schemaLocation="https://xbrl.sec.gov/exch/2026/exch-2026.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2026" schemaLocation="https://xbrl.sec.gov/naics/2026/naics-2026.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2026" schemaLocation="https://xbrl.sec.gov/sic/2026/sic-2026.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2026" schemaLocation="https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"/>
  <import namespace="http://fasb.org/us-types/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd"/>
  <import namespace="http://fasb.org/srt/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd"/>
  <import namespace="http://fasb.org/srt-types/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd"/>
  <import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/idr_BalanceSheets" id="idr_BalanceSheets">
        <link:definition>0002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/idr_BalanceSheetsParenthetical" id="idr_BalanceSheetsParenthetical">
        <link:definition>0003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/idr_StatementsOfOperations" id="idr_StatementsOfOperations">
        <link:definition>0004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit" id="idr_StatementsOfChangesInShareholdersDeficit">
        <link:definition>0005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' ( DEFICIT) EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical" id="ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical">
        <link:definition>0006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' ( DEFICIT) EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/idr_StatementsOfCashFlows" id="idr_StatementsOfCashFlows">
        <link:definition>0007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/DescriptionOfBusiness" id="DescriptionOfBusiness">
        <link:definition>0008 - Disclosure - Description of business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>0009 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/BalanceSheetComponents" id="BalanceSheetComponents">
        <link:definition>0010 - Disclosure - Balance sheet components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/Leases" id="Leases">
        <link:definition>0011 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/ShareCapital" id="ShareCapital">
        <link:definition>0012 - Disclosure - Share capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/StockBasedCompensation" id="StockBasedCompensation">
        <link:definition>0013 - Disclosure - Stock-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>0014 - Disclosure - Related party transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>0015 - Disclosure - Fair value measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/CommitmentAndContingencies" id="CommitmentAndContingencies">
        <link:definition>0016 - Disclosure - Commitments and contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/SegmentReporting" id="SegmentReporting">
        <link:definition>0017 - Disclosure - Segment reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/Debentures" id="Debentures">
        <link:definition>0018 - Disclosure - Debentures and Secured Promissory Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/RestrictedCash" id="RestrictedCash">
        <link:definition>0019 - Disclosure - Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/Liquidity" id="Liquidity">
        <link:definition>0020 - Disclosure - Liquidity and Going Concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/LossPerShare" id="LossPerShare">
        <link:definition>0021 - Disclosure - Loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>0022 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>9960701 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/BalanceSheetComponentsTables" id="BalanceSheetComponentsTables">
        <link:definition>9960702 - Disclosure - Balance sheet components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/LeasesTables" id="LeasesTables">
        <link:definition>9960703 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/ShareCapitalTables" id="ShareCapitalTables">
        <link:definition>9960704 - Disclosure - Share capital (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
        <link:definition>9960705 - Disclosure - Stock-based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/FairValueMeasurementTables" id="FairValueMeasurementTables">
        <link:definition>9960706 - Disclosure - Fair value measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>9960707 - Disclosure - Commitments and contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesTables" id="ResearchAndDevelopmentRDExpensesTables">
        <link:definition>9960708 - Disclosure - Segment reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/DebenturesTables" id="DebenturesTables">
        <link:definition>9960709 - Disclosure - Debentures and Secured Promissory Notes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/LossPerShareTables" id="LossPerShareTables">
        <link:definition>9960710 - Disclosure - Loss per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/TESTTESTTESTTables" id="TESTTESTTESTTables">
        <link:definition>9960711 - Disclosure - Subsequent events (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" id="SummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9960712 - Disclosure - Summary of significant accounting policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/BalanceSheetComponentsDetails" id="BalanceSheetComponentsDetails">
        <link:definition>9960713 - Disclosure - Balance sheet components (Schedule of prepaid expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/BalanceSheetComponentsDetails1" id="BalanceSheetComponentsDetails1">
        <link:definition>9960714 - Disclosure - Balance sheet components (Schedule of accrued expenses and other current liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/LeasesDetails" id="LeasesDetails">
        <link:definition>9960715 - Disclosure - Leases (Schedule of operating leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/LeasesDetails1" id="LeasesDetails1">
        <link:definition>9960716 - Disclosure - Leases (Schedule of lease cost) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/LeasesDetails2" id="LeasesDetails2">
        <link:definition>9960717 - Disclosure - Leases (Schedule of future minimum lease payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails" id="ShareCapitalNarrativeDetails">
        <link:definition>9960718 - Disclosure - Share capital (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/ShareCapitalDetails" id="ShareCapitalDetails">
        <link:definition>9960719 - Disclosure - Share capital (Schedule of assumptions used to estimate the fair value of warrants) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/ShareCapitalScheduleOfWarrantsContinuityDetails" id="ShareCapitalScheduleOfWarrantsContinuityDetails">
        <link:definition>9960720 - Disclosure - Share capital (Schedule of warrants continuity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/ShareCapitalDetails1" id="ShareCapitalDetails1">
        <link:definition>9960721 - Disclosure - Share capital (Schedule of warrants outstanding) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails" id="StockBasedCompensationNarrativeDetails">
        <link:definition>9960722 - Disclosure - Stock-based compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails" id="StockBasedCompensationScheduleOfStockOptionActivityDetails">
        <link:definition>9960723 - Disclosure - Stock-based compensation (Schedule of stock option activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfWeightedaverageAssumptionsToDetermineFairValueOfStockOptionsGrantedDetails" id="StockBasedCompensationScheduleOfWeightedaverageAssumptionsToDetermineFairValueOfStockOptionsGrantedDetails">
        <link:definition>9960724 - Disclosure - Stock-based compensation (Schedule of assumptions used to estimate the fair value of options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/RelatedPartyTransactionsNarrativeDetails" id="RelatedPartyTransactionsNarrativeDetails">
        <link:definition>9960725 - Disclosure - Related party transactions (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/FairValueMeasurementsNarrativeDetails" id="FairValueMeasurementsNarrativeDetails">
        <link:definition>9960726 - Disclosure - Fair value measurements (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/FairValueMeasurementDetails" id="FairValueMeasurementDetails">
        <link:definition>9960727 - Disclosure - Fair value measurements - Schedule of fair value on a recurring basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/CommitmentsAndContingenciesN" id="CommitmentsAndContingenciesN">
        <link:definition>9960728 - Disclosure - Commitments and contingencies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails" id="CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails">
        <link:definition>9960729 - Disclosure - Commitments and contingencies (Schedule of contingent consideration) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/SegmentReportingNarrativeDetails" id="SegmentReportingNarrativeDetails">
        <link:definition>9960730 - Disclosure - Segment reporting (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails" id="ResearchAndDevelopmentRDExpensesDetails">
        <link:definition>9960731 - Disclosure - Segment reporting (Schedule of reconciliation to consolidated operating expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/DebenturesNarrativeDetails" id="DebenturesNarrativeDetails">
        <link:definition>9960732 - Disclosure - Debentures and Secured Promissory Notes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/DebenturesScheduleOfDebentureContinuityDetails" id="DebenturesScheduleOfDebentureContinuityDetails">
        <link:definition>9960733 - Disclosure - Debentures and Secured Promissory Notes (Schedule of debenture continuity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/DebenturesAndPromissoryNotesNdfd" id="DebenturesAndPromissoryNotesNdfd">
        <link:definition>9960734 - Disclosure - Debentures and Secured Promissory Notes (Schedule of promissory notes)  (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/RestrictedCashNarrativeDetails" id="RestrictedCashNarrativeDetails">
        <link:definition>9960735 - Disclosure - Restricted Cash (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/LossPerShareDetails" id="LossPerShareDetails">
        <link:definition>9960736 - Disclosure - Loss per share (Schedule of basic and diluted net loss per share ) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/TESTTESTTESTDetails" id="TESTTESTTESTDetails">
        <link:definition>9960737 - Disclosure - Loss per share (Schedule of dilutive securities excluded from computation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.medicuspharma.com/role/SubsequentEventsNarrativeDetails" id="SubsequentEventsNarrativeDetails">
        <link:definition>9960738 - Disclosure - Subsequent events (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="mdcx-20260630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="mdcx-20260630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="mdcx-20260630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="mdcx-20260630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AccrualOfAtmIssuanceCosts" id="mdcx_AccrualOfAtmIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AccruedInterestConvertedIntoCommonShares" id="mdcx_AccruedInterestConvertedIntoCommonShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AccruedInterestRepaid" id="mdcx_AccruedInterestRepaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AccrueDividendsPreferredSharesRate" id="mdcx_AccrueDividendsPreferredSharesRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AdditionalRestrictedStockUnitIssued" id="mdcx_AdditionalRestrictedStockUnitIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" id="mdcx_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares" id="mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgentsMember" id="mdcx_AgentsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement" id="mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AntevAssetAgreementAbstract" id="mdcx_AntevAssetAgreementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AntevLimitedMember" id="mdcx_AntevLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AtmAgreementMember" id="mdcx_AtmAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BalanceSheetComponentsAbstract" id="mdcx_BalanceSheetComponentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BasisOfPresentationAndConsolidationPolicyTextBlock" id="mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BusinessCombinationConsiderationTransferredEquityInterestTypeAxis" id="mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="BusinessCombinationConsiderationTransferredEquityInterestTypeDomain" id="mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BusinessCombinationDiscountPercentageAppliedToClosingPrice" id="mdcx_BusinessCombinationDiscountPercentageAppliedToClosingPrice" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BusinessCombinationDiscountPricePerShare" id="mdcx_BusinessCombinationDiscountPricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BusinessCombinationReverseTakeoverTransactionTextBlock" id="mdcx_BusinessCombinationReverseTakeoverTransactionTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CashReceivedForInterest" id="mdcx_CashReceivedForInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ChangeInFairValueOfDebentures" id="mdcx_ChangeInFairValueOfDebentures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes" id="mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ClassOfWarrantOrRightExercisable" id="mdcx_ClassOfWarrantOrRightExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClassOfWarrantOrRightExpiryDate" id="mdcx_ClassOfWarrantOrRightExpiryDate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClinicalManufacturingAndRegulatoryActivitiesMember" id="mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommissionsPayableToAgents" id="mdcx_CommissionsPayableToAgents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="CommonSharesToBeIssued" id="mdcx_CommonSharesToBeIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ComprehensiveLossAttributableToParent" id="mdcx_ComprehensiveLossAttributableToParent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ContingentConsiderationPhasesFourMember" id="mdcx_ContingentConsiderationPhasesFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ContingentConsiderationPhasesOneMember" id="mdcx_ContingentConsiderationPhasesOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ContingentConsiderationPhasesThreeMember" id="mdcx_ContingentConsiderationPhasesThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ContingentConsiderationPhasesTwoMember" id="mdcx_ContingentConsiderationPhasesTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfStockConversionOneMember" id="mdcx_ConversionOfStockConversionOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfStockConversionThreeMember" id="mdcx_ConversionOfStockConversionThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfStockConversionTwoMember" id="mdcx_ConversionOfStockConversionTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConvertibleDebtAccretionExpense" id="mdcx_ConvertibleDebtAccretionExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ConvertiblePromissoryNotesMember" id="mdcx_ConvertiblePromissoryNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CostsToIssueDebenturesAndSecuredPromissoryNotes" id="mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DebentureContinuityOneMember" id="mdcx_DebentureContinuityOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DebenturesAndSecuredPromissoryNotes" id="mdcx_DebenturesAndSecuredPromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DebenturesIssuedPercentageOfDiscountedPrice" id="mdcx_DebenturesIssuedPercentageOfDiscountedPrice" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DebenturesMember" id="mdcx_DebenturesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DebtConversionAdditionalDebtAmount" id="mdcx_DebtConversionAdditionalDebtAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DebtConversionConvertibleInstrumentPricePerPreferredShares" id="mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DebtConversionConvertibleIntoPreferredSharesAmount" id="mdcx_DebtConversionConvertibleIntoPreferredSharesAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount" id="mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest" id="mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DebtConversionRemainingConvertibleAmount" id="mdcx_DebtConversionRemainingConvertibleAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DebtDefaultBalanceIncreasePercentage" id="mdcx_DebtDefaultBalanceIncreasePercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DebtInstrumentConvertibleExtinguished" id="mdcx_DebtInstrumentConvertibleExtinguished" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DebtInstrumentCovenantSharePriceThresholdPercentage" id="mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DebtInstrumentExchangeThresholdAmount" id="mdcx_DebtInstrumentExchangeThresholdAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DebtInstrumentMaximumExchangeLimitAmount" id="mdcx_DebtInstrumentMaximumExchangeLimitAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DebtInstrumentPeriodicPaymentInterestInCash" id="mdcx_DebtInstrumentPeriodicPaymentInterestInCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DebtInstrumentRedemptionLimitAmount" id="mdcx_DebtInstrumentRedemptionLimitAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DebtInstrumentVolumeBasedRedemptionPercentageLimit" id="mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DebtIssuanceDiscount" id="mdcx_DebtIssuanceDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeemedDividendOnWarrantInducement" id="mdcx_DeemedDividendOnWarrantInducement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredAtmOfferingCostsOffsetAgainstAdditionalPaidInCapital" id="mdcx_DeferredAtmOfferingCostsOffsetAgainstAdditionalPaidInCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement" id="mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredTaxAssetConvertibleDebentures" id="mdcx_DeferredTaxAssetConvertibleDebentures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredTaxAssetsAdditionalOperatingLossCarryforwardsForeign" id="mdcx_DeferredTaxAssetsAdditionalOperatingLossCarryforwardsForeign" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredTaxAssetsOperatingLossCarryforwardsNonCapital" id="mdcx_DeferredTaxAssetsOperatingLossCarryforwardsNonCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="EarningsFromDiscontinuedOperationsMember" id="mdcx_EarningsFromDiscontinuedOperationsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EffectiveInterestRateOnDebt" id="mdcx_EffectiveInterestRateOnDebt" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeeStockPurchasePlanMember" id="mdcx_EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EquityDistributionAgreementCommissionRate" id="mdcx_EquityDistributionAgreementCommissionRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExerciseOfPublicWarrantsMember" id="mdcx_ExerciseOfPublicWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExerciseOfRegulationAWarrantsMember" id="mdcx_ExerciseOfRegulationAWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExerciseSeriesAAndBWarrantsIssuedMember" id="mdcx_ExerciseSeriesAAndBWarrantsIssuedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FairValueLossOfDebt" id="mdcx_FairValueLossOfDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairValueOfAdditionalRestrictedStockUnit" id="mdcx_FairValueOfAdditionalRestrictedStockUnit" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FairValueOfWarrantsGranted" id="mdcx_FairValueOfWarrantsGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FairValuePerShare" id="mdcx_FairValuePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FairValuePerWarrant" id="mdcx_FairValuePerWarrant" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ForeignCurrencyTransactionsPolicyTextBlock" id="mdcx_ForeignCurrencyTransactionsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FormerHoldersMember" id="mdcx_FormerHoldersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GainLossOnSettlements" id="mdcx_GainLossOnSettlements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="GrantDateOneMember" id="mdcx_GrantDateOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GrantDateThreeMember" id="mdcx_GrantDateThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GrantDateTwoMember" id="mdcx_GrantDateTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GrantedRegulationAWarrantsMember" id="mdcx_GrantedRegulationAWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GrantedSeriesAAndBWarrantsIssuedMember" id="mdcx_GrantedSeriesAAndBWarrantsIssuedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GrantedWarrantsMember" id="mdcx_GrantedWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IncreaseDecreaseInCostsRelatedToSettlements" id="mdcx_IncreaseDecreaseInCostsRelatedToSettlements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseDecreaseInOperatingLeaseRightofuseAssets" id="mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncrementalFairValueOfWarrantsGranted" id="mdcx_IncrementalFairValueOfWarrantsGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IndividualsMember" id="mdcx_IndividualsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InProcessResearchAndDevelopment" id="mdcx_InProcessResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="InteractiveCapitalPartnersCorporationMember" id="mdcx_InteractiveCapitalPartnersCorporationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InterimRemeasurementMember" id="mdcx_InterimRemeasurementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssuanceCostsIncludedInAccountsPayable" id="mdcx_IssuanceCostsIncludedInAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IssuanceCostsInConnectionWithEquityFinancing" id="mdcx_IssuanceCostsInConnectionWithEquityFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IssuanceCostsInConnectionWithInitialPublicOffering" id="mdcx_IssuanceCostsInConnectionWithInitialPublicOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IssuanceCostsInConnectionWithPrivatePlacement" id="mdcx_IssuanceCostsInConnectionWithPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IssuanceCostsInConnectionWithRegulationA" id="mdcx_IssuanceCostsInConnectionWithRegulationA" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered" id="mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="June2025PublicOfferingMember" id="mdcx_June2025PublicOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LesseeOperatingLeasesDisclosureTableTextBlock" id="mdcx_LesseeOperatingLeasesDisclosureTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LimitOfOptionsAsPercentageOfSharesOutstanding" id="mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LiquidityAbstract" id="mdcx_LiquidityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LiquidityTextBlock" id="mdcx_LiquidityTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LongTermIncentivePlanMember" id="mdcx_LongTermIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MeasurementInputValuationDateSharePriceMember" id="mdcx_MeasurementInputValuationDateSharePriceMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MoneyMarketFunds" id="mdcx_MoneyMarketFunds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts" id="mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="NetOfAllocatedShareBasedCompensationExpense" id="mdcx_NetOfAllocatedShareBasedCompensationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NoInsiderTradingFlag" id="mdcx_NoInsiderTradingFlag" type="xbrli:booleanItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NoteAMember" id="mdcx_NoteAMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NoteBMember" id="mdcx_NoteBMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement" id="mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfCommonShareWarrantsExercisable" id="mdcx_NumberOfCommonShareWarrantsExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfCommonShareWarrantsExercisableExerciseInPeriod" id="mdcx_NumberOfCommonShareWarrantsExercisableExerciseInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfCommonShareWarrantsExercisableGrantsInPeriod" id="mdcx_NumberOfCommonShareWarrantsExercisableGrantsInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfCommonShareWarrantsOutstandingExerciseInPeriod" id="mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfCommonShareWarrantsOutstandingGrantsInPeriod" id="mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfConvertibleNotesSubscribed" id="mdcx_NumberOfConvertibleNotesSubscribed" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfSharesIssuedAfter210DaysFromAcquisition" id="mdcx_NumberOfSharesIssuedAfter210DaysFromAcquisition" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfTradingDays" id="mdcx_NumberOfTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsExercisable" id="mdcx_NumberOfWarrantsExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsExercised" id="mdcx_NumberOfWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsExercisedForCash" id="mdcx_NumberOfWarrantsExercisedForCash" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OriginalEarningsBeforeInterestTaxDepreciationAndAmortization" id="mdcx_OriginalEarningsBeforeInterestTaxDepreciationAndAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PaymentOfStructuringFee" id="mdcx_PaymentOfStructuringFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PaymentsToAcquireBusinessesAdvance" id="mdcx_PaymentsToAcquireBusinessesAdvance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PreferredStockRedeemablePercentage" id="mdcx_PreferredStockRedeemablePercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PrepaidContractResearch" id="mdcx_PrepaidContractResearch" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PrepaidExpensesPolicyTextBlock" id="mdcx_PrepaidExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PrepaidProfessionalServices" id="mdcx_PrepaidProfessionalServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PrepaidServices" id="mdcx_PrepaidServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromCommonSharesNetOfCommissionsPayableToAgents" id="mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromConcurrentFinancing" id="mdcx_ProceedsFromConcurrentFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts" id="mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromIssuanceOfSharesUnderSettlements" id="mdcx_ProceedsFromIssuanceOfSharesUnderSettlements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromOrionEquityInvestment" id="mdcx_ProceedsFromOrionEquityInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromSaleOfCommonStockOnAtMarketProgram" id="mdcx_ProceedsFromSaleOfCommonStockOnAtMarketProgram" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromSaleOfRoyaltyInterest" id="mdcx_ProceedsFromSaleOfRoyaltyInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures" id="mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromSimpleAgreementForFutureEquity" id="mdcx_ProceedsFromSimpleAgreementForFutureEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProfessionalServicesAndIntellectualPropertyMember" id="mdcx_ProfessionalServicesAndIntellectualPropertyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PublicWarrantsMember" id="mdcx_PublicWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RbxCapitalLPMember" id="mdcx_RbxCapitalLPMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ReceivableForProceedsOfWarrantExercises" id="mdcx_ReceivableForProceedsOfWarrantExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ReceivablesForProceedsOfWarrantExercises" id="mdcx_ReceivablesForProceedsOfWarrantExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" id="mdcx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RegulationAOfferingMember" id="mdcx_RegulationAOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RegulationAWarrantsMember" id="mdcx_RegulationAWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RelatedPartyPayableCurrent" id="mdcx_RelatedPartyPayableCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RelatedPartyTransactionAdditionalExpenses" id="mdcx_RelatedPartyTransactionAdditionalExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RepaymentOfDebenturesOnExtinguishment" id="mdcx_RepaymentOfDebenturesOnExtinguishment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RepaymentsOfInterest" id="mdcx_RepaymentsOfInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RestrictedCashDisclosureTextBlock" id="mdcx_RestrictedCashDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RestrictedCashLineItems" id="mdcx_RestrictedCashLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RestrictedCashTable" id="mdcx_RestrictedCashTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="RoyaltyLiability" id="mdcx_RoyaltyLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ScheduleOfPrepaidExpensesTableTextBlock" id="mdcx_ScheduleOfPrepaidExpensesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock" id="mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecuredPromissoryNotesMember" id="mdcx_SecuredPromissoryNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecuritiesPurchaseAgreementMember" id="mdcx_SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesAAndBWarrantsGrantedMember" id="mdcx_SeriesAAndBWarrantsGrantedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesAAndSeriesA1PreferredSharesMember" id="mdcx_SeriesAAndSeriesA1PreferredSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesAWarrantsMember" id="mdcx_SeriesAWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesBWarrantsMember" id="mdcx_SeriesBWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesCAndDWarrantsGrantedMember" id="mdcx_SeriesCAndDWarrantsGrantedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesCAndDWarrantsMember" id="mdcx_SeriesCAndDWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SettledConvertibleNotesAlongWithAccruedButUnpaidInterestInShares" id="mdcx_SettledConvertibleNotesAlongWithAccruedButUnpaidInterestInShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SettlementDateRemeasurementMember" id="mdcx_SettlementDateRemeasurementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" id="mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAcceleratedVestingNumber" id="mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAcceleratedVestingNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" id="mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice" id="mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationAwardTrancheFiveMember" id="mdcx_ShareBasedCompensationAwardTrancheFiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationAwardTrancheFourMember" id="mdcx_ShareBasedCompensationAwardTrancheFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationAwardTrancheSixMember" id="mdcx_ShareBasedCompensationAwardTrancheSixMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedPaymentAwardGrantDateAxis" id="mdcx_ShareBasedPaymentAwardGrantDateAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="ShareBasedPaymentAwardGrantDateDomain" id="mdcx_ShareBasedPaymentAwardGrantDateDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareCapitalNoteDisclosureLineItems" id="mdcx_ShareCapitalNoteDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareCapitalNoteDisclosureTable" id="mdcx_ShareCapitalNoteDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="ShareConsolidationAxis" id="mdcx_ShareConsolidationAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="ShareConsolidationDomain" id="mdcx_ShareConsolidationDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareConsolidationMember" id="mdcx_ShareConsolidationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareIssuanceCosts" id="mdcx_ShareIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SharePriceAsPercentageOfMarketPrice" id="mdcx_SharePriceAsPercentageOfMarketPrice" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SharesIssuedForAcquisitionOfAntev" id="mdcx_SharesIssuedForAcquisitionOfAntev" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SharesIssuedMember" id="mdcx_SharesIssuedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SharesToBeIssuedForAcquisitionOfAntev" id="mdcx_SharesToBeIssuedForAcquisitionOfAntev" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ShortTermIncentivePlanMember" id="mdcx_ShortTermIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SimpleAgreementForFutureEquityMember" id="mdcx_SimpleAgreementForFutureEquityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SkinjectIncMember" id="mdcx_SkinjectIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SpecialStockOptionsAndPerformanceShareUnitsMember" id="mdcx_SpecialStockOptionsAndPerformanceShareUnitsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SpecialStockOptionsMember" id="mdcx_SpecialStockOptionsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StandbyEquityPurchaseAgreementMember" id="mdcx_StandbyEquityPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesCommonStockIssuedForAmortizedIssuanceCosts" id="mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForAmortizedIssuanceCosts" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesCommonStockIssuedForCompensation" id="mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForCompensation" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesCommonStockIssuedForPsus" id="mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForPsus" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits" id="mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesCommonStockIssuedForRsus" id="mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRsus" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts" id="mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesConnectionWithEquityFinancing" id="mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesConnectionWithFinancing" id="mdcx_StockIssuedDuringPeriodSharesConnectionWithFinancing" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts" id="mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts" id="mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesConversionOfDebt" id="mdcx_StockIssuedDuringPeriodSharesConversionOfDebt" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesConversionOfNotePayable" id="mdcx_StockIssuedDuringPeriodSharesConversionOfNotePayable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesConversionOfPreferredShares" id="mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesExerciseOfWarrants" id="mdcx_StockIssuedDuringPeriodSharesExerciseOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesForCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts" id="mdcx_StockIssuedDuringPeriodSharesForCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered" id="mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesOfCommonStock" id="mdcx_StockIssuedDuringPeriodSharesOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants" id="mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodValueCommonStockIssuedForAmortizedIssuanceCosts" id="mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForAmortizedIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueCommonStockIssuedForCompensation" id="mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="StockIssuedDuringPeriodValueCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts" id="mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="StockIssuedDuringPeriodValueCommonStockIssuedForPsus" id="mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForPsus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueCommonStockIssuedForRestrictedStockUnits" id="mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRestrictedStockUnits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueCommonStockIssuedForRsus" id="mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRsus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost" id="mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueConnectionWithEquityFinancing" id="mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueConnectionWithFinancing" id="mdcx_StockIssuedDuringPeriodValueConnectionWithFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts" id="mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" id="mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueConversionOfDebt" id="mdcx_StockIssuedDuringPeriodValueConversionOfDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueConversionOfNotePayable" id="mdcx_StockIssuedDuringPeriodValueConversionOfNotePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueConversionOfPreferredShares" id="mdcx_StockIssuedDuringPeriodValueConversionOfPreferredShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueExerciseOfWarrants" id="mdcx_StockIssuedDuringPeriodValueExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueForPaymentOfIncomeTaxesRemittedOnRsusAndPsus" id="mdcx_StockIssuedDuringPeriodValueForPaymentOfIncomeTaxesRemittedOnRsusAndPsus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered" id="mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueOfCommonShares" id="mdcx_StockIssuedDuringPeriodValueOfCommonShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueUponExerciseOfStockWarrants" id="mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockOptionsMember" id="mdcx_StockOptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockPurchaseWarrantsTerm" id="mdcx_StockPurchaseWarrantsTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TeverelixMember" id="mdcx_TeverelixMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ThresholdLimitOfFinancing" id="mdcx_ThresholdLimitOfFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="TotalShareholderReturnPerformanceSharesMember" id="mdcx_TotalShareholderReturnPerformanceSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoZeroOneNineStockIncentivePlanMember" id="mdcx_TwoZeroOneNineStockIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoZeroOneThreeStockIncentivePlanMember" id="mdcx_TwoZeroOneThreeStockIncentivePlanMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoZeroTwoZeroStockIncentivePlanMember" id="mdcx_TwoZeroTwoZeroStockIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement" id="mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="VelocityFundManagementLLCMember" id="mdcx_VelocityFundManagementLLCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="VestUponCommonSharesAchievingCertainVolumeWeightedAverageTradingPricesMember" id="mdcx_VestUponCommonSharesAchievingCertainVolumeWeightedAverageTradingPricesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantLiabilityIssuedDuringPeriod" id="mdcx_WarrantLiabilityIssuedDuringPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="WarrantsIssuedAsPartOfIpoMember" id="mdcx_WarrantsIssuedAsPartOfIpoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsIssuedUnderWarrantInducement" id="mdcx_WarrantsIssuedUnderWarrantInducement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="WarrantWithExpiryDateJune302030WarrantsMember" id="mdcx_WarrantWithExpiryDateJune302030WarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantWithExpiryDateMarch102030Member" id="mdcx_WarrantWithExpiryDateMarch102030Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WeightedAverageExercisePriceOfWarrant" id="mdcx_WeightedAverageExercisePriceOfWarrant" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WeightedAverageExercisePriceWarrantExercise" id="mdcx_WeightedAverageExercisePriceWarrantExercise" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WeightedAverageExercisePriceWarrantGranted" id="mdcx_WeightedAverageExercisePriceWarrantGranted" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WeightedAverageRemainingContractualTermOfWarrant" id="mdcx_WeightedAverageRemainingContractualTermOfWarrant" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WeightedAverageRemainingContractualTermOfWarrantGranted" id="mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WithholdingOfEmployeeTaxPaymentsOnRestrictedStockUnits" id="mdcx_WithholdingOfEmployeeTaxPaymentsOnRestrictedStockUnits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="YaIiPnLtdMember" id="mdcx_YaIiPnLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="YorkvilleMember" id="mdcx_YorkvilleMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>mdcx-20260630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#idr_BalanceSheets" roleURI="http://www.medicuspharma.com/role/idr_BalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#idr_StatementsOfOperations" roleURI="http://www.medicuspharma.com/role/idr_StatementsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#idr_StatementsOfCashFlows" roleURI="http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#BalanceSheetComponentsDetails" roleURI="http://www.medicuspharma.com/role/BalanceSheetComponentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#BalanceSheetComponentsDetails1" roleURI="http://www.medicuspharma.com/role/BalanceSheetComponentsDetails1"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#LeasesDetails2" roleURI="http://www.medicuspharma.com/role/LeasesDetails2"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#ResearchAndDevelopmentRDExpensesDetails" roleURI="http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/idr_BalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaap_DeferredCostsCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_6"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_CommonSharesToBeIssued" xlink:label="loc_mdcx_CommonSharesToBeIssued_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SecuredLongTermDebt" xlink:label="loc_us-gaap_SecuredLongTermDebt_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaap_LongTermLoansPayable_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_17"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RelatedPartyPayableCurrent" xlink:label="loc_mdcx_RelatedPartyPayableCurrent_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SecuredDebtCurrent" xlink:label="loc_us-gaap_SecuredDebtCurrent_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_26"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0" xlink:to="loc_us-gaap_DeferredCostsCurrent_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5" xlink:to="loc_us-gaap_MinorityInterest_5" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5" xlink:to="loc_us-gaap_StockholdersEquity_6" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6" xlink:to="loc_us-gaap_CommonStockValue_6" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6" xlink:to="loc_mdcx_CommonSharesToBeIssued_7" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6" xlink:to="loc_us-gaap_AdditionalPaidInCapital_10" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4" xlink:to="loc_us-gaap_Liabilities_13" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_13" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_13" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_13" xlink:to="loc_us-gaap_SecuredLongTermDebt_14" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_13" xlink:to="loc_us-gaap_LongTermLoansPayable_15" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_13" xlink:to="loc_us-gaap_LiabilitiesCurrent_16" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_16" xlink:to="loc_us-gaap_AccountsPayableCurrent_16" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_16" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_17" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_16" xlink:to="loc_mdcx_RelatedPartyPayableCurrent_18" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_16" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_19" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_16" xlink:to="loc_us-gaap_SecuredDebtCurrent_20" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_23" xlink:to="loc_us-gaap_AssetsCurrent_24" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_23" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_25" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_23" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_26" order="20" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/idr_StatementsOfOperations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GainLossOnSettlements" xlink:label="loc_mdcx_GainLossOnSettlements_5"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ChangeInFairValueOfDebentures" xlink:label="loc_mdcx_ChangeInFairValueOfDebentures_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0" xlink:to="loc_us-gaap_ProfitLoss_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_2" xlink:to="loc_us-gaap_InvestmentIncomeNet_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_2" xlink:to="loc_us-gaap_InterestExpense_3" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_2" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_2" xlink:to="loc_mdcx_GainLossOnSettlements_5" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_2" xlink:to="loc_mdcx_ChangeInFairValueOfDebentures_6" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_2" xlink:to="loc_us-gaap_OperatingIncomeLoss_8" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8" xlink:to="loc_us-gaap_OperatingExpenses_8" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/idr_StatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts" xlink:label="loc_mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:label="loc_mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets_6"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GainLossOnSettlements" xlink:label="loc_mdcx_GainLossOnSettlements_7"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes" xlink:label="loc_mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_14"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes" xlink:label="loc_mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes_15"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered" xlink:label="loc_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_18"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromConcurrentFinancing" xlink:label="loc_mdcx_ProceedsFromConcurrentFinancing_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_22"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromIssuanceOfSharesUnderSettlements" xlink:label="loc_mdcx_ProceedsFromIssuanceOfSharesUnderSettlements_23"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts" xlink:label="loc_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_28"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xlink:to="loc_mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts_1" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" xlink:to="loc_us-gaap_ProfitLoss_3" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" xlink:to="loc_us-gaap_PaidInKindInterest_4" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" xlink:to="loc_us-gaap_ShareBasedCompensation_5" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" xlink:to="loc_mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets_6" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" xlink:to="loc_mdcx_GainLossOnSettlements_7" order="40" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" xlink:to="loc_mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes_8" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_9" order="60" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_10" order="70" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_11" order="80" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_12" order="90" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_13" order="100" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_14" order="110" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" xlink:to="loc_mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes_15" order="120" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" xlink:to="loc_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered_16" order="130" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_18" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_18" xlink:to="loc_mdcx_ProceedsFromConcurrentFinancing_18" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_18" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_19" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_18" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_20" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_18" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_21" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_18" xlink:to="loc_us-gaap_RepaymentsOfDebt_22" order="40" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_18" xlink:to="loc_mdcx_ProceedsFromIssuanceOfSharesUnderSettlements_23" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_18" xlink:to="loc_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts_24" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_18" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_25" order="70" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_18" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_26" order="80" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_28" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/BalanceSheetComponentsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_0"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PrepaidContractResearch" xlink:label="loc_mdcx_PrepaidContractResearch_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance_2"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PrepaidServices" xlink:label="loc_mdcx_PrepaidServices_3"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PrepaidProfessionalServices" xlink:label="loc_mdcx_PrepaidProfessionalServices_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_0" xlink:to="loc_mdcx_PrepaidContractResearch_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_0" xlink:to="loc_us-gaap_PrepaidInsurance_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_0" xlink:to="loc_mdcx_PrepaidServices_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_0" xlink:to="loc_mdcx_PrepaidProfessionalServices_4" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/BalanceSheetComponentsDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3" order="20" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/LeasesDetails2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaap_LaborAndRelatedExpense_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ChangeInFairValueOfDebentures" xlink:label="loc_mdcx_ChangeInFairValueOfDebentures_2"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GainLossOnSettlements" xlink:label="loc_mdcx_GainLossOnSettlements_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaap_LaborAndRelatedExpense_9"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_2" xlink:to="loc_mdcx_ChangeInFairValueOfDebentures_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_2" xlink:to="loc_mdcx_GainLossOnSettlements_3" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_2" xlink:to="loc_us-gaap_InvestmentIncomeNet_4" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_2" xlink:to="loc_us-gaap_InterestExpense_5" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1" xlink:to="loc_us-gaap_OperatingExpenses_7" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_8" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_8" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_8" xlink:to="loc_us-gaap_LaborAndRelatedExpense_9" order="10" use="optional" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>mdcx-20260630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#idr_DocumentDocumentAndEntityInformation" roleURI="http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#idr_StatementsOfChangesInShareholdersDeficit" roleURI="http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#ShareCapitalNarrativeDetails" roleURI="http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#ShareCapitalDetails" roleURI="http://www.medicuspharma.com/role/ShareCapitalDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#ShareCapitalScheduleOfWarrantsContinuityDetails" roleURI="http://www.medicuspharma.com/role/ShareCapitalScheduleOfWarrantsContinuityDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#ShareCapitalDetails1" roleURI="http://www.medicuspharma.com/role/ShareCapitalDetails1"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#StockBasedCompensationNarrativeDetails" roleURI="http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#StockBasedCompensationScheduleOfWeightedaverageAssumptionsToDetermineFairValueOfStockOptionsGrantedDetails" roleURI="http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfWeightedaverageAssumptionsToDetermineFairValueOfStockOptionsGrantedDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#RelatedPartyTransactionsNarrativeDetails" roleURI="http://www.medicuspharma.com/role/RelatedPartyTransactionsNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#FairValueMeasurementDetails" roleURI="http://www.medicuspharma.com/role/FairValueMeasurementDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#CommitmentsAndContingenciesN" roleURI="http://www.medicuspharma.com/role/CommitmentsAndContingenciesN"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails" roleURI="http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#ResearchAndDevelopmentRDExpensesDetails" roleURI="http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#DebenturesNarrativeDetails" roleURI="http://www.medicuspharma.com/role/DebenturesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#DebenturesScheduleOfDebentureContinuityDetails" roleURI="http://www.medicuspharma.com/role/DebenturesScheduleOfDebentureContinuityDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#DebenturesAndPromissoryNotesNdfd" roleURI="http://www.medicuspharma.com/role/DebenturesAndPromissoryNotesNdfd"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#RestrictedCashNarrativeDetails" roleURI="http://www.medicuspharma.com/role/RestrictedCashNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#TESTTESTTESTDetails" roleURI="http://www.medicuspharma.com/role/TESTTESTTESTDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#SubsequentEventsNarrativeDetails" roleURI="http://www.medicuspharma.com/role/SubsequentEventsNarrativeDetails"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentDescription" xlink:label="loc_dei_DocumentDescription_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_dei_DocumentPeriodStartDate_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PhoneFaxNumberDescription" xlink:label="loc_dei_PhoneFaxNumberDescription_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12gTitle" xlink:label="loc_dei_Security12gTitle_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityListingParValuePerShare" xlink:label="loc_dei_EntityListingParValuePerShare_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_dei_NoTradingSymbolFlag_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_51"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_52"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_dei_AuditorOpinionTextBlock_53"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_WarrantMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityRegistrantName_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCentralIndexKey_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentType_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentAnnualReport_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentQuarterlyReport_12" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentDescription_13" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityFileNumber_14" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentPeriodStartDate_15" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_16" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentPeriodEndDate_17" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalYearFocus_18" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_19" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_20" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityTaxIdentificationNumber_21" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine1_22" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine2_23" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressCityOrTown_24" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressStateOrProvince_25" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressPostalZipCode_26" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_CityAreaCode_27" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_LocalPhoneNumber_28" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_PhoneFaxNumberDescription_29" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_Security12gTitle_30" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_TradingSymbol_31" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_SecurityExchangeName_32" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityListingParValuePerShare_33" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_34" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityVoluntaryFilers_35" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCurrentReportingStatus_36" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityInteractiveDataCurrent_37" order="310" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityFilerCategory_38" order="320" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntitySmallBusiness_39" order="330" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityEmergingGrowthCompany_40" order="340" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityShellCompany_41" order="350" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityPublicFloat_42" order="360" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_43" order="370" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AmendmentFlag_44" order="380" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AmendmentDescription_45" order="390" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_NoTradingSymbolFlag_46" order="400" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentTransitionReport_47" order="410" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityExTransitionPeriod_48" order="420" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AuditorFirmId_49" order="430" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AuditorName_50" order="440" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AuditorLocation_51" order="450" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_52" order="460" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AuditorOpinionTextBlock_53" order="470" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SharesIssuedMember" xlink:label="loc_mdcx_SharesIssuedMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts_15"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts_16"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing_17"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing_18"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareIssuanceCosts" xlink:label="loc_mdcx_ShareIssuanceCosts_19"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants_20"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_23"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConversionOfDebt" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_24"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConversionOfDebt" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_25"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts_26"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts_27"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost_28"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts_29"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered_30"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_34"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueOfCommonShares" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueOfCommonShares_35"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesOfCommonStock" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesOfCommonStock_36"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares" xlink:label="loc_mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares_37"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantsIssuedUnderWarrantInducement" xlink:label="loc_mdcx_WarrantsIssuedUnderWarrantInducement_38"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DeemedDividendOnWarrantInducement" xlink:label="loc_mdcx_DeemedDividendOnWarrantInducement_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_41"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_mdcx_SharesIssuedMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_NoncontrollingInterestMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts_15" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts_16" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing_17" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing_18" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mdcx_ShareIssuanceCosts_19" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants_20" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants_21" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_22" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_23" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_24" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_25" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts_26" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts_27" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost_28" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts_29" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered_30" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered_31" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_32" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_33" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_34" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mdcx_StockIssuedDuringPeriodValueOfCommonShares_35" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mdcx_StockIssuedDuringPeriodSharesOfCommonStock_36" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares_37" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mdcx_WarrantsIssuedUnderWarrantInducement_38" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_mdcx_DeemedDividendOnWarrantInducement_39" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProfitLoss_40" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_41" order="310" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails">
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareCapitalNoteDisclosureLineItems" xlink:label="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareCapitalNoteDisclosureTable" xlink:label="loc_mdcx_ShareCapitalNoteDisclosureTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_2"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RegulationAOfferingMember" xlink:label="loc_mdcx_RegulationAOfferingMember_3"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_June2025PublicOfferingMember" xlink:label="loc_mdcx_June2025PublicOfferingMember_4"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StandbyEquityPurchaseAgreementMember" xlink:label="loc_mdcx_StandbyEquityPurchaseAgreementMember_5"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AtmAgreementMember" xlink:label="loc_mdcx_AtmAgreementMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_10"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesAWarrantsMember" xlink:label="loc_mdcx_SeriesAWarrantsMember_10"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesBWarrantsMember" xlink:label="loc_mdcx_SeriesBWarrantsMember_11"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesAAndBWarrantsGrantedMember" xlink:label="loc_mdcx_SeriesAAndBWarrantsGrantedMember_12"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesCAndDWarrantsGrantedMember" xlink:label="loc_mdcx_SeriesCAndDWarrantsGrantedMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_17"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_YaIiPnLtdMember" xlink:label="loc_mdcx_YaIiPnLtdMember_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaap_CommonStockConversionBasis_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_28"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares_29"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionAdditionalDebtAmount" xlink:label="loc_mdcx_DebtConversionAdditionalDebtAmount_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:label="loc_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_32"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest" xlink:label="loc_mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionDescription" xlink:label="loc_us-gaap_DebtConversionDescription_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_35"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AccruedInterestConvertedIntoCommonShares" xlink:label="loc_mdcx_AccruedInterestConvertedIntoCommonShares_36"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConversionOfDebt" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_37"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConversionOfDebt" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_38"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement" xlink:label="loc_mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement_39"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement" xlink:label="loc_mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_42"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SharePriceAsPercentageOfMarketPrice" xlink:label="loc_mdcx_SharePriceAsPercentageOfMarketPrice_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_45"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures" xlink:label="loc_mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures_46"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement" xlink:label="loc_mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_49"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice_50"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantLiabilityIssuedDuringPeriod" xlink:label="loc_mdcx_WarrantLiabilityIssuedDuringPeriod_51"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares" xlink:label="loc_mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares_52"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionRemainingConvertibleAmount" xlink:label="loc_mdcx_DebtConversionRemainingConvertibleAmount_53"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount" xlink:label="loc_mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount_54"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_55"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromSimpleAgreementForFutureEquity" xlink:label="loc_mdcx_ProceedsFromSimpleAgreementForFutureEquity_56"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ThresholdLimitOfFinancing" xlink:label="loc_mdcx_ThresholdLimitOfFinancing_57"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_58"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_59"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_61"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockPurchaseWarrantsTerm" xlink:label="loc_mdcx_StockPurchaseWarrantsTerm_62"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IncrementalFairValueOfWarrantsGranted" xlink:label="loc_mdcx_IncrementalFairValueOfWarrantsGranted_63"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_FairValueOfWarrantsGranted" xlink:label="loc_mdcx_FairValueOfWarrantsGranted_64"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_65"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_66"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_FairValuePerShare" xlink:label="loc_mdcx_FairValuePerShare_67"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_FairValuePerWarrant" xlink:label="loc_mdcx_FairValuePerWarrant_68"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfWarrantsExercised" xlink:label="loc_mdcx_NumberOfWarrantsExercised_69"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_70"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfWarrantsExercisedForCash" xlink:label="loc_mdcx_NumberOfWarrantsExercisedForCash_71"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_72"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_73"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PaymentOfStructuringFee" xlink:label="loc_mdcx_PaymentOfStructuringFee_74"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_75"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_76"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_EquityDistributionAgreementCommissionRate" xlink:label="loc_mdcx_EquityDistributionAgreementCommissionRate_77"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_ShareCapitalNoteDisclosureTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_PrivatePlacementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_IPOMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_mdcx_RegulationAOfferingMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_mdcx_June2025PublicOfferingMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_mdcx_StandbyEquityPurchaseAgreementMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_mdcx_AtmAgreementMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_10" xlink:to="loc_us-gaap_ClassOfStockDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_10" xlink:to="loc_mdcx_SeriesAWarrantsMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_10" xlink:to="loc_mdcx_SeriesBWarrantsMember_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_10" xlink:to="loc_mdcx_SeriesAAndBWarrantsGrantedMember_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_10" xlink:to="loc_mdcx_SeriesCAndDWarrantsGrantedMember_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_10" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureTable_1" xlink:to="loc_dei_LegalEntityAxis_17" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_17" xlink:to="loc_dei_EntityDomain_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_17" xlink:to="loc_mdcx_YaIiPnLtdMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_17" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_21" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_21" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_21" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_21" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_21" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_21" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_26" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_CommonStockConversionBasis_27" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_28" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares_29" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_DebtConversionAdditionalDebtAmount_30" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_31" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_32" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest_33" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_DebtConversionDescription_34" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_35" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_AccruedInterestConvertedIntoCommonShares_36" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_37" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_38" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement_39" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement_40" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_41" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_42" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_SharePriceAsPercentageOfMarketPrice_43" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_44" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_45" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures_46" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement_47" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_48" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_49" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice_50" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_WarrantLiabilityIssuedDuringPeriod_51" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares_52" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_DebtConversionRemainingConvertibleAmount_53" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount_54" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_55" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_ProceedsFromSimpleAgreementForFutureEquity_56" order="310" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_ThresholdLimitOfFinancing_57" order="320" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_58" order="330" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_59" order="340" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" order="350" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_61" order="360" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_StockPurchaseWarrantsTerm_62" order="370" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_IncrementalFairValueOfWarrantsGranted_63" order="380" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_FairValueOfWarrantsGranted_64" order="390" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_65" order="400" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_66" order="410" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_FairValuePerShare_67" order="420" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_FairValuePerWarrant_68" order="430" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_NumberOfWarrantsExercised_69" order="440" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_70" order="450" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_NumberOfWarrantsExercisedForCash_71" order="460" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_72" order="470" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_73" order="480" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_PaymentOfStructuringFee_74" order="490" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_LegalFees_75" order="500" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_76" order="510" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_0" xlink:to="loc_mdcx_EquityDistributionAgreementCommissionRate_77" order="520" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/ShareCapitalDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RegulationAWarrantsMember" xlink:label="loc_mdcx_RegulationAWarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_2"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PublicWarrantsMember" xlink:label="loc_mdcx_PublicWarrantsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_MeasurementInputValuationDateSharePriceMember" xlink:label="loc_mdcx_MeasurementInputValuationDateSharePriceMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_17"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_mdcx_RegulationAWarrantsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_us-gaap_WarrantMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_mdcx_PublicWarrantsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7" xlink:to="loc_mdcx_MeasurementInputValuationDateSharePriceMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7" xlink:to="loc_us-gaap_MeasurementInputExercisePriceMember_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_10" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_11" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_12" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_17" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/ShareCapitalScheduleOfWarrantsContinuityDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_7"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod_8"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageExercisePriceOfWarrant" xlink:label="loc_mdcx_WeightedAverageExercisePriceOfWarrant_9"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageExercisePriceWarrantGranted" xlink:label="loc_mdcx_WeightedAverageExercisePriceWarrantGranted_10"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageExercisePriceWarrantExercise" xlink:label="loc_mdcx_WeightedAverageExercisePriceWarrantExercise_11"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageRemainingContractualTermOfWarrant" xlink:label="loc_mdcx_WeightedAverageRemainingContractualTermOfWarrant_12"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted" xlink:label="loc_mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted_13"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_us-gaap_WarrantMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_mdcx_WeightedAverageExercisePriceOfWarrant_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_mdcx_WeightedAverageExercisePriceWarrantGranted_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_mdcx_WeightedAverageExercisePriceWarrantExercise_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_mdcx_WeightedAverageRemainingContractualTermOfWarrant_12" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted_13" order="70" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/ShareCapitalDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantsIssuedAsPartOfIpoMember" xlink:label="loc_mdcx_WarrantsIssuedAsPartOfIpoMember_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RegulationAWarrantsMember" xlink:label="loc_mdcx_RegulationAWarrantsMember_2"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantWithExpiryDateJune302030WarrantsMember" xlink:label="loc_mdcx_WarrantWithExpiryDateJune302030WarrantsMember_3"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesCAndDWarrantsMember" xlink:label="loc_mdcx_SeriesCAndDWarrantsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ClassOfWarrantOrRightExpiryDate" xlink:label="loc_mdcx_ClassOfWarrantOrRightExpiryDate_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_11"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ClassOfWarrantOrRightExercisable" xlink:label="loc_mdcx_ClassOfWarrantOrRightExercisable_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_mdcx_WarrantsIssuedAsPartOfIpoMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_mdcx_RegulationAWarrantsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_mdcx_WarrantWithExpiryDateJune302030WarrantsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_mdcx_SeriesCAndDWarrantsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_mdcx_ClassOfWarrantOrRightExpiryDate_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_11" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_mdcx_ClassOfWarrantOrRightExercisable_12" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_10"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IndividualsMember" xlink:label="loc_mdcx_IndividualsMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding" xlink:label="loc_mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_27"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_VestingAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_5" xlink:to="loc_us-gaap_VestingDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_5" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_5" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_5" xlink:to="loc_us-gaap_VestingDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_10" xlink:to="loc_us-gaap_RelatedPartyDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_10" xlink:to="loc_mdcx_IndividualsMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_10" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_18" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_19" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_20" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_21" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_22" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_23" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_24" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_25" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_26" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_27" order="130" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfWeightedaverageAssumptionsToDetermineFairValueOfStockOptionsGrantedDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharePrice_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_11" order="60" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/RelatedPartyTransactionsNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_VelocityFundManagementLLCMember" xlink:label="loc_mdcx_VelocityFundManagementLLCMember_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RbxCapitalLPMember" xlink:label="loc_mdcx_RbxCapitalLPMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ManagementMember" xlink:label="loc_srt_ManagementMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensation_8"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RelatedPartyTransactionAdditionalExpenses" xlink:label="loc_mdcx_RelatedPartyTransactionAdditionalExpenses_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_11"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfConvertibleNotesSubscribed" xlink:label="loc_mdcx_NumberOfConvertibleNotesSubscribed_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_14"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_mdcx_VelocityFundManagementLLCMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_mdcx_RbxCapitalLPMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_srt_ManagementMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_SalariesWagesAndOfficersCompensation_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_mdcx_RelatedPartyTransactionAdditionalExpenses_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_10" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_11" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_mdcx_NumberOfConvertibleNotesSubscribed_12" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_13" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_14" order="70" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/FairValueMeasurementDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_12" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_12" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_12" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_16" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_16" order="0" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/CommitmentsAndContingenciesN">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AntevLimitedMember" xlink:label="loc_mdcx_AntevLimitedMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_mdcx_AntevLimitedMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AntevLimitedMember" xlink:label="loc_mdcx_AntevLimitedMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_5"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ContingentConsiderationPhasesOneMember" xlink:label="loc_mdcx_ContingentConsiderationPhasesOneMember_5"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ContingentConsiderationPhasesTwoMember" xlink:label="loc_mdcx_ContingentConsiderationPhasesTwoMember_6"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ContingentConsiderationPhasesThreeMember" xlink:label="loc_mdcx_ContingentConsiderationPhasesThreeMember_7"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ContingentConsiderationPhasesFourMember" xlink:label="loc_mdcx_ContingentConsiderationPhasesFourMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis" xlink:label="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis_12"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain" xlink:label="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_12"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain" xlink:label="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_22"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_mdcx_AntevLimitedMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_5" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_5" xlink:to="loc_mdcx_ContingentConsiderationPhasesOneMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_5" xlink:to="loc_mdcx_ContingentConsiderationPhasesTwoMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_5" xlink:to="loc_mdcx_ContingentConsiderationPhasesThreeMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_5" xlink:to="loc_mdcx_ContingentConsiderationPhasesFourMember_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_5" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" xlink:to="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis_12" xlink:to="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain_12" xlink:to="loc_us-gaap_CommonStockMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis_12" xlink:to="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" xlink:to="loc_srt_RangeAxis_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_16" xlink:to="loc_srt_RangeMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_16" xlink:to="loc_srt_MaximumMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_16" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_21" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_22" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SkinjectIncMember" xlink:label="loc_mdcx_SkinjectIncMember_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_TeverelixMember" xlink:label="loc_mdcx_TeverelixMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_6"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember" xlink:label="loc_mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember_6"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProfessionalServicesAndIntellectualPropertyMember" xlink:label="loc_mdcx_ProfessionalServicesAndIntellectualPropertyMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaap_LaborAndRelatedExpense_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_18"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GainLossOnSettlements" xlink:label="loc_mdcx_GainLossOnSettlements_19"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ChangeInFairValueOfDebentures" xlink:label="loc_mdcx_ChangeInFairValueOfDebentures_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_22"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_mdcx_SkinjectIncMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_mdcx_TeverelixMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6" xlink:to="loc_us-gaap_ProjectMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_6" xlink:to="loc_mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_6" xlink:to="loc_mdcx_ProfessionalServicesAndIntellectualPropertyMember_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6" xlink:to="loc_us-gaap_ProjectMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0" xlink:to="loc_us-gaap_LaborAndRelatedExpense_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_15" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0" xlink:to="loc_us-gaap_OperatingExpenses_16" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_17" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_17" xlink:to="loc_us-gaap_InvestmentIncomeNet_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_17" xlink:to="loc_us-gaap_InterestExpense_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_17" xlink:to="loc_mdcx_GainLossOnSettlements_19" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_17" xlink:to="loc_mdcx_ChangeInFairValueOfDebentures_20" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_17" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_21" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_17" xlink:to="loc_us-gaap_ProfitLoss_22" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/DebenturesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SecuredPromissoryNotesMember" xlink:label="loc_mdcx_SecuredPromissoryNotesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NoteAMember" xlink:label="loc_mdcx_NoteAMember_5"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NoteBMember" xlink:label="loc_mdcx_NoteBMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_10"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_InterimRemeasurementMember" xlink:label="loc_mdcx_InterimRemeasurementMember_10"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SettlementDateRemeasurementMember" xlink:label="loc_mdcx_SettlementDateRemeasurementMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SecuritiesPurchaseAgreementMember" xlink:label="loc_mdcx_SecuritiesPurchaseAgreementMember_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaap_DebtInstrumentIssuedPrincipal_25"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtIssuanceDiscount" xlink:label="loc_mdcx_DebtIssuanceDiscount_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_27"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebenturesIssuedPercentageOfDiscountedPrice" xlink:label="loc_mdcx_DebenturesIssuedPercentageOfDiscountedPrice_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_35"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentConvertibleExtinguished" xlink:label="loc_mdcx_DebtInstrumentConvertibleExtinguished_36"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ConvertibleDebtAccretionExpense" xlink:label="loc_mdcx_ConvertibleDebtAccretionExpense_37"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_EffectiveInterestRateOnDebt" xlink:label="loc_mdcx_EffectiveInterestRateOnDebt_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_39"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AccruedInterestRepaid" xlink:label="loc_mdcx_AccruedInterestRepaid_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_43"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentRedemptionLimitAmount" xlink:label="loc_mdcx_DebtInstrumentRedemptionLimitAmount_44"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtDefaultBalanceIncreasePercentage" xlink:label="loc_mdcx_DebtDefaultBalanceIncreasePercentage_45"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit" xlink:label="loc_mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit_46"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage" xlink:label="loc_mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault" xlink:label="loc_us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault_49"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentExchangeThresholdAmount" xlink:label="loc_mdcx_DebtInstrumentExchangeThresholdAmount_50"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentMaximumExchangeLimitAmount" xlink:label="loc_mdcx_DebtInstrumentMaximumExchangeLimitAmount_51"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1" xlink:to="loc_mdcx_SecuredPromissoryNotesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5" xlink:to="loc_mdcx_NoteAMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5" xlink:to="loc_mdcx_NoteBMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_10" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_10" xlink:to="loc_mdcx_InterimRemeasurementMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_10" xlink:to="loc_mdcx_SettlementDateRemeasurementMember_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_10" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_srt_RangeAxis_15" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_15" xlink:to="loc_srt_RangeMember_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_15" xlink:to="loc_srt_MinimumMember_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_15" xlink:to="loc_srt_MaximumMember_16" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_15" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_20" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_20" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20" xlink:to="loc_mdcx_SecuritiesPurchaseAgreementMember_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_20" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentIssuedPrincipal_25" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_mdcx_DebtIssuanceDiscount_26" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_27" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_mdcx_DebenturesIssuedPercentageOfDiscountedPrice_28" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_29" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_30" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_31" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_32" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_33" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_34" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_35" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_mdcx_DebtInstrumentConvertibleExtinguished_36" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_mdcx_ConvertibleDebtAccretionExpense_37" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_mdcx_EffectiveInterestRateOnDebt_38" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_RepaymentsOfDebt_39" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_mdcx_AccruedInterestRepaid_40" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_41" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_42" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_InterestPayableCurrent_43" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_mdcx_DebtInstrumentRedemptionLimitAmount_44" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_mdcx_DebtDefaultBalanceIncreasePercentage_45" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit_46" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage_47" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_48" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault_49" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_mdcx_DebtInstrumentExchangeThresholdAmount_50" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_mdcx_DebtInstrumentMaximumExchangeLimitAmount_51" order="270" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/DebenturesScheduleOfDebentureContinuityDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebentureContinuityOneMember" xlink:label="loc_mdcx_DebentureContinuityOneMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_7"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ConvertibleDebtAccretionExpense" xlink:label="loc_mdcx_ConvertibleDebtAccretionExpense_8"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RepaymentsOfInterest" xlink:label="loc_mdcx_RepaymentsOfInterest_9"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1" xlink:to="loc_mdcx_DebentureContinuityOneMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtCurrent_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_RepaymentsOfDebt_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_mdcx_ConvertibleDebtAccretionExpense_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_mdcx_RepaymentsOfInterest_9" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/DebenturesAndPromissoryNotesNdfd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SecuredPromissoryNotesMember" xlink:label="loc_mdcx_SecuredPromissoryNotesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NoteAMember" xlink:label="loc_mdcx_NoteAMember_5"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NoteBMember" xlink:label="loc_mdcx_NoteBMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1" xlink:to="loc_mdcx_SecuredPromissoryNotesMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5" xlink:to="loc_mdcx_NoteAMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5" xlink:to="loc_mdcx_NoteBMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_InterestExpenseDebt_14" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_NotesPayable_15" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/RestrictedCashNarrativeDetails">
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RestrictedCashLineItems" xlink:label="loc_mdcx_RestrictedCashLineItems_0"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RestrictedCashTable" xlink:label="loc_mdcx_RestrictedCashTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NoteBMember" xlink:label="loc_mdcx_NoteBMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mdcx_RestrictedCashLineItems_0" xlink:to="loc_mdcx_RestrictedCashTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mdcx_RestrictedCashTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1" xlink:to="loc_mdcx_NoteBMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mdcx_RestrictedCashLineItems_0" xlink:to="loc_us-gaap_RestrictedCashCurrent_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/TESTTESTTESTDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockOptionsMember" xlink:label="loc_mdcx_StockOptionsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_2"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebenturesMember" xlink:label="loc_mdcx_DebenturesMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_mdcx_StockOptionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_WarrantMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_mdcx_DebenturesMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/SubsequentEventsNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_5"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AgentsMember" xlink:label="loc_mdcx_AgentsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_12"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents" xlink:label="loc_mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents_13"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5" xlink:to="loc_mdcx_AgentsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_12" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents_13" order="40" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>mdcx-20260630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_GB" xlink:label="loc_country_GB_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_GB" xlink:label="loc_country_GB_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_US" xlink:label="loc_country_US_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2026/country-2026.xsd#country_US" xlink:label="loc_country_US_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_dei_AuditorOpinionTextBlock_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_dei_AuditorOpinionTextBlock_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentDescription" xlink:label="loc_dei_DocumentDescription_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_dei_DocumentPeriodStartDate_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityListingParValuePerShare" xlink:label="loc_dei_EntityListingParValuePerShare_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_51"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_dei_NoTradingSymbolFlag_52"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PhoneFaxNumberDescription" xlink:label="loc_dei_PhoneFaxNumberDescription_53"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12gTitle" xlink:label="loc_dei_Security12gTitle_54"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_55"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_56"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AccrualOfAtmIssuanceCosts" xlink:label="loc_mdcx_AccrualOfAtmIssuanceCosts_57"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AccrualOfAtmIssuanceCosts" xlink:label="loc_mdcx_AccrualOfAtmIssuanceCosts_58"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AccruedInterestConvertedIntoCommonShares" xlink:label="loc_mdcx_AccruedInterestConvertedIntoCommonShares_59"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AccruedInterestConvertedIntoCommonShares" xlink:label="loc_mdcx_AccruedInterestConvertedIntoCommonShares_60"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AccruedInterestConvertedIntoCommonShares" xlink:label="loc_mdcx_AccruedInterestConvertedIntoCommonShares_61"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AccruedInterestRepaid" xlink:label="loc_mdcx_AccruedInterestRepaid_62"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AccruedInterestRepaid" xlink:label="loc_mdcx_AccruedInterestRepaid_63"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AccruedInterestRepaid" xlink:label="loc_mdcx_AccruedInterestRepaid_64"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AccrueDividendsPreferredSharesRate" xlink:label="loc_mdcx_AccrueDividendsPreferredSharesRate_65"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AccrueDividendsPreferredSharesRate" xlink:label="loc_mdcx_AccrueDividendsPreferredSharesRate_66"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AccrueDividendsPreferredSharesRate" xlink:label="loc_mdcx_AccrueDividendsPreferredSharesRate_67"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AdditionalRestrictedStockUnitIssued" xlink:label="loc_mdcx_AdditionalRestrictedStockUnitIssued_68"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AdditionalRestrictedStockUnitIssued" xlink:label="loc_mdcx_AdditionalRestrictedStockUnitIssued_69"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AdditionalRestrictedStockUnitIssued" xlink:label="loc_mdcx_AdditionalRestrictedStockUnitIssued_70"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" xlink:label="loc_mdcx_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_71"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" xlink:label="loc_mdcx_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_72"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization" xlink:label="loc_mdcx_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_73"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares" xlink:label="loc_mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares_74"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares" xlink:label="loc_mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares_75"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares" xlink:label="loc_mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares_76"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AgentsMember" xlink:label="loc_mdcx_AgentsMember_77"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AgentsMember" xlink:label="loc_mdcx_AgentsMember_78"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement" xlink:label="loc_mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement_79"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement" xlink:label="loc_mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement_80"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement" xlink:label="loc_mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement_81"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AntevAssetAgreementAbstract" xlink:label="loc_mdcx_AntevAssetAgreementAbstract_82"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AntevLimitedMember" xlink:label="loc_mdcx_AntevLimitedMember_83"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AntevLimitedMember" xlink:label="loc_mdcx_AntevLimitedMember_84"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AtmAgreementMember" xlink:label="loc_mdcx_AtmAgreementMember_85"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AtmAgreementMember" xlink:label="loc_mdcx_AtmAgreementMember_86"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AtmAgreementMember" xlink:label="loc_mdcx_AtmAgreementMember_87"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BalanceSheetComponentsAbstract" xlink:label="loc_mdcx_BalanceSheetComponentsAbstract_88"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock" xlink:label="loc_mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock_89"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock" xlink:label="loc_mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock_90"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock" xlink:label="loc_mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock_91"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis" xlink:label="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis_92"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis" xlink:label="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis_93"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain" xlink:label="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain_94"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain" xlink:label="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain_95"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BusinessCombinationDiscountPercentageAppliedToClosingPrice" xlink:label="loc_mdcx_BusinessCombinationDiscountPercentageAppliedToClosingPrice_96"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BusinessCombinationDiscountPercentageAppliedToClosingPrice" xlink:label="loc_mdcx_BusinessCombinationDiscountPercentageAppliedToClosingPrice_97"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BusinessCombinationDiscountPercentageAppliedToClosingPrice" xlink:label="loc_mdcx_BusinessCombinationDiscountPercentageAppliedToClosingPrice_98"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BusinessCombinationDiscountPricePerShare" xlink:label="loc_mdcx_BusinessCombinationDiscountPricePerShare_99"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BusinessCombinationDiscountPricePerShare" xlink:label="loc_mdcx_BusinessCombinationDiscountPricePerShare_100"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BusinessCombinationDiscountPricePerShare" xlink:label="loc_mdcx_BusinessCombinationDiscountPricePerShare_101"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BusinessCombinationReverseTakeoverTransactionTextBlock" xlink:label="loc_mdcx_BusinessCombinationReverseTakeoverTransactionTextBlock_102"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BusinessCombinationReverseTakeoverTransactionTextBlock" xlink:label="loc_mdcx_BusinessCombinationReverseTakeoverTransactionTextBlock_103"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BusinessCombinationReverseTakeoverTransactionTextBlock" xlink:label="loc_mdcx_BusinessCombinationReverseTakeoverTransactionTextBlock_104"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_CashReceivedForInterest" xlink:label="loc_mdcx_CashReceivedForInterest_105"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_CashReceivedForInterest" xlink:label="loc_mdcx_CashReceivedForInterest_106"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_CashReceivedForInterest" xlink:label="loc_mdcx_CashReceivedForInterest_107"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ChangeInFairValueOfDebentures" xlink:label="loc_mdcx_ChangeInFairValueOfDebentures_108"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ChangeInFairValueOfDebentures" xlink:label="loc_mdcx_ChangeInFairValueOfDebentures_109"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ChangeInFairValueOfDebentures" xlink:label="loc_mdcx_ChangeInFairValueOfDebentures_110"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ChangeInFairValueOfDebentures" xlink:label="loc_mdcx_ChangeInFairValueOfDebentures_111"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes" xlink:label="loc_mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes_112"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes" xlink:label="loc_mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes_113"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes" xlink:label="loc_mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes_114"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ClassOfWarrantOrRightExercisable" xlink:label="loc_mdcx_ClassOfWarrantOrRightExercisable_115"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ClassOfWarrantOrRightExercisable" xlink:label="loc_mdcx_ClassOfWarrantOrRightExercisable_116"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ClassOfWarrantOrRightExercisable" xlink:label="loc_mdcx_ClassOfWarrantOrRightExercisable_117"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ClassOfWarrantOrRightExercisable" xlink:label="loc_mdcx_ClassOfWarrantOrRightExercisable_118"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ClassOfWarrantOrRightExpiryDate" xlink:label="loc_mdcx_ClassOfWarrantOrRightExpiryDate_119"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ClassOfWarrantOrRightExpiryDate" xlink:label="loc_mdcx_ClassOfWarrantOrRightExpiryDate_120"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ClassOfWarrantOrRightExpiryDate" xlink:label="loc_mdcx_ClassOfWarrantOrRightExpiryDate_121"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember" xlink:label="loc_mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember_122"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember" xlink:label="loc_mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember_123"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember" xlink:label="loc_mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember_124"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_CommissionsPayableToAgents" xlink:label="loc_mdcx_CommissionsPayableToAgents_125"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_CommissionsPayableToAgents" xlink:label="loc_mdcx_CommissionsPayableToAgents_126"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_CommissionsPayableToAgents" xlink:label="loc_mdcx_CommissionsPayableToAgents_127"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_CommonSharesToBeIssued" xlink:label="loc_mdcx_CommonSharesToBeIssued_128"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_CommonSharesToBeIssued" xlink:label="loc_mdcx_CommonSharesToBeIssued_129"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_CommonSharesToBeIssued" xlink:label="loc_mdcx_CommonSharesToBeIssued_130"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ComprehensiveLossAttributableToParent" xlink:label="loc_mdcx_ComprehensiveLossAttributableToParent_131"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ComprehensiveLossAttributableToParent" xlink:label="loc_mdcx_ComprehensiveLossAttributableToParent_132"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ComprehensiveLossAttributableToParent" xlink:label="loc_mdcx_ComprehensiveLossAttributableToParent_133"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ContingentConsiderationPhasesFourMember" xlink:label="loc_mdcx_ContingentConsiderationPhasesFourMember_134"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ContingentConsiderationPhasesFourMember" xlink:label="loc_mdcx_ContingentConsiderationPhasesFourMember_135"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ContingentConsiderationPhasesFourMember" xlink:label="loc_mdcx_ContingentConsiderationPhasesFourMember_136"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ContingentConsiderationPhasesOneMember" xlink:label="loc_mdcx_ContingentConsiderationPhasesOneMember_137"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ContingentConsiderationPhasesOneMember" xlink:label="loc_mdcx_ContingentConsiderationPhasesOneMember_138"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ContingentConsiderationPhasesOneMember" xlink:label="loc_mdcx_ContingentConsiderationPhasesOneMember_139"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ContingentConsiderationPhasesThreeMember" xlink:label="loc_mdcx_ContingentConsiderationPhasesThreeMember_140"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ContingentConsiderationPhasesThreeMember" xlink:label="loc_mdcx_ContingentConsiderationPhasesThreeMember_141"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ContingentConsiderationPhasesThreeMember" xlink:label="loc_mdcx_ContingentConsiderationPhasesThreeMember_142"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ContingentConsiderationPhasesTwoMember" xlink:label="loc_mdcx_ContingentConsiderationPhasesTwoMember_143"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ContingentConsiderationPhasesTwoMember" xlink:label="loc_mdcx_ContingentConsiderationPhasesTwoMember_144"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ContingentConsiderationPhasesTwoMember" xlink:label="loc_mdcx_ContingentConsiderationPhasesTwoMember_145"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ConversionOfStockConversionOneMember" xlink:label="loc_mdcx_ConversionOfStockConversionOneMember_146"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ConversionOfStockConversionOneMember" xlink:label="loc_mdcx_ConversionOfStockConversionOneMember_147"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ConversionOfStockConversionThreeMember" xlink:label="loc_mdcx_ConversionOfStockConversionThreeMember_148"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ConversionOfStockConversionThreeMember" xlink:label="loc_mdcx_ConversionOfStockConversionThreeMember_149"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ConversionOfStockConversionThreeMember" xlink:label="loc_mdcx_ConversionOfStockConversionThreeMember_150"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ConversionOfStockConversionTwoMember" xlink:label="loc_mdcx_ConversionOfStockConversionTwoMember_151"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ConversionOfStockConversionTwoMember" xlink:label="loc_mdcx_ConversionOfStockConversionTwoMember_152"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ConversionOfStockConversionTwoMember" xlink:label="loc_mdcx_ConversionOfStockConversionTwoMember_153"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ConvertibleDebtAccretionExpense" xlink:label="loc_mdcx_ConvertibleDebtAccretionExpense_154"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ConvertibleDebtAccretionExpense" xlink:label="loc_mdcx_ConvertibleDebtAccretionExpense_155"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ConvertibleDebtAccretionExpense" xlink:label="loc_mdcx_ConvertibleDebtAccretionExpense_156"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ConvertibleDebtAccretionExpense" xlink:label="loc_mdcx_ConvertibleDebtAccretionExpense_157"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ConvertiblePromissoryNotesMember" xlink:label="loc_mdcx_ConvertiblePromissoryNotesMember_158"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ConvertiblePromissoryNotesMember" xlink:label="loc_mdcx_ConvertiblePromissoryNotesMember_159"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ConvertiblePromissoryNotesMember" xlink:label="loc_mdcx_ConvertiblePromissoryNotesMember_160"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes" xlink:label="loc_mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes_161"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes" xlink:label="loc_mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes_162"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes" xlink:label="loc_mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes_163"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebentureContinuityOneMember" xlink:label="loc_mdcx_DebentureContinuityOneMember_164"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebentureContinuityOneMember" xlink:label="loc_mdcx_DebentureContinuityOneMember_165"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebentureContinuityOneMember" xlink:label="loc_mdcx_DebentureContinuityOneMember_166"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebenturesAndSecuredPromissoryNotes" xlink:label="loc_mdcx_DebenturesAndSecuredPromissoryNotes_167"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebenturesAndSecuredPromissoryNotes" xlink:label="loc_mdcx_DebenturesAndSecuredPromissoryNotes_168"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebenturesAndSecuredPromissoryNotes" xlink:label="loc_mdcx_DebenturesAndSecuredPromissoryNotes_169"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebenturesAndSecuredPromissoryNotes" xlink:label="loc_mdcx_DebenturesAndSecuredPromissoryNotes_170"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebenturesIssuedPercentageOfDiscountedPrice" xlink:label="loc_mdcx_DebenturesIssuedPercentageOfDiscountedPrice_171"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebenturesIssuedPercentageOfDiscountedPrice" xlink:label="loc_mdcx_DebenturesIssuedPercentageOfDiscountedPrice_172"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebenturesIssuedPercentageOfDiscountedPrice" xlink:label="loc_mdcx_DebenturesIssuedPercentageOfDiscountedPrice_173"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebenturesMember" xlink:label="loc_mdcx_DebenturesMember_174"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebenturesMember" xlink:label="loc_mdcx_DebenturesMember_175"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionAdditionalDebtAmount" xlink:label="loc_mdcx_DebtConversionAdditionalDebtAmount_176"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionAdditionalDebtAmount" xlink:label="loc_mdcx_DebtConversionAdditionalDebtAmount_177"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionAdditionalDebtAmount" xlink:label="loc_mdcx_DebtConversionAdditionalDebtAmount_178"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares" xlink:label="loc_mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares_179"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares" xlink:label="loc_mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares_180"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares" xlink:label="loc_mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares_181"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionConvertibleIntoPreferredSharesAmount" xlink:label="loc_mdcx_DebtConversionConvertibleIntoPreferredSharesAmount_182"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionConvertibleIntoPreferredSharesAmount" xlink:label="loc_mdcx_DebtConversionConvertibleIntoPreferredSharesAmount_183"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionConvertibleIntoPreferredSharesAmount" xlink:label="loc_mdcx_DebtConversionConvertibleIntoPreferredSharesAmount_184"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount" xlink:label="loc_mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount_185"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount" xlink:label="loc_mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount_186"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount" xlink:label="loc_mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount_187"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest" xlink:label="loc_mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest_188"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest" xlink:label="loc_mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest_189"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest" xlink:label="loc_mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest_190"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionRemainingConvertibleAmount" xlink:label="loc_mdcx_DebtConversionRemainingConvertibleAmount_191"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionRemainingConvertibleAmount" xlink:label="loc_mdcx_DebtConversionRemainingConvertibleAmount_192"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionRemainingConvertibleAmount" xlink:label="loc_mdcx_DebtConversionRemainingConvertibleAmount_193"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtDefaultBalanceIncreasePercentage" xlink:label="loc_mdcx_DebtDefaultBalanceIncreasePercentage_194"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtDefaultBalanceIncreasePercentage" xlink:label="loc_mdcx_DebtDefaultBalanceIncreasePercentage_195"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtDefaultBalanceIncreasePercentage" xlink:label="loc_mdcx_DebtDefaultBalanceIncreasePercentage_196"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentConvertibleExtinguished" xlink:label="loc_mdcx_DebtInstrumentConvertibleExtinguished_197"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentConvertibleExtinguished" xlink:label="loc_mdcx_DebtInstrumentConvertibleExtinguished_198"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentConvertibleExtinguished" xlink:label="loc_mdcx_DebtInstrumentConvertibleExtinguished_199"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage" xlink:label="loc_mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage_200"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage" xlink:label="loc_mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage_201"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage" xlink:label="loc_mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage_202"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentExchangeThresholdAmount" xlink:label="loc_mdcx_DebtInstrumentExchangeThresholdAmount_203"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentExchangeThresholdAmount" xlink:label="loc_mdcx_DebtInstrumentExchangeThresholdAmount_204"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentExchangeThresholdAmount" xlink:label="loc_mdcx_DebtInstrumentExchangeThresholdAmount_205"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentMaximumExchangeLimitAmount" xlink:label="loc_mdcx_DebtInstrumentMaximumExchangeLimitAmount_206"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentMaximumExchangeLimitAmount" xlink:label="loc_mdcx_DebtInstrumentMaximumExchangeLimitAmount_207"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentMaximumExchangeLimitAmount" xlink:label="loc_mdcx_DebtInstrumentMaximumExchangeLimitAmount_208"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentPeriodicPaymentInterestInCash" xlink:label="loc_mdcx_DebtInstrumentPeriodicPaymentInterestInCash_209"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentPeriodicPaymentInterestInCash" xlink:label="loc_mdcx_DebtInstrumentPeriodicPaymentInterestInCash_210"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentPeriodicPaymentInterestInCash" xlink:label="loc_mdcx_DebtInstrumentPeriodicPaymentInterestInCash_211"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentRedemptionLimitAmount" xlink:label="loc_mdcx_DebtInstrumentRedemptionLimitAmount_212"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentRedemptionLimitAmount" xlink:label="loc_mdcx_DebtInstrumentRedemptionLimitAmount_213"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentRedemptionLimitAmount" xlink:label="loc_mdcx_DebtInstrumentRedemptionLimitAmount_214"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit" xlink:label="loc_mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit_215"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit" xlink:label="loc_mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit_216"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit" xlink:label="loc_mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit_217"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtIssuanceDiscount" xlink:label="loc_mdcx_DebtIssuanceDiscount_218"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtIssuanceDiscount" xlink:label="loc_mdcx_DebtIssuanceDiscount_219"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtIssuanceDiscount" xlink:label="loc_mdcx_DebtIssuanceDiscount_220"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DeemedDividendOnWarrantInducement" xlink:label="loc_mdcx_DeemedDividendOnWarrantInducement_221"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DeemedDividendOnWarrantInducement" xlink:label="loc_mdcx_DeemedDividendOnWarrantInducement_222"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DeemedDividendOnWarrantInducement" xlink:label="loc_mdcx_DeemedDividendOnWarrantInducement_223"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DeferredAtmOfferingCostsOffsetAgainstAdditionalPaidInCapital" xlink:label="loc_mdcx_DeferredAtmOfferingCostsOffsetAgainstAdditionalPaidInCapital_224"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DeferredAtmOfferingCostsOffsetAgainstAdditionalPaidInCapital" xlink:label="loc_mdcx_DeferredAtmOfferingCostsOffsetAgainstAdditionalPaidInCapital_225"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DeferredAtmOfferingCostsOffsetAgainstAdditionalPaidInCapital" xlink:label="loc_mdcx_DeferredAtmOfferingCostsOffsetAgainstAdditionalPaidInCapital_226"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement" xlink:label="loc_mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement_227"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement" xlink:label="loc_mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement_228"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement" xlink:label="loc_mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement_229"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DeferredTaxAssetConvertibleDebentures" xlink:label="loc_mdcx_DeferredTaxAssetConvertibleDebentures_230"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DeferredTaxAssetConvertibleDebentures" xlink:label="loc_mdcx_DeferredTaxAssetConvertibleDebentures_231"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DeferredTaxAssetConvertibleDebentures" xlink:label="loc_mdcx_DeferredTaxAssetConvertibleDebentures_232"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DeferredTaxAssetsAdditionalOperatingLossCarryforwardsForeign" xlink:label="loc_mdcx_DeferredTaxAssetsAdditionalOperatingLossCarryforwardsForeign_233"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DeferredTaxAssetsAdditionalOperatingLossCarryforwardsForeign" xlink:label="loc_mdcx_DeferredTaxAssetsAdditionalOperatingLossCarryforwardsForeign_234"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DeferredTaxAssetsAdditionalOperatingLossCarryforwardsForeign" xlink:label="loc_mdcx_DeferredTaxAssetsAdditionalOperatingLossCarryforwardsForeign_235"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DeferredTaxAssetsOperatingLossCarryforwardsNonCapital" xlink:label="loc_mdcx_DeferredTaxAssetsOperatingLossCarryforwardsNonCapital_236"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DeferredTaxAssetsOperatingLossCarryforwardsNonCapital" xlink:label="loc_mdcx_DeferredTaxAssetsOperatingLossCarryforwardsNonCapital_237"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DeferredTaxAssetsOperatingLossCarryforwardsNonCapital" xlink:label="loc_mdcx_DeferredTaxAssetsOperatingLossCarryforwardsNonCapital_238"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_EarningsFromDiscontinuedOperationsMember" xlink:label="loc_mdcx_EarningsFromDiscontinuedOperationsMember_239"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_EarningsFromDiscontinuedOperationsMember" xlink:label="loc_mdcx_EarningsFromDiscontinuedOperationsMember_240"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_EarningsFromDiscontinuedOperationsMember" xlink:label="loc_mdcx_EarningsFromDiscontinuedOperationsMember_241"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_EffectiveInterestRateOnDebt" xlink:label="loc_mdcx_EffectiveInterestRateOnDebt_242"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_EffectiveInterestRateOnDebt" xlink:label="loc_mdcx_EffectiveInterestRateOnDebt_243"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_EffectiveInterestRateOnDebt" xlink:label="loc_mdcx_EffectiveInterestRateOnDebt_244"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_EmployeeStockPurchasePlanMember" xlink:label="loc_mdcx_EmployeeStockPurchasePlanMember_245"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_EmployeeStockPurchasePlanMember" xlink:label="loc_mdcx_EmployeeStockPurchasePlanMember_246"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_EquityDistributionAgreementCommissionRate" xlink:label="loc_mdcx_EquityDistributionAgreementCommissionRate_247"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_EquityDistributionAgreementCommissionRate" xlink:label="loc_mdcx_EquityDistributionAgreementCommissionRate_248"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_EquityDistributionAgreementCommissionRate" xlink:label="loc_mdcx_EquityDistributionAgreementCommissionRate_249"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ExerciseOfPublicWarrantsMember" xlink:label="loc_mdcx_ExerciseOfPublicWarrantsMember_250"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ExerciseOfPublicWarrantsMember" xlink:label="loc_mdcx_ExerciseOfPublicWarrantsMember_251"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ExerciseOfRegulationAWarrantsMember" xlink:label="loc_mdcx_ExerciseOfRegulationAWarrantsMember_252"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ExerciseOfRegulationAWarrantsMember" xlink:label="loc_mdcx_ExerciseOfRegulationAWarrantsMember_253"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ExerciseSeriesAAndBWarrantsIssuedMember" xlink:label="loc_mdcx_ExerciseSeriesAAndBWarrantsIssuedMember_254"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ExerciseSeriesAAndBWarrantsIssuedMember" xlink:label="loc_mdcx_ExerciseSeriesAAndBWarrantsIssuedMember_255"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_FairValueLossOfDebt" xlink:label="loc_mdcx_FairValueLossOfDebt_256"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_FairValueLossOfDebt" xlink:label="loc_mdcx_FairValueLossOfDebt_257"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_FairValueLossOfDebt" xlink:label="loc_mdcx_FairValueLossOfDebt_258"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_FairValueOfAdditionalRestrictedStockUnit" xlink:label="loc_mdcx_FairValueOfAdditionalRestrictedStockUnit_259"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_FairValueOfAdditionalRestrictedStockUnit" xlink:label="loc_mdcx_FairValueOfAdditionalRestrictedStockUnit_260"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_FairValueOfWarrantsGranted" xlink:label="loc_mdcx_FairValueOfWarrantsGranted_261"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_FairValueOfWarrantsGranted" xlink:label="loc_mdcx_FairValueOfWarrantsGranted_262"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_FairValuePerShare" xlink:label="loc_mdcx_FairValuePerShare_263"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_FairValuePerShare" xlink:label="loc_mdcx_FairValuePerShare_264"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_FairValuePerShare" xlink:label="loc_mdcx_FairValuePerShare_265"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_FairValuePerWarrant" xlink:label="loc_mdcx_FairValuePerWarrant_266"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_FairValuePerWarrant" xlink:label="loc_mdcx_FairValuePerWarrant_267"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_FairValuePerWarrant" xlink:label="loc_mdcx_FairValuePerWarrant_268"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ForeignCurrencyTransactionsPolicyTextBlock" xlink:label="loc_mdcx_ForeignCurrencyTransactionsPolicyTextBlock_269"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ForeignCurrencyTransactionsPolicyTextBlock" xlink:label="loc_mdcx_ForeignCurrencyTransactionsPolicyTextBlock_270"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ForeignCurrencyTransactionsPolicyTextBlock" xlink:label="loc_mdcx_ForeignCurrencyTransactionsPolicyTextBlock_271"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_FormerHoldersMember" xlink:label="loc_mdcx_FormerHoldersMember_272"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_FormerHoldersMember" xlink:label="loc_mdcx_FormerHoldersMember_273"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GainLossOnSettlements" xlink:label="loc_mdcx_GainLossOnSettlements_274"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GainLossOnSettlements" xlink:label="loc_mdcx_GainLossOnSettlements_275"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GainLossOnSettlements" xlink:label="loc_mdcx_GainLossOnSettlements_276"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GainLossOnSettlements" xlink:label="loc_mdcx_GainLossOnSettlements_277"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GainLossOnSettlements" xlink:label="loc_mdcx_GainLossOnSettlements_278"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GrantDateOneMember" xlink:label="loc_mdcx_GrantDateOneMember_279"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GrantDateOneMember" xlink:label="loc_mdcx_GrantDateOneMember_280"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GrantDateOneMember" xlink:label="loc_mdcx_GrantDateOneMember_281"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GrantDateThreeMember" xlink:label="loc_mdcx_GrantDateThreeMember_282"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GrantDateThreeMember" xlink:label="loc_mdcx_GrantDateThreeMember_283"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GrantDateThreeMember" xlink:label="loc_mdcx_GrantDateThreeMember_284"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GrantDateTwoMember" xlink:label="loc_mdcx_GrantDateTwoMember_285"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GrantDateTwoMember" xlink:label="loc_mdcx_GrantDateTwoMember_286"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GrantDateTwoMember" xlink:label="loc_mdcx_GrantDateTwoMember_287"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GrantedRegulationAWarrantsMember" xlink:label="loc_mdcx_GrantedRegulationAWarrantsMember_288"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GrantedRegulationAWarrantsMember" xlink:label="loc_mdcx_GrantedRegulationAWarrantsMember_289"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GrantedSeriesAAndBWarrantsIssuedMember" xlink:label="loc_mdcx_GrantedSeriesAAndBWarrantsIssuedMember_290"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GrantedSeriesAAndBWarrantsIssuedMember" xlink:label="loc_mdcx_GrantedSeriesAAndBWarrantsIssuedMember_291"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GrantedWarrantsMember" xlink:label="loc_mdcx_GrantedWarrantsMember_292"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GrantedWarrantsMember" xlink:label="loc_mdcx_GrantedWarrantsMember_293"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IncreaseDecreaseInCostsRelatedToSettlements" xlink:label="loc_mdcx_IncreaseDecreaseInCostsRelatedToSettlements_294"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IncreaseDecreaseInCostsRelatedToSettlements" xlink:label="loc_mdcx_IncreaseDecreaseInCostsRelatedToSettlements_295"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IncreaseDecreaseInCostsRelatedToSettlements" xlink:label="loc_mdcx_IncreaseDecreaseInCostsRelatedToSettlements_296"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:label="loc_mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets_297"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:label="loc_mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets_298"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:label="loc_mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets_299"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IncrementalFairValueOfWarrantsGranted" xlink:label="loc_mdcx_IncrementalFairValueOfWarrantsGranted_300"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IncrementalFairValueOfWarrantsGranted" xlink:label="loc_mdcx_IncrementalFairValueOfWarrantsGranted_301"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IncrementalFairValueOfWarrantsGranted" xlink:label="loc_mdcx_IncrementalFairValueOfWarrantsGranted_302"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IndividualsMember" xlink:label="loc_mdcx_IndividualsMember_303"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IndividualsMember" xlink:label="loc_mdcx_IndividualsMember_304"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_InProcessResearchAndDevelopment" xlink:label="loc_mdcx_InProcessResearchAndDevelopment_305"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_InProcessResearchAndDevelopment" xlink:label="loc_mdcx_InProcessResearchAndDevelopment_306"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_InProcessResearchAndDevelopment" xlink:label="loc_mdcx_InProcessResearchAndDevelopment_307"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_InteractiveCapitalPartnersCorporationMember" xlink:label="loc_mdcx_InteractiveCapitalPartnersCorporationMember_308"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_InteractiveCapitalPartnersCorporationMember" xlink:label="loc_mdcx_InteractiveCapitalPartnersCorporationMember_309"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_InterimRemeasurementMember" xlink:label="loc_mdcx_InterimRemeasurementMember_310"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_InterimRemeasurementMember" xlink:label="loc_mdcx_InterimRemeasurementMember_311"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_InterimRemeasurementMember" xlink:label="loc_mdcx_InterimRemeasurementMember_312"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceCostsIncludedInAccountsPayable" xlink:label="loc_mdcx_IssuanceCostsIncludedInAccountsPayable_313"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceCostsIncludedInAccountsPayable" xlink:label="loc_mdcx_IssuanceCostsIncludedInAccountsPayable_314"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceCostsInConnectionWithEquityFinancing" xlink:label="loc_mdcx_IssuanceCostsInConnectionWithEquityFinancing_315"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceCostsInConnectionWithEquityFinancing" xlink:label="loc_mdcx_IssuanceCostsInConnectionWithEquityFinancing_316"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceCostsInConnectionWithEquityFinancing" xlink:label="loc_mdcx_IssuanceCostsInConnectionWithEquityFinancing_317"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceCostsInConnectionWithInitialPublicOffering" xlink:label="loc_mdcx_IssuanceCostsInConnectionWithInitialPublicOffering_318"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceCostsInConnectionWithInitialPublicOffering" xlink:label="loc_mdcx_IssuanceCostsInConnectionWithInitialPublicOffering_319"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceCostsInConnectionWithInitialPublicOffering" xlink:label="loc_mdcx_IssuanceCostsInConnectionWithInitialPublicOffering_320"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceCostsInConnectionWithPrivatePlacement" xlink:label="loc_mdcx_IssuanceCostsInConnectionWithPrivatePlacement_321"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceCostsInConnectionWithPrivatePlacement" xlink:label="loc_mdcx_IssuanceCostsInConnectionWithPrivatePlacement_322"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceCostsInConnectionWithPrivatePlacement" xlink:label="loc_mdcx_IssuanceCostsInConnectionWithPrivatePlacement_323"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceCostsInConnectionWithPrivatePlacement" xlink:label="loc_mdcx_IssuanceCostsInConnectionWithPrivatePlacement_324"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceCostsInConnectionWithRegulationA" xlink:label="loc_mdcx_IssuanceCostsInConnectionWithRegulationA_325"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceCostsInConnectionWithRegulationA" xlink:label="loc_mdcx_IssuanceCostsInConnectionWithRegulationA_326"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceCostsInConnectionWithRegulationA" xlink:label="loc_mdcx_IssuanceCostsInConnectionWithRegulationA_327"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered" xlink:label="loc_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered_328"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered" xlink:label="loc_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered_329"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered" xlink:label="loc_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered_330"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered" xlink:label="loc_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered_331"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_June2025PublicOfferingMember" xlink:label="loc_mdcx_June2025PublicOfferingMember_332"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_June2025PublicOfferingMember" xlink:label="loc_mdcx_June2025PublicOfferingMember_333"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_LesseeOperatingLeasesDisclosureTableTextBlock" xlink:label="loc_mdcx_LesseeOperatingLeasesDisclosureTableTextBlock_334"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_LesseeOperatingLeasesDisclosureTableTextBlock" xlink:label="loc_mdcx_LesseeOperatingLeasesDisclosureTableTextBlock_335"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_LesseeOperatingLeasesDisclosureTableTextBlock" xlink:label="loc_mdcx_LesseeOperatingLeasesDisclosureTableTextBlock_336"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding" xlink:label="loc_mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding_337"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding" xlink:label="loc_mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding_338"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding" xlink:label="loc_mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding_339"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_LiquidityAbstract" xlink:label="loc_mdcx_LiquidityAbstract_340"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_LiquidityTextBlock" xlink:label="loc_mdcx_LiquidityTextBlock_341"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_LiquidityTextBlock" xlink:label="loc_mdcx_LiquidityTextBlock_342"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_LiquidityTextBlock" xlink:label="loc_mdcx_LiquidityTextBlock_343"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_LongTermIncentivePlanMember" xlink:label="loc_mdcx_LongTermIncentivePlanMember_344"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_LongTermIncentivePlanMember" xlink:label="loc_mdcx_LongTermIncentivePlanMember_345"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_LongTermIncentivePlanMember" xlink:label="loc_mdcx_LongTermIncentivePlanMember_346"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_MeasurementInputValuationDateSharePriceMember" xlink:label="loc_mdcx_MeasurementInputValuationDateSharePriceMember_347"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_MeasurementInputValuationDateSharePriceMember" xlink:label="loc_mdcx_MeasurementInputValuationDateSharePriceMember_348"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_MeasurementInputValuationDateSharePriceMember" xlink:label="loc_mdcx_MeasurementInputValuationDateSharePriceMember_349"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_MoneyMarketFunds" xlink:label="loc_mdcx_MoneyMarketFunds_350"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_MoneyMarketFunds" xlink:label="loc_mdcx_MoneyMarketFunds_351"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_MoneyMarketFunds" xlink:label="loc_mdcx_MoneyMarketFunds_352"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts" xlink:label="loc_mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts_353"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts" xlink:label="loc_mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts_354"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts" xlink:label="loc_mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts_355"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts" xlink:label="loc_mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts_356"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NetOfAllocatedShareBasedCompensationExpense" xlink:label="loc_mdcx_NetOfAllocatedShareBasedCompensationExpense_357"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NetOfAllocatedShareBasedCompensationExpense" xlink:label="loc_mdcx_NetOfAllocatedShareBasedCompensationExpense_358"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NetOfAllocatedShareBasedCompensationExpense" xlink:label="loc_mdcx_NetOfAllocatedShareBasedCompensationExpense_359"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NoInsiderTradingFlag" xlink:label="loc_mdcx_NoInsiderTradingFlag_360"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NoInsiderTradingFlag" xlink:label="loc_mdcx_NoInsiderTradingFlag_361"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NoteAMember" xlink:label="loc_mdcx_NoteAMember_362"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NoteAMember" xlink:label="loc_mdcx_NoteAMember_363"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NoteBMember" xlink:label="loc_mdcx_NoteBMember_364"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NoteBMember" xlink:label="loc_mdcx_NoteBMember_365"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement" xlink:label="loc_mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement_366"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement" xlink:label="loc_mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement_367"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement" xlink:label="loc_mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement_368"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsExercisable" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsExercisable_369"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsExercisable" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsExercisable_370"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsExercisable" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsExercisable_371"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsExercisable" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsExercisable_372"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsExercisableExerciseInPeriod" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsExercisableExerciseInPeriod_373"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsExercisableExerciseInPeriod" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsExercisableExerciseInPeriod_374"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsExercisableExerciseInPeriod" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsExercisableExerciseInPeriod_375"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsExercisableGrantsInPeriod" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsExercisableGrantsInPeriod_376"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsExercisableGrantsInPeriod" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsExercisableGrantsInPeriod_377"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsExercisableGrantsInPeriod" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsExercisableGrantsInPeriod_378"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod_379"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod_380"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod_381"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod_382"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_383"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_384"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_385"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_386"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfConvertibleNotesSubscribed" xlink:label="loc_mdcx_NumberOfConvertibleNotesSubscribed_387"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfSharesIssuedAfter210DaysFromAcquisition" xlink:label="loc_mdcx_NumberOfSharesIssuedAfter210DaysFromAcquisition_388"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfSharesIssuedAfter210DaysFromAcquisition" xlink:label="loc_mdcx_NumberOfSharesIssuedAfter210DaysFromAcquisition_389"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfSharesIssuedAfter210DaysFromAcquisition" xlink:label="loc_mdcx_NumberOfSharesIssuedAfter210DaysFromAcquisition_390"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfTradingDays" xlink:label="loc_mdcx_NumberOfTradingDays_391"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfTradingDays" xlink:label="loc_mdcx_NumberOfTradingDays_392"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfTradingDays" xlink:label="loc_mdcx_NumberOfTradingDays_393"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfWarrantsExercisable" xlink:label="loc_mdcx_NumberOfWarrantsExercisable_394"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfWarrantsExercisable" xlink:label="loc_mdcx_NumberOfWarrantsExercisable_395"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfWarrantsExercisable" xlink:label="loc_mdcx_NumberOfWarrantsExercisable_396"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfWarrantsExercisable" xlink:label="loc_mdcx_NumberOfWarrantsExercisable_397"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfWarrantsExercised" xlink:label="loc_mdcx_NumberOfWarrantsExercised_398"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfWarrantsExercised" xlink:label="loc_mdcx_NumberOfWarrantsExercised_399"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfWarrantsExercised" xlink:label="loc_mdcx_NumberOfWarrantsExercised_400"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfWarrantsExercised" xlink:label="loc_mdcx_NumberOfWarrantsExercised_401"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfWarrantsExercisedForCash" xlink:label="loc_mdcx_NumberOfWarrantsExercisedForCash_402"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfWarrantsExercisedForCash" xlink:label="loc_mdcx_NumberOfWarrantsExercisedForCash_403"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfWarrantsExercisedForCash" xlink:label="loc_mdcx_NumberOfWarrantsExercisedForCash_404"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_OriginalEarningsBeforeInterestTaxDepreciationAndAmortization" xlink:label="loc_mdcx_OriginalEarningsBeforeInterestTaxDepreciationAndAmortization_405"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_OriginalEarningsBeforeInterestTaxDepreciationAndAmortization" xlink:label="loc_mdcx_OriginalEarningsBeforeInterestTaxDepreciationAndAmortization_406"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_OriginalEarningsBeforeInterestTaxDepreciationAndAmortization" xlink:label="loc_mdcx_OriginalEarningsBeforeInterestTaxDepreciationAndAmortization_407"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PaymentOfStructuringFee" xlink:label="loc_mdcx_PaymentOfStructuringFee_408"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PaymentOfStructuringFee" xlink:label="loc_mdcx_PaymentOfStructuringFee_409"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PaymentsToAcquireBusinessesAdvance" xlink:label="loc_mdcx_PaymentsToAcquireBusinessesAdvance_410"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PaymentsToAcquireBusinessesAdvance" xlink:label="loc_mdcx_PaymentsToAcquireBusinessesAdvance_411"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PaymentsToAcquireBusinessesAdvance" xlink:label="loc_mdcx_PaymentsToAcquireBusinessesAdvance_412"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PreferredStockRedeemablePercentage" xlink:label="loc_mdcx_PreferredStockRedeemablePercentage_413"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PreferredStockRedeemablePercentage" xlink:label="loc_mdcx_PreferredStockRedeemablePercentage_414"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PreferredStockRedeemablePercentage" xlink:label="loc_mdcx_PreferredStockRedeemablePercentage_415"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PrepaidContractResearch" xlink:label="loc_mdcx_PrepaidContractResearch_416"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PrepaidContractResearch" xlink:label="loc_mdcx_PrepaidContractResearch_417"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PrepaidContractResearch" xlink:label="loc_mdcx_PrepaidContractResearch_418"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PrepaidExpensesPolicyTextBlock" xlink:label="loc_mdcx_PrepaidExpensesPolicyTextBlock_419"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PrepaidExpensesPolicyTextBlock" xlink:label="loc_mdcx_PrepaidExpensesPolicyTextBlock_420"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PrepaidExpensesPolicyTextBlock" xlink:label="loc_mdcx_PrepaidExpensesPolicyTextBlock_421"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PrepaidProfessionalServices" xlink:label="loc_mdcx_PrepaidProfessionalServices_422"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PrepaidProfessionalServices" xlink:label="loc_mdcx_PrepaidProfessionalServices_423"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PrepaidProfessionalServices" xlink:label="loc_mdcx_PrepaidProfessionalServices_424"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PrepaidServices" xlink:label="loc_mdcx_PrepaidServices_425"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PrepaidServices" xlink:label="loc_mdcx_PrepaidServices_426"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PrepaidServices" xlink:label="loc_mdcx_PrepaidServices_427"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents" xlink:label="loc_mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents_428"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents" xlink:label="loc_mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents_429"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents" xlink:label="loc_mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents_430"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromConcurrentFinancing" xlink:label="loc_mdcx_ProceedsFromConcurrentFinancing_431"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromConcurrentFinancing" xlink:label="loc_mdcx_ProceedsFromConcurrentFinancing_432"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromConcurrentFinancing" xlink:label="loc_mdcx_ProceedsFromConcurrentFinancing_433"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromConcurrentFinancing" xlink:label="loc_mdcx_ProceedsFromConcurrentFinancing_434"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts" xlink:label="loc_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts_435"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts" xlink:label="loc_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts_436"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts" xlink:label="loc_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts_437"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts" xlink:label="loc_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts_438"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromIssuanceOfSharesUnderSettlements" xlink:label="loc_mdcx_ProceedsFromIssuanceOfSharesUnderSettlements_439"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromIssuanceOfSharesUnderSettlements" xlink:label="loc_mdcx_ProceedsFromIssuanceOfSharesUnderSettlements_440"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromIssuanceOfSharesUnderSettlements" xlink:label="loc_mdcx_ProceedsFromIssuanceOfSharesUnderSettlements_441"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromOrionEquityInvestment" xlink:label="loc_mdcx_ProceedsFromOrionEquityInvestment_442"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromOrionEquityInvestment" xlink:label="loc_mdcx_ProceedsFromOrionEquityInvestment_443"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromOrionEquityInvestment" xlink:label="loc_mdcx_ProceedsFromOrionEquityInvestment_444"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromSaleOfCommonStockOnAtMarketProgram" xlink:label="loc_mdcx_ProceedsFromSaleOfCommonStockOnAtMarketProgram_445"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromSaleOfCommonStockOnAtMarketProgram" xlink:label="loc_mdcx_ProceedsFromSaleOfCommonStockOnAtMarketProgram_446"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromSaleOfCommonStockOnAtMarketProgram" xlink:label="loc_mdcx_ProceedsFromSaleOfCommonStockOnAtMarketProgram_447"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromSaleOfCommonStockOnAtMarketProgram" xlink:label="loc_mdcx_ProceedsFromSaleOfCommonStockOnAtMarketProgram_448"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromSaleOfRoyaltyInterest" xlink:label="loc_mdcx_ProceedsFromSaleOfRoyaltyInterest_449"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromSaleOfRoyaltyInterest" xlink:label="loc_mdcx_ProceedsFromSaleOfRoyaltyInterest_450"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromSaleOfRoyaltyInterest" xlink:label="loc_mdcx_ProceedsFromSaleOfRoyaltyInterest_451"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures" xlink:label="loc_mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures_452"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures" xlink:label="loc_mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures_453"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures" xlink:label="loc_mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures_454"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromSimpleAgreementForFutureEquity" xlink:label="loc_mdcx_ProceedsFromSimpleAgreementForFutureEquity_455"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromSimpleAgreementForFutureEquity" xlink:label="loc_mdcx_ProceedsFromSimpleAgreementForFutureEquity_456"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromSimpleAgreementForFutureEquity" xlink:label="loc_mdcx_ProceedsFromSimpleAgreementForFutureEquity_457"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProfessionalServicesAndIntellectualPropertyMember" xlink:label="loc_mdcx_ProfessionalServicesAndIntellectualPropertyMember_458"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProfessionalServicesAndIntellectualPropertyMember" xlink:label="loc_mdcx_ProfessionalServicesAndIntellectualPropertyMember_459"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProfessionalServicesAndIntellectualPropertyMember" xlink:label="loc_mdcx_ProfessionalServicesAndIntellectualPropertyMember_460"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PublicWarrantsMember" xlink:label="loc_mdcx_PublicWarrantsMember_461"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PublicWarrantsMember" xlink:label="loc_mdcx_PublicWarrantsMember_462"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RbxCapitalLPMember" xlink:label="loc_mdcx_RbxCapitalLPMember_463"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RbxCapitalLPMember" xlink:label="loc_mdcx_RbxCapitalLPMember_464"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RbxCapitalLPMember" xlink:label="loc_mdcx_RbxCapitalLPMember_465"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ReceivableForProceedsOfWarrantExercises" xlink:label="loc_mdcx_ReceivableForProceedsOfWarrantExercises_466"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ReceivableForProceedsOfWarrantExercises" xlink:label="loc_mdcx_ReceivableForProceedsOfWarrantExercises_467"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ReceivableForProceedsOfWarrantExercises" xlink:label="loc_mdcx_ReceivableForProceedsOfWarrantExercises_468"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ReceivablesForProceedsOfWarrantExercises" xlink:label="loc_mdcx_ReceivablesForProceedsOfWarrantExercises_469"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ReceivablesForProceedsOfWarrantExercises" xlink:label="loc_mdcx_ReceivablesForProceedsOfWarrantExercises_470"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ReceivablesForProceedsOfWarrantExercises" xlink:label="loc_mdcx_ReceivablesForProceedsOfWarrantExercises_471"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:label="loc_mdcx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_472"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:label="loc_mdcx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_473"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:label="loc_mdcx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_474"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RegulationAOfferingMember" xlink:label="loc_mdcx_RegulationAOfferingMember_475"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RegulationAOfferingMember" xlink:label="loc_mdcx_RegulationAOfferingMember_476"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RegulationAWarrantsMember" xlink:label="loc_mdcx_RegulationAWarrantsMember_477"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RegulationAWarrantsMember" xlink:label="loc_mdcx_RegulationAWarrantsMember_478"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RelatedPartyPayableCurrent" xlink:label="loc_mdcx_RelatedPartyPayableCurrent_479"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RelatedPartyPayableCurrent" xlink:label="loc_mdcx_RelatedPartyPayableCurrent_480"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RelatedPartyPayableCurrent" xlink:label="loc_mdcx_RelatedPartyPayableCurrent_481"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RelatedPartyTransactionAdditionalExpenses" xlink:label="loc_mdcx_RelatedPartyTransactionAdditionalExpenses_482"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RelatedPartyTransactionAdditionalExpenses" xlink:label="loc_mdcx_RelatedPartyTransactionAdditionalExpenses_483"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RelatedPartyTransactionAdditionalExpenses" xlink:label="loc_mdcx_RelatedPartyTransactionAdditionalExpenses_484"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RepaymentOfDebenturesOnExtinguishment" xlink:label="loc_mdcx_RepaymentOfDebenturesOnExtinguishment_485"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RepaymentOfDebenturesOnExtinguishment" xlink:label="loc_mdcx_RepaymentOfDebenturesOnExtinguishment_486"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RepaymentOfDebenturesOnExtinguishment" xlink:label="loc_mdcx_RepaymentOfDebenturesOnExtinguishment_487"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RepaymentsOfInterest" xlink:label="loc_mdcx_RepaymentsOfInterest_488"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RepaymentsOfInterest" xlink:label="loc_mdcx_RepaymentsOfInterest_489"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RepaymentsOfInterest" xlink:label="loc_mdcx_RepaymentsOfInterest_490"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RepaymentsOfInterest" xlink:label="loc_mdcx_RepaymentsOfInterest_491"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RestrictedCashDisclosureTextBlock" xlink:label="loc_mdcx_RestrictedCashDisclosureTextBlock_492"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RestrictedCashDisclosureTextBlock" xlink:label="loc_mdcx_RestrictedCashDisclosureTextBlock_493"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RestrictedCashDisclosureTextBlock" xlink:label="loc_mdcx_RestrictedCashDisclosureTextBlock_494"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RestrictedCashLineItems" xlink:label="loc_mdcx_RestrictedCashLineItems_495"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RestrictedCashTable" xlink:label="loc_mdcx_RestrictedCashTable_496"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RoyaltyLiability" xlink:label="loc_mdcx_RoyaltyLiability_497"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RoyaltyLiability" xlink:label="loc_mdcx_RoyaltyLiability_498"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RoyaltyLiability" xlink:label="loc_mdcx_RoyaltyLiability_499"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ScheduleOfPrepaidExpensesTableTextBlock" xlink:label="loc_mdcx_ScheduleOfPrepaidExpensesTableTextBlock_500"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ScheduleOfPrepaidExpensesTableTextBlock" xlink:label="loc_mdcx_ScheduleOfPrepaidExpensesTableTextBlock_501"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ScheduleOfPrepaidExpensesTableTextBlock" xlink:label="loc_mdcx_ScheduleOfPrepaidExpensesTableTextBlock_502"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock" xlink:label="loc_mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock_503"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock" xlink:label="loc_mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock_504"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock" xlink:label="loc_mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock_505"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SecuredPromissoryNotesMember" xlink:label="loc_mdcx_SecuredPromissoryNotesMember_506"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SecuredPromissoryNotesMember" xlink:label="loc_mdcx_SecuredPromissoryNotesMember_507"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SecuredPromissoryNotesMember" xlink:label="loc_mdcx_SecuredPromissoryNotesMember_508"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SecuritiesPurchaseAgreementMember" xlink:label="loc_mdcx_SecuritiesPurchaseAgreementMember_509"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SecuritiesPurchaseAgreementMember" xlink:label="loc_mdcx_SecuritiesPurchaseAgreementMember_510"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SecuritiesPurchaseAgreementMember" xlink:label="loc_mdcx_SecuritiesPurchaseAgreementMember_511"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesAAndBWarrantsGrantedMember" xlink:label="loc_mdcx_SeriesAAndBWarrantsGrantedMember_512"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesAAndBWarrantsGrantedMember" xlink:label="loc_mdcx_SeriesAAndBWarrantsGrantedMember_513"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesAAndBWarrantsGrantedMember" xlink:label="loc_mdcx_SeriesAAndBWarrantsGrantedMember_514"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesAAndSeriesA1PreferredSharesMember" xlink:label="loc_mdcx_SeriesAAndSeriesA1PreferredSharesMember_515"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesAAndSeriesA1PreferredSharesMember" xlink:label="loc_mdcx_SeriesAAndSeriesA1PreferredSharesMember_516"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesAWarrantsMember" xlink:label="loc_mdcx_SeriesAWarrantsMember_517"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesAWarrantsMember" xlink:label="loc_mdcx_SeriesAWarrantsMember_518"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesBWarrantsMember" xlink:label="loc_mdcx_SeriesBWarrantsMember_519"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesBWarrantsMember" xlink:label="loc_mdcx_SeriesBWarrantsMember_520"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesCAndDWarrantsGrantedMember" xlink:label="loc_mdcx_SeriesCAndDWarrantsGrantedMember_521"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesCAndDWarrantsGrantedMember" xlink:label="loc_mdcx_SeriesCAndDWarrantsGrantedMember_522"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesCAndDWarrantsGrantedMember" xlink:label="loc_mdcx_SeriesCAndDWarrantsGrantedMember_523"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesCAndDWarrantsMember" xlink:label="loc_mdcx_SeriesCAndDWarrantsMember_524"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesCAndDWarrantsMember" xlink:label="loc_mdcx_SeriesCAndDWarrantsMember_525"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesCAndDWarrantsMember" xlink:label="loc_mdcx_SeriesCAndDWarrantsMember_526"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SettledConvertibleNotesAlongWithAccruedButUnpaidInterestInShares" xlink:label="loc_mdcx_SettledConvertibleNotesAlongWithAccruedButUnpaidInterestInShares_527"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SettledConvertibleNotesAlongWithAccruedButUnpaidInterestInShares" xlink:label="loc_mdcx_SettledConvertibleNotesAlongWithAccruedButUnpaidInterestInShares_528"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SettledConvertibleNotesAlongWithAccruedButUnpaidInterestInShares" xlink:label="loc_mdcx_SettledConvertibleNotesAlongWithAccruedButUnpaidInterestInShares_529"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SettlementDateRemeasurementMember" xlink:label="loc_mdcx_SettlementDateRemeasurementMember_530"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SettlementDateRemeasurementMember" xlink:label="loc_mdcx_SettlementDateRemeasurementMember_531"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SettlementDateRemeasurementMember" xlink:label="loc_mdcx_SettlementDateRemeasurementMember_532"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:label="loc_mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_533"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:label="loc_mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_534"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAcceleratedVestingNumber" xlink:label="loc_mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAcceleratedVestingNumber_535"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAcceleratedVestingNumber" xlink:label="loc_mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAcceleratedVestingNumber_536"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAcceleratedVestingNumber" xlink:label="loc_mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAcceleratedVestingNumber_537"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:label="loc_mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_538"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:label="loc_mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_539"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:label="loc_mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_540"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice_541"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice_542"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice_543"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedCompensationAwardTrancheFiveMember" xlink:label="loc_mdcx_ShareBasedCompensationAwardTrancheFiveMember_544"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedCompensationAwardTrancheFiveMember" xlink:label="loc_mdcx_ShareBasedCompensationAwardTrancheFiveMember_545"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedCompensationAwardTrancheFiveMember" xlink:label="loc_mdcx_ShareBasedCompensationAwardTrancheFiveMember_546"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedCompensationAwardTrancheFourMember" xlink:label="loc_mdcx_ShareBasedCompensationAwardTrancheFourMember_547"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedCompensationAwardTrancheFourMember" xlink:label="loc_mdcx_ShareBasedCompensationAwardTrancheFourMember_548"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedCompensationAwardTrancheFourMember" xlink:label="loc_mdcx_ShareBasedCompensationAwardTrancheFourMember_549"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedCompensationAwardTrancheSixMember" xlink:label="loc_mdcx_ShareBasedCompensationAwardTrancheSixMember_550"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedCompensationAwardTrancheSixMember" xlink:label="loc_mdcx_ShareBasedCompensationAwardTrancheSixMember_551"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedCompensationAwardTrancheSixMember" xlink:label="loc_mdcx_ShareBasedCompensationAwardTrancheSixMember_552"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedPaymentAwardGrantDateAxis" xlink:label="loc_mdcx_ShareBasedPaymentAwardGrantDateAxis_553"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedPaymentAwardGrantDateAxis" xlink:label="loc_mdcx_ShareBasedPaymentAwardGrantDateAxis_554"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedPaymentAwardGrantDateDomain" xlink:label="loc_mdcx_ShareBasedPaymentAwardGrantDateDomain_555"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedPaymentAwardGrantDateDomain" xlink:label="loc_mdcx_ShareBasedPaymentAwardGrantDateDomain_556"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareCapitalNoteDisclosureLineItems" xlink:label="loc_mdcx_ShareCapitalNoteDisclosureLineItems_557"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareCapitalNoteDisclosureLineItems" xlink:label="loc_mdcx_ShareCapitalNoteDisclosureLineItems_558"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareCapitalNoteDisclosureTable" xlink:label="loc_mdcx_ShareCapitalNoteDisclosureTable_559"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareCapitalNoteDisclosureTable" xlink:label="loc_mdcx_ShareCapitalNoteDisclosureTable_560"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareConsolidationAxis" xlink:label="loc_mdcx_ShareConsolidationAxis_561"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareConsolidationAxis" xlink:label="loc_mdcx_ShareConsolidationAxis_562"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareConsolidationDomain" xlink:label="loc_mdcx_ShareConsolidationDomain_563"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareConsolidationDomain" xlink:label="loc_mdcx_ShareConsolidationDomain_564"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareConsolidationMember" xlink:label="loc_mdcx_ShareConsolidationMember_565"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareConsolidationMember" xlink:label="loc_mdcx_ShareConsolidationMember_566"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareIssuanceCosts" xlink:label="loc_mdcx_ShareIssuanceCosts_567"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareIssuanceCosts" xlink:label="loc_mdcx_ShareIssuanceCosts_568"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareIssuanceCosts" xlink:label="loc_mdcx_ShareIssuanceCosts_569"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SharePriceAsPercentageOfMarketPrice" xlink:label="loc_mdcx_SharePriceAsPercentageOfMarketPrice_570"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SharePriceAsPercentageOfMarketPrice" xlink:label="loc_mdcx_SharePriceAsPercentageOfMarketPrice_571"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SharePriceAsPercentageOfMarketPrice" xlink:label="loc_mdcx_SharePriceAsPercentageOfMarketPrice_572"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SharesIssuedForAcquisitionOfAntev" xlink:label="loc_mdcx_SharesIssuedForAcquisitionOfAntev_573"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SharesIssuedForAcquisitionOfAntev" xlink:label="loc_mdcx_SharesIssuedForAcquisitionOfAntev_574"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SharesIssuedForAcquisitionOfAntev" xlink:label="loc_mdcx_SharesIssuedForAcquisitionOfAntev_575"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SharesIssuedMember" xlink:label="loc_mdcx_SharesIssuedMember_576"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SharesIssuedMember" xlink:label="loc_mdcx_SharesIssuedMember_577"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SharesIssuedMember" xlink:label="loc_mdcx_SharesIssuedMember_578"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SharesIssuedMember" xlink:label="loc_mdcx_SharesIssuedMember_579"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SharesToBeIssuedForAcquisitionOfAntev" xlink:label="loc_mdcx_SharesToBeIssuedForAcquisitionOfAntev_580"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SharesToBeIssuedForAcquisitionOfAntev" xlink:label="loc_mdcx_SharesToBeIssuedForAcquisitionOfAntev_581"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SharesToBeIssuedForAcquisitionOfAntev" xlink:label="loc_mdcx_SharesToBeIssuedForAcquisitionOfAntev_582"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShortTermIncentivePlanMember" xlink:label="loc_mdcx_ShortTermIncentivePlanMember_583"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShortTermIncentivePlanMember" xlink:label="loc_mdcx_ShortTermIncentivePlanMember_584"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SimpleAgreementForFutureEquityMember" xlink:label="loc_mdcx_SimpleAgreementForFutureEquityMember_585"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SimpleAgreementForFutureEquityMember" xlink:label="loc_mdcx_SimpleAgreementForFutureEquityMember_586"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SimpleAgreementForFutureEquityMember" xlink:label="loc_mdcx_SimpleAgreementForFutureEquityMember_587"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SkinjectIncMember" xlink:label="loc_mdcx_SkinjectIncMember_588"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SkinjectIncMember" xlink:label="loc_mdcx_SkinjectIncMember_589"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SpecialStockOptionsAndPerformanceShareUnitsMember" xlink:label="loc_mdcx_SpecialStockOptionsAndPerformanceShareUnitsMember_590"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SpecialStockOptionsAndPerformanceShareUnitsMember" xlink:label="loc_mdcx_SpecialStockOptionsAndPerformanceShareUnitsMember_591"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SpecialStockOptionsMember" xlink:label="loc_mdcx_SpecialStockOptionsMember_592"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SpecialStockOptionsMember" xlink:label="loc_mdcx_SpecialStockOptionsMember_593"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StandbyEquityPurchaseAgreementMember" xlink:label="loc_mdcx_StandbyEquityPurchaseAgreementMember_594"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StandbyEquityPurchaseAgreementMember" xlink:label="loc_mdcx_StandbyEquityPurchaseAgreementMember_595"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StandbyEquityPurchaseAgreementMember" xlink:label="loc_mdcx_StandbyEquityPurchaseAgreementMember_596"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForAmortizedIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForAmortizedIssuanceCosts_597"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForAmortizedIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForAmortizedIssuanceCosts_598"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForAmortizedIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForAmortizedIssuanceCosts_599"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForCompensation" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForCompensation_600"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForCompensation" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForCompensation_601"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForCompensation" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForCompensation_602"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForPsus" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForPsus_603"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForPsus" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForPsus_604"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForPsus" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForPsus_605"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits_606"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits_607"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits_608"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits_609"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRsus" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRsus_610"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRsus" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRsus_611"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRsus" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRsus_612"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts_613"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts_614"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts_615"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing_616"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing_617"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing_618"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithFinancing" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithFinancing_619"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithFinancing" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithFinancing_620"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithFinancing" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithFinancing_621"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithFinancing" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithFinancing_622"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts_623"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts_624"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts_625"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts_626"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts_627"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts_628"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts_629"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConversionOfDebt" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_630"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConversionOfDebt" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_631"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConversionOfDebt" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_632"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConversionOfDebt" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_633"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConversionOfNotePayable" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfNotePayable_634"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConversionOfNotePayable" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfNotePayable_635"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConversionOfNotePayable" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfNotePayable_636"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares_637"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares_638"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares_639"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesExerciseOfWarrants_640"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesExerciseOfWarrants_641"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesExerciseOfWarrants_642"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesForCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesForCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_643"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesForCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesForCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_644"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesForCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesForCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_645"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered_646"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered_647"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered_648"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesOfCommonStock" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesOfCommonStock_649"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesOfCommonStock" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesOfCommonStock_650"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesOfCommonStock" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesOfCommonStock_651"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants_652"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants_653"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants_654"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForAmortizedIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForAmortizedIssuanceCosts_655"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForAmortizedIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForAmortizedIssuanceCosts_656"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForAmortizedIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForAmortizedIssuanceCosts_657"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForCompensation" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForCompensation_658"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForCompensation" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForCompensation_659"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_660"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_661"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_662"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForPsus" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForPsus_663"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForPsus" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForPsus_664"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForPsus" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForPsus_665"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRestrictedStockUnits" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRestrictedStockUnits_666"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRestrictedStockUnits" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRestrictedStockUnits_667"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRestrictedStockUnits" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRestrictedStockUnits_668"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRsus" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRsus_669"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRsus" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRsus_670"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRsus" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRsus_671"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost_672"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost_673"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost_674"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing_675"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing_676"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing_677"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithFinancing" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithFinancing_678"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithFinancing" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithFinancing_679"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithFinancing" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithFinancing_680"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithFinancing" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithFinancing_681"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts_682"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts_683"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts_684"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts_685"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts_686"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts_687"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts_688"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConversionOfDebt" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_689"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConversionOfDebt" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_690"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConversionOfDebt" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_691"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConversionOfDebt" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_692"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConversionOfNotePayable" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConversionOfNotePayable_693"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConversionOfNotePayable" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConversionOfNotePayable_694"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConversionOfNotePayable" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConversionOfNotePayable_695"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConversionOfPreferredShares" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConversionOfPreferredShares_696"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConversionOfPreferredShares" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConversionOfPreferredShares_697"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConversionOfPreferredShares" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConversionOfPreferredShares_698"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueExerciseOfWarrants_699"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueExerciseOfWarrants_700"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueExerciseOfWarrants_701"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueForPaymentOfIncomeTaxesRemittedOnRsusAndPsus" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueForPaymentOfIncomeTaxesRemittedOnRsusAndPsus_702"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueForPaymentOfIncomeTaxesRemittedOnRsusAndPsus" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueForPaymentOfIncomeTaxesRemittedOnRsusAndPsus_703"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueForPaymentOfIncomeTaxesRemittedOnRsusAndPsus" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueForPaymentOfIncomeTaxesRemittedOnRsusAndPsus_704"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered_705"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered_706"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered_707"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueOfCommonShares" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueOfCommonShares_708"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueOfCommonShares" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueOfCommonShares_709"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueOfCommonShares" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueOfCommonShares_710"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants_711"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants_712"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants_713"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockOptionsMember" xlink:label="loc_mdcx_StockOptionsMember_714"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockOptionsMember" xlink:label="loc_mdcx_StockOptionsMember_715"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockPurchaseWarrantsTerm" xlink:label="loc_mdcx_StockPurchaseWarrantsTerm_716"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockPurchaseWarrantsTerm" xlink:label="loc_mdcx_StockPurchaseWarrantsTerm_717"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockPurchaseWarrantsTerm" xlink:label="loc_mdcx_StockPurchaseWarrantsTerm_718"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_TeverelixMember" xlink:label="loc_mdcx_TeverelixMember_719"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_TeverelixMember" xlink:label="loc_mdcx_TeverelixMember_720"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ThresholdLimitOfFinancing" xlink:label="loc_mdcx_ThresholdLimitOfFinancing_721"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ThresholdLimitOfFinancing" xlink:label="loc_mdcx_ThresholdLimitOfFinancing_722"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ThresholdLimitOfFinancing" xlink:label="loc_mdcx_ThresholdLimitOfFinancing_723"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_TotalShareholderReturnPerformanceSharesMember" xlink:label="loc_mdcx_TotalShareholderReturnPerformanceSharesMember_724"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_TotalShareholderReturnPerformanceSharesMember" xlink:label="loc_mdcx_TotalShareholderReturnPerformanceSharesMember_725"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_TotalShareholderReturnPerformanceSharesMember" xlink:label="loc_mdcx_TotalShareholderReturnPerformanceSharesMember_726"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_TwoZeroOneNineStockIncentivePlanMember" xlink:label="loc_mdcx_TwoZeroOneNineStockIncentivePlanMember_727"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_TwoZeroOneNineStockIncentivePlanMember" xlink:label="loc_mdcx_TwoZeroOneNineStockIncentivePlanMember_728"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_TwoZeroOneNineStockIncentivePlanMember" xlink:label="loc_mdcx_TwoZeroOneNineStockIncentivePlanMember_729"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_TwoZeroOneThreeStockIncentivePlanMember" xlink:label="loc_mdcx_TwoZeroOneThreeStockIncentivePlanMember_730"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_TwoZeroOneThreeStockIncentivePlanMember" xlink:label="loc_mdcx_TwoZeroOneThreeStockIncentivePlanMember_731"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_TwoZeroOneThreeStockIncentivePlanMember" xlink:label="loc_mdcx_TwoZeroOneThreeStockIncentivePlanMember_732"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_TwoZeroTwoZeroStockIncentivePlanMember" xlink:label="loc_mdcx_TwoZeroTwoZeroStockIncentivePlanMember_733"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_TwoZeroTwoZeroStockIncentivePlanMember" xlink:label="loc_mdcx_TwoZeroTwoZeroStockIncentivePlanMember_734"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_TwoZeroTwoZeroStockIncentivePlanMember" xlink:label="loc_mdcx_TwoZeroTwoZeroStockIncentivePlanMember_735"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement" xlink:label="loc_mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement_736"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement" xlink:label="loc_mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement_737"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement" xlink:label="loc_mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement_738"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_VelocityFundManagementLLCMember" xlink:label="loc_mdcx_VelocityFundManagementLLCMember_739"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_VelocityFundManagementLLCMember" xlink:label="loc_mdcx_VelocityFundManagementLLCMember_740"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_VelocityFundManagementLLCMember" xlink:label="loc_mdcx_VelocityFundManagementLLCMember_741"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_VestUponCommonSharesAchievingCertainVolumeWeightedAverageTradingPricesMember" xlink:label="loc_mdcx_VestUponCommonSharesAchievingCertainVolumeWeightedAverageTradingPricesMember_742"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_VestUponCommonSharesAchievingCertainVolumeWeightedAverageTradingPricesMember" xlink:label="loc_mdcx_VestUponCommonSharesAchievingCertainVolumeWeightedAverageTradingPricesMember_743"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantLiabilityIssuedDuringPeriod" xlink:label="loc_mdcx_WarrantLiabilityIssuedDuringPeriod_744"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantLiabilityIssuedDuringPeriod" xlink:label="loc_mdcx_WarrantLiabilityIssuedDuringPeriod_745"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantLiabilityIssuedDuringPeriod" xlink:label="loc_mdcx_WarrantLiabilityIssuedDuringPeriod_746"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantLiabilityIssuedDuringPeriod" xlink:label="loc_mdcx_WarrantLiabilityIssuedDuringPeriod_747"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantsIssuedAsPartOfIpoMember" xlink:label="loc_mdcx_WarrantsIssuedAsPartOfIpoMember_748"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantsIssuedAsPartOfIpoMember" xlink:label="loc_mdcx_WarrantsIssuedAsPartOfIpoMember_749"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantsIssuedAsPartOfIpoMember" xlink:label="loc_mdcx_WarrantsIssuedAsPartOfIpoMember_750"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantsIssuedUnderWarrantInducement" xlink:label="loc_mdcx_WarrantsIssuedUnderWarrantInducement_751"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantsIssuedUnderWarrantInducement" xlink:label="loc_mdcx_WarrantsIssuedUnderWarrantInducement_752"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantsIssuedUnderWarrantInducement" xlink:label="loc_mdcx_WarrantsIssuedUnderWarrantInducement_753"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantWithExpiryDateJune302030WarrantsMember" xlink:label="loc_mdcx_WarrantWithExpiryDateJune302030WarrantsMember_754"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantWithExpiryDateJune302030WarrantsMember" xlink:label="loc_mdcx_WarrantWithExpiryDateJune302030WarrantsMember_755"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantWithExpiryDateJune302030WarrantsMember" xlink:label="loc_mdcx_WarrantWithExpiryDateJune302030WarrantsMember_756"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantWithExpiryDateMarch102030Member" xlink:label="loc_mdcx_WarrantWithExpiryDateMarch102030Member_757"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantWithExpiryDateMarch102030Member" xlink:label="loc_mdcx_WarrantWithExpiryDateMarch102030Member_758"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantWithExpiryDateMarch102030Member" xlink:label="loc_mdcx_WarrantWithExpiryDateMarch102030Member_759"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageExercisePriceOfWarrant" xlink:label="loc_mdcx_WeightedAverageExercisePriceOfWarrant_760"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageExercisePriceOfWarrant" xlink:label="loc_mdcx_WeightedAverageExercisePriceOfWarrant_761"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageExercisePriceOfWarrant" xlink:label="loc_mdcx_WeightedAverageExercisePriceOfWarrant_762"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageExercisePriceOfWarrant" xlink:label="loc_mdcx_WeightedAverageExercisePriceOfWarrant_763"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageExercisePriceWarrantExercise" xlink:label="loc_mdcx_WeightedAverageExercisePriceWarrantExercise_764"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageExercisePriceWarrantExercise" xlink:label="loc_mdcx_WeightedAverageExercisePriceWarrantExercise_765"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageExercisePriceWarrantExercise" xlink:label="loc_mdcx_WeightedAverageExercisePriceWarrantExercise_766"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageExercisePriceWarrantGranted" xlink:label="loc_mdcx_WeightedAverageExercisePriceWarrantGranted_767"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageExercisePriceWarrantGranted" xlink:label="loc_mdcx_WeightedAverageExercisePriceWarrantGranted_768"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageExercisePriceWarrantGranted" xlink:label="loc_mdcx_WeightedAverageExercisePriceWarrantGranted_769"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageRemainingContractualTermOfWarrant" xlink:label="loc_mdcx_WeightedAverageRemainingContractualTermOfWarrant_770"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageRemainingContractualTermOfWarrant" xlink:label="loc_mdcx_WeightedAverageRemainingContractualTermOfWarrant_771"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageRemainingContractualTermOfWarrant" xlink:label="loc_mdcx_WeightedAverageRemainingContractualTermOfWarrant_772"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted" xlink:label="loc_mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted_773"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted" xlink:label="loc_mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted_774"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted" xlink:label="loc_mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted_775"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WithholdingOfEmployeeTaxPaymentsOnRestrictedStockUnits" xlink:label="loc_mdcx_WithholdingOfEmployeeTaxPaymentsOnRestrictedStockUnits_776"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WithholdingOfEmployeeTaxPaymentsOnRestrictedStockUnits" xlink:label="loc_mdcx_WithholdingOfEmployeeTaxPaymentsOnRestrictedStockUnits_777"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WithholdingOfEmployeeTaxPaymentsOnRestrictedStockUnits" xlink:label="loc_mdcx_WithholdingOfEmployeeTaxPaymentsOnRestrictedStockUnits_778"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_YaIiPnLtdMember" xlink:label="loc_mdcx_YaIiPnLtdMember_779"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_YaIiPnLtdMember" xlink:label="loc_mdcx_YaIiPnLtdMember_780"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_YaIiPnLtdMember" xlink:label="loc_mdcx_YaIiPnLtdMember_781"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_YaIiPnLtdMember" xlink:label="loc_mdcx_YaIiPnLtdMember_782"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_YorkvilleMember" xlink:label="loc_mdcx_YorkvilleMember_783"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_YorkvilleMember" xlink:label="loc_mdcx_YorkvilleMember_784"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_785"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_786"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_787"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srt_ChiefFinancialOfficerMember_788"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srt_ChiefFinancialOfficerMember_789"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srt_ChiefFinancialOfficerMember_790"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_791"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_792"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ManagementMember" xlink:label="loc_srt_ManagementMember_793"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ManagementMember" xlink:label="loc_srt_ManagementMember_794"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_795"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_796"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_797"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_798"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_799"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_800"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_801"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_802"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_803"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_804"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_805"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_806"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_807"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_808"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_809"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_810"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_811"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_812"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_813"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_814"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_815"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_816"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_817"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_818"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_819"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_820"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_821"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_822"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_823"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_824"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_825"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_826"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_827"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_828"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_829"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_830"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_831"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_832"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_833"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_834"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_835"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_836"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_837"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_838"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_839"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_840"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_841"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_842"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_843"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_844"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_845"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_846"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_847"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="loc_us-gaap_AssetAcquisitionTableTextBlock_848"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="loc_us-gaap_AssetAcquisitionTableTextBlock_849"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_850"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_851"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_852"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_853"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_854"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_855"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_856"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_857"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_858"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_859"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_860"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_861"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_862"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_863"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_864"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_865"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_866"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_867"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_868"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription_869"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription_870"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_871"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_872"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_873"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_874"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_875"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_876"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_877"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_878"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_879"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_880"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_881"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_882"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_883"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_884"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_885"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_886"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_887"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_888"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_889"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_890"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_891"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_892"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_893"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_894"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_895"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_896"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_897"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_898"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_899"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_900"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_901"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_902"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_903"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_904"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_905"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_906"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_907"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_908"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_909"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_910"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_911"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_912"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_913"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_914"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_915"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_916"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_917"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_918"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_919"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_920"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_921"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_922"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_923"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_924"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_925"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_926"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_927"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_928"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_929"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_930"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_931"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaap_CommonStockConversionBasis_932"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaap_CommonStockConversionBasis_933"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_934"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_935"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_936"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_937"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_938"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_939"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_940"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_941"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_942"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_943"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_944"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_945"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_946"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_947"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_948"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_949"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_950"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_951"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_952"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_953"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_954"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_955"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_956"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_957"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_958"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_959"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_960"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_961"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_962"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_963"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_964"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_965"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_966"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_967"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_968"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_969"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_970"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_971"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_972"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_973"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_974"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_975"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_976"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_977"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_978"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_979"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_980"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_981"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_982"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionDescription" xlink:label="loc_us-gaap_DebtConversionDescription_983"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionDescription" xlink:label="loc_us-gaap_DebtConversionDescription_984"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_985"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_986"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear" xlink:label="loc_us-gaap_DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear_987"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear" xlink:label="loc_us-gaap_DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear_988"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:label="loc_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_989"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:label="loc_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_990"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_991"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_992"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_993"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_994"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_995"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_996"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_997"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_998"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_999"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1000"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1001"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1002"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1003"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_1004"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_1005"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1006"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1007"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaap_DebtInstrumentIssuedPrincipal_1008"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaap_DebtInstrumentIssuedPrincipal_1009"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1010"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_1011"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_1012"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1013"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_1014"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_1015"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1016"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1017"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1018"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1019"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1020"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault" xlink:label="loc_us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault_1021"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault" xlink:label="loc_us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault_1022"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaap_DeferredCostsCurrent_1023"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1024"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1025"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1026"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1027"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1028"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1029"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward_1030"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward_1031"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_1032"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_1033"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1034"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1035"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1036"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1037"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1038"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1039"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1040"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1041"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1042"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1043"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1044"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_1045"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_1046"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_1047"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_1048"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_1049"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_1050"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_1051"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_1052"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1053"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1054"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_1055"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_1056"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1057"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1058"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1059"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_1060"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_1061"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1062"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1063"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1064"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1065"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1066"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1067"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1068"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1069"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1070"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1071"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1072"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1073"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1074"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1075"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1076"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1077"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1078"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1079"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1080"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1081"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1082"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1083"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1084"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1085"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1086"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_1087"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_1088"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_1089"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_1090"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_1091"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1092"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1093"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_1094"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1095"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1096"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1097"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1098"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1099"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1100"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1101"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1102"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1103"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1104"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1105"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1106"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1107"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1108"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1109"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1110"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1111"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1112"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1113"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1114"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1115"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1116"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1117"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1118"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1119"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1120"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1121"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1122"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1123"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1124"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1125"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1126"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1127"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1128"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1129"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1130"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1131"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_1132"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_1133"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_1134"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1135"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1136"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1137"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1138"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1139"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1140"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1141"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1142"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1143"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1144"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1145"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_1146"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1147"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1148"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1149"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1150"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1151"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1152"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1153"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1154"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1155"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1156"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1157"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1158"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1159"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1160"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1161"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1162"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1163"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1164"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1165"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1166"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_1167"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_1168"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_1169"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_1170"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1171"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1172"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1173"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_1174"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_1175"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_1176"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1177"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1178"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1179"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1180"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1181"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1182"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1183"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_1184"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_1185"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1186"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1187"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1188"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1189"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1190"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1191"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1192"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1193"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_1194"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_1195"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_1196"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_1197"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_1198"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_1199"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_1200"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_1201"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_1202"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_1203"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_1204"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_1205"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_1206"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentCompanyNonconsolidatedSubsidiaryAxis" xlink:label="loc_us-gaap_InvestmentCompanyNonconsolidatedSubsidiaryAxis_1207"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentCompanyNonconsolidatedSubsidiaryDomain" xlink:label="loc_us-gaap_InvestmentCompanyNonconsolidatedSubsidiaryDomain_1208"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_1209"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_1210"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_1211"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1212"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1213"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaap_LaborAndRelatedExpense_1214"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaap_LaborAndRelatedExpense_1215"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_1216"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_1217"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1218"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_1219"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_1220"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_1221"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_1222"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1223"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1224"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1225"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1226"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1227"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1228"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1229"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1230"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1231"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1232"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1233"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_1234"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_1235"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1236"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1237"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_1238"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_1239"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1240"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1241"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1242"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1243"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1244"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1245"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1246"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1247"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_1248"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_1249"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1250"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1251"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaap_LongTermDebtTextBlock_1252"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaap_LongTermDebtTextBlock_1253"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1254"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1255"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaap_LongTermLoansPayable_1256"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaap_LongTermLoansPayable_1257"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaap_LongTermLoansPayable_1258"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_1259"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_1260"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1261"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1262"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_1263"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_1264"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_1265"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_1266"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_1267"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1268"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1269"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1270"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1271"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_1272"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_1273"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_1274"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_1275"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1276"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1277"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1278"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1279"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1280"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1281"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1282"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1283"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1284"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1285"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1286"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1287"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1288"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1289"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1290"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1291"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1292"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1293"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1294"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_1295"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_1296"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1297"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1298"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1299"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1300"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_1301"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_1302"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_1303"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_1304"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_1305"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1306"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1307"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_1308"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_1309"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_1310"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_1311"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_1312"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1313"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1314"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1315"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1316"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1317"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1318"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_1319"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_1320"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1321"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1322"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1323"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1324"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1325"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1326"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1327"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1328"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1329"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1330"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1331"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1332"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1333"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1334"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1335"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_1336"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1337"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1338"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1339"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1340"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1341"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1342"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_1343"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_1344"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_1345"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_1346"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_1347"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_1348"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherIncomeMember" xlink:label="loc_us-gaap_OtherIncomeMember_1349"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherIncomeMember" xlink:label="loc_us-gaap_OtherIncomeMember_1350"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_1351"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_1352"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_1353"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_1354"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1355"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1356"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1357"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1358"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_1359"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_1360"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_1361"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_1362"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_1363"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1364"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1365"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1366"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1367"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1368"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_1369"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_1370"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1371"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1372"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1373"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1374"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1375"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1376"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_1377"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_1378"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_1379"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_1380"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1381"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1382"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1383"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1384"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1385"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1386"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1387"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance_1388"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance_1389"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_1390"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_1391"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1392"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1393"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1394"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1395"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1396"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1397"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1398"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_1399"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_1400"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_1401"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_1402"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_1403"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1404"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1405"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1406"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1407"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1408"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1409"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1410"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1411"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_1412"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_1413"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_1414"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_1415"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_1416"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_1417"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1418"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1419"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1420"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1421"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1422"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_1423"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1424"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1425"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1426"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1427"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1428"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1429"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1430"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1431"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1432"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_1433"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_1434"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_1435"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_1436"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_1437"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_1438"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_1439"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1440"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1441"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_1442"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_1443"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1444"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1445"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1446"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1447"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1448"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1449"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_RestrictedAssetsDisclosureTextBlock_1450"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_RestrictedAssetsDisclosureTextBlock_1451"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1452"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1453"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1454"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1455"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_1456"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_1457"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_1458"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_1459"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1460"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1461"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1462"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_1463"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_1464"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensation_1465"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensation_1466"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1467"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1468"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1469"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1470"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1471"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1472"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1473"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1474"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1475"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1476"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1477"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1478"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1479"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock_1480"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock_1481"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1482"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_1483"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_1484"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1485"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1486"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1487"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1488"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1489"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1490"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1491"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1492"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1493"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1494"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1495"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1496"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1497"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1498"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1499"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1500"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1501"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1502"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1503"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_1504"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_1505"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1506"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1507"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1508"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_1509"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_1510"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_1511"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_1512"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1513"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1514"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1515"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1516"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1517"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_1518"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1519"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1520"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1521"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1522"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SecuredDebtCurrent" xlink:label="loc_us-gaap_SecuredDebtCurrent_1523"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SecuredDebtCurrent" xlink:label="loc_us-gaap_SecuredDebtCurrent_1524"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SecuredLongTermDebt" xlink:label="loc_us-gaap_SecuredLongTermDebt_1525"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SecuredLongTermDebt" xlink:label="loc_us-gaap_SecuredLongTermDebt_1526"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SecuredLongTermDebt" xlink:label="loc_us-gaap_SecuredLongTermDebt_1527"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_1528"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1529"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1530"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_1531"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1532"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1533"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1534"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1535"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1536"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1537"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1538"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1539"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1540"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_1541"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_1542"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_1543"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_1544"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1545"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1546"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1547"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1548"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1549"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1550"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1551"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1552"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1553"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1554"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1555"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1556"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1557"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1558"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1559"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1560"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1561"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1562"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1563"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1564"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1565"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1566"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1567"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1568"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1569"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1570"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1571"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1572"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1573"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1574"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_1575"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_1576"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1577"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1578"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_1579"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_1580"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1581"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1582"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1583"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1584"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1585"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1586"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1587"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1588"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1589"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1590"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1591"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1592"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1593"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1594"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1595"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1596"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1597"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1598"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1599"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1600"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1601"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1602"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1603"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1604"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1605"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1606"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1607"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1608"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1609"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1610"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1611"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1612"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1613"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1614"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1615"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1616"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1617"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1618"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1619"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1620"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1621"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1622"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1623"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1624"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1625"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1626"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1627"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1628"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1629"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1630"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1631"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_1632"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_1633"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1634"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1635"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1636"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1637"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1638"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1639"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1640"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1641"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1642"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1643"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1644"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1645"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1646"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1647"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1648"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1649"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1650"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1651"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1652"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1653"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1654"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1655"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1656"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1657"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1658"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1659"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1660"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1661"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_1662"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_1663"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_1664"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1665"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1666"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1667"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1668"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1669"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1670"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1671"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1672"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1673"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1674"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1675"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1676"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1677"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1678"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1679"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1680"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1681"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1682"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1683"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1684"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1685"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1686"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1687"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1688"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1689"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1690"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1691"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1692"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1693"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1694"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1695"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1696"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1697"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1698"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1699"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1700"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1701"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1702"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1703"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1704"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1705"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1706"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:label="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_1707"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1708"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1709"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1710"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1711"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_1712"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_1713"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1714"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1715"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1716"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_1717"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1718"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1719"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1720"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1721"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1722"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1723"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1724"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1725"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_1726"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_1727"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_GB_0" xml:lang="en-US">UNITED KINGDOM</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_GB_1" xml:lang="en-US">United Kingdom [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US_0" xml:lang="en-US">UNITED STATES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_US_1" xml:lang="en-US">United States [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentDescription_0" xml:lang="en-US">Amendment Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorFirmId_0" xml:lang="en-US">Auditor Firm ID</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorLocation_0" xml:lang="en-US">Auditor Location</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorName_0" xml:lang="en-US">Auditor Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorOpinionTextBlock_0" xml:lang="en-US">Auditor Opinion [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_AuditorOpinionTextBlock_1" xml:lang="en-US">Auditor Opinion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode_0" xml:lang="en-US">City Area Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract_0" xml:lang="en-US">Cover [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport_0" xml:lang="en-US">Document Annual Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentDescription_0" xml:lang="en-US">Document Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag_0" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodStartDate_0" xml:lang="en-US">Document Period Start Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentQuarterlyReport_0" xml:lang="en-US">Document Quarterly Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock_0" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock_1" xml:lang="en-US">Documents Incorporated by Reference</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport_0" xml:lang="en-US">Document Transition Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1_0" xml:lang="en-US">Entity Address, Address Line One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2_0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown_0" xml:lang="en-US">Entity Address, City or Town</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode_0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince_0" xml:lang="en-US">Entity Address, State or Province</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Registrant CIK</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus_0" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain_0" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany_0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod_0" xml:lang="en-US">Entity Ex Transition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber_0" xml:lang="en-US">Entity File Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory_0" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode_0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent_0" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityListingParValuePerShare_0" xml:lang="en-US">Entity Listing, Par Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat_0" xml:lang="en-US">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany_0" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness_0" xml:lang="en-US">Entity Small Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber_0" xml:lang="en-US">Entity Tax Identification Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers_0" xml:lang="en-US">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis_0" xml:lang="en-US">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber_0" xml:lang="en-US">Local Phone Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_NoTradingSymbolFlag_0" xml:lang="en-US">No Trading Symbol Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_PhoneFaxNumberDescription_0" xml:lang="en-US">Phone Fax Number Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12gTitle_0" xml:lang="en-US">Title of 12(g) Security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName_0" xml:lang="en-US">Security Exchange Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol_0" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_AccrualOfAtmIssuanceCosts_0" xml:lang="en-US">Information about Accrual of ATM issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_AccrualOfAtmIssuanceCosts_1" xml:lang="en-US">Accrual of ATM issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_AccruedInterestConvertedIntoCommonShares_0" xml:lang="en-US">Represents accrued interest converted into common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_AccruedInterestConvertedIntoCommonShares_1" xml:lang="en-US">Accrued interest converted into common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_AccruedInterestConvertedIntoCommonShares_2" xml:lang="en-US">Accrued interest converted into common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_AccruedInterestRepaid_0" xml:lang="en-US">Amount of accrued interest repaid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_AccruedInterestRepaid_1" xml:lang="en-US">Accrued Interest Repaid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_AccruedInterestRepaid_2" xml:lang="en-US">Accrued interest paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_AccrueDividendsPreferredSharesRate_0" xml:lang="en-US">Represents the percentage rate at which preferred shares were entitled to accrue dividends.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_AccrueDividendsPreferredSharesRate_1" xml:lang="en-US">Accrue Dividends Preferred Shares, Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_AccrueDividendsPreferredSharesRate_2" xml:lang="en-US">Percentage rate of accrue dividends</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_AdditionalRestrictedStockUnitIssued_0" xml:lang="en-US">It represents additional Restricted stock unit issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_AdditionalRestrictedStockUnitIssued_1" xml:lang="en-US">Additional Restricted Stock Unit Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_AdditionalRestrictedStockUnitIssued_2" xml:lang="en-US">Additional restricted stock unit issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_0" xml:lang="en-US">Measure computed for a company that takes its earnings and adds back interest expenses, taxes, and depreciation charges, plus other adjustments to the metric.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_1" xml:lang="en-US">Adjusted Earnings Before Interest Tax Depreciation And Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_2" xml:lang="en-US">Adjusted EBITDA threshold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares_0" xml:lang="en-US">Represents the shares of adjustments to additional paid in capital share based compensation requisite service period recognition value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares_1" xml:lang="en-US">Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares_2" xml:lang="en-US">Share-based compensation (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_AgentsMember_0" xml:lang="en-US">This member stands for agents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_AgentsMember_1" xml:lang="en-US">Agents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement_0" xml:lang="en-US">Represents amount of available to exercise in relation to standby equity purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement_1" xml:lang="en-US">Amount Available To Exercise In Relation To Standby Equity Purchase Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement_2" xml:lang="en-US">Amount available to exercise in relation to SEPA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_AntevAssetAgreementAbstract_0" xml:lang="en-US">Antev Asset Agreement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_AntevLimitedMember_0" xml:lang="en-US">Series of individually immaterial business combinations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_AntevLimitedMember_1" xml:lang="en-US">Antev Limited [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_AtmAgreementMember_0" xml:lang="en-US">This member stands for ATM agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_AtmAgreementMember_1" xml:lang="en-US">Atm Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_AtmAgreementMember_2" xml:lang="en-US">ATM Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_BalanceSheetComponentsAbstract_0" xml:lang="en-US">Balance Sheet Components [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy for basis of presentation and consolidation..</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock_1" xml:lang="en-US">Basis Of Presentation And Consolidation [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock_2" xml:lang="en-US">Basis of presentation and consolidation [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis_0" xml:lang="en-US">Information by consideration transferred equity interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis_1" xml:lang="en-US">Business Combination Consideration Transferred Equity Interest Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain_0" xml:lang="en-US">Type of consideration transferred equity interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain_1" xml:lang="en-US">Business Combination Consideration Transferred Equity Interest Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_BusinessCombinationDiscountPercentageAppliedToClosingPrice_0" xml:lang="en-US">Business Combination discount percentage applied to closing price shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_BusinessCombinationDiscountPercentageAppliedToClosingPrice_1" xml:lang="en-US">Business Combination, Discount Percentage Applied To Closing Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_BusinessCombinationDiscountPercentageAppliedToClosingPrice_2" xml:lang="en-US">Discount percentage applied to closing price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_BusinessCombinationDiscountPricePerShare_0" xml:lang="en-US">Discount per share price of saleable stock paid or offered to be paid by acquirer in business combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_BusinessCombinationDiscountPricePerShare_1" xml:lang="en-US">Business Combination, Discount Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_BusinessCombinationDiscountPricePerShare_2" xml:lang="en-US">Business combination, discount price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_BusinessCombinationReverseTakeoverTransactionTextBlock_0" xml:lang="en-US">The entire disclosure for business combination, reverse acquisition completed during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_BusinessCombinationReverseTakeoverTransactionTextBlock_1" xml:lang="en-US">Business Combination, Reverse Takeover Transaction [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_BusinessCombinationReverseTakeoverTransactionTextBlock_2" xml:lang="en-US">Reverse takeover transaction [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_CashReceivedForInterest_0" xml:lang="en-US">This represents the amount of cash received for interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_CashReceivedForInterest_1" xml:lang="en-US">Cash Received For Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_CashReceivedForInterest_2" xml:lang="en-US">Cash received for interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ChangeInFairValueOfDebentures_0" xml:lang="en-US">Represents the amount if change in fair value of debentures.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ChangeInFairValueOfDebentures_1" xml:lang="en-US">Change In Fair Value Of Debentures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_ChangeInFairValueOfDebentures_2" xml:lang="en-US">Change in fair value of debentures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ChangeInFairValueOfDebentures_3" xml:lang="en-US">Change in fair value of debentures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes_0" xml:lang="en-US">Represents the amount of change in fair value of debentures and secured promissory notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes_1" xml:lang="en-US">Change In Fair Value Of Debentures And Secured Promissory Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes_2" xml:lang="en-US">Change in fair value of debentures and secured promissory notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ClassOfWarrantOrRightExercisable_0" xml:lang="en-US">Represents the number of warrants exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ClassOfWarrantOrRightExercisable_1" xml:lang="en-US">Class Of Warrant Or Right Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_ClassOfWarrantOrRightExercisable_2" xml:lang="en-US">Number exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ClassOfWarrantOrRightExercisable_3" xml:lang="en-US">Number of options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ClassOfWarrantOrRightExpiryDate_0" xml:lang="en-US">Represents about class of warrant or right, expiry date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ClassOfWarrantOrRightExpiryDate_1" xml:lang="en-US">Class Of Warrant Or Right, Expiry Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ClassOfWarrantOrRightExpiryDate_2" xml:lang="en-US">Expiry date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember_0" xml:lang="en-US">This member stands for clinical, manufacturing and regulatory activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember_1" xml:lang="en-US">Clinical, Manufacturing And Regulatory Activities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember_2" xml:lang="en-US">Clinical, manufacturing and regulatory activities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_CommissionsPayableToAgents_0" xml:lang="en-US">Represent the amount of commission payable to agents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_CommissionsPayableToAgents_1" xml:lang="en-US">Commissions Payable To Agents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_CommissionsPayableToAgents_2" xml:lang="en-US">Commissions payable to agents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_CommonSharesToBeIssued_0" xml:lang="en-US">Represents the amount of common shares to be issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_CommonSharesToBeIssued_1" xml:lang="en-US">Common Shares To Be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_CommonSharesToBeIssued_2" xml:lang="en-US">Common shares to be issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ComprehensiveLossAttributableToParent_0" xml:lang="en-US">Represents the amount of comprehensive loss attributable to parent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ComprehensiveLossAttributableToParent_1" xml:lang="en-US">Comprehensive Loss Attributable To Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ComprehensiveLossAttributableToParent_2" xml:lang="en-US">Common shareholders of the Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ContingentConsiderationPhasesFourMember_0" xml:lang="en-US">Contingent Consideration Phases Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ContingentConsiderationPhasesFourMember_1" xml:lang="en-US">Contingent Consideration Phases Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_ContingentConsiderationPhasesFourMember_2" xml:lang="en-US">FDA NDA approval - AUR prevention [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ContingentConsiderationPhasesOneMember_0" xml:lang="en-US">Contingent Consideration Phases One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ContingentConsiderationPhasesOneMember_1" xml:lang="en-US">Contingent Consideration Phases One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_ContingentConsiderationPhasesOneMember_2" xml:lang="en-US">Advanced Prostate Cancer - Phase 2 success or registration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ContingentConsiderationPhasesThreeMember_0" xml:lang="en-US">Contingent Consideration Phases Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ContingentConsiderationPhasesThreeMember_1" xml:lang="en-US">Contingent Consideration Phases Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_ContingentConsiderationPhasesThreeMember_2" xml:lang="en-US">FDA NDA approval - Hormone therapy for prostate cancer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ContingentConsiderationPhasesTwoMember_0" xml:lang="en-US">Contingent Consideration Phases Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ContingentConsiderationPhasesTwoMember_1" xml:lang="en-US">Contingent Consideration Phases Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_ContingentConsiderationPhasesTwoMember_2" xml:lang="en-US">Acute Urinary Retention (AUR) Prevention - Phase 2 success or registration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ConversionOfStockConversionOneMember_0" xml:lang="en-US">Conversion Of Stock, Conversion One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ConversionOfStockConversionOneMember_1" xml:lang="en-US">Conversion one</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ConversionOfStockConversionThreeMember_0" xml:lang="en-US">Conversion Of Stock, Conversion Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ConversionOfStockConversionThreeMember_1" xml:lang="en-US">Conversion Of Stock, Conversion Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ConversionOfStockConversionThreeMember_2" xml:lang="en-US">Conversion three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ConversionOfStockConversionTwoMember_0" xml:lang="en-US">Conversion Of Stock, Conversion Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ConversionOfStockConversionTwoMember_1" xml:lang="en-US">Conversion Of Stock, Conversion Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ConversionOfStockConversionTwoMember_2" xml:lang="en-US">Conversion two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ConvertibleDebtAccretionExpense_0" xml:lang="en-US">The amount of accretion expense for convertible debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ConvertibleDebtAccretionExpense_1" xml:lang="en-US">Convertible Debt Accretion Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_mdcx_ConvertibleDebtAccretionExpense_2" xml:lang="en-US">Interest Expense, Debt, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ConvertibleDebtAccretionExpense_3" xml:lang="en-US">Interest accretion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ConvertiblePromissoryNotesMember_0" xml:lang="en-US">Convertible promissory notes [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ConvertiblePromissoryNotesMember_1" xml:lang="en-US">Convertible Promissory Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ConvertiblePromissoryNotesMember_2" xml:lang="en-US">Convertible Promissory Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes_0" xml:lang="en-US">Represents the amount of costs to issue debentures and secured promissory notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes_1" xml:lang="en-US">Costs To Issue Debentures And Secured Promissory Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes_2" xml:lang="en-US">Cost to issue debentures and secured promissory notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DebentureContinuityOneMember_0" xml:lang="en-US">It represents as a debenture continuity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DebentureContinuityOneMember_1" xml:lang="en-US">Debenture Continuity One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_DebentureContinuityOneMember_2" xml:lang="en-US">Debenture issued on September 17, 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DebenturesAndSecuredPromissoryNotes_0" xml:lang="en-US">The amount of debentures and secured promissory notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DebenturesAndSecuredPromissoryNotes_1" xml:lang="en-US">Debentures And Secured Promissory Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_DebenturesAndSecuredPromissoryNotes_2" xml:lang="en-US">Debentures and secured promissory notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_mdcx_DebenturesAndSecuredPromissoryNotes_3" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DebenturesIssuedPercentageOfDiscountedPrice_0" xml:lang="en-US">Debentures issued percentage of discounted price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DebenturesIssuedPercentageOfDiscountedPrice_1" xml:lang="en-US">Debentures Issued Percentage Of Discounted Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_DebenturesIssuedPercentageOfDiscountedPrice_2" xml:lang="en-US">Debentures issued percentage of discounted price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DebenturesMember_0" xml:lang="en-US">Debentures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DebenturesMember_1" xml:lang="en-US">Debentures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DebtConversionAdditionalDebtAmount_0" xml:lang="en-US">Represents the amount of the additional debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DebtConversionAdditionalDebtAmount_1" xml:lang="en-US">Debt Conversion, Additional Debt, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_DebtConversionAdditionalDebtAmount_2" xml:lang="en-US">Principal amount of additional convertible promissory notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares_0" xml:lang="en-US">Represents the per price of preferred shares issued on the conversion of the convertible promissory notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares_1" xml:lang="en-US">Debt Conversion, Convertible Instrument, Price Per Preferred Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares_2" xml:lang="en-US">Conversion price of preferred shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DebtConversionConvertibleIntoPreferredSharesAmount_0" xml:lang="en-US">Represents the value of convertible promissory notes that could be converted into preferred shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DebtConversionConvertibleIntoPreferredSharesAmount_1" xml:lang="en-US">Debt Conversion, Convertible Into Preferred Shares, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_DebtConversionConvertibleIntoPreferredSharesAmount_2" xml:lang="en-US">Value of convertible promissory notes that could be converted into preferred shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount_0" xml:lang="en-US">Represents the value used as determinant for converting remaining value of convertible promissory notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount_1" xml:lang="en-US">Debt Conversion, Determinant For Converting Remaining Value Of Convertible Instrument, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount_2" xml:lang="en-US">Determinant for converting remaining value of convertible promissory notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest_0" xml:lang="en-US">Represents the percentage of price per preferred shares for unpaid accrued interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest_1" xml:lang="en-US">Debt Conversion, Percentage Of Price Per Preferred Shares, Unpaid Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest_2" xml:lang="en-US">Percentage of price per preferred shares for unpaid accrued interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DebtConversionRemainingConvertibleAmount_0" xml:lang="en-US">Represents the value of convertible promissory notes remaining for conversion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DebtConversionRemainingConvertibleAmount_1" xml:lang="en-US">Debt Conversion, Remaining Convertible, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_DebtConversionRemainingConvertibleAmount_2" xml:lang="en-US">Value of convertible promissory notes remaining for conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DebtDefaultBalanceIncreasePercentage_0" xml:lang="en-US">Percentage of debt default balance increase percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DebtDefaultBalanceIncreasePercentage_1" xml:lang="en-US">Debt Default Balance Increase Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_DebtDefaultBalanceIncreasePercentage_2" xml:lang="en-US">Increase of outstanding balance on redemption failure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DebtInstrumentConvertibleExtinguished_0" xml:lang="en-US">Represents the amount of convertible debt extinguished.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DebtInstrumentConvertibleExtinguished_1" xml:lang="en-US">Debt Instrument Convertible Extinguished</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_DebtInstrumentConvertibleExtinguished_2" xml:lang="en-US">Loss on extinguishment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage_0" xml:lang="en-US">Debt instrument covenant share price threshold percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage_1" xml:lang="en-US">Debt Instrument Covenant Share Price Threshold Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage_2" xml:lang="en-US">Share price threshold, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DebtInstrumentExchangeThresholdAmount_0" xml:lang="en-US">Amount of debt instrument exchange threshold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DebtInstrumentExchangeThresholdAmount_1" xml:lang="en-US">Debt Instrument Exchange Threshold Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_DebtInstrumentExchangeThresholdAmount_2" xml:lang="en-US">Principal amount repaid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DebtInstrumentMaximumExchangeLimitAmount_0" xml:lang="en-US">Debt instrument maximum exchange limit amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DebtInstrumentMaximumExchangeLimitAmount_1" xml:lang="en-US">Debt Instrument Maximum Exchange Limit Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_DebtInstrumentMaximumExchangeLimitAmount_2" xml:lang="en-US">Debt instrument maximum exchange limit amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DebtInstrumentPeriodicPaymentInterestInCash_0" xml:lang="en-US">Represents the amount of the interest paid in cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DebtInstrumentPeriodicPaymentInterestInCash_1" xml:lang="en-US">Debt Instrument Periodic Payment Interest In Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_DebtInstrumentPeriodicPaymentInterestInCash_2" xml:lang="en-US">Value of accrued interest paid in cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DebtInstrumentRedemptionLimitAmount_0" xml:lang="en-US">The amount of debt instrument redemption limit amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DebtInstrumentRedemptionLimitAmount_1" xml:lang="en-US">Debt Instrument Redemption Limit Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_DebtInstrumentRedemptionLimitAmount_2" xml:lang="en-US">Monthly redemptions ceiling</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit_0" xml:lang="en-US">Debt instrument volume based redemption percentage limit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit_1" xml:lang="en-US">Debt Instrument Volume Based Redemption Percentage Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit_2" xml:lang="en-US">Cumulative daily dollar trading volume (Volume-based limit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DebtIssuanceDiscount_0" xml:lang="en-US">Represent the value of debenture issued at a discount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DebtIssuanceDiscount_1" xml:lang="en-US">Debt Issuance Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_DebtIssuanceDiscount_2" xml:lang="en-US">Debt issuance discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DeemedDividendOnWarrantInducement_0" xml:lang="en-US">Deemed dividend on warrant inducement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_mdcx_DeemedDividendOnWarrantInducement_1" xml:lang="en-US">Deemed dividend on warrant inducement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DeemedDividendOnWarrantInducement_2" xml:lang="en-US">Deemed dividend on warrant inducement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DeferredAtmOfferingCostsOffsetAgainstAdditionalPaidInCapital_0" xml:lang="en-US">Information about Deferred ATM offering costs offset against additional paid-in capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DeferredAtmOfferingCostsOffsetAgainstAdditionalPaidInCapital_1" xml:lang="en-US">Deferred ATM offering costs offset against additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_DeferredAtmOfferingCostsOffsetAgainstAdditionalPaidInCapital_2" xml:lang="en-US">Deferred ATM offering costs offset against additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement_0" xml:lang="en-US">Represents the amount of deferred issuance costs on issued shares related to SEPA agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement_1" xml:lang="en-US">Deferred Issuance Costs On Issued Shares Related To Sepa Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement_2" xml:lang="en-US">Deferred issuance costs on issued shares related to SEPA agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DeferredTaxAssetConvertibleDebentures_0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from convertible debentures.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DeferredTaxAssetConvertibleDebentures_1" xml:lang="en-US">Deferred Tax Asset, Convertible Debentures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_DeferredTaxAssetConvertibleDebentures_2" xml:lang="en-US">Convertible Debentures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DeferredTaxAssetsAdditionalOperatingLossCarryforwardsForeign_0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign additional operating loss carryforwards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DeferredTaxAssetsAdditionalOperatingLossCarryforwardsForeign_1" xml:lang="en-US">Deferred Tax Assets, Additional Operating Loss Carryforwards, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_DeferredTaxAssetsAdditionalOperatingLossCarryforwardsForeign_2" xml:lang="en-US">Additional net operating losses carry forward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_DeferredTaxAssetsOperatingLossCarryforwardsNonCapital_0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_DeferredTaxAssetsOperatingLossCarryforwardsNonCapital_1" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Non Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_DeferredTaxAssetsOperatingLossCarryforwardsNonCapital_2" xml:lang="en-US">Non-capital losses carry forward - Canada</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_EarningsFromDiscontinuedOperationsMember_0" xml:lang="en-US">Primary financial statement caption encompassing earnings from discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_EarningsFromDiscontinuedOperationsMember_1" xml:lang="en-US">Earnings From Discontinued Operations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_EarningsFromDiscontinuedOperationsMember_2" xml:lang="en-US">Earnings from discontinued operations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_EffectiveInterestRateOnDebt_0" xml:lang="en-US">Represent the effective interest rate on debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_EffectiveInterestRateOnDebt_1" xml:lang="en-US">Effective Interest Rate On Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_EffectiveInterestRateOnDebt_2" xml:lang="en-US">Effective interest rate on debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_EmployeeStockPurchasePlanMember_0" xml:lang="en-US">Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_EmployeeStockPurchasePlanMember_1" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_EquityDistributionAgreementCommissionRate_0" xml:lang="en-US">Represent the equity distribution agreement commission rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_EquityDistributionAgreementCommissionRate_1" xml:lang="en-US">Equity Distribution Agreement Commission Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_EquityDistributionAgreementCommissionRate_2" xml:lang="en-US">Equity distribution agreement commission rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ExerciseOfPublicWarrantsMember_0" xml:lang="en-US">Information about exercise of public warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ExerciseOfPublicWarrantsMember_1" xml:lang="en-US">Exercise Of Public Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ExerciseOfRegulationAWarrantsMember_0" xml:lang="en-US">Information about exercise of regulation A warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ExerciseOfRegulationAWarrantsMember_1" xml:lang="en-US">Exercise Of Regulation A Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ExerciseSeriesAAndBWarrantsIssuedMember_0" xml:lang="en-US">Represent the member of exercise series A and B warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ExerciseSeriesAAndBWarrantsIssuedMember_1" xml:lang="en-US">Exercise Series A And B Warrants Issued [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_FairValueLossOfDebt_0" xml:lang="en-US">It represents fair value loss of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_FairValueLossOfDebt_1" xml:lang="en-US">Fair Value Loss Of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_FairValueLossOfDebt_2" xml:lang="en-US">Fair value loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_FairValueOfAdditionalRestrictedStockUnit_0" xml:lang="en-US">It represents fair value of additional restricted stock unit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_FairValueOfAdditionalRestrictedStockUnit_1" xml:lang="en-US">Fair value of additional restricted stock unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_FairValueOfWarrantsGranted_0" xml:lang="en-US">Fair value of warrants granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_FairValueOfWarrantsGranted_1" xml:lang="en-US">Fair value of warrants granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_FairValuePerShare_0" xml:lang="en-US">Represents the fair value per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_FairValuePerShare_1" xml:lang="en-US">Fair Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_FairValuePerShare_2" xml:lang="en-US">Fair value per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_FairValuePerWarrant_0" xml:lang="en-US">Represents the fair value per warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_FairValuePerWarrant_1" xml:lang="en-US">Fair Value Per Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_FairValuePerWarrant_2" xml:lang="en-US">Fair value per warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ForeignCurrencyTransactionsPolicyTextBlock_0" xml:lang="en-US">Represent the foreign currency transactions policies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ForeignCurrencyTransactionsPolicyTextBlock_1" xml:lang="en-US">Foreign Currency Transactions [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_ForeignCurrencyTransactionsPolicyTextBlock_2" xml:lang="en-US">Foreign currency transactions [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_FormerHoldersMember_0" xml:lang="en-US">Former Holders [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_FormerHoldersMember_1" xml:lang="en-US">Former holders [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_GainLossOnSettlements_0" xml:lang="en-US">Represents the amount of gain loss on settlements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_mdcx_GainLossOnSettlements_1" xml:lang="en-US">Loss on SEPA settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_GainLossOnSettlements_2" xml:lang="en-US">Gain Loss On Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_GainLossOnSettlements_3" xml:lang="en-US">Loss on SEPA settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_GainLossOnSettlements_4" xml:lang="en-US">Loss on SEPA (as defined below) settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_GrantDateOneMember_0" xml:lang="en-US">Grant Date One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_GrantDateOneMember_1" xml:lang="en-US">Grant Date One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_GrantDateOneMember_2" xml:lang="en-US">December 17, 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_GrantDateThreeMember_0" xml:lang="en-US">Grant Date Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_GrantDateThreeMember_1" xml:lang="en-US">Grant Date Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_GrantDateThreeMember_2" xml:lang="en-US">June 30, 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_GrantDateTwoMember_0" xml:lang="en-US">Grant Date Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_GrantDateTwoMember_1" xml:lang="en-US">Grant Date Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_GrantDateTwoMember_2" xml:lang="en-US">December 17, 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_GrantedRegulationAWarrantsMember_0" xml:lang="en-US">Information about granted regulation A warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_GrantedRegulationAWarrantsMember_1" xml:lang="en-US">Granted Regulation A Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_GrantedSeriesAAndBWarrantsIssuedMember_0" xml:lang="en-US">Information about granted series A and B warrants issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_GrantedSeriesAAndBWarrantsIssuedMember_1" xml:lang="en-US">Granted Series A And B Warrants Issued [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_GrantedWarrantsMember_0" xml:lang="en-US">Information about granted warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_GrantedWarrantsMember_1" xml:lang="en-US">Granted Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_IncreaseDecreaseInCostsRelatedToSettlements_0" xml:lang="en-US">Represents the amount of increase decrease in costs related to settlements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_IncreaseDecreaseInCostsRelatedToSettlements_1" xml:lang="en-US">Increase Decrease In Costs Related To Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_IncreaseDecreaseInCostsRelatedToSettlements_2" xml:lang="en-US">Issuance cost related to SEPA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets_0" xml:lang="en-US">Represents the amount of operating lease right-of-use assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets_1" xml:lang="en-US">Increase Decrease In Operating Lease Rightofuse Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets_2" xml:lang="en-US">Change in operating lease right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_IncrementalFairValueOfWarrantsGranted_0" xml:lang="en-US">Represent the amount of incremental fair value of warrants granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_IncrementalFairValueOfWarrantsGranted_1" xml:lang="en-US">Incremental Fair Value Of Warrants Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_IncrementalFairValueOfWarrantsGranted_2" xml:lang="en-US">Incremental fair value of warrants granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_IndividualsMember_0" xml:lang="en-US">This member stands for individuals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_IndividualsMember_1" xml:lang="en-US">Individuals [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_InProcessResearchAndDevelopment_0" xml:lang="en-US">Amount of in process research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_InProcessResearchAndDevelopment_1" xml:lang="en-US">In Process Research And Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_InProcessResearchAndDevelopment_2" xml:lang="en-US">IPR&amp;D - Teverelix</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_InteractiveCapitalPartnersCorporationMember_0" xml:lang="en-US">Interactive Capital Partners Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_InteractiveCapitalPartnersCorporationMember_1" xml:lang="en-US">Interactive [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_InterimRemeasurementMember_0" xml:lang="en-US">This member stands for interim remeasurement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_InterimRemeasurementMember_1" xml:lang="en-US">Interim Remeasurement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_InterimRemeasurementMember_2" xml:lang="en-US">Interim remeasurement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_IssuanceCostsIncludedInAccountsPayable_0" xml:lang="en-US">Issuance costs included in accounts payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_IssuanceCostsIncludedInAccountsPayable_1" xml:lang="en-US">Issuance costs included in accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_IssuanceCostsInConnectionWithEquityFinancing_0" xml:lang="en-US">Represents issuuance costs in connection with equity financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_IssuanceCostsInConnectionWithEquityFinancing_1" xml:lang="en-US">Issuance Costs In Connection With Equity Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_IssuanceCostsInConnectionWithEquityFinancing_2" xml:lang="en-US">Issuance costs in connection with equity financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_IssuanceCostsInConnectionWithInitialPublicOffering_0" xml:lang="en-US">Represents issuance costs in connection with initial public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_IssuanceCostsInConnectionWithInitialPublicOffering_1" xml:lang="en-US">Issuance Costs In Connection With Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_IssuanceCostsInConnectionWithInitialPublicOffering_2" xml:lang="en-US">Issuance costs in connection with initial public offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_IssuanceCostsInConnectionWithPrivatePlacement_0" xml:lang="en-US">Represents issuance costs in connection with a private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_IssuanceCostsInConnectionWithPrivatePlacement_1" xml:lang="en-US">Issuance Costs In Connection With Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_IssuanceCostsInConnectionWithPrivatePlacement_2" xml:lang="en-US">Issuance costs in connection with a private placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_IssuanceCostsInConnectionWithPrivatePlacement_3" xml:lang="en-US">Value of finders fees in connection with a private placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_IssuanceCostsInConnectionWithRegulationA_0" xml:lang="en-US">Represents issuance costs in connection with regulation A.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_IssuanceCostsInConnectionWithRegulationA_1" xml:lang="en-US">Issuance Costs In Connection With Regulation A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_IssuanceCostsInConnectionWithRegulationA_2" xml:lang="en-US">Issuance costs in connection with Regulation A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered_0" xml:lang="en-US">Represent the amount of issuance of common shares in connection with non-cash compensation for services rendered.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered_1" xml:lang="en-US">Issuance of common shares in connection with non-cash compensation for services rendered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered_2" xml:lang="en-US">Issuance Of Common Shares Connection With Non Cash Compensation For Services Rendered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered_3" xml:lang="en-US">Issuance of common shares in connection with non-cash compensation for services rendered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_June2025PublicOfferingMember_0" xml:lang="en-US">June 2025 Public Offering [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_June2025PublicOfferingMember_1" xml:lang="en-US">June 2025 Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_LesseeOperatingLeasesDisclosureTableTextBlock_0" xml:lang="en-US">Represent the lessee operating leases disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_LesseeOperatingLeasesDisclosureTableTextBlock_1" xml:lang="en-US">Lessee Operating Leases Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_LesseeOperatingLeasesDisclosureTableTextBlock_2" xml:lang="en-US">Schedule of operating leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding_0" xml:lang="en-US">Limit of options as a percentage of shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding_1" xml:lang="en-US">Limit Of Options As Percentage Of Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding_2" xml:lang="en-US">Limit of options as a percentage of shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_LiquidityAbstract_0" xml:lang="en-US">Liquidity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_LiquidityTextBlock_0" xml:lang="en-US">The entire disclosure liquidity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_LiquidityTextBlock_1" xml:lang="en-US">Liquidity [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_LiquidityTextBlock_2" xml:lang="en-US">Liquidity and Going Concern [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_LongTermIncentivePlanMember_0" xml:lang="en-US">Represents information of Long Term Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_LongTermIncentivePlanMember_1" xml:lang="en-US">Long Term Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_LongTermIncentivePlanMember_2" xml:lang="en-US">2021 Long-Term Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_MeasurementInputValuationDateSharePriceMember_0" xml:lang="en-US">This member stands for measurement input, valuation date share price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_MeasurementInputValuationDateSharePriceMember_1" xml:lang="en-US">Measurement Input, Valuation Date Share Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_MeasurementInputValuationDateSharePriceMember_2" xml:lang="en-US">Valuation date share price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_MoneyMarketFunds_0" xml:lang="en-US">Represents the amount of money market funds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_MoneyMarketFunds_1" xml:lang="en-US">Money Market Funds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_MoneyMarketFunds_2" xml:lang="en-US">Money market funds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts_0" xml:lang="en-US">Represents the amount of net cash paid for antev asset acquisition including transaction costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts_1" xml:lang="en-US">Net cash paid for Antev asset acquisition including transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts_2" xml:lang="en-US">Net Cash Paid For Antev Asset Acquisition Including Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts_3" xml:lang="en-US">Net cash paid for Antev asset acquisition including transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_NetOfAllocatedShareBasedCompensationExpense_0" xml:lang="en-US">Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_NetOfAllocatedShareBasedCompensationExpense_1" xml:lang="en-US">Net of Allocated Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_NetOfAllocatedShareBasedCompensationExpense_2" xml:lang="en-US">Net stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_NoInsiderTradingFlag_0" xml:lang="en-US">No Insider Trading Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_NoInsiderTradingFlag_1" xml:lang="en-US">No Insider Trading Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_NoteAMember_0" xml:lang="en-US">This member stands for Note A.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_NoteAMember_1" xml:lang="en-US">Note A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_NoteBMember_0" xml:lang="en-US">This member stands for Note B.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_NoteBMember_1" xml:lang="en-US">Note B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement_0" xml:lang="en-US">Represents the number of common shares issued in connection with a private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement_1" xml:lang="en-US">Number Of Common Shares Issued In Connection With Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement_2" xml:lang="en-US">Number of common shares issued in connection with a private placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_NumberOfCommonShareWarrantsExercisable_0" xml:lang="en-US">Number of common share warrants exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_mdcx_NumberOfCommonShareWarrantsExercisable_1" xml:lang="en-US">Number of common share warrants exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_mdcx_NumberOfCommonShareWarrantsExercisable_2" xml:lang="en-US">Number of common share warrants exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_NumberOfCommonShareWarrantsExercisable_3" xml:lang="en-US">Number Of Common Share Warrants Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_NumberOfCommonShareWarrantsExercisableExerciseInPeriod_0" xml:lang="en-US">Number of common share warrants exercisable exercise during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_NumberOfCommonShareWarrantsExercisableExerciseInPeriod_1" xml:lang="en-US">Number Of Common Share Warrants Exercisable Exercise In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_NumberOfCommonShareWarrantsExercisableExerciseInPeriod_2" xml:lang="en-US">Number of common share warrants exercisable exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_NumberOfCommonShareWarrantsExercisableGrantsInPeriod_0" xml:lang="en-US">Number of common share warrants exercisable granted during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_NumberOfCommonShareWarrantsExercisableGrantsInPeriod_1" xml:lang="en-US">Number Of Common Share Warrants Exercisable Grants In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_NumberOfCommonShareWarrantsExercisableGrantsInPeriod_2" xml:lang="en-US">Number of common share warrants exercisable granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod_0" xml:lang="en-US">Number of common share warrants outstanding exercise during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod_1" xml:lang="en-US">Warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod_2" xml:lang="en-US">Number Of Common Share Warrants Outstanding Exercise In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod_3" xml:lang="en-US">Warrants outstanding exercise during the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_0" xml:lang="en-US">Number of common share warrants outstanding granted during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_1" xml:lang="en-US">Number Of Common Share Warrants Outstanding Grants In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_2" xml:lang="en-US">Number of warrants granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_3" xml:lang="en-US">Warrants granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_NumberOfConvertibleNotesSubscribed_0" xml:lang="en-US">Number of convertible notes subscribed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_NumberOfSharesIssuedAfter210DaysFromAcquisition_0" xml:lang="en-US">Description of number of shares issues after 210 days from acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_NumberOfSharesIssuedAfter210DaysFromAcquisition_1" xml:lang="en-US">Number Of Shares Issued After 210 Days From Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_NumberOfSharesIssuedAfter210DaysFromAcquisition_2" xml:lang="en-US">Number of shares issued after 210 days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_NumberOfTradingDays_0" xml:lang="en-US">Represents number of trading days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_NumberOfTradingDays_1" xml:lang="en-US">Number Of Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_NumberOfTradingDays_2" xml:lang="en-US">Number of consecutive trading days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_NumberOfWarrantsExercisable_0" xml:lang="en-US">Represents the number of warrants exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_NumberOfWarrantsExercisable_1" xml:lang="en-US">Number Of Warrants Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_NumberOfWarrantsExercisable_2" xml:lang="en-US">Number exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_NumberOfWarrantsExercisable_3" xml:lang="en-US">Number of options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_NumberOfWarrantsExercised_0" xml:lang="en-US">Represents the number of warrants exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_NumberOfWarrantsExercised_1" xml:lang="en-US">Number of warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_NumberOfWarrantsExercised_2" xml:lang="en-US">Number exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_NumberOfWarrantsExercised_3" xml:lang="en-US">Number of options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_NumberOfWarrantsExercisedForCash_0" xml:lang="en-US">Represents the number of warrants exercised for cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_NumberOfWarrantsExercisedForCash_1" xml:lang="en-US">Number Of Warrants Exercised For Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_NumberOfWarrantsExercisedForCash_2" xml:lang="en-US">Number of warrants exercised for cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_OriginalEarningsBeforeInterestTaxDepreciationAndAmortization_0" xml:lang="en-US">Measure computed for a company that takes its earnings and adds back interest expenses, taxes, and depreciation charges, plus other adjustments to the metric.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_OriginalEarningsBeforeInterestTaxDepreciationAndAmortization_1" xml:lang="en-US">Original Earnings Before Interest Tax Depreciation And Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_OriginalEarningsBeforeInterestTaxDepreciationAndAmortization_2" xml:lang="en-US">Original EBITDA threshold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_PaymentOfStructuringFee_0" xml:lang="en-US">Represents the amount of payment of structuring fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_PaymentOfStructuringFee_1" xml:lang="en-US">Payment of structuring fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_PaymentsToAcquireBusinessesAdvance_0" xml:lang="en-US">The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price in advance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_PaymentsToAcquireBusinessesAdvance_1" xml:lang="en-US">Payments To Acquire Businesses, Advance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_PaymentsToAcquireBusinessesAdvance_2" xml:lang="en-US">Payments to acquire businesses, advance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_PreferredStockRedeemablePercentage_0" xml:lang="en-US">Preferred stock, redeemable percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_PreferredStockRedeemablePercentage_1" xml:lang="en-US">Preferred Stock, Redeemable Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_PreferredStockRedeemablePercentage_2" xml:lang="en-US">Preferred stock, redeemable percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_PrepaidContractResearch_0" xml:lang="en-US">Amount of contract research organizations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_PrepaidContractResearch_1" xml:lang="en-US">Prepaid Contract Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_PrepaidContractResearch_2" xml:lang="en-US">Contract research organizations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_PrepaidExpensesPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy for prepaid expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_PrepaidExpensesPolicyTextBlock_1" xml:lang="en-US">Prepaid Expenses [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_PrepaidExpensesPolicyTextBlock_2" xml:lang="en-US">Prepaid expenses [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_PrepaidProfessionalServices_0" xml:lang="en-US">Amount of prepaid professional services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_PrepaidProfessionalServices_1" xml:lang="en-US">Prepaid Professional Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_PrepaidProfessionalServices_2" xml:lang="en-US">Professional services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_PrepaidServices_0" xml:lang="en-US">Amount of prepaid services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_PrepaidServices_1" xml:lang="en-US">Prepaid Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_PrepaidServices_2" xml:lang="en-US">Prepaid services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents_0" xml:lang="en-US">Information about proceeds from common shares net of commissions payable to agents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents_1" xml:lang="en-US">Proceeds From Common Shares Net Of Commissions Payable To Agents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents_2" xml:lang="en-US">Proceeds from common shares net of commissions payable to Agents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ProceedsFromConcurrentFinancing_0" xml:lang="en-US">Represents the proceeds from concurrent financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_mdcx_ProceedsFromConcurrentFinancing_1" xml:lang="en-US">Proceeds from concurrent financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ProceedsFromConcurrentFinancing_2" xml:lang="en-US">Proceeds From Concurrent Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_ProceedsFromConcurrentFinancing_3" xml:lang="en-US">Proceeds from concurrent financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts_0" xml:lang="en-US">Represents the amount of proceeds from issuance of common stock at the market offering net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts_1" xml:lang="en-US">Proceeds from issuance of common shares under ATM, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts_2" xml:lang="en-US">Proceeds From Issuance of Common Stock at the Market Offering Net of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts_3" xml:lang="en-US">Proceeds from issuance of common shares under ATM, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ProceedsFromIssuanceOfSharesUnderSettlements_0" xml:lang="en-US">Represents the amount of proceeds from issuance of shares under settlements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ProceedsFromIssuanceOfSharesUnderSettlements_1" xml:lang="en-US">Proceeds From Issuance Of Shares Under Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ProceedsFromIssuanceOfSharesUnderSettlements_2" xml:lang="en-US">Proceeds from issuance of common shares under SEPA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ProceedsFromOrionEquityInvestment_0" xml:lang="en-US">Represents the amount of proceeds from orion equity investment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ProceedsFromOrionEquityInvestment_1" xml:lang="en-US">Proceeds From Orion Equity Investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ProceedsFromOrionEquityInvestment_2" xml:lang="en-US">Net proceeds from Orion Equity Investment, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ProceedsFromSaleOfCommonStockOnAtMarketProgram_0" xml:lang="en-US">Proceeds from sale of common stock on at-the market ("ATM") program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ProceedsFromSaleOfCommonStockOnAtMarketProgram_1" xml:lang="en-US">Proceeds From Sale Of Common Stock On At Market Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_ProceedsFromSaleOfCommonStockOnAtMarketProgram_2" xml:lang="en-US">Proceeds from sale of common stock on at-the market ("ATM") program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ProceedsFromSaleOfCommonStockOnAtMarketProgram_3" xml:lang="en-US">Proceeds from sale of common stock through at-the market ("ATM") program, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ProceedsFromSaleOfRoyaltyInterest_0" xml:lang="en-US">Proceeds From Sale Of Royalty Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ProceedsFromSaleOfRoyaltyInterest_1" xml:lang="en-US">Proceeds From Sale Of Royalty Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_ProceedsFromSaleOfRoyaltyInterest_2" xml:lang="en-US">Proceeds from sale of royalty interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures_0" xml:lang="en-US">Proceeds from share issuance used to repay outstanding debentures.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures_1" xml:lang="en-US">Proceeds From Share Issuance Used To Repay Outstanding Debentures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures_2" xml:lang="en-US">Proceeds from share issuance used to repay outstanding debentures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ProceedsFromSimpleAgreementForFutureEquity_0" xml:lang="en-US">Proceeds from simple agreement for future equity ("SAFE")</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ProceedsFromSimpleAgreementForFutureEquity_1" xml:lang="en-US">Proceeds From Simple Agreement For Future Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ProceedsFromSimpleAgreementForFutureEquity_2" xml:lang="en-US">Proceeds from simple agreement for future equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ProfessionalServicesAndIntellectualPropertyMember_0" xml:lang="en-US">This member stands for professional services and intellectual property.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ProfessionalServicesAndIntellectualPropertyMember_1" xml:lang="en-US">Professional Services And Intellectual Property [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ProfessionalServicesAndIntellectualPropertyMember_2" xml:lang="en-US">Professional services and intellectual property [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_PublicWarrantsMember_0" xml:lang="en-US">This member stands for public warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_PublicWarrantsMember_1" xml:lang="en-US">Public Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_RbxCapitalLPMember_0" xml:lang="en-US">This member represent information about the RBx Capital, LP.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_RbxCapitalLPMember_1" xml:lang="en-US">Rbx Capital, L P [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_RbxCapitalLPMember_2" xml:lang="en-US">RBx Capital, LP ("RBx") [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ReceivableForProceedsOfWarrantExercises_0" xml:lang="en-US">Represents the amount of receivable for proceeds of warrant exercises.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ReceivableForProceedsOfWarrantExercises_1" xml:lang="en-US">Receivable For Proceeds Of Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ReceivableForProceedsOfWarrantExercises_2" xml:lang="en-US">Receivable for proceeds of warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ReceivablesForProceedsOfWarrantExercises_0" xml:lang="en-US">Receivables for proceeds of warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ReceivablesForProceedsOfWarrantExercises_1" xml:lang="en-US">Receivables For Proceeds Of Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ReceivablesForProceedsOfWarrantExercises_2" xml:lang="en-US">Receivable for proceeds of warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy for recently issued accounting pronouncements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_1" xml:lang="en-US">Recently Issued Accounting Pronouncements [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_2" xml:lang="en-US">Recently issued accounting pronouncements [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_RegulationAOfferingMember_0" xml:lang="en-US">This member stands for regulation A offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_RegulationAOfferingMember_1" xml:lang="en-US">Regulation A Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_RegulationAWarrantsMember_0" xml:lang="en-US">This member stands for regulation A warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_RegulationAWarrantsMember_1" xml:lang="en-US">Regulation A Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_RelatedPartyPayableCurrent_0" xml:lang="en-US">Represents the related party payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_RelatedPartyPayableCurrent_1" xml:lang="en-US">Related Party Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_RelatedPartyPayableCurrent_2" xml:lang="en-US">Related party payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_RelatedPartyTransactionAdditionalExpenses_0" xml:lang="en-US">Amount of transactions with related party during the financial reporting period for additional expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_RelatedPartyTransactionAdditionalExpenses_1" xml:lang="en-US">Related Party Transaction, Additional Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_RelatedPartyTransactionAdditionalExpenses_2" xml:lang="en-US">Additional expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_RepaymentOfDebenturesOnExtinguishment_0" xml:lang="en-US">Represents the amount of repayment of debentures on extinguishment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_mdcx_RepaymentOfDebenturesOnExtinguishment_1" xml:lang="en-US">Repayment of debentures on extinguishment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_RepaymentOfDebenturesOnExtinguishment_2" xml:lang="en-US">Repayment Of Debentures On Extinguishment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_RepaymentsOfInterest_0" xml:lang="en-US">It represents repayments of interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_mdcx_RepaymentsOfInterest_1" xml:lang="en-US">Interest payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_RepaymentsOfInterest_2" xml:lang="en-US">Repayments Of Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_RepaymentsOfInterest_3" xml:lang="en-US">Interest payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_RestrictedCashDisclosureTextBlock_0" xml:lang="en-US">The entire disclosure for cash and cash equivalents restricted as to withdrawal or usage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_RestrictedCashDisclosureTextBlock_1" xml:lang="en-US">Restricted Cash Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_RestrictedCashDisclosureTextBlock_2" xml:lang="en-US">Restricted Cash [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_RestrictedCashLineItems_0" xml:lang="en-US">Restricted Cash [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_RestrictedCashTable_0" xml:lang="en-US">Restricted Cash [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_RoyaltyLiability_0" xml:lang="en-US">Represent the royalty liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_RoyaltyLiability_1" xml:lang="en-US">Royalty Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_RoyaltyLiability_2" xml:lang="en-US">Royalty liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ScheduleOfPrepaidExpensesTableTextBlock_0" xml:lang="en-US">Tabular disclosure of prepaid expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ScheduleOfPrepaidExpensesTableTextBlock_1" xml:lang="en-US">Schedule Of Prepaid Expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ScheduleOfPrepaidExpensesTableTextBlock_2" xml:lang="en-US">Schedule of prepaid expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock_0" xml:lang="en-US">Tabular disclosure of information about the warrants continuity outstanding and exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock_1" xml:lang="en-US">Schedule Of Warrants Continuity Outstanding And Exercisable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock_2" xml:lang="en-US">Schedule of warrants continuity outstanding and exercisable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_SecuredPromissoryNotesMember_0" xml:lang="en-US">This member stands for secured promissory notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_SecuredPromissoryNotesMember_1" xml:lang="en-US">Secured Promissory Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_SecuredPromissoryNotesMember_2" xml:lang="en-US">Secured promissory notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_SecuritiesPurchaseAgreementMember_0" xml:lang="en-US">It represents as securities purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_SecuritiesPurchaseAgreementMember_1" xml:lang="en-US">Securities Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_SecuritiesPurchaseAgreementMember_2" xml:lang="en-US">Securities purchase agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_SeriesAAndBWarrantsGrantedMember_0" xml:lang="en-US">Series A and B warrants granted [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_SeriesAAndBWarrantsGrantedMember_1" xml:lang="en-US">Series A and B Warrants Granted [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_SeriesAAndBWarrantsGrantedMember_2" xml:lang="en-US">Series A and B Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_SeriesAAndSeriesA1PreferredSharesMember_0" xml:lang="en-US">Series A and Series A-1 preferred shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_SeriesAAndSeriesA1PreferredSharesMember_1" xml:lang="en-US">Series A and Series A-1 Preferred Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_SeriesAWarrantsMember_0" xml:lang="en-US">Series A warrants [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_SeriesAWarrantsMember_1" xml:lang="en-US">Series A Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_SeriesBWarrantsMember_0" xml:lang="en-US">Series B warrants [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_SeriesBWarrantsMember_1" xml:lang="en-US">Series B Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_SeriesCAndDWarrantsGrantedMember_0" xml:lang="en-US">Represent the member of series A and B warrants granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_SeriesCAndDWarrantsGrantedMember_1" xml:lang="en-US">Series C And D Warrants Granted [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_SeriesCAndDWarrantsGrantedMember_2" xml:lang="en-US">Series C and D Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_SeriesCAndDWarrantsMember_0" xml:lang="en-US">This member stands for series C and D warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_SeriesCAndDWarrantsMember_1" xml:lang="en-US">Series C And D Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_SeriesCAndDWarrantsMember_2" xml:lang="en-US">Series C and D Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_SettledConvertibleNotesAlongWithAccruedButUnpaidInterestInShares_0" xml:lang="en-US">Represent information about the settlement of convertible notes, along with accrued but unpaid interest in shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_SettledConvertibleNotesAlongWithAccruedButUnpaidInterestInShares_1" xml:lang="en-US">Settled Convertible Notes, Along With Accrued But Unpaid Interest In Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_SettledConvertibleNotesAlongWithAccruedButUnpaidInterestInShares_2" xml:lang="en-US">Settled the convertible notes, along with accrued but unpaid interest as common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_SettlementDateRemeasurementMember_0" xml:lang="en-US">This member stands for settlement date remeasurement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_SettlementDateRemeasurementMember_1" xml:lang="en-US">Settlement Date Remeasurement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_SettlementDateRemeasurementMember_2" xml:lang="en-US">Settlement date remeasurement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_0" xml:lang="en-US">The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issued In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAcceleratedVestingNumber_0" xml:lang="en-US">Number of share-based payment award options for which the vesting period was accelerated during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAcceleratedVestingNumber_1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Accelerated Vesting Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAcceleratedVestingNumber_2" xml:lang="en-US">Number of share options with accelerated vesting</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_0" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days, Granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_2" xml:lang="en-US">Stock options, Granted, Weighted average remaining contractual life (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award, Warrants, Grants In Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice_2" xml:lang="en-US">Exercise price of warrants granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ShareBasedCompensationAwardTrancheFiveMember_0" xml:lang="en-US">Fifth portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ShareBasedCompensationAwardTrancheFiveMember_1" xml:lang="en-US">Share Based Compensation Award Tranche Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ShareBasedCompensationAwardTrancheFiveMember_2" xml:lang="en-US">Vest upon the Company achieving annual adjusted EBITDA of $65 million</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ShareBasedCompensationAwardTrancheFourMember_0" xml:lang="en-US">Fourth portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ShareBasedCompensationAwardTrancheFourMember_1" xml:lang="en-US">Share Based Compensation Award Tranche Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ShareBasedCompensationAwardTrancheFourMember_2" xml:lang="en-US">Vest upon the Company achieving annual adjusted EBITDA of $43 million</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ShareBasedCompensationAwardTrancheSixMember_0" xml:lang="en-US">Sixth portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ShareBasedCompensationAwardTrancheSixMember_1" xml:lang="en-US">Share Based Compensation Award Tranche Six [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ShareBasedCompensationAwardTrancheSixMember_2" xml:lang="en-US">Vest upon the Company achieving annual adjusted EBITDA of $87 million</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ShareBasedPaymentAwardGrantDateAxis_0" xml:lang="en-US">The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ShareBasedPaymentAwardGrantDateAxis_1" xml:lang="en-US">Share Based Payment Award Grant Date [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ShareBasedPaymentAwardGrantDateDomain_0" xml:lang="en-US">It's represents the share based payment award grant date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ShareBasedPaymentAwardGrantDateDomain_1" xml:lang="en-US">Share Based Payment Award Grant Date [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ShareCapitalNoteDisclosureLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ShareCapitalNoteDisclosureLineItems_1" xml:lang="en-US">Share Capital Note Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ShareCapitalNoteDisclosureTable_0" xml:lang="en-US">Disclosure of information about share capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ShareCapitalNoteDisclosureTable_1" xml:lang="en-US">Share Capital Note Disclosure [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ShareConsolidationAxis_0" xml:lang="en-US">Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ShareConsolidationAxis_1" xml:lang="en-US">Share Consolidation [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ShareConsolidationDomain_0" xml:lang="en-US">Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ShareConsolidationDomain_1" xml:lang="en-US">Share Consolidation [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ShareConsolidationMember_0" xml:lang="en-US">Share Consolidation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ShareConsolidationMember_1" xml:lang="en-US">Share Consolidation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ShareIssuanceCosts_0" xml:lang="en-US">Represent the amount of share issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_mdcx_ShareIssuanceCosts_1" xml:lang="en-US">Share issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ShareIssuanceCosts_2" xml:lang="en-US">Share Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_SharePriceAsPercentageOfMarketPrice_0" xml:lang="en-US">Share price as percentage of market price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_SharePriceAsPercentageOfMarketPrice_1" xml:lang="en-US">Share Price As Percentage Of Market Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_SharePriceAsPercentageOfMarketPrice_2" xml:lang="en-US">Share price as percentage of market price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_SharesIssuedForAcquisitionOfAntev_0" xml:lang="en-US">Represents the amount of shares issued for acquisition of Antev.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_SharesIssuedForAcquisitionOfAntev_1" xml:lang="en-US">Shares Issued For Acquisition Of Antev</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_SharesIssuedForAcquisitionOfAntev_2" xml:lang="en-US">Shares issued for Antev asset acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_SharesIssuedMember_0" xml:lang="en-US">Represent the member of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_SharesIssuedMember_1" xml:lang="en-US">Shares Issued [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_SharesIssuedMember_2" xml:lang="en-US">Shares Issued [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_SharesIssuedMember_3" xml:lang="en-US">Shares to be issued [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_SharesToBeIssuedForAcquisitionOfAntev_0" xml:lang="en-US">Represents the amount of shares to be issued for acquisition of Antev.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_SharesToBeIssuedForAcquisitionOfAntev_1" xml:lang="en-US">Shares To Be Issued For Acquisition Of Antev</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_SharesToBeIssuedForAcquisitionOfAntev_2" xml:lang="en-US">Shares to be issued for Antev asset acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ShortTermIncentivePlanMember_0" xml:lang="en-US">Information of Short-Term Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ShortTermIncentivePlanMember_1" xml:lang="en-US">Short Term Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_SimpleAgreementForFutureEquityMember_0" xml:lang="en-US">Simple Agreement for Future Equity ("SAFE") [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_SimpleAgreementForFutureEquityMember_1" xml:lang="en-US">Simple Agreement For Future Equity [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_SimpleAgreementForFutureEquityMember_2" xml:lang="en-US">Simple Agreement For Future Equity ("SAFE") [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_SkinjectIncMember_0" xml:lang="en-US">Skinject, Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_SkinjectIncMember_1" xml:lang="en-US">SkinJect [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_SpecialStockOptionsAndPerformanceShareUnitsMember_0" xml:lang="en-US">Aggregate reported amount of Special Stock Options and PSUs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_SpecialStockOptionsAndPerformanceShareUnitsMember_1" xml:lang="en-US">Special Stock Options And Performance Share Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_SpecialStockOptionsMember_0" xml:lang="en-US">Special Stock Options granted as part of CEO David Colo's appointment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_SpecialStockOptionsMember_1" xml:lang="en-US">Special Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StandbyEquityPurchaseAgreementMember_0" xml:lang="en-US">This member stands for standby equity purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StandbyEquityPurchaseAgreementMember_1" xml:lang="en-US">Standby Equity Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_StandbyEquityPurchaseAgreementMember_2" xml:lang="en-US">Standby Equity Purchase Agreement (the "SEPA") [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForAmortizedIssuanceCosts_0" xml:lang="en-US">Represents the value of common stock of amortized issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForAmortizedIssuanceCosts_1" xml:lang="en-US">Stock Issued During Period Shares Common Stock Issued For Amortized Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForAmortizedIssuanceCosts_2" xml:lang="en-US">Common stock issued for ATM Program, net of amortized issuance costs (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForCompensation_0" xml:lang="en-US">Represents the shares common stock issued for compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForCompensation_1" xml:lang="en-US">Stock Issued During Period Shares Common Stock Issued For Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForCompensation_2" xml:lang="en-US">Common stock issued for compensation (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForPsus_0" xml:lang="en-US">Represents the number of common stock issued For Psus.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForPsus_1" xml:lang="en-US">Stock Issued During Period Shares Common Stock Issued For Psus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForPsus_2" xml:lang="en-US">Common stock issued for PSUs (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits_0" xml:lang="en-US">Represents the amount of stock issued during period shares common stock issued for restricted stock units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits_1" xml:lang="en-US">Stock Issued During Period Shares Common Stock Issued For Restricted Stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits_2" xml:lang="en-US">Common stock issued for performance stock units ("PSUs")</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits_3" xml:lang="en-US">Number of restricted share units issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRsus_0" xml:lang="en-US">Represents the shares common stock issued for Rsus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRsus_1" xml:lang="en-US">Stock Issued During Period Shares Common Stock Issued For Rsus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRsus_2" xml:lang="en-US">Common stock issued for RSUs (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts_0" xml:lang="en-US">Represents the shares of stock issued during period value connection with at the market offering, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts_1" xml:lang="en-US">Stock Issued During Period Shares Connection With At The Market Offering, Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts_2" xml:lang="en-US">Issuance of common shares in connection with ATM, net of issuance cost (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing_0" xml:lang="en-US">Represents the shares of stock issued during period value connection with equity financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing_1" xml:lang="en-US">Stock Issued During Period Shares Connection With Equity Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing_2" xml:lang="en-US">Issuance of common shares and warrants in connection with June equity financing, net of offering costs (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithFinancing_0" xml:lang="en-US">Represents the shares of stock issued during period value connection with financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithFinancing_1" xml:lang="en-US">Stock Issued During Period Shares Connection With Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithFinancing_2" xml:lang="en-US">Issuance of common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithFinancing_3" xml:lang="en-US">Issuance of common shares in connection with financing (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts_0" xml:lang="en-US">Represents the shares of stock issued during period value connection with a private placement, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts_1" xml:lang="en-US">Stock Issued During Period Shares Connection With Private Placement, Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts_2" xml:lang="en-US">Issuance of common shares in connection with a private placement, net of issuance costs (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts_0" xml:lang="en-US">Represents the shares of stock issued during period value connection with SEPA offering costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts_1" xml:lang="en-US">Stock Issued During Period Shares Connection With Sepa Offering Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts_2" xml:lang="en-US">Issuance of common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts_3" xml:lang="en-US">Issuance of common shares in connection with SEPA offering costs (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_0" xml:lang="en-US">Represents the shares of stock issued during period value conversion of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_1" xml:lang="en-US">Stock Issued During Period Shares Conversion Of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_2" xml:lang="en-US">Issuance of common shares upon conversion of debt (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_3" xml:lang="en-US">Issuance of common shares upon conversion of debt (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConversionOfNotePayable_0" xml:lang="en-US">Represents the share of stock issued during period shares conversion of note payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConversionOfNotePayable_1" xml:lang="en-US">Stock Issued During Period Shares Conversion Of Note Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConversionOfNotePayable_2" xml:lang="en-US">Issuance of common shares upon conversion of note payable (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares_0" xml:lang="en-US">Represents the shares of stock issued during period shares conversion of preferred shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares_1" xml:lang="en-US">Stock Issued During Period Shares Conversion Of Preferred Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares_2" xml:lang="en-US">Issuance of common shares upon conversion of preferred shares (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesExerciseOfWarrants_0" xml:lang="en-US">Represent the Common stock issued for exercise of warrants (Shares).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesExerciseOfWarrants_1" xml:lang="en-US">Stock Issued During Period Shares Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesExerciseOfWarrants_2" xml:lang="en-US">Common stock issued for exercise of warrants (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesForCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_0" xml:lang="en-US">Represents the amount of stock issued during period shares for common stock issued for Orion Equity Investment, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesForCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_1" xml:lang="en-US">Stock Issued During Period Shares For Common Stock Issued For Orion Equity Investment, Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesForCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_2" xml:lang="en-US">Common stock issued for Orion Equity Investment, net of issuance costs (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered_0" xml:lang="en-US">Represents the shares of stock issued during period value non-cash compensation for services rendered.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered_1" xml:lang="en-US">Stock Issued During Period Shares Noncash Compensation Services Rendered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered_2" xml:lang="en-US">Issuance of common shares in connection with noncash compensation for services rendered (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesOfCommonStock_0" xml:lang="en-US">Represents the shares of stock issued during period value of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesOfCommonStock_1" xml:lang="en-US">Stock Issued During Period Shares Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesOfCommonStock_2" xml:lang="en-US">Issuance of common shares (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants_0" xml:lang="en-US">Represents the shares of stock issued during period value upon exercise of stock warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants_1" xml:lang="en-US">Stock Issued During Period Shares Upon Exercise Of Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants_2" xml:lang="en-US">Issuance of common shares upon exercise of stock warrants (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForAmortizedIssuanceCosts_0" xml:lang="en-US">Represents the value of common stock issued for amortized issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForAmortizedIssuanceCosts_1" xml:lang="en-US">Stock Issued During Period Value Common Stock Issued For Amortized Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForAmortizedIssuanceCosts_2" xml:lang="en-US">Common stock issued for ATM Program, net of amortized issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForCompensation_0" xml:lang="en-US">Stock Issued During Period Value Common Stock Issued For Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForCompensation_1" xml:lang="en-US">Common stock issued for compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_0" xml:lang="en-US">Represents the amount of stock issued during period value common stock issued for Orion Equity Investment, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_1" xml:lang="en-US">Stock Issued During Period Value Common Stock Issued For Orion Equity Investment, Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_2" xml:lang="en-US">Common stock issued for Orion Equity Investment, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForPsus_0" xml:lang="en-US">Represents the value Common Stock Issued For Psus.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForPsus_1" xml:lang="en-US">Stock Issued During Period Value Common Stock Issued For Psus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForPsus_2" xml:lang="en-US">Common stock issued for PSUs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRestrictedStockUnits_0" xml:lang="en-US">Represents the amount of stock issued during period value stock issued for restricted stock units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRestrictedStockUnits_1" xml:lang="en-US">Stock Issued During Period Value Common Stock Issued For Restricted Stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRestrictedStockUnits_2" xml:lang="en-US">Common stock issued for performance stock units ("PSUs")</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRsus_0" xml:lang="en-US">Represents the value common stock issued for RSUs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRsus_1" xml:lang="en-US">Stock Issued During Period Value Common Stock Issued For Rsus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRsus_2" xml:lang="en-US">Common stock issued for RSUs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost_0" xml:lang="en-US">Represents the amount of stock issued during period value connection with at the market offering, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost_1" xml:lang="en-US">Stock Issued During Period Value Connection With At The Market Offering, Net Of Issuance Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost_2" xml:lang="en-US">Issuance of common shares in connection with ATM, net of issuance cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing_0" xml:lang="en-US">Represents the amount of stock issued during period value connection with equity financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing_1" xml:lang="en-US">Stock Issued During Period Value Connection With Equity Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing_2" xml:lang="en-US">Issuance of common shares and warrants in connection with June equity financing, net of offering costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithFinancing_0" xml:lang="en-US">Represents the amount of stock issued during period value connection with financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithFinancing_1" xml:lang="en-US">Stock Issued During Period Value Connection With Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithFinancing_2" xml:lang="en-US">Aggregate gross proceeds through issuance of common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithFinancing_3" xml:lang="en-US">Issuance of common shares in connection with financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts_0" xml:lang="en-US">Represents the value of stock issued during period value connection with a private placement, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts_1" xml:lang="en-US">Stock Issued During Period Value Connection With Private Placement, Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts_2" xml:lang="en-US">Issuance of common shares in connection with a private placement, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts_0" xml:lang="en-US">Represents the amount of stock issued during period value connection with SEPA offering costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts_1" xml:lang="en-US">Stock Issued During Period Value Connection With Sepa Offering Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts_2" xml:lang="en-US">Aggregate gross proceeds through issuance of common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts_3" xml:lang="en-US">Issuance of common shares in connection with SEPA offering costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_0" xml:lang="en-US">Represents the amount of stock issued during period value conversion of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_1" xml:lang="en-US">Stock Issued During Period Value Conversion Of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_2" xml:lang="en-US">Issuance of common shares upon conversion of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_3" xml:lang="en-US">Issuance of common shares upon conversion of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConversionOfNotePayable_0" xml:lang="en-US">Represents the amount of stock issued during period value conversion of note payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConversionOfNotePayable_1" xml:lang="en-US">Stock Issued During Period Value Conversion Of Note Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConversionOfNotePayable_2" xml:lang="en-US">Issuance of common shares upon conversion of note payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConversionOfPreferredShares_0" xml:lang="en-US">Represents the amount of stock issued during period value conversion of preferred shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConversionOfPreferredShares_1" xml:lang="en-US">Stock Issued During Period Value Conversion Of Preferred Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueConversionOfPreferredShares_2" xml:lang="en-US">Issuance of common shares upon conversion of preferred shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueExerciseOfWarrants_0" xml:lang="en-US">Represent Common stock issued for exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueExerciseOfWarrants_1" xml:lang="en-US">Stock Issued During Period Value Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueExerciseOfWarrants_2" xml:lang="en-US">Common stock issued for exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueForPaymentOfIncomeTaxesRemittedOnRsusAndPsus_0" xml:lang="en-US">Represents the amount of stock issued during period value for payment of income taxes remitted on RSUs and PSUs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueForPaymentOfIncomeTaxesRemittedOnRsusAndPsus_1" xml:lang="en-US">Stock Issued During Period Value For Payment Of Income Taxes Remitted On Rsus And Psus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueForPaymentOfIncomeTaxesRemittedOnRsusAndPsus_2" xml:lang="en-US">Payment of income taxes remitted on RSUs and PSUs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered_0" xml:lang="en-US">Represents the amount of stock issued during period value non-cash compensation for services rendered.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered_1" xml:lang="en-US">Stock Issued During Period Value Noncash Compensation For Services Rendered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered_2" xml:lang="en-US">Issuance of common shares in connection with noncash compensation for services rendered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueOfCommonShares_0" xml:lang="en-US">Represents the amount of stock issued during period value of common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueOfCommonShares_1" xml:lang="en-US">Stock Issued During Period Value Of Common Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueOfCommonShares_2" xml:lang="en-US">Issuance of common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants_0" xml:lang="en-US">Represents the amount of stock issued during period value upon exercise of stock warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants_1" xml:lang="en-US">Stock Issued During Period Value Upon Exercise Of Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants_2" xml:lang="en-US">Issuance of common shares upon exercise of stock warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockOptionsMember_0" xml:lang="en-US">Stock options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockOptionsMember_1" xml:lang="en-US">Stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_StockPurchaseWarrantsTerm_0" xml:lang="en-US">The contractual term of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_StockPurchaseWarrantsTerm_1" xml:lang="en-US">Stock Purchase Warrants Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_StockPurchaseWarrantsTerm_2" xml:lang="en-US">Warrant term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_TeverelixMember_0" xml:lang="en-US">This member stands for Teverelix.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_TeverelixMember_1" xml:lang="en-US">Teverelix [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ThresholdLimitOfFinancing_0" xml:lang="en-US">Represents the threshold limit of financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ThresholdLimitOfFinancing_1" xml:lang="en-US">Threshold Limit Of Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ThresholdLimitOfFinancing_2" xml:lang="en-US">Threshold limit of financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_TotalShareholderReturnPerformanceSharesMember_0" xml:lang="en-US">This member stands for total shareholder return performance shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_TotalShareholderReturnPerformanceSharesMember_1" xml:lang="en-US">Total Shareholder Return Performance Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_TotalShareholderReturnPerformanceSharesMember_2" xml:lang="en-US">Total Shareholder Return Performance Share Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_TwoZeroOneNineStockIncentivePlanMember_0" xml:lang="en-US">Represent the information of 2019 stock incentive plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_TwoZeroOneNineStockIncentivePlanMember_1" xml:lang="en-US">Two Zero One Nine Stock Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_TwoZeroOneNineStockIncentivePlanMember_2" xml:lang="en-US">2019 Short-Term Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_TwoZeroOneThreeStockIncentivePlanMember_0" xml:lang="en-US">Represent the information of 2013 stock incentive plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_TwoZeroOneThreeStockIncentivePlanMember_1" xml:lang="en-US">Two Zero One Three Stock Incentive Plan[Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_TwoZeroOneThreeStockIncentivePlanMember_2" xml:lang="en-US">2013 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_TwoZeroTwoZeroStockIncentivePlanMember_0" xml:lang="en-US">Represent the information of 2020 stock incentive plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_TwoZeroTwoZeroStockIncentivePlanMember_1" xml:lang="en-US">Two Zero Two Zero Stock Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_TwoZeroTwoZeroStockIncentivePlanMember_2" xml:lang="en-US">2020 Short-Term Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement_0" xml:lang="en-US">Represents the value of common shares issued in connection with a private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement_1" xml:lang="en-US">Value Of Common Shares Issued In Connection With Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement_2" xml:lang="en-US">Value of common shares issued in connection with a private placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_VelocityFundManagementLLCMember_0" xml:lang="en-US">This member represent information about the Velocity Fund Management, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_VelocityFundManagementLLCMember_1" xml:lang="en-US">Velocity Fund Management, L L C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_VelocityFundManagementLLCMember_2" xml:lang="en-US">Velocity Fund Management, LLC ("VFM") [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_VestUponCommonSharesAchievingCertainVolumeWeightedAverageTradingPricesMember_0" xml:lang="en-US">Vest Upon Common Shares Achieving Certain Volume Weighted Average Trading Prices [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_VestUponCommonSharesAchievingCertainVolumeWeightedAverageTradingPricesMember_1" xml:lang="en-US">Vest upon Common Shares achieving certain volume-weighted average trading prices [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_WarrantLiabilityIssuedDuringPeriod_0" xml:lang="en-US">Represents the value of warrant liability issued during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_WarrantLiabilityIssuedDuringPeriod_1" xml:lang="en-US">Warrant liability issued during period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_WarrantLiabilityIssuedDuringPeriod_2" xml:lang="en-US">Warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_WarrantLiabilityIssuedDuringPeriod_3" xml:lang="en-US">Issued during the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_WarrantsIssuedAsPartOfIpoMember_0" xml:lang="en-US">This member stands for warrants issued as part of the IPO.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_WarrantsIssuedAsPartOfIpoMember_1" xml:lang="en-US">Warrants Issued As Part Of Ipo [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_WarrantsIssuedAsPartOfIpoMember_2" xml:lang="en-US">Warrants issued as part of the IPO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_WarrantsIssuedUnderWarrantInducement_0" xml:lang="en-US">Warrants issued under warrant inducement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_WarrantsIssuedUnderWarrantInducement_1" xml:lang="en-US">Warrants issued under warrant inducement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_WarrantsIssuedUnderWarrantInducement_2" xml:lang="en-US">Warrants issued under warrant inducements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_WarrantWithExpiryDateJune302030WarrantsMember_0" xml:lang="en-US">This member stands for June 30, 2030 warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_WarrantWithExpiryDateJune302030WarrantsMember_1" xml:lang="en-US">Warrant With Expiry Date June 30, 2030 Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_WarrantWithExpiryDateJune302030WarrantsMember_2" xml:lang="en-US">June 30, 2030 Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_WarrantWithExpiryDateMarch102030Member_0" xml:lang="en-US">Warrant With Expiry Date March 10, 2030 [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_WarrantWithExpiryDateMarch102030Member_1" xml:lang="en-US">Warrant With Expiry Date March 10, 2030 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_WarrantWithExpiryDateMarch102030Member_2" xml:lang="en-US">Regulation A Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_WeightedAverageExercisePriceOfWarrant_0" xml:lang="en-US">Weighted average price of warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_mdcx_WeightedAverageExercisePriceOfWarrant_1" xml:lang="en-US">Weighted average exercise price of warrants, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_mdcx_WeightedAverageExercisePriceOfWarrant_2" xml:lang="en-US">Weighted average exercise price of warrants, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_WeightedAverageExercisePriceOfWarrant_3" xml:lang="en-US">Weighted Average Exercise Price Of Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_WeightedAverageExercisePriceWarrantExercise_0" xml:lang="en-US">Weighted average exercise price warrant granted exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_WeightedAverageExercisePriceWarrantExercise_1" xml:lang="en-US">Weighted Average Exercise Price Warrant Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_WeightedAverageExercisePriceWarrantExercise_2" xml:lang="en-US">Weighted average exercise price of warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_WeightedAverageExercisePriceWarrantGranted_0" xml:lang="en-US">Weighted average exercise price warrant granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_WeightedAverageExercisePriceWarrantGranted_1" xml:lang="en-US">Weighted Average Exercise Price Warrant Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_WeightedAverageExercisePriceWarrantGranted_2" xml:lang="en-US">Weighted average exercise price of warrants granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_WeightedAverageRemainingContractualTermOfWarrant_0" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_WeightedAverageRemainingContractualTermOfWarrant_1" xml:lang="en-US">Weighted Average Remaining Contractual Term Of Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_WeightedAverageRemainingContractualTermOfWarrant_2" xml:lang="en-US">Weighted average remaining contractual term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted_0" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted_1" xml:lang="en-US">Weighted Average Remaining Contractual Term Of Warrant Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted_2" xml:lang="en-US">Weighted average remaining contractual term granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_WithholdingOfEmployeeTaxPaymentsOnRestrictedStockUnits_0" xml:lang="en-US">Information about Withholding of employee tax payments on restricted stock units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_mdcx_WithholdingOfEmployeeTaxPaymentsOnRestrictedStockUnits_1" xml:lang="en-US">Withholding of employee tax payments on RSUs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_WithholdingOfEmployeeTaxPaymentsOnRestrictedStockUnits_2" xml:lang="en-US">Withholding Of Employee Tax Payments On Restricted Stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_YaIiPnLtdMember_0" xml:lang="en-US">Information about YA II PN, Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_YaIiPnLtdMember_1" xml:lang="en-US">Ya Ii Pn Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_mdcx_YaIiPnLtdMember_2" xml:lang="en-US">Yorkville [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_mdcx_YaIiPnLtdMember_3" xml:lang="en-US">YA II PN Ltd (Yorkville) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_mdcx_YorkvilleMember_0" xml:lang="en-US">This member stand for Yorkville.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_mdcx_YorkvilleMember_1" xml:lang="en-US">Yorkville [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ChiefExecutiveOfficerMember_0" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ChiefExecutiveOfficerMember_1" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_ChiefExecutiveOfficerMember_2" xml:lang="en-US">CEO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ChiefFinancialOfficerMember_0" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ChiefFinancialOfficerMember_1" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_ChiefFinancialOfficerMember_2" xml:lang="en-US">CFO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidationItemsAxis_0" xml:lang="en-US">Consolidation Items [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidationItemsDomain_0" xml:lang="en-US">Consolidation Items [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ManagementMember_0" xml:lang="en-US">Management [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ManagementMember_1" xml:lang="en-US">Key Management Personnel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_MaximumMember_1" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_MinimumMember_1" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember_0" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain_0" xml:lang="en-US">Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis_0" xml:lang="en-US">Geographical [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xml:lang="en-US">Title and Position [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_0" xml:lang="en-US">Accounts and Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_1" xml:lang="en-US">Other receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent_0" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent_1" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_0" xml:lang="en-US">Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_1" xml:lang="en-US">Total amount of accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_0" xml:lang="en-US">Accrued and other accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1" xml:lang="en-US">Accrued Liabilities and Other Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_0" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_1" xml:lang="en-US">Accrued legal fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1" xml:lang="en-US">Accumulated other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1" xml:lang="en-US">Accumulated Other Comprehensive Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital_0" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_1" xml:lang="en-US">Additional paid-in capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xml:lang="en-US">Stock-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2" xml:lang="en-US">Stock-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_1" xml:lang="en-US">Gross stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_2" xml:lang="en-US">Stock-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xml:lang="en-US">Potentially dilutive securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred_0" xml:lang="en-US">Asset Acquisition, Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred_1" xml:lang="en-US">Total fair value for allocation to net assets of Antev</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred_2" xml:lang="en-US">Net assets acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_0" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Contingent Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_1" xml:lang="en-US">Contingent consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_2" xml:lang="en-US">Business Combination, Contingent Consideration, Asset, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_0" xml:lang="en-US">Transaction expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_1" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Transaction Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_2" xml:lang="en-US">Transaction expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionTableTextBlock_0" xml:lang="en-US">Asset Acquisition [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetAcquisitionTableTextBlock_1" xml:lang="en-US">Schedule of assets acquired [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets_0" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Assets_1" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets_2" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract_0" xml:lang="en-US">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract_1" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent_0" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent_1" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0" xml:lang="en-US">Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract_1" xml:lang="en-US">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_0" xml:lang="en-US">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_1" xml:lang="en-US">Total assets measured at fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_0" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_1" xml:lang="en-US">Current assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis_0" xml:lang="en-US">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardTypeAxis_1" xml:lang="en-US">Award Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AwardTypeAxis_2" xml:lang="en-US">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_0" xml:lang="en-US">Business Combination [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_0" xml:lang="en-US">Business Combination [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0" xml:lang="en-US">Business Combination, Contingent Consideration [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription_0" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interest, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription_1" xml:lang="en-US">Business combination, equity interest description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_0" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_1" xml:lang="en-US">Value of shares exchanged</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_0" xml:lang="en-US">Business Combination [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_0" xml:lang="en-US">Business Combination, Voting Equity Interest Acquired, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1" xml:lang="en-US">Ownership acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2" xml:lang="en-US">Business combination, ownership percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_0" xml:lang="en-US">Business Combination, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_1" xml:lang="en-US">Contingent Consideration, price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_0" xml:lang="en-US">Business Combination, Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_1" xml:lang="en-US">Total fair value consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_1" xml:lang="en-US">Contingent Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_0" xml:lang="en-US">Business Combination [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_1" xml:lang="en-US">Antev Asset Acquisition [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1" xml:lang="en-US">Net liabilities assumed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_0" xml:lang="en-US">Business Combination, Achieved in Stages, Preacquisition Equity Interest in Acquiree, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_1" xml:lang="en-US">Fair value of non-controlling interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0" xml:lang="en-US">Project [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash_0" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Cash_1" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Cash_2" xml:lang="en-US">Payments to Acquire Productive Assets, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract_0" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Cash and cash equivalents, end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US">Cash and cash equivalents, beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" xml:lang="en-US">Cash and Cash Equivalent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5" xml:lang="en-US">Fair value of cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1" xml:lang="en-US">Fair value of cash and cash equivalents and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Cash and cash equivalents and restricted cash, end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">Cash and cash equivalents and restricted cash, beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1" xml:lang="en-US">Net increase in cash and cash equivalents during the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2" xml:lang="en-US">Net change in cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1" xml:lang="en-US">Net increase in cash and cash equivalents and restricted cash during the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2" xml:lang="en-US">Net change in cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2" xml:lang="en-US">Supplemental cash flow information</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain_0" xml:lang="en-US">Class of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" xml:lang="en-US">Warrants exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xml:lang="en-US">Exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_0" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0" xml:lang="en-US">Number of common share warrants outstanding, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_1" xml:lang="en-US">Number of common share warrants outstanding, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_2" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_3" xml:lang="en-US">Number outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_0" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies_1" xml:lang="en-US">Commitments and contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" xml:lang="en-US">Commitments and contingencies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockConversionBasis_0" xml:lang="en-US">Common Stock, Conversion Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockConversionBasis_1" xml:lang="en-US">Common stock, conversion basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember_0" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember_1" xml:lang="en-US">Common shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockNoParValue_0" xml:lang="en-US">Common Stock, No Par Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockNoParValue_1" xml:lang="en-US">Common stock, par or stated value per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US">Common stock, par or stated value per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_1" xml:lang="en-US">Common stock, Shares, Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued_0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued_1" xml:lang="en-US">Common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued_2" xml:lang="en-US">Issued common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0" xml:lang="en-US">Ending Balance (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1" xml:lang="en-US">Beginning Balance (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_3" xml:lang="en-US">Outstanding common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue_0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue_1" xml:lang="en-US">Common shares, no par value; unlimited shares authorized; 60,168,044 and 25,176,303 shares issued and outstanding as of June 30, 2026, and December 31, 2025, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_1" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_2" xml:lang="en-US">Common shareholders of the Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_1" xml:lang="en-US">Comprehensive loss attributable to</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1" xml:lang="en-US">Non-controlling interests</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1" xml:lang="en-US">Comprehensive loss for the period attributable to common shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis_0" xml:lang="en-US">Business Combination, Contingent Consideration, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain_0" xml:lang="en-US">Business Combination, Contingent Consideration, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_0" xml:lang="en-US">Stock Conversion Description [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockNameDomain_0" xml:lang="en-US">Conversion of Stock, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1_0" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1_1" xml:lang="en-US">Converted shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1_0" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1_1" xml:lang="en-US">Consolidated common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_0" xml:lang="en-US">Convertible Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_1" xml:lang="en-US">Schedule of debenture continuity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_0" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_1" xml:lang="en-US">Convertible Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_2" xml:lang="en-US">Convertible Promissory Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_0" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_1" xml:lang="en-US">Number of common shares issued on conversion of preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_0" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_1" xml:lang="en-US">Current tax (benefit) expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_0" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1" xml:lang="en-US">Domestic provincial income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_0" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_1" xml:lang="en-US">Convertible promissory notes converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_0" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1" xml:lang="en-US">Shares issued on conversion of notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionDescription_0" xml:lang="en-US">Debt Conversion, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtConversionDescription_1" xml:lang="en-US">Terms of conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1_0" xml:lang="en-US">Debt Conversion, Original Debt, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1_1" xml:lang="en-US">Principal amount of convertible promissory notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear_0" xml:lang="en-US">Debt Conversion, Original Debt, Due Date of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear_1" xml:lang="en-US">Maturity date of convertible promissory notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_0" xml:lang="en-US">Debt Conversion, Original Debt, Interest Rate of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_1" xml:lang="en-US">Interest rate of convertible promissory notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_us-gaap_DebtCurrent_0" xml:lang="en-US">Net balance as at December 31, 2025</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_DebtCurrent_1" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_DebtCurrent_2" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_DebtCurrent_3" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtCurrent_4" xml:lang="en-US">Debt, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DebtCurrent_5" xml:lang="en-US">Debt, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract_0" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis_0" xml:lang="en-US">Debt Instrument [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_0" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_1" xml:lang="en-US">Conversion price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_1" xml:lang="en-US">Face amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_2" xml:lang="en-US">Promissory note face value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_0" xml:lang="en-US">Debt Instrument, Interest Rate, Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_1" xml:lang="en-US">Potential increase in interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1" xml:lang="en-US">Interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentIssuedPrincipal_0" xml:lang="en-US">Debt Instrument, Issued, Principal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentIssuedPrincipal_1" xml:lang="en-US">Aggregate principal amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems_0" xml:lang="en-US">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate_0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate_1" xml:lang="en-US">Debentures maturity date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_0" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_0" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_1" xml:lang="en-US">Prepayment price percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable_0" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_0" xml:lang="en-US">Discount on debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_1" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_2" xml:lang="en-US">Notes issue discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_3" xml:lang="en-US">Discount on debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault_0" xml:lang="en-US">Debt Instrument, Debt Default, Description of Violation or Event of Default</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault_1" xml:lang="en-US">Description of violation or event of default of long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCostsCurrent_0" xml:lang="en-US">Deferred financing costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0" xml:lang="en-US">Deferred income tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_1" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_2" xml:lang="en-US">Deferred tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3" xml:lang="en-US">Deferred tax (benefit) expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_0" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_1" xml:lang="en-US">Total deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetInterestCarryforward_0" xml:lang="en-US">Deferred Tax Asset, Interest Carryforward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetInterestCarryforward_1" xml:lang="en-US">Financing charges and interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_0" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_1" xml:lang="en-US">Capital losses carried forward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_0" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1" xml:lang="en-US">Intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_1" xml:lang="en-US">Total deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_2" xml:lang="en-US">Total deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1" xml:lang="en-US">Research and development tax credits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_2" xml:lang="en-US">Research and development tax credits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_1" xml:lang="en-US">Deferred tax assets, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_2" xml:lang="en-US">Deferred tax assets, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_1" xml:lang="en-US">Non-capital losses carry forward - Canada</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_1" xml:lang="en-US">Net operating losses carryforward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_1" xml:lang="en-US">Operating loss carryforwards not subject to expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_1" xml:lang="en-US">Operating loss carryforwards subject to expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_0" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_1" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_1" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0" xml:lang="en-US">Less: valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/negativeLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1" xml:lang="en-US">Less: valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation_0" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Depreciation_1" xml:lang="en-US">Depreciation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" xml:lang="en-US">Stock-based compensation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember_0" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DomesticCountryMember_1" xml:lang="en-US">Domestic Federal [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract_0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic_0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_1" xml:lang="en-US">Net loss per share attributable to common shareholders - basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_2" xml:lang="en-US">Basic and diluted net loss per share attributable to shareholders - basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1" xml:lang="en-US">Net loss per share attributable to common shareholders - diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_2" xml:lang="en-US">Basic and diluted net loss per share attributable to shareholders - diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_1" xml:lang="en-US">Loss per share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1" xml:lang="en-US">Income tax (benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2" xml:lang="en-US">Income tax (benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xml:lang="en-US">Income tax recovery at the statutory rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2" xml:lang="en-US">Federal statutory income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1" xml:lang="en-US">Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1" xml:lang="en-US">Statutory income tax differential</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_1" xml:lang="en-US">Non-taxable and non-deductible items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_1" xml:lang="en-US">Non-deductible and other expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1" xml:lang="en-US">Domestic provincial income taxes attributable to Ontario rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">Foreign currency effect on cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" xml:lang="en-US">Accrued compensation and benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xml:lang="en-US">Period for recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1" xml:lang="en-US">Unrecognized stock-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember_0" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember_1" xml:lang="en-US">Stock options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember_2" xml:lang="en-US">Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain_0" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_0" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interest, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interest, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_0" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1" xml:lang="en-US">Schedule of assumptions used to estimate the fair value of warrants [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2" xml:lang="en-US">Schedule of assumptions used to estimate the fair value of warrants [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_0" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_0" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_1" xml:lang="en-US">Fair value measurements [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_1" xml:lang="en-US">Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_1" xml:lang="en-US">Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_1" xml:lang="en-US">Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_0" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_0" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis_0" xml:lang="en-US">Financial Instrument [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCountryMember_0" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCountryMember_1" xml:lang="en-US">Foreign Tax [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForeignCountryMember_2" xml:lang="en-US">US [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" xml:lang="en-US">Foreign operations remeasurement and translation [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_1" xml:lang="en-US">Total general and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_2" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0" xml:lang="en-US">Loss attributed to Canadian operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2" xml:lang="en-US">Canada</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_0" xml:lang="en-US">Loss attributed to US foreign operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2" xml:lang="en-US">Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract_0" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_0" xml:lang="en-US">Statement of Income Location, Balance [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_0" xml:lang="en-US">Statement of Income Location, Balance [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_0" xml:lang="en-US">Income Tax Jurisdiction [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_0" xml:lang="en-US">Income Tax Jurisdiction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_0" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_1" xml:lang="en-US">Income taxes [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1" xml:lang="en-US">Income tax expense (benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2" xml:lang="en-US">Income tax expense (benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1" xml:lang="en-US">Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1" xml:lang="en-US">Impact of tax rate changes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1" xml:lang="en-US">Statutory income tax differential</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1" xml:lang="en-US">Income tax recovery at the statutory rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2" xml:lang="en-US">Income tax recovery at the statutory rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_1" xml:lang="en-US">Non-taxable and non-deductible items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_1" xml:lang="en-US">Non-deductible and other expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_1" xml:lang="en-US">Related party payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_2" xml:lang="en-US">Increase (Decrease) in Due to Related Parties, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_2" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1" xml:lang="en-US">Operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_0" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_1" xml:lang="en-US">Accounts payable and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0" xml:lang="en-US">Other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/negativeLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1" xml:lang="en-US">Other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3" xml:lang="en-US">Other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xml:lang="en-US">Prepaid expenses and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_0" xml:lang="en-US">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_1" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense_0" xml:lang="en-US">Interest (expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_InterestExpense_1" xml:lang="en-US">Interest income (expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense_2" xml:lang="en-US">Interest Expense, Operating and Nonoperating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpense_3" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestExpense_4" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseDebt_0" xml:lang="en-US">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestExpenseDebt_1" xml:lang="en-US">Interest accretion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet_0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPaidNet_1" xml:lang="en-US">Cash paid for interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestPaidNet_2" xml:lang="en-US">Value of accrued interest paid in cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPayableCurrent_0" xml:lang="en-US">Interest Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPayableCurrent_1" xml:lang="en-US">Accrued interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestPayableCurrent_2" xml:lang="en-US">Interest accretion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentCompanyNonconsolidatedSubsidiaryAxis_0" xml:lang="en-US">Investment Company, Nonconsolidated Subsidiary [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentCompanyNonconsolidatedSubsidiaryDomain_0" xml:lang="en-US">Investment Company, Nonconsolidated Subsidiary [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InvestmentIncomeNet_0" xml:lang="en-US">Finance (income) expense, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeNet_1" xml:lang="en-US">Investment Income, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentIncomeNet_2" xml:lang="en-US">Finance income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember_0" xml:lang="en-US">IPO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IPOMember_1" xml:lang="en-US">Initial Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LaborAndRelatedExpense_0" xml:lang="en-US">Labor and Related Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LaborAndRelatedExpense_1" xml:lang="en-US">Salaries and benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_1" xml:lang="en-US">Schedule of lease cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract_0" xml:lang="en-US">Leases [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LegalFees_0" xml:lang="en-US">Legal Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LegalFees_1" xml:lang="en-US">Legal fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate_0" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate_1" xml:lang="en-US">Discount rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1" xml:lang="en-US">Schedule of future minimum lease payments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xml:lang="en-US">Total future minimum lease payments, undiscounted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1" xml:lang="en-US">2026</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1" xml:lang="en-US">2027</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0" xml:lang="en-US">Present value discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2" xml:lang="en-US">Present value discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_0" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_1" xml:lang="en-US">Remaining lease term (in years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_1" xml:lang="en-US">Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities_0" xml:lang="en-US">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities_1" xml:lang="en-US">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0" xml:lang="en-US">Total liabilities and shareholders&apos; deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US">Total liabilities and shareholders' (deficit) equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&apos; (DEFICIT) EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" xml:lang="en-US">Liabilities and Shareholder's equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent_0" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0" xml:lang="en-US">Current liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_1" xml:lang="en-US">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_0" xml:lang="en-US">Liabilities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_1" xml:lang="en-US">Total liabilities measured at fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_0" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_1" xml:lang="en-US">Liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtTextBlock_0" xml:lang="en-US">Long-Term Debt [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtTextBlock_1" xml:lang="en-US">Debentures and Secured Promissory Notes [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_0" xml:lang="en-US">Long-Term Debt, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_0" xml:lang="en-US">Long-Term Debt, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermLoansPayable_0" xml:lang="en-US">Loans Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermLoansPayable_1" xml:lang="en-US">Loan payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermLoansPayable_2" xml:lang="en-US">Loan payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExercisePriceMember_0" xml:lang="en-US">Measurement Input, Exercise Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputExercisePriceMember_1" xml:lang="en-US">Exercise price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember_0" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember_1" xml:lang="en-US">Dividend yield [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_0" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_1" xml:lang="en-US">Expected warrant life[Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_2" xml:lang="en-US">Expected warrant life [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_0" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_1" xml:lang="en-US">Expected volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_0" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_1" xml:lang="en-US">Risk-free interest rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_0" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_0" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterest_0" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterest_1" xml:lang="en-US">Non-controlling interests</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue_0" xml:lang="en-US">Cash Equivalent, Money Market Fund, Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue_1" xml:lang="en-US">Money market funds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">Cash flows from financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xml:lang="en-US">Cash flows from financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US">Net cash used in investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2" xml:lang="en-US">Net cash used in investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US">Cash flows from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xml:lang="en-US">Cash flows from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_NetIncomeLoss_0" xml:lang="en-US">Net loss attributable to shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss_1" xml:lang="en-US">Net Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_2" xml:lang="en-US">Net Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_3" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_4" xml:lang="en-US">Common shareholders of the Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAbstract_0" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAbstract_1" xml:lang="en-US">Net loss attributable to</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1" xml:lang="en-US">Non-controlling interests</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xml:lang="en-US">Recently issued accounting pronouncements [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncontrollingInterestMember_0" xml:lang="en-US">Noncontrolling Interest [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncontrollingInterestMember_1" xml:lang="en-US">Non-Controlling Interest [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayable_0" xml:lang="en-US">Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotesPayable_1" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NotesPayable_2" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfOperatingSegments_0" xml:lang="en-US">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfOperatingSegments_1" xml:lang="en-US">Number of operating segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfReportableSegments_0" xml:lang="en-US">Number of Reportable Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfReportableSegments_1" xml:lang="en-US">Number of reportable segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses_0" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses_1" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpenses_2" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0" xml:lang="en-US">Operating expenses:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract_1" xml:lang="en-US">Operating expenses:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_0" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_1" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss_2" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_3" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseExpense_0" xml:lang="en-US">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseExpense_1" xml:lang="en-US">Operating lease cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability_0" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_1" xml:lang="en-US">Total lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_2" xml:lang="en-US">Total lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_1" xml:lang="en-US">Operating lease liabilities - current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_2" xml:lang="en-US">Operating lease liability, current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1" xml:lang="en-US">Operating lease liabilities - non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2" xml:lang="en-US">Operating lease liability, non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingLeasePayments_0" xml:lang="en-US">Operating cash flows used in operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments_1" xml:lang="en-US">Operating cash flows used in operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments_2" xml:lang="en-US">Other information</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_1" xml:lang="en-US">Operating lease right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_2" xml:lang="en-US">Operating lease right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_0" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_0" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" xml:lang="en-US">Description of business [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1" xml:lang="en-US">Accrued other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_0" xml:lang="en-US">Foreign exchange gain/loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_1" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_2" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_3" xml:lang="en-US">Foreign currency translation adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_0" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_1" xml:lang="en-US">Other comprehensive loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeMember_0" xml:lang="en-US">Other Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherIncomeMember_1" xml:lang="en-US">Other income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherLiabilities_0" xml:lang="en-US">Other liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilities_1" xml:lang="en-US">Other Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilities_2" xml:lang="en-US">Other liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherLiabilities_3" xml:lang="en-US">Other Liabilities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_0" xml:lang="en-US">Total other income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_1" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_2" xml:lang="en-US">Total other income (expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_3" xml:lang="en-US">Total other income (expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_1" xml:lang="en-US">Other income (expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_2" xml:lang="en-US">Other income (expense):</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaidInKindInterest_0" xml:lang="en-US">Paid-in-Kind Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaidInKindInterest_1" xml:lang="en-US">Non-cash interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_0" xml:lang="en-US">Cost to issue debentures and secured promissory notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_1" xml:lang="en-US">Debt issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_2" xml:lang="en-US">Payments of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_3" xml:lang="en-US">Cost to issue debentures and secured promissory notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_4" xml:lang="en-US">Debt issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_0" xml:lang="en-US">Cash paid for financing costs in connection with SEPA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_1" xml:lang="en-US">Payments of Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_0" xml:lang="en-US">Issuance costs for common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_1" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_2" xml:lang="en-US">Issuance costs for common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_3" xml:lang="en-US">Payments of Financing Costs, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_4" xml:lang="en-US">Share issuance cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain_0" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionRatio_0" xml:lang="en-US">Preferred Stock, Convertible, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionRatio_1" xml:lang="en-US">Number of common shares issued upon conversion for each share of preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage_0" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage_1" xml:lang="en-US">Preferred stock, dividend rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued_0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued_1" xml:lang="en-US">Number of preferred shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_1" xml:lang="en-US">Number of preferred shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_0" xml:lang="en-US">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_1" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_2" xml:lang="en-US">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidInsurance_0" xml:lang="en-US">Prepaid Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidInsurance_1" xml:lang="en-US">Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember_0" xml:lang="en-US">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrivatePlacementMember_1" xml:lang="en-US">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1" xml:lang="en-US">Proceeds from initial public offering, net of offering expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2" xml:lang="en-US">Total proceeds from IPO</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Proceeds from issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2" xml:lang="en-US">Proceeds from common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3" xml:lang="en-US">Net proceeds from issuance of common shares and warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt_0" xml:lang="en-US">Proceeds from issuance of debentures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt_1" xml:lang="en-US">Proceeds of debentures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt_2" xml:lang="en-US">Proceeds from Issuance of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt_3" xml:lang="en-US">Proceeds from issuance of debentures and secured promissory notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt_4" xml:lang="en-US">Proceeds from issuance of debentures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1" xml:lang="en-US">Proceeds from Issuance of long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/measurementGuidance" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0" xml:lang="en-US">Proceeds from offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1" xml:lang="en-US">Proceeds from issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_3" xml:lang="en-US">Proceeds from common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_4" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5" xml:lang="en-US">Proceeds from issuance of common shares, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_0" xml:lang="en-US">Proceeds from Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_1" xml:lang="en-US">Aggregate principal of the notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_2" xml:lang="en-US">Proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_1" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_2" xml:lang="en-US">Proceeds from warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ProfitLoss_0" xml:lang="en-US">Net loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss_1" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss_2" xml:lang="en-US">Net loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProfitLoss_3" xml:lang="en-US">Net loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfitLoss_4" xml:lang="en-US">Net loss and comprehensive loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProjectMember_0" xml:lang="en-US">Project [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain_0" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_0" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1" xml:lang="en-US">Amounts of transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_0" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_0" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_0" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" xml:lang="en-US">Related party transactions [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfDebt_0" xml:lang="en-US">Repayment of debenture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_RepaymentsOfDebt_1" xml:lang="en-US">Repayment of debentures and secured promissory notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfDebt_2" xml:lang="en-US">Repayments of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RepaymentsOfDebt_3" xml:lang="en-US">Outstanding principal repaid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract_0" xml:lang="en-US">Research and Development [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_0" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_1" xml:lang="en-US">Research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_0" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_1" xml:lang="en-US">Schedule of research and development expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_1" xml:lang="en-US">Total research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_2" xml:lang="en-US">Total research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_3" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_0" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1" xml:lang="en-US">Research and Development (R&amp;D) expenses [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedAssetsDisclosureTextBlock_0" xml:lang="en-US">Restricted Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedAssetsDisclosureTextBlock_1" xml:lang="en-US">Restricted Cash [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Restricted Cash and Cash Equivalent, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" xml:lang="en-US">Restricted Cash and Cash Equivalent, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_3" xml:lang="en-US">Restricted deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashCurrent_0" xml:lang="en-US">Restricted Cash, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashCurrent_1" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_0" xml:lang="en-US">Restricted Cash, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_1" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember_0" xml:lang="en-US">Retained Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember_1" xml:lang="en-US">Accumulated deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalariesWagesAndOfficersCompensation_0" xml:lang="en-US">Salary and Wage, Excluding Cost of Good and Service Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SalariesWagesAndOfficersCompensation_1" xml:lang="en-US">Reimbursable salaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0" xml:lang="en-US">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1" xml:lang="en-US">Issued common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2" xml:lang="en-US">Number of units issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_1" xml:lang="en-US">Sale of stock, price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_2" xml:lang="en-US">Price per share in IPO</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1" xml:lang="en-US">Schedule of accrued expenses and other current liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" xml:lang="en-US">Schedule of dilutive securities excluded from computation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_0" xml:lang="en-US">Business Combination, Contingent Consideration [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock_0" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interest [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock_1" xml:lang="en-US">Schedule of contingent consideration [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0" xml:lang="en-US">Business Combination [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_0" xml:lang="en-US">Business Combination [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_1" xml:lang="en-US">Schedule of consideration paid [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1" xml:lang="en-US">Schedule of income tax (benefit) expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_0" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1" xml:lang="en-US">Schedule of promissory notes [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xml:lang="en-US">Schedule of deferred tax assets and liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" xml:lang="en-US">Schedule of basic and diluted net loss per share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1" xml:lang="en-US">Schedule of effective income tax rate reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xml:lang="en-US">Schedule of Allocation of Share-Based Compensation Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1" xml:lang="en-US">Schedule of financial assets and liabilities that measured at fair value on a recurring basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_0" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1" xml:lang="en-US">Schedule of future minimum lease payments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1" xml:lang="en-US">Schedule of income before income tax, domestic and foreign [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_0" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_1" xml:lang="en-US">Schedule of Non-Vested Equity Awards [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0" xml:lang="en-US">Related Party Transaction [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_0" xml:lang="en-US">Research and Development, Contract to Perform for Others [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0" xml:lang="en-US">Segment Reporting [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_1" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Performance-Based Units, Vested and Expected to Vest [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_1" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award, Performance-Based Units, Vested and Expected to Vest [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_0" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1" xml:lang="en-US">Schedule of Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xml:lang="en-US">Schedule of stock option activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_0" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xml:lang="en-US">Schedule of assumptions used to estimate the fair value of options [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1" xml:lang="en-US">Schedule of warrants outstanding [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SecuredDebtCurrent_0" xml:lang="en-US">Secured Debt, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SecuredDebtCurrent_1" xml:lang="en-US">Debentures and secured promissory notes, current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SecuredLongTermDebt_0" xml:lang="en-US">Secured Long-Term Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SecuredLongTermDebt_1" xml:lang="en-US">Debentures and secured promissory notes, non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_SecuredLongTermDebt_2" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingAbstract_0" xml:lang="en-US">Segment Reporting [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_1" xml:lang="en-US">Segment reporting [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems_0" xml:lang="en-US">Segment Reporting [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_1" xml:lang="en-US">Operating segments [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1" xml:lang="en-US">Selling, general and administrative expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_0" xml:lang="en-US">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation_1" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_2" xml:lang="en-US">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_3" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_4" xml:lang="en-US">Stock-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_0" xml:lang="en-US">Share-Based Payment Arrangement, Accelerated Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_1" xml:lang="en-US">Remaining expense for accelerated share options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_1" xml:lang="en-US">Number of accelerated vesting</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xml:lang="en-US">Award vesting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1" xml:lang="en-US">Expiration period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1" xml:lang="en-US">Exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xml:lang="en-US">Expected dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2" xml:lang="en-US">Dividend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xml:lang="en-US">Expected term (in years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2" xml:lang="en-US">Estimated life (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xml:lang="en-US">Expected volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2" xml:lang="en-US">Expected volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2" xml:lang="en-US">Risk-free interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1" xml:lang="en-US">Number of shares available for grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" xml:lang="en-US">Stock options, Exercisable, Aggregate intrinsic value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" xml:lang="en-US">Number of options, Exercisable, end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" xml:lang="en-US">Weighted- average exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2" xml:lang="en-US">Stock options Exercisable, Weighted-average exercise price end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1" xml:lang="en-US">Stock options, Exercisable, Weighted average remaining contractual life (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_1" xml:lang="en-US">Weighted average grant-date fair value of options forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0" xml:lang="en-US">Number of options, Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_1" xml:lang="en-US">Stock options, Granted, Aggregate intrinsic value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US">Number of options, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xml:lang="en-US">Number of stock options issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Weighted average grant-date fair value of options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1" xml:lang="en-US">Number of options, Unvested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Options exercisable price per shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" xml:lang="en-US">Stock options Unvested, Weighted average exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1" xml:lang="en-US">Stock options, Outstanding, Aggregate intrinsic value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xml:lang="en-US">Number of options outstanding, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xml:lang="en-US">Number of options outstanding, Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Weighted average exercise price, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Weighted average exercise price, Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1" xml:lang="en-US">Contractual term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2" xml:lang="en-US">Stock options, Outstanding, Weighted average remaining contractual life (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1" xml:lang="en-US">Stock options, Unvested, Aggregate intrinsic value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1" xml:lang="en-US">Options vesting per tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1" xml:lang="en-US">Unvested, Weighted average remaining contractual life (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xml:lang="en-US">All Award Types</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xml:lang="en-US">Award Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xml:lang="en-US">Award type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Weighted average exercise price, exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2" xml:lang="en-US">Exercise price of options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Weighted average exercise price, Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Weighted average exercise price, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4" xml:lang="en-US">Exercise price of warrants granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5" xml:lang="en-US">Stock options Unvested, Weighted average exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1" xml:lang="en-US">Tranche one [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2" xml:lang="en-US">Vest upon achieving a trading price of $5.00 per share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_0" xml:lang="en-US">Share-based Compensation Award, Tranche Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1" xml:lang="en-US">Adjusted EBITDA of $140 million</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_2" xml:lang="en-US">Vest upon achieving a trading price of $14.00 per share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1" xml:lang="en-US">Tranche two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2" xml:lang="en-US">Adjusted EBITDA of $110 million</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_0" xml:lang="en-US">Share-based Payment Arrangement, Performance Shares, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_1" xml:lang="en-US">Schedule of Non-Vested PSU Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice_0" xml:lang="en-US">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice_1" xml:lang="en-US">Share price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_0" xml:lang="en-US">Share price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_1" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_2" xml:lang="en-US">Shares issued price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_3" xml:lang="en-US">Common shares, price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis_0" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain_0" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1" xml:lang="en-US">Summary of significant accounting policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis_0" xml:lang="en-US">Class of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems_0" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_0" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable_0" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity_0" xml:lang="en-US">Equity, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity_1" xml:lang="en-US">Total shareholders' (deficit) equity attributable to Medicus Pharma Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0" xml:lang="en-US">Shareholders&apos; deficit:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract_1" xml:lang="en-US">Shareholders' (deficit) equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" xml:lang="en-US">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1" xml:lang="en-US">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3" xml:lang="en-US">Total shareholders' (deficit) equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_0" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0" xml:lang="en-US">Equity [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xml:lang="en-US">Share capital [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit_0" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit_1" xml:lang="en-US">Reverse share split ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit_2" xml:lang="en-US">Description of the reverse stock split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1" xml:lang="en-US">Number of common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2" xml:lang="en-US">Issuance of common shares for asset acquisition (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1" xml:lang="en-US">Settled the convertible notes, along with accrued but unpaid interest as common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2" xml:lang="en-US">Issuance of common shares upon conversion of promissory notes (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0" xml:lang="en-US">Issuance of common shares and warrants in connection with Regulation A, net of issuance costs (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2" xml:lang="en-US">Common shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3" xml:lang="en-US">Proceeds from Issuance of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0" xml:lang="en-US">Number of options, exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xml:lang="en-US">Number of options, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3" xml:lang="en-US">Issuance of common shares upon exercise of stock options (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4" xml:lang="en-US">Number of options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_0" xml:lang="en-US">Issuance of common shares upon acquisition of Interactive Capital Partners Ltd</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2" xml:lang="en-US">Fair value of common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_3" xml:lang="en-US">Issuance of common shares for asset acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1" xml:lang="en-US">Principal amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2" xml:lang="en-US">Issuance of common shares upon conversion of promissory notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0" xml:lang="en-US">Total proceeds from all SEPA issuances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_2" xml:lang="en-US">Value of common shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3" xml:lang="en-US">Issuance of common shares and warrants in connection with Regulation A, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" xml:lang="en-US">Issuance of common shares upon exercise of stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems_0" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember_0" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventMember_1" xml:lang="en-US">Subsequent event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US">Subsequent events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable_0" xml:lang="en-US">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_0" xml:lang="en-US">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_0" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1" xml:lang="en-US">Balance sheet components [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_1" xml:lang="en-US">Supplemental information</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalIncomeStatementElementsAbstract_0" xml:lang="en-US">Supplemental Income Statement Elements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xml:lang="en-US">Financial Instruments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates_0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates_1" xml:lang="en-US">Use of estimates [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis_0" xml:lang="en-US">Vesting [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain_0" xml:lang="en-US">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember_0" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantMember_1" xml:lang="en-US">Public Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantMember_2" xml:lang="en-US">Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_0" xml:lang="en-US">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_0" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1" xml:lang="en-US">Measurement input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US">Weighted average number of common shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2" xml:lang="en-US">Weighted average number of common shares outstanding during the year - diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US">Weighted average number of common shares outstanding - basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2" xml:lang="en-US">Weighted average number of common shares outstanding during the year - basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember_0" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember_1" xml:lang="en-US">SARs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB_1" xlink:to="lab_country_GB_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB_2" xlink:to="lab_country_GB_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_3" xlink:to="lab_country_US_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_4" xlink:to="lab_country_US_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription_5" xlink:to="lab_dei_AmendmentDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_6" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId_7" xlink:to="lab_dei_AuditorFirmId_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation_8" xlink:to="lab_dei_AuditorLocation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName_9" xlink:to="lab_dei_AuditorName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorOpinionTextBlock_10" xlink:to="lab_dei_AuditorOpinionTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorOpinionTextBlock_11" xlink:to="lab_dei_AuditorOpinionTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_12" xlink:to="lab_dei_CityAreaCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_13" xlink:to="lab_dei_CoverAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_14" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport_15" xlink:to="lab_dei_DocumentAnnualReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentDescription_16" xlink:to="lab_dei_DocumentDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag_17" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_18" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_19" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_20" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodStartDate_21" xlink:to="lab_dei_DocumentPeriodStartDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_22" xlink:to="lab_dei_DocumentQuarterlyReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock_23" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock_24" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_25" xlink:to="lab_dei_DocumentTransitionReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_26" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_27" xlink:to="lab_dei_EntityAddressAddressLine1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_28" xlink:to="lab_dei_EntityAddressAddressLine2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_29" xlink:to="lab_dei_EntityAddressCityOrTown_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_30" xlink:to="lab_dei_EntityAddressPostalZipCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_31" xlink:to="lab_dei_EntityAddressStateOrProvince_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_32" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_33" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_34" xlink:to="lab_dei_EntityCurrentReportingStatus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_35" xlink:to="lab_dei_EntityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_36" xlink:to="lab_dei_EntityEmergingGrowthCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_37" xlink:to="lab_dei_EntityExTransitionPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_38" xlink:to="lab_dei_EntityFileNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_39" xlink:to="lab_dei_EntityFilerCategory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_40" xlink:to="lab_dei_EntityIncorporationStateCountryCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_41" xlink:to="lab_dei_EntityInteractiveDataCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingParValuePerShare_42" xlink:to="lab_dei_EntityListingParValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_43" xlink:to="lab_dei_EntityPublicFloat_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_44" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_45" xlink:to="lab_dei_EntityShellCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_46" xlink:to="lab_dei_EntitySmallBusiness_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_47" xlink:to="lab_dei_EntityTaxIdentificationNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_48" xlink:to="lab_dei_EntityVoluntaryFilers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_49" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_50" xlink:to="lab_dei_LegalEntityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_51" xlink:to="lab_dei_LocalPhoneNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_NoTradingSymbolFlag_52" xlink:to="lab_dei_NoTradingSymbolFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PhoneFaxNumberDescription_53" xlink:to="lab_dei_PhoneFaxNumberDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12gTitle_54" xlink:to="lab_dei_Security12gTitle_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_55" xlink:to="lab_dei_SecurityExchangeName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_56" xlink:to="lab_dei_TradingSymbol_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AccrualOfAtmIssuanceCosts_57" xlink:to="lab_mdcx_AccrualOfAtmIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AccrualOfAtmIssuanceCosts_58" xlink:to="lab_mdcx_AccrualOfAtmIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AccruedInterestConvertedIntoCommonShares_59" xlink:to="lab_mdcx_AccruedInterestConvertedIntoCommonShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AccruedInterestConvertedIntoCommonShares_60" xlink:to="lab_mdcx_AccruedInterestConvertedIntoCommonShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AccruedInterestConvertedIntoCommonShares_61" xlink:to="lab_mdcx_AccruedInterestConvertedIntoCommonShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AccruedInterestRepaid_62" xlink:to="lab_mdcx_AccruedInterestRepaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AccruedInterestRepaid_63" xlink:to="lab_mdcx_AccruedInterestRepaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AccruedInterestRepaid_64" xlink:to="lab_mdcx_AccruedInterestRepaid_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AccrueDividendsPreferredSharesRate_65" xlink:to="lab_mdcx_AccrueDividendsPreferredSharesRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AccrueDividendsPreferredSharesRate_66" xlink:to="lab_mdcx_AccrueDividendsPreferredSharesRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AccrueDividendsPreferredSharesRate_67" xlink:to="lab_mdcx_AccrueDividendsPreferredSharesRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AdditionalRestrictedStockUnitIssued_68" xlink:to="lab_mdcx_AdditionalRestrictedStockUnitIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AdditionalRestrictedStockUnitIssued_69" xlink:to="lab_mdcx_AdditionalRestrictedStockUnitIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AdditionalRestrictedStockUnitIssued_70" xlink:to="lab_mdcx_AdditionalRestrictedStockUnitIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_71" xlink:to="lab_mdcx_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_72" xlink:to="lab_mdcx_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_73" xlink:to="lab_mdcx_AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares_74" xlink:to="lab_mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares_75" xlink:to="lab_mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares_76" xlink:to="lab_mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AgentsMember_77" xlink:to="lab_mdcx_AgentsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AgentsMember_78" xlink:to="lab_mdcx_AgentsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement_79" xlink:to="lab_mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement_80" xlink:to="lab_mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement_81" xlink:to="lab_mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AntevAssetAgreementAbstract_82" xlink:to="lab_mdcx_AntevAssetAgreementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AntevLimitedMember_83" xlink:to="lab_mdcx_AntevLimitedMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AntevLimitedMember_84" xlink:to="lab_mdcx_AntevLimitedMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AtmAgreementMember_85" xlink:to="lab_mdcx_AtmAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AtmAgreementMember_86" xlink:to="lab_mdcx_AtmAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_AtmAgreementMember_87" xlink:to="lab_mdcx_AtmAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_BalanceSheetComponentsAbstract_88" xlink:to="lab_mdcx_BalanceSheetComponentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock_89" xlink:to="lab_mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock_90" xlink:to="lab_mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock_91" xlink:to="lab_mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis_92" xlink:to="lab_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis_93" xlink:to="lab_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain_94" xlink:to="lab_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain_95" xlink:to="lab_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_BusinessCombinationDiscountPercentageAppliedToClosingPrice_96" xlink:to="lab_mdcx_BusinessCombinationDiscountPercentageAppliedToClosingPrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_BusinessCombinationDiscountPercentageAppliedToClosingPrice_97" xlink:to="lab_mdcx_BusinessCombinationDiscountPercentageAppliedToClosingPrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_BusinessCombinationDiscountPercentageAppliedToClosingPrice_98" xlink:to="lab_mdcx_BusinessCombinationDiscountPercentageAppliedToClosingPrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_BusinessCombinationDiscountPricePerShare_99" xlink:to="lab_mdcx_BusinessCombinationDiscountPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_BusinessCombinationDiscountPricePerShare_100" xlink:to="lab_mdcx_BusinessCombinationDiscountPricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_BusinessCombinationDiscountPricePerShare_101" xlink:to="lab_mdcx_BusinessCombinationDiscountPricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_BusinessCombinationReverseTakeoverTransactionTextBlock_102" xlink:to="lab_mdcx_BusinessCombinationReverseTakeoverTransactionTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_BusinessCombinationReverseTakeoverTransactionTextBlock_103" xlink:to="lab_mdcx_BusinessCombinationReverseTakeoverTransactionTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_BusinessCombinationReverseTakeoverTransactionTextBlock_104" xlink:to="lab_mdcx_BusinessCombinationReverseTakeoverTransactionTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_CashReceivedForInterest_105" xlink:to="lab_mdcx_CashReceivedForInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_CashReceivedForInterest_106" xlink:to="lab_mdcx_CashReceivedForInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_CashReceivedForInterest_107" xlink:to="lab_mdcx_CashReceivedForInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ChangeInFairValueOfDebentures_108" xlink:to="lab_mdcx_ChangeInFairValueOfDebentures_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ChangeInFairValueOfDebentures_109" xlink:to="lab_mdcx_ChangeInFairValueOfDebentures_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ChangeInFairValueOfDebentures_110" xlink:to="lab_mdcx_ChangeInFairValueOfDebentures_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ChangeInFairValueOfDebentures_111" xlink:to="lab_mdcx_ChangeInFairValueOfDebentures_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes_112" xlink:to="lab_mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes_113" xlink:to="lab_mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes_114" xlink:to="lab_mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ClassOfWarrantOrRightExercisable_115" xlink:to="lab_mdcx_ClassOfWarrantOrRightExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ClassOfWarrantOrRightExercisable_116" xlink:to="lab_mdcx_ClassOfWarrantOrRightExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ClassOfWarrantOrRightExercisable_117" xlink:to="lab_mdcx_ClassOfWarrantOrRightExercisable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ClassOfWarrantOrRightExercisable_118" xlink:to="lab_mdcx_ClassOfWarrantOrRightExercisable_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ClassOfWarrantOrRightExpiryDate_119" xlink:to="lab_mdcx_ClassOfWarrantOrRightExpiryDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ClassOfWarrantOrRightExpiryDate_120" xlink:to="lab_mdcx_ClassOfWarrantOrRightExpiryDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ClassOfWarrantOrRightExpiryDate_121" xlink:to="lab_mdcx_ClassOfWarrantOrRightExpiryDate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember_122" xlink:to="lab_mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember_123" xlink:to="lab_mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember_124" xlink:to="lab_mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_CommissionsPayableToAgents_125" xlink:to="lab_mdcx_CommissionsPayableToAgents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_CommissionsPayableToAgents_126" xlink:to="lab_mdcx_CommissionsPayableToAgents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_CommissionsPayableToAgents_127" xlink:to="lab_mdcx_CommissionsPayableToAgents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_CommonSharesToBeIssued_128" xlink:to="lab_mdcx_CommonSharesToBeIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_CommonSharesToBeIssued_129" xlink:to="lab_mdcx_CommonSharesToBeIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_CommonSharesToBeIssued_130" xlink:to="lab_mdcx_CommonSharesToBeIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ComprehensiveLossAttributableToParent_131" xlink:to="lab_mdcx_ComprehensiveLossAttributableToParent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ComprehensiveLossAttributableToParent_132" xlink:to="lab_mdcx_ComprehensiveLossAttributableToParent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ComprehensiveLossAttributableToParent_133" xlink:to="lab_mdcx_ComprehensiveLossAttributableToParent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ContingentConsiderationPhasesFourMember_134" xlink:to="lab_mdcx_ContingentConsiderationPhasesFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ContingentConsiderationPhasesFourMember_135" xlink:to="lab_mdcx_ContingentConsiderationPhasesFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ContingentConsiderationPhasesFourMember_136" xlink:to="lab_mdcx_ContingentConsiderationPhasesFourMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ContingentConsiderationPhasesOneMember_137" xlink:to="lab_mdcx_ContingentConsiderationPhasesOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ContingentConsiderationPhasesOneMember_138" xlink:to="lab_mdcx_ContingentConsiderationPhasesOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ContingentConsiderationPhasesOneMember_139" xlink:to="lab_mdcx_ContingentConsiderationPhasesOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ContingentConsiderationPhasesThreeMember_140" xlink:to="lab_mdcx_ContingentConsiderationPhasesThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ContingentConsiderationPhasesThreeMember_141" xlink:to="lab_mdcx_ContingentConsiderationPhasesThreeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ContingentConsiderationPhasesThreeMember_142" xlink:to="lab_mdcx_ContingentConsiderationPhasesThreeMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ContingentConsiderationPhasesTwoMember_143" xlink:to="lab_mdcx_ContingentConsiderationPhasesTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ContingentConsiderationPhasesTwoMember_144" xlink:to="lab_mdcx_ContingentConsiderationPhasesTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ContingentConsiderationPhasesTwoMember_145" xlink:to="lab_mdcx_ContingentConsiderationPhasesTwoMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ConversionOfStockConversionOneMember_146" xlink:to="lab_mdcx_ConversionOfStockConversionOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ConversionOfStockConversionOneMember_147" xlink:to="lab_mdcx_ConversionOfStockConversionOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ConversionOfStockConversionThreeMember_148" xlink:to="lab_mdcx_ConversionOfStockConversionThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ConversionOfStockConversionThreeMember_149" xlink:to="lab_mdcx_ConversionOfStockConversionThreeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ConversionOfStockConversionThreeMember_150" xlink:to="lab_mdcx_ConversionOfStockConversionThreeMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ConversionOfStockConversionTwoMember_151" xlink:to="lab_mdcx_ConversionOfStockConversionTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ConversionOfStockConversionTwoMember_152" xlink:to="lab_mdcx_ConversionOfStockConversionTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ConversionOfStockConversionTwoMember_153" xlink:to="lab_mdcx_ConversionOfStockConversionTwoMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ConvertibleDebtAccretionExpense_154" xlink:to="lab_mdcx_ConvertibleDebtAccretionExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ConvertibleDebtAccretionExpense_155" xlink:to="lab_mdcx_ConvertibleDebtAccretionExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ConvertibleDebtAccretionExpense_156" xlink:to="lab_mdcx_ConvertibleDebtAccretionExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ConvertibleDebtAccretionExpense_157" xlink:to="lab_mdcx_ConvertibleDebtAccretionExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ConvertiblePromissoryNotesMember_158" xlink:to="lab_mdcx_ConvertiblePromissoryNotesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ConvertiblePromissoryNotesMember_159" xlink:to="lab_mdcx_ConvertiblePromissoryNotesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ConvertiblePromissoryNotesMember_160" xlink:to="lab_mdcx_ConvertiblePromissoryNotesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes_161" xlink:to="lab_mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes_162" xlink:to="lab_mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes_163" xlink:to="lab_mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebentureContinuityOneMember_164" xlink:to="lab_mdcx_DebentureContinuityOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebentureContinuityOneMember_165" xlink:to="lab_mdcx_DebentureContinuityOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebentureContinuityOneMember_166" xlink:to="lab_mdcx_DebentureContinuityOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebenturesAndSecuredPromissoryNotes_167" xlink:to="lab_mdcx_DebenturesAndSecuredPromissoryNotes_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebenturesAndSecuredPromissoryNotes_168" xlink:to="lab_mdcx_DebenturesAndSecuredPromissoryNotes_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebenturesAndSecuredPromissoryNotes_169" xlink:to="lab_mdcx_DebenturesAndSecuredPromissoryNotes_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebenturesAndSecuredPromissoryNotes_170" xlink:to="lab_mdcx_DebenturesAndSecuredPromissoryNotes_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebenturesIssuedPercentageOfDiscountedPrice_171" xlink:to="lab_mdcx_DebenturesIssuedPercentageOfDiscountedPrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebenturesIssuedPercentageOfDiscountedPrice_172" xlink:to="lab_mdcx_DebenturesIssuedPercentageOfDiscountedPrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebenturesIssuedPercentageOfDiscountedPrice_173" xlink:to="lab_mdcx_DebenturesIssuedPercentageOfDiscountedPrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebenturesMember_174" xlink:to="lab_mdcx_DebenturesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebenturesMember_175" xlink:to="lab_mdcx_DebenturesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtConversionAdditionalDebtAmount_176" xlink:to="lab_mdcx_DebtConversionAdditionalDebtAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtConversionAdditionalDebtAmount_177" xlink:to="lab_mdcx_DebtConversionAdditionalDebtAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtConversionAdditionalDebtAmount_178" xlink:to="lab_mdcx_DebtConversionAdditionalDebtAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares_179" xlink:to="lab_mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares_180" xlink:to="lab_mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares_181" xlink:to="lab_mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtConversionConvertibleIntoPreferredSharesAmount_182" xlink:to="lab_mdcx_DebtConversionConvertibleIntoPreferredSharesAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtConversionConvertibleIntoPreferredSharesAmount_183" xlink:to="lab_mdcx_DebtConversionConvertibleIntoPreferredSharesAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtConversionConvertibleIntoPreferredSharesAmount_184" xlink:to="lab_mdcx_DebtConversionConvertibleIntoPreferredSharesAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount_185" xlink:to="lab_mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount_186" xlink:to="lab_mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount_187" xlink:to="lab_mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest_188" xlink:to="lab_mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest_189" xlink:to="lab_mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest_190" xlink:to="lab_mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtConversionRemainingConvertibleAmount_191" xlink:to="lab_mdcx_DebtConversionRemainingConvertibleAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtConversionRemainingConvertibleAmount_192" xlink:to="lab_mdcx_DebtConversionRemainingConvertibleAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtConversionRemainingConvertibleAmount_193" xlink:to="lab_mdcx_DebtConversionRemainingConvertibleAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtDefaultBalanceIncreasePercentage_194" xlink:to="lab_mdcx_DebtDefaultBalanceIncreasePercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtDefaultBalanceIncreasePercentage_195" xlink:to="lab_mdcx_DebtDefaultBalanceIncreasePercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtDefaultBalanceIncreasePercentage_196" xlink:to="lab_mdcx_DebtDefaultBalanceIncreasePercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtInstrumentConvertibleExtinguished_197" xlink:to="lab_mdcx_DebtInstrumentConvertibleExtinguished_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtInstrumentConvertibleExtinguished_198" xlink:to="lab_mdcx_DebtInstrumentConvertibleExtinguished_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtInstrumentConvertibleExtinguished_199" xlink:to="lab_mdcx_DebtInstrumentConvertibleExtinguished_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage_200" xlink:to="lab_mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage_201" xlink:to="lab_mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage_202" xlink:to="lab_mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtInstrumentExchangeThresholdAmount_203" xlink:to="lab_mdcx_DebtInstrumentExchangeThresholdAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtInstrumentExchangeThresholdAmount_204" xlink:to="lab_mdcx_DebtInstrumentExchangeThresholdAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtInstrumentExchangeThresholdAmount_205" xlink:to="lab_mdcx_DebtInstrumentExchangeThresholdAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtInstrumentMaximumExchangeLimitAmount_206" xlink:to="lab_mdcx_DebtInstrumentMaximumExchangeLimitAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtInstrumentMaximumExchangeLimitAmount_207" xlink:to="lab_mdcx_DebtInstrumentMaximumExchangeLimitAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtInstrumentMaximumExchangeLimitAmount_208" xlink:to="lab_mdcx_DebtInstrumentMaximumExchangeLimitAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtInstrumentPeriodicPaymentInterestInCash_209" xlink:to="lab_mdcx_DebtInstrumentPeriodicPaymentInterestInCash_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtInstrumentPeriodicPaymentInterestInCash_210" xlink:to="lab_mdcx_DebtInstrumentPeriodicPaymentInterestInCash_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtInstrumentPeriodicPaymentInterestInCash_211" xlink:to="lab_mdcx_DebtInstrumentPeriodicPaymentInterestInCash_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtInstrumentRedemptionLimitAmount_212" xlink:to="lab_mdcx_DebtInstrumentRedemptionLimitAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtInstrumentRedemptionLimitAmount_213" xlink:to="lab_mdcx_DebtInstrumentRedemptionLimitAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtInstrumentRedemptionLimitAmount_214" xlink:to="lab_mdcx_DebtInstrumentRedemptionLimitAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit_215" xlink:to="lab_mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit_216" xlink:to="lab_mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit_217" xlink:to="lab_mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtIssuanceDiscount_218" xlink:to="lab_mdcx_DebtIssuanceDiscount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtIssuanceDiscount_219" xlink:to="lab_mdcx_DebtIssuanceDiscount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DebtIssuanceDiscount_220" xlink:to="lab_mdcx_DebtIssuanceDiscount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DeemedDividendOnWarrantInducement_221" xlink:to="lab_mdcx_DeemedDividendOnWarrantInducement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DeemedDividendOnWarrantInducement_222" xlink:to="lab_mdcx_DeemedDividendOnWarrantInducement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DeemedDividendOnWarrantInducement_223" xlink:to="lab_mdcx_DeemedDividendOnWarrantInducement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DeferredAtmOfferingCostsOffsetAgainstAdditionalPaidInCapital_224" xlink:to="lab_mdcx_DeferredAtmOfferingCostsOffsetAgainstAdditionalPaidInCapital_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DeferredAtmOfferingCostsOffsetAgainstAdditionalPaidInCapital_225" xlink:to="lab_mdcx_DeferredAtmOfferingCostsOffsetAgainstAdditionalPaidInCapital_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DeferredAtmOfferingCostsOffsetAgainstAdditionalPaidInCapital_226" xlink:to="lab_mdcx_DeferredAtmOfferingCostsOffsetAgainstAdditionalPaidInCapital_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement_227" xlink:to="lab_mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement_228" xlink:to="lab_mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement_229" xlink:to="lab_mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DeferredTaxAssetConvertibleDebentures_230" xlink:to="lab_mdcx_DeferredTaxAssetConvertibleDebentures_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DeferredTaxAssetConvertibleDebentures_231" xlink:to="lab_mdcx_DeferredTaxAssetConvertibleDebentures_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DeferredTaxAssetConvertibleDebentures_232" xlink:to="lab_mdcx_DeferredTaxAssetConvertibleDebentures_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DeferredTaxAssetsAdditionalOperatingLossCarryforwardsForeign_233" xlink:to="lab_mdcx_DeferredTaxAssetsAdditionalOperatingLossCarryforwardsForeign_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DeferredTaxAssetsAdditionalOperatingLossCarryforwardsForeign_234" xlink:to="lab_mdcx_DeferredTaxAssetsAdditionalOperatingLossCarryforwardsForeign_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DeferredTaxAssetsAdditionalOperatingLossCarryforwardsForeign_235" xlink:to="lab_mdcx_DeferredTaxAssetsAdditionalOperatingLossCarryforwardsForeign_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DeferredTaxAssetsOperatingLossCarryforwardsNonCapital_236" xlink:to="lab_mdcx_DeferredTaxAssetsOperatingLossCarryforwardsNonCapital_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DeferredTaxAssetsOperatingLossCarryforwardsNonCapital_237" xlink:to="lab_mdcx_DeferredTaxAssetsOperatingLossCarryforwardsNonCapital_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_DeferredTaxAssetsOperatingLossCarryforwardsNonCapital_238" xlink:to="lab_mdcx_DeferredTaxAssetsOperatingLossCarryforwardsNonCapital_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_EarningsFromDiscontinuedOperationsMember_239" xlink:to="lab_mdcx_EarningsFromDiscontinuedOperationsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_EarningsFromDiscontinuedOperationsMember_240" xlink:to="lab_mdcx_EarningsFromDiscontinuedOperationsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_EarningsFromDiscontinuedOperationsMember_241" xlink:to="lab_mdcx_EarningsFromDiscontinuedOperationsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_EffectiveInterestRateOnDebt_242" xlink:to="lab_mdcx_EffectiveInterestRateOnDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_EffectiveInterestRateOnDebt_243" xlink:to="lab_mdcx_EffectiveInterestRateOnDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_EffectiveInterestRateOnDebt_244" xlink:to="lab_mdcx_EffectiveInterestRateOnDebt_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_EmployeeStockPurchasePlanMember_245" xlink:to="lab_mdcx_EmployeeStockPurchasePlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_EmployeeStockPurchasePlanMember_246" xlink:to="lab_mdcx_EmployeeStockPurchasePlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_EquityDistributionAgreementCommissionRate_247" xlink:to="lab_mdcx_EquityDistributionAgreementCommissionRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_EquityDistributionAgreementCommissionRate_248" xlink:to="lab_mdcx_EquityDistributionAgreementCommissionRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_EquityDistributionAgreementCommissionRate_249" xlink:to="lab_mdcx_EquityDistributionAgreementCommissionRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ExerciseOfPublicWarrantsMember_250" xlink:to="lab_mdcx_ExerciseOfPublicWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ExerciseOfPublicWarrantsMember_251" xlink:to="lab_mdcx_ExerciseOfPublicWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ExerciseOfRegulationAWarrantsMember_252" xlink:to="lab_mdcx_ExerciseOfRegulationAWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ExerciseOfRegulationAWarrantsMember_253" xlink:to="lab_mdcx_ExerciseOfRegulationAWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ExerciseSeriesAAndBWarrantsIssuedMember_254" xlink:to="lab_mdcx_ExerciseSeriesAAndBWarrantsIssuedMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ExerciseSeriesAAndBWarrantsIssuedMember_255" xlink:to="lab_mdcx_ExerciseSeriesAAndBWarrantsIssuedMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_FairValueLossOfDebt_256" xlink:to="lab_mdcx_FairValueLossOfDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_FairValueLossOfDebt_257" xlink:to="lab_mdcx_FairValueLossOfDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_FairValueLossOfDebt_258" xlink:to="lab_mdcx_FairValueLossOfDebt_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_FairValueOfAdditionalRestrictedStockUnit_259" xlink:to="lab_mdcx_FairValueOfAdditionalRestrictedStockUnit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_FairValueOfAdditionalRestrictedStockUnit_260" xlink:to="lab_mdcx_FairValueOfAdditionalRestrictedStockUnit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_FairValueOfWarrantsGranted_261" xlink:to="lab_mdcx_FairValueOfWarrantsGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_FairValueOfWarrantsGranted_262" xlink:to="lab_mdcx_FairValueOfWarrantsGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_FairValuePerShare_263" xlink:to="lab_mdcx_FairValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_FairValuePerShare_264" xlink:to="lab_mdcx_FairValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_FairValuePerShare_265" xlink:to="lab_mdcx_FairValuePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_FairValuePerWarrant_266" xlink:to="lab_mdcx_FairValuePerWarrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_FairValuePerWarrant_267" xlink:to="lab_mdcx_FairValuePerWarrant_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_FairValuePerWarrant_268" xlink:to="lab_mdcx_FairValuePerWarrant_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ForeignCurrencyTransactionsPolicyTextBlock_269" xlink:to="lab_mdcx_ForeignCurrencyTransactionsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ForeignCurrencyTransactionsPolicyTextBlock_270" xlink:to="lab_mdcx_ForeignCurrencyTransactionsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ForeignCurrencyTransactionsPolicyTextBlock_271" xlink:to="lab_mdcx_ForeignCurrencyTransactionsPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_FormerHoldersMember_272" xlink:to="lab_mdcx_FormerHoldersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_FormerHoldersMember_273" xlink:to="lab_mdcx_FormerHoldersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_GainLossOnSettlements_274" xlink:to="lab_mdcx_GainLossOnSettlements_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_GainLossOnSettlements_275" xlink:to="lab_mdcx_GainLossOnSettlements_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_GainLossOnSettlements_276" xlink:to="lab_mdcx_GainLossOnSettlements_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_GainLossOnSettlements_277" xlink:to="lab_mdcx_GainLossOnSettlements_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_GainLossOnSettlements_278" xlink:to="lab_mdcx_GainLossOnSettlements_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_GrantDateOneMember_279" xlink:to="lab_mdcx_GrantDateOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_GrantDateOneMember_280" xlink:to="lab_mdcx_GrantDateOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_GrantDateOneMember_281" xlink:to="lab_mdcx_GrantDateOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_GrantDateThreeMember_282" xlink:to="lab_mdcx_GrantDateThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_GrantDateThreeMember_283" xlink:to="lab_mdcx_GrantDateThreeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_GrantDateThreeMember_284" xlink:to="lab_mdcx_GrantDateThreeMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_GrantDateTwoMember_285" xlink:to="lab_mdcx_GrantDateTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_GrantDateTwoMember_286" xlink:to="lab_mdcx_GrantDateTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_GrantDateTwoMember_287" xlink:to="lab_mdcx_GrantDateTwoMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_GrantedRegulationAWarrantsMember_288" xlink:to="lab_mdcx_GrantedRegulationAWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_GrantedRegulationAWarrantsMember_289" xlink:to="lab_mdcx_GrantedRegulationAWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_GrantedSeriesAAndBWarrantsIssuedMember_290" xlink:to="lab_mdcx_GrantedSeriesAAndBWarrantsIssuedMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_GrantedSeriesAAndBWarrantsIssuedMember_291" xlink:to="lab_mdcx_GrantedSeriesAAndBWarrantsIssuedMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_GrantedWarrantsMember_292" xlink:to="lab_mdcx_GrantedWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_GrantedWarrantsMember_293" xlink:to="lab_mdcx_GrantedWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IncreaseDecreaseInCostsRelatedToSettlements_294" xlink:to="lab_mdcx_IncreaseDecreaseInCostsRelatedToSettlements_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IncreaseDecreaseInCostsRelatedToSettlements_295" xlink:to="lab_mdcx_IncreaseDecreaseInCostsRelatedToSettlements_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IncreaseDecreaseInCostsRelatedToSettlements_296" xlink:to="lab_mdcx_IncreaseDecreaseInCostsRelatedToSettlements_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets_297" xlink:to="lab_mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets_298" xlink:to="lab_mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets_299" xlink:to="lab_mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IncrementalFairValueOfWarrantsGranted_300" xlink:to="lab_mdcx_IncrementalFairValueOfWarrantsGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IncrementalFairValueOfWarrantsGranted_301" xlink:to="lab_mdcx_IncrementalFairValueOfWarrantsGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IncrementalFairValueOfWarrantsGranted_302" xlink:to="lab_mdcx_IncrementalFairValueOfWarrantsGranted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IndividualsMember_303" xlink:to="lab_mdcx_IndividualsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IndividualsMember_304" xlink:to="lab_mdcx_IndividualsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_InProcessResearchAndDevelopment_305" xlink:to="lab_mdcx_InProcessResearchAndDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_InProcessResearchAndDevelopment_306" xlink:to="lab_mdcx_InProcessResearchAndDevelopment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_InProcessResearchAndDevelopment_307" xlink:to="lab_mdcx_InProcessResearchAndDevelopment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_InteractiveCapitalPartnersCorporationMember_308" xlink:to="lab_mdcx_InteractiveCapitalPartnersCorporationMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_InteractiveCapitalPartnersCorporationMember_309" xlink:to="lab_mdcx_InteractiveCapitalPartnersCorporationMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_InterimRemeasurementMember_310" xlink:to="lab_mdcx_InterimRemeasurementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_InterimRemeasurementMember_311" xlink:to="lab_mdcx_InterimRemeasurementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_InterimRemeasurementMember_312" xlink:to="lab_mdcx_InterimRemeasurementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IssuanceCostsIncludedInAccountsPayable_313" xlink:to="lab_mdcx_IssuanceCostsIncludedInAccountsPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IssuanceCostsIncludedInAccountsPayable_314" xlink:to="lab_mdcx_IssuanceCostsIncludedInAccountsPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IssuanceCostsInConnectionWithEquityFinancing_315" xlink:to="lab_mdcx_IssuanceCostsInConnectionWithEquityFinancing_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IssuanceCostsInConnectionWithEquityFinancing_316" xlink:to="lab_mdcx_IssuanceCostsInConnectionWithEquityFinancing_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IssuanceCostsInConnectionWithEquityFinancing_317" xlink:to="lab_mdcx_IssuanceCostsInConnectionWithEquityFinancing_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IssuanceCostsInConnectionWithInitialPublicOffering_318" xlink:to="lab_mdcx_IssuanceCostsInConnectionWithInitialPublicOffering_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IssuanceCostsInConnectionWithInitialPublicOffering_319" xlink:to="lab_mdcx_IssuanceCostsInConnectionWithInitialPublicOffering_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IssuanceCostsInConnectionWithInitialPublicOffering_320" xlink:to="lab_mdcx_IssuanceCostsInConnectionWithInitialPublicOffering_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IssuanceCostsInConnectionWithPrivatePlacement_321" xlink:to="lab_mdcx_IssuanceCostsInConnectionWithPrivatePlacement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IssuanceCostsInConnectionWithPrivatePlacement_322" xlink:to="lab_mdcx_IssuanceCostsInConnectionWithPrivatePlacement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IssuanceCostsInConnectionWithPrivatePlacement_323" xlink:to="lab_mdcx_IssuanceCostsInConnectionWithPrivatePlacement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IssuanceCostsInConnectionWithPrivatePlacement_324" xlink:to="lab_mdcx_IssuanceCostsInConnectionWithPrivatePlacement_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IssuanceCostsInConnectionWithRegulationA_325" xlink:to="lab_mdcx_IssuanceCostsInConnectionWithRegulationA_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IssuanceCostsInConnectionWithRegulationA_326" xlink:to="lab_mdcx_IssuanceCostsInConnectionWithRegulationA_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IssuanceCostsInConnectionWithRegulationA_327" xlink:to="lab_mdcx_IssuanceCostsInConnectionWithRegulationA_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered_328" xlink:to="lab_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered_329" xlink:to="lab_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered_330" xlink:to="lab_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered_331" xlink:to="lab_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_June2025PublicOfferingMember_332" xlink:to="lab_mdcx_June2025PublicOfferingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_June2025PublicOfferingMember_333" xlink:to="lab_mdcx_June2025PublicOfferingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_LesseeOperatingLeasesDisclosureTableTextBlock_334" xlink:to="lab_mdcx_LesseeOperatingLeasesDisclosureTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_LesseeOperatingLeasesDisclosureTableTextBlock_335" xlink:to="lab_mdcx_LesseeOperatingLeasesDisclosureTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_LesseeOperatingLeasesDisclosureTableTextBlock_336" xlink:to="lab_mdcx_LesseeOperatingLeasesDisclosureTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding_337" xlink:to="lab_mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding_338" xlink:to="lab_mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding_339" xlink:to="lab_mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_LiquidityAbstract_340" xlink:to="lab_mdcx_LiquidityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_LiquidityTextBlock_341" xlink:to="lab_mdcx_LiquidityTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_LiquidityTextBlock_342" xlink:to="lab_mdcx_LiquidityTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_LiquidityTextBlock_343" xlink:to="lab_mdcx_LiquidityTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_LongTermIncentivePlanMember_344" xlink:to="lab_mdcx_LongTermIncentivePlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_LongTermIncentivePlanMember_345" xlink:to="lab_mdcx_LongTermIncentivePlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_LongTermIncentivePlanMember_346" xlink:to="lab_mdcx_LongTermIncentivePlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_MeasurementInputValuationDateSharePriceMember_347" xlink:to="lab_mdcx_MeasurementInputValuationDateSharePriceMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_MeasurementInputValuationDateSharePriceMember_348" xlink:to="lab_mdcx_MeasurementInputValuationDateSharePriceMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_MeasurementInputValuationDateSharePriceMember_349" xlink:to="lab_mdcx_MeasurementInputValuationDateSharePriceMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_MoneyMarketFunds_350" xlink:to="lab_mdcx_MoneyMarketFunds_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_MoneyMarketFunds_351" xlink:to="lab_mdcx_MoneyMarketFunds_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_MoneyMarketFunds_352" xlink:to="lab_mdcx_MoneyMarketFunds_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts_353" xlink:to="lab_mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts_354" xlink:to="lab_mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts_355" xlink:to="lab_mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts_356" xlink:to="lab_mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NetOfAllocatedShareBasedCompensationExpense_357" xlink:to="lab_mdcx_NetOfAllocatedShareBasedCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NetOfAllocatedShareBasedCompensationExpense_358" xlink:to="lab_mdcx_NetOfAllocatedShareBasedCompensationExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NetOfAllocatedShareBasedCompensationExpense_359" xlink:to="lab_mdcx_NetOfAllocatedShareBasedCompensationExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NoInsiderTradingFlag_360" xlink:to="lab_mdcx_NoInsiderTradingFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NoInsiderTradingFlag_361" xlink:to="lab_mdcx_NoInsiderTradingFlag_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NoteAMember_362" xlink:to="lab_mdcx_NoteAMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NoteAMember_363" xlink:to="lab_mdcx_NoteAMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NoteBMember_364" xlink:to="lab_mdcx_NoteBMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NoteBMember_365" xlink:to="lab_mdcx_NoteBMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement_366" xlink:to="lab_mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement_367" xlink:to="lab_mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement_368" xlink:to="lab_mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfCommonShareWarrantsExercisable_369" xlink:to="lab_mdcx_NumberOfCommonShareWarrantsExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfCommonShareWarrantsExercisable_370" xlink:to="lab_mdcx_NumberOfCommonShareWarrantsExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfCommonShareWarrantsExercisable_371" xlink:to="lab_mdcx_NumberOfCommonShareWarrantsExercisable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfCommonShareWarrantsExercisable_372" xlink:to="lab_mdcx_NumberOfCommonShareWarrantsExercisable_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfCommonShareWarrantsExercisableExerciseInPeriod_373" xlink:to="lab_mdcx_NumberOfCommonShareWarrantsExercisableExerciseInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfCommonShareWarrantsExercisableExerciseInPeriod_374" xlink:to="lab_mdcx_NumberOfCommonShareWarrantsExercisableExerciseInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfCommonShareWarrantsExercisableExerciseInPeriod_375" xlink:to="lab_mdcx_NumberOfCommonShareWarrantsExercisableExerciseInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfCommonShareWarrantsExercisableGrantsInPeriod_376" xlink:to="lab_mdcx_NumberOfCommonShareWarrantsExercisableGrantsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfCommonShareWarrantsExercisableGrantsInPeriod_377" xlink:to="lab_mdcx_NumberOfCommonShareWarrantsExercisableGrantsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfCommonShareWarrantsExercisableGrantsInPeriod_378" xlink:to="lab_mdcx_NumberOfCommonShareWarrantsExercisableGrantsInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod_379" xlink:to="lab_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod_380" xlink:to="lab_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod_381" xlink:to="lab_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod_382" xlink:to="lab_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_383" xlink:to="lab_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_384" xlink:to="lab_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_385" xlink:to="lab_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_386" xlink:to="lab_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfConvertibleNotesSubscribed_387" xlink:to="lab_mdcx_NumberOfConvertibleNotesSubscribed_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfSharesIssuedAfter210DaysFromAcquisition_388" xlink:to="lab_mdcx_NumberOfSharesIssuedAfter210DaysFromAcquisition_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfSharesIssuedAfter210DaysFromAcquisition_389" xlink:to="lab_mdcx_NumberOfSharesIssuedAfter210DaysFromAcquisition_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfSharesIssuedAfter210DaysFromAcquisition_390" xlink:to="lab_mdcx_NumberOfSharesIssuedAfter210DaysFromAcquisition_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfTradingDays_391" xlink:to="lab_mdcx_NumberOfTradingDays_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfTradingDays_392" xlink:to="lab_mdcx_NumberOfTradingDays_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfTradingDays_393" xlink:to="lab_mdcx_NumberOfTradingDays_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfWarrantsExercisable_394" xlink:to="lab_mdcx_NumberOfWarrantsExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfWarrantsExercisable_395" xlink:to="lab_mdcx_NumberOfWarrantsExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfWarrantsExercisable_396" xlink:to="lab_mdcx_NumberOfWarrantsExercisable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfWarrantsExercisable_397" xlink:to="lab_mdcx_NumberOfWarrantsExercisable_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfWarrantsExercised_398" xlink:to="lab_mdcx_NumberOfWarrantsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfWarrantsExercised_399" xlink:to="lab_mdcx_NumberOfWarrantsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfWarrantsExercised_400" xlink:to="lab_mdcx_NumberOfWarrantsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfWarrantsExercised_401" xlink:to="lab_mdcx_NumberOfWarrantsExercised_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfWarrantsExercisedForCash_402" xlink:to="lab_mdcx_NumberOfWarrantsExercisedForCash_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfWarrantsExercisedForCash_403" xlink:to="lab_mdcx_NumberOfWarrantsExercisedForCash_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_NumberOfWarrantsExercisedForCash_404" xlink:to="lab_mdcx_NumberOfWarrantsExercisedForCash_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_OriginalEarningsBeforeInterestTaxDepreciationAndAmortization_405" xlink:to="lab_mdcx_OriginalEarningsBeforeInterestTaxDepreciationAndAmortization_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_OriginalEarningsBeforeInterestTaxDepreciationAndAmortization_406" xlink:to="lab_mdcx_OriginalEarningsBeforeInterestTaxDepreciationAndAmortization_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_OriginalEarningsBeforeInterestTaxDepreciationAndAmortization_407" xlink:to="lab_mdcx_OriginalEarningsBeforeInterestTaxDepreciationAndAmortization_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PaymentOfStructuringFee_408" xlink:to="lab_mdcx_PaymentOfStructuringFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PaymentOfStructuringFee_409" xlink:to="lab_mdcx_PaymentOfStructuringFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PaymentsToAcquireBusinessesAdvance_410" xlink:to="lab_mdcx_PaymentsToAcquireBusinessesAdvance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PaymentsToAcquireBusinessesAdvance_411" xlink:to="lab_mdcx_PaymentsToAcquireBusinessesAdvance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PaymentsToAcquireBusinessesAdvance_412" xlink:to="lab_mdcx_PaymentsToAcquireBusinessesAdvance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PreferredStockRedeemablePercentage_413" xlink:to="lab_mdcx_PreferredStockRedeemablePercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PreferredStockRedeemablePercentage_414" xlink:to="lab_mdcx_PreferredStockRedeemablePercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PreferredStockRedeemablePercentage_415" xlink:to="lab_mdcx_PreferredStockRedeemablePercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PrepaidContractResearch_416" xlink:to="lab_mdcx_PrepaidContractResearch_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PrepaidContractResearch_417" xlink:to="lab_mdcx_PrepaidContractResearch_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PrepaidContractResearch_418" xlink:to="lab_mdcx_PrepaidContractResearch_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PrepaidExpensesPolicyTextBlock_419" xlink:to="lab_mdcx_PrepaidExpensesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PrepaidExpensesPolicyTextBlock_420" xlink:to="lab_mdcx_PrepaidExpensesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PrepaidExpensesPolicyTextBlock_421" xlink:to="lab_mdcx_PrepaidExpensesPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PrepaidProfessionalServices_422" xlink:to="lab_mdcx_PrepaidProfessionalServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PrepaidProfessionalServices_423" xlink:to="lab_mdcx_PrepaidProfessionalServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PrepaidProfessionalServices_424" xlink:to="lab_mdcx_PrepaidProfessionalServices_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PrepaidServices_425" xlink:to="lab_mdcx_PrepaidServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PrepaidServices_426" xlink:to="lab_mdcx_PrepaidServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PrepaidServices_427" xlink:to="lab_mdcx_PrepaidServices_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents_428" xlink:to="lab_mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents_429" xlink:to="lab_mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents_430" xlink:to="lab_mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromConcurrentFinancing_431" xlink:to="lab_mdcx_ProceedsFromConcurrentFinancing_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromConcurrentFinancing_432" xlink:to="lab_mdcx_ProceedsFromConcurrentFinancing_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromConcurrentFinancing_433" xlink:to="lab_mdcx_ProceedsFromConcurrentFinancing_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromConcurrentFinancing_434" xlink:to="lab_mdcx_ProceedsFromConcurrentFinancing_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts_435" xlink:to="lab_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts_436" xlink:to="lab_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts_437" xlink:to="lab_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts_438" xlink:to="lab_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromIssuanceOfSharesUnderSettlements_439" xlink:to="lab_mdcx_ProceedsFromIssuanceOfSharesUnderSettlements_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromIssuanceOfSharesUnderSettlements_440" xlink:to="lab_mdcx_ProceedsFromIssuanceOfSharesUnderSettlements_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromIssuanceOfSharesUnderSettlements_441" xlink:to="lab_mdcx_ProceedsFromIssuanceOfSharesUnderSettlements_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromOrionEquityInvestment_442" xlink:to="lab_mdcx_ProceedsFromOrionEquityInvestment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromOrionEquityInvestment_443" xlink:to="lab_mdcx_ProceedsFromOrionEquityInvestment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromOrionEquityInvestment_444" xlink:to="lab_mdcx_ProceedsFromOrionEquityInvestment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromSaleOfCommonStockOnAtMarketProgram_445" xlink:to="lab_mdcx_ProceedsFromSaleOfCommonStockOnAtMarketProgram_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromSaleOfCommonStockOnAtMarketProgram_446" xlink:to="lab_mdcx_ProceedsFromSaleOfCommonStockOnAtMarketProgram_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromSaleOfCommonStockOnAtMarketProgram_447" xlink:to="lab_mdcx_ProceedsFromSaleOfCommonStockOnAtMarketProgram_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromSaleOfCommonStockOnAtMarketProgram_448" xlink:to="lab_mdcx_ProceedsFromSaleOfCommonStockOnAtMarketProgram_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromSaleOfRoyaltyInterest_449" xlink:to="lab_mdcx_ProceedsFromSaleOfRoyaltyInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromSaleOfRoyaltyInterest_450" xlink:to="lab_mdcx_ProceedsFromSaleOfRoyaltyInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromSaleOfRoyaltyInterest_451" xlink:to="lab_mdcx_ProceedsFromSaleOfRoyaltyInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures_452" xlink:to="lab_mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures_453" xlink:to="lab_mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures_454" xlink:to="lab_mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromSimpleAgreementForFutureEquity_455" xlink:to="lab_mdcx_ProceedsFromSimpleAgreementForFutureEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromSimpleAgreementForFutureEquity_456" xlink:to="lab_mdcx_ProceedsFromSimpleAgreementForFutureEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProceedsFromSimpleAgreementForFutureEquity_457" xlink:to="lab_mdcx_ProceedsFromSimpleAgreementForFutureEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProfessionalServicesAndIntellectualPropertyMember_458" xlink:to="lab_mdcx_ProfessionalServicesAndIntellectualPropertyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProfessionalServicesAndIntellectualPropertyMember_459" xlink:to="lab_mdcx_ProfessionalServicesAndIntellectualPropertyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ProfessionalServicesAndIntellectualPropertyMember_460" xlink:to="lab_mdcx_ProfessionalServicesAndIntellectualPropertyMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PublicWarrantsMember_461" xlink:to="lab_mdcx_PublicWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_PublicWarrantsMember_462" xlink:to="lab_mdcx_PublicWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RbxCapitalLPMember_463" xlink:to="lab_mdcx_RbxCapitalLPMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RbxCapitalLPMember_464" xlink:to="lab_mdcx_RbxCapitalLPMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RbxCapitalLPMember_465" xlink:to="lab_mdcx_RbxCapitalLPMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ReceivableForProceedsOfWarrantExercises_466" xlink:to="lab_mdcx_ReceivableForProceedsOfWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ReceivableForProceedsOfWarrantExercises_467" xlink:to="lab_mdcx_ReceivableForProceedsOfWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ReceivableForProceedsOfWarrantExercises_468" xlink:to="lab_mdcx_ReceivableForProceedsOfWarrantExercises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ReceivablesForProceedsOfWarrantExercises_469" xlink:to="lab_mdcx_ReceivablesForProceedsOfWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ReceivablesForProceedsOfWarrantExercises_470" xlink:to="lab_mdcx_ReceivablesForProceedsOfWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ReceivablesForProceedsOfWarrantExercises_471" xlink:to="lab_mdcx_ReceivablesForProceedsOfWarrantExercises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_472" xlink:to="lab_mdcx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_473" xlink:to="lab_mdcx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_474" xlink:to="lab_mdcx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RegulationAOfferingMember_475" xlink:to="lab_mdcx_RegulationAOfferingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RegulationAOfferingMember_476" xlink:to="lab_mdcx_RegulationAOfferingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RegulationAWarrantsMember_477" xlink:to="lab_mdcx_RegulationAWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RegulationAWarrantsMember_478" xlink:to="lab_mdcx_RegulationAWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RelatedPartyPayableCurrent_479" xlink:to="lab_mdcx_RelatedPartyPayableCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RelatedPartyPayableCurrent_480" xlink:to="lab_mdcx_RelatedPartyPayableCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RelatedPartyPayableCurrent_481" xlink:to="lab_mdcx_RelatedPartyPayableCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RelatedPartyTransactionAdditionalExpenses_482" xlink:to="lab_mdcx_RelatedPartyTransactionAdditionalExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RelatedPartyTransactionAdditionalExpenses_483" xlink:to="lab_mdcx_RelatedPartyTransactionAdditionalExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RelatedPartyTransactionAdditionalExpenses_484" xlink:to="lab_mdcx_RelatedPartyTransactionAdditionalExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RepaymentOfDebenturesOnExtinguishment_485" xlink:to="lab_mdcx_RepaymentOfDebenturesOnExtinguishment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RepaymentOfDebenturesOnExtinguishment_486" xlink:to="lab_mdcx_RepaymentOfDebenturesOnExtinguishment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RepaymentOfDebenturesOnExtinguishment_487" xlink:to="lab_mdcx_RepaymentOfDebenturesOnExtinguishment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RepaymentsOfInterest_488" xlink:to="lab_mdcx_RepaymentsOfInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RepaymentsOfInterest_489" xlink:to="lab_mdcx_RepaymentsOfInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RepaymentsOfInterest_490" xlink:to="lab_mdcx_RepaymentsOfInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RepaymentsOfInterest_491" xlink:to="lab_mdcx_RepaymentsOfInterest_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RestrictedCashDisclosureTextBlock_492" xlink:to="lab_mdcx_RestrictedCashDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RestrictedCashDisclosureTextBlock_493" xlink:to="lab_mdcx_RestrictedCashDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RestrictedCashDisclosureTextBlock_494" xlink:to="lab_mdcx_RestrictedCashDisclosureTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RestrictedCashLineItems_495" xlink:to="lab_mdcx_RestrictedCashLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RestrictedCashTable_496" xlink:to="lab_mdcx_RestrictedCashTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RoyaltyLiability_497" xlink:to="lab_mdcx_RoyaltyLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RoyaltyLiability_498" xlink:to="lab_mdcx_RoyaltyLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_RoyaltyLiability_499" xlink:to="lab_mdcx_RoyaltyLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ScheduleOfPrepaidExpensesTableTextBlock_500" xlink:to="lab_mdcx_ScheduleOfPrepaidExpensesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ScheduleOfPrepaidExpensesTableTextBlock_501" xlink:to="lab_mdcx_ScheduleOfPrepaidExpensesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ScheduleOfPrepaidExpensesTableTextBlock_502" xlink:to="lab_mdcx_ScheduleOfPrepaidExpensesTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock_503" xlink:to="lab_mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock_504" xlink:to="lab_mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock_505" xlink:to="lab_mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SecuredPromissoryNotesMember_506" xlink:to="lab_mdcx_SecuredPromissoryNotesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SecuredPromissoryNotesMember_507" xlink:to="lab_mdcx_SecuredPromissoryNotesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SecuredPromissoryNotesMember_508" xlink:to="lab_mdcx_SecuredPromissoryNotesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SecuritiesPurchaseAgreementMember_509" xlink:to="lab_mdcx_SecuritiesPurchaseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SecuritiesPurchaseAgreementMember_510" xlink:to="lab_mdcx_SecuritiesPurchaseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SecuritiesPurchaseAgreementMember_511" xlink:to="lab_mdcx_SecuritiesPurchaseAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SeriesAAndBWarrantsGrantedMember_512" xlink:to="lab_mdcx_SeriesAAndBWarrantsGrantedMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SeriesAAndBWarrantsGrantedMember_513" xlink:to="lab_mdcx_SeriesAAndBWarrantsGrantedMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SeriesAAndBWarrantsGrantedMember_514" xlink:to="lab_mdcx_SeriesAAndBWarrantsGrantedMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SeriesAAndSeriesA1PreferredSharesMember_515" xlink:to="lab_mdcx_SeriesAAndSeriesA1PreferredSharesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SeriesAAndSeriesA1PreferredSharesMember_516" xlink:to="lab_mdcx_SeriesAAndSeriesA1PreferredSharesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SeriesAWarrantsMember_517" xlink:to="lab_mdcx_SeriesAWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SeriesAWarrantsMember_518" xlink:to="lab_mdcx_SeriesAWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SeriesBWarrantsMember_519" xlink:to="lab_mdcx_SeriesBWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SeriesBWarrantsMember_520" xlink:to="lab_mdcx_SeriesBWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SeriesCAndDWarrantsGrantedMember_521" xlink:to="lab_mdcx_SeriesCAndDWarrantsGrantedMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SeriesCAndDWarrantsGrantedMember_522" xlink:to="lab_mdcx_SeriesCAndDWarrantsGrantedMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SeriesCAndDWarrantsGrantedMember_523" xlink:to="lab_mdcx_SeriesCAndDWarrantsGrantedMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SeriesCAndDWarrantsMember_524" xlink:to="lab_mdcx_SeriesCAndDWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SeriesCAndDWarrantsMember_525" xlink:to="lab_mdcx_SeriesCAndDWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SeriesCAndDWarrantsMember_526" xlink:to="lab_mdcx_SeriesCAndDWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SettledConvertibleNotesAlongWithAccruedButUnpaidInterestInShares_527" xlink:to="lab_mdcx_SettledConvertibleNotesAlongWithAccruedButUnpaidInterestInShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SettledConvertibleNotesAlongWithAccruedButUnpaidInterestInShares_528" xlink:to="lab_mdcx_SettledConvertibleNotesAlongWithAccruedButUnpaidInterestInShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SettledConvertibleNotesAlongWithAccruedButUnpaidInterestInShares_529" xlink:to="lab_mdcx_SettledConvertibleNotesAlongWithAccruedButUnpaidInterestInShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SettlementDateRemeasurementMember_530" xlink:to="lab_mdcx_SettlementDateRemeasurementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SettlementDateRemeasurementMember_531" xlink:to="lab_mdcx_SettlementDateRemeasurementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SettlementDateRemeasurementMember_532" xlink:to="lab_mdcx_SettlementDateRemeasurementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_533" xlink:to="lab_mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_534" xlink:to="lab_mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAcceleratedVestingNumber_535" xlink:to="lab_mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAcceleratedVestingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAcceleratedVestingNumber_536" xlink:to="lab_mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAcceleratedVestingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAcceleratedVestingNumber_537" xlink:to="lab_mdcx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAcceleratedVestingNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_538" xlink:to="lab_mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_539" xlink:to="lab_mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_540" xlink:to="lab_mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice_541" xlink:to="lab_mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice_542" xlink:to="lab_mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice_543" xlink:to="lab_mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareBasedCompensationAwardTrancheFiveMember_544" xlink:to="lab_mdcx_ShareBasedCompensationAwardTrancheFiveMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareBasedCompensationAwardTrancheFiveMember_545" xlink:to="lab_mdcx_ShareBasedCompensationAwardTrancheFiveMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareBasedCompensationAwardTrancheFiveMember_546" xlink:to="lab_mdcx_ShareBasedCompensationAwardTrancheFiveMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareBasedCompensationAwardTrancheFourMember_547" xlink:to="lab_mdcx_ShareBasedCompensationAwardTrancheFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareBasedCompensationAwardTrancheFourMember_548" xlink:to="lab_mdcx_ShareBasedCompensationAwardTrancheFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareBasedCompensationAwardTrancheFourMember_549" xlink:to="lab_mdcx_ShareBasedCompensationAwardTrancheFourMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareBasedCompensationAwardTrancheSixMember_550" xlink:to="lab_mdcx_ShareBasedCompensationAwardTrancheSixMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareBasedCompensationAwardTrancheSixMember_551" xlink:to="lab_mdcx_ShareBasedCompensationAwardTrancheSixMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareBasedCompensationAwardTrancheSixMember_552" xlink:to="lab_mdcx_ShareBasedCompensationAwardTrancheSixMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareBasedPaymentAwardGrantDateAxis_553" xlink:to="lab_mdcx_ShareBasedPaymentAwardGrantDateAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareBasedPaymentAwardGrantDateAxis_554" xlink:to="lab_mdcx_ShareBasedPaymentAwardGrantDateAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareBasedPaymentAwardGrantDateDomain_555" xlink:to="lab_mdcx_ShareBasedPaymentAwardGrantDateDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareBasedPaymentAwardGrantDateDomain_556" xlink:to="lab_mdcx_ShareBasedPaymentAwardGrantDateDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_557" xlink:to="lab_mdcx_ShareCapitalNoteDisclosureLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_558" xlink:to="lab_mdcx_ShareCapitalNoteDisclosureLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureTable_559" xlink:to="lab_mdcx_ShareCapitalNoteDisclosureTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureTable_560" xlink:to="lab_mdcx_ShareCapitalNoteDisclosureTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareConsolidationAxis_561" xlink:to="lab_mdcx_ShareConsolidationAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareConsolidationAxis_562" xlink:to="lab_mdcx_ShareConsolidationAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareConsolidationDomain_563" xlink:to="lab_mdcx_ShareConsolidationDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareConsolidationDomain_564" xlink:to="lab_mdcx_ShareConsolidationDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareConsolidationMember_565" xlink:to="lab_mdcx_ShareConsolidationMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareConsolidationMember_566" xlink:to="lab_mdcx_ShareConsolidationMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareIssuanceCosts_567" xlink:to="lab_mdcx_ShareIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareIssuanceCosts_568" xlink:to="lab_mdcx_ShareIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShareIssuanceCosts_569" xlink:to="lab_mdcx_ShareIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SharePriceAsPercentageOfMarketPrice_570" xlink:to="lab_mdcx_SharePriceAsPercentageOfMarketPrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SharePriceAsPercentageOfMarketPrice_571" xlink:to="lab_mdcx_SharePriceAsPercentageOfMarketPrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SharePriceAsPercentageOfMarketPrice_572" xlink:to="lab_mdcx_SharePriceAsPercentageOfMarketPrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SharesIssuedForAcquisitionOfAntev_573" xlink:to="lab_mdcx_SharesIssuedForAcquisitionOfAntev_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SharesIssuedForAcquisitionOfAntev_574" xlink:to="lab_mdcx_SharesIssuedForAcquisitionOfAntev_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SharesIssuedForAcquisitionOfAntev_575" xlink:to="lab_mdcx_SharesIssuedForAcquisitionOfAntev_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SharesIssuedMember_576" xlink:to="lab_mdcx_SharesIssuedMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SharesIssuedMember_577" xlink:to="lab_mdcx_SharesIssuedMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SharesIssuedMember_578" xlink:to="lab_mdcx_SharesIssuedMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SharesIssuedMember_579" xlink:to="lab_mdcx_SharesIssuedMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SharesToBeIssuedForAcquisitionOfAntev_580" xlink:to="lab_mdcx_SharesToBeIssuedForAcquisitionOfAntev_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SharesToBeIssuedForAcquisitionOfAntev_581" xlink:to="lab_mdcx_SharesToBeIssuedForAcquisitionOfAntev_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SharesToBeIssuedForAcquisitionOfAntev_582" xlink:to="lab_mdcx_SharesToBeIssuedForAcquisitionOfAntev_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShortTermIncentivePlanMember_583" xlink:to="lab_mdcx_ShortTermIncentivePlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ShortTermIncentivePlanMember_584" xlink:to="lab_mdcx_ShortTermIncentivePlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SimpleAgreementForFutureEquityMember_585" xlink:to="lab_mdcx_SimpleAgreementForFutureEquityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SimpleAgreementForFutureEquityMember_586" xlink:to="lab_mdcx_SimpleAgreementForFutureEquityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SimpleAgreementForFutureEquityMember_587" xlink:to="lab_mdcx_SimpleAgreementForFutureEquityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SkinjectIncMember_588" xlink:to="lab_mdcx_SkinjectIncMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SkinjectIncMember_589" xlink:to="lab_mdcx_SkinjectIncMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SpecialStockOptionsAndPerformanceShareUnitsMember_590" xlink:to="lab_mdcx_SpecialStockOptionsAndPerformanceShareUnitsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SpecialStockOptionsAndPerformanceShareUnitsMember_591" xlink:to="lab_mdcx_SpecialStockOptionsAndPerformanceShareUnitsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SpecialStockOptionsMember_592" xlink:to="lab_mdcx_SpecialStockOptionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_SpecialStockOptionsMember_593" xlink:to="lab_mdcx_SpecialStockOptionsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StandbyEquityPurchaseAgreementMember_594" xlink:to="lab_mdcx_StandbyEquityPurchaseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StandbyEquityPurchaseAgreementMember_595" xlink:to="lab_mdcx_StandbyEquityPurchaseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StandbyEquityPurchaseAgreementMember_596" xlink:to="lab_mdcx_StandbyEquityPurchaseAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForAmortizedIssuanceCosts_597" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForAmortizedIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForAmortizedIssuanceCosts_598" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForAmortizedIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForAmortizedIssuanceCosts_599" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForAmortizedIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForCompensation_600" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForCompensation_601" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForCompensation_602" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForCompensation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForPsus_603" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForPsus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForPsus_604" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForPsus_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForPsus_605" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForPsus_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits_606" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits_607" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits_608" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits_609" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRestrictedStockUnits_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRsus_610" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRsus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRsus_611" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRsus_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRsus_612" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesCommonStockIssuedForRsus_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts_613" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts_614" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts_615" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing_616" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing_617" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing_618" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithFinancing_619" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithFinancing_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithFinancing_620" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithFinancing_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithFinancing_621" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithFinancing_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithFinancing_622" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithFinancing_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts_623" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts_624" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts_625" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts_626" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts_627" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts_628" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts_629" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_630" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_631" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_632" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_633" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfNotePayable_634" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConversionOfNotePayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfNotePayable_635" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConversionOfNotePayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfNotePayable_636" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConversionOfNotePayable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares_637" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares_638" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares_639" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesExerciseOfWarrants_640" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesExerciseOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesExerciseOfWarrants_641" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesExerciseOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesExerciseOfWarrants_642" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesExerciseOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesForCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_643" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesForCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesForCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_644" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesForCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesForCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_645" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesForCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered_646" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered_647" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered_648" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesOfCommonStock_649" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesOfCommonStock_650" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesOfCommonStock_651" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesOfCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants_652" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants_653" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants_654" xlink:to="lab_mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForAmortizedIssuanceCosts_655" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForAmortizedIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForAmortizedIssuanceCosts_656" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForAmortizedIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForAmortizedIssuanceCosts_657" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForAmortizedIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForCompensation_658" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForCompensation_659" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_660" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_661" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_662" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForOrionEquityInvestmentNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForPsus_663" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForPsus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForPsus_664" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForPsus_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForPsus_665" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForPsus_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRestrictedStockUnits_666" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRestrictedStockUnits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRestrictedStockUnits_667" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRestrictedStockUnits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRestrictedStockUnits_668" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRestrictedStockUnits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRsus_669" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRsus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRsus_670" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRsus_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRsus_671" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueCommonStockIssuedForRsus_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost_672" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost_673" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost_674" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing_675" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing_676" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing_677" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithFinancing_678" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithFinancing_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithFinancing_679" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithFinancing_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithFinancing_680" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithFinancing_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithFinancing_681" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithFinancing_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts_682" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts_683" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts_684" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts_685" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts_686" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts_687" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts_688" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_689" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_690" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_691" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_692" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConversionOfNotePayable_693" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConversionOfNotePayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConversionOfNotePayable_694" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConversionOfNotePayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConversionOfNotePayable_695" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConversionOfNotePayable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConversionOfPreferredShares_696" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConversionOfPreferredShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConversionOfPreferredShares_697" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConversionOfPreferredShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueConversionOfPreferredShares_698" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueConversionOfPreferredShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueExerciseOfWarrants_699" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueExerciseOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueExerciseOfWarrants_700" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueExerciseOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueExerciseOfWarrants_701" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueExerciseOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueForPaymentOfIncomeTaxesRemittedOnRsusAndPsus_702" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueForPaymentOfIncomeTaxesRemittedOnRsusAndPsus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueForPaymentOfIncomeTaxesRemittedOnRsusAndPsus_703" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueForPaymentOfIncomeTaxesRemittedOnRsusAndPsus_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueForPaymentOfIncomeTaxesRemittedOnRsusAndPsus_704" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueForPaymentOfIncomeTaxesRemittedOnRsusAndPsus_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered_705" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered_706" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered_707" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueOfCommonShares_708" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueOfCommonShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueOfCommonShares_709" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueOfCommonShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueOfCommonShares_710" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueOfCommonShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants_711" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants_712" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants_713" xlink:to="lab_mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockOptionsMember_714" xlink:to="lab_mdcx_StockOptionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockOptionsMember_715" xlink:to="lab_mdcx_StockOptionsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockPurchaseWarrantsTerm_716" xlink:to="lab_mdcx_StockPurchaseWarrantsTerm_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockPurchaseWarrantsTerm_717" xlink:to="lab_mdcx_StockPurchaseWarrantsTerm_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_StockPurchaseWarrantsTerm_718" xlink:to="lab_mdcx_StockPurchaseWarrantsTerm_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_TeverelixMember_719" xlink:to="lab_mdcx_TeverelixMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_TeverelixMember_720" xlink:to="lab_mdcx_TeverelixMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ThresholdLimitOfFinancing_721" xlink:to="lab_mdcx_ThresholdLimitOfFinancing_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ThresholdLimitOfFinancing_722" xlink:to="lab_mdcx_ThresholdLimitOfFinancing_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ThresholdLimitOfFinancing_723" xlink:to="lab_mdcx_ThresholdLimitOfFinancing_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_TotalShareholderReturnPerformanceSharesMember_724" xlink:to="lab_mdcx_TotalShareholderReturnPerformanceSharesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_TotalShareholderReturnPerformanceSharesMember_725" xlink:to="lab_mdcx_TotalShareholderReturnPerformanceSharesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_TotalShareholderReturnPerformanceSharesMember_726" xlink:to="lab_mdcx_TotalShareholderReturnPerformanceSharesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_TwoZeroOneNineStockIncentivePlanMember_727" xlink:to="lab_mdcx_TwoZeroOneNineStockIncentivePlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_TwoZeroOneNineStockIncentivePlanMember_728" xlink:to="lab_mdcx_TwoZeroOneNineStockIncentivePlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_TwoZeroOneNineStockIncentivePlanMember_729" xlink:to="lab_mdcx_TwoZeroOneNineStockIncentivePlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_TwoZeroOneThreeStockIncentivePlanMember_730" xlink:to="lab_mdcx_TwoZeroOneThreeStockIncentivePlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_TwoZeroOneThreeStockIncentivePlanMember_731" xlink:to="lab_mdcx_TwoZeroOneThreeStockIncentivePlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_TwoZeroOneThreeStockIncentivePlanMember_732" xlink:to="lab_mdcx_TwoZeroOneThreeStockIncentivePlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_TwoZeroTwoZeroStockIncentivePlanMember_733" xlink:to="lab_mdcx_TwoZeroTwoZeroStockIncentivePlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_TwoZeroTwoZeroStockIncentivePlanMember_734" xlink:to="lab_mdcx_TwoZeroTwoZeroStockIncentivePlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_TwoZeroTwoZeroStockIncentivePlanMember_735" xlink:to="lab_mdcx_TwoZeroTwoZeroStockIncentivePlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement_736" xlink:to="lab_mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement_737" xlink:to="lab_mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement_738" xlink:to="lab_mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_VelocityFundManagementLLCMember_739" xlink:to="lab_mdcx_VelocityFundManagementLLCMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_VelocityFundManagementLLCMember_740" xlink:to="lab_mdcx_VelocityFundManagementLLCMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_VelocityFundManagementLLCMember_741" xlink:to="lab_mdcx_VelocityFundManagementLLCMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_VestUponCommonSharesAchievingCertainVolumeWeightedAverageTradingPricesMember_742" xlink:to="lab_mdcx_VestUponCommonSharesAchievingCertainVolumeWeightedAverageTradingPricesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_VestUponCommonSharesAchievingCertainVolumeWeightedAverageTradingPricesMember_743" xlink:to="lab_mdcx_VestUponCommonSharesAchievingCertainVolumeWeightedAverageTradingPricesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WarrantLiabilityIssuedDuringPeriod_744" xlink:to="lab_mdcx_WarrantLiabilityIssuedDuringPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WarrantLiabilityIssuedDuringPeriod_745" xlink:to="lab_mdcx_WarrantLiabilityIssuedDuringPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WarrantLiabilityIssuedDuringPeriod_746" xlink:to="lab_mdcx_WarrantLiabilityIssuedDuringPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WarrantLiabilityIssuedDuringPeriod_747" xlink:to="lab_mdcx_WarrantLiabilityIssuedDuringPeriod_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WarrantsIssuedAsPartOfIpoMember_748" xlink:to="lab_mdcx_WarrantsIssuedAsPartOfIpoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WarrantsIssuedAsPartOfIpoMember_749" xlink:to="lab_mdcx_WarrantsIssuedAsPartOfIpoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WarrantsIssuedAsPartOfIpoMember_750" xlink:to="lab_mdcx_WarrantsIssuedAsPartOfIpoMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WarrantsIssuedUnderWarrantInducement_751" xlink:to="lab_mdcx_WarrantsIssuedUnderWarrantInducement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WarrantsIssuedUnderWarrantInducement_752" xlink:to="lab_mdcx_WarrantsIssuedUnderWarrantInducement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WarrantsIssuedUnderWarrantInducement_753" xlink:to="lab_mdcx_WarrantsIssuedUnderWarrantInducement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WarrantWithExpiryDateJune302030WarrantsMember_754" xlink:to="lab_mdcx_WarrantWithExpiryDateJune302030WarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WarrantWithExpiryDateJune302030WarrantsMember_755" xlink:to="lab_mdcx_WarrantWithExpiryDateJune302030WarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WarrantWithExpiryDateJune302030WarrantsMember_756" xlink:to="lab_mdcx_WarrantWithExpiryDateJune302030WarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WarrantWithExpiryDateMarch102030Member_757" xlink:to="lab_mdcx_WarrantWithExpiryDateMarch102030Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WarrantWithExpiryDateMarch102030Member_758" xlink:to="lab_mdcx_WarrantWithExpiryDateMarch102030Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WarrantWithExpiryDateMarch102030Member_759" xlink:to="lab_mdcx_WarrantWithExpiryDateMarch102030Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WeightedAverageExercisePriceOfWarrant_760" xlink:to="lab_mdcx_WeightedAverageExercisePriceOfWarrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WeightedAverageExercisePriceOfWarrant_761" xlink:to="lab_mdcx_WeightedAverageExercisePriceOfWarrant_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WeightedAverageExercisePriceOfWarrant_762" xlink:to="lab_mdcx_WeightedAverageExercisePriceOfWarrant_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WeightedAverageExercisePriceOfWarrant_763" xlink:to="lab_mdcx_WeightedAverageExercisePriceOfWarrant_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WeightedAverageExercisePriceWarrantExercise_764" xlink:to="lab_mdcx_WeightedAverageExercisePriceWarrantExercise_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WeightedAverageExercisePriceWarrantExercise_765" xlink:to="lab_mdcx_WeightedAverageExercisePriceWarrantExercise_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WeightedAverageExercisePriceWarrantExercise_766" xlink:to="lab_mdcx_WeightedAverageExercisePriceWarrantExercise_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WeightedAverageExercisePriceWarrantGranted_767" xlink:to="lab_mdcx_WeightedAverageExercisePriceWarrantGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WeightedAverageExercisePriceWarrantGranted_768" xlink:to="lab_mdcx_WeightedAverageExercisePriceWarrantGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WeightedAverageExercisePriceWarrantGranted_769" xlink:to="lab_mdcx_WeightedAverageExercisePriceWarrantGranted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WeightedAverageRemainingContractualTermOfWarrant_770" xlink:to="lab_mdcx_WeightedAverageRemainingContractualTermOfWarrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WeightedAverageRemainingContractualTermOfWarrant_771" xlink:to="lab_mdcx_WeightedAverageRemainingContractualTermOfWarrant_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WeightedAverageRemainingContractualTermOfWarrant_772" xlink:to="lab_mdcx_WeightedAverageRemainingContractualTermOfWarrant_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted_773" xlink:to="lab_mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted_774" xlink:to="lab_mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted_775" xlink:to="lab_mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WithholdingOfEmployeeTaxPaymentsOnRestrictedStockUnits_776" xlink:to="lab_mdcx_WithholdingOfEmployeeTaxPaymentsOnRestrictedStockUnits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WithholdingOfEmployeeTaxPaymentsOnRestrictedStockUnits_777" xlink:to="lab_mdcx_WithholdingOfEmployeeTaxPaymentsOnRestrictedStockUnits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_WithholdingOfEmployeeTaxPaymentsOnRestrictedStockUnits_778" xlink:to="lab_mdcx_WithholdingOfEmployeeTaxPaymentsOnRestrictedStockUnits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_YaIiPnLtdMember_779" xlink:to="lab_mdcx_YaIiPnLtdMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_YaIiPnLtdMember_780" xlink:to="lab_mdcx_YaIiPnLtdMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_YaIiPnLtdMember_781" xlink:to="lab_mdcx_YaIiPnLtdMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_YaIiPnLtdMember_782" xlink:to="lab_mdcx_YaIiPnLtdMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_YorkvilleMember_783" xlink:to="lab_mdcx_YorkvilleMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mdcx_YorkvilleMember_784" xlink:to="lab_mdcx_YorkvilleMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember_785" xlink:to="lab_srt_ChiefExecutiveOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember_786" xlink:to="lab_srt_ChiefExecutiveOfficerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember_787" xlink:to="lab_srt_ChiefExecutiveOfficerMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember_788" xlink:to="lab_srt_ChiefFinancialOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember_789" xlink:to="lab_srt_ChiefFinancialOfficerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember_790" xlink:to="lab_srt_ChiefFinancialOfficerMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis_791" xlink:to="lab_srt_ConsolidationItemsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain_792" xlink:to="lab_srt_ConsolidationItemsDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ManagementMember_793" xlink:to="lab_srt_ManagementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ManagementMember_794" xlink:to="lab_srt_ManagementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_795" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_796" xlink:to="lab_srt_MaximumMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_797" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_798" xlink:to="lab_srt_MinimumMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_799" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_800" xlink:to="lab_srt_RangeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_801" xlink:to="lab_srt_SegmentGeographicalDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_802" xlink:to="lab_srt_StatementGeographicalAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_803" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_804" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_805" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_806" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_807" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_808" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_809" xlink:to="lab_us-gaap_AccountsPayableCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_810" xlink:to="lab_us-gaap_AccountsPayableCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_811" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_812" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_813" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_814" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_815" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_816" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_817" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_818" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_819" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_820" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_821" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_822" xlink:to="lab_us-gaap_AdditionalPaidInCapital_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_823" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_824" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_825" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_826" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_827" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_828" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_829" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_830" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_831" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_832" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_833" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_834" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_835" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_836" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_837" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_838" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred_839" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred_840" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred_841" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_842" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_843" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_844" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_845" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_846" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_847" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTableTextBlock_848" xlink:to="lab_us-gaap_AssetAcquisitionTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTableTextBlock_849" xlink:to="lab_us-gaap_AssetAcquisitionTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_850" xlink:to="lab_us-gaap_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_851" xlink:to="lab_us-gaap_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_852" xlink:to="lab_us-gaap_Assets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_853" xlink:to="lab_us-gaap_AssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_854" xlink:to="lab_us-gaap_AssetsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_855" xlink:to="lab_us-gaap_AssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_856" xlink:to="lab_us-gaap_AssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_857" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_858" xlink:to="lab_us-gaap_AssetsCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_859" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_860" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_861" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_862" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_863" xlink:to="lab_us-gaap_AwardTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_864" xlink:to="lab_us-gaap_AwardTypeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_865" xlink:to="lab_us-gaap_AwardTypeAxis_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_866" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_867" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_868" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription_869" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription_870" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_871" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_872" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_873" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_874" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_875" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_876" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice_877" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice_878" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_879" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_880" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_881" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_882" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_883" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_884" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_885" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_886" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_887" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_888" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_889" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_890" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_891" xlink:to="lab_us-gaap_Cash_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_892" xlink:to="lab_us-gaap_Cash_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_893" xlink:to="lab_us-gaap_Cash_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_894" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_895" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_896" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_897" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_898" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_899" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_900" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_901" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_902" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_903" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_904" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_905" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_906" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_907" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_908" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_909" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_910" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_911" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_912" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_913" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_914" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_915" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_916" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_917" xlink:to="lab_us-gaap_ClassOfStockDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_918" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_919" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_920" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_921" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_922" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_923" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_924" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_925" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_926" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_927" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_928" xlink:to="lab_us-gaap_CommitmentsAndContingencies_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_929" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_930" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_931" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockConversionBasis_932" xlink:to="lab_us-gaap_CommonStockConversionBasis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockConversionBasis_933" xlink:to="lab_us-gaap_CommonStockConversionBasis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_934" xlink:to="lab_us-gaap_CommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_935" xlink:to="lab_us-gaap_CommonStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue_936" xlink:to="lab_us-gaap_CommonStockNoParValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue_937" xlink:to="lab_us-gaap_CommonStockNoParValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_938" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_939" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_940" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_941" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_942" xlink:to="lab_us-gaap_CommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_943" xlink:to="lab_us-gaap_CommonStockSharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_944" xlink:to="lab_us-gaap_CommonStockSharesIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_945" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_946" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_947" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_948" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_949" xlink:to="lab_us-gaap_CommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_950" xlink:to="lab_us-gaap_CommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_951" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_952" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_953" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_954" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_955" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_956" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_957" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_958" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_959" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_960" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_961" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_962" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_963" xlink:to="lab_us-gaap_ConversionOfStockNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1_964" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1_965" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1_966" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1_967" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock_968" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock_969" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember_970" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember_971" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember_972" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_973" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_974" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_975" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_976" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_977" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_978" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_979" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_980" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_981" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_982" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionDescription_983" xlink:to="lab_us-gaap_DebtConversionDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionDescription_984" xlink:to="lab_us-gaap_DebtConversionDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtAmount1_985" xlink:to="lab_us-gaap_DebtConversionOriginalDebtAmount1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtAmount1_986" xlink:to="lab_us-gaap_DebtConversionOriginalDebtAmount1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear_987" xlink:to="lab_us-gaap_DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear_988" xlink:to="lab_us-gaap_DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_989" xlink:to="lab_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_990" xlink:to="lab_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_991" xlink:to="lab_us-gaap_DebtCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_992" xlink:to="lab_us-gaap_DebtCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_993" xlink:to="lab_us-gaap_DebtCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_994" xlink:to="lab_us-gaap_DebtCurrent_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_995" xlink:to="lab_us-gaap_DebtCurrent_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_996" xlink:to="lab_us-gaap_DebtCurrent_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_997" xlink:to="lab_us-gaap_DebtDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_998" xlink:to="lab_us-gaap_DebtInstrumentAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_999" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1000" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_1001" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_1002" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_1003" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_1004" xlink:to="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_1005" xlink:to="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1006" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1007" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentIssuedPrincipal_1008" xlink:to="lab_us-gaap_DebtInstrumentIssuedPrincipal_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentIssuedPrincipal_1009" xlink:to="lab_us-gaap_DebtInstrumentIssuedPrincipal_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1010" xlink:to="lab_us-gaap_DebtInstrumentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate_1011" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate_1012" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1013" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_1014" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_1015" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_1016" xlink:to="lab_us-gaap_DebtInstrumentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1017" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1018" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1019" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1020" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault_1021" xlink:to="lab_us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault_1022" xlink:to="lab_us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCurrent_1023" xlink:to="lab_us-gaap_DeferredCostsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1024" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1025" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1026" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1027" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1028" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1029" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetInterestCarryforward_1030" xlink:to="lab_us-gaap_DeferredTaxAssetInterestCarryforward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetInterestCarryforward_1031" xlink:to="lab_us-gaap_DeferredTaxAssetInterestCarryforward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_1032" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_1033" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1034" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1035" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1036" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1037" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1038" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1039" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1040" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1041" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1042" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1043" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1044" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_1045" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_1046" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_1047" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_1048" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_1049" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_1050" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_1051" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_1052" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_1053" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_1054" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_1055" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_1056" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1057" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1058" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1059" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_1060" xlink:to="lab_us-gaap_Depreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_1061" xlink:to="lab_us-gaap_Depreciation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1062" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1063" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1064" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_1065" xlink:to="lab_us-gaap_DomesticCountryMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_1066" xlink:to="lab_us-gaap_DomesticCountryMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1067" xlink:to="lab_us-gaap_EarningsPerShareAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_1068" xlink:to="lab_us-gaap_EarningsPerShareBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_1069" xlink:to="lab_us-gaap_EarningsPerShareBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_1070" xlink:to="lab_us-gaap_EarningsPerShareBasic_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_1071" xlink:to="lab_us-gaap_EarningsPerShareDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_1072" xlink:to="lab_us-gaap_EarningsPerShareDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_1073" xlink:to="lab_us-gaap_EarningsPerShareDiluted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_1074" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_1075" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1076" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1077" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1078" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1079" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1080" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1081" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1082" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1083" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1084" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1085" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1086" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_1087" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_1088" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_1089" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_1090" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_1091" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1092" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1093" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_1094" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1095" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1096" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1097" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1098" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1099" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1100" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1101" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1102" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1103" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_1104" xlink:to="lab_us-gaap_EmployeeStockOptionMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_1105" xlink:to="lab_us-gaap_EmployeeStockOptionMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_1106" xlink:to="lab_us-gaap_EmployeeStockOptionMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_1107" xlink:to="lab_us-gaap_EquityComponentDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1108" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1109" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1110" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1111" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1112" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1113" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1114" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1115" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1116" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1117" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1118" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1119" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_1120" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_1121" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_1122" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_1123" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_1124" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_1125" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_1126" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_1127" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1128" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1129" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_1130" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1131" xlink:to="lab_us-gaap_FinancialInstrumentAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_1132" xlink:to="lab_us-gaap_ForeignCountryMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_1133" xlink:to="lab_us-gaap_ForeignCountryMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_1134" xlink:to="lab_us-gaap_ForeignCountryMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1135" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1136" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_1137" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_1138" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_1139" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1140" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1141" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1142" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1143" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1144" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1145" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_1146" xlink:to="lab_us-gaap_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1147" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1148" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1149" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1150" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1151" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_1152" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_1153" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1154" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1155" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1156" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1157" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1158" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1159" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1160" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1161" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1162" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1163" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1164" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1165" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1166" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_1167" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_1168" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_1169" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_1170" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1171" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1172" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1173" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_1174" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_1175" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_1176" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1177" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1178" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1179" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1180" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1181" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1182" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1183" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_1184" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_1185" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1186" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1187" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1188" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1189" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1190" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1191" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1192" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1193" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_1194" xlink:to="lab_us-gaap_InterestExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_1195" xlink:to="lab_us-gaap_InterestExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_1196" xlink:to="lab_us-gaap_InterestExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_1197" xlink:to="lab_us-gaap_InterestExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_1198" xlink:to="lab_us-gaap_InterestExpense_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_1199" xlink:to="lab_us-gaap_InterestExpenseDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_1200" xlink:to="lab_us-gaap_InterestExpenseDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_1201" xlink:to="lab_us-gaap_InterestPaidNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_1202" xlink:to="lab_us-gaap_InterestPaidNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_1203" xlink:to="lab_us-gaap_InterestPaidNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent_1204" xlink:to="lab_us-gaap_InterestPayableCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent_1205" xlink:to="lab_us-gaap_InterestPayableCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent_1206" xlink:to="lab_us-gaap_InterestPayableCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentCompanyNonconsolidatedSubsidiaryAxis_1207" xlink:to="lab_us-gaap_InvestmentCompanyNonconsolidatedSubsidiaryAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentCompanyNonconsolidatedSubsidiaryDomain_1208" xlink:to="lab_us-gaap_InvestmentCompanyNonconsolidatedSubsidiaryDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet_1209" xlink:to="lab_us-gaap_InvestmentIncomeNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet_1210" xlink:to="lab_us-gaap_InvestmentIncomeNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet_1211" xlink:to="lab_us-gaap_InvestmentIncomeNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_1212" xlink:to="lab_us-gaap_IPOMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_1213" xlink:to="lab_us-gaap_IPOMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense_1214" xlink:to="lab_us-gaap_LaborAndRelatedExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense_1215" xlink:to="lab_us-gaap_LaborAndRelatedExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_1216" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_1217" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_1218" xlink:to="lab_us-gaap_LeasesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees_1219" xlink:to="lab_us-gaap_LegalFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees_1220" xlink:to="lab_us-gaap_LegalFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate_1221" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate_1222" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1223" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1224" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1225" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1226" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1227" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1228" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1229" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1230" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1231" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1232" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1233" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_1234" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_1235" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_1236" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_1237" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_1238" xlink:to="lab_us-gaap_Liabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_1239" xlink:to="lab_us-gaap_Liabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1240" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1241" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1242" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1243" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_1244" xlink:to="lab_us-gaap_LiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_1245" xlink:to="lab_us-gaap_LiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1246" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1247" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_1248" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_1249" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1250" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1251" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock_1252" xlink:to="lab_us-gaap_LongTermDebtTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock_1253" xlink:to="lab_us-gaap_LongTermDebtTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1254" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1255" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLoansPayable_1256" xlink:to="lab_us-gaap_LongTermLoansPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLoansPayable_1257" xlink:to="lab_us-gaap_LongTermLoansPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLoansPayable_1258" xlink:to="lab_us-gaap_LongTermLoansPayable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExercisePriceMember_1259" xlink:to="lab_us-gaap_MeasurementInputExercisePriceMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExercisePriceMember_1260" xlink:to="lab_us-gaap_MeasurementInputExercisePriceMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1261" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1262" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_1263" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_1264" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_1265" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember_1266" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember_1267" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1268" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1269" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1270" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1271" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_1272" xlink:to="lab_us-gaap_MinorityInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_1273" xlink:to="lab_us-gaap_MinorityInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsAtCarryingValue_1274" xlink:to="lab_us-gaap_MoneyMarketFundsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsAtCarryingValue_1275" xlink:to="lab_us-gaap_MoneyMarketFundsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1276" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1277" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1278" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1279" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1280" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1281" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1282" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1283" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1284" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1285" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1286" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1287" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1288" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1289" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_1290" xlink:to="lab_us-gaap_NetIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_1291" xlink:to="lab_us-gaap_NetIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_1292" xlink:to="lab_us-gaap_NetIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_1293" xlink:to="lab_us-gaap_NetIncomeLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_1294" xlink:to="lab_us-gaap_NetIncomeLoss_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract_1295" xlink:to="lab_us-gaap_NetIncomeLossAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract_1296" xlink:to="lab_us-gaap_NetIncomeLossAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1297" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1298" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1299" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1300" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_1301" xlink:to="lab_us-gaap_NoncontrollingInterestMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_1302" xlink:to="lab_us-gaap_NoncontrollingInterestMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable_1303" xlink:to="lab_us-gaap_NotesPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable_1304" xlink:to="lab_us-gaap_NotesPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable_1305" xlink:to="lab_us-gaap_NotesPayable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_1306" xlink:to="lab_us-gaap_NumberOfOperatingSegments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_1307" xlink:to="lab_us-gaap_NumberOfOperatingSegments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_1308" xlink:to="lab_us-gaap_NumberOfReportableSegments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_1309" xlink:to="lab_us-gaap_NumberOfReportableSegments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_1310" xlink:to="lab_us-gaap_OperatingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_1311" xlink:to="lab_us-gaap_OperatingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_1312" xlink:to="lab_us-gaap_OperatingExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1313" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1314" xlink:to="lab_us-gaap_OperatingExpensesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_1315" xlink:to="lab_us-gaap_OperatingIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_1316" xlink:to="lab_us-gaap_OperatingIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_1317" xlink:to="lab_us-gaap_OperatingIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_1318" xlink:to="lab_us-gaap_OperatingIncomeLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense_1319" xlink:to="lab_us-gaap_OperatingLeaseExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense_1320" xlink:to="lab_us-gaap_OperatingLeaseExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_1321" xlink:to="lab_us-gaap_OperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_1322" xlink:to="lab_us-gaap_OperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_1323" xlink:to="lab_us-gaap_OperatingLeaseLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_1324" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_1325" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_1326" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1327" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1328" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1329" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_1330" xlink:to="lab_us-gaap_OperatingLeasePayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_1331" xlink:to="lab_us-gaap_OperatingLeasePayments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_1332" xlink:to="lab_us-gaap_OperatingLeasePayments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_1333" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_1334" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_1335" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1336" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1337" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1338" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1339" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1340" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1341" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1342" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_1343" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_1344" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_1345" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_1346" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_1347" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_1348" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeMember_1349" xlink:to="lab_us-gaap_OtherIncomeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeMember_1350" xlink:to="lab_us-gaap_OtherIncomeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities_1351" xlink:to="lab_us-gaap_OtherLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities_1352" xlink:to="lab_us-gaap_OtherLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities_1353" xlink:to="lab_us-gaap_OtherLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities_1354" xlink:to="lab_us-gaap_OtherLiabilities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_1355" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_1356" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_1357" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_1358" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_1359" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_1360" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_1361" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest_1362" xlink:to="lab_us-gaap_PaidInKindInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest_1363" xlink:to="lab_us-gaap_PaidInKindInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1364" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1365" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1366" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1367" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1368" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts_1369" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts_1370" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_1371" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_1372" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_1373" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_1374" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_1375" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_1376" xlink:to="lab_us-gaap_PlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleConversionRatio_1377" xlink:to="lab_us-gaap_PreferredStockConvertibleConversionRatio_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleConversionRatio_1378" xlink:to="lab_us-gaap_PreferredStockConvertibleConversionRatio_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendRatePercentage_1379" xlink:to="lab_us-gaap_PreferredStockDividendRatePercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendRatePercentage_1380" xlink:to="lab_us-gaap_PreferredStockDividendRatePercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_1381" xlink:to="lab_us-gaap_PreferredStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_1382" xlink:to="lab_us-gaap_PreferredStockSharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_1383" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_1384" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_1385" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_1386" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_1387" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance_1388" xlink:to="lab_us-gaap_PrepaidInsurance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance_1389" xlink:to="lab_us-gaap_PrepaidInsurance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_1390" xlink:to="lab_us-gaap_PrivatePlacementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_1391" xlink:to="lab_us-gaap_PrivatePlacementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1392" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1393" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1394" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1395" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1396" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1397" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1398" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt_1399" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt_1400" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt_1401" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt_1402" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt_1403" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1404" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1405" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1406" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1407" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1408" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1409" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1410" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1411" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable_1412" xlink:to="lab_us-gaap_ProceedsFromNotesPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable_1413" xlink:to="lab_us-gaap_ProceedsFromNotesPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable_1414" xlink:to="lab_us-gaap_ProceedsFromNotesPayable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_1415" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_1416" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_1417" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_1418" xlink:to="lab_us-gaap_ProfitLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_1419" xlink:to="lab_us-gaap_ProfitLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_1420" xlink:to="lab_us-gaap_ProfitLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_1421" xlink:to="lab_us-gaap_ProfitLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_1422" xlink:to="lab_us-gaap_ProfitLoss_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember_1423" xlink:to="lab_us-gaap_ProjectMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_1424" xlink:to="lab_us-gaap_RelatedPartyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1425" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1426" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1427" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1428" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1429" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1430" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1431" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1432" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_1433" xlink:to="lab_us-gaap_RepaymentsOfDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_1434" xlink:to="lab_us-gaap_RepaymentsOfDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_1435" xlink:to="lab_us-gaap_RepaymentsOfDebt_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_1436" xlink:to="lab_us-gaap_RepaymentsOfDebt_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_1437" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_1438" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_1439" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1440" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1441" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_1442" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_1443" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_1444" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_1445" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_1446" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_1447" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1448" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1449" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedAssetsDisclosureTextBlock_1450" xlink:to="lab_us-gaap_RestrictedAssetsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedAssetsDisclosureTextBlock_1451" xlink:to="lab_us-gaap_RestrictedAssetsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1452" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1453" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1454" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1455" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent_1456" xlink:to="lab_us-gaap_RestrictedCashCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent_1457" xlink:to="lab_us-gaap_RestrictedCashCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent_1458" xlink:to="lab_us-gaap_RestrictedCashNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent_1459" xlink:to="lab_us-gaap_RestrictedCashNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1460" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1461" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1462" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_1463" xlink:to="lab_us-gaap_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_1464" xlink:to="lab_us-gaap_RetainedEarningsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesWagesAndOfficersCompensation_1465" xlink:to="lab_us-gaap_SalariesWagesAndOfficersCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesWagesAndOfficersCompensation_1466" xlink:to="lab_us-gaap_SalariesWagesAndOfficersCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1467" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1468" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1469" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1470" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_1471" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_1472" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_1473" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1474" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1475" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1476" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1477" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1478" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1479" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock_1480" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock_1481" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1482" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_1483" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_1484" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1485" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1486" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1487" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1488" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1489" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1490" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1491" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1492" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1493" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1494" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1495" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1496" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1497" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1498" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1499" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1500" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1501" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1502" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1503" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_1504" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_1505" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1506" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1507" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1508" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_1509" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_1510" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_1511" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_1512" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1513" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1514" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1515" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1516" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1517" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_1518" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1519" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1520" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1521" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1522" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtCurrent_1523" xlink:to="lab_us-gaap_SecuredDebtCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtCurrent_1524" xlink:to="lab_us-gaap_SecuredDebtCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredLongTermDebt_1525" xlink:to="lab_us-gaap_SecuredLongTermDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredLongTermDebt_1526" xlink:to="lab_us-gaap_SecuredLongTermDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredLongTermDebt_1527" xlink:to="lab_us-gaap_SecuredLongTermDebt_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_1528" xlink:to="lab_us-gaap_SegmentReportingAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_1529" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_1530" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1531" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1532" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1533" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1534" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1535" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_1536" xlink:to="lab_us-gaap_ShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_1537" xlink:to="lab_us-gaap_ShareBasedCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_1538" xlink:to="lab_us-gaap_ShareBasedCompensation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_1539" xlink:to="lab_us-gaap_ShareBasedCompensation_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_1540" xlink:to="lab_us-gaap_ShareBasedCompensation_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_1541" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_1542" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_1543" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_1544" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1545" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1546" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1547" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1548" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1549" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1550" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1551" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1552" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1553" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1554" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1555" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1556" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1557" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1558" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1559" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1560" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1561" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1562" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1563" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1564" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1565" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1566" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1567" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1568" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1569" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1570" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1571" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1572" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1573" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1574" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_1575" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_1576" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1577" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1578" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_1579" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_1580" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1581" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1582" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1583" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1584" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1585" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1586" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1587" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1588" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1589" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1590" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1591" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1592" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1593" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1594" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1595" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1596" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1597" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1598" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1599" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1600" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1601" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1602" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1603" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1604" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1605" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1606" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1607" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1608" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1609" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1610" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1611" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1612" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1613" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1614" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1615" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1616" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1617" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1618" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1619" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1620" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1621" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1622" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1623" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1624" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1625" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1626" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1627" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1628" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1629" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1630" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1631" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_1632" xlink:to="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_1633" xlink:to="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_1634" xlink:to="lab_us-gaap_SharePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_1635" xlink:to="lab_us-gaap_SharePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_1636" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_1637" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_1638" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_1639" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1640" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_1641" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1642" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1643" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1644" xlink:to="lab_us-gaap_StatementClassOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1645" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_1646" xlink:to="lab_us-gaap_StatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1647" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1648" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1649" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_1650" xlink:to="lab_us-gaap_StatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_1651" xlink:to="lab_us-gaap_StockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_1652" xlink:to="lab_us-gaap_StockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1653" xlink:to="lab_us-gaap_StockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1654" xlink:to="lab_us-gaap_StockholdersEquityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1655" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1656" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1657" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1658" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1659" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1660" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1661" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityReverseStockSplit_1662" xlink:to="lab_us-gaap_StockholdersEquityReverseStockSplit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityReverseStockSplit_1663" xlink:to="lab_us-gaap_StockholdersEquityReverseStockSplit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityReverseStockSplit_1664" xlink:to="lab_us-gaap_StockholdersEquityReverseStockSplit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1665" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1666" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1667" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1668" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1669" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1670" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1671" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1672" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1673" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1674" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1675" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1676" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1677" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1678" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1679" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1680" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1681" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1682" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1683" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1684" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1685" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1686" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1687" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1688" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1689" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1690" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1691" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1692" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_1693" xlink:to="lab_us-gaap_SubsequentEventLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_1694" xlink:to="lab_us-gaap_SubsequentEventMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_1695" xlink:to="lab_us-gaap_SubsequentEventMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1696" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_1697" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_1698" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_1699" xlink:to="lab_us-gaap_SubsequentEventTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1700" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1701" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1702" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1703" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1704" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1705" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1706" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_1707" xlink:to="lab_us-gaap_SupplementalIncomeStatementElementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1708" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1709" xlink:to="lab_us-gaap_TypeOfArrangementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_1710" xlink:to="lab_us-gaap_UseOfEstimates_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_1711" xlink:to="lab_us-gaap_UseOfEstimates_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis_1712" xlink:to="lab_us-gaap_VestingAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_1713" xlink:to="lab_us-gaap_VestingDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_1714" xlink:to="lab_us-gaap_WarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_1715" xlink:to="lab_us-gaap_WarrantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_1716" xlink:to="lab_us-gaap_WarrantMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_1717" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1718" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1719" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1720" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1721" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1722" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1723" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1724" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1725" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember_1726" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember_1727" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember_1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>mdcx-20260630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#idr_DocumentDocumentAndEntityInformation" roleURI="http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#idr_BalanceSheets" roleURI="http://www.medicuspharma.com/role/idr_BalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#idr_BalanceSheetsParenthetical" roleURI="http://www.medicuspharma.com/role/idr_BalanceSheetsParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#idr_StatementsOfOperations" roleURI="http://www.medicuspharma.com/role/idr_StatementsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#idr_StatementsOfChangesInShareholdersDeficit" roleURI="http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical" roleURI="http://www.medicuspharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#idr_StatementsOfCashFlows" roleURI="http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#DescriptionOfBusiness" roleURI="http://www.medicuspharma.com/role/DescriptionOfBusiness"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#BalanceSheetComponents" roleURI="http://www.medicuspharma.com/role/BalanceSheetComponents"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#Leases" roleURI="http://www.medicuspharma.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#ShareCapital" roleURI="http://www.medicuspharma.com/role/ShareCapital"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#StockBasedCompensation" roleURI="http://www.medicuspharma.com/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#RelatedPartyTransactions" roleURI="http://www.medicuspharma.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#FairValueMeasurements" roleURI="http://www.medicuspharma.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#CommitmentAndContingencies" roleURI="http://www.medicuspharma.com/role/CommitmentAndContingencies"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#SegmentReporting" roleURI="http://www.medicuspharma.com/role/SegmentReporting"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#Debentures" roleURI="http://www.medicuspharma.com/role/Debentures"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#RestrictedCash" roleURI="http://www.medicuspharma.com/role/RestrictedCash"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#Liquidity" roleURI="http://www.medicuspharma.com/role/Liquidity"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#LossPerShare" roleURI="http://www.medicuspharma.com/role/LossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#SubsequentEvents" roleURI="http://www.medicuspharma.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#BalanceSheetComponentsTables" roleURI="http://www.medicuspharma.com/role/BalanceSheetComponentsTables"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#LeasesTables" roleURI="http://www.medicuspharma.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#ShareCapitalTables" roleURI="http://www.medicuspharma.com/role/ShareCapitalTables"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#StockBasedCompensationTables" roleURI="http://www.medicuspharma.com/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#FairValueMeasurementTables" roleURI="http://www.medicuspharma.com/role/FairValueMeasurementTables"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#CommitmentsAndContingenciesTables" roleURI="http://www.medicuspharma.com/role/CommitmentsAndContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#ResearchAndDevelopmentRDExpensesTables" roleURI="http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#DebenturesTables" roleURI="http://www.medicuspharma.com/role/DebenturesTables"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#LossPerShareTables" roleURI="http://www.medicuspharma.com/role/LossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#TESTTESTTESTTables" roleURI="http://www.medicuspharma.com/role/TESTTESTTESTTables"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#BalanceSheetComponentsDetails" roleURI="http://www.medicuspharma.com/role/BalanceSheetComponentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#BalanceSheetComponentsDetails1" roleURI="http://www.medicuspharma.com/role/BalanceSheetComponentsDetails1"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#LeasesDetails" roleURI="http://www.medicuspharma.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#LeasesDetails1" roleURI="http://www.medicuspharma.com/role/LeasesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#LeasesDetails2" roleURI="http://www.medicuspharma.com/role/LeasesDetails2"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#ShareCapitalNarrativeDetails" roleURI="http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#ShareCapitalDetails" roleURI="http://www.medicuspharma.com/role/ShareCapitalDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#ShareCapitalScheduleOfWarrantsContinuityDetails" roleURI="http://www.medicuspharma.com/role/ShareCapitalScheduleOfWarrantsContinuityDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#ShareCapitalDetails1" roleURI="http://www.medicuspharma.com/role/ShareCapitalDetails1"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#StockBasedCompensationNarrativeDetails" roleURI="http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#StockBasedCompensationScheduleOfStockOptionActivityDetails" roleURI="http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#StockBasedCompensationScheduleOfWeightedaverageAssumptionsToDetermineFairValueOfStockOptionsGrantedDetails" roleURI="http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfWeightedaverageAssumptionsToDetermineFairValueOfStockOptionsGrantedDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#RelatedPartyTransactionsNarrativeDetails" roleURI="http://www.medicuspharma.com/role/RelatedPartyTransactionsNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#FairValueMeasurementsNarrativeDetails" roleURI="http://www.medicuspharma.com/role/FairValueMeasurementsNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#FairValueMeasurementDetails" roleURI="http://www.medicuspharma.com/role/FairValueMeasurementDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#CommitmentsAndContingenciesN" roleURI="http://www.medicuspharma.com/role/CommitmentsAndContingenciesN"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails" roleURI="http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#SegmentReportingNarrativeDetails" roleURI="http://www.medicuspharma.com/role/SegmentReportingNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#ResearchAndDevelopmentRDExpensesDetails" roleURI="http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#DebenturesNarrativeDetails" roleURI="http://www.medicuspharma.com/role/DebenturesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#DebenturesScheduleOfDebentureContinuityDetails" roleURI="http://www.medicuspharma.com/role/DebenturesScheduleOfDebentureContinuityDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#DebenturesAndPromissoryNotesNdfd" roleURI="http://www.medicuspharma.com/role/DebenturesAndPromissoryNotesNdfd"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#RestrictedCashNarrativeDetails" roleURI="http://www.medicuspharma.com/role/RestrictedCashNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#LossPerShareDetails" roleURI="http://www.medicuspharma.com/role/LossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#TESTTESTTESTDetails" roleURI="http://www.medicuspharma.com/role/TESTTESTTESTDetails"/>
  <roleRef xlink:type="simple" xlink:href="mdcx-20260630.xsd#SubsequentEventsNarrativeDetails" roleURI="http://www.medicuspharma.com/role/SubsequentEventsNarrativeDetails"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentDescription" xlink:label="loc_dei_DocumentDescription_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_dei_DocumentPeriodStartDate_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PhoneFaxNumberDescription" xlink:label="loc_dei_PhoneFaxNumberDescription_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12gTitle" xlink:label="loc_dei_Security12gTitle_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityListingParValuePerShare" xlink:label="loc_dei_EntityListingParValuePerShare_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_dei_NoTradingSymbolFlag_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_dei_AuditorOpinionTextBlock_51"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_WarrantMember_2" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_5" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityRegistrantName_5" order="7.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityCentralIndexKey_6" order="8.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_CurrentFiscalYearEndDate_7" order="9.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_DocumentType_8" order="10.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_DocumentAnnualReport_9" order="11.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_DocumentQuarterlyReport_10" order="12.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_DocumentDescription_11" order="13.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityFileNumber_12" order="14.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_DocumentPeriodStartDate_13" order="15.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_14" order="16.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_DocumentPeriodEndDate_15" order="17.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_DocumentFiscalYearFocus_16" order="18.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_17" order="19.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_18" order="20.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityTaxIdentificationNumber_19" order="21.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityAddressAddressLine1_20" order="22.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityAddressAddressLine2_21" order="23.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityAddressCityOrTown_22" order="24.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityAddressStateOrProvince_23" order="25.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityAddressPostalZipCode_24" order="26.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_CityAreaCode_25" order="27.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_LocalPhoneNumber_26" order="28.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_PhoneFaxNumberDescription_27" order="29.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_Security12gTitle_28" order="30.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_TradingSymbol_29" order="31.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_SecurityExchangeName_30" order="32.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityListingParValuePerShare_31" order="33.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_32" order="34.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityVoluntaryFilers_33" order="35.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityCurrentReportingStatus_34" order="36.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityInteractiveDataCurrent_35" order="37.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityFilerCategory_36" order="38.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntitySmallBusiness_37" order="39.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityEmergingGrowthCompany_38" order="40.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityShellCompany_39" order="41.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityPublicFloat_40" order="42.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_41" order="43.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_AmendmentFlag_42" order="44.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_AmendmentDescription_43" order="45.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_NoTradingSymbolFlag_44" order="46.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_DocumentTransitionReport_45" order="47.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_EntityExTransitionPeriod_46" order="48.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_AuditorFirmId_47" order="49.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_AuditorName_48" order="50.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_AuditorLocation_49" order="51.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_50" order="52.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_dei_AuditorOpinionTextBlock_51" order="53.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/idr_BalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaap_DeferredCostsCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_11"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RelatedPartyPayableCurrent" xlink:label="loc_mdcx_RelatedPartyPayableCurrent_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SecuredDebtCurrent" xlink:label="loc_us-gaap_SecuredDebtCurrent_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SecuredLongTermDebt" xlink:label="loc_us-gaap_SecuredLongTermDebt_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaap_LongTermLoansPayable_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_22"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_CommonSharesToBeIssued" xlink:label="loc_mdcx_CommonSharesToBeIssued_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_31"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_2" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_DeferredCostsCurrent_3" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AssetsCurrent_4" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_6" order="7.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7" order="8.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_8" order="9.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" order="10.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_10" order="11.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_AccountsPayableCurrent_10" order="12.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_11" order="13.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_mdcx_RelatedPartyPayableCurrent_12" order="14.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_13" order="15.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_SecuredDebtCurrent_14" order="16.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_LiabilitiesCurrent_15" order="17.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_SecuredLongTermDebt_17" order="18.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_LongTermLoansPayable_18" order="19.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_19" order="20.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_Liabilities_20" order="21.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_CommitmentsAndContingencies_21" order="22.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_StockholdersEquityAbstract_22" order="23.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_CommonStockValue_22" order="24.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_mdcx_CommonSharesToBeIssued_23" order="25.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_AdditionalPaidInCapital_24" order="26.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_25" order="27.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_26" order="28.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_StockholdersEquity_27" order="29.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_MinorityInterest_28" order="30.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_29" order="31.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_31" order="32.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/idr_BalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockNoParValue_1" order="1.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_3" order="3.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4" order="4.0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/idr_StatementsOfOperations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GainLossOnSettlements" xlink:label="loc_mdcx_GainLossOnSettlements_8"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ChangeInFairValueOfDebentures" xlink:label="loc_mdcx_ChangeInFairValueOfDebentures_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:label="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_25"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_OperatingExpenses_3" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_5" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_6" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_6" xlink:to="loc_us-gaap_InvestmentIncomeNet_6" order="7.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_6" xlink:to="loc_us-gaap_InterestExpense_7" order="8.0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_6" xlink:to="loc_mdcx_GainLossOnSettlements_8" order="9.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_6" xlink:to="loc_mdcx_ChangeInFairValueOfDebentures_9" order="10.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_10" order="11.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_ProfitLoss_12" order="12.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_13" order="13.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_14" order="14.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_15" order="15.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_15" xlink:to="loc_us-gaap_NetIncomeLossAbstract_15" order="16.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_15" xlink:to="loc_us-gaap_NetIncomeLoss_15" order="17.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_15" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_16" order="18.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_15" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_18" order="19.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_18" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_18" order="20.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_18" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_19" order="21.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasic_22" order="22.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_23" order="23.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_24" order="24.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_25" order="25.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SharesIssuedMember" xlink:label="loc_mdcx_SharesIssuedMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_12"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts_13"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts_14"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing_15"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing_16"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareIssuanceCosts" xlink:label="loc_mdcx_ShareIssuanceCosts_17"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants_18"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConversionOfDebt" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_22"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConversionOfDebt" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_23"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts_24"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts_25"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost_26"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts_27"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered_28"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_32"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueOfCommonShares" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueOfCommonShares_33"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesOfCommonStock" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesOfCommonStock_34"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares" xlink:label="loc_mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares_35"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantsIssuedUnderWarrantInducement" xlink:label="loc_mdcx_WarrantsIssuedUnderWarrantInducement_36"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DeemedDividendOnWarrantInducement" xlink:label="loc_mdcx_DeemedDividendOnWarrantInducement_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_41"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="2.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_mdcx_SharesIssuedMember_2" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5" order="7.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_NoncontrollingInterestMember_6" order="8.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_7" order="9.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_9" order="10.0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9" order="11.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_10" order="12.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_11" order="13.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_12" order="14.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts_13" order="15.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts_14" order="16.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing_15" order="17.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing_16" order="18.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_mdcx_ShareIssuanceCosts_17" order="19.0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants_18" order="20.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants_19" order="21.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_20" order="22.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21" order="23.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_22" order="24.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_23" order="25.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts_24" order="26.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts_25" order="27.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost_26" order="28.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts_27" order="29.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered_28" order="30.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered_29" order="31.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_30" order="32.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_31" order="33.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_32" order="34.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_mdcx_StockIssuedDuringPeriodValueOfCommonShares_33" order="35.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_mdcx_StockIssuedDuringPeriodSharesOfCommonStock_34" order="36.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares_35" order="37.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_mdcx_WarrantsIssuedUnderWarrantInducement_36" order="38.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_mdcx_DeemedDividendOnWarrantInducement_37" order="39.0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_ProfitLoss_38" order="40.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_39" order="41.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_40" order="42.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_41" order="43.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceCostsInConnectionWithPrivatePlacement" xlink:label="loc_mdcx_IssuanceCostsInConnectionWithPrivatePlacement_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceCostsInConnectionWithInitialPublicOffering" xlink:label="loc_mdcx_IssuanceCostsInConnectionWithInitialPublicOffering_2"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceCostsInConnectionWithRegulationA" xlink:label="loc_mdcx_IssuanceCostsInConnectionWithRegulationA_3"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceCostsInConnectionWithEquityFinancing" xlink:label="loc_mdcx_IssuanceCostsInConnectionWithEquityFinancing_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_mdcx_IssuanceCostsInConnectionWithPrivatePlacement_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_mdcx_IssuanceCostsInConnectionWithInitialPublicOffering_2" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_mdcx_IssuanceCostsInConnectionWithRegulationA_3" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_mdcx_IssuanceCostsInConnectionWithEquityFinancing_4" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/idr_StatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_3"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:label="loc_mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets_4"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GainLossOnSettlements" xlink:label="loc_mdcx_GainLossOnSettlements_5"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes" xlink:label="loc_mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes_6"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes" xlink:label="loc_mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes_7"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered" xlink:label="loc_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_23"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromIssuanceOfSharesUnderSettlements" xlink:label="loc_mdcx_ProceedsFromIssuanceOfSharesUnderSettlements_24"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts" xlink:label="loc_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement" xlink:label="loc_mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement_34"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IssuanceCostsIncludedInAccountsPayable" xlink:label="loc_mdcx_IssuanceCostsIncludedInAccountsPayable_35"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_ProfitLoss_1" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_ShareBasedCompensation_2" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_PaidInKindInterest_3" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets_4" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_mdcx_GainLossOnSettlements_5" order="7.0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes_6" order="8.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes_7" order="9.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered_8" order="10.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_10" order="11.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_10" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_10" order="12.0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_10" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_11" order="13.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_10" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_12" order="14.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_10" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_13" order="15.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_10" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_14" order="16.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_16" order="17.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" order="18.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_18" order="19.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_19" order="20.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_20" order="21.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_21" order="22.0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_22" order="23.0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_RepaymentsOfDebt_23" order="24.0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_mdcx_ProceedsFromIssuanceOfSharesUnderSettlements_24" order="25.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts_25" order="26.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26" order="27.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_28" order="28.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_29" order="29.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30" order="30.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_31" order="31.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_32" order="32.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_32" xlink:to="loc_us-gaap_InterestPaidNet_32" order="33.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" order="34.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement_34" order="35.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_mdcx_IssuanceCostsIncludedInAccountsPayable_35" order="36.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/DescriptionOfBusiness">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/BalanceSheetComponents">
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BalanceSheetComponentsAbstract" xlink:label="loc_mdcx_BalanceSheetComponentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_BalanceSheetComponentsAbstract_0" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/Leases">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/ShareCapital">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/StockBasedCompensation">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/FairValueMeasurements">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/CommitmentAndContingencies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/SegmentReporting">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/Debentures">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaap_LongTermDebtTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_LongTermDebtTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/RestrictedCash">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_RestrictedAssetsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0" xlink:to="loc_us-gaap_RestrictedAssetsDisclosureTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/Liquidity">
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_LiquidityAbstract" xlink:label="loc_mdcx_LiquidityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_LiquidityTextBlock" xlink:label="loc_mdcx_LiquidityTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_LiquidityAbstract_0" xlink:to="loc_mdcx_LiquidityTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/LossPerShare">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock" xlink:label="loc_mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_2" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_3" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_4" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/BalanceSheetComponentsTables">
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BalanceSheetComponentsAbstract" xlink:label="loc_mdcx_BalanceSheetComponentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ScheduleOfPrepaidExpensesTableTextBlock" xlink:label="loc_mdcx_ScheduleOfPrepaidExpensesTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_BalanceSheetComponentsAbstract_0" xlink:to="loc_mdcx_ScheduleOfPrepaidExpensesTableTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_BalanceSheetComponentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_LesseeOperatingLeasesDisclosureTableTextBlock" xlink:label="loc_mdcx_LesseeOperatingLeasesDisclosureTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_mdcx_LesseeOperatingLeasesDisclosureTableTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_2" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/ShareCapitalTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock" xlink:label="loc_mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock_2" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/FairValueMeasurementTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/CommitmentsAndContingenciesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/DebenturesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_2" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/LossPerShareTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/TESTTESTTESTTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NumberOfOperatingSegments_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/BalanceSheetComponentsDetails">
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BalanceSheetComponentsAbstract" xlink:label="loc_mdcx_BalanceSheetComponentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PrepaidContractResearch" xlink:label="loc_mdcx_PrepaidContractResearch_2"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PrepaidProfessionalServices" xlink:label="loc_mdcx_PrepaidProfessionalServices_3"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PrepaidServices" xlink:label="loc_mdcx_PrepaidServices_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_BalanceSheetComponentsAbstract_0" xlink:to="loc_us-gaap_PrepaidInsurance_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_BalanceSheetComponentsAbstract_0" xlink:to="loc_mdcx_PrepaidContractResearch_2" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_BalanceSheetComponentsAbstract_0" xlink:to="loc_mdcx_PrepaidProfessionalServices_3" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_BalanceSheetComponentsAbstract_0" xlink:to="loc_mdcx_PrepaidServices_4" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_BalanceSheetComponentsAbstract_0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_5" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/BalanceSheetComponentsDetails1">
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BalanceSheetComponentsAbstract" xlink:label="loc_mdcx_BalanceSheetComponentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_BalanceSheetComponentsAbstract_0" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_BalanceSheetComponentsAbstract_0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_BalanceSheetComponentsAbstract_0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_BalanceSheetComponentsAbstract_0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/LeasesDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseExpense_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_OperatingLeasePayments_2" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_3" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_4" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/LeasesDetails2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiability_5" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareCapitalNoteDisclosureTable" xlink:label="loc_mdcx_ShareCapitalNoteDisclosureTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_2"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RegulationAOfferingMember" xlink:label="loc_mdcx_RegulationAOfferingMember_3"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_June2025PublicOfferingMember" xlink:label="loc_mdcx_June2025PublicOfferingMember_4"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StandbyEquityPurchaseAgreementMember" xlink:label="loc_mdcx_StandbyEquityPurchaseAgreementMember_5"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AtmAgreementMember" xlink:label="loc_mdcx_AtmAgreementMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_9"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesAWarrantsMember" xlink:label="loc_mdcx_SeriesAWarrantsMember_9"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesBWarrantsMember" xlink:label="loc_mdcx_SeriesBWarrantsMember_10"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesAAndBWarrantsGrantedMember" xlink:label="loc_mdcx_SeriesAAndBWarrantsGrantedMember_11"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesCAndDWarrantsGrantedMember" xlink:label="loc_mdcx_SeriesCAndDWarrantsGrantedMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_15"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_YaIiPnLtdMember" xlink:label="loc_mdcx_YaIiPnLtdMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_18"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareCapitalNoteDisclosureLineItems" xlink:label="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaap_CommonStockConversionBasis_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_23"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares_24"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionAdditionalDebtAmount" xlink:label="loc_mdcx_DebtConversionAdditionalDebtAmount_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:label="loc_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_27"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest" xlink:label="loc_mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtConversionDescription" xlink:label="loc_us-gaap_DebtConversionDescription_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_30"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AccruedInterestConvertedIntoCommonShares" xlink:label="loc_mdcx_AccruedInterestConvertedIntoCommonShares_31"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodValueConversionOfDebt" xlink:label="loc_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_32"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockIssuedDuringPeriodSharesConversionOfDebt" xlink:label="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_33"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement" xlink:label="loc_mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement_34"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement" xlink:label="loc_mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_37"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SharePriceAsPercentageOfMarketPrice" xlink:label="loc_mdcx_SharePriceAsPercentageOfMarketPrice_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_40"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures" xlink:label="loc_mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures_41"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement" xlink:label="loc_mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_44"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice_45"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantLiabilityIssuedDuringPeriod" xlink:label="loc_mdcx_WarrantLiabilityIssuedDuringPeriod_46"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares" xlink:label="loc_mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares_47"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionRemainingConvertibleAmount" xlink:label="loc_mdcx_DebtConversionRemainingConvertibleAmount_48"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount" xlink:label="loc_mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_50"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromSimpleAgreementForFutureEquity" xlink:label="loc_mdcx_ProceedsFromSimpleAgreementForFutureEquity_51"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ThresholdLimitOfFinancing" xlink:label="loc_mdcx_ThresholdLimitOfFinancing_52"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_53"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_54"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_55"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_56"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockPurchaseWarrantsTerm" xlink:label="loc_mdcx_StockPurchaseWarrantsTerm_57"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IncrementalFairValueOfWarrantsGranted" xlink:label="loc_mdcx_IncrementalFairValueOfWarrantsGranted_58"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_FairValueOfWarrantsGranted" xlink:label="loc_mdcx_FairValueOfWarrantsGranted_59"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_60"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_61"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_FairValuePerShare" xlink:label="loc_mdcx_FairValuePerShare_62"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_FairValuePerWarrant" xlink:label="loc_mdcx_FairValuePerWarrant_63"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfWarrantsExercised" xlink:label="loc_mdcx_NumberOfWarrantsExercised_64"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_65"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfWarrantsExercisedForCash" xlink:label="loc_mdcx_NumberOfWarrantsExercisedForCash_66"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_67"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_68"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PaymentOfStructuringFee" xlink:label="loc_mdcx_PaymentOfStructuringFee_69"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_70"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_EquityDistributionAgreementCommissionRate" xlink:label="loc_mdcx_EquityDistributionAgreementCommissionRate_72"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_mdcx_ShareCapitalNoteDisclosureTable_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_PrivatePlacementMember_1" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_IPOMember_2" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_mdcx_RegulationAOfferingMember_3" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_mdcx_June2025PublicOfferingMember_4" order="7.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_mdcx_StandbyEquityPurchaseAgreementMember_5" order="8.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_mdcx_AtmAgreementMember_6" order="9.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9" order="10.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9" xlink:to="loc_us-gaap_ClassOfStockDomain_9" order="11.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9" xlink:to="loc_mdcx_SeriesAWarrantsMember_9" order="12.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9" xlink:to="loc_mdcx_SeriesBWarrantsMember_10" order="13.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9" xlink:to="loc_mdcx_SeriesAAndBWarrantsGrantedMember_11" order="14.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9" xlink:to="loc_mdcx_SeriesCAndDWarrantsGrantedMember_12" order="15.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureTable_1" xlink:to="loc_dei_LegalEntityAxis_15" order="16.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_15" xlink:to="loc_dei_EntityDomain_15" order="17.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_15" xlink:to="loc_mdcx_YaIiPnLtdMember_15" order="18.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_18" order="19.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_18" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_18" order="20.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_18" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_18" order="21.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureTable_1" xlink:to="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" order="22.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_21" order="23.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_CommonStockConversionBasis_22" order="24.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_23" order="25.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares_24" order="26.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_DebtConversionAdditionalDebtAmount_25" order="27.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_26" order="28.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_27" order="29.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest_28" order="30.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_DebtConversionDescription_29" order="31.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_30" order="32.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_AccruedInterestConvertedIntoCommonShares_31" order="33.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_StockIssuedDuringPeriodValueConversionOfDebt_32" order="34.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_StockIssuedDuringPeriodSharesConversionOfDebt_33" order="35.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement_34" order="36.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement_35" order="37.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_36" order="38.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_37" order="39.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/measurementGuidance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_SharePriceAsPercentageOfMarketPrice_38" order="40.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_39" order="41.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_40" order="42.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures_41" order="43.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement_42" order="44.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_43" order="45.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_44" order="46.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice_45" order="47.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_WarrantLiabilityIssuedDuringPeriod_46" order="48.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares_47" order="49.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_DebtConversionRemainingConvertibleAmount_48" order="50.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount_49" order="51.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_50" order="52.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_ProceedsFromSimpleAgreementForFutureEquity_51" order="53.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_ThresholdLimitOfFinancing_52" order="54.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_53" order="55.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_54" order="56.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_55" order="57.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_56" order="58.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_StockPurchaseWarrantsTerm_57" order="59.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_IncrementalFairValueOfWarrantsGranted_58" order="60.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_FairValueOfWarrantsGranted_59" order="61.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_60" order="62.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_61" order="63.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_FairValuePerShare_62" order="64.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_FairValuePerWarrant_63" order="65.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_NumberOfWarrantsExercised_64" order="66.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_65" order="67.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_NumberOfWarrantsExercisedForCash_66" order="68.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_67" order="69.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_68" order="70.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_PaymentOfStructuringFee_69" order="71.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_LegalFees_70" order="72.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_71" order="73.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_ShareCapitalNoteDisclosureLineItems_21" xlink:to="loc_mdcx_EquityDistributionAgreementCommissionRate_72" order="74.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/ShareCapitalDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RegulationAWarrantsMember" xlink:label="loc_mdcx_RegulationAWarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_2"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_PublicWarrantsMember" xlink:label="loc_mdcx_PublicWarrantsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_MeasurementInputValuationDateSharePriceMember" xlink:label="loc_mdcx_MeasurementInputValuationDateSharePriceMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_mdcx_RegulationAWarrantsMember_1" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_us-gaap_WarrantMember_2" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_mdcx_PublicWarrantsMember_3" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_6" order="7.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6" order="8.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6" xlink:to="loc_mdcx_MeasurementInputValuationDateSharePriceMember_6" order="9.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6" xlink:to="loc_us-gaap_MeasurementInputExercisePriceMember_7" order="10.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_8" order="11.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_9" order="12.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_10" order="13.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_11" order="14.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_14" order="15.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_14" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_14" order="16.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/ShareCapitalScheduleOfWarrantsContinuityDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_5"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod" xlink:label="loc_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageExercisePriceOfWarrant" xlink:label="loc_mdcx_WeightedAverageExercisePriceOfWarrant_8"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageExercisePriceWarrantGranted" xlink:label="loc_mdcx_WeightedAverageExercisePriceWarrantGranted_9"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageExercisePriceWarrantExercise" xlink:label="loc_mdcx_WeightedAverageExercisePriceWarrantExercise_10"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageExercisePriceOfWarrant" xlink:label="loc_mdcx_WeightedAverageExercisePriceOfWarrant_11"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageRemainingContractualTermOfWarrant" xlink:label="loc_mdcx_WeightedAverageRemainingContractualTermOfWarrant_12"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted" xlink:label="loc_mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:to="loc_us-gaap_WarrantMember_1" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4" order="7.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod_5" order="8.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod_6" order="9.0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7" order="10.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_mdcx_WeightedAverageExercisePriceOfWarrant_8" order="11.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_mdcx_WeightedAverageExercisePriceWarrantGranted_9" order="12.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_mdcx_WeightedAverageExercisePriceWarrantExercise_10" order="13.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_mdcx_WeightedAverageExercisePriceOfWarrant_11" order="14.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_mdcx_WeightedAverageRemainingContractualTermOfWarrant_12" order="15.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted_13" order="16.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/ShareCapitalDetails1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantsIssuedAsPartOfIpoMember" xlink:label="loc_mdcx_WarrantsIssuedAsPartOfIpoMember_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RegulationAWarrantsMember" xlink:label="loc_mdcx_RegulationAWarrantsMember_2"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_WarrantWithExpiryDateJune302030WarrantsMember" xlink:label="loc_mdcx_WarrantWithExpiryDateJune302030WarrantsMember_3"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SeriesCAndDWarrantsMember" xlink:label="loc_mdcx_SeriesCAndDWarrantsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_7"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ClassOfWarrantOrRightExpiryDate" xlink:label="loc_mdcx_ClassOfWarrantOrRightExpiryDate_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ClassOfWarrantOrRightExercisable" xlink:label="loc_mdcx_ClassOfWarrantOrRightExercisable_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_mdcx_WarrantsIssuedAsPartOfIpoMember_1" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_mdcx_RegulationAWarrantsMember_2" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_mdcx_WarrantWithExpiryDateJune302030WarrantsMember_3" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_mdcx_SeriesCAndDWarrantsMember_4" order="7.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_7" order="8.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7" xlink:to="loc_mdcx_ClassOfWarrantOrRightExpiryDate_7" order="9.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8" order="10.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_9" order="11.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7" xlink:to="loc_mdcx_ClassOfWarrantOrRightExercisable_10" order="12.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_8"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_IndividualsMember" xlink:label="loc_mdcx_IndividualsMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding" xlink:label="loc_mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_23"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_VestingAxis_4" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_4" xlink:to="loc_us-gaap_VestingDomain_4" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_4" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4" order="7.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_4" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_5" order="8.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" order="9.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" xlink:to="loc_us-gaap_RelatedPartyDomain_8" order="10.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8" xlink:to="loc_mdcx_IndividualsMember_8" order="11.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" order="12.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding_11" order="13.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_12" order="14.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_13" order="15.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_14" order="16.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_15" order="17.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_16" order="18.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_17" order="19.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_18" order="20.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_19" order="21.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_20" order="22.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_21" order="23.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_22" order="24.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_23" order="25.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_14"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted" xlink:label="loc_mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_22"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_7" order="7.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8" order="8.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9" order="9.0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_10" order="10.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_11" order="11.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12" order="12.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_13" order="13.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_14" order="14.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted_15" order="15.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_16" order="16.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_17" order="17.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_18" order="18.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_19" order="19.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20" order="20.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_21" order="21.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_22" order="22.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfWeightedaverageAssumptionsToDetermineFairValueOfStockOptionsGrantedDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_4" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_SharePrice_5" order="7.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6" order="8.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7" order="9.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8" order="10.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9" order="11.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/RelatedPartyTransactionsNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_VelocityFundManagementLLCMember" xlink:label="loc_mdcx_VelocityFundManagementLLCMember_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RbxCapitalLPMember" xlink:label="loc_mdcx_RbxCapitalLPMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ManagementMember" xlink:label="loc_srt_ManagementMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensation_6"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RelatedPartyTransactionAdditionalExpenses" xlink:label="loc_mdcx_RelatedPartyTransactionAdditionalExpenses_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_9"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NumberOfConvertibleNotesSubscribed" xlink:label="loc_mdcx_NumberOfConvertibleNotesSubscribed_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_mdcx_VelocityFundManagementLLCMember_1" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_mdcx_RbxCapitalLPMember_2" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_srt_ManagementMember_3" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_6" order="7.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6" xlink:to="loc_us-gaap_SalariesWagesAndOfficersCompensation_6" order="8.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6" xlink:to="loc_mdcx_RelatedPartyTransactionAdditionalExpenses_7" order="9.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_8" order="10.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_9" order="11.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6" xlink:to="loc_mdcx_NumberOfConvertibleNotesSubscribed_10" order="12.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_11" order="13.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_12" order="14.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/FairValueMeasurementsNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/FairValueMeasurementDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="7.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5" order="8.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6" order="9.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9" order="10.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_9" order="11.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_9" order="12.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_10" order="13.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_11" order="14.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_13" order="15.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_13" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_13" order="16.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/CommitmentsAndContingenciesN">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AntevLimitedMember" xlink:label="loc_mdcx_AntevLimitedMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_mdcx_AntevLimitedMember_1" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_4" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_4" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AntevLimitedMember" xlink:label="loc_mdcx_AntevLimitedMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_4"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ContingentConsiderationPhasesOneMember" xlink:label="loc_mdcx_ContingentConsiderationPhasesOneMember_4"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ContingentConsiderationPhasesTwoMember" xlink:label="loc_mdcx_ContingentConsiderationPhasesTwoMember_5"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ContingentConsiderationPhasesThreeMember" xlink:label="loc_mdcx_ContingentConsiderationPhasesThreeMember_6"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ContingentConsiderationPhasesFourMember" xlink:label="loc_mdcx_ContingentConsiderationPhasesFourMember_7"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis" xlink:label="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis_10"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain" xlink:label="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_17"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:to="loc_mdcx_AntevLimitedMember_1" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_4" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_4" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_4" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_4" xlink:to="loc_mdcx_ContingentConsiderationPhasesOneMember_4" order="7.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_4" xlink:to="loc_mdcx_ContingentConsiderationPhasesTwoMember_5" order="8.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_4" xlink:to="loc_mdcx_ContingentConsiderationPhasesThreeMember_6" order="9.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_4" xlink:to="loc_mdcx_ContingentConsiderationPhasesFourMember_7" order="10.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" xlink:to="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis_10" order="11.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis_10" xlink:to="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain_10" order="12.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain_10" xlink:to="loc_us-gaap_CommonStockMember_10" order="13.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" xlink:to="loc_srt_RangeAxis_13" order="14.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_13" xlink:to="loc_srt_RangeMember_13" order="15.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13" xlink:to="loc_srt_MaximumMember_13" order="16.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_16" order="17.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_16" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_16" order="18.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_16" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_17" order="19.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/SegmentReportingNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_NumberOfReportableSegments_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SkinjectIncMember" xlink:label="loc_mdcx_SkinjectIncMember_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_TeverelixMember" xlink:label="loc_mdcx_TeverelixMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaap_ProjectMember_5"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember" xlink:label="loc_mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember_5"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProfessionalServicesAndIntellectualPropertyMember" xlink:label="loc_mdcx_ProfessionalServicesAndIntellectualPropertyMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaap_LaborAndRelatedExpense_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_15"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_GainLossOnSettlements" xlink:label="loc_mdcx_GainLossOnSettlements_16"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ChangeInFairValueOfDebentures" xlink:label="loc_mdcx_ChangeInFairValueOfDebentures_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_19"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_mdcx_SkinjectIncMember_1" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_mdcx_TeverelixMember_2" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_5" xlink:to="loc_us-gaap_ProjectMember_5" order="7.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_5" xlink:to="loc_mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember_5" order="8.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_5" xlink:to="loc_mdcx_ProfessionalServicesAndIntellectualPropertyMember_6" order="9.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9" order="10.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_9" order="11.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9" xlink:to="loc_us-gaap_LaborAndRelatedExpense_10" order="12.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_11" order="13.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_12" order="14.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9" xlink:to="loc_us-gaap_OperatingExpenses_13" order="15.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_14" order="16.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_14" xlink:to="loc_us-gaap_InvestmentIncomeNet_14" order="17.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_14" xlink:to="loc_us-gaap_InterestExpense_15" order="18.0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_14" xlink:to="loc_mdcx_GainLossOnSettlements_16" order="19.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_14" xlink:to="loc_mdcx_ChangeInFairValueOfDebentures_17" order="20.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_14" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_18" order="21.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_14" xlink:to="loc_us-gaap_ProfitLoss_19" order="22.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/DebenturesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SecuredPromissoryNotesMember" xlink:label="loc_mdcx_SecuredPromissoryNotesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NoteAMember" xlink:label="loc_mdcx_NoteAMember_4"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NoteBMember" xlink:label="loc_mdcx_NoteBMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_8"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_InterimRemeasurementMember" xlink:label="loc_mdcx_InterimRemeasurementMember_8"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SettlementDateRemeasurementMember" xlink:label="loc_mdcx_SettlementDateRemeasurementMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SecuritiesPurchaseAgreementMember" xlink:label="loc_mdcx_SecuritiesPurchaseAgreementMember_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaap_DebtInstrumentIssuedPrincipal_19"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtIssuanceDiscount" xlink:label="loc_mdcx_DebtIssuanceDiscount_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_21"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebenturesIssuedPercentageOfDiscountedPrice" xlink:label="loc_mdcx_DebenturesIssuedPercentageOfDiscountedPrice_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_29"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentConvertibleExtinguished" xlink:label="loc_mdcx_DebtInstrumentConvertibleExtinguished_30"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ConvertibleDebtAccretionExpense" xlink:label="loc_mdcx_ConvertibleDebtAccretionExpense_31"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_EffectiveInterestRateOnDebt" xlink:label="loc_mdcx_EffectiveInterestRateOnDebt_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_33"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AccruedInterestRepaid" xlink:label="loc_mdcx_AccruedInterestRepaid_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_37"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentRedemptionLimitAmount" xlink:label="loc_mdcx_DebtInstrumentRedemptionLimitAmount_38"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtDefaultBalanceIncreasePercentage" xlink:label="loc_mdcx_DebtDefaultBalanceIncreasePercentage_39"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit" xlink:label="loc_mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit_40"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage" xlink:label="loc_mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault" xlink:label="loc_us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault_43"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentExchangeThresholdAmount" xlink:label="loc_mdcx_DebtInstrumentExchangeThresholdAmount_44"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebtInstrumentMaximumExchangeLimitAmount" xlink:label="loc_mdcx_DebtInstrumentMaximumExchangeLimitAmount_45"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1" xlink:to="loc_mdcx_SecuredPromissoryNotesMember_1" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_4" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4" xlink:to="loc_mdcx_NoteAMember_4" order="7.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4" xlink:to="loc_mdcx_NoteBMember_5" order="8.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_8" order="9.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_8" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_8" order="10.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8" xlink:to="loc_mdcx_InterimRemeasurementMember_8" order="11.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8" xlink:to="loc_mdcx_SettlementDateRemeasurementMember_9" order="12.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_srt_RangeAxis_12" order="13.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_12" xlink:to="loc_srt_RangeMember_12" order="14.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_12" xlink:to="loc_srt_MinimumMember_12" order="15.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_12" xlink:to="loc_srt_MaximumMember_13" order="16.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_16" order="17.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_16" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16" order="18.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16" xlink:to="loc_mdcx_SecuritiesPurchaseAgreementMember_16" order="19.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_19" order="20.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_us-gaap_DebtInstrumentIssuedPrincipal_19" order="21.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_mdcx_DebtIssuanceDiscount_20" order="22.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_21" order="23.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_mdcx_DebenturesIssuedPercentageOfDiscountedPrice_22" order="24.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_23" order="25.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_24" order="26.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_25" order="27.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_26" order="28.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_27" order="29.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_28" order="30.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_29" order="31.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_mdcx_DebtInstrumentConvertibleExtinguished_30" order="32.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_mdcx_ConvertibleDebtAccretionExpense_31" order="33.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_mdcx_EffectiveInterestRateOnDebt_32" order="34.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_us-gaap_RepaymentsOfDebt_33" order="35.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_mdcx_AccruedInterestRepaid_34" order="36.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_35" order="37.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_36" order="38.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_us-gaap_InterestPayableCurrent_37" order="39.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_mdcx_DebtInstrumentRedemptionLimitAmount_38" order="40.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_mdcx_DebtDefaultBalanceIncreasePercentage_39" order="41.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit_40" order="42.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage_41" order="43.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_42" order="44.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault_43" order="45.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_mdcx_DebtInstrumentExchangeThresholdAmount_44" order="46.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_19" xlink:to="loc_mdcx_DebtInstrumentMaximumExchangeLimitAmount_45" order="47.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/DebenturesScheduleOfDebentureContinuityDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebentureContinuityOneMember" xlink:label="loc_mdcx_DebentureContinuityOneMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_5"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ConvertibleDebtAccretionExpense" xlink:label="loc_mdcx_ConvertibleDebtAccretionExpense_6"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RepaymentsOfInterest" xlink:label="loc_mdcx_RepaymentsOfInterest_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1" xlink:to="loc_mdcx_DebentureContinuityOneMember_1" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4" xlink:to="loc_us-gaap_DebtCurrent_4" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4" xlink:to="loc_us-gaap_RepaymentsOfDebt_5" order="7.0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4" xlink:to="loc_mdcx_ConvertibleDebtAccretionExpense_6" order="8.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4" xlink:to="loc_mdcx_RepaymentsOfInterest_7" order="9.0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4" xlink:to="loc_us-gaap_DebtCurrent_8" order="10.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/DebenturesAndPromissoryNotesNdfd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_SecuredPromissoryNotesMember" xlink:label="loc_mdcx_SecuredPromissoryNotesMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NoteAMember" xlink:label="loc_mdcx_NoteAMember_4"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NoteBMember" xlink:label="loc_mdcx_NoteBMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1" xlink:to="loc_mdcx_SecuredPromissoryNotesMember_1" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_4" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4" xlink:to="loc_mdcx_NoteAMember_4" order="7.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4" xlink:to="loc_mdcx_NoteBMember_5" order="8.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_8" order="9.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_8" order="10.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9" order="11.0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_10" order="12.0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8" xlink:to="loc_us-gaap_InterestExpenseDebt_11" order="13.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8" xlink:to="loc_us-gaap_NotesPayable_12" order="14.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/RestrictedCashNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RestrictedCashTable" xlink:label="loc_mdcx_RestrictedCashTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_NoteBMember" xlink:label="loc_mdcx_NoteBMember_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_RestrictedCashLineItems" xlink:label="loc_mdcx_RestrictedCashLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0" xlink:to="loc_mdcx_RestrictedCashTable_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_RestrictedCashTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_1" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1" xlink:to="loc_mdcx_NoteBMember_1" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_RestrictedCashTable_1" xlink:to="loc_mdcx_RestrictedCashLineItems_4" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mdcx_RestrictedCashLineItems_4" xlink:to="loc_us-gaap_RestrictedCashCurrent_4" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/LossPerShareDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasic_3" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/TESTTESTTESTDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_StockOptionsMember" xlink:label="loc_mdcx_StockOptionsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_2"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_DebenturesMember" xlink:label="loc_mdcx_DebenturesMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_mdcx_StockOptionsMember_1" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_WarrantMember_2" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_mdcx_DebenturesMember_3" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6" order="7.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6" order="8.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.medicuspharma.com/role/SubsequentEventsNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_4"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_AgentsMember" xlink:label="loc_mdcx_AgentsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9"/>
    <loc xlink:type="locator" xlink:href="mdcx-20260630.xsd#mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents" xlink:label="loc_mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="1.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="2.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="3.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="4.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4" order="5.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4" xlink:to="loc_us-gaap_RelatedPartyDomain_4" order="6.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4" xlink:to="loc_mdcx_AgentsMember_4" order="7.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_7" order="8.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7" order="9.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8" order="10.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9" order="11.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7" xlink:to="loc_mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents_10" order="12.0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Aug. 10, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">MEDICUS PHARMA LTD.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Registrant CIK</a></td>
<td class="text">0001997296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-42408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1778211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">300 Conshohocken State Rd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">W. Conshohocken<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">636-0184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,180,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12gTitle', window );">Title of 12(g) Security</a></td>
<td class="text">Common shares, no par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDCX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12gTitle', window );">Title of 12(g) Security</a></td>
<td class="text">Warrants<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDCXW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12gTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(g) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection g<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12gTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,174,128<span></span>
</td>
<td class="nump">$ 8,705,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,807,461<span></span>
</td>
<td class="nump">1,086,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred financing costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">99,305<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">16,981,589<span></span>
</td>
<td class="nump">9,890,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">10,017,412<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">117,184<span></span>
</td>
<td class="nump">170,733<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">27,116,185<span></span>
</td>
<td class="nump">10,061,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,734,310<span></span>
</td>
<td class="nump">3,435,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">308,007<span></span>
</td>
<td class="nump">995,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_RelatedPartyPayableCurrent', window );">Related party payable</a></td>
<td class="nump">161,846<span></span>
</td>
<td class="nump">116,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">137,330<span></span>
</td>
<td class="nump">145,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebtCurrent', window );">Debentures and secured promissory notes, current</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">5,245,543<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,841,493<span></span>
</td>
<td class="nump">9,938,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Debentures and secured promissory notes, non-current</a></td>
<td class="nump">17,982,542<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Loan payable</a></td>
<td class="nump">17,114<span></span>
</td>
<td class="nump">25,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">60,139<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">28,841,149<span></span>
</td>
<td class="nump">10,024,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' (deficit) equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, no par value; unlimited shares authorized; 60,168,044 and 25,176,303 shares issued and outstanding as of June 30, 2026, and December 31, 2025, respectively</a></td>
<td class="nump">74,298,513<span></span>
</td>
<td class="nump">57,076,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_CommonSharesToBeIssued', window );">Common shares to be issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">313,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">8,884,707<span></span>
</td>
<td class="nump">6,879,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">61,095<span></span>
</td>
<td class="nump">10,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(85,007,966)<span></span>
</td>
<td class="num">(64,348,118)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' (deficit) equity attributable to Medicus Pharma Ltd.</a></td>
<td class="num">(1,763,651)<span></span>
</td>
<td class="num">(67,554)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests</a></td>
<td class="nump">38,687<span></span>
</td>
<td class="nump">104,865<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders' (deficit) equity</a></td>
<td class="num">(1,724,964)<span></span>
</td>
<td class="nump">37,311<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' (deficit) equity</a></td>
<td class="nump">$ 27,116,185<span></span>
</td>
<td class="nump">$ 10,061,377<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_CommonSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of common shares to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_CommonSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_RelatedPartyPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the related party payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_RelatedPartyPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-7<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480339/815-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480339/815-10-65-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480339/815-10-65-8<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481229/860-50-50-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 35: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 36: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 67: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 70: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 71: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 72: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 73: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common Stock, No Par Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, Shares, Authorized</a></td>
<td class="nump">60,168,044<span></span>
</td>
<td class="nump">25,176,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">60,168,044<span></span>
</td>
<td class="nump">25,176,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">60,168,044<span></span>
</td>
<td class="nump">25,176,303<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 6,571,097<span></span>
</td>
<td class="nump">$ 4,576,524<span></span>
</td>
<td class="nump">$ 12,463,781<span></span>
</td>
<td class="nump">$ 7,696,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,907,692<span></span>
</td>
<td class="nump">1,439,564<span></span>
</td>
<td class="nump">7,612,085<span></span>
</td>
<td class="nump">3,445,778<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">11,478,789<span></span>
</td>
<td class="nump">6,016,088<span></span>
</td>
<td class="nump">20,075,866<span></span>
</td>
<td class="nump">11,142,362<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(11,478,789)<span></span>
</td>
<td class="num">(6,016,088)<span></span>
</td>
<td class="num">(20,075,866)<span></span>
</td>
<td class="num">(11,142,362)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Finance income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,004<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">63,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest (expense)</a></td>
<td class="num">(205,638)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(523,789)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_GainLossOnSettlements', window );">Loss on SEPA (as defined below) settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(127,083)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ChangeInFairValueOfDebentures', window );">Change in fair value of debentures</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(205,638)<span></span>
</td>
<td class="num">(159,996)<span></span>
</td>
<td class="num">(650,872)<span></span>
</td>
<td class="num">(136,130)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">(11,684,427)<span></span>
</td>
<td class="num">(6,176,084)<span></span>
</td>
<td class="num">(20,726,738)<span></span>
</td>
<td class="num">(11,278,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">255,177<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,928<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss for the period attributable to common shareholders</a></td>
<td class="num">(11,429,250)<span></span>
</td>
<td class="num">(6,176,084)<span></span>
</td>
<td class="num">(20,675,810)<span></span>
</td>
<td class="num">(11,278,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Net loss attributable to</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Common shareholders of the Company</a></td>
<td class="num">(11,617,705)<span></span>
</td>
<td class="num">(6,176,084)<span></span>
</td>
<td class="num">(20,659,848)<span></span>
</td>
<td class="num">(11,278,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Non-controlling interests</a></td>
<td class="num">(66,722)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(66,890)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss attributable to</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Common shareholders of the Company</a></td>
<td class="num">(11,438,822)<span></span>
</td>
<td class="num">(6,176,084)<span></span>
</td>
<td class="num">(20,676,523)<span></span>
</td>
<td class="num">(11,278,492)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Non-controlling interests</a></td>
<td class="nump">$ 3,572<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 713<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common shareholders - basic</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.81)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common shareholders - diluted</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.81)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding - basic</a></td>
<td class="nump">55,055,225<span></span>
</td>
<td class="nump">14,284,261<span></span>
</td>
<td class="nump">47,566,945<span></span>
</td>
<td class="nump">13,853,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">55,055,225<span></span>
</td>
<td class="nump">14,284,261<span></span>
</td>
<td class="nump">47,566,945<span></span>
</td>
<td class="nump">13,853,305<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_ChangeInFairValueOfDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount if change in fair value of debentures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_ChangeInFairValueOfDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_GainLossOnSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of gain loss on settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_GainLossOnSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 44: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' ( DEFICIT) EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common shares [Member]</div></th>
<th class="th"><div>Shares to be issued [Member]</div></th>
<th class="th"><div>Additional paid-in capital [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income [Member]</div></th>
<th class="th"><div>Non-Controlling Interest [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 30,518,195<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,520,412<span></span>
</td>
<td class="num">$ (28,903,903)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,134,704<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (Shares) at Dec. 31, 2024</a></td>
<td class="nump">11,816,721<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares and warrants in connection with Regulation A, net of issuance costs</a></td>
<td class="nump">$ 2,076,507<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,612,474<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,688,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares and warrants in connection with Regulation A, net of issuance costs (Shares)</a></td>
<td class="nump">1,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts', window );">Issuance of common shares in connection with SEPA offering costs</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts', window );">Issuance of common shares in connection with SEPA offering costs (Shares)</a></td>
<td class="nump">105,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants', window );">Issuance of common shares upon exercise of stock warrants</a></td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(14,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants', window );">Issuance of common shares upon exercise of stock warrants (Shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">112,277<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">112,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,102,408)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,102,408)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 32,908,702<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,245,163<span></span>
</td>
<td class="num">(34,006,311)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,147,554<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (Shares) at Mar. 31, 2025</a></td>
<td class="nump">13,417,561<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 30,518,195<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,520,412<span></span>
</td>
<td class="num">(28,903,903)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,134,704<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (Shares) at Dec. 31, 2024</a></td>
<td class="nump">11,816,721<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,278,492)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jun. 30, 2025</a></td>
<td class="nump">$ 37,833,999<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,597,106<span></span>
</td>
<td class="num">(40,182,395)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,248,710<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (Shares) at Jun. 30, 2025</a></td>
<td class="nump">15,936,266<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 32,908,702<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,245,163<span></span>
</td>
<td class="num">(34,006,311)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,147,554<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (Shares) at Mar. 31, 2025</a></td>
<td class="nump">13,417,561<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing', window );">Issuance of common shares and warrants in connection with June equity financing, net of offering costs</a></td>
<td class="nump">$ 3,961,899<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,234,495<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,196,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing', window );">Issuance of common shares and warrants in connection with June equity financing, net of offering costs (Shares)</a></td>
<td class="nump">2,260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants', window );">Issuance of common shares upon exercise of stock warrants</a></td>
<td class="nump">$ 963,398<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">963,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants', window );">Issuance of common shares upon exercise of stock warrants (Shares)</a></td>
<td class="nump">258,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">117,448<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">117,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,176,084)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,176,084)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jun. 30, 2025</a></td>
<td class="nump">$ 37,833,999<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,597,106<span></span>
</td>
<td class="num">(40,182,395)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,248,710<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (Shares) at Jun. 30, 2025</a></td>
<td class="nump">15,936,266<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2025</a></td>
<td class="nump">$ 57,076,175<span></span>
</td>
<td class="nump">$ 313,934<span></span>
</td>
<td class="nump">6,879,575<span></span>
</td>
<td class="num">(64,348,118)<span></span>
</td>
<td class="nump">10,880<span></span>
</td>
<td class="nump">104,865<span></span>
</td>
<td class="nump">$ 37,311<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (Shares) at Dec. 31, 2025</a></td>
<td class="nump">25,176,303<span></span>
</td>
<td class="nump">205,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,176,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts', window );">Issuance of common shares in connection with SEPA offering costs</a></td>
<td class="nump">$ 4,229,823<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 4,229,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts', window );">Issuance of common shares in connection with SEPA offering costs (Shares)</a></td>
<td class="nump">5,336,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost', window );">Issuance of common shares in connection with ATM, net of issuance cost</a></td>
<td class="nump">$ 5,808,013<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,808,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts', window );">Issuance of common shares in connection with ATM, net of issuance cost (Shares)</a></td>
<td class="nump">9,482,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">599,306<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">599,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,042,143)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(168)<span></span>
</td>
<td class="num">(9,042,311)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Other comprehensive loss for the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(201,390)<span></span>
</td>
<td class="num">(2,859)<span></span>
</td>
<td class="num">(204,249)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Mar. 31, 2026</a></td>
<td class="nump">$ 67,114,012<span></span>
</td>
<td class="nump">$ 313,934<span></span>
</td>
<td class="nump">7,478,881<span></span>
</td>
<td class="num">(73,390,261)<span></span>
</td>
<td class="num">(190,510)<span></span>
</td>
<td class="nump">101,838<span></span>
</td>
<td class="nump">1,427,894<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (Shares) at Mar. 31, 2026</a></td>
<td class="nump">39,995,463<span></span>
</td>
<td class="nump">205,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2025</a></td>
<td class="nump">$ 57,076,175<span></span>
</td>
<td class="nump">$ 313,934<span></span>
</td>
<td class="nump">6,879,575<span></span>
</td>
<td class="num">(64,348,118)<span></span>
</td>
<td class="nump">10,880<span></span>
</td>
<td class="nump">104,865<span></span>
</td>
<td class="nump">$ 37,311<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (Shares) at Dec. 31, 2025</a></td>
<td class="nump">25,176,303<span></span>
</td>
<td class="nump">205,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,176,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (20,726,738)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jun. 30, 2026</a></td>
<td class="nump">$ 74,298,513<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">8,884,707<span></span>
</td>
<td class="num">(85,007,966)<span></span>
</td>
<td class="nump">61,095<span></span>
</td>
<td class="nump">38,687<span></span>
</td>
<td class="num">$ (1,724,964)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (Shares) at Jun. 30, 2026</a></td>
<td class="nump">60,168,044<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,168,044<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Mar. 31, 2026</a></td>
<td class="nump">$ 67,114,012<span></span>
</td>
<td class="nump">$ 313,934<span></span>
</td>
<td class="nump">7,478,881<span></span>
</td>
<td class="num">(73,390,261)<span></span>
</td>
<td class="num">(190,510)<span></span>
</td>
<td class="nump">101,838<span></span>
</td>
<td class="nump">$ 1,427,894<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (Shares) at Mar. 31, 2026</a></td>
<td class="nump">39,995,463<span></span>
</td>
<td class="nump">205,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost', window );">Issuance of common shares in connection with ATM, net of issuance cost</a></td>
<td class="nump">$ 6,492,497<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,492,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts', window );">Issuance of common shares in connection with ATM, net of issuance cost (Shares)</a></td>
<td class="nump">18,766,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered', window );">Issuance of common shares in connection with noncash compensation for services rendered</a></td>
<td class="nump">$ 378,070<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">378,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered', window );">Issuance of common shares in connection with noncash compensation for services rendered (Shares)</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common shares for asset acquisition</a></td>
<td class="nump">$ 313,934<span></span>
</td>
<td class="num">$ (313,934)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common shares for asset acquisition (Shares)</a></td>
<td class="nump">205,980<span></span>
</td>
<td class="num">(205,980)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,405,826<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,405,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,617,705)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(66,722)<span></span>
</td>
<td class="num">(11,684,427)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Other comprehensive loss for the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">251,605<span></span>
</td>
<td class="nump">3,572<span></span>
</td>
<td class="nump">255,177<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jun. 30, 2026</a></td>
<td class="nump">$ 74,298,513<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,884,707<span></span>
</td>
<td class="num">$ (85,007,966)<span></span>
</td>
<td class="nump">$ 61,095<span></span>
</td>
<td class="nump">$ 38,687<span></span>
</td>
<td class="num">$ (1,724,964)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (Shares) at Jun. 30, 2026</a></td>
<td class="nump">60,168,044<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,168,044<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the shares of stock issued during period value connection with at the market offering, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the shares of stock issued during period value connection with equity financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the shares of stock issued during period value connection with SEPA offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the shares of stock issued during period value non-cash compensation for services rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the shares of stock issued during period value upon exercise of stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of stock issued during period value connection with at the market offering, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of stock issued during period value connection with equity financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of stock issued during period value connection with SEPA offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of stock issued during period value non-cash compensation for services rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of stock issued during period value upon exercise of stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 44: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480339/815-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480339/815-10-65-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480339/815-10-65-8<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481229/860-50-50-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 35: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 36: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 67: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 70: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 71: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 72: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 73: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' ( DEFICIT) EQUITY (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_IssuanceCostsInConnectionWithRegulationA', window );">Issuance costs in connection with Regulation A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_IssuanceCostsInConnectionWithEquityFinancing', window );">Issuance costs in connection with equity financing</a></td>
<td class="nump">$ 809,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_IssuanceCostsInConnectionWithEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents issuuance costs in connection with equity financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_IssuanceCostsInConnectionWithEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_IssuanceCostsInConnectionWithRegulationA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents issuance costs in connection with regulation A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_IssuanceCostsInConnectionWithRegulationA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">$ (20,726,738)<span></span>
</td>
<td class="num">$ (11,278,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,005,132<span></span>
</td>
<td class="nump">229,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">480,594<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets', window );">Change in operating lease right-of-use assets</a></td>
<td class="nump">53,549<span></span>
</td>
<td class="nump">47,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_GainLossOnSettlements', window );">Loss on SEPA settlements</a></td>
<td class="nump">127,083<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes', window );">Change in fair value of debentures and secured promissory notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes', window );">Cost to issue debentures and secured promissory notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">111,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered', window );">Issuance of common shares in connection with non-cash compensation for services rendered</a></td>
<td class="nump">378,070<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(707,316)<span></span>
</td>
<td class="num">(113,201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">3,147,801<span></span>
</td>
<td class="nump">404,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(680,071)<span></span>
</td>
<td class="nump">1,065,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(76,605)<span></span>
</td>
<td class="num">(56,113)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Related party payable</a></td>
<td class="nump">45,370<span></span>
</td>
<td class="num">(21,186)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(15,953,129)<span></span>
</td>
<td class="num">(9,409,825)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common shares and warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,790,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debentures and secured promissory notes</a></td>
<td class="nump">22,000,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">977,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Cost to issue debentures and secured promissory notes</a></td>
<td class="num">(615,000)<span></span>
</td>
<td class="num">(54,582)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Cash paid for financing costs in connection with SEPA</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(297,783)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debentures and secured promissory notes</a></td>
<td class="num">(5,532,613)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ProceedsFromIssuanceOfSharesUnderSettlements', window );">Proceeds from issuance of common shares under SEPA</a></td>
<td class="nump">4,102,740<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts', window );">Proceeds from issuance of common shares under ATM, net of issuance costs</a></td>
<td class="nump">12,399,815<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">32,354,942<span></span>
</td>
<td class="nump">14,915,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Foreign currency effect on cash and cash equivalents</a></td>
<td class="nump">84,509<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents and restricted cash during the period</a></td>
<td class="nump">16,486,322<span></span>
</td>
<td class="nump">5,505,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash, beginning of the period</a></td>
<td class="nump">8,705,218<span></span>
</td>
<td class="nump">4,164,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash, end of the period</a></td>
<td class="nump">25,191,540<span></span>
</td>
<td class="nump">9,669,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">330,626<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement', window );">Deferred issuance costs on issued shares related to SEPA agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_IssuanceCostsIncludedInAccountsPayable', window );">Issuance costs included in accounts payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 271,618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of change in fair value of debentures and secured promissory notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of costs to issue debentures and secured promissory notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of deferred issuance costs on issued shares related to SEPA agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_GainLossOnSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of gain loss on settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_GainLossOnSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_IssuanceCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance costs included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_IssuanceCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of issuance of common shares in connection with non-cash compensation for services rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of proceeds from issuance of common stock at the market offering net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_ProceedsFromIssuanceOfSharesUnderSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of proceeds from issuance of shares under settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_ProceedsFromIssuanceOfSharesUnderSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 44: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of business [Text Block]</a></td>
<td class="text">
    <p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1. Description of business</strong></span></span></p>
    <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Medicus Pharma Ltd. (the "Company"), formerly Interactive Capital Partners Corporation, is a clinical stage, multi-strategy, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets.</span></span></p>
    <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is a public limited company originally incorporated pursuant to the provisions of the <i>Business Corporations Act</i> (Ontario) on April 30, 2008, as a private company named Interactive Capital Partners Corporation, with nominal assets and liabilities. The Company's registered office is located at 100 King Street West, Suite 3400, One First Canadian Place, Toronto, Ontario, Canada, and its head office is located at 300 Conshohocken State Rd., Suite 200, W. Conshohocken, PA.</span></span></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.4-03(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies [Text Block]</a></td>
<td class="text">
    <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2. Summary of significant accounting policies </strong></span></span></p>

      <div>
        <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Basis of presentation and consolidation</strong></span></span></p>
        <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying unaudited condensed consolidated financial statements included herein have been prepared in conformity with generally accepted accounting principles in the United States ("GAAP") and under the rules and regulations of the United States Securities and Exchange Commission ("SEC") for interim reporting. The accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, that are necessary to present fairly the Company's financial position, results of operations, and cash flows. The condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosures of the Company normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC's rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto for the year ended December 31, 2025, included in the Company's Annual Report on Form 10-K, as amended, originally filed with the SEC on March 25, 2026 (the "2025 Annual Report"). These condensed consolidated financial statements include the financial statements of the Company and its subsidiaries, SkinJect, Inc., Medicus Pharma Inc., Antev Limited ("Antev") and MDCX Holdings, LLC. All intercompany balances and transactions have been eliminated on consolidation. Non-controlling interest in the consolidated financial statements represents the portion of Antev not 100% owned by the Company. The functional currency of the Company and its three wholly-owned subsidiaries, SkinJect, Inc., Medicus Pharma Inc. and MDCX Holdings, LLC. is the United States dollar (USD). The functional currency of the Company's other subsidiary, Antev is Pound Sterling (GBP).</span></span></p>
      </div>


      <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Foreign operations remeasurement and translation</strong></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions, and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates, are generally recognized in the condensed consolidated statements of operations and comprehensive loss. The results and financial position of foreign operation which has functional currency different from presentation currency are translated into the presentation currency as follows: assets and liabilities are translated at the closing rate at the date of that statement of financial position, income and expenses are translated at average exchange rates, and all resulting translated exchange differences are recognized in a separate component of other comprehensive loss within the condensed consolidated statement of changes in shareholders equity.</span></span></p>


      <div>
        <div>
          <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Use of estimates</strong></span></span></p>
        </div>
        <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of these condensed consolidated financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements, and the reported amounts of income and expenses during the reporting period. Such estimates include the valuation of stock-based awards, the incremental borrowing rate used to discount the Company's operating lease liabilities, fair value of the Company's debentures and secured promissory notes and warrants, and valuation allowance on deferred tax assets, all of which are management's best estimates. Estimates are based on historical experience, where applicable, and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. By their nature, these estimates are subject to measurement uncertainty and the effect on the financial statements of changes in estimates in future years could be significant. Management believes that the estimates utilized in preparing the financial statements are reasonable, however, actual results could differ from those estimates.</span></span></p>
      </div>

    <p style="margin:0pt">&#160;</p>
    <div></div>

      <div>
        <div>
          <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Operating segments</strong></span></span></p>
        </div>
        <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating segments are identified as components of an entity about which separate discrete financial information is available for evaluation by the chief operating decision-maker ("CODM") in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.</span></span></p>
      </div>


      <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Recently issued accounting pronouncements </strong></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2024, the FASB issued ASU 2024-03 "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures" to provide greater transparency about the components of specific expense categories in the income statements. The effective dates of ASU 2024-03 were subsequently clarified by ASU 2025-01. ASU 2025-01 is effective for our annual period beginning January 1, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting the amendment on the Company's financial statements.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">There were no other significant updates to the recently issued accounting standards which may be applicable to the Company. Although there are several other new accounting pronouncements issued or proposed by the FASB, the Company does not believe any of those accounting pronouncements have had or will have a material impact on its financial position or operating results.</span></span></p>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance sheet components<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_BalanceSheetComponentsAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance sheet components [Text Block]</a></td>
<td class="text">
    <div>
      <p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>3.</strong>&#160;<strong>Balance sheet components</strong></span></span></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Prepaid expenses include the following:</span></span></span></span></p>

        <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>June 30, 2026</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>December 31, 2025</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Insurance</span></span></span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>109,405</span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>345,084</span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Contract research organizations</span></span></span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>390,000</span></span></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>410,000</span></span></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Professional services</span></span></span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>330,400</span></span></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>300,033</span></span></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Prepaid services</span></span></span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>977,656</span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>31,004</span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt">&#160;</td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>1,807,461</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>1,086,121</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>

        </table>

      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued expenses and other current liabilities include the following:</span></span></span></span></p>

        <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>June 30, 2026</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>December 31, 2025</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued legal fees</span></span></span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>110,976</span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>352,864</span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued compensation and benefits</span></span></span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>195,082</span></span></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>300,181</span></span></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued other</span></span></span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,949</span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>342,245</span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt">&#160;</td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>308,007</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:2%">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>995,290</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:2%">&#160;</td>
            </tr>

        </table>

    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_BalanceSheetComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_BalanceSheetComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases [Text Block]</a></td>
<td class="text">
    <div>
      <p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>4. Leases</strong></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2026, the Company had one operating lease for its corporate office that commenced in 2024, for which the Company recorded a right-of-use asset and lease liability as of the commencement date. The Company's lease does not contain a purchase option. Where the Company's lease contains an option to extend the lease term, the extended lease term is only included in the measurement of the lease when it is reasonably certain to remain in the lease beyond the non-cancellable term. The Company's lease also contains variable lease costs, which pertain to common area maintenance and other operating charges, that are expensed as incurred.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance sheet information related to the Company's lease is presented below:</span></span></p>

        <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

            <tr>
              <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Six Months Ended </strong><br/><strong>June 30, 2026</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Year Ended </strong><br/><strong>December 31,2025</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Operating lease</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease right-of-use assets</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">117,184</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">170,733</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease liabilities - current</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">137,330</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">145,456</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease liabilities - non-current</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">60,139</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>

        </table>

      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other information related to leases is presented below:</span></span></p>

        <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

            <tr>
              <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap">&#160;</td>
              <td colspan="4" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Six months ended June 30,</strong></span></span></span></span></td>
              <td colspan="1" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2026</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2025</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease cost</span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease cost</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">61,889</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">61,889</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other information</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating cash flows used in operating leases</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(76,952</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(70,080</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">)</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Remaining lease term (in years)</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.00</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.92</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Discount rate</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10%</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10%</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>

        </table>

      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2026, the annual future minimum lease payments of the Company's operating lease liabilities were as follows:</span></span></p>

        <div>
          <table cellpadding="0" cellspacing="0" style="width:50%;border-collapse:collapse;font-size:10pt;border-color:#000000">

              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#231f20">2026</span></span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#231f20">74,348</span></span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2027</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#231f20">74,348</span></span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#231f20">Total future minimum lease payments, undiscounted</span></span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">148,696</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value discount</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(11,366</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total lease liability</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>137,330</strong></span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000">&#160;</td>
              </tr>

          </table>
        </div>

    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Share capital [Text Block]</a></td>
<td class="text">
    <div>
      <p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>5. Share capital</strong></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Authorized</i></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has authorized an unlimited number of common shares participating, voting and without nominal or par value. Each holder of common shares is entitled to one vote for each share owned on all matters voted upon by shareholders.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Regulation A Offering</i></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On March 10, 2025, the Company closed a Tier II Regulation A offering for gross proceeds of $4,172,000. The Company issued 1,490,000 units at a price of $2.80 per unit. Each unit consisted of one common share of the Company and one warrant to purchase one common share of the Company (each a "Regulation A Warrant"). The Regulation A Warrants have an exercise price of $2.80 per share and will expire 5 years from the date of issuance on March 10, 2030. The Company incurred total issuance costs of $483,020, including legal fees and placement fees directly related to the issuance. The issuance costs incurred were recognized as a reduction in equity and allocated based on the relative fair values of the Regulation A Warrants and common shares on a standalone basis. The fair value of the common shares was based on the Company's share price on the day of issuance of $3.40 and the fair value of the Regulation A Warrants was $2.63 per warrant. The Regulation A Warrants were recognized in additional paid-in capital as they met the criteria for equity classification.</span></span></p>
      <div></div>
      <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company's Regulation A Warrants are not actively traded and are therefore classified as Level 3 within the fair value hierarchy. The fair value of these warrants is estimated using a Black-Scholes option pricing model. The valuation incorporates significant unobservable inputs and management judgment.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2026, 133,800 of the 1,490,000 Regulation A Warrants have been exercised for cash for proceeds to the Company of $374,640. No Regulation A Warrants were exercised during the six months ended June 30, 2026.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the Regulation A Warrants were estimated using the Black-Scholes model with the following assumptions:</span></span></p>

        <div>
          <table cellpadding="0" cellspacing="0" style="width:50%;border-collapse:collapse;font-size:10pt;border-color:#000000;margin-left:auto;margin-right:auto">

              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Issue Date</strong><br/><strong>March 10,<br/>2025</strong></span></span></span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuation date share price</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.40</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise price</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.80</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.98%</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected warrant life</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.00 years</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">97.81%</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>

          </table>
        </div>

      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrant activity as below:</span></span></p>

        <div>
          <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Number of </strong><br/><strong>common share </strong><br/><strong>warrants </strong><br/><strong>outstanding</strong></span></span></span></span></td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Weighted<br/>average exercise<br/>price $</strong></span></span></span></span></td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Weighted average<br/>remaining life<br/>(years)</strong></span></span></span></span></td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding as at December 31, 2025</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,281,795</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.70</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.90</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants granted</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants exercised</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total Warrants outstanding as at June 30, 2026</strong></span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:10%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>7,281,795</strong></span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:10%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2.70</strong></span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:10%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>4.41</strong></span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>

          </table>
        </div>

      <p style="margin:0pt">&#160;</p>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">The number of warrants outstanding as at the six months ended June 30, 2026:</p>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>

        <div>
          <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt">

              <tr>
                <td style="width:20%;vertical-align:top;border-bottom:0.75pt solid #000000;text-align:center;padding-left:5pt;padding-right:5pt;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
                <td colspan="4" style="padding-right:5pt;padding-left:5pt;vertical-align:top;border-bottom:0.75pt solid #000000;text-align:center;width:80%;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Warrants outstanding</strong></span></span></span></span></td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;border-bottom:0.75pt solid #000000;white-space:nowrap;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;border-bottom:0.75pt solid #000000;white-space:nowrap;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Expiry date</strong></span></span></span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Exercise price</strong></span></span></span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Number outstanding</strong></span></span></span></span></td>
                <td style="width:20%;vertical-align:top;border-bottom:0.75pt solid #000000;text-align:right;padding-left:5pt;padding-right:5pt;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Number<br/>exercisable </strong></span></span></span></span></td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants issued as part of the IPO</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">November 15, 2029</span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$ 4.64</span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">985,595</span></span></td>
                <td style="width:20%;vertical-align:top;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:right;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">985,595</span></span></td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Regulation A Warrants</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">March 10, 2030</span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$ 2.80</span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">16,200</span></span></td>
                <td style="width:20%;vertical-align:top;text-align:right;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">16,200</span></span></td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30, 2030 Warrants</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 2, 2030</span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;background-color:#e6efff;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$ 3.10</span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;background-color:#e6efff;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,260,000</span></span></td>
                <td style="width:20%;vertical-align:top;background-color:#e6efff;text-align:right;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,260,000</span></span></td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Series C and D Warrants</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 5, 2031</span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$ 2.00</span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,020,000</span></span></td>
                <td style="width:20%;vertical-align:top;text-align:right;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,020,000</span></span></td>
              </tr>

          </table>
        </div>

      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Standby Equity Purchase Agreement </i></span></span></p>
      <div></div>
      <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On February 10, 2025, the Company also announced that it had entered into a standby equity purchase agreement (the "SEPA") with YA II PN, Ltd. ("Yorkville"). Pursuant to the SEPA and subject to the satisfaction of certain conditions, Yorkville has committed to purchase the Company's common shares in increments up to an aggregate gross sales price of $15,000,000 during the 36 months following the date of the SEPA (such shares, the "Shares"). The Shares will be sold at the Company's option pursuant to the SEPA at 97% of the Market Price (as defined pursuant to the SEPA) and purchases are subject to certain limitations set forth in the SEPA. For the six months ended June 30, 2026, the Company issued 5,336,780 common shares pursuant to the SEPA at market prices for gross proceeds of $4,229,823 and net proceeds of&#160; $4,102,740. During the six months ended June 30, 2026, $3,223,980 of the gross proceeds received under the SEPA were held back to partially repay the Company's Yorkville debenture and related interest obligations. As at June 30, 2026 the Company has $2,489,206 available to exercise in relation to the SEPA.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 29, 2025, the Company entered into an equity distribution agreement (the "ATM Agreement") with Maxim Group LLC and Yorkville Securities LLC ("Yorkville Securities" and together with Maxim Group LLC, the "Agents") to create an at-the-market equity program (the "ATM"). Under the ATM Agreement, the Company may offer and sell its common shares from time to time through the Agents. The Company agreed to pay the Agents a commission equal to 3% of the gross sales from the sales of the shares pursuant to the ATM Agreement. For the six months ended June 30, 2026, the Company has issued 28,248,981 common shares as part of the program. The gross proceeds from the issuance were $12,868,181.</span></span></p>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479951/505-20-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479982/505-20-S25-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479951/505-20-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479982/505-20-S25-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 1.D.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479921/505-20-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479951/505-20-S50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 1.B.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480148/855-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479982/505-20-S25-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based compensation [Text Block]</a></td>
<td class="text">
    <div>
      <p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>6.</strong>&#160;<strong>Stock-based compensation </strong></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">At June 30, 2026, the Company had in place a stock option plan for employee, non-employee directors, and consultants of the Company (the "Plan"). The Plan provides both for the direct award or sale of shares and for the grant of options to purchase shares. Under the plan, the total number of shares available for options cannot exceed 10% of the Company's issued and outstanding common shares at the time of any grant. The Company is authorized to issue options to employees, non-employee directors and consultants under the plan.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On March 30, 2026, the Company issued 975,000 stock options to directors, officers, and employees of the Company. The options are exercisable at $0.50 per share, expire five years from the grant date, and vest quarterly over a one-year period. On June 3, 2026, the Company issued an additional 2,075,000 stock options to directors, officers, and employees of the Company. The options are exercisable at $0.36 per share, expire five years from the grant date, and vest quarterly over a one-year period. During the three months ended June 30, 2026, the Company accelerated the vesting of all options outstanding except the 2,075,000 options that were granted on June 3, 2026.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table summarizes option transactions for the Plan:</span></span></p>

        <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-size:10pt;width:100%;border-color:#000000">

            <tr>
              <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Number of</strong><br/><strong>options</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Weighted</strong><br/><strong>average</strong><br/><strong>exercise price</strong><br/><strong>$</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Weighted</strong><br/><strong>average</strong><br/><strong>remaining</strong><br/><strong>contractual life</strong><br/><strong>(years)</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Aggregate</strong><br/><strong>intrinsic value</strong><br/><strong>$</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
            </tr>
            <tr style="background-color:rgb(230, 239, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding at December 31, 2024</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1,185,000</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1.47</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>4.18</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1.18</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>100,000</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2.60</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>5.00</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(230, 239, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding at June 30, 2025</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1,285,000</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1.56</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>3.79</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1.43</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Exercisable at June 30, 2025</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>980,000</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1.25</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>4.01</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1.74</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(230, 239, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Unvested at June 30, 2025</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>305,000</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2.56</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>4.44</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(230, 239, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding at December 31, 2025</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2,505,000</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2.05</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2.75</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:20pt;padding-right:5pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>3,050,000</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>0.40</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>4.87</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(230, 239, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:20pt;padding-right:5pt;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(45,000</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1.79</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding at June 30, 2026</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>5,510,000</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1.14</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>4.32</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(230, 239, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Exercisable at June 30, 2026</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>3,435,000</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1.62</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>3.94</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Unvested at June 30, 2026</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2,075,000</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>0.36</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>4.93</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>

        </table>

      <p style="margin:0pt">&#160;</p>
      <div></div>
      <p style="margin:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2026, there were $419,075 of unrecognized stock-based compensation cost related to share options outstanding, which is expected to be recognized over a weighted-average period of 0.93 years.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The weighted average grant date fair value of awards for options granted during the six months ended June 30, 2026, was $0.24. The fair value of options granted was estimated using the Black-Scholes option pricing model, resulting in the following weighted average assumptions for the options granted:</span></span></p>

        <div>
          <table cellpadding="0" cellspacing="0" style="width:90%;border-collapse:collapse;font-size:10pt;border-color:#000000">

              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>June 30, 2026</strong><br/><strong>Weighted-average</strong></span></span></span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise price</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.40</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share price</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.37</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.13%</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Estimated life (in years)</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">76.33%</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>

          </table>
        </div>

      <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>For the three and six months ended June 30, 2026, stock-based compensation expense was $1,405,826 and $2,005,133, respectively. For the three and six months ended June 30, 2025, stock-based compensation expense was $117,448 and $585,442, respectively. Stock-based compensation expense has been reported in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss within the line items &#8216;general and administrative&#8217; expenses</span></span>.</span></span></p>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related party transactions [Text Block]</a></td>
<td class="text">
    <div>
      <div>
        <p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>7.</strong>&#160;<strong>Related party transactions</strong></span></span></p>
        <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 18, 2023, the Company signed an agreement with RBx Capital, LP ("RBx"), a family office controlled by the Company's Executive Chairman and CEO, that provides for certain managerial positions to be filled from within RBx. RBx is responsible for the payment and provision of all wages, bonuses, and benefits for these positions. In January 2026, reimbursable salaries paid to RBx pursuant to this agreement were increased to $125,000 per month from $100,000 per month. Reimbursable salaries paid to RBx were $750,000 and $600,000 during the six months ended June 30, 2026 and 2025, respectively. Additional expenses of $455,486 and $64,046 were incurred by RBx on behalf of the Company during the three months ended June 30, 2026 and 2025, respectively. Additional expenses of $898,983 and $104,911 were incurred by RBx on behalf of the Company during the six months ended June 30, 2026 and 2025, respectively.&#160;The total amount of accounts payable to RBx was $161,846 and $121,273 as of June 30, 2026 and 2025, respectively.</span></span></p>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(e)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurements [Text Block]</a></td>
<td class="text">
    <p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>8.</strong>&#160;<strong>Fair value measurements</strong></span></span></p>
    <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accounting guidance for fair value establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></span></p>
    <p style="margin-left:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1: Observable inputs such as quoted prices in active markets;</span></span></p>
    <p style="margin-left:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly; and</span></span></p>
    <p style="margin-left:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 3: Unobservable inputs in which there is little or no market data, or which require the reporting entity to develop its own assumptions.</span></span></p>
    <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company's cash and cash equivalents and restricted cash are classified as Level 1. The fair value of the Company's cash and cash equivalents is determined based on market pricing that is both objective and publicly available. As of June 30, 2026 and December 31, 2025, the fair value of the Company's cash and cash equivalents and restricted cash were $25,191,540 and $8,705,218, respectively. As of June 30, 2026 and December 31, 2025, the Company's cash equivalents are invested in money market funds.</span></span></p>
    <div></div>
    <div style="margin-top:0pt;margin-bottom:0pt">

        <div style="margin-top:0pt;margin-bottom:0pt">
          <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;width:100%;border-color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

              <tr style="margin-top:0pt;margin-bottom:0pt">
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">June 30, 2026</strong></span></span></span></p>
                </td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt">
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Level 1</strong></span></span></span></td>
                <td style="vertical-align:bottom;text-align:center;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Level 2</strong></span></span></span></td>
                <td style="vertical-align:bottom;text-align:center;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Level 3</strong></span></span></span></td>
                <td style="vertical-align:bottom;text-align:center;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Total</strong></span></span></span></td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">
                <td style="padding-right:5.4pt;padding-left:16.2pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Current assets:</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
                <td style="padding-right:5.4pt;padding-left:27pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Money market funds</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">13,573,269</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">-</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">-</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">13,573,269</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">
                <td style="padding-right:5.4pt;padding-left:52.2pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Total assets measured at fair value</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">13,573,269</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">-</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">-</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">13,573,269</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;text-align:right;width:10%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;width:1%;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);text-align:center;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">December 31, 2025</strong></span></span></span></td>
                <td style="vertical-align:bottom;width:2%;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Level 1</strong></span></span></span></td>
                <td style="vertical-align:bottom;width:2%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Level 2</strong></span></span></span></td>
                <td style="vertical-align:bottom;width:2%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Level 3</strong></span></span></span></td>
                <td style="vertical-align:bottom;width:2%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Total</strong></span></span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:2%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">
                <td style="padding-right:5.4pt;padding-left:16.2pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Current assets:</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
                <td style="padding-right:5.4pt;padding-left:27pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Cash and cash equivalents</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">8,705,218</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">-</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">-</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">8,705,218</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">
                <td style="padding-right:5.4pt;padding-left:52.2pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Total assets measured at fair value</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">8,705,218</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">-</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">-</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">8,705,218</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
              </tr>

          </table>
        </div>

    </div>
    <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company did not reclassify any investments between levels in the fair value hierarchy during the periods presented.</span></span></p>
    <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The carrying value of the Company's secured promissory notes described in Note 12 below approximates the fair value since the financial instrument is short-term with a maturity date of November 27, 2027. As of June 30, 2026 and December 31, 2025, the carrying amounts of the Company's other financial instruments, which include cash and cash equivalents and restricted cash, accounts payable and accrued expenses approximate fair values because of their short-term maturities.</span></span></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies [Text Block]</a></td>
<td class="text">
    <div>
      <div>
        <div>
          <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>9.</strong>&#160;<strong>Commitments and contingencies</strong></span></span></p>
          <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Commitments</i></span></span></p>
          <div>
            <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As part of the acquisition of Antev, the Company may be required to make future payments contingent on the achievement of specified milestones. These potential payments represent a commitment and may result in future cash outflows. As these milestones conditions are not considered probable, the Company has not recognized liability related to the contingent consideration.</span></span></p>
            <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to the terms of the Antev acquisition, the Company acquired 98.60% ownership in Antev, including all the assets and its In-Process Research and Development (IPR&amp;D) &#8211; Teverelix. There was additional contingent consideration based on the following development milestones of the IPR&amp;D:</span></span></p>

              <table border="0" style="border-collapse:collapse" width="100%">

                  <tr style="background-color:rgb(230, 239, 255)">
                    <td style="vertical-align:top;padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Phases</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Contingent Consideration agreed for Antev shares acquired through issue of shares</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Contingent Consideration agreed for Antev shares acquired by cash payment</span></span></span></span></span></span></td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(i) Advanced Prostate Cancer - Phase 2 success or registration</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$2.00 per common share issued</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$1.47 per Antev share (pro rata interest in $5,333,200)</span></span></span></span></span></span></td>
                  </tr>
                  <tr style="background-color:rgb(230, 239, 255)">
                    <td style="padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(ii)Acute Urinary Retention Prevention - Phase 2 success or registration</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$7.50 per common share issued</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$5.52 per Antev share (pro rata interest in $19,999,500)</span></span></span></span></span></span></td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(iii) FDA NDA approval - Hormone therapy for prostate cancer</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Up to $20,000,000 (subject to pro rata reduction)</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$5.52 per Antev share (pro rata interest in $20,000,000</span></span></span></span></span></span></td>
                  </tr>
                  <tr style="background-color:rgb(230, 239, 255)">
                    <td style="padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(iv) FDA NDA approval &#8211; AUR prevention</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Up to $20,000,000 (subject to pro rata reduction)</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$5.52 per Antev share (pro rata interest in $20,000,000)</span></span></span></span></span></span></td>
                  </tr>

              </table>

          </div>
          <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2026, the Company had no other long-term commitments.</span></span></p>
          <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Contingencies </i></span></span></p>
          <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In the ordinary course of business, from time to time, the Company may be involved in various claims related to operations, rights, commercial, employment or other claims. Although such matters cannot be predicted with certainty, management does not consider the Company's exposure to such claims to be material to these consolidated financial statements.</span></span></p>
        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment reporting<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment reporting [Text Block]</a></td>
<td class="text">
    <div>
      <div>
        <p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>10.</strong>&#160;<strong>Segment reporting</strong></span></span></span></span></p>
        <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the CODM in deciding how to allocate resources to an individual segment and in assessing performance. The Company manages the business activities on a consolidated basis and operates as&#160;one reportable segment that constitutes all of the consolidated entity, which is the business of advancing the clinical development program of the Company&#8217;s product, while opportunistically identifying, evaluating, and acquiring accretive assets, properties or businesses. The Company&#8217;s CODM is its Chief Executive Officer. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM uses consolidated net loss to measure segment loss, allocate resources and assess performance. The significant segment expense categories (general and administrative and research and development) are consistent with those presented on the face of the statements of operations and comprehensive loss. Other segment items are interest (income) expenses which are consistent with those presented on the face of the statements of operations and comprehensive loss. Additionally, the CODM reviews cash forecast models to determine where the Company will invest in planned research and development activities.&#160;As the Company&#8217;s operations are comprised of a single reporting segment, the segment assets are reflected on the accompanying condensed consolidated balance sheet as Total Assets. Segment asset information is not used by the CODM to allocate resources.</span></span></span></span></span></span></p>
        <div>
          <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company's single reporting segment. A reconciliation to consolidated operating expenses as the Company&#8217;s single segment operating loss for the three and six months ended June 30, 2026 and 2025 is included in the table below:</span></span></span></p>

            <table cellpadding="0" cellspacing="0" style="font-size:10pt;border-collapse:collapse;width:100%;border-color:#000000">

                <tr>
                  <td style="vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="4" style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Three Months Ended June 30,</strong></span></span></span></td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="4" style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Six Months Ended June 30,</strong></span></span></span></td>
                  <td colspan="1" style="vertical-align:bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></td>
                  <td style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>2026</strong></span></span></span></td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>2025</strong></span></span></span></td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>2026</strong></span></span></span></td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>2025</strong></span></span></span></td>
                  <td colspan="1" style="vertical-align:bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Research and development expenses:</strong></span></span></span></td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>SkinJect</strong></span></span></span></td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-left:10pt;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Clinical, manufacturing and regulatory activities</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,268,747</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,011,362</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2,011,288</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2,453,931</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-left:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Professional services and intellectual property</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>96,653</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>71,561</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>145,227</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>116,678</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Teverelix</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-left:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Clinical, manufacturing and regulatory activities</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2,927,793</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>3,850,023</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-left:10pt;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Professional services and intellectual property</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>46,169</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>78,341</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Salaries and benefits</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>568,329</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>356,641</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,527,207</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>875,169</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Total research and development expenses</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>4,907,692</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>1,439,564</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>7,612,085</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>3,445,778</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Total general and administrative expenses</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>6,571,097</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>4,576,524</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>12,463,781</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>7,696,584</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Total operating expenses</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>11,478,789</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>6,016,088</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>20,075,866</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>11,142,362</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Other income (expense):</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Finance income</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>40,004</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>63,870</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Interest income (expense)</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(205,638</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(523,789</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Loss on SEPA settlements</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(127,083</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Change in fair value of debentures</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(200,000</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(200,000</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Total other income (expense)</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(205,638</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(159,996</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(650,872</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(136,130</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Net loss for the period</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(11,684,427</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(6,176,084</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(20,726,738</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(11,278,492</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                </tr>

            </table>

        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debentures and Secured Promissory Notes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Debentures and Secured Promissory Notes [Text Block]</a></td>
<td class="text">
    <div>
      <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>11. Debentures and Secured Promissory Notes</strong></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On September 17, 2025, the Company entered into a securities purchase agreement with Yorkville to issue a debenture with the principal amount of $8,000,000 issued at a discount of $633,707 for proceeds of approximately $7,366,293. Interest accrued on the outstanding principal amount of the debenture at an annual rate of 8%, subject to a potential increase to 18% per annum upon the occurrence of certain events of default. The debenture had a maturity date of September 17, 2026, and was to be repaid using proceeds from the SEPA; however, on May 27, 2026, the Company used part of the proceeds from the issuance of the Secured Promissory Notes (as defined herein) to repay and extinguish the outstanding balance and accrued interest owing on the debenture.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The debenture was initially recorded at fair value, based on the discounted proceeds. Subsequently, the Company accounted for the debenture at amortized cost using the effective interest rate method, resulting in accretion expense of $374,712 for the six months ended June 30, 2026. The effective interest rate calculated was 32.75% as of June 30, 2026. On May 27, 2026, the Company repaid the outstanding principal balance of $2,343,778 related to the Yorkville debenture, together with accrued interest of $135,664, using proceeds received from the issuance of the Secured Promissory Notes.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 27, 2026, the Company entered into a Note Purchase Agreement with Streeterville Capital, LLC ("Streeterville"), pursuant to which the Company issued two secured promissory notes with aggregate principal amounts of $22,864,225. The first promissory note ("Note A") was issued with a face value of $12,864,225 and a purchase price of $12,000,000, resulting in an issue discount of $864,225. The second promissory note ("Note B") was issued with a principal amount of $10,000,000. Note A bears interest at 8.75% per annum compounded daily and Note B bears interest at 5.0% per annum compounded daily. Both promissory notes mature on November 27, 2027.</span></span></p>
      <div style="margin-top:0pt;margin-bottom:0pt"></div>
      <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span id="page_21"></span></span></span></p>
      <p style="text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">The Secured Promissory Notes are secured by a first-ranking security interest over substantially all assets of the Company. Guarantees are provided by the Company's subsidiaries.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company evaluated the transaction under ASC 470-50, Debt Modifications and Extinguishments, and determined that the issuance of the Streeterville promissory notes and repayment of the Yorkville debenture should be accounted for as an extinguishment of debt. Accordingly, the carrying amount of the Yorkville debenture was derecognized upon settlement, and the newly issued promissory notes were recognized as new debt instruments.</span></span></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company initially recorded the Note A and Note B ("promissory notes") at fair value based on the proceeds received, net of directly attributable debt issuance costs. Subsequently, the Company accounts for the promissory notes at amortized cost using the effective interest method. Debt issuance costs are amortized over the contractual life of the respective promissory notes. The&#160;Company&#160;incurred $615,000 in debt issuance cost related to the promissory notes.</span></span></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Note A permits the lender to require monthly redemptions beginning on the seventh month following the issuance, subject to the terms of the agreement. Beginning on the seventh month following the issuance date,&#160;the lender has the right to require monthly redemptions of up to $500,000 per month plus make-whole interest calculated as if the redeemed amount had remained outstanding until maturity. If the Company fails to satisfy a redemption notice within the required period, the outstanding balance is increased by 20% of the applicable redemption amount. In addition, beginning on the sixth month following the issuance date, both Note A and Note B permit the lender to require limited redemptions of up to 5% of the cumulative daily dollar trading volume during specified redemption windows when the Company's common shares trade at least 15% above the defined Minimum Price per the agreement. Such limited redemptions are payable at 110% of the applicable redemption amount.</span></span></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Both Note A and Note B contain customary trigger event and event of default provisions, including payment defaults, insolvency events, delisting determinations and specified corporate transactions.&#160;&#160;Upon the occurrence of such trigger events, the lender may increase the outstanding balance by 5% for certain minor trigger events or 15% for certain major trigger events, as more fully described in Note A and Note B, subject to contractual limitations. Following an event of default, the lender may accelerate repayment and default interest may accrue at a rate of up to 18% per annum, subject to applicable law.</span></span></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As at June 30, 2026, the Company was in compliance with the terms and covenants of both notes.</span></span></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In connection with Note B, $10,000,000 of the proceeds were deposited into a restricted deposit account maintained pursuant to a Deposit Account Control Agreement. The lender has control rights over the account upon the occurrence of specified trigger events and may direct the disposition of funds in the account. Under certain circumstances, amounts outstanding under Note B may be exchanged into additional Note A borrowings. Specifically, for each $2.0 million of Note A principal repaid, up to $1.0 million of the outstanding Note B balance may be exchanged into a new Note A advance, subject to the conditions set out in the financing agreements.</span></span></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company evaluated the embedded features contained within the promissory notes and concluded that certain features would require bifurcation under ASC 815; however, the fair value of such features was determined to be de minimis. Accordingly, no embedded derivative liability was recorded as of June 30, 2026.</span></span></p>

        <div>
          <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Debenture issued on September 17, 2025:</span></span></td>
                <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30, 2026</strong></span></span></td>
                <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net balance as at December 31, 2025</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,245,543</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Repayment of new debenture</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3,180,084</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              </tr>
              <tr>
                <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest accretion</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">374,712</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest payment</span></span></td>
                <td style="vertical-align:bottom;text-align:left;border-bottom:0.75pt solid #000000;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(96,393</span></span></td>
                <td style="vertical-align:bottom;text-align:left;border-bottom:0.75pt solid #000000;width:2%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              </tr>
              <tr>
                <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ending balance as of March 31, 2026</span></span></td>
                <td style="vertical-align:bottom;text-align:left;border-bottom:2.25pt double #000000;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                <td style="vertical-align:bottom;text-align:right;border-bottom:2.25pt double #000000;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,343,778</span></span></td>
                <td style="vertical-align:bottom;text-align:left;border-bottom:2.25pt double #000000;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Repayment of Yorkville debenture</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2,343,778</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              </tr>
              <tr>
                <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Ending balance as of June 30, 2026</strong></span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;border-bottom:2.25pt double #000000;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;border-bottom:2.25pt double #000000;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;border-bottom:2.25pt double #000000;width:2%;background-color:#e6efff">&#160;</td>
              </tr>

          </table>
        </div>

      <div>

          <div>
            <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
            <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

                <tr>
                  <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Note A issued on May 27, 2026:</strong></span></span></td>
                  <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30, 2026</strong></span></span></td>
                  <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds of Note A</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,864,225</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Discount on debt</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(864,225</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Debt issuance costs</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(349,091</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest accretion</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">79,257</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Ending balance</strong></span></span></td>
                  <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;border-bottom:2.25pt double #000000;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                  <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;border-bottom:2.25pt double #000000;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,730,166</span></span></td>
                  <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;border-bottom:2.25pt double #000000;width:2%;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Note B issued on May 27, 2026:</strong></span></span></td>
                  <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30, 2026</strong></span></span></td>
                  <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds of Note B</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,000,000</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Debt issuance costs</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(265,909</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest accretion</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">18,286</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Ending balance</strong></span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                  <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,752,376</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
                </tr>

            </table>
          </div>

      </div>
      <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif">&#160;</p>
      <div></div>
      <div style="margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">As of June 30, 2026, accrued interest of $81,426 related to the promissory notes was included in accounts payable on the condensed consolidated balance sheet, with the corresponding amount recognized in interest expense in the condensed consolidated statement of operations and comprehensive loss.</span></span></p>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedAssetsDisclosureTextBlock', window );">Restricted Cash [Text Block]</a></td>
<td class="text">
    <div>
      <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>12. Restricted Cash</strong></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of June 30, 2026, cash of US$10.0 million was held in a restricted deposit account maintained by a subsidiary of the Company pursuant to the Deposit Account Control Agreement entered into in connection with the Note B financing. The funds are subject to a first-ranking security interest in favour of the lender and are not available for general corporate purposes except in accordance with the financing arrangements. Accordingly, the balance has been presented as restricted cash in the condensed interim consolidated statement of financial position.</span></span></p>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478482/942-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(3)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_LiquidityAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_LiquidityTextBlock', window );">Liquidity and Going Concern [Text Block]</a></td>
<td class="text">
    <div>
      <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>13. Liquidity and Going Concern</strong></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. In addition to the ATM, SEPA and Debenture (as defined herein), management believes that the Company has access to additional capital resources through public and/or private equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, it is possible that the Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. Further, the terms of any financing may adversely affect the holdings or the rights of the Company's shareholders. If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays or entirely prevent the Company's continued efforts to progress its research and development program, pursue product portfolio expansion or commercialize its current or future products, each of which is critical to the realization of the Company's business plan and its future operations. This uncertainty, along with the Company's history of losses, indicates that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. The financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is subject to risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company's research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable.</span></span></p>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_LiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_LiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_LiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_LiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss per share [Text Block]</a></td>
<td class="text">
    <div>
      <p style="margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>14.</strong>&#160;<strong>Loss per share</strong></span></span></p>
      <p style="margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows:</span></span></p>

        <table cellpadding="0" cellspacing="0" style="font-size:10pt;border-collapse:collapse;width:100%;border-color:#000000">

            <tr>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td colspan="4" style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Three Months Ended June 30,</strong></span></span></td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td colspan="4" style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Six Months Ended June 30,</strong></span></span></td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2026</strong></span></span></td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2025</strong></span></span></td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2026</strong></span></span></td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2025</strong></span></span></td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Net loss attributable to shareholders</strong></span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(11,617,705</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6,176,084</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(20,659,848</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(11,278,492</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
            </tr>
            <tr>
              <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Weighted average number of common shares outstanding </strong></span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">55,055,225</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14,284,261</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">47,566,945</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13,853,305</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Basic and diluted net loss per share attributable to shareholders</strong></span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.21</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.43</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.43</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.81</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
            </tr>

        </table>

      <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
      <p style="text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:10pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">The Company's potentially dilutive securities as of June 30, 2026 and 2025, include stock options, warrants, and debentures. The Company excluded the potential ordinary shares outstanding at each period end from the computation of diluted net loss per share attributable to ordinary shareholders for the period ended June 30, 2026 and 2025 because including them would have had an anti-dilutive effect.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:</span></span></p>
    </div>

      <div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-size:10pt;border-collapse:collapse;width:100%;border-color:#000000">

                <tr>
                  <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
                  <td colspan="1" style="vertical-align:bottom">&#160;</td>
                  <td colspan="4" style="vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>For the Period Ended</strong></span></span></td>
                  <td colspan="1" style="vertical-align:bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30, 2026</strong></span></span></td>
                  <td style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30, 2025</strong></span></span></td>
                  <td style="vertical-align:bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock options</span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,510,000</span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,285,000</span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants</span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,281,795</span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,596,795</span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Debentures</span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,000,000</span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>12,791,795</strong></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>10,881,795</strong></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                </tr>

            </table>
          </div>
        </div>
      </div>

    <p style="text-align:justify;margin-top:0pt;margin-bottom:0pt">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481468/505-20-05-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events [Text Block]</a></td>
<td class="text">
    <div>
      <p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>15.</strong>&#160;<strong>Subsequent events</strong></span></span></p>
      <div>
        <p style="margin-top:10pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Subsequent to the period ended June 30, 2026, the Company completed sales under its ATM pursuant to which it issued 2,812,566 common shares for gross proceeds of approximately $840,471 or approximately $815,257 after incurring commissions payable to the Agents.</span></span></p>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock', window );">Basis of presentation and consolidation [Policy Text Block]</a></td>
<td class="text">
      <div>
        <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Basis of presentation and consolidation</strong></span></span></p>
        <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying unaudited condensed consolidated financial statements included herein have been prepared in conformity with generally accepted accounting principles in the United States ("GAAP") and under the rules and regulations of the United States Securities and Exchange Commission ("SEC") for interim reporting. The accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, that are necessary to present fairly the Company's financial position, results of operations, and cash flows. The condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosures of the Company normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC's rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto for the year ended December 31, 2025, included in the Company's Annual Report on Form 10-K, as amended, originally filed with the SEC on March 25, 2026 (the "2025 Annual Report"). These condensed consolidated financial statements include the financial statements of the Company and its subsidiaries, SkinJect, Inc., Medicus Pharma Inc., Antev Limited ("Antev") and MDCX Holdings, LLC. All intercompany balances and transactions have been eliminated on consolidation. Non-controlling interest in the consolidated financial statements represents the portion of Antev not 100% owned by the Company. The functional currency of the Company and its three wholly-owned subsidiaries, SkinJect, Inc., Medicus Pharma Inc. and MDCX Holdings, LLC. is the United States dollar (USD). The functional currency of the Company's other subsidiary, Antev is Pound Sterling (GBP).</span></span></p>
      </div>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign operations remeasurement and translation [Policy Text Block]</a></td>
<td class="text">
      <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Foreign operations remeasurement and translation</strong></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions, and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates, are generally recognized in the condensed consolidated statements of operations and comprehensive loss. The results and financial position of foreign operation which has functional currency different from presentation currency are translated into the presentation currency as follows: assets and liabilities are translated at the closing rate at the date of that statement of financial position, income and expenses are translated at average exchange rates, and all resulting translated exchange differences are recognized in a separate component of other comprehensive loss within the condensed consolidated statement of changes in shareholders equity.</span></span></p>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates [Policy Text Block]</a></td>
<td class="text">
      <div>
        <div>
          <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Use of estimates</strong></span></span></p>
        </div>
        <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of these condensed consolidated financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements, and the reported amounts of income and expenses during the reporting period. Such estimates include the valuation of stock-based awards, the incremental borrowing rate used to discount the Company's operating lease liabilities, fair value of the Company's debentures and secured promissory notes and warrants, and valuation allowance on deferred tax assets, all of which are management's best estimates. Estimates are based on historical experience, where applicable, and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. By their nature, these estimates are subject to measurement uncertainty and the effect on the financial statements of changes in estimates in future years could be significant. Management believes that the estimates utilized in preparing the financial statements are reasonable, however, actual results could differ from those estimates.</span></span></p>
      </div>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating segments [Policy Text Block]</a></td>
<td class="text">
      <div>
        <div>
          <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Operating segments</strong></span></span></p>
        </div>
        <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating segments are identified as components of an entity about which separate discrete financial information is available for evaluation by the chief operating decision-maker ("CODM") in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.</span></span></p>
      </div>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements [Policy Text Block]</a></td>
<td class="text">
      <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Recently issued accounting pronouncements </strong></span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In November 2024, the FASB issued ASU 2024-03 "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures" to provide greater transparency about the components of specific expense categories in the income statements. The effective dates of ASU 2024-03 were subsequently clarified by ASU 2025-01. ASU 2025-01 is effective for our annual period beginning January 1, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting the amendment on the Company's financial statements.</span></span></p>
      <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">There were no other significant updates to the recently issued accounting standards which may be applicable to the Company. Although there are several other new accounting pronouncements issued or proposed by the FASB, the Company does not believe any of those accounting pronouncements have had or will have a material impact on its financial position or operating results.</span></span></p>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of presentation and consolidation..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance sheet components (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_BalanceSheetComponentsAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ScheduleOfPrepaidExpensesTableTextBlock', window );">Schedule of prepaid expenses [Table Text Block]</a></td>
<td class="text">
        <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>June 30, 2026</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>December 31, 2025</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Insurance</span></span></span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>109,405</span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>345,084</span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Contract research organizations</span></span></span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>390,000</span></span></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>410,000</span></span></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Professional services</span></span></span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>330,400</span></span></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>300,033</span></span></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Prepaid services</span></span></span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>977,656</span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>31,004</span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt">&#160;</td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>1,807,461</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>1,086,121</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>

        </table>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses and other current liabilities [Table Text Block]</a></td>
<td class="text">
        <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>June 30, 2026</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>December 31, 2025</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued legal fees</span></span></span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>110,976</span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$</span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>352,864</span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued compensation and benefits</span></span></span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>195,082</span></span></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>300,181</span></span></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued other</span></span></span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,949</span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>342,245</span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt">&#160;</td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>308,007</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:2%">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>995,290</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:2%">&#160;</td>
            </tr>

        </table>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_BalanceSheetComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_BalanceSheetComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_ScheduleOfPrepaidExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_ScheduleOfPrepaidExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_LesseeOperatingLeasesDisclosureTableTextBlock', window );">Schedule of operating leases [Table Text Block]</a></td>
<td class="text">
        <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

            <tr>
              <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Six Months Ended </strong><br/><strong>June 30, 2026</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Year Ended </strong><br/><strong>December 31,2025</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Operating lease</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease right-of-use assets</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">117,184</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">170,733</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease liabilities - current</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">137,330</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">145,456</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease liabilities - non-current</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">60,139</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>

        </table>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease cost [Table Text Block]</a></td>
<td class="text">
        <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

            <tr>
              <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap">&#160;</td>
              <td colspan="4" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Six months ended June 30,</strong></span></span></span></span></td>
              <td colspan="1" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2026</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2025</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease cost</span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease cost</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">61,889</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">61,889</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other information</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating cash flows used in operating leases</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(76,952</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(70,080</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">)</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Remaining lease term (in years)</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.00</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.92</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
            </tr>
            <tr>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Discount rate</span></span></td>
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10%</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10%</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
            </tr>

        </table>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum lease payments [Table Text Block]</a></td>
<td class="text">
        <div>
          <table cellpadding="0" cellspacing="0" style="width:50%;border-collapse:collapse;font-size:10pt;border-color:#000000">

              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#231f20">2026</span></span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#231f20">74,348</span></span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2027</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#231f20">74,348</span></span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#231f20">Total future minimum lease payments, undiscounted</span></span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">148,696</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value discount</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(11,366</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total lease liability</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>137,330</strong></span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000">&#160;</td>
              </tr>

          </table>
        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_LesseeOperatingLeasesDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the lessee operating leases disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_LesseeOperatingLeasesDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of assumptions used to estimate the fair value of warrants [Table Text Block]</a></td>
<td class="text">
        <div>
          <table cellpadding="0" cellspacing="0" style="width:50%;border-collapse:collapse;font-size:10pt;border-color:#000000;margin-left:auto;margin-right:auto">

              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Issue Date</strong><br/><strong>March 10,<br/>2025</strong></span></span></span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuation date share price</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.40</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise price</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.80</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.98%</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected warrant life</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.00 years</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">97.81%</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>

          </table>
        </div>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock', window );">Schedule of warrants continuity outstanding and exercisable [Table Text Block]</a></td>
<td class="text">
        <div>
          <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Number of </strong><br/><strong>common share </strong><br/><strong>warrants </strong><br/><strong>outstanding</strong></span></span></span></span></td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Weighted<br/>average exercise<br/>price $</strong></span></span></span></span></td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Weighted average<br/>remaining life<br/>(years)</strong></span></span></span></span></td>
                <td style="vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Outstanding as at December 31, 2025</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,281,795</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.70</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.90</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants granted</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants exercised</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:10%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total Warrants outstanding as at June 30, 2026</strong></span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:10%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>7,281,795</strong></span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:10%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2.70</strong></span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:10%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>4.41</strong></span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>

          </table>
        </div>
      <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants outstanding [Table Text Block]</a></td>
<td class="text">
        <div>
          <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt">

              <tr>
                <td style="width:20%;vertical-align:top;border-bottom:0.75pt solid #000000;text-align:center;padding-left:5pt;padding-right:5pt;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
                <td colspan="4" style="padding-right:5pt;padding-left:5pt;vertical-align:top;border-bottom:0.75pt solid #000000;text-align:center;width:80%;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Warrants outstanding</strong></span></span></span></span></td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;border-bottom:0.75pt solid #000000;white-space:nowrap;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;border-bottom:0.75pt solid #000000;white-space:nowrap;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Expiry date</strong></span></span></span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Exercise price</strong></span></span></span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Number outstanding</strong></span></span></span></span></td>
                <td style="width:20%;vertical-align:top;border-bottom:0.75pt solid #000000;text-align:right;padding-left:5pt;padding-right:5pt;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Number<br/>exercisable </strong></span></span></span></span></td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants issued as part of the IPO</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">November 15, 2029</span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$ 4.64</span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">985,595</span></span></td>
                <td style="width:20%;vertical-align:top;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:right;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">985,595</span></span></td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Regulation A Warrants</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">March 10, 2030</span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$ 2.80</span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">16,200</span></span></td>
                <td style="width:20%;vertical-align:top;text-align:right;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">16,200</span></span></td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 30, 2030 Warrants</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 2, 2030</span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;background-color:#e6efff;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$ 3.10</span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;background-color:#e6efff;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,260,000</span></span></td>
                <td style="width:20%;vertical-align:top;background-color:#e6efff;text-align:right;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,260,000</span></span></td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Series C and D Warrants</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">June 5, 2031</span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$ 2.00</span></span></td>
                <td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,020,000</span></span></td>
                <td style="width:20%;vertical-align:top;text-align:right;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,020,000</span></span></td>
              </tr>

          </table>
        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about the warrants continuity outstanding and exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity [Table Text Block]</a></td>
<td class="text">
        <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-size:10pt;width:100%;border-color:#000000">

            <tr>
              <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Number of</strong><br/><strong>options</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Weighted</strong><br/><strong>average</strong><br/><strong>exercise price</strong><br/><strong>$</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Weighted</strong><br/><strong>average</strong><br/><strong>remaining</strong><br/><strong>contractual life</strong><br/><strong>(years)</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Aggregate</strong><br/><strong>intrinsic value</strong><br/><strong>$</strong></span></span></span></span></td>
              <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
            </tr>
            <tr style="background-color:rgb(230, 239, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding at December 31, 2024</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1,185,000</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1.47</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>4.18</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1.18</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>100,000</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2.60</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>5.00</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(230, 239, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding at June 30, 2025</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1,285,000</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1.56</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>3.79</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1.43</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Exercisable at June 30, 2025</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>980,000</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1.25</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>4.01</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1.74</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(230, 239, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Unvested at June 30, 2025</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>305,000</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2.56</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>4.44</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(230, 239, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding at December 31, 2025</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2,505,000</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2.05</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2.75</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:20pt;padding-right:5pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>3,050,000</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>0.40</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>4.87</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(230, 239, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:20pt;padding-right:5pt;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Forfeited</span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(45,000</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1.79</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td>
              <td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding at June 30, 2026</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>5,510,000</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1.14</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>4.32</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(230, 239, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Exercisable at June 30, 2026</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>3,435,000</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1.62</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>3.94</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)">&#160;</td>
            </tr>
            <tr style="background-color:rgb(255, 255, 255)">
              <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Unvested at June 30, 2026</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2,075,000</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>0.36</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>4.93</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)">&#160;</td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td>
              <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)">&#160;</td>
            </tr>

        </table>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to estimate the fair value of options [Table Text Block]</a></td>
<td class="text">
        <div>
          <table cellpadding="0" cellspacing="0" style="width:90%;border-collapse:collapse;font-size:10pt;border-color:#000000">

              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>June 30, 2026</strong><br/><strong>Weighted-average</strong></span></span></span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise price</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.40</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share price</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.37</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.13%</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Estimated life (in years)</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">76.33%</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
              </tr>

          </table>
        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of financial assets and liabilities that measured at fair value on a recurring basis [Table Text Block]</a></td>
<td class="text">
        <div style="margin-top:0pt;margin-bottom:0pt">
          <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;width:100%;border-color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt">

              <tr style="margin-top:0pt;margin-bottom:0pt">
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">June 30, 2026</strong></span></span></span></p>
                </td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt">
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Level 1</strong></span></span></span></td>
                <td style="vertical-align:bottom;text-align:center;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Level 2</strong></span></span></span></td>
                <td style="vertical-align:bottom;text-align:center;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Level 3</strong></span></span></span></td>
                <td style="vertical-align:bottom;text-align:center;white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Total</strong></span></span></span></td>
                <td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">
                <td style="padding-right:5.4pt;padding-left:16.2pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Current assets:</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
                <td style="padding-right:5.4pt;padding-left:27pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Money market funds</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">13,573,269</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">-</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">-</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">13,573,269</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">
                <td style="padding-right:5.4pt;padding-left:52.2pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Total assets measured at fair value</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">13,573,269</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">-</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">-</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">13,573,269</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;text-align:right;width:10%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;width:1%;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);text-align:center;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">December 31, 2025</strong></span></span></span></td>
                <td style="vertical-align:bottom;width:2%;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Level 1</strong></span></span></span></td>
                <td style="vertical-align:bottom;width:2%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Level 2</strong></span></span></span></td>
                <td style="vertical-align:bottom;width:2%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Level 3</strong></span></span></span></td>
                <td style="vertical-align:bottom;width:2%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Total</strong></span></span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:2%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">
                <td style="padding-right:5.4pt;padding-left:16.2pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Current assets:</span></span></td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;background-color:rgb(230, 239, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
                <td style="padding-right:5.4pt;padding-left:27pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Cash and cash equivalents</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">8,705,218</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">-</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">-</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">8,705,218</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">&#160;</td>
              </tr>
              <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">
                <td style="padding-right:5.4pt;padding-left:52.2pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Total assets measured at fair value</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">8,705,218</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">-</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">-</span></span></td>
                <td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">8,705,218</span></span></td>
                <td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)">&#160;</td>
              </tr>

          </table>
        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock', window );">Schedule of contingent consideration [Table Text Block]</a></td>
<td class="text">
              <table border="0" style="border-collapse:collapse" width="100%">

                  <tr style="background-color:rgb(230, 239, 255)">
                    <td style="vertical-align:top;padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Phases</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Contingent Consideration agreed for Antev shares acquired through issue of shares</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Contingent Consideration agreed for Antev shares acquired by cash payment</span></span></span></span></span></span></td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(i) Advanced Prostate Cancer - Phase 2 success or registration</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$2.00 per common share issued</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$1.47 per Antev share (pro rata interest in $5,333,200)</span></span></span></span></span></span></td>
                  </tr>
                  <tr style="background-color:rgb(230, 239, 255)">
                    <td style="padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(ii)Acute Urinary Retention Prevention - Phase 2 success or registration</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$7.50 per common share issued</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$5.52 per Antev share (pro rata interest in $19,999,500)</span></span></span></span></span></span></td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(iii) FDA NDA approval - Hormone therapy for prostate cancer</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Up to $20,000,000 (subject to pro rata reduction)</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(255, 255, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$5.52 per Antev share (pro rata interest in $20,000,000</span></span></span></span></span></span></td>
                  </tr>
                  <tr style="background-color:rgb(230, 239, 255)">
                    <td style="padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(iv) FDA NDA approval &#8211; AUR prevention</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Up to $20,000,000 (subject to pro rata reduction)</span></span></span></span></span></span></td>
                    <td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>$5.52 per Antev share (pro rata interest in $20,000,000)</span></span></span></span></span></span></td>
                  </tr>

              </table>
            <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity interest issued or issuable by acquirer as part of consideration transferred in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock', window );">Schedule of research and development expenses [Table Text Block]</a></td>
<td class="text">
            <table cellpadding="0" cellspacing="0" style="font-size:10pt;border-collapse:collapse;width:100%;border-color:#000000">

                <tr>
                  <td style="vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td colspan="4" style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Three Months Ended June 30,</strong></span></span></span></td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="4" style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Six Months Ended June 30,</strong></span></span></span></td>
                  <td colspan="1" style="vertical-align:bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></td>
                  <td style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>2026</strong></span></span></span></td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>2025</strong></span></span></span></td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>2026</strong></span></span></span></td>
                  <td style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>2025</strong></span></span></span></td>
                  <td colspan="1" style="vertical-align:bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Research and development expenses:</strong></span></span></span></td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>SkinJect</strong></span></span></span></td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-left:10pt;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Clinical, manufacturing and regulatory activities</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,268,747</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,011,362</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2,011,288</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2,453,931</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-left:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Professional services and intellectual property</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>96,653</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>71,561</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>145,227</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>116,678</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Teverelix</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-left:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Clinical, manufacturing and regulatory activities</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2,927,793</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>3,850,023</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;padding-left:10pt;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Professional services and intellectual property</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>46,169</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>78,341</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Salaries and benefits</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>568,329</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>356,641</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,527,207</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>875,169</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Total research and development expenses</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>4,907,692</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>1,439,564</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>7,612,085</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>3,445,778</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Total general and administrative expenses</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>6,571,097</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>4,576,524</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>12,463,781</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>7,696,584</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Total operating expenses</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>11,478,789</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>6,016,088</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>20,075,866</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>11,142,362</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Other income (expense):</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right">&#160;</td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Finance income</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>40,004</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>63,870</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Interest income (expense)</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(205,638</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(523,789</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Loss on SEPA settlements</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(127,083</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Change in fair value of debentures</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(200,000</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>&#160;</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(200,000</span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Total other income (expense)</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(205,638</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(159,996</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(650,872</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(136,130</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>Net loss for the period</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(11,684,427</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(6,176,084</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(20,726,738</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000">&#160;</td>
                  <td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>(11,278,492</strong></span></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>)</strong></span></span></span></td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debentures and Secured Promissory Notes (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of debenture continuity [Table Text Block]</a></td>
<td class="text">
        <div>
          <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

              <tr>
                <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Debenture issued on September 17, 2025:</span></span></td>
                <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30, 2026</strong></span></span></td>
                <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
              </tr>
              <tr>
                <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net balance as at December 31, 2025</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,245,543</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Repayment of new debenture</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3,180,084</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              </tr>
              <tr>
                <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest accretion</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">374,712</span></span></td>
                <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest payment</span></span></td>
                <td style="vertical-align:bottom;text-align:left;border-bottom:0.75pt solid #000000;width:1%">&#160;</td>
                <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(96,393</span></span></td>
                <td style="vertical-align:bottom;text-align:left;border-bottom:0.75pt solid #000000;width:2%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              </tr>
              <tr>
                <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ending balance as of March 31, 2026</span></span></td>
                <td style="vertical-align:bottom;text-align:left;border-bottom:2.25pt double #000000;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                <td style="vertical-align:bottom;text-align:right;border-bottom:2.25pt double #000000;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,343,778</span></span></td>
                <td style="vertical-align:bottom;text-align:left;border-bottom:2.25pt double #000000;width:2%;background-color:#e6efff">&#160;</td>
              </tr>
              <tr>
                <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Repayment of Yorkville debenture</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2,343,778</span></span></td>
                <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              </tr>
              <tr>
                <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Ending balance as of June 30, 2026</strong></span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;border-bottom:2.25pt double #000000;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;border-bottom:2.25pt double #000000;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;border-bottom:2.25pt double #000000;width:2%;background-color:#e6efff">&#160;</td>
              </tr>

          </table>
        </div>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of promissory notes [Table Text Block]</a></td>
<td class="text">
          <div>
            <p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>
            <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000">

                <tr>
                  <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Note A issued on May 27, 2026:</strong></span></span></td>
                  <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30, 2026</strong></span></span></td>
                  <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds of Note A</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,864,225</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Discount on debt</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(864,225</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Debt issuance costs</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(349,091</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest accretion</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">79,257</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Ending balance</strong></span></span></td>
                  <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;border-bottom:2.25pt double #000000;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                  <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;border-bottom:2.25pt double #000000;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,730,166</span></span></td>
                  <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;border-bottom:2.25pt double #000000;width:2%;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Note B issued on May 27, 2026:</strong></span></span></td>
                  <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30, 2026</strong></span></span></td>
                  <td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds of Note B</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,000,000</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Debt issuance costs</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(265,909</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest accretion</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">18,286</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Ending balance</strong></span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
                  <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,752,376</span></span></td>
                  <td style="vertical-align:bottom;text-align:left;width:2%">&#160;</td>
                </tr>

            </table>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per share [Table Text Block]</a></td>
<td class="text">
        <table cellpadding="0" cellspacing="0" style="font-size:10pt;border-collapse:collapse;width:100%;border-color:#000000">

            <tr>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td colspan="4" style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Three Months Ended June 30,</strong></span></span></td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td colspan="4" style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Six Months Ended June 30,</strong></span></span></td>
              <td colspan="1" style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2026</strong></span></span></td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2025</strong></span></span></td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2026</strong></span></span></td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2025</strong></span></span></td>
              <td style="vertical-align:bottom;white-space:nowrap;text-align:center">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Net loss attributable to shareholders</strong></span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(11,617,705</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6,176,084</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(20,659,848</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(11,278,492</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
            </tr>
            <tr>
              <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Weighted average number of common shares outstanding </strong></span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">55,055,225</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">14,284,261</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">47,566,945</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13,853,305</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Basic and diluted net loss per share attributable to shareholders</strong></span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.21</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.43</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.43</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
              <td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(0.81</span></span></td>
              <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
            </tr>

        </table>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of dilutive securities excluded from computation [Table Text Block]</a></td>
<td class="text">
      <div>
        <div>
          <div>
            <table cellpadding="0" cellspacing="0" style="font-size:10pt;border-collapse:collapse;width:100%;border-color:#000000">

                <tr>
                  <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
                  <td colspan="1" style="vertical-align:bottom">&#160;</td>
                  <td colspan="4" style="vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>For the Period Ended</strong></span></span></td>
                  <td colspan="1" style="vertical-align:bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
                  <td style="vertical-align:bottom">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30, 2026</strong></span></span></td>
                  <td style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center">&#160;</td>
                  <td style="vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30, 2025</strong></span></span></td>
                  <td style="vertical-align:bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock options</span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,510,000</span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,285,000</span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants</span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,281,795</span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,596,795</span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Debentures</span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,000,000</span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>12,791,795</strong></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:1%;text-align:left">&#160;</td>
                  <td style="vertical-align:bottom;width:12%;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>10,881,795</strong></span></span></td>
                  <td style="vertical-align:bottom;width:2%;text-align:left">&#160;</td>
                </tr>

            </table>
          </div>
        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2026 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance sheet components (Schedule of prepaid expenses) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_BalanceSheetComponentsAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">$ 109,405<span></span>
</td>
<td class="nump">$ 345,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_PrepaidContractResearch', window );">Contract research organizations</a></td>
<td class="nump">390,000<span></span>
</td>
<td class="nump">410,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_PrepaidProfessionalServices', window );">Professional services</a></td>
<td class="nump">330,400<span></span>
</td>
<td class="nump">300,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_PrepaidServices', window );">Prepaid services</a></td>
<td class="nump">977,656<span></span>
</td>
<td class="nump">31,004<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 1,807,461<span></span>
</td>
<td class="nump">$ 1,086,121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_BalanceSheetComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_BalanceSheetComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_PrepaidContractResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contract research organizations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_PrepaidContractResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_PrepaidProfessionalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prepaid professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_PrepaidProfessionalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_PrepaidServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prepaid services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_PrepaidServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance sheet components (Schedule of accrued expenses and other current liabilities) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_BalanceSheetComponentsAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal fees</a></td>
<td class="nump">$ 110,976<span></span>
</td>
<td class="nump">$ 352,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">195,082<span></span>
</td>
<td class="nump">300,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">1,949<span></span>
</td>
<td class="nump">342,245<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 308,007<span></span>
</td>
<td class="nump">$ 995,290<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_BalanceSheetComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_BalanceSheetComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule of operating leases) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 117,184<span></span>
</td>
<td class="nump">$ 170,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="nump">137,330<span></span>
</td>
<td class="nump">145,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - non-current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 60,139<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Schedule of lease cost) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease cost</a></td>
<td class="nump">$ 61,889<span></span>
</td>
<td class="nump">$ 61,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used in operating leases</a></td>
<td class="num">$ (76,952)<span></span>
</td>
<td class="num">$ (70,080)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year 11 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule of future minimum lease payments) (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 74,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">74,348<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments, undiscounted</a></td>
<td class="nump">148,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value discount</a></td>
<td class="num">(11,366)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 137,330<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 10, 2025</div></th>
<th class="th"><div>Feb. 10, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 29, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ShareCapitalNoteDisclosureLineItems', window );"><strong>Share Capital Note Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,790,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,688,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 977,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mdcx_RegulationAOfferingMember', window );">Regulation A Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ShareCapitalNoteDisclosureLineItems', window );"><strong>Share Capital Note Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from offering</a></td>
<td class="nump">$ 4,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of units issued</a></td>
<td class="nump">1,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common shares, price per share</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of warrants granted</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_StockPurchaseWarrantsTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Share issuance cost</a></td>
<td class="nump">$ 483,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_FairValuePerShare', window );">Fair value per share</a></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_FairValuePerWarrant', window );">Fair value per warrant</a></td>
<td class="nump">$ 2.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_NumberOfWarrantsExercised', window );">Number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod', window );">Number of warrants granted</a></td>
<td class="nump">1,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 374,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mdcx_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement (the "SEPA") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ShareCapitalNoteDisclosureLineItems', window );"><strong>Share Capital Note Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,102,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_SharePriceAsPercentageOfMarketPrice', window );">Share price as percentage of market price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,336,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,229,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures', window );">Proceeds from share issuance used to repay outstanding debentures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,223,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement', window );">Amount available to exercise in relation to SEPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,489,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mdcx_AtmAgreementMember', window );">ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ShareCapitalNoteDisclosureLineItems', window );"><strong>Share Capital Note Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,868,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,248,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_EquityDistributionAgreementCommissionRate', window );">Equity distribution agreement commission rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount of available to exercise in relation to standby equity purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_EquityDistributionAgreementCommissionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the equity distribution agreement commission rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_EquityDistributionAgreementCommissionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_FairValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_FairValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_FairValuePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value per warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_FairValuePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common share warrants outstanding granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from share issuance used to repay outstanding debentures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_ShareCapitalNoteDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_ShareCapitalNoteDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_SharePriceAsPercentageOfMarketPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share price as percentage of market price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_SharePriceAsPercentageOfMarketPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_StockPurchaseWarrantsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The contractual term of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_StockPurchaseWarrantsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mdcx_RegulationAOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mdcx_RegulationAOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mdcx_StandbyEquityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mdcx_StandbyEquityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mdcx_AtmAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mdcx_AtmAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share capital (Schedule of assumptions used to estimate the fair value of warrants) (Details) - Regulation A Warrants [Member]<br></strong></div></th>
<th class="th">
<div>Mar. 10, 2025 </div>
<div>Percentage </div>
<div>USD_PER_SHARE </div>
<div>Year</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mdcx_RegulationAWarrantsMember', window );">Valuation date share price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input | USD_PER_SHARE</a></td>
<td class="nump">3.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mdcx_RegulationAWarrantsMember', window );">Exercise price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input | USD_PER_SHARE</a></td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mdcx_RegulationAWarrantsMember', window );">Dividend yield [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mdcx_RegulationAWarrantsMember', window );">Risk-free interest rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.0398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mdcx_RegulationAWarrantsMember', window );">Expected warrant life [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input | Year</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=mdcx_RegulationAWarrantsMember', window );">Expected volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">97.81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481229/860-50-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=mdcx_RegulationAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=mdcx_RegulationAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=mdcx_MeasurementInputValuationDateSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=mdcx_MeasurementInputValuationDateSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital (Schedule of warrants continuity) (Details) - Public Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of common share warrants outstanding, beginning balance</a></td>
<td class="nump">7,281,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod', window );">Warrants granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod', window );">Warrants exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of common share warrants outstanding, ending balance</a></td>
<td class="nump">7,281,795<span></span>
</td>
<td class="nump">7,281,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_WeightedAverageExercisePriceOfWarrant', window );">Weighted average exercise price of warrants, beginning balance</a></td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_WeightedAverageExercisePriceWarrantGranted', window );">Weighted average exercise price of warrants granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_WeightedAverageExercisePriceWarrantExercise', window );">Weighted average exercise price of warrants exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_WeightedAverageExercisePriceOfWarrant', window );">Weighted average exercise price of warrants, ending balance</a></td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_WeightedAverageRemainingContractualTermOfWarrant', window );">Weighted average remaining contractual term</a></td>
<td class="text">4 years 4 months 28 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common share warrants outstanding exercise during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common share warrants outstanding granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_WeightedAverageExercisePriceOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_WeightedAverageExercisePriceOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_WeightedAverageExercisePriceWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price warrant granted exercise</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_WeightedAverageExercisePriceWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_WeightedAverageExercisePriceWarrantGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price warrant granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_WeightedAverageExercisePriceWarrantGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_WeightedAverageRemainingContractualTermOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_WeightedAverageRemainingContractualTermOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital (Schedule of warrants outstanding) (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2026 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mdcx_WarrantsIssuedAsPartOfIpoMember', window );">Warrants issued as part of the IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ClassOfWarrantOrRightExpiryDate', window );">Expiry date</a></td>
<td class="text">November 15, 2029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 4.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding</a></td>
<td class="nump">985,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ClassOfWarrantOrRightExercisable', window );">Number exercisable</a></td>
<td class="nump">985,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mdcx_RegulationAWarrantsMember', window );">Regulation A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ClassOfWarrantOrRightExpiryDate', window );">Expiry date</a></td>
<td class="text">March 10, 2030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding</a></td>
<td class="nump">16,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ClassOfWarrantOrRightExercisable', window );">Number exercisable</a></td>
<td class="nump">16,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mdcx_WarrantWithExpiryDateJune302030WarrantsMember', window );">June 30, 2030 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ClassOfWarrantOrRightExpiryDate', window );">Expiry date</a></td>
<td class="text">June 2, 2030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding</a></td>
<td class="nump">2,260,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ClassOfWarrantOrRightExercisable', window );">Number exercisable</a></td>
<td class="nump">2,260,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mdcx_SeriesCAndDWarrantsMember', window );">Series C and D Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ClassOfWarrantOrRightExpiryDate', window );">Expiry date</a></td>
<td class="text">June 5, 2031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number outstanding</a></td>
<td class="nump">4,020,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ClassOfWarrantOrRightExercisable', window );">Number exercisable</a></td>
<td class="nump">4,020,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_ClassOfWarrantOrRightExpiryDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents about class of warrant or right, expiry date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_ClassOfWarrantOrRightExpiryDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mdcx_WarrantsIssuedAsPartOfIpoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mdcx_WarrantsIssuedAsPartOfIpoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mdcx_RegulationAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mdcx_RegulationAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mdcx_WarrantWithExpiryDateJune302030WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mdcx_WarrantWithExpiryDateJune302030WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mdcx_SeriesCAndDWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mdcx_SeriesCAndDWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 03, 2026</div></th>
<th class="th"><div>Mar. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding', window );">Limit of options as a percentage of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,050,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 419,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 419,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,405,826<span></span>
</td>
<td class="nump">$ 117,448<span></span>
</td>
<td class="nump">$ 2,005,133<span></span>
</td>
<td class="nump">$ 585,442<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member] | Individuals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options issued</a></td>
<td class="nump">2,075,000<span></span>
</td>
<td class="nump">975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of warrants granted</a></td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Limit of options as a percentage of shares outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant to expiration date of share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mdcx_IndividualsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mdcx_IndividualsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Schedule of stock option activity) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, Beginning balance</a></td>
<td class="nump">2,505,000<span></span>
</td>
<td class="nump">1,185,000<span></span>
</td>
<td class="nump">1,185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted</a></td>
<td class="nump">3,050,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, Forfeited</a></td>
<td class="num">(45,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, Ending balance</a></td>
<td class="nump">5,510,000<span></span>
</td>
<td class="nump">1,285,000<span></span>
</td>
<td class="nump">2,505,000<span></span>
</td>
<td class="nump">1,185,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Exercisable, end of year</a></td>
<td class="nump">3,435,000<span></span>
</td>
<td class="nump">980,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of options, Unvested</a></td>
<td class="nump">2,075,000<span></span>
</td>
<td class="nump">305,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Beginning balance</a></td>
<td class="nump">$ 2.05<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="nump">1.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending balance</a></td>
<td class="nump">1.14<span></span>
</td>
<td class="nump">1.56<span></span>
</td>
<td class="nump">$ 2.05<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Stock options Exercisable, Weighted-average exercise price end of year</a></td>
<td class="nump">1.62<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Stock options Unvested, Weighted average exercise price</a></td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="nump">$ 2.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted', window );">Stock options, Granted, Weighted average remaining contractual life (years)</a></td>
<td class="text">4 years 10 months 13 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Stock options, Outstanding, Weighted average remaining contractual life (years)</a></td>
<td class="text">4 years 3 months 25 days<span></span>
</td>
<td class="text">3 years 9 months 14 days<span></span>
</td>
<td class="text">2 years 9 months<span></span>
</td>
<td class="text">4 years 2 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Stock options, Exercisable, Weighted average remaining contractual life (years)</a></td>
<td class="text">3 years 11 months 8 days<span></span>
</td>
<td class="text">4 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Unvested, Weighted average remaining contractual life (years)</a></td>
<td class="text">4 years 11 months 4 days<span></span>
</td>
<td class="text">4 years 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Stock options, Outstanding, Aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Stock options, Exercisable, Aggregate intrinsic value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Stock options, Unvested, Aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days, Granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average contractual term remaining for vested portion of option outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average contractual term remaining for option award outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Schedule of assumptions used to estimate the fair value of options) (Details) - Stock options [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2026 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 0.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest</a></td>
<td class="nump">4.13%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Estimated life (years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">76.33%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions (Narrative) (Details) - RBx Capital, LP ("RBx") [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 18, 2023</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Reimbursable salaries</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_RelatedPartyTransactionAdditionalExpenses', window );">Additional expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 455,486<span></span>
</td>
<td class="nump">$ 64,046<span></span>
</td>
<td class="nump">898,983<span></span>
</td>
<td class="nump">104,911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Total amount of accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,846<span></span>
</td>
<td class="nump">$ 121,273<span></span>
</td>
<td class="nump">$ 161,846<span></span>
</td>
<td class="nump">$ 121,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_RelatedPartyTransactionAdditionalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period for additional expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_RelatedPartyTransactionAdditionalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(e)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 970<br> -SubTopic 810<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477383/970-810-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mdcx_RbxCapitalLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mdcx_RbxCapitalLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair value of cash and cash equivalents and restricted cash</a></td>
<td class="nump">$ 25,191,540<span></span>
</td>
<td class="nump">$ 8,705,218<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Schedule of fair value on a recurring basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,174,128<span></span>
</td>
<td class="nump">$ 8,705,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">13,573,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,705,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">13,573,269<span></span>
</td>
<td class="nump">8,705,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">13,573,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,705,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">13,573,269<span></span>
</td>
<td class="nump">8,705,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and contingencies (Narrative) (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mdcx_AntevLimitedMember', window );">Antev Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Combination, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Ownership acquired</a></td>
<td class="nump">98.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interest acquired in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-38<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mdcx_AntevLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mdcx_AntevLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and contingencies (Schedule of contingent consideration) (Details) - Antev Limited [Member]<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mdcx_AntevLimitedMember', window );">Advanced Prostate Cancer - Phase 2 success or registration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Combination, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Contingent Consideration, price per share | $ / shares</a></td>
<td class="nump">$ 1.47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mdcx_AntevLimitedMember', window );">Advanced Prostate Cancer - Phase 2 success or registration [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Combination, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Contingent Consideration, price per share | $ / shares</a></td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration | $</a></td>
<td class="nump">$ 5,333,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mdcx_AntevLimitedMember', window );">Acute Urinary Retention (AUR) Prevention - Phase 2 success or registration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Combination, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Contingent Consideration, price per share | $ / shares</a></td>
<td class="nump">$ 5.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration | $</a></td>
<td class="nump">$ 19,999,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mdcx_AntevLimitedMember', window );">Acute Urinary Retention (AUR) Prevention - Phase 2 success or registration [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Combination, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Contingent Consideration, price per share | $ / shares</a></td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mdcx_AntevLimitedMember', window );">FDA NDA approval - Hormone therapy for prostate cancer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Combination, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Contingent Consideration, price per share | $ / shares</a></td>
<td class="nump">$ 5.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration | $</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mdcx_AntevLimitedMember', window );">FDA NDA approval - Hormone therapy for prostate cancer [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Combination, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration | $</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mdcx_AntevLimitedMember', window );">FDA NDA approval - AUR prevention [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Combination, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Contingent Consideration, price per share | $ / shares</a></td>
<td class="nump">$ 5.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration | $</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mdcx_AntevLimitedMember', window );">FDA NDA approval - AUR prevention [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Combination, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration | $</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share price of saleable stock paid or offered to be paid by acquirer in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479299/805-40-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-42<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mdcx_AntevLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mdcx_AntevLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mdcx_ContingentConsiderationPhasesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mdcx_ContingentConsiderationPhasesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mdcx_ContingentConsiderationPhasesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mdcx_ContingentConsiderationPhasesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mdcx_ContingentConsiderationPhasesThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mdcx_ContingentConsiderationPhasesThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mdcx_ContingentConsiderationPhasesFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mdcx_ContingentConsiderationPhasesFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment reporting (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2026 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment reporting (Schedule of reconciliation to consolidated operating expenses) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">$ 568,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,527,207<span></span>
</td>
<td class="nump">$ 875,169<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">4,907,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,439,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,612,085<span></span>
</td>
<td class="nump">3,445,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">6,571,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,576,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,463,781<span></span>
</td>
<td class="nump">7,696,584<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">11,478,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,016,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,075,866<span></span>
</td>
<td class="nump">11,142,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Finance income</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">63,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest income (expense)</a></td>
<td class="num">(205,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(523,789)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_GainLossOnSettlements', window );">Loss on SEPA settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127,083)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ChangeInFairValueOfDebentures', window );">Change in fair value of debentures</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(205,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(159,996)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(650,872)<span></span>
</td>
<td class="num">(136,130)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">(11,684,427)<span></span>
</td>
<td class="num">$ (9,042,311)<span></span>
</td>
<td class="num">(6,176,084)<span></span>
</td>
<td class="num">$ (5,102,408)<span></span>
</td>
<td class="num">(20,726,738)<span></span>
</td>
<td class="num">(11,278,492)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mdcx_SkinjectIncMember', window );">SkinJect [Member] | Clinical, manufacturing and regulatory activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Research and development expenses</a></td>
<td class="nump">1,268,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,011,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,011,288<span></span>
</td>
<td class="nump">2,453,931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mdcx_SkinjectIncMember', window );">SkinJect [Member] | Professional services and intellectual property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Research and development expenses</a></td>
<td class="nump">96,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,227<span></span>
</td>
<td class="nump">116,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mdcx_TeverelixMember', window );">Teverelix [Member] | Clinical, manufacturing and regulatory activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Research and development expenses</a></td>
<td class="nump">2,927,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,850,023<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=mdcx_TeverelixMember', window );">Teverelix [Member] | Professional services and intellectual property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Research and development expenses</a></td>
<td class="nump">$ 46,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,341<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_ChangeInFairValueOfDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount if change in fair value of debentures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_ChangeInFairValueOfDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_GainLossOnSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of gain loss on settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_GainLossOnSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 44: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mdcx_SkinjectIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mdcx_SkinjectIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mdcx_ProfessionalServicesAndIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mdcx_ProfessionalServicesAndIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mdcx_TeverelixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mdcx_TeverelixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debentures and Secured Promissory Notes (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 27, 2026</div></th>
<th class="th"><div>Sep. 17, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debentures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Outstanding principal repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,532,613<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Cost to issue debentures and secured promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">615,000<span></span>
</td>
<td class="nump">$ 54,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mdcx_SecuritiesPurchaseAgreementMember', window );">Securities purchase agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_DebtIssuanceDiscount', window );">Debt issuance discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,366,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Potential increase in interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debentures maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 17,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ConvertibleDebtAccretionExpense', window );">Interest accretion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 374,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_EffectiveInterestRateOnDebt', window );">Effective interest rate on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Outstanding principal repaid</a></td>
<td class="nump">$ 2,343,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_AccruedInterestRepaid', window );">Accrued interest paid</a></td>
<td class="nump">135,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdcx_NoteAMember', window );">Note A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_DebtInstrumentExchangeThresholdAmount', window );">Principal amount repaid</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdcx_NoteBMember', window );">Note B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted deposit</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_DebtInstrumentMaximumExchangeLimitAmount', window );">Debt instrument maximum exchange limit amount</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mdcx_SecuredPromissoryNotesMember', window );">Secured promissory notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Aggregate principal of the notes</a></td>
<td class="nump">$ 22,864,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debentures maturity date</a></td>
<td class="text">Nov. 27,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Cost to issue debentures and secured promissory notes</a></td>
<td class="nump">$ 615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault', window );">Description of violation or event of default of long-term debt</a></td>
<td class="text">Upon the occurrence of such trigger events, the lender may increase the outstanding balance by 5% for certain minor trigger events or 15% for certain major trigger events, as more fully described in Note A and Note B, subject to contractual limitations. Following an event of default, the lender may accelerate repayment and default interest may accrue at a rate of up to 18% per annum, subject to applicable law.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mdcx_SecuredPromissoryNotesMember', window );">Secured promissory notes [Member] | Note A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Promissory note face value</a></td>
<td class="nump">$ 12,864,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Aggregate principal of the notes</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,864,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Notes issue discount</a></td>
<td class="nump">$ 864,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">864,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Cost to issue debentures and secured promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_DebtDefaultBalanceIncreasePercentage', window );">Increase of outstanding balance on redemption failure</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit', window );">Cumulative daily dollar trading volume (Volume-based limit)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage', window );">Share price threshold, Percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Prepayment price percentage</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mdcx_SecuredPromissoryNotesMember', window );">Secured promissory notes [Member] | Note A [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_DebtInstrumentRedemptionLimitAmount', window );">Monthly redemptions ceiling</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mdcx_SecuredPromissoryNotesMember', window );">Secured promissory notes [Member] | Note B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Aggregate principal of the notes</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Cost to issue debentures and secured promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_AccruedInterestRepaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest repaid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_AccruedInterestRepaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_ConvertibleDebtAccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accretion expense for convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_ConvertibleDebtAccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_DebtDefaultBalanceIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of debt default balance increase percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_DebtDefaultBalanceIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument covenant share price threshold percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_DebtInstrumentExchangeThresholdAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt instrument exchange threshold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_DebtInstrumentExchangeThresholdAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_DebtInstrumentMaximumExchangeLimitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument maximum exchange limit amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_DebtInstrumentMaximumExchangeLimitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_DebtInstrumentRedemptionLimitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt instrument redemption limit amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_DebtInstrumentRedemptionLimitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument volume based redemption percentage limit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_DebtIssuanceDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the value of debenture issued at a discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_DebtIssuanceDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_EffectiveInterestRateOnDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the effective interest rate on debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_EffectiveInterestRateOnDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 41: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 42: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discussion of the facts and amounts pertaining to each failure to comply with an affirmative or negative covenant of a long-term debt instrument, including violating payment terms or an inability to meet certain minimum financial requirements or achieve or maintain certain financial ratios. The discussion would generally be expected to also include whether or not the failure can and will be overcome and a description of the terms of any waivers, including the amount of the waiver and the period of time covered by the waiver, and if reclassification of long-term debt to current has been made in the current balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mdcx_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mdcx_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdcx_NoteAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdcx_NoteAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdcx_NoteBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdcx_NoteBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mdcx_SecuredPromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mdcx_SecuredPromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debentures and Secured Promissory Notes (Schedule of debenture continuity) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debenture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,532,613)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mdcx_DebentureContinuityOneMember', window );">Debenture issued on September 17, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Beginning balance</a></td>
<td class="nump">$ 2,343,778<span></span>
</td>
<td class="nump">$ 5,245,543<span></span>
</td>
<td class="nump">5,245,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debenture</a></td>
<td class="num">(2,343,778)<span></span>
</td>
<td class="num">(3,180,084)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ConvertibleDebtAccretionExpense', window );">Interest accretion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">374,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_RepaymentsOfInterest', window );">Interest payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96,393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,343,778<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_ConvertibleDebtAccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accretion expense for convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_ConvertibleDebtAccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_RepaymentsOfInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents repayments of interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_RepaymentsOfInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 41: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 42: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mdcx_DebentureContinuityOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mdcx_DebentureContinuityOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debentures and Secured Promissory Notes (Schedule of promissory notes)  (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 27, 2026</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (615,000)<span></span>
</td>
<td class="num">$ (54,582)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mdcx_SecuredPromissoryNotesMember', window );">Secured promissory notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds</a></td>
<td class="nump">$ 22,864,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="num">(615,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mdcx_SecuredPromissoryNotesMember', window );">Secured promissory notes [Member] | Note A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">12,864,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount on debt</a></td>
<td class="num">(864,225)<span></span>
</td>
<td class="num">(864,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(349,091)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest accretion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,730,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mdcx_SecuredPromissoryNotesMember', window );">Secured promissory notes [Member] | Note B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(265,909)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest accretion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,752,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 41: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 42: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mdcx_SecuredPromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mdcx_SecuredPromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdcx_NoteAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdcx_NoteAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdcx_NoteBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdcx_NoteBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restricted Cash (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mdcx_NoteBMember', window );">Note B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_RestrictedCashLineItems', window );"><strong>Restricted Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_RestrictedCashLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_RestrictedCashLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mdcx_NoteBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mdcx_NoteBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share (Schedule of basic and diluted net loss per share ) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to shareholders</a></td>
<td class="num">$ (11,617,705)<span></span>
</td>
<td class="num">$ (6,176,084)<span></span>
</td>
<td class="num">$ (20,659,848)<span></span>
</td>
<td class="num">$ (11,278,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">55,055,225<span></span>
</td>
<td class="nump">14,284,261<span></span>
</td>
<td class="nump">47,566,945<span></span>
</td>
<td class="nump">13,853,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per share attributable to shareholders - basic</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.81)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted net loss per share attributable to shareholders - diluted</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.81)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share (Schedule of dilutive securities excluded from computation) (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">12,791,795<span></span>
</td>
<td class="nump">10,881,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mdcx_StockOptionsMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">5,510,000<span></span>
</td>
<td class="nump">1,285,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">7,281,795<span></span>
</td>
<td class="nump">4,596,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mdcx_DebenturesMember', window );">Debentures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mdcx_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mdcx_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mdcx_DebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mdcx_DebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,790,015<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common shares issued</a></td>
<td class="nump">2,812,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common shares</a></td>
<td class="nump">$ 840,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents', window );">Proceeds from common shares net of commissions payable to Agents</a></td>
<td class="nump">$ 815,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information about proceeds from common shares net of commissions payable to agents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mdcx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>177</ContextCount>
  <ElementCount>277</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/idr_BalanceSheets</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/idr_BalanceSheetsParenthetical</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/idr_StatementsOfOperations</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' ( DEFICIT) EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' ( DEFICIT) EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' ( DEFICIT) EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' ( DEFICIT) EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/idr_StatementsOfCashFlows</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - Description of business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/DescriptionOfBusiness</Role>
      <ShortName>Description of business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - Balance sheet components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance sheet components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - Share capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/ShareCapital</Role>
      <ShortName>Share capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - Stock-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - Related party transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related party transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - Fair value measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair value measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/CommitmentAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - Segment reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/SegmentReporting</Role>
      <ShortName>Segment reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - Debentures and Secured Promissory Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.medicuspharma.com/role/Debentures</Role>
      <ShortName>Debentures and Secured Promissory Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/RestrictedCash</Role>
      <ShortName>Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0020 - Disclosure - Liquidity and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/Liquidity</Role>
      <ShortName>Liquidity and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0021 - Disclosure - Loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/LossPerShare</Role>
      <ShortName>Loss per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0022 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9960701 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9960702 - Disclosure - Balance sheet components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance sheet components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/BalanceSheetComponents</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9960703 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/Leases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9960704 - Disclosure - Share capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/ShareCapitalTables</Role>
      <ShortName>Share capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/ShareCapital</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9960705 - Disclosure - Stock-based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/StockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9960706 - Disclosure - Fair value measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair value measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/FairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9960707 - Disclosure - Commitments and contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/CommitmentAndContingencies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9960708 - Disclosure - Segment reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesTables</Role>
      <ShortName>Segment reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/SegmentReporting</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9960709 - Disclosure - Debentures and Secured Promissory Notes (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.medicuspharma.com/role/DebenturesTables</Role>
      <ShortName>Debentures and Secured Promissory Notes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/Debentures</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9960710 - Disclosure - Loss per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/LossPerShareTables</Role>
      <ShortName>Loss per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/LossPerShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9960712 - Disclosure - Summary of significant accounting policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of significant accounting policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9960713 - Disclosure - Balance sheet components (Schedule of prepaid expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/BalanceSheetComponentsDetails</Role>
      <ShortName>Balance sheet components (Schedule of prepaid expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/BalanceSheetComponentsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9960714 - Disclosure - Balance sheet components (Schedule of accrued expenses and other current liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/BalanceSheetComponentsDetails1</Role>
      <ShortName>Balance sheet components (Schedule of accrued expenses and other current liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/BalanceSheetComponentsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9960715 - Disclosure - Leases (Schedule of operating leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/LeasesDetails</Role>
      <ShortName>Leases (Schedule of operating leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/LeasesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9960716 - Disclosure - Leases (Schedule of lease cost) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/LeasesDetails1</Role>
      <ShortName>Leases (Schedule of lease cost) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/LeasesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9960717 - Disclosure - Leases (Schedule of future minimum lease payments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/LeasesDetails2</Role>
      <ShortName>Leases (Schedule of future minimum lease payments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/LeasesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9960718 - Disclosure - Share capital (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails</Role>
      <ShortName>Share capital (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/ShareCapitalTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9960719 - Disclosure - Share capital (Schedule of assumptions used to estimate the fair value of warrants) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/ShareCapitalDetails</Role>
      <ShortName>Share capital (Schedule of assumptions used to estimate the fair value of warrants) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/ShareCapitalTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9960720 - Disclosure - Share capital (Schedule of warrants continuity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/ShareCapitalScheduleOfWarrantsContinuityDetails</Role>
      <ShortName>Share capital (Schedule of warrants continuity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/ShareCapitalTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9960721 - Disclosure - Share capital (Schedule of warrants outstanding) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/ShareCapitalDetails1</Role>
      <ShortName>Share capital (Schedule of warrants outstanding) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/ShareCapitalTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9960722 - Disclosure - Stock-based compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-based compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9960723 - Disclosure - Stock-based compensation (Schedule of stock option activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Stock-based compensation (Schedule of stock option activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9960724 - Disclosure - Stock-based compensation (Schedule of assumptions used to estimate the fair value of options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfWeightedaverageAssumptionsToDetermineFairValueOfStockOptionsGrantedDetails</Role>
      <ShortName>Stock-based compensation (Schedule of assumptions used to estimate the fair value of options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/StockBasedCompensationTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9960725 - Disclosure - Related party transactions (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/RelatedPartyTransactionsNarrativeDetails</Role>
      <ShortName>Related party transactions (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/RelatedPartyTransactions</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9960726 - Disclosure - Fair value measurements (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair value measurements (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/FairValueMeasurementTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9960727 - Disclosure - Fair value measurements - Schedule of fair value on a recurring basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/FairValueMeasurementDetails</Role>
      <ShortName>Fair value measurements - Schedule of fair value on a recurring basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9960728 - Disclosure - Commitments and contingencies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/CommitmentsAndContingenciesN</Role>
      <ShortName>Commitments and contingencies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9960729 - Disclosure - Commitments and contingencies (Schedule of contingent consideration) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails</Role>
      <ShortName>Commitments and contingencies (Schedule of contingent consideration) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9960730 - Disclosure - Segment reporting (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/SegmentReportingNarrativeDetails</Role>
      <ShortName>Segment reporting (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9960731 - Disclosure - Segment reporting (Schedule of reconciliation to consolidated operating expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails</Role>
      <ShortName>Segment reporting (Schedule of reconciliation to consolidated operating expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9960732 - Disclosure - Debentures and Secured Promissory Notes (Narrative) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.medicuspharma.com/role/DebenturesNarrativeDetails</Role>
      <ShortName>Debentures and Secured Promissory Notes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/DebenturesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9960733 - Disclosure - Debentures and Secured Promissory Notes (Schedule of debenture continuity) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.medicuspharma.com/role/DebenturesScheduleOfDebentureContinuityDetails</Role>
      <ShortName>Debentures and Secured Promissory Notes (Schedule of debenture continuity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/DebenturesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9960734 - Disclosure - Debentures and Secured Promissory Notes (Schedule of promissory notes)  (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.medicuspharma.com/role/DebenturesAndPromissoryNotesNdfd</Role>
      <ShortName>Debentures and Secured Promissory Notes (Schedule of promissory notes)  (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/DebenturesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9960735 - Disclosure - Restricted Cash (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/RestrictedCashNarrativeDetails</Role>
      <ShortName>Restricted Cash (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/RestrictedCash</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9960736 - Disclosure - Loss per share (Schedule of basic and diluted net loss per share ) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/LossPerShareDetails</Role>
      <ShortName>Loss per share (Schedule of basic and diluted net loss per share ) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/LossPerShareTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9960737 - Disclosure - Loss per share (Schedule of dilutive securities excluded from computation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/TESTTESTTESTDetails</Role>
      <ShortName>Loss per share (Schedule of dilutive securities excluded from computation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/LossPerShareTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="form10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9960738 - Disclosure - Subsequent events (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medicuspharma.com/role/SubsequentEventsNarrativeDetails</Role>
      <ShortName>Subsequent events (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medicuspharma.com/role/SubsequentEvents</ParentRole>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="form10q.htm">form10q.htm</File>
    <File>mdcx-20260630.xsd</File>
    <File>mdcx-20260630_cal.xml</File>
    <File>mdcx-20260630_def.xml</File>
    <File>mdcx-20260630_lab.xml</File>
    <File>mdcx-20260630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="608">http://fasb.org/us-gaap/2026</BaseTaxonomy>
    <BaseTaxonomy items="34">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10q.htm": {
   "nsprefix": "mdcx",
   "nsuri": "http://www.medicuspharma.com/20260630",
   "dts": {
    "inline": {
     "local": [
      "form10q.htm"
     ]
    },
    "schema": {
     "local": [
      "mdcx-20260630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd",
      "https://xbrl.sec.gov/country/2026/country-2026.xsd",
      "https://xbrl.sec.gov/currency/2026/currency-2026.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
      "https://xbrl.sec.gov/exch/2026/exch-2026.xsd",
      "https://xbrl.sec.gov/naics/2026/naics-2026.xsd",
      "https://xbrl.sec.gov/sic/2026/sic-2026.xsd",
      "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "mdcx-20260630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mdcx-20260630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "mdcx-20260630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mdcx-20260630_pre.xml"
     ]
    }
   },
   "keyStandard": 213,
   "keyCustom": 64,
   "axisStandard": 18,
   "axisCustom": 1,
   "memberStandard": 18,
   "memberCustom": 27,
   "hidden": {
    "total": 4,
    "http://xbrl.sec.gov/dei/2026": 4
   },
   "contextCount": 177,
   "entityCount": 1,
   "segmentCount": 49,
   "elementCount": 526,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2026": 608,
    "http://xbrl.sec.gov/dei/2026": 34
   },
   "report": {
    "R1": {
     "role": "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation",
     "longName": "0001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "strong",
       "span",
       "span",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "strong",
       "span",
       "span",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.medicuspharma.com/role/idr_BalanceSheets",
     "longName": "0002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_20260630",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "strong",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260630",
      "name": "us-gaap:DeferredCostsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "strong",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.medicuspharma.com/role/idr_BalanceSheetsParenthetical",
     "longName": "0003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_20260630",
      "name": "us-gaap:CommonStockNoParValue",
      "unitRef": "USD_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260630",
      "name": "us-gaap:CommonStockNoParValue",
      "unitRef": "USD_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.medicuspharma.com/role/idr_StatementsOfOperations",
     "longName": "0004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_20260401to20260630",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "strong",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260401to20260630",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "strong",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit",
     "longName": "0005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' ( DEFICIT) EQUITY",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' ( DEFICIT) EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "strong",
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.medicuspharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical",
     "longName": "0006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' ( DEFICIT) EQUITY (Parenthetical)",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' ( DEFICIT) EQUITY (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_20250101to20250331",
      "name": "mdcx:IssuanceCostsInConnectionWithRegulationA",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250101to20250331",
      "name": "mdcx:IssuanceCostsInConnectionWithRegulationA",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows",
     "longName": "0007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "strong",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.medicuspharma.com/role/DescriptionOfBusiness",
     "longName": "0008 - Disclosure - Description of business",
     "shortName": "Description of business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "0009 - Disclosure - Summary of significant accounting policies",
     "shortName": "Summary of significant accounting policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.medicuspharma.com/role/BalanceSheetComponents",
     "longName": "0010 - Disclosure - Balance sheet components",
     "shortName": "Balance sheet components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.medicuspharma.com/role/Leases",
     "longName": "0011 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.medicuspharma.com/role/ShareCapital",
     "longName": "0012 - Disclosure - Share capital",
     "shortName": "Share capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.medicuspharma.com/role/StockBasedCompensation",
     "longName": "0013 - Disclosure - Stock-based compensation",
     "shortName": "Stock-based compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.medicuspharma.com/role/RelatedPartyTransactions",
     "longName": "0014 - Disclosure - Related party transactions",
     "shortName": "Related party transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.medicuspharma.com/role/FairValueMeasurements",
     "longName": "0015 - Disclosure - Fair value measurements",
     "shortName": "Fair value measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.medicuspharma.com/role/CommitmentAndContingencies",
     "longName": "0016 - Disclosure - Commitments and contingencies",
     "shortName": "Commitments and contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.medicuspharma.com/role/SegmentReporting",
     "longName": "0017 - Disclosure - Segment reporting",
     "shortName": "Segment reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.medicuspharma.com/role/Debentures",
     "longName": "0018 - Disclosure - Debentures and Secured Promissory Notes",
     "shortName": "Debentures and Secured Promissory Notes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.medicuspharma.com/role/RestrictedCash",
     "longName": "0019 - Disclosure - Restricted Cash",
     "shortName": "Restricted Cash",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:RestrictedAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:RestrictedAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.medicuspharma.com/role/Liquidity",
     "longName": "0020 - Disclosure - Liquidity and Going Concern",
     "shortName": "Liquidity and Going Concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "mdcx:LiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "mdcx:LiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.medicuspharma.com/role/LossPerShare",
     "longName": "0021 - Disclosure - Loss per share",
     "shortName": "Loss per share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.medicuspharma.com/role/SubsequentEvents",
     "longName": "0022 - Disclosure - Subsequent events",
     "shortName": "Subsequent events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "9960701 - Disclosure - Summary of significant accounting policies (Policies)",
     "shortName": "Summary of significant accounting policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "mdcx:BasisOfPresentationAndConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "mdcx:BasisOfPresentationAndConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.medicuspharma.com/role/BalanceSheetComponentsTables",
     "longName": "9960702 - Disclosure - Balance sheet components (Tables)",
     "shortName": "Balance sheet components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "mdcx:ScheduleOfPrepaidExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "mdcx:ScheduleOfPrepaidExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.medicuspharma.com/role/LeasesTables",
     "longName": "9960703 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "mdcx:LesseeOperatingLeasesDisclosureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "mdcx:LesseeOperatingLeasesDisclosureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.medicuspharma.com/role/ShareCapitalTables",
     "longName": "9960704 - Disclosure - Share capital (Tables)",
     "shortName": "Share capital (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.medicuspharma.com/role/StockBasedCompensationTables",
     "longName": "9960705 - Disclosure - Stock-based compensation (Tables)",
     "shortName": "Stock-based compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.medicuspharma.com/role/FairValueMeasurementTables",
     "longName": "9960706 - Disclosure - Fair value measurements (Tables)",
     "shortName": "Fair value measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.medicuspharma.com/role/CommitmentsAndContingenciesTables",
     "longName": "9960707 - Disclosure - Commitments and contingencies (Tables)",
     "shortName": "Commitments and contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesTables",
     "longName": "9960708 - Disclosure - Segment reporting (Tables)",
     "shortName": "Segment reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.medicuspharma.com/role/DebenturesTables",
     "longName": "9960709 - Disclosure - Debentures and Secured Promissory Notes (Tables)",
     "shortName": "Debentures and Secured Promissory Notes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.medicuspharma.com/role/LossPerShareTables",
     "longName": "9960710 - Disclosure - Loss per share (Tables)",
     "shortName": "Loss per share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9960712 - Disclosure - Summary of significant accounting policies (Narrative) (Details)",
     "shortName": "Summary of significant accounting policies (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.medicuspharma.com/role/BalanceSheetComponentsDetails",
     "longName": "9960713 - Disclosure - Balance sheet components (Schedule of prepaid expenses) (Details)",
     "shortName": "Balance sheet components (Schedule of prepaid expenses) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_20260630",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "mdcx:ScheduleOfPrepaidExpensesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260630",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "mdcx:ScheduleOfPrepaidExpensesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.medicuspharma.com/role/BalanceSheetComponentsDetails1",
     "longName": "9960714 - Disclosure - Balance sheet components (Schedule of accrued expenses and other current liabilities) (Details)",
     "shortName": "Balance sheet components (Schedule of accrued expenses and other current liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_20260630",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260630",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.medicuspharma.com/role/LeasesDetails",
     "longName": "9960715 - Disclosure - Leases (Schedule of operating leases) (Details)",
     "shortName": "Leases (Schedule of operating leases) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_20260630",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "strong",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://www.medicuspharma.com/role/LeasesDetails1",
     "longName": "9960716 - Disclosure - Leases (Schedule of lease cost) (Details)",
     "shortName": "Leases (Schedule of lease cost) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.medicuspharma.com/role/LeasesDetails2",
     "longName": "9960717 - Disclosure - Leases (Schedule of future minimum lease payments) (Details)",
     "shortName": "Leases (Schedule of future minimum lease payments) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_20260630",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260630",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails",
     "longName": "9960718 - Disclosure - Share capital (Narrative) (Details)",
     "shortName": "Share capital (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "strong",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250310to20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember",
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.medicuspharma.com/role/ShareCapitalDetails",
     "longName": "9960719 - Disclosure - Share capital (Schedule of assumptions used to estimate the fair value of warrants) (Details)",
     "shortName": "Share capital (Schedule of assumptions used to estimate the fair value of warrants) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_mdcxMeasurementInputValuationDateSharePriceMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "USD_PER_SHARE",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_mdcxMeasurementInputValuationDateSharePriceMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "USD_PER_SHARE",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.medicuspharma.com/role/ShareCapitalScheduleOfWarrantsContinuityDetails",
     "longName": "9960720 - Disclosure - Share capital (Schedule of warrants continuity) (Details)",
     "shortName": "Share capital (Schedule of warrants continuity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_20251231_usgaapFinancialInstrumentAxis_usgaapWarrantMember",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mdcx:ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630_usgaapFinancialInstrumentAxis_usgaapWarrantMember",
      "name": "mdcx:NumberOfCommonShareWarrantsOutstandingGrantsInPeriod",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mdcx:ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.medicuspharma.com/role/ShareCapitalDetails1",
     "longName": "9960721 - Disclosure - Share capital (Schedule of warrants outstanding) (Details)",
     "shortName": "Share capital (Schedule of warrants outstanding) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantsIssuedAsPartOfIpoMember",
      "name": "mdcx:ClassOfWarrantOrRightExpiryDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantsIssuedAsPartOfIpoMember",
      "name": "mdcx:ClassOfWarrantOrRightExpiryDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails",
     "longName": "9960722 - Disclosure - Stock-based compensation (Narrative) (Details)",
     "shortName": "Stock-based compensation (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "mdcx:LimitOfOptionsAsPercentageOfSharesOutstanding",
      "unitRef": "Percent",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "mdcx:LimitOfOptionsAsPercentageOfSharesOutstanding",
      "unitRef": "Percent",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails",
     "longName": "9960723 - Disclosure - Stock-based compensation (Schedule of stock option activity) (Details)",
     "shortName": "Stock-based compensation (Schedule of stock option activity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_20251231",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "strong",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "strong",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfWeightedaverageAssumptionsToDetermineFairValueOfStockOptionsGrantedDetails",
     "longName": "9960724 - Disclosure - Stock-based compensation (Schedule of assumptions used to estimate the fair value of options) (Details)",
     "shortName": "Stock-based compensation (Schedule of assumptions used to estimate the fair value of options) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_20260630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "USD_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "USD_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.medicuspharma.com/role/RelatedPartyTransactionsNarrativeDetails",
     "longName": "9960725 - Disclosure - Related party transactions (Narrative) (Details)",
     "shortName": "Related party transactions (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_20231018to20231018_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember",
      "name": "us-gaap:SalariesWagesAndOfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20231018to20231018_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember",
      "name": "us-gaap:SalariesWagesAndOfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.medicuspharma.com/role/FairValueMeasurementsNarrativeDetails",
     "longName": "9960726 - Disclosure - Fair value measurements (Narrative) (Details)",
     "shortName": "Fair value measurements (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_20260630",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260630",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.medicuspharma.com/role/FairValueMeasurementDetails",
     "longName": "9960727 - Disclosure - Fair value measurements - Schedule of fair value on a recurring basis (Details)",
     "shortName": "Fair value measurements - Schedule of fair value on a recurring basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_20260630",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "strong",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260630_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember",
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.medicuspharma.com/role/CommitmentsAndContingenciesN",
     "longName": "9960728 - Disclosure - Commitments and contingencies (Narrative) (Details)",
     "shortName": "Commitments and contingencies (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "unitRef": "Percent",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "unitRef": "Percent",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails",
     "longName": "9960729 - Disclosure - Commitments and contingencies (Schedule of contingent consideration) (Details)",
     "shortName": "Commitments and contingencies (Schedule of contingent consideration) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesOneMember",
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "unitRef": "USD_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesOneMember",
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "unitRef": "USD_Per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.medicuspharma.com/role/SegmentReportingNarrativeDetails",
     "longName": "9960730 - Disclosure - Segment reporting (Narrative) (Details)",
     "shortName": "Segment reporting (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "p",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "p",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails",
     "longName": "9960731 - Disclosure - Segment reporting (Schedule of reconciliation to consolidated operating expenses) (Details)",
     "shortName": "Segment reporting (Schedule of reconciliation to consolidated operating expenses) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_20260401to20260630",
      "name": "us-gaap:LaborAndRelatedExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260401to20260630",
      "name": "us-gaap:LaborAndRelatedExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.medicuspharma.com/role/DebenturesNarrativeDetails",
     "longName": "9960732 - Disclosure - Debentures and Secured Promissory Notes (Narrative) (Details)",
     "shortName": "Debentures and Secured Promissory Notes (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:ProceedsFromIssuanceOfDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20250901to20250917_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember",
      "name": "us-gaap:DebtInstrumentIssuedPrincipal",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.medicuspharma.com/role/DebenturesScheduleOfDebentureContinuityDetails",
     "longName": "9960733 - Disclosure - Debentures and Secured Promissory Notes (Schedule of debenture continuity) (Details)",
     "shortName": "Debentures and Secured Promissory Notes (Schedule of debenture continuity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:RepaymentsOfDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260401to20260630_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember",
      "name": "us-gaap:RepaymentsOfDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.medicuspharma.com/role/DebenturesAndPromissoryNotesNdfd",
     "longName": "9960734 - Disclosure - Debentures and Secured Promissory Notes (Schedule of promissory notes)  (Details)",
     "shortName": "Debentures and Secured Promissory Notes (Schedule of promissory notes)  (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:PaymentsOfDebtIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.medicuspharma.com/role/RestrictedCashNarrativeDetails",
     "longName": "9960735 - Disclosure - Restricted Cash (Narrative) (Details)",
     "shortName": "Restricted Cash (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_20260630_usgaapDebtInstrumentAxis_mdcxNoteBMember",
      "name": "us-gaap:RestrictedCashCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "us-gaap:RestrictedAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260630_usgaapDebtInstrumentAxis_mdcxNoteBMember",
      "name": "us-gaap:RestrictedCashCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "us-gaap:RestrictedAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.medicuspharma.com/role/LossPerShareDetails",
     "longName": "9960736 - Disclosure - Loss per share (Schedule of basic and diluted net loss per share ) (Details)",
     "shortName": "Loss per share (Schedule of basic and diluted net loss per share ) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_20260401to20260630",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "strong",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R58": {
     "role": "http://www.medicuspharma.com/role/TESTTESTTESTDetails",
     "longName": "9960737 - Disclosure - Loss per share (Schedule of dilutive securities excluded from computation) (Details)",
     "shortName": "Loss per share (Schedule of dilutive securities excluded from computation) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "strong",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "strong",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.medicuspharma.com/role/SubsequentEventsNarrativeDetails",
     "longName": "9960738 - Disclosure - Subsequent events (Narrative) (Details)",
     "shortName": "Subsequent events (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_20260101to20260630",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "strong",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_20260701to20260731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts and Other Receivables, Net, Current",
        "verboseLabel": "Other receivable",
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/BalanceSheetComponentsDetails1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/BalanceSheetComponentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Accrued expenses and other current liabilities",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r847",
      "r893",
      "r898"
     ]
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable",
        "terseLabel": "Total amount of accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r1043",
      "r1044",
      "r1045",
      "r1050"
     ]
    },
    "mdcx_AccruedInterestConvertedIntoCommonShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "AccruedInterestConvertedIntoCommonShares",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents accrued interest converted into common shares.",
        "label": "Accrued interest converted into common shares",
        "terseLabel": "Accrued interest converted into common shares"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_AccruedInterestRepaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "AccruedInterestRepaid",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued interest repaid.",
        "label": "Accrued Interest Repaid",
        "terseLabel": "Accrued interest paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accrued and other accounts payable",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/BalanceSheetComponentsDetails1": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/BalanceSheetComponentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "verboseLabel": "Accrued legal fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r29",
      "r95",
      "r329",
      "r600",
      "r601",
      "r611",
      "r650",
      "r670",
      "r671",
      "r1015"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8",
      "r12",
      "r484",
      "r487",
      "r490",
      "r545",
      "r666",
      "r667",
      "r907",
      "r908",
      "r909",
      "r924",
      "r925",
      "r926",
      "r927",
      "r967",
      "r969"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r329",
      "r600",
      "r601",
      "r611",
      "r847",
      "r1054"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "verboseLabel": "Additional paid-in capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r644",
      "r687",
      "r924",
      "r925",
      "r926",
      "r927",
      "r1016",
      "r1059"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "totalLabel": "Stock-based compensation",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "mdcx_Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the shares of adjustments to additional paid in capital share based compensation requisite service period recognition value.",
        "label": "Adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalueshares",
        "verboseLabel": "Share-based compensation (Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_AgentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "AgentsMember",
     "presentation": [
      "http://www.medicuspharma.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for agents.",
        "label": "Agents [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Gross stock-based compensation expense",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r403",
      "r404"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of available to exercise in relation to standby equity purchase agreement.",
        "label": "Amount Available To Exercise In Relation To Standby Equity Purchase Agreement",
        "terseLabel": "Amount available to exercise in relation to SEPA"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_AntevLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "AntevLimitedMember",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesN",
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series of individually immaterial business combinations.",
        "label": "Antev Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.medicuspharma.com/role/TESTTESTTESTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Potentially dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/TESTTESTTESTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.medicuspharma.com/role/TESTTESTTESTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.medicuspharma.com/role/TESTTESTTESTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r74",
      "r122",
      "r124",
      "r125",
      "r160",
      "r172",
      "r185",
      "r188",
      "r227",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r332",
      "r476",
      "r480",
      "r523",
      "r600",
      "r601",
      "r603",
      "r622",
      "r623",
      "r646",
      "r722",
      "r801",
      "r802",
      "r815",
      "r847",
      "r850",
      "r851",
      "r862",
      "r952",
      "r953",
      "r1037"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total current assets",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r100",
      "r122",
      "r124",
      "r125",
      "r227",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r332",
      "r476",
      "r480",
      "r523",
      "r847",
      "r890",
      "r952",
      "r953",
      "r1037"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Total assets measured at fair value",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r504",
      "r834"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.medicuspharma.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_AtmAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "AtmAgreementMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for ATM agreement.",
        "label": "Atm Agreement [Member]",
        "terseLabel": "ATM Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r869",
      "r870"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r869",
      "r870"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AuditorName",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r869",
      "r870"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]",
        "terseLabel": "Auditor Opinion"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfWeightedaverageAssumptionsToDetermineFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "verboseLabel": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396"
     ]
    },
    "mdcx_BalanceSheetComponentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "BalanceSheetComponentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Components [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_BasisOfPresentationAndConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "BasisOfPresentationAndConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of presentation and consolidation..",
        "label": "Basis Of Presentation And Consolidation [Policy Text Block]",
        "terseLabel": "Basis of presentation and consolidation [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesN",
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Domain]",
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r673",
      "r779",
      "r821",
      "r822",
      "r1003",
      "r1006",
      "r1007"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesN",
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r673",
      "r779",
      "r821",
      "r822",
      "r1003",
      "r1006",
      "r1007"
     ]
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesN",
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r462",
      "r463",
      "r464",
      "r468",
      "r469",
      "r470"
     ]
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesN"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Voting Equity Interest Acquired, Percentage",
        "terseLabel": "Ownership acquired",
        "verboseLabel": "Business combination, ownership percentage",
        "documentation": "Percentage of voting equity interest acquired in business combination."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r826",
      "r827"
     ]
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BusinessAcquisitionSharePrice",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Price Per Share",
        "terseLabel": "Contingent Consideration, price per share",
        "documentation": "Per share price of saleable stock paid or offered to be paid by acquirer in business combination."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r1004",
      "r1005",
      "r1008",
      "r1012"
     ]
    },
    "mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestTypeAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by consideration transferred equity interest.",
        "label": "Business Combination Consideration Transferred Equity Interest Type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_BusinessCombinationConsiderationTransferredEquityInterestTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestTypeDomain",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of consideration transferred equity interest.",
        "label": "Business Combination Consideration Transferred Equity Interest Type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Liability",
        "verboseLabel": "Contingent Consideration",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r468",
      "r505",
      "r506",
      "r507",
      "r826",
      "r828"
     ]
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Project [Axis]",
        "documentation": "Information by project."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r597",
      "r1042"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/FairValueMeasurementDetails",
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "positiveLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Fair value of cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r117",
      "r119",
      "r781",
      "r1039"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Fair value of cash and cash equivalents and restricted cash",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r520",
      "r521",
      "r1018",
      "r1019"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and cash equivalents and restricted cash, end of the period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash, beginning of the period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r117",
      "r119"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "totalLabel": "Net increase in cash and cash equivalents and restricted cash during the period",
        "verboseLabel": "Net change in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r36"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities",
        "verboseLabel": "Supplemental cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_ChangeInFairValueOfDebentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ChangeInFairValueOfDebentures",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount if change in fair value of debentures.",
        "label": "Change In Fair Value Of Debentures",
        "terseLabel": "Change in fair value of debentures",
        "verboseLabel": "Change in fair value of debentures"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of change in fair value of debentures and secured promissory notes.",
        "label": "Change In Fair Value Of Debentures And Secured Promissory Notes",
        "verboseLabel": "Change in fair value of debentures and secured promissory notes"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r69",
      "r70",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r122",
      "r125",
      "r149",
      "r150",
      "r152",
      "r154",
      "r162",
      "r163",
      "r227",
      "r263",
      "r265",
      "r266",
      "r267",
      "r270",
      "r271",
      "r292",
      "r293",
      "r295",
      "r296",
      "r298",
      "r300",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r316",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r331",
      "r332",
      "r333",
      "r523",
      "r600",
      "r601",
      "r608",
      "r609",
      "r610",
      "r644",
      "r677",
      "r678",
      "r679",
      "r680",
      "r687",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r710",
      "r730",
      "r752",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r877",
      "r918",
      "r921",
      "r928",
      "r968",
      "r970"
     ]
    },
    "mdcx_ClassOfWarrantOrRightExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ClassOfWarrantOrRightExercisable",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of warrants exercisable.",
        "label": "Class Of Warrant Or Right Exercisable",
        "terseLabel": "Number exercisable",
        "verboseLabel": "Number of options exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails1",
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants exercise price",
        "verboseLabel": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r126",
      "r322"
     ]
    },
    "mdcx_ClassOfWarrantOrRightExpiryDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ClassOfWarrantOrRightExpiryDate",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about class of warrant or right, expiry date.",
        "label": "Class Of Warrant Or Right, Expiry Date",
        "verboseLabel": "Expiry date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails1",
      "http://www.medicuspharma.com/role/ShareCapitalScheduleOfWarrantsContinuityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of common share warrants outstanding, ending balance",
        "periodStartLabel": "Number of common share warrants outstanding, beginning balance",
        "label": "Class of Warrant or Right, Outstanding",
        "verboseLabel": "Number outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "mdcx_ClinicalManufacturingAndRegulatoryActivitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ClinicalManufacturingAndRegulatoryActivitiesMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for clinical, manufacturing and regulatory activities.",
        "label": "Clinical, Manufacturing And Regulatory Activities [Member]",
        "verboseLabel": "Clinical, manufacturing and regulatory activities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r600",
      "r601",
      "r607",
      "r648",
      "r709"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and contingencies [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r776",
      "r945",
      "r950",
      "r951"
     ]
    },
    "mdcx_CommonSharesToBeIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "CommonSharesToBeIssued",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of common shares to be issued.",
        "label": "Common Shares To Be Issued",
        "terseLabel": "Common shares to be issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockConversionBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockConversionBasis",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Conversion Basis",
        "terseLabel": "Common stock, conversion basis",
        "documentation": "Description of basis for conversion of convertible common stock."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r328",
      "r600",
      "r601",
      "r610",
      "r964"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails",
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation",
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common shares [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r328",
      "r600",
      "r601",
      "r610",
      "r852",
      "r853",
      "r854",
      "r856",
      "r857",
      "r858",
      "r859",
      "r924",
      "r925",
      "r927",
      "r1016",
      "r1053",
      "r1059"
     ]
    },
    "us-gaap_CommonStockNoParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockNoParValue",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, No Par Value",
        "terseLabel": "Common stock, par or stated value per share",
        "documentation": "Face amount per share of no-par value common stock."
       }
      }
     },
     "auth_ref": [
      "r904",
      "r966",
      "r1043",
      "r1044",
      "r1048"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, Shares, Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r328",
      "r600",
      "r601",
      "r610",
      "r710"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common shares",
        "verboseLabel": "Issued common shares",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r328",
      "r600",
      "r601",
      "r610"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheetsParenthetical",
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending Balance (Shares)",
        "periodStartLabel": "Beginning Balance (Shares)",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Outstanding common shares",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r328",
      "r600",
      "r601",
      "r610",
      "r710",
      "r728",
      "r963",
      "r1059",
      "r1060"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common shares, no par value; unlimited shares authorized; 60,168,044 and 25,176,303 shares issued and outstanding as of June 30, 2026, and December 31, 2025, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r293",
      "r299",
      "r328",
      "r600",
      "r601",
      "r610",
      "r649",
      "r847"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total",
        "verboseLabel": "Common shareholders of the Company",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r102",
      "r104",
      "r111",
      "r620",
      "r660",
      "r662"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss attributable to"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "verboseLabel": "Non-controlling interests",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r24",
      "r27",
      "r102",
      "r104",
      "r110",
      "r619",
      "r660",
      "r661"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss for the period attributable to common shareholders",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r46",
      "r102",
      "r104",
      "r109",
      "r618",
      "r660"
     ]
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Type [Axis]",
        "documentation": "Information by type of contingent consideration arrangement in business combination."
       }
      }
     },
     "auth_ref": [
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014"
     ]
    },
    "mdcx_ContingentConsiderationPhasesFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ContingentConsiderationPhasesFourMember",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration Phases Four [Member]",
        "label": "Contingent Consideration Phases Four [Member]",
        "terseLabel": "FDA NDA approval - AUR prevention [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_ContingentConsiderationPhasesOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ContingentConsiderationPhasesOneMember",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration Phases One [Member]",
        "label": "Contingent Consideration Phases One [Member]",
        "terseLabel": "Advanced Prostate Cancer - Phase 2 success or registration [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_ContingentConsiderationPhasesThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ContingentConsiderationPhasesThreeMember",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration Phases Three [Member]",
        "label": "Contingent Consideration Phases Three [Member]",
        "terseLabel": "FDA NDA approval - Hormone therapy for prostate cancer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_ContingentConsiderationPhasesTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ContingentConsiderationPhasesTwoMember",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration Phases Two [Member]",
        "label": "Contingent Consideration Phases Two [Member]",
        "terseLabel": "Acute Urinary Retention (AUR) Prevention - Phase 2 success or registration [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Type [Domain]",
        "documentation": "Type of contingent consideration arrangement in business combination."
       }
      }
     },
     "auth_ref": [
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014"
     ]
    },
    "mdcx_ConvertibleDebtAccretionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ConvertibleDebtAccretionExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails",
      "http://www.medicuspharma.com/role/DebenturesScheduleOfDebentureContinuityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accretion expense for convertible debt.",
        "label": "Convertible Debt Accretion Expense",
        "totalLabel": "Interest Expense, Debt, Total",
        "verboseLabel": "Interest accretion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConvertibleDebtTableTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Table Text Block]",
        "verboseLabel": "Schedule of debenture continuity [Table Text Block]",
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConvertibleNotesPayableMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Notes [Member]",
        "verboseLabel": "Convertible Promissory Notes [Member]",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "verboseLabel": "Number of common shares issued on conversion of preferred stock",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r319",
      "r322"
     ]
    },
    "mdcx_CostsToIssueDebenturesAndSecuredPromissoryNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "CostsToIssueDebenturesAndSecuredPromissoryNotes",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 120.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of costs to issue debentures and secured promissory notes.",
        "label": "Costs To Issue Debentures And Secured Promissory Notes",
        "verboseLabel": "Cost to issue debentures and secured promissory notes"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_DebentureContinuityOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "DebentureContinuityOneMember",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesScheduleOfDebentureContinuityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents as a debenture continuity.",
        "label": "Debenture Continuity One [Member]",
        "verboseLabel": "Debenture issued on September 17, 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_DebenturesIssuedPercentageOfDiscountedPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "DebenturesIssuedPercentageOfDiscountedPrice",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures issued percentage of discounted price.",
        "label": "Debentures Issued Percentage Of Discounted Price",
        "terseLabel": "Debentures issued percentage of discounted price"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_DebenturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "DebenturesMember",
     "presentation": [
      "http://www.medicuspharma.com/role/TESTTESTTESTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debentures [Member]",
        "documentation": "Debentures"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_DebtConversionAdditionalDebtAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "DebtConversionAdditionalDebtAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of the additional debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Additional Debt, Amount",
        "verboseLabel": "Principal amount of additional convertible promissory notes"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_DebtConversionConvertibleInstrumentPricePerPreferredShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "DebtConversionConvertibleInstrumentPricePerPreferredShares",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the per price of preferred shares issued on the conversion of the convertible promissory notes.",
        "label": "Debt Conversion, Convertible Instrument, Price Per Preferred Shares",
        "verboseLabel": "Conversion price of preferred shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtConversionDescription",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Description",
        "verboseLabel": "Terms of conversion",
        "documentation": "Description of conversion of original debt instrument in noncash or part noncash transaction."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "mdcx_DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "DebtConversionDeterminantForConvertingRemainingValueOfConvertibleInstrumentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value used as determinant for converting remaining value of convertible promissory notes.",
        "label": "Debt Conversion, Determinant For Converting Remaining Value Of Convertible Instrument, Amount",
        "verboseLabel": "Determinant for converting remaining value of convertible promissory notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtConversionOriginalDebtAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Original Debt, Amount",
        "verboseLabel": "Principal amount of convertible promissory notes",
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_DebtConversionOriginalDebtInterestRateOfDebt": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtConversionOriginalDebtInterestRateOfDebt",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Original Debt, Interest Rate of Debt",
        "verboseLabel": "Interest rate of convertible promissory notes",
        "documentation": "The rate of interest that was being paid on the original debt issue that is being converted in the noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "mdcx_DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "DebtConversionPercentageOfPricePerPreferredSharesUnpaidAccruedInterest",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of price per preferred shares for unpaid accrued interest.",
        "label": "Debt Conversion, Percentage Of Price Per Preferred Shares, Unpaid Accrued Interest",
        "verboseLabel": "Percentage of price per preferred shares for unpaid accrued interest"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_DebtConversionRemainingConvertibleAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "DebtConversionRemainingConvertibleAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of convertible promissory notes remaining for conversion.",
        "label": "Debt Conversion, Remaining Convertible, Amount",
        "verboseLabel": "Value of convertible promissory notes remaining for conversion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesScheduleOfDebentureContinuityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net balance as at December 31, 2025",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "positiveTerseLabel": "Ending balance",
        "label": "Debt, Current",
        "totalLabel": "Debt, Current, Total",
        "documentation": "Amount of debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "mdcx_DebtDefaultBalanceIncreasePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "DebtDefaultBalanceIncreasePercentage",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of debt default balance increase percentage.",
        "label": "Debt Default Balance Increase Percentage",
        "terseLabel": "Increase of outstanding balance on redemption failure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesAndPromissoryNotesNdfd",
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails",
      "http://www.medicuspharma.com/role/RestrictedCashNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r76",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r84",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r322",
      "r600",
      "r601",
      "r606",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r845",
      "r916",
      "r917",
      "r920",
      "r923",
      "r946",
      "r947",
      "r948",
      "r1029",
      "r1030",
      "r1049"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Price",
        "verboseLabel": "Conversion price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r274"
     ]
    },
    "mdcx_DebtInstrumentConvertibleExtinguished": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "DebtInstrumentConvertibleExtinguished",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of convertible debt extinguished.",
        "label": "Debt Instrument Convertible Extinguished",
        "verboseLabel": "Loss on extinguishment"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_DebtInstrumentCovenantSharePriceThresholdPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "DebtInstrumentCovenantSharePriceThresholdPercentage",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument covenant share price threshold percentage.",
        "label": "Debt Instrument Covenant Share Price Threshold Percentage",
        "terseLabel": "Share price threshold, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_DebtInstrumentExchangeThresholdAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "DebtInstrumentExchangeThresholdAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt instrument exchange threshold.",
        "label": "Debt Instrument Exchange Threshold Amount",
        "terseLabel": "Principal amount repaid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails",
      "http://www.medicuspharma.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount",
        "verboseLabel": "Promissory note face value",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r535",
      "r536",
      "r811",
      "r812",
      "r845"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Increase (Decrease)",
        "verboseLabel": "Potential increase in interest rate",
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r78",
      "r273",
      "r600",
      "r601",
      "r606"
     ]
    },
    "us-gaap_DebtInstrumentIssuedPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentIssuedPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Issued, Principal",
        "terseLabel": "Aggregate principal amount",
        "documentation": "Amount of principal of debt issued."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesAndPromissoryNotesNdfd",
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails",
      "http://www.medicuspharma.com/role/DebenturesScheduleOfDebentureContinuityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r84",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r322",
      "r482",
      "r600",
      "r601",
      "r606",
      "r625",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r845",
      "r916",
      "r917",
      "r920",
      "r923",
      "r1029",
      "r1030"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Debentures maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r79",
      "r600",
      "r601",
      "r606",
      "r810",
      "r1021",
      "r1022"
     ]
    },
    "mdcx_DebtInstrumentMaximumExchangeLimitAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "DebtInstrumentMaximumExchangeLimitAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument maximum exchange limit amount.",
        "label": "Debt Instrument Maximum Exchange Limit Amount",
        "terseLabel": "Debt instrument maximum exchange limit amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesAndPromissoryNotesNdfd",
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails",
      "http://www.medicuspharma.com/role/RestrictedCashNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r76",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r84",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r322",
      "r600",
      "r601",
      "r606",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r845",
      "r916",
      "r917",
      "r920",
      "r923",
      "r946",
      "r947",
      "r948",
      "r1029",
      "r1030",
      "r1049"
     ]
    },
    "mdcx_DebtInstrumentRedemptionLimitAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "DebtInstrumentRedemptionLimitAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt instrument redemption limit amount.",
        "label": "Debt Instrument Redemption Limit Amount",
        "terseLabel": "Monthly redemptions ceiling"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Prepayment price percentage",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesAndPromissoryNotesNdfd",
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails",
      "http://www.medicuspharma.com/role/DebenturesScheduleOfDebentureContinuityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r50",
      "r52",
      "r53",
      "r72",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r84",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r322",
      "r482",
      "r600",
      "r601",
      "r606",
      "r625",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r845",
      "r916",
      "r917",
      "r920",
      "r923",
      "r1029",
      "r1030"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesAndPromissoryNotesNdfd",
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Discount on debt",
        "label": "Debt Instrument, Unamortized Discount",
        "terseLabel": "Notes issue discount",
        "verboseLabel": "Discount on debt",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r961",
      "r1028",
      "r1029",
      "r1030"
     ]
    },
    "mdcx_DebtInstrumentVolumeBasedRedemptionPercentageLimit": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "DebtInstrumentVolumeBasedRedemptionPercentageLimit",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument volume based redemption percentage limit.",
        "label": "Debt Instrument Volume Based Redemption Percentage Limit",
        "terseLabel": "Cumulative daily dollar trading volume (Volume-based limit)"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_DebtIssuanceDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "DebtIssuanceDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the value of debenture issued at a discount.",
        "label": "Debt Issuance Discount",
        "terseLabel": "Debt issuance discount"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_DeemedDividendOnWarrantInducement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "DeemedDividendOnWarrantInducement",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deemed dividend on warrant inducement.",
        "negatedLabel": "Deemed dividend on warrant inducement",
        "label": "Deemed dividend on warrant inducement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Debt Default, Description of Violation or Event of Default",
        "terseLabel": "Description of violation or event of default of long-term debt",
        "documentation": "Discussion of the facts and amounts pertaining to each failure to comply with an affirmative or negative covenant of a long-term debt instrument, including violating payment terms or an inability to meet certain minimum financial requirements or achieve or maintain certain financial ratios. The discussion would generally be expected to also include whether or not the failure can and will be overcome and a description of the terms of any waivers, including the amount of the waiver and the period of time covered by the waiver, and if reclassification of long-term debt to current has been made in the current balance sheet."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r122",
      "r123"
     ]
    },
    "us-gaap_DeferredCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DeferredCostsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred financing costs",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r783",
      "r905"
     ]
    },
    "mdcx_DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of deferred issuance costs on issued shares related to SEPA agreement.",
        "label": "Deferred Issuance Costs On Issued Shares Related To Sepa Agreement",
        "verboseLabel": "Deferred issuance costs on issued shares related to SEPA agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "verboseLabel": "Stock-based compensation [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r369",
      "r398",
      "r399",
      "r401",
      "r824"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r869",
      "r870"
     ]
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentDescription",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r869",
      "r870",
      "r872"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentType",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.medicuspharma.com/role/LossPerShareDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common shareholders - basic",
        "verboseLabel": "Basic and diluted net loss per share attributable to shareholders - basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r112",
      "r132",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r147",
      "r149",
      "r152",
      "r153",
      "r154",
      "r159",
      "r255",
      "r291",
      "r349",
      "r402",
      "r417",
      "r473",
      "r499",
      "r500",
      "r621",
      "r663",
      "r792"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.medicuspharma.com/role/LossPerShareDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common shareholders - diluted",
        "verboseLabel": "Basic and diluted net loss per share attributable to shareholders - diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r112",
      "r132",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r149",
      "r152",
      "r153",
      "r154",
      "r159",
      "r255",
      "r291",
      "r349",
      "r402",
      "r417",
      "r473",
      "r499",
      "r500",
      "r621",
      "r663",
      "r792"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss per share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r155",
      "r156",
      "r157",
      "r158",
      "r337"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "verboseLabel": "Foreign currency effect on cash and cash equivalents",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "mdcx_EffectiveInterestRateOnDebt": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "EffectiveInterestRateOnDebt",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the effective interest rate on debt.",
        "label": "Effective Interest Rate On Debt",
        "verboseLabel": "Effective interest rate on debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/BalanceSheetComponentsDetails1": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/BalanceSheetComponentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation and benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Period for recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfWeightedaverageAssumptionsToDetermineFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "verboseLabel": "Stock options [Member]",
        "terseLabel": "Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registrant CIK",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails",
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails1",
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation",
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r69",
      "r91",
      "r92",
      "r105",
      "r106",
      "r107",
      "r129",
      "r130",
      "r131",
      "r133",
      "r140",
      "r142",
      "r144",
      "r161",
      "r228",
      "r229",
      "r254",
      "r255",
      "r256",
      "r290",
      "r321",
      "r326",
      "r327",
      "r328",
      "r331",
      "r333",
      "r336",
      "r347",
      "r348",
      "r350",
      "r351",
      "r402",
      "r410",
      "r411",
      "r414",
      "r415",
      "r416",
      "r418",
      "r472",
      "r473",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r498",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r538",
      "r545",
      "r593",
      "r600",
      "r601",
      "r609",
      "r610",
      "r644",
      "r658",
      "r666",
      "r667",
      "r668",
      "r687",
      "r752",
      "r970"
     ]
    },
    "mdcx_EquityDistributionAgreementCommissionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "EquityDistributionAgreementCommissionRate",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the equity distribution agreement commission rate.",
        "label": "Equity Distribution Agreement Commission Rate",
        "terseLabel": "Equity distribution agreement commission rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 80.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.medicuspharma.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r503",
      "r504",
      "r512",
      "r834"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.medicuspharma.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r503",
      "r504",
      "r512",
      "r834"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r506",
      "r507",
      "r826",
      "r828",
      "r836",
      "r1040"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r506",
      "r507",
      "r826",
      "r828",
      "r836",
      "r1040"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of assumptions used to estimate the fair value of warrants [Table Text Block]",
        "verboseLabel": "Schedule of assumptions used to estimate the fair value of warrants [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r506",
      "r836"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r501",
      "r502",
      "r504",
      "r505",
      "r506",
      "r507",
      "r511",
      "r512",
      "r513",
      "r519",
      "r560",
      "r561",
      "r562",
      "r567",
      "r811",
      "r812",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r834",
      "r836",
      "r843",
      "r844"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r504",
      "r505",
      "r507",
      "r834",
      "r1021",
      "r1024"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair value measurements [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r598",
      "r834",
      "r837"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.medicuspharma.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r353",
      "r358",
      "r360",
      "r504",
      "r512",
      "r519",
      "r560",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r834",
      "r843",
      "r844"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.medicuspharma.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r353",
      "r358",
      "r360",
      "r362",
      "r504",
      "r505",
      "r512",
      "r519",
      "r561",
      "r811",
      "r812",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r834",
      "r843",
      "r844"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.medicuspharma.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r504",
      "r505",
      "r506",
      "r507",
      "r512",
      "r519",
      "r562",
      "r811",
      "r812",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r834",
      "r836",
      "r843",
      "r844"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.medicuspharma.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r504",
      "r505",
      "r507",
      "r834",
      "r1021",
      "r1024"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.medicuspharma.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r501",
      "r502",
      "r504",
      "r505",
      "r506",
      "r507",
      "r511",
      "r512",
      "r513",
      "r519",
      "r560",
      "r561",
      "r562",
      "r567",
      "r811",
      "r812",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r834",
      "r836",
      "r843",
      "r844"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.medicuspharma.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1024"
     ]
    },
    "mdcx_FairValueOfWarrantsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "FairValueOfWarrantsGranted",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrants granted",
        "label": "Fair value of warrants granted"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_FairValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "FairValuePerShare",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the fair value per share.",
        "label": "Fair Value Per Share",
        "verboseLabel": "Fair value per share"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_FairValuePerWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "FairValuePerWarrant",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the fair value per warrant.",
        "label": "Fair Value Per Warrant",
        "verboseLabel": "Fair value per warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails",
      "http://www.medicuspharma.com/role/ShareCapitalScheduleOfWarrantsContinuityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r288",
      "r320",
      "r482",
      "r518",
      "r522",
      "r524",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r564",
      "r565",
      "r566",
      "r567",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r645",
      "r659",
      "r808",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r939",
      "r940",
      "r941",
      "r942",
      "r1017",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign operations remeasurement and translation [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "mdcx_GainLossOnSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "GainLossOnSettlements",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 30.0
      },
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows",
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of gain loss on settlements.",
        "negatedLabel": "Loss on SEPA settlements",
        "label": "Gain Loss On Settlements",
        "terseLabel": "Loss on SEPA settlements",
        "verboseLabel": "Loss on SEPA (as defined below) settlements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r18",
      "r19"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "Total general and administrative expenses",
        "verboseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r732"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IPOMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "verboseLabel": "Initial Public Offering [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 90.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 110.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable, Related Parties",
        "terseLabel": "Related party payable",
        "totalLabel": "Increase (Decrease) in Due to Related Parties, Current, Total",
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 100.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 70.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r878",
      "r914"
     ]
    },
    "mdcx_IncreaseDecreaseInOperatingLeaseRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "IncreaseDecreaseInOperatingLeaseRightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of operating lease right-of-use assets.",
        "label": "Increase Decrease In Operating Lease Rightofuse Assets",
        "terseLabel": "Change in operating lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "mdcx_IncrementalFairValueOfWarrantsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "IncrementalFairValueOfWarrantsGranted",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the amount of incremental fair value of warrants granted.",
        "label": "Incremental Fair Value Of Warrants Granted",
        "terseLabel": "Incremental fair value of warrants granted"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_IndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "IndividualsMember",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for individuals.",
        "label": "Individuals [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 10.0
      },
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest (expense)",
        "negatedTerseLabel": "Interest income (expense)",
        "label": "Interest Expense, Operating and Nonoperating",
        "terseLabel": "Interest expense",
        "verboseLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r172",
      "r173",
      "r174",
      "r188",
      "r534",
      "r801",
      "r802",
      "r1056"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesAndPromissoryNotesNdfd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt",
        "verboseLabel": "Interest accretion",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r285",
      "r289",
      "r813",
      "r814",
      "r1056"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "terseLabel": "Cash paid for interest",
        "verboseLabel": "Value of accrued interest paid in cash",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r115",
      "r118"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest",
        "verboseLabel": "Interest accretion",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "mdcx_InterimRemeasurementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "InterimRemeasurementMember",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for interim remeasurement.",
        "label": "Interim Remeasurement [Member]",
        "terseLabel": "Interim remeasurement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance (income) expense, net",
        "label": "Investment Income, Net",
        "verboseLabel": "Finance income",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "mdcx_IssuanceCostsInConnectionWithEquityFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "IssuanceCostsInConnectionWithEquityFinancing",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents issuuance costs in connection with equity financing.",
        "label": "Issuance Costs In Connection With Equity Financing",
        "terseLabel": "Issuance costs in connection with equity financing"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_IssuanceCostsInConnectionWithInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "IssuanceCostsInConnectionWithInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents issuance costs in connection with initial public offering.",
        "label": "Issuance Costs In Connection With Initial Public Offering",
        "verboseLabel": "Issuance costs in connection with initial public offering"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_IssuanceCostsInConnectionWithPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "IssuanceCostsInConnectionWithPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents issuance costs in connection with a private placement.",
        "label": "Issuance Costs In Connection With Private Placement",
        "terseLabel": "Issuance costs in connection with a private placement",
        "verboseLabel": "Value of finders fees in connection with a private placement"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_IssuanceCostsInConnectionWithRegulationA": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "IssuanceCostsInConnectionWithRegulationA",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents issuance costs in connection with regulation A.",
        "label": "Issuance Costs In Connection With Regulation A",
        "terseLabel": "Issuance costs in connection with Regulation A"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_IssuanceCostsIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "IssuanceCostsIncludedInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance costs included in accounts payable.",
        "label": "Issuance costs included in accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 130.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the amount of issuance of common shares in connection with non-cash compensation for services rendered.",
        "negatedLabel": "Issuance of common shares in connection with non-cash compensation for services rendered",
        "label": "Issuance Of Common Shares Connection With Non Cash Compensation For Services Rendered",
        "verboseLabel": "Issuance of common shares in connection with non-cash compensation for services rendered"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_June2025PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "June2025PublicOfferingMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June 2025 Public Offering [Member].",
        "label": "June 2025 Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Labor and Related Expense",
        "verboseLabel": "Salaries and benefits",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r790",
      "r910"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of lease cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails",
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Fees",
        "terseLabel": "Legal fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r1057",
      "r1058"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.medicuspharma.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Discount rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of future minimum lease payments [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/LeasesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/LeasesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments, undiscounted",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r917",
      "r923",
      "r1049"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/LeasesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/LeasesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r917",
      "r923",
      "r1049"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/LeasesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/LeasesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r917",
      "r923",
      "r1049"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/LeasesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Present value discount",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "verboseLabel": "Present value discount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.medicuspharma.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "verboseLabel": "Remaining lease term (in years)",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r1032"
     ]
    },
    "mdcx_LesseeOperatingLeasesDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "LesseeOperatingLeasesDisclosureTableTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the lessee operating leases disclosure",
        "label": "Lessee Operating Leases Disclosure [Table Text Block]",
        "terseLabel": "Schedule of operating leases [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r122",
      "r124",
      "r125",
      "r227",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r332",
      "r477",
      "r480",
      "r481",
      "r523",
      "r708",
      "r794",
      "r815",
      "r862",
      "r906",
      "r952",
      "r1037",
      "r1038"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total liabilities and shareholders' deficit",
        "totalLabel": "Total liabilities and shareholders' (deficit) equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r600",
      "r601",
      "r613",
      "r653",
      "r847",
      "r850",
      "r851",
      "r916",
      "r922",
      "r943",
      "r1027"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY",
        "terseLabel": "Liabilities and Shareholder's equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r68",
      "r77",
      "r122",
      "r124",
      "r125",
      "r227",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r332",
      "r477",
      "r480",
      "r481",
      "r523",
      "r847",
      "r952",
      "r1037",
      "r1038"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:",
        "verboseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Total liabilities measured at fair value",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r1018"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.medicuspharma.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_LimitOfOptionsAsPercentageOfSharesOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "LimitOfOptionsAsPercentageOfSharesOutstanding",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Limit of options as a percentage of shares outstanding",
        "label": "Limit Of Options As Percentage Of Shares Outstanding",
        "verboseLabel": "Limit of options as a percentage of shares outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_LiquidityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "LiquidityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_LiquidityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "LiquidityTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/Liquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure liquidity.",
        "label": "Liquidity [Text Block]",
        "terseLabel": "Liquidity and Going Concern [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/Debentures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt [Text Block]",
        "terseLabel": "Debentures and Secured Promissory Notes [Text Block]",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r600",
      "r601",
      "r606"
     ]
    },
    "us-gaap_LongTermLoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LongTermLoansPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable, Noncurrent",
        "terseLabel": "Loan payable",
        "verboseLabel": "Loan payable",
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r902"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesAndPromissoryNotesNdfd",
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails",
      "http://www.medicuspharma.com/role/DebenturesScheduleOfDebentureContinuityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r600",
      "r601",
      "r606",
      "r946",
      "r947",
      "r948"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesAndPromissoryNotesNdfd",
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails",
      "http://www.medicuspharma.com/role/DebenturesScheduleOfDebentureContinuityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r72",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r600",
      "r601",
      "r606",
      "r946",
      "r947",
      "r948"
     ]
    },
    "srt_ManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ManagementMember",
     "presentation": [
      "http://www.medicuspharma.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management [Member]",
        "terseLabel": "Key Management Personnel [Member]"
       }
      }
     },
     "auth_ref": [
      "r937",
      "r1035"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails",
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "verboseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r167",
      "r259",
      "r260",
      "r261",
      "r262",
      "r364",
      "r393",
      "r394",
      "r395",
      "r405",
      "r507",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r594",
      "r664",
      "r665",
      "r672",
      "r700",
      "r701",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r772",
      "r773",
      "r774",
      "r775",
      "r777",
      "r778",
      "r807",
      "r823",
      "r826",
      "r828",
      "r829",
      "r836",
      "r837",
      "r841",
      "r842",
      "r849",
      "r957",
      "r962"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "verboseLabel": "Exercise price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r992",
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "verboseLabel": "Dividend yield [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected warrant life[Member]",
        "verboseLabel": "Expected warrant life [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "verboseLabel": "Expected volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r836",
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "verboseLabel": "Risk-free interest rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails",
      "http://www.medicuspharma.com/role/ShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r505",
      "r506",
      "r507",
      "r826",
      "r828",
      "r829",
      "r836",
      "r1040"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails",
      "http://www.medicuspharma.com/role/ShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r506",
      "r507",
      "r826",
      "r828",
      "r829",
      "r836",
      "r1040"
     ]
    },
    "mdcx_MeasurementInputValuationDateSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "MeasurementInputValuationDateSharePriceMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for measurement input, valuation date share price.",
        "label": "Measurement Input, Valuation Date Share Price [Member]",
        "verboseLabel": "Valuation date share price [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "verboseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r167",
      "r259",
      "r260",
      "r261",
      "r262",
      "r364",
      "r393",
      "r394",
      "r395",
      "r405",
      "r507",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r594",
      "r664",
      "r665",
      "r672",
      "r700",
      "r701",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r772",
      "r773",
      "r774",
      "r775",
      "r777",
      "r778",
      "r807",
      "r823",
      "r826",
      "r828",
      "r829",
      "r836",
      "r837",
      "r841",
      "r849",
      "r957",
      "r962"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interests",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r122",
      "r124",
      "r125",
      "r227",
      "r263",
      "r265",
      "r266",
      "r267",
      "r270",
      "r271",
      "r332",
      "r600",
      "r601",
      "r612",
      "r652",
      "r712",
      "r1027"
     ]
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MoneyMarketFundsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalent, Money Market Fund, Carrying Value",
        "verboseLabel": "Money market funds",
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "mdcx_NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "NetCashPaidForAntevAssetAcquisitionIncludingTransactionCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of net cash paid for antev asset acquisition including transaction costs.",
        "negatedLabel": "Net cash paid for Antev asset acquisition including transaction costs",
        "label": "Net Cash Paid For Antev Asset Acquisition Including Transaction Costs",
        "verboseLabel": "Net cash paid for Antev asset acquisition including transaction costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash provided by financing activities",
        "totalLabel": "Net cash provided by financing activities",
        "verboseLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:",
        "verboseLabel": "Cash flows from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "totalLabel": "Net cash used in investing activities",
        "verboseLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities",
        "verboseLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES",
        "terseLabel": "Cash flows from operating activities",
        "verboseLabel": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/LossPerShareDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "positiveLabel": "Net loss attributable to shareholders",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net Income (Loss) Attributable to Parent, Total",
        "verboseLabel": "Common shareholders of the Company",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r38",
      "r48",
      "r59",
      "r64",
      "r65",
      "r101",
      "r103",
      "r107",
      "r122",
      "r124",
      "r125",
      "r128",
      "r132",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r143",
      "r144",
      "r151",
      "r227",
      "r255",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r291",
      "r294",
      "r297",
      "r301",
      "r332",
      "r349",
      "r402",
      "r417",
      "r473",
      "r500",
      "r523",
      "r657",
      "r729",
      "r750",
      "r751",
      "r788",
      "r790",
      "r791",
      "r860",
      "r952"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Net loss attributable to"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "verboseLabel": "Non-controlling interests",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r47",
      "r64",
      "r65",
      "r101",
      "r103",
      "r140",
      "r143",
      "r144",
      "r227",
      "r656",
      "r909"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting pronouncements [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-Controlling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r331",
      "r333",
      "r924",
      "r925",
      "r926",
      "r927",
      "r1059"
     ]
    },
    "mdcx_NoteAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "NoteAMember",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesAndPromissoryNotesNdfd",
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Note A.",
        "label": "Note A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_NoteBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "NoteBMember",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesAndPromissoryNotesNdfd",
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails",
      "http://www.medicuspharma.com/role/RestrictedCashNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Note B.",
        "label": "Note B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesAndPromissoryNotesNdfd"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable",
        "terseLabel": "Ending balance",
        "totalLabel": "Ending balance",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r900",
      "r902",
      "r1043",
      "r1044",
      "r1046",
      "r1051",
      "r1052"
     ]
    },
    "mdcx_NumberOfCommonShareWarrantsOutstandingExerciseInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "NumberOfCommonShareWarrantsOutstandingExerciseInPeriod",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalScheduleOfWarrantsContinuityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common share warrants outstanding exercise during the period.",
        "negatedLabel": "Warrants exercised",
        "label": "Number Of Common Share Warrants Outstanding Exercise In Period",
        "verboseLabel": "Warrants outstanding exercise during the period"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_NumberOfCommonShareWarrantsOutstandingGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "NumberOfCommonShareWarrantsOutstandingGrantsInPeriod",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails",
      "http://www.medicuspharma.com/role/ShareCapitalScheduleOfWarrantsContinuityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common share warrants outstanding granted during the period.",
        "label": "Number Of Common Share Warrants Outstanding Grants In Period",
        "terseLabel": "Number of warrants granted",
        "verboseLabel": "Warrants granted"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "NumberOfCommonSharesIssuedInConnectionWithPrivatePlacement",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of common shares issued in connection with a private placement.",
        "label": "Number Of Common Shares Issued In Connection With Private Placement",
        "verboseLabel": "Number of common shares issued in connection with a private placement"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_NumberOfConvertibleNotesSubscribed": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "NumberOfConvertibleNotesSubscribed",
     "presentation": [
      "http://www.medicuspharma.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of convertible notes subscribed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r932"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.medicuspharma.com/role/SegmentReportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r806",
      "r932"
     ]
    },
    "mdcx_NumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "NumberOfWarrantsExercised",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of warrants exercised.",
        "label": "Number of warrants exercised",
        "terseLabel": "Number exercisable",
        "verboseLabel": "Number of options exercised"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_NumberOfWarrantsExercisedForCash": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "NumberOfWarrantsExercisedForCash",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of warrants exercised for cash.",
        "label": "Number Of Warrants Exercised For Cash",
        "verboseLabel": "Number of warrants exercised for cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      },
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "verboseLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r791",
      "r887",
      "r888",
      "r943"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss from operations",
        "negatedTotalLabel": "Loss from operations",
        "label": "Loss from operations",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r791",
      "r795",
      "r887",
      "r888",
      "r931",
      "r933",
      "r934",
      "r935",
      "r936",
      "r943"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "verboseLabel": "Operating lease cost",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/LeasesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liability",
        "verboseLabel": "Total lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/LeasesDetails",
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities - current",
        "verboseLabel": "Operating lease liability, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r786"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/LeasesDetails",
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities - non-current",
        "verboseLabel": "Operating lease liability, non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating cash flows used in operating leases",
        "label": "Operating cash flows used in operating leases",
        "verboseLabel": "Other information",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r542"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/LeasesDetails",
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/DescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "Description of business [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r60",
      "r61",
      "r62",
      "r674",
      "r675"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/BalanceSheetComponentsDetails1": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/BalanceSheetComponentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Accrued other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign exchange gain/loss",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Total",
        "verboseLabel": "Foreign currency translation adjustment",
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r29",
      "r658"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherComprehensiveIncomeLossTax",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax",
        "terseLabel": "Other comprehensive loss for the period",
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r105",
      "r108",
      "r409",
      "r412",
      "r413",
      "r527",
      "r530",
      "r532",
      "r617",
      "r658"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total other income",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)",
        "verboseLabel": "Total other income (expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r833"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense)",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Non-cash interest expense",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "mdcx_PaymentOfStructuringFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "PaymentOfStructuringFee",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of payment of structuring fee.",
        "label": "Payment of structuring fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 80.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesAndPromissoryNotesNdfd",
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost to issue debentures and secured promissory notes",
        "negatedTerseLabel": "Debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Cost to issue debentures and secured promissory notes",
        "verboseLabel": "Debt issuance costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash paid for financing costs in connection with SEPA",
        "label": "Payments of Financing Costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Issuance costs for common shares",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Issuance costs for common shares",
        "totalLabel": "Payments of Financing Costs, Total",
        "verboseLabel": "Share issuance cost",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_PrepaidContractResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "PrepaidContractResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/BalanceSheetComponentsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/BalanceSheetComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contract research organizations.",
        "label": "Prepaid Contract Research",
        "verboseLabel": "Contract research organizations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.medicuspharma.com/role/BalanceSheetComponentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/BalanceSheetComponentsDetails",
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r246",
      "r247",
      "r784"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/BalanceSheetComponentsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/BalanceSheetComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "verboseLabel": "Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r785",
      "r809",
      "r944"
     ]
    },
    "mdcx_PrepaidProfessionalServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "PrepaidProfessionalServices",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/BalanceSheetComponentsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/BalanceSheetComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prepaid professional services.",
        "label": "Prepaid Professional Services",
        "verboseLabel": "Professional services"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_PrepaidServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "PrepaidServices",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/BalanceSheetComponentsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/BalanceSheetComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prepaid services.",
        "label": "Prepaid Services",
        "terseLabel": "Prepaid services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "verboseLabel": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_ProceedsFromCommonSharesNetOfCommissionsPayableToAgents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ProceedsFromCommonSharesNetOfCommissionsPayableToAgents",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about proceeds from common shares net of commissions payable to agents.",
        "label": "Proceeds From Common Shares Net Of Commissions Payable To Agents",
        "verboseLabel": "Proceeds from common shares net of commissions payable to Agents"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_ProceedsFromConcurrentFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ProceedsFromConcurrentFinancing",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the proceeds from concurrent financing.",
        "negatedLabel": "Proceeds from concurrent financing",
        "label": "Proceeds From Concurrent Financing",
        "terseLabel": "Proceeds from concurrent financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering, net of offering expenses",
        "verboseLabel": "Total proceeds from IPO",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 70.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails",
      "http://www.medicuspharma.com/role/SubsequentEventsNarrativeDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "positiveTerseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from common shares",
        "verboseLabel": "Net proceeds from issuance of common shares and warrants",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "mdcx_ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 60.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of proceeds from issuance of common stock at the market offering net of issuance costs.",
        "negatedLabel": "Proceeds from issuance of common shares under ATM, net of issuance costs",
        "label": "Proceeds From Issuance of Common Stock at the Market Offering Net of Issuance Costs",
        "verboseLabel": "Proceeds from issuance of common shares under ATM, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "disclosureGuidance": "Proceeds from issuance of debentures",
        "positiveTerseLabel": "Proceeds of debentures",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debentures and secured promissory notes",
        "verboseLabel": "Proceeds from issuance of debentures",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Long-Term Debt",
        "verboseLabel": "Proceeds from Issuance of long-term debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r677"
     ]
    },
    "mdcx_ProceedsFromIssuanceOfSharesUnderSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ProceedsFromIssuanceOfSharesUnderSettlements",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 50.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of proceeds from issuance of shares under settlements.",
        "label": "Proceeds From Issuance Of Shares Under Settlements",
        "verboseLabel": "Proceeds from issuance of common shares under SEPA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "measurementGuidance": "Proceeds from offering",
        "positiveTerseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from common shares",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total",
        "verboseLabel": "Proceeds from issuance of common shares, net of issuance costs",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r677"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesAndPromissoryNotesNdfd",
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Aggregate principal of the notes",
        "verboseLabel": "Proceeds",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "mdcx_ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from share issuance used to repay outstanding debentures.",
        "label": "Proceeds From Share Issuance Used To Repay Outstanding Debentures",
        "verboseLabel": "Proceeds from share issuance used to repay outstanding debentures"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_ProceedsFromSimpleAgreementForFutureEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ProceedsFromSimpleAgreementForFutureEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from simple agreement for future equity (\"SAFE\")",
        "label": "Proceeds From Simple Agreement For Future Equity",
        "verboseLabel": "Proceeds from simple agreement for future equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of warrants",
        "verboseLabel": "Proceeds from warrants exercised",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "mdcx_ProfessionalServicesAndIntellectualPropertyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ProfessionalServicesAndIntellectualPropertyMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for professional services and intellectual property.",
        "label": "Professional Services And Intellectual Property [Member]",
        "verboseLabel": "Professional services and intellectual property [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows",
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit",
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "positiveLabel": "Net loss for the period",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss for the period",
        "totalLabel": "Net loss for the period",
        "verboseLabel": "Net loss and comprehensive loss for the period",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r64",
      "r65",
      "r101",
      "r103",
      "r116",
      "r122",
      "r124",
      "r125",
      "r128",
      "r132",
      "r140",
      "r143",
      "r144",
      "r227",
      "r255",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r291",
      "r332",
      "r349",
      "r402",
      "r417",
      "r473",
      "r475",
      "r478",
      "r479",
      "r500",
      "r523",
      "r622",
      "r624",
      "r655",
      "r686",
      "r729",
      "r750",
      "r751",
      "r780",
      "r831",
      "r832",
      "r861",
      "r909",
      "r952"
     ]
    },
    "us-gaap_ProjectMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProjectMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Project [Domain]",
        "documentation": "Planned program of work."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r597",
      "r1042"
     ]
    },
    "mdcx_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for public warrants.",
        "label": "Public Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails",
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r167",
      "r259",
      "r260",
      "r261",
      "r262",
      "r352",
      "r364",
      "r393",
      "r394",
      "r395",
      "r401",
      "r405",
      "r507",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r577",
      "r594",
      "r664",
      "r665",
      "r672",
      "r700",
      "r701",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r772",
      "r773",
      "r774",
      "r775",
      "r777",
      "r778",
      "r807",
      "r823",
      "r826",
      "r828",
      "r829",
      "r836",
      "r837",
      "r841",
      "r842",
      "r849",
      "r854",
      "r949",
      "r957",
      "r962",
      "r1021"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "RangeMember",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails",
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r167",
      "r259",
      "r260",
      "r261",
      "r262",
      "r352",
      "r364",
      "r393",
      "r394",
      "r395",
      "r401",
      "r405",
      "r507",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r577",
      "r594",
      "r664",
      "r665",
      "r672",
      "r700",
      "r701",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r772",
      "r773",
      "r774",
      "r775",
      "r777",
      "r778",
      "r807",
      "r823",
      "r826",
      "r828",
      "r829",
      "r836",
      "r837",
      "r841",
      "r842",
      "r849",
      "r854",
      "r949",
      "r957",
      "r962",
      "r1021"
     ]
    },
    "mdcx_RbxCapitalLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "RbxCapitalLPMember",
     "presentation": [
      "http://www.medicuspharma.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represent information about the RBx Capital, LP.",
        "label": "Rbx Capital, L P [Member]",
        "terseLabel": "RBx Capital, LP (\"RBx\") [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_RegulationAOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "RegulationAOfferingMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for regulation A offering.",
        "label": "Regulation A Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_RegulationAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "RegulationAWarrantsMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails",
      "http://www.medicuspharma.com/role/ShareCapitalDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for regulation A warrants.",
        "label": "Regulation A Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.medicuspharma.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.medicuspharma.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r75",
      "r83",
      "r85",
      "r122",
      "r127",
      "r128",
      "r196",
      "r359",
      "r363",
      "r549",
      "r550",
      "r600",
      "r601",
      "r604",
      "r605",
      "r606",
      "r614",
      "r647",
      "r654",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r727",
      "r759",
      "r782",
      "r1055",
      "r1061"
     ]
    },
    "mdcx_RelatedPartyPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "RelatedPartyPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the related party payable.",
        "label": "Related Party Payable, Current",
        "terseLabel": "Related party payable"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_RelatedPartyTransactionAdditionalExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "RelatedPartyTransactionAdditionalExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period for additional expenses.",
        "label": "Related Party Transaction, Additional Expenses",
        "terseLabel": "Additional expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Amounts of transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.medicuspharma.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r127",
      "r128",
      "r196",
      "r549",
      "r550",
      "r551",
      "r600",
      "r601",
      "r604",
      "r605",
      "r606",
      "r614",
      "r733",
      "r734",
      "r737",
      "r1061"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.medicuspharma.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r75",
      "r83",
      "r85",
      "r122",
      "r127",
      "r128",
      "r196",
      "r359",
      "r363",
      "r549",
      "r550",
      "r600",
      "r601",
      "r604",
      "r605",
      "r606",
      "r614",
      "r647",
      "r654",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r727",
      "r759",
      "r782",
      "r1036",
      "r1055",
      "r1061"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related party transactions [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r547",
      "r548",
      "r550",
      "r552",
      "r600",
      "r601",
      "r615",
      "r682",
      "r683",
      "r684",
      "r735",
      "r736",
      "r737",
      "r756",
      "r758"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails",
      "http://www.medicuspharma.com/role/DebenturesScheduleOfDebentureContinuityDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of debenture",
        "negatedTerseLabel": "Repayment of debentures and secured promissory notes",
        "label": "Repayments of Debt",
        "terseLabel": "Outstanding principal repaid",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "mdcx_RepaymentsOfInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "RepaymentsOfInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesScheduleOfDebentureContinuityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents repayments of interest.",
        "negatedLabel": "Interest payment",
        "label": "Repayments Of Interest",
        "verboseLabel": "Interest payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross",
        "terseLabel": "Research and development expenses",
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r1002"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others [Table Text Block]",
        "verboseLabel": "Schedule of research and development expenses [Table Text Block]",
        "documentation": "Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate."
       }
      }
     },
     "auth_ref": [
      "r1001",
      "r1002"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Total research and development expenses",
        "totalLabel": "Total research and development expenses",
        "verboseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r779",
      "r788",
      "r789",
      "r801",
      "r1041"
     ]
    },
    "us-gaap_RestrictedAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestrictedAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/RestrictedCash"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Assets Disclosure [Text Block]",
        "terseLabel": "Restricted Cash [Text Block]",
        "documentation": "The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r600",
      "r601",
      "r602",
      "r919"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalent, Current",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash and Cash Equivalent, Current, Total",
        "verboseLabel": "Restricted deposit",
        "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r117",
      "r119"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/RestrictedCashNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r119",
      "r895"
     ]
    },
    "mdcx_RestrictedCashLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "RestrictedCashLineItems",
     "presentation": [
      "http://www.medicuspharma.com/role/RestrictedCashNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "verboseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r117",
      "r119",
      "r892",
      "r896"
     ]
    },
    "mdcx_RestrictedCashTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "RestrictedCashTable",
     "presentation": [
      "http://www.medicuspharma.com/role/RestrictedCashNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "verboseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r96",
      "r329",
      "r600",
      "r601",
      "r611",
      "r651",
      "r669",
      "r671",
      "r681",
      "r711",
      "r847"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings",
        "verboseLabel": "Accumulated deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r129",
      "r130",
      "r131",
      "r133",
      "r140",
      "r142",
      "r144",
      "r228",
      "r229",
      "r254",
      "r255",
      "r256",
      "r290",
      "r326",
      "r336",
      "r347",
      "r348",
      "r350",
      "r351",
      "r402",
      "r410",
      "r411",
      "r414",
      "r415",
      "r416",
      "r418",
      "r472",
      "r473",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488",
      "r489",
      "r491",
      "r498",
      "r538",
      "r593",
      "r644",
      "r666",
      "r668",
      "r687",
      "r967",
      "r969",
      "r1059"
     ]
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SalariesWagesAndOfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salary and Wage, Excluding Cost of Good and Service Sold",
        "terseLabel": "Reimbursable salaries",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Issued common shares",
        "verboseLabel": "Number of units issued",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share",
        "verboseLabel": "Price per share in IPO",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/BalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of accrued expenses and other current liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.medicuspharma.com/role/TESTTESTTESTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "verboseLabel": "Schedule of dilutive securities excluded from computation [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesN",
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesScheduleOfContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration [Table]",
        "documentation": "Disclosure of information about contingent consideration arrangement in business combination."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r462",
      "r463",
      "r464",
      "r468",
      "r469",
      "r470"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred, Equity Interest [Table Text Block]",
        "verboseLabel": "Schedule of contingent consideration [Table Text Block]",
        "documentation": "Tabular disclosure of equity interest issued or issuable by acquirer as part of consideration transferred in business combination."
       }
      }
     },
     "auth_ref": [
      "r1008",
      "r1012"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of promissory notes [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r50",
      "r52",
      "r53",
      "r811",
      "r813",
      "r894",
      "r900",
      "r901",
      "r917",
      "r923",
      "r964",
      "r1029",
      "r1049"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted net loss per share [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Schedule of financial assets and liabilities that measured at fair value on a recurring basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1018",
      "r1019"
     ]
    },
    "mdcx_ScheduleOfPrepaidExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ScheduleOfPrepaidExpensesTableTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/BalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of prepaid expenses.",
        "label": "Schedule Of Prepaid Expenses [Table Text Block]",
        "verboseLabel": "Schedule of prepaid expenses [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.medicuspharma.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r127",
      "r128",
      "r549",
      "r550",
      "r551",
      "r600",
      "r601",
      "r604",
      "r605",
      "r606",
      "r614",
      "r733",
      "r734",
      "r737",
      "r1061"
     ]
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development, Contract to Perform for Others [Table]",
        "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r1002"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalScheduleOfWarrantsContinuityDetails",
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfWeightedaverageAssumptionsToDetermineFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r368",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r401"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Schedule of stock option activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r42"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used to estimate the fair value of options [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "verboseLabel": "Schedule of warrants outstanding [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "mdcx_ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about the warrants continuity outstanding and exercisable.",
        "label": "Schedule Of Warrants Continuity Outstanding And Exercisable [Table Text Block]",
        "verboseLabel": "Schedule of warrants continuity outstanding and exercisable [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SecuredDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Debt, Current",
        "verboseLabel": "Debentures and secured promissory notes, current",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_SecuredLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SecuredLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Long-Term Debt, Noncurrent",
        "terseLabel": "Debentures and secured promissory notes, non-current",
        "totalLabel": "Long-Term Debt, Excluding Current Maturities, Total",
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r902"
     ]
    },
    "mdcx_SecuredPromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "SecuredPromissoryNotesMember",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesAndPromissoryNotesNdfd",
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for secured promissory notes.",
        "label": "Secured Promissory Notes [Member]",
        "verboseLabel": "Secured promissory notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents as securities purchase agreement.",
        "label": "Securities Purchase Agreement [Member]",
        "verboseLabel": "Securities purchase agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12gTitle",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "Segment reporting [Text Block]",
        "documentation": "The entire disclosure for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r175",
      "r176",
      "r177",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r193",
      "r195",
      "r796",
      "r799",
      "r800",
      "r801",
      "r803",
      "r805",
      "r806"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Operating segments [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r191",
      "r194",
      "r797",
      "r798",
      "r804"
     ]
    },
    "mdcx_SeriesAAndBWarrantsGrantedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "SeriesAAndBWarrantsGrantedMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A and B warrants granted [Member].",
        "label": "Series A and B Warrants Granted [Member]",
        "verboseLabel": "Series A and B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_SeriesAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "SeriesAWarrantsMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A warrants [Member].",
        "label": "Series A Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B warrants [Member].",
        "label": "Series B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_SeriesCAndDWarrantsGrantedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "SeriesCAndDWarrantsGrantedMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the member of series A and B warrants granted",
        "label": "Series C And D Warrants Granted [Member]",
        "verboseLabel": "Series C and D Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_SeriesCAndDWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "SeriesCAndDWarrantsMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for series C and D warrants.",
        "label": "Series C And D Warrants [Member]",
        "verboseLabel": "Series C and D Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_SettlementDateRemeasurementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "SettlementDateRemeasurementMember",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for settlement date remeasurement.",
        "label": "Settlement Date Remeasurement [Member]",
        "terseLabel": "Settlement date remeasurement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Accelerated Cost",
        "verboseLabel": "Remaining expense for accelerated share options",
        "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfWeightedaverageAssumptionsToDetermineFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfWeightedaverageAssumptionsToDetermineFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Dividend",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfWeightedaverageAssumptionsToDetermineFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "verboseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfWeightedaverageAssumptionsToDetermineFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "verboseLabel": "Risk-free interest",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalScheduleOfWarrantsContinuityDetails",
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfWeightedaverageAssumptionsToDetermineFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r368",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Number of shares available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Number of options, Exercisable, end of year",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted- average exercise price",
        "verboseLabel": "Stock options Exercisable, Weighted-average exercise price end of year",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Intrinsic Value",
        "verboseLabel": "Weighted average grant-date fair value of options forfeited",
        "documentation": "The combined weighted average of the accumulated differences between the fair values on underlying shares and exercises prices to acquire such shares as of the grant date on options that were either forfeited or lapsed."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Number of options, Forfeited",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r891",
      "r903",
      "r904",
      "r965",
      "r966"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value",
        "verboseLabel": "Stock options, Granted, Aggregate intrinsic value",
        "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options, Granted",
        "verboseLabel": "Number of stock options issued",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r891",
      "r903",
      "r904",
      "r965",
      "r966"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant-date fair value of options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "verboseLabel": "Stock options, Outstanding, Aggregate intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of options outstanding, Ending balance",
        "periodStartLabel": "Number of options outstanding, Beginning balance",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalScheduleOfWarrantsContinuityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, Ending balance",
        "periodStartLabel": "Weighted average exercise price, Beginning balance",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "verboseLabel": "Stock options, Unvested, Aggregate intrinsic value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfWeightedaverageAssumptionsToDetermineFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "verboseLabel": "Award Type [Domain]",
        "terseLabel": "Award type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails",
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercised",
        "verboseLabel": "Exercise price of options exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price, Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Weighted average exercise price, Granted",
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Beginning Balance",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercise price of warrants granted",
        "verboseLabel": "Stock options Unvested, Weighted average exercise price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "mdcx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award, Warrants, Grants In Period, Weighted Average Exercise Price",
        "terseLabel": "Exercise price of warrants granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche one [Member]",
        "verboseLabel": "Vest upon achieving a trading price of $5.00 per share [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche two [Member]",
        "verboseLabel": "Adjusted EBITDA of $110 million",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997"
     ]
    },
    "mdcx_ShareCapitalNoteDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ShareCapitalNoteDisclosureLineItems",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Capital Note Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_ShareCapitalNoteDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ShareCapitalNoteDisclosureTable",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share capital.",
        "label": "Share Capital Note Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_ShareIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ShareIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the amount of share issuance costs",
        "negatedLabel": "Share issuance costs",
        "label": "Share Issuance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharePrice",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfWeightedaverageAssumptionsToDetermineFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_SharePriceAsPercentageOfMarketPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "SharePriceAsPercentageOfMarketPrice",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price as percentage of market price",
        "label": "Share Price As Percentage Of Market Price",
        "verboseLabel": "Share price as percentage of market price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number",
        "verboseLabel": "Number of accelerated vesting",
        "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period",
        "documentation": "Period from grant to expiration date of share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfWeightedaverageAssumptionsToDetermineFairValueOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "verboseLabel": "Estimated life (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Stock options, Exercisable, Aggregate intrinsic value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Stock options, Exercisable, Weighted average remaining contractual life (years)",
        "documentation": "Weighted-average contractual term remaining for vested portion of option outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "verboseLabel": "Number of options, Unvested",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable price per shares",
        "verboseLabel": "Stock options Unvested, Weighted average exercise price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Contractual term",
        "verboseLabel": "Stock options, Outstanding, Weighted average remaining contractual life (years)",
        "documentation": "Weighted-average contractual term remaining for option award outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "mdcx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days, Granted.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term, Granted",
        "terseLabel": "Stock options, Granted, Weighted average remaining contractual life (years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Unvested, Weighted average remaining contractual life (years)",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "mdcx_SharesIssuedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "SharesIssuedMember",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the member of shares issued",
        "label": "Shares Issued [Member]",
        "terseLabel": "Shares Issued [Member]",
        "verboseLabel": "Shares to be issued [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "disclosureGuidance": "Share price",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued price per share",
        "verboseLabel": "Common shares, price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r893",
      "r897",
      "r946",
      "r947",
      "r948"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r893",
      "r897",
      "r946",
      "r947",
      "r948"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121"
     ]
    },
    "mdcx_SkinjectIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "SkinjectIncMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Skinject, Inc. [Member]",
        "terseLabel": "SkinJect [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_StandbyEquityPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "StandbyEquityPurchaseAgreementMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for standby equity purchase agreement.",
        "label": "Standby Equity Purchase Agreement [Member]",
        "verboseLabel": "Standby Equity Purchase Agreement (the \"SEPA\") [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r69",
      "r70",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r122",
      "r125",
      "r149",
      "r150",
      "r152",
      "r154",
      "r162",
      "r163",
      "r227",
      "r263",
      "r265",
      "r266",
      "r267",
      "r270",
      "r271",
      "r292",
      "r293",
      "r295",
      "r296",
      "r298",
      "r300",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r316",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r331",
      "r332",
      "r333",
      "r523",
      "r600",
      "r601",
      "r608",
      "r609",
      "r610",
      "r644",
      "r677",
      "r678",
      "r679",
      "r680",
      "r687",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r710",
      "r730",
      "r752",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r877",
      "r918",
      "r921",
      "r928",
      "r968",
      "r970"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails1",
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation",
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r69",
      "r91",
      "r92",
      "r105",
      "r106",
      "r107",
      "r129",
      "r130",
      "r131",
      "r133",
      "r140",
      "r142",
      "r144",
      "r161",
      "r228",
      "r229",
      "r254",
      "r255",
      "r256",
      "r290",
      "r321",
      "r326",
      "r327",
      "r328",
      "r331",
      "r333",
      "r336",
      "r347",
      "r348",
      "r350",
      "r351",
      "r402",
      "r410",
      "r411",
      "r414",
      "r415",
      "r416",
      "r418",
      "r472",
      "r473",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r498",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r538",
      "r545",
      "r593",
      "r600",
      "r601",
      "r609",
      "r610",
      "r644",
      "r658",
      "r666",
      "r667",
      "r668",
      "r687",
      "r752",
      "r970"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation",
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r71",
      "r72",
      "r75",
      "r83",
      "r85",
      "r87",
      "r90",
      "r91",
      "r92",
      "r96",
      "r129",
      "r130",
      "r131",
      "r161",
      "r292",
      "r293",
      "r295",
      "r298",
      "r303",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r335",
      "r336",
      "r346",
      "r538",
      "r595",
      "r600",
      "r601",
      "r608",
      "r609",
      "r610",
      "r676",
      "r688",
      "r699",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r710",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r731",
      "r732",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r752",
      "r782",
      "r790",
      "r791",
      "r855",
      "r1055"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementTable",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation",
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r69",
      "r70",
      "r71",
      "r72",
      "r75",
      "r83",
      "r85",
      "r87",
      "r90",
      "r91",
      "r92",
      "r96",
      "r129",
      "r130",
      "r131",
      "r161",
      "r196",
      "r292",
      "r293",
      "r295",
      "r298",
      "r303",
      "r321",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r335",
      "r336",
      "r346",
      "r538",
      "r595",
      "r600",
      "r601",
      "r608",
      "r609",
      "r610",
      "r644",
      "r676",
      "r688",
      "r699",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r710",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r731",
      "r732",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r752",
      "r782",
      "r790",
      "r791",
      "r855",
      "r1055"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Number of common shares",
        "verboseLabel": "Issuance of common shares for asset acquisition (Shares)",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r891",
      "r903",
      "r904",
      "r963",
      "r965",
      "r966",
      "r967",
      "r969",
      "r1043",
      "r1044",
      "r1047",
      "r1048"
     ]
    },
    "mdcx_StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the shares of stock issued during period value connection with at the market offering, net of issuance costs.",
        "label": "Stock Issued During Period Shares Connection With At The Market Offering, Net Of Issuance Costs",
        "verboseLabel": "Issuance of common shares in connection with ATM, net of issuance cost (Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_StockIssuedDuringPeriodSharesConnectionWithEquityFinancing": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "StockIssuedDuringPeriodSharesConnectionWithEquityFinancing",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the shares of stock issued during period value connection with equity financing.",
        "label": "Stock Issued During Period Shares Connection With Equity Financing",
        "terseLabel": "Issuance of common shares and warrants in connection with June equity financing, net of offering costs (Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "StockIssuedDuringPeriodSharesConnectionWithPrivatePlacementNetOfIssuanceCosts",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the shares of stock issued during period value connection with a private placement, net of issuance costs.",
        "label": "Stock Issued During Period Shares Connection With Private Placement, Net Of Issuance Costs",
        "verboseLabel": "Issuance of common shares in connection with a private placement, net of issuance costs (Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the shares of stock issued during period value connection with SEPA offering costs.",
        "label": "Stock Issued During Period Shares Connection With Sepa Offering Costs",
        "terseLabel": "Issuance of common shares",
        "verboseLabel": "Issuance of common shares in connection with SEPA offering costs (Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.medicuspharma.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Settled the convertible notes, along with accrued but unpaid interest as common shares",
        "verboseLabel": "Issuance of common shares upon conversion of promissory notes (Shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r322",
      "r891",
      "r903",
      "r904",
      "r963",
      "r965",
      "r966",
      "r967",
      "r969",
      "r1043",
      "r1044",
      "r1047",
      "r1048"
     ]
    },
    "mdcx_StockIssuedDuringPeriodSharesConversionOfDebt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "StockIssuedDuringPeriodSharesConversionOfDebt",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the shares of stock issued during period value conversion of debt.",
        "label": "Stock Issued During Period Shares Conversion Of Debt",
        "terseLabel": "Issuance of common shares upon conversion of debt (Shares)",
        "verboseLabel": "Issuance of common shares upon conversion of debt (Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_StockIssuedDuringPeriodSharesConversionOfPreferredShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "StockIssuedDuringPeriodSharesConversionOfPreferredShares",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the shares of stock issued during period shares conversion of preferred shares.",
        "label": "Stock Issued During Period Shares Conversion Of Preferred Shares",
        "verboseLabel": "Issuance of common shares upon conversion of preferred shares (Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails",
      "http://www.medicuspharma.com/role/SubsequentEventsNarrativeDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "positiveTerseLabel": "Issuance of common shares and warrants in connection with Regulation A, net of issuance costs (Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Common shares issued",
        "verboseLabel": "Proceeds from Issuance of shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r677",
      "r752",
      "r766",
      "r891",
      "r903",
      "r904",
      "r963",
      "r965",
      "r966",
      "r967",
      "r969",
      "r1043",
      "r1044",
      "r1047",
      "r1048"
     ]
    },
    "mdcx_StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the shares of stock issued during period value non-cash compensation for services rendered.",
        "label": "Stock Issued During Period Shares Noncash Compensation Services Rendered",
        "terseLabel": "Issuance of common shares in connection with noncash compensation for services rendered (Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_StockIssuedDuringPeriodSharesOfCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "StockIssuedDuringPeriodSharesOfCommonStock",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the shares of stock issued during period value of common stock.",
        "label": "Stock Issued During Period Shares Of Common Stock",
        "verboseLabel": "Issuance of common shares (Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails",
      "http://www.medicuspharma.com/role/StockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, exercised",
        "positiveLabel": "Number of options, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common shares upon exercise of stock options (Shares)",
        "verboseLabel": "Number of options exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r891",
      "r903",
      "r904",
      "r963",
      "r965",
      "r966",
      "r967",
      "r969",
      "r1043",
      "r1044",
      "r1047",
      "r1048"
     ]
    },
    "mdcx_StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the shares of stock issued during period value upon exercise of stock warrants.",
        "label": "Stock Issued During Period Shares Upon Exercise Of Stock Warrants",
        "verboseLabel": "Issuance of common shares upon exercise of stock warrants (Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Issuance of common shares upon acquisition of Interactive Capital Partners Ltd",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Fair value of common shares",
        "verboseLabel": "Issuance of common shares for asset acquisition",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r891",
      "r903",
      "r904",
      "r963",
      "r965",
      "r966",
      "r967",
      "r969",
      "r1043",
      "r1044",
      "r1047",
      "r1048"
     ]
    },
    "mdcx_StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of stock issued during period value connection with at the market offering, net of issuance costs.",
        "label": "Stock Issued During Period Value Connection With At The Market Offering, Net Of Issuance Cost",
        "terseLabel": "Issuance of common shares in connection with ATM, net of issuance cost"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_StockIssuedDuringPeriodValueConnectionWithEquityFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "StockIssuedDuringPeriodValueConnectionWithEquityFinancing",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of stock issued during period value connection with equity financing.",
        "label": "Stock Issued During Period Value Connection With Equity Financing",
        "terseLabel": "Issuance of common shares and warrants in connection with June equity financing, net of offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "StockIssuedDuringPeriodValueConnectionWithPrivatePlacementNetOfIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of stock issued during period value connection with a private placement, net of issuance costs.",
        "label": "Stock Issued During Period Value Connection With Private Placement, Net Of Issuance Costs",
        "verboseLabel": "Issuance of common shares in connection with a private placement, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of stock issued during period value connection with SEPA offering costs.",
        "label": "Stock Issued During Period Value Connection With Sepa Offering Costs",
        "terseLabel": "Aggregate gross proceeds through issuance of common shares",
        "verboseLabel": "Issuance of common shares in connection with SEPA offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Principal amount",
        "verboseLabel": "Issuance of common shares upon conversion of promissory notes",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r891",
      "r903",
      "r904",
      "r963",
      "r965",
      "r966",
      "r967",
      "r969",
      "r1043",
      "r1044",
      "r1047",
      "r1048"
     ]
    },
    "mdcx_StockIssuedDuringPeriodValueConversionOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "StockIssuedDuringPeriodValueConversionOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of stock issued during period value conversion of debt.",
        "label": "Stock Issued During Period Value Conversion Of Debt",
        "terseLabel": "Issuance of common shares upon conversion of debt",
        "verboseLabel": "Issuance of common shares upon conversion of debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "positiveLabel": "Total proceeds from all SEPA issuances",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Value of common shares issued",
        "verboseLabel": "Issuance of common shares and warrants in connection with Regulation A, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r752",
      "r766",
      "r861",
      "r891",
      "r903",
      "r904",
      "r963",
      "r965",
      "r966",
      "r967",
      "r969",
      "r1043",
      "r1044",
      "r1047",
      "r1048"
     ]
    },
    "mdcx_StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of stock issued during period value non-cash compensation for services rendered.",
        "label": "Stock Issued During Period Value Noncash Compensation For Services Rendered",
        "terseLabel": "Issuance of common shares in connection with noncash compensation for services rendered"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_StockIssuedDuringPeriodValueOfCommonShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "StockIssuedDuringPeriodValueOfCommonShares",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of stock issued during period value of common shares.",
        "label": "Stock Issued During Period Value Of Common Shares",
        "verboseLabel": "Issuance of common shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common shares upon exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r891",
      "r903",
      "r904",
      "r963",
      "r965",
      "r966",
      "r967",
      "r969",
      "r1043",
      "r1044",
      "r1047",
      "r1048"
     ]
    },
    "mdcx_StockIssuedDuringPeriodValueUponExerciseOfStockWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "StockIssuedDuringPeriodValueUponExerciseOfStockWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of stock issued during period value upon exercise of stock warrants.",
        "label": "Stock Issued During Period Value Upon Exercise Of Stock Warrants",
        "terseLabel": "Issuance of common shares upon exercise of stock warrants"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://www.medicuspharma.com/role/TESTTESTTESTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options [Member]",
        "documentation": "Stock options"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_StockPurchaseWarrantsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "StockPurchaseWarrantsTerm",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The contractual term of warrants.",
        "label": "Stock Purchase Warrants Term",
        "terseLabel": "Warrant term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total shareholders' (deficit) equity attributable to Medicus Pharma Ltd.",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r712",
      "r728",
      "r753",
      "r754",
      "r847",
      "r862",
      "r906",
      "r916",
      "r921",
      "r922",
      "r943",
      "r1027",
      "r1059"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' deficit:",
        "verboseLabel": "Shareholders' (deficit) equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.medicuspharma.com/role/idr_BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.medicuspharma.com/role/idr_BalanceSheets",
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total shareholders' (deficit) equity",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r25",
      "r58",
      "r59",
      "r92",
      "r106",
      "r129",
      "r130",
      "r131",
      "r133",
      "r140",
      "r142",
      "r228",
      "r229",
      "r254",
      "r255",
      "r256",
      "r290",
      "r321",
      "r327",
      "r328",
      "r331",
      "r333",
      "r347",
      "r348",
      "r350",
      "r351",
      "r402",
      "r410",
      "r411",
      "r414",
      "r415",
      "r416",
      "r418",
      "r472",
      "r473",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r498",
      "r527",
      "r528",
      "r532",
      "r545",
      "r593",
      "r600",
      "r601",
      "r609",
      "r610",
      "r667",
      "r668",
      "r685",
      "r712",
      "r728",
      "r753",
      "r754",
      "r770",
      "r850",
      "r851",
      "r861",
      "r891",
      "r903",
      "r916",
      "r921",
      "r922",
      "r943",
      "r1027",
      "r1059"
     ]
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapital"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "verboseLabel": "Share capital [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r91",
      "r92",
      "r97",
      "r302",
      "r305",
      "r307",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r322",
      "r327",
      "r328",
      "r331",
      "r333",
      "r334",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r482",
      "r496",
      "r497",
      "r556",
      "r755",
      "r757",
      "r771"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse share split ratio",
        "verboseLabel": "Description of the reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r339",
      "r342"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.medicuspharma.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r554"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.medicuspharma.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "verboseLabel": "Subsequent event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r554"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.medicuspharma.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r554"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r554"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.medicuspharma.com/role/SubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r554"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r555"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.medicuspharma.com/role/BalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance sheet components [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalIncomeStatementElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SupplementalIncomeStatementElementsAbstract",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Income Statement Elements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_TeverelixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "TeverelixMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ResearchAndDevelopmentRDExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Teverelix.",
        "label": "Teverelix [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_ThresholdLimitOfFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ThresholdLimitOfFinancing",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold limit of financing.",
        "label": "Threshold Limit Of Financing",
        "verboseLabel": "Threshold limit of financing"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails",
      "http://www.medicuspharma.com/role/ShareCapitalScheduleOfWarrantsContinuityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r288",
      "r320",
      "r482",
      "r518",
      "r522",
      "r524",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r564",
      "r565",
      "r566",
      "r567",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r645",
      "r659",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r848",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r939",
      "r940",
      "r941",
      "r942",
      "r1017",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/DebenturesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.medicuspharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r164",
      "r165",
      "r166",
      "r167",
      "r622",
      "r624",
      "r793"
     ]
    },
    "mdcx_ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "ValueOfCommonSharesIssuedInConnectionWithPrivatePlacement",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of common shares issued in connection with a private placement.",
        "label": "Value Of Common Shares Issued In Connection With Private Placement",
        "verboseLabel": "Value of common shares issued in connection with a private placement"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_VelocityFundManagementLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "VelocityFundManagementLLCMember",
     "presentation": [
      "http://www.medicuspharma.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represent information about the Velocity Fund Management, LLC.",
        "label": "Velocity Fund Management, L L C [Member]",
        "terseLabel": "Velocity Fund Management, LLC (\"VFM\") [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.medicuspharma.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997"
     ]
    },
    "mdcx_WarrantLiabilityIssuedDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "WarrantLiabilityIssuedDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of warrant liability issued during period.",
        "label": "Warrant liability issued during period",
        "terseLabel": "Warrant liability",
        "verboseLabel": "Issued during the period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails",
      "http://www.medicuspharma.com/role/ShareCapitalScheduleOfWarrantsContinuityDetails",
      "http://www.medicuspharma.com/role/TESTTESTTESTDetails",
      "http://www.medicuspharma.com/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "verboseLabel": "Public Warrants [Member]",
        "terseLabel": "Warrants [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r852",
      "r853",
      "r856",
      "r857",
      "r858",
      "r859"
     ]
    },
    "mdcx_WarrantWithExpiryDateJune302030WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "WarrantWithExpiryDateJune302030WarrantsMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for June 30, 2030 warrants.",
        "label": "Warrant With Expiry Date June 30, 2030 Warrants [Member]",
        "verboseLabel": "June 30, 2030 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails",
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "verboseLabel": "Measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "mdcx_WarrantsIssuedAsPartOfIpoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "WarrantsIssuedAsPartOfIpoMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for warrants issued as part of the IPO.",
        "label": "Warrants Issued As Part Of Ipo [Member]",
        "verboseLabel": "Warrants issued as part of the IPO [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_WarrantsIssuedUnderWarrantInducement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "WarrantsIssuedUnderWarrantInducement",
     "crdr": "credit",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfChangesInShareholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issued under warrant inducement",
        "label": "Warrants issued under warrant inducement",
        "terseLabel": "Warrants issued under warrant inducements"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_WeightedAverageExercisePriceOfWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "WeightedAverageExercisePriceOfWarrant",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalScheduleOfWarrantsContinuityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of warrant.",
        "periodEndLabel": "Weighted average exercise price of warrants, ending balance",
        "periodStartLabel": "Weighted average exercise price of warrants, beginning balance",
        "label": "Weighted Average Exercise Price Of Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_WeightedAverageExercisePriceWarrantExercise": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "WeightedAverageExercisePriceWarrantExercise",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalScheduleOfWarrantsContinuityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price warrant granted exercise",
        "label": "Weighted Average Exercise Price Warrant Exercise",
        "verboseLabel": "Weighted average exercise price of warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_WeightedAverageExercisePriceWarrantGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "WeightedAverageExercisePriceWarrantGranted",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalScheduleOfWarrantsContinuityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price warrant granted.",
        "label": "Weighted Average Exercise Price Warrant Granted",
        "verboseLabel": "Weighted average exercise price of warrants granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.medicuspharma.com/role/LossPerShareDetails",
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of common shares outstanding",
        "verboseLabel": "Weighted average number of common shares outstanding during the year - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r154"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.medicuspharma.com/role/idr_StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding - basic",
        "verboseLabel": "Weighted average number of common shares outstanding during the year - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r154"
     ]
    },
    "mdcx_WeightedAverageRemainingContractualTermOfWarrant": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "WeightedAverageRemainingContractualTermOfWarrant",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalScheduleOfWarrantsContinuityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Contractual Term Of Warrant",
        "verboseLabel": "Weighted average remaining contractual term"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_WeightedAverageRemainingContractualTermOfWarrantGranted": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "WeightedAverageRemainingContractualTermOfWarrantGranted",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalScheduleOfWarrantsContinuityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Contractual Term Of Warrant Granted",
        "verboseLabel": "Weighted average remaining contractual term granted"
       }
      }
     },
     "auth_ref": []
    },
    "mdcx_YaIiPnLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.medicuspharma.com/20260630",
     "localname": "YaIiPnLtdMember",
     "presentation": [
      "http://www.medicuspharma.com/role/ShareCapitalNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about YA II PN, Ltd.",
        "label": "Ya Ii Pn Ltd [Member]",
        "terseLabel": "Yorkville [Member]",
        "verboseLabel": "YA II PN Ltd (Yorkville) [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.4-03(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480868/205-20-S45-2"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.Z.5.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-2"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-13"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-12"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-20"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3C"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480125/505-10-S35-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-4"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-8"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-6"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 5.Q.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-7"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481468/505-20-05-5"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 1.D.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479921/505-20-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-11"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "45",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480865/815-45-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 1.B.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480148/855-10-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(cc)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-5"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii)(B)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479664/932-10-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477385/932-360-S50-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478482/942-210-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7)(e)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7)(e)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.9-06)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(ff)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(fff)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-38"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479299/805-40-55-10"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-7"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(3)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-3"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-42"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-1B"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.9-06)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "810",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477383/970-810-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001062993-26-004230-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062993-26-004230-xbrl.zip
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MEYN3K_]R<]!OT>]&]/M1R_]2]5]02P,$%     @ =*H,70>*T/Y9!P  IQH
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M_Q1?:0$C*F5S'N($IXU..<YY%%7C4EFIT*P'Y42T@2Y_I&TG\G.560]SA[^
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MMNUI[LSP%ZL+[DT&\ROM)^?<\2?D B O%@LZ@PV3=P;K--ZTK/.O5G[@S((
M2;--,$J^726%-YO(>8PE2X@8$?1"]VD,._@R&!#TAAWY7)H_\77#7- 7JT-[
M'73LX<9KT7<YEW?"V=.VG^#O5WXV&3BKD)_ @>O,PNG(1KPWIX:D*]+9QP\C
M: \^?IC R!;P3SKPOS/W^R]GE[Z'YAUU'M'ZG@E._.Z7LP@MQSLLV=\+#KI=
M"*-?OCY^[IAG[SY^B-QH##]^B1\FW).G"3?1X/Q"^(RX7@!2YY]"1_CLCN$
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MG)%L6?R-0WJWME[[L$3L-T0YX$Z_H0K<,@?W,>"6.;@I!K?"P7T,N!4.[EK
M?5)H/&D :#BFPNU2*J3;Z=JE6NH64PQN;I=RN[2UX.9V*;=+&0#W2:'QI %
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MH@<;39% "KWY8K^XD]F$#O$_"B#=%A!:L(OY\IU]Q&]7%O!TY?>"=$RS!V<
M#E,&8$JS%/_LSP*J,<R%^$[*,<T<'/X<I*T$Z:D BF[ZJ4N'//4C.R+G%\61
MGDM_,O4]]#;<%F2CG(Q;YW1([*HD<E9T(,F^Y.P.!@3:]OC>=@?77E)HT2;2
M;IWBB9#Y 48VDF:#GAUX2!?1O;%B3_KFSXU1PBX73"M4'JI41JFL4L$A.VLK
MQV5@LS*05I@4EYRD2<C(#F!X'88S1JS6'7B(^W1D)L6HL%S>G<6 L#QP7TX5
M7+"V<GL(RUO?PW<+_/$8*=LT&=P&WD@OVS;#ZD5E*T#2=9S99$8.8+B+1C#
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M,4YVYV@E[,ZI()@[W_ C;][PLQM';9 LF.,0LTW<*$+L"<>(Z9#8Q5IN_"I
MI/%>!7+>K.V0K,65'=D"+D1<%SR+>RR'%1]FZ$I5TI+*L:0KG-#O/ IO<$;<
M>"\K\GER031R0S1B>XH+R*J60O%XY\(%AF];)#HD2S, \H^MO$JO.3$Q+1-)
M4K7H:!_?(*C:PAB-#'D-CH/X)K Q^#&4 JS/<C\5T-IU<K\()XCAT%."5*1C
M=P7-XA5K;^R3H 5_QA\CT?DC&J7?GB-E#LG0!G#H>J26FV0<SS8,[4P4SG(_
MW#B LU@[GVT8P1FN_"1L#N2GCIS:&,N&Q0;&HB*'L)9^RJ8<XQNJ^'X58.XF
MGTH%'9B"@P<5#7X#QQ\WV*I6NMO2-2X2@&IXZ0NI*P7]DU//BDV-X!)1[=D/
M7@\J1":W(11WDML0'S1/$.<$=%F!B,X(&_8WJ1DVUKH0E%5-D7*<-C+U3[/0
M]6!8Q%?;=W-N?3)B1Q'M/C0JYU95H;67;_.T"*N:JBLY6$TG_C<R[\O4U&L$
MLRP&]X9;;'9<2Y3K:;C#/.><N.1(0WD^\:AG86SOH[G&V\MS-G$BEP$_:_R*
M'_[#18_&CH2'QNICR?O=#8G&2T[7P.8GWJ2#+\8=L0=V, @%O'?''6RJ$E+>
MV&_W,/4I]*&1-YNZK-A[+1*- YIB2CDN=>]EL9<YWGY__%[FW:Q"[<H>X$>'
M(^3US3W>-PCUQ)V-MQ5N=RX9"MOL"SDDGQ'>+"UG#T0?+]A18KDE8.N2:$=W
M]HR&(0!)%/"<18R2  H_\%_),G\F02_?R]MR;<D:<D!6<YE)H'U154#Z>85W
MLXC(2"0L<]<=W>Y,P#VMR(=Q#S $9L=%QE_XR]GU[>=58GBS26?@DXIB? DN
MJQ6!*8E+Q;WIR#^F&>R\*B&D5,BQZ"16XR\&N8$[F@KES^/NRN:X.QHAA0T
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M/>/L8__Z;[?=1R8<9S1:6=M*ZZ3"9&-CFDSUSH(>TX^UYM-JV1>C;L[/,90
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MV_DH2NR)U1W#>1N&:U*,\0H)EW8XBM.@^ 4.@7^WQTF<M CJ#XVAQ7&^E4W
M>$D:MQ-^KHCMDPG+.3V8:I[AUC;(^-QF%9B:+!G FI\;.@L[^&3/"PR6KC?
M__062.E&EW80X.U7_\)E0[G=D$GOZ7DWY*_]JS,A1(L&2>QWT159VM$3&6@B
M,%01R&:F)W+I="-PC,E6E&K'GF'!"*_\W#K6*,02LJ0;H"R6T(",C]LXGB5,
MT9 T40:Y'$$/(U!BJA=4O]7;FHGZO0_@U';C/:A>F%0AQ%4ASKI53X\ZKL2N
MVR4&ZK/_BXD# !1=61<'"3U[,3FWG:E9ED843<D051W0H1#W0P9':_5*RU14
MZU"4EJ:D@"B9.C+;<E%*#SBYCYBKI*[@$ ;!XJ0HLJ$II$PGE1&7W)+RQ,]
M\,'_?TNE"5M$=^E(*@ @R;*LJ9;TK9A*2ZE_B4E>OD:+#R'Z'PS\LX^=BI38
M 71EP/LK."G.+OLJSUULDJM3"[)):2K5LD1%TLK5ITWQ"27.8=-^QZ./-[UE
M_+Z]!" [)O6F^J/C1 =U7J*BRYF@45SX4X=WJ(N6"43-M*K5K(6)>,H^)+.
M+P1T15(-;5^@EZ<-1=.21%U5*U&(]<*;$B^TT/,>()(B<=\ZG$!L@0]XO+%:
MR!$S 3(Q94,Q55G_=I1_MB !3D+<^IY3@UZ11 D8H@KD;7KEQ#-OS<"O MCE
M^CM[P.Y0*;\K-, 36LWY+'>+3E'0)MM3$5@[_K!#=BVW,V6UZA[+YS(V" ;^
M#&]UH]Z(V\]KT4P]4_TQ)_D-IO@#GMC=\&L(B9%7J;9!J@:8N:9=Z<'!8E3E
M;@RC7%#,E9$M,V-F[8O^\G)GAB0:BE)EI*]&T+/DW%0>ZJ,YQ%=B@@"/M$PY
M04DV;:$M#0-LB/%5J19EI!6!CC1C;A:@W.!>>1*"BJ39CBD5EHZ<=0Y5L9JN
M95S*C2Q3GBZ51$D'HF(8E<4):^04EES0MIF_93,FF[N;*L$]1\XQR*EG:-P7
M*(\A;Y*.G&D3NO[(#N#('^/FUG\5W@S@T'7<Z"W9G!6]MM=;H-&8J79'* /V
M,K74/O:A)V>!4<<>[&CN$['FN)U6"K7KD$S<MMJO-<9X86/1*:9H4*GM%%/<
M@.(&%&O;@KN.@YX=A?@H(MQ)ERI118..;3KGHZFZ+F7+71.RW<=4JZ' 6Q<-
M1145(/'MOZ<&UR(PU65@*,;!,"TM[Z*(JJ*)LE5RVJ6E1C-M^W\17@)\<M>6
M)A6K]C4]NHH&0ZMY765JAIDC!#!1EX+/76]PAXFZ]%&5JDN13%&2<B4"=Q+:
MC-UBBDO1+;DLS):XZ19KL5QCBQZH<I\J5XL])(=ES\]XI=VQ8B\<0XUM7%0]
M:D"5@&)JB_*]R<!YN4B@@D_N>JW/EP,Z$$U5IT,A<D^.'D^.H%0%0),/1VEY
M)71 %U4C%Z7T@),[<KDJ<'W3UOPL6#%UY*C2AVTU@/=QWDQ%T75I^V:4U/A]
MK4-)*8:H*)2$&[G71IG7AG25M&/?8 &PEJ>K5$U4M69U5;O=M?D A*6C,]<.
M:-R&,2$&F4!0]G[7T)<Z$CXAZ,R")!9)#FC%KEW@XU-[_> 5GT6,[SM7:].E
MM>)6[#Y-*A1)E74=9-H"Y&NF?DP*1*"H!FVDB)HDB9*T51^UV$TZJ@4@%4 \
M H#YVJ80 $O3,)HH(QVCJ7G;<[D'U'S]UVI+O9.H JNFS1AE;I&FZ9*:V7.[
ME 6HPQ621%,%HFKE[LVGM+E>6UTF9E%?S*_2##E3;50([25VV+,44Y3TW(Y?
MC&&<$I>KJ8!S8>\)4;E#8V"0"LNU(0V(C6))LC1=EDQMU2C.9K/6C.(;=/='
M&$RP<5RI9C1$RY216;RU/2!%^0*.X9H:JV_'[DJ.:S_L5M5CD"*0GKA+=^.C
M']%8MM'6B/]>)XHHLJ2H!3O6IJR,*9H6(5>LC@"HJGT@][^H!? QP,WM>5L0
MN*7Y7+(FFGK)9WQP7ZI4D&TIJ6BS]\1T$]#] HVFE0TT;DAI5])\O?X#LG@K
MIU;#OUC$T40:L@S8EZ8,=4D$2NXY-@SB_L1]N=7TW*FEY<KH/$JCO;V/7M4E
M /3,IK2:MI[))LG< ;6&8[%*)C8#/F:[6NPRS9&%.%%53#D3=:UI0QUNR"NK
MHJ277*1).0.RY#2WS6CGG7L/6@SN[O'.O=Q]B1GRTI],W&@"<8<F7$&!]2/R
MBJ'GX!Z^;V[]" K6V]:Y, L\9Z!>C!(%<L.JI1BRE2DK7UKQKC>X7%[OHH["
M2^A>>.[XE[,HF$$TF",+=N<L5,7Z<TRL8D*5U>R)3/MA(M=DI1P3"S'[$WF#
M\TWX_6*K3=$=,\D&F ^CA:P.H/U'QQY&,+B8VL]P><P.6E,8O!]!3,<+;?KR
M/A[UGR7R7W8ZZ1<)&B3I+V?OXH%68P_A7V&DX(%_T]$G?^ITD"1V1GX@=#H9
MRRCY)UZ"@?L]9_6 AL?S4TQFO,Y"K%F)"^/ \3C9'S5_C^[II.^3VRUFGZIE
MM#IC>QK"B_3%^[6]48OK%JLX5Y%+P#O012A/J.C6N0Y4K7DC>'MW?*&0=7Q$
M/OM<DB45'&'1'9-+/Y> 6?39=/@AA\\635:5S&-L9V:IK&BFTLBSCU_S9<?@
M"->@-KE5CZ^ [)H0BZU0% HT^S T4U-T,Q,<C^_4CWSGCUO_W@[^98]G!<M/
MOMW#X!N1G$7"=)T0.CA4]P,IIQ!ZA>*(EJH V3 RV_&*#CK'9#]RT)Z?8\ZM
M?8";00G?\9#>HT>/761/PD%"*\&>1<B>0/0?O-]--K0"&E 51+DM*T F$][-
MHC!";B.R'@HL1.$%R 97BPU: <I6LL6#O@[#&1S0,%X@*=EMQYGQ=N?$JW;,
M."NMFZ*DYM47[H0?#AX4D B:8LJ2IAP+K77!4"6I\* -S5# ;E)MA%;]XT7*
M[TAHE3AF61.!H8N*E+>_<">T$B'FDL6-.[8NP"'8H> /A;_//"@0K8YX0B07
M74$'3IY@("B ?(Q4([K-%**[?H?CU_)LO:4XY YSJT"8HC*CFKJLN6)D6[DN
M(70/]7H8* U5E"U31&KCL-3YX16JVVW3TD%"#SZWN0/4Y) U$VQ33WO8J@<V
M8C!$"0E+9#SOE4AN$(Y[NDHG$.)9<96$R!>>8**_FE [IQ'+*;A)PE!E<\?N
M'M*3,F%Y0L%'_Q,L[#;46 U=%<^7#AAZL+I'1*JYC3SY&%W9R+,?1LL[_@(H
MHJ7D[D"C$:4\B+>.P.Y@X&**V6-A:KN#CNL)CCUU(WO,':*&'2(=@.PY3'-R
MW2-J77N7,:VJ](M,T315T3CT/ ON%K73+3)E([.+M#@ZR]L[(YJ&)6K<.6+7
M.>HZSFPRBX^P2,Y>\B?3 (Z@%[K?D:/DH?=;&R.P:GPRY2A9EJ84;(.P1%%R
MALWE,CVO"3EO_#"\A='=\-%^J?0802!*5JYPX.[4J;I3^4C.[8MP/)++W%!B
MFOL=T,0]+9H\K24UE]1V'4F[HDV2&S1R#Q@BE2[;FX(^FZEF*PX>8&2['AST
M[,!SO>=P"0A7,0XJ5(!"B-;TE[,.\N,T?"BA:.5O2"M%&QX'R/ULZPJ)_9:.
M]6"$09OU5@LRIF8H67?U(,8L2Y\O&%-7144U10#,LI4[X_RX?9\1]Z.WMIX(
MMU>3VU$4N$^S>$- Y M?X,!U9J%PCWXVL86;:'!>LA0\I!%R+=[,<0VV*7'B
MM\O!N>^C*NA=02^>E#<D".H1U-1BIP#1T!51UT#59LI!G;GW<HP8LE':RIW-
M!B2.X\K<B$0AKJS 2#%$32L]S\LR)Y9IG9Q ^.,6]XQ$%P?^>(SK=%V\$1.&
M45BJC;MWIX &G*Q#&BU0$@8I*,YT4]$+&AE?7,\/D!"[3N!0Z9EJIJB;U:6Q
MC^VY4T>^^T2XA>(,^BXNR57Z!;BDQ#R#NG=O9A:X@P<,C@D85.!N5->^K&['
MI-(F>TP$&.:!5B 9>O;DRHS/<NTYXQG>KW7O!_ANW:5PU*./V^XN3,4:3(.5
MZ(.LBI9^X*$*M'! X]Y1E7$*+CA8B'T43,Q8FE4@\EB2O"BO[MT0%9 ;H:0>
MX[RVHVI+:JGK=WP,83V-?6B0D*5Z@,V:5I1$51:6E4)DU\9FQEUO4&O&YJ.,
M#Y_2132V5MM*M$.ZM<Q)<1 G94I#DM&[$IBRU+;C.A 5(S?.>0*\N&R<_)1\
M,.\N^6[@?E]M,[G6M7 ;/(08'P(!R/M]^U-6_,1-4#^:#QY'4+ =O"/#]EYQ
MXH:<H"P@BT; K2H1CI\#LGDPB'#CE6@$0XAP;"-K'5>Z(J0/H!?&KTARCQ3
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M(H'0$9[LT'4$VQL( W<\B^" YI!@A1KSY^:.8F%CQSP.O%B2IFF*D8F9].S
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MA,&Q/0WA1?KB_8(LYC1:NFP!U;.YR$CBRF7*PA\CQ*X=/':()/"/P)X6,"7
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MN!'GZ++H"W1%-NBA+PE,Y7^U$J[*OR0.8G%PL,G\M[[7V43Z>4!F$^'C,(W
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M\SH#>KF$QC&QSKF'F=@K50#T\#EWAT^[(\@MC(2Q'X:"[<4E W,#+/X8$5Y
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M^:8OB\#\<00%V\&M.6SO%:%!\/P(76T'Z&,$< 2(Y\ >"U,[B' !";("0H@
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M(("/&9KD( %>RI^4NX 7,Q8O& LLK!(N4G)>#AI8YQYG=%26:L'^P$502RH
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M>:QU'I.&HER()&S-8\V=6J@2KP_[--O3/"5/5#X6#!,W6#:#>2 NF=AAARR
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MAS>EABC"4(+_TW6MCC))S9H#:I,C$<G1S:]VFL"5#5LXIF%U3/M).I+]5-E
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MN/?>#&Y=<)9M<:X7<CXQ'2,(8%4<?FR[3R0(*8%Q#R1\)L3E'%2) 7S%A?"
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MIH,I%M'O&Q Q+RV0HLK:2"X4Q9RD@5%%A=TW,515%^3*6.T9F!@'$Q!]N.-
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M0L=@3;(C^O@&18?$ZT.%EZ2BI&;*;F+[( -6( I8HO@=OWK#C"6& P9F,)*
M\--&"37AJH#W7<@-R#L)'^&YXUE%*"8+S?QM*2QQR6,&NF.#7:P&.S.RE_%#
M(-;ZFDT4=$$9"@5O:V\"/0F05L4'5^UB-PZ\;A,JC*&K2KJR(1SSS4W-]S6A
MP],"[GH9 7+7<PMB-Q$2[TJ%1/WX=@$'DBKHS8O@-4AXUPTDB$(EA0^8OAUS
M#\3P@Z7M!KYD'9B"\2:(PPTQFBW#C$<A\/T\%KW<85G&T$RP.?"H$<C8,L!<
MHK*:$?G.D)<D(.AC0+Y9JEX/>7E3<^5!D:;7 7[ O?- C!0,/1J>)!B4J7&4
M*XJRI&P*#V^(3#9JSM6-27[QGEA(,K;$M=60Y!JW(I,YL#G] (%(?IA.9&4R
M)+9[1#:QXB3R%_13S5^H2%/)H##_S7P+.J@&6(TDEMI(XAB6.(JFV@]&UD:H
MWTLB?/1?%Q<@,\RIYW,7%U6I0EM[V:<%E[MUYP"&3U)'^6&![AIZ>!>^X7Y'
M^SA.85ADXC]/(&F"Z 'C;G%(''YP1A 0YCEGO/$!]T=DP*-"$K\))/23;;%7
M9:[[6T"?:%NVX=NG%@9)\M+PYUTV H(^+XNVP:<A@"&(-3]J+I\;W[[G%$VX
M4 4>$V="[K-GV1/;-/ :ED!SF9[!T# D.UJR,!HRHP<WX13LBM( 4RZB4M"+
M^!@_B6XF]Y0$ [E@ZD6.A<=8^2,* Y^1.2)*G@-WA@-N;.(1"7R5G'.8AN\O
MD)SRY^%E;WRFYU)XR/+HTB,/>E"Y[*C.8(!WN^392>,]Q1@//(/+/ 8>"S?0
M!0(M)^J\2&IG0'@E9U4(K]@ER-BHKU^M@@U\L]RQ5OY4JQ#AY &F#.\V?!2B
M* A#WWZ(:!9E#.R$-/'LJLXI6*9.KD"WVYV%L6.P >.N_#JH-%H^BPHU2JD
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M *9-,$$C<XE[Y&V,:&,<T';C]U)"L>(Z:;XR_\0.T@PP:E'6H!U5@?]I0Z5
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M14KB!0H;ZVF) E%5>5^5F;V14H%9LI.NT[D,S4@@ZW@NSQB$V?%@/=!H%,D
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M_'W" BUBMQZ[$W<6-#=#[(#YX9VNW8>IG'GV@[$9#O.;>F*<8GZ,UY)5Q%;
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MOKH0$@OW F8T^ IDF06:6 $#7@4U+(2>ZG(6D0TL2"*3O@"0PB8&+,"OB2V
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M XX'-]&H!;$3@P'GWQ<CG>CR1.02T$W>JXN"',YJOK-1(4)6">6=+_XK:A.
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M.LRL0U&4R_/.^#>Y ='VH4FV)G\KKSV4Y0@4"&?1+?7P6&5]"I>L<3%Q/)#
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MY#5 9AN'X]_R7/2"QNP?5@\^^G^-!G@9PTD8:8W&0DXK@T$155[@PCG?M#J
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M2L>%EX&^&4?.-%:JE!3@"$F,:-9E0HH,%$E)HY%VUM3.D98 !_"<OJ@?E6$
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M.T=Q"?'+&'AAC)RO^%#JZK9N61@[:G&@Y8-G_,\R%#87VUH)PH.O0+U)0,J
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M"=X.YI:IF<H5OJB?0_[JNLH*4O2J0SV2JK.2RV54O7)!ZLVJ"A"W0=J/F5R
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M@TY+<IZU7<[;%8-5#?!Y/CH'BG9E[6\)#^5+>GF9S V;)93\E 3>>@2?64?
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MKU7^//8MQ:M;#DJ]=,=W*>A)TS&Z;3WUXCB,[GFCLO.&6<I\5,9)97VY8ME
M&SFW(;5LV SWE3O&U>"^(Q#*+<666XY'U1IT8\A:QLCO]LC&K0JS<74(H*VX
M=<LAK%J)+@&]<!?O#\%P+<_=5(/GCD :VXH9.[7JK BRGL:^U(%,^^1-/=E5
M9C,,;%>8@:N#^H[BTVZM-/<">NPWXV,#VY0WLIC!*=4ETP/AQ4Z%>?$(Y'-7
M,6FO5J850=8?J8-L<O^@VRF[Y.I8THO9F$**1GY:X&K>C.7SY<7_:G^&/K6\
MX>PLF\0.6,!&7K(Y[[5;8>;?+MG(C+RIJB?,IOG?M1Y] N1XISK9WYKZ*0"%
M>C/0B>]5SS[9$O<JURDO=Y\]WU0LWX8,;\#S1H1N.$-RG_L^+=DR+'5%WHD&
M3L#BQM>?/KNGM\%?+.#TXU99&5(L1<[6ELGYI6J<!5@_P !9[\&7P@"[@;VE
MQ+8%8KN6VT\!W9/EMMG3OC=OFA=-18!FRS964FG?Z!P,E>Y9=%A*3%L@IFLY
MO1M@/UE.'P'!;P74IF$V/WZY^>]:]):"YV/@8\^5_WUW_8G&9U'/J,MPF%),
MJ"%F 8C/7?FY&S+>1-"9S9@3R0Y[U-O8X37[E^#1 LGZZ#'R'H[8.H#629PQ
M;R* 5]U<M]C5/+\AN=Y"5P!%?*^I.4"N><(JH&?(.N#6'ZT7U/JC\XC6'P""
M$CR;-F_B4+>)J-M$U&TBMFZR3-WASP8&V8Q.RVC^C%VN8V\N_JQMQ%T!/*\D
MOSD_PR"<W@,))BR(Z=;H<,*FCE+C53;?RJ'P#UBX^7/J<]*[./]4>]=/!^$*
M8KIP_*'L8?G)"WX,L'1\QZ1U")SW#Y>-,IJ[?/^A%G>[!/H**KW$"2'>7HET
MEV#QG4%&BY_.W]7R[^D@7$%9GYP!\U^VY)M%+*.VJ^OWM>3;)=!7T.<5G^.P
M7P6]I=!=NQ9II9"YH$%25\YX6<SME'?I37B/3B]'07PN7X!]ZGD/\*P4PSS;
M":4\"^Y[QF5^G2JP4!WV7C)HB$J(L$\%AIZ7QY=KNG\,W>^3T/='Z8=&VFD4
M>/&D)F]$0XEMMVJ=*HCU_SQHL;XFT+< %PQ\NFKFL1S'P\>US"+OEL:.16C_
MC#SL&X_)]/P8EU,REEPYL1@9R O.<L/'PJE'1E5^F"YO\FZ8IP,<A'/J>6>+
MDU^:VK?<-31\[^">CS%*G!]\>-"(\ZT6I[.9S_@(1O\>]CH3LV <-6Q.;2-6
MYZ4Q/SB%AL6)O'%:-K)E(7/ZNI@$/8K\Z8+;<,3YT^XC\J>'ARJ93;OY^,>7
M\V_?K]_?+,V@'>:(A(\T[2N,7"J04#7I9<.TBH/A\_.W<'XXEDBX?$("'PLL
MYLZ+D>PX8!U>-6 3QQ])!B<!PA\0<Q+3 ,=BICB'.$V 'G""_+-G*JR9(<]3
M_Q,U:*O4<EI02; !/,I?3JR3M1?867\R3KV?WU]^O/A^HUW]>7[]^5S[].WR
MX6S[TZV.-6'VN)?:6WAG9XV7UF#8$ABV0.J78"2]4?T6Q<3$C1BF2R"TA3.\
MNW^SD1TC4M>H4=G1J5['K[5KY]^.]B[\,7$BK[H"9PO ^>),V>:0OBM>BYHU
M1I>.J?(2?Q5*=XZQ['K"Q<3QP,&D6=WPB\=&BW<7?AM$KW\_?>!RPX9#\[6V
MK,%0&PVUT3!G-%PX4>C?!Z!E@@"$4F5%3FTVB#QQC<]*&0U8RT&!Z9RML'#M
M:]Y6R![ +YT/AV$:)#BP<Z7I<)RW9^PUHK^;#_;R%5X/0O<>_C-)IO[O_Q]0
M2P,$%     @ =*H,71M_8"3_'   16H! !$   !M9&-X+3(P,C8P-C,P+GAS
M9.U=6W?;.))^GU_!]<MV/SB^9#H]R4EZCFS+:<UQ+*^E]&5?^E D9&&:)-0$
MZ5CSZQ<%DB)(@" H*3:8Y4-W+**J@*H/UT(!>/_/IS!P'E%,,8D^')V].CUR
M4.01'T</'X[29'G\CZ-__O2W]]1;H=!U&'%$WX6^]_3A:)4DZW<G)U^^?'D5
M(A][*5VOW#AT7WDD/#D_/7]S^N8UD\99*M1?7K\B\0,C.3T[^>W3S8R+S@G?
M!3CZLT+]M(B#@O[U"20O7(H*<DCUDRV#2/S#29:X)0TT<G^[88)%H5A#C".:
MN)%7%D(J=*[BV=NW;T]X:D$:H0<W07ZC\+<G,0G024Y6<,5HV<CQYH2E%H0^
M6L?(:\G!C3V>R=+UDF/TM [<R$U(O+EFO[>"DO@XV:P15<MAR2>0##B?'Y^^
M/GY]5A8!5^&@R'OU0!Y/6 *O%@6A1](HB3=JXCRQRI#&,:N;31QY:H4%/7DK
M-3FD5$@C%WM43<N3*L04>VI2EE E3-9Q R5+J9"FM&;QI4L7W-I%2E5RG,B4
M[&.=J$GH-JEJL"@-SU7-Z?R4F2Q!$<6+ !T#&8K=A'4:]/C\U:F@PX/KKI4J
M0$*>5^+&#RBY=4-$UZZ'C/L2%* 01<DUB<,KM'33@)G@K]0-\!*SQO+3WQSG
M_7\='SN3V_GXX^0W9[%QQO\Y_NWB_L8Y/N:I.%R3.'$B9<Y-C3SK^VZ(Q_75
ML,"OXX+O&#X=GYVSIO'JB?I')UT+4'9UW0I0\'4L@+KK-,RZ8( \?]A%W7J_
M9Y)O$,<5+LC\+2A\]F:O(ABJ+62?[)VUOD\V+8XH95P*Z5BZAEY;50C:1 Y_
M',,?G3.L]OQ&F8HLQ8\=,Z\.(F:YBSS;7[OE+XQ*1GEOZ?E?N^4ICFY&F98,
MV9^[95N.E$:9%N3PQXX9E@.N68X%/?_+.,^F45N;IW*</$%!0K=BNA>@G R8
MY5W09_G"_&"7+'=06LYX1XVKLXP]+ Y?NM4RLUE24Y%J X)>3.<11CE;-RJ*
M@I/_ID(9W"@B"1<"/^'#>HVC)<E^L=\P(7D'X]*<<3KPQ^?[2<N<CP]CV(__
MN")>"G.^XM]1Y(^C!">;"<N"44.^1PYFZQUCZJ)@1=%\M,01Y@J<LC6I<^P4
M[.*?;N0[F2Q'$/;^I"ZB)CRER)]&/_&_V=J,,E&<$=:;.7-.HF$LQ7=B\]S
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M+YOJ_FJ8EUT2'A,_FM# \1DB:IO::8K"P23U!A'HPR=(PLHD)<:&4/'ZF*0
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M.+(55DC*I@AL5C<]5\VMXM5W+6CE5)^;KEG:?OKES[Z*"^8JWLEX=:WHI?P
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MYJ?M$]GCK&!K)>3"6S"KX^;A2ONL:1PJYTA\99WV.3;&(L9A5-U4@''ZLF+
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M,ZS:X/RH+924"1W>RP=--JA&25%Q ZZ]4*ZK)MULX&'P^6]02P,$%     @
M=*H,7=!:OQ8U+P  42D# !4   !M9&-X+3(P,C8P-C,P7V1E9BYX;6SM?5E[
MV[BRX/O]%9G,<^+(2]+=7_>YG[QE?*]C>VQW^IQYP4>3D,P;BE03I&.=7S\
M*6X25A($05D/W9$E+%6%I594_?Z?KXO@W0N,D1^%?[R??/ST_AT,W<CSP_D?
M[]-D]N&7]__YC__X/?##'T\.@N]P\Q#]\?XY29:_'1S\_/GSX^M3''R,XOG!
MX:=/1P=%P_=YR]]>D=]H_?.H:#LY^.>WZP?W&2Z<#WZ($B=TJUYD&%J_R:^_
M_GJ0_8J;(O\WE/6_CEPGR1 0PO6.V8+\]:%H]H%\]6%R^.%H\O$5>25<N(V7
ME-/4!S@YR']\_X__>/?N]__UX<.[JYO'BZ]7_WSWM'IW\>\/_SR]OW[WX4/V
M:QP%\![.WF6(_):LEO"/]\A?+ -"@.R[YQC._GB_\-Q7#,GAYT^?CSX1./ZW
M[\7@/'+3!0R3XM]IZ%V$B9^LKL)9%"\R2KQ_1^;X\_ZJ09(%]'PW1<MG!S?[
MZ$:+ ]+J0'K0 PW0/R1. LD,Z'9V]NR$<XBNP@<,$7R. @]OQ',X\UT_4<9
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MGZ"]&2J&W#>CJ U@X))I^ACMS?V_ 2<7F=(9:>?5L 6ETK9G>"5W'-6Z>W+
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MF8-(/!'YAZ1E>W&"3.E)SK#&L\+G.8LAX&X,I9' L6DN6NR6M51R1@)&N9(
MO0,X5N2.4G?O/?3@8ID[WA=^PA049;N"8T46QX%RK=2>.@'9J 4SY0H=TGW!
M<1^<['L4X']/\4Q>19UJTHQ.<L25&0D<Z^%QFPSU!89.F%0)RT@R7_0<!7QY
MK^U0X-CT0V76-LX@;"'3,D< QZ89ZGK;UWW:YQ"YL9^!=SO[[D=!]FC@-K[
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MXD3D'TR*$Y%?T8$ R^DXRS<H_^(G(A^""^_;;XD<!C[ QKR#.X%AI\2#^YO
MJ\UJ:'35'=)^+V>4-2!CS!&P0<:8YML@0R/MYV[R="<\(9^%?Q7%I;JVH6U)
M#G!H-)@,#HU\DL&A4;YS=0CK.KQR97Y<>[Z\$(\@3UG'0G9G)H!&(V!&H-%H
ME0EH0T."<$*CT9_.4F"&K(X&"O\VCM8R2:)X^S%*1V)NM09D:/1G(F1H]&<B
M9(CT)W"39+[\U8WQ"L4\OI.KI[18I<<E^U;8/?D ()$BF0-(I%'F !*IECF
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M,0&0*-")BDKS$*EUPV-VKX>9 ?A4>F,)/I4*68)/HTV[LO)Y!AX+[W6?N_(
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M]//QN6_L>94:P!!JSO%@")5DS[S&&-*0'@ 1:@8-($)UV"M PQ]H2 ^ "#6
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M]%[ .(I#2P'R'-[&9,ES>"B3)<_AU=#=9>@W")0X_!MF2AR>##,E#I^%XE)
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MO<GR*B6 (-3O\2 (];5\>Z2L9WPSK!-+4P: 1*B&5) (M8L*$HTR/0B8:HM
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M^5*]&]Q[4>1U8D#,/J_(012/:L_C.WR%^_)%Q)Y,\J-YNS\FQ5^3KFW14?:
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M79.7<0:!.;<',AWF=GV4.M!R"^-NAW84W]=F@*5=7X6))7M4706O]T7:6BK
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M4>1_ED$P"V%,2-UP)7>/KP_AV&$&:=KR)9AIVO(R*GPQ-+)!A# #0K?E4Q!
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MO7F1$+OG:)H0NR]8@+H7\;/T1'5FH'ZJ .>P7A[*9(ECV"K$@#:W(I91?M1
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MMA2MF&GVA_QOSH#0;>D; 71;:D< G5_[,+8VWE+!R,%NN/T8A5X4)E$@?=S
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M?<KL\09;4.97#(]LR U&D"*WIV&!(K=W8H$BMT?3@JZ*RW4$Q08C2)';S[%
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M,OWLQF+H7'*D3:P 6Y[:9"K @@>6QM*#R;\*"C]XW: W-Y!BC^/'0LJ"]U/
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M0(C/@H; ^#R*,2P!MLK.2=@N?WE=TBDM.#43EE>@AM!L;GD5S0D,!@!&KN]
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M'38RY&M)VDL*E6F-OUKQ?\!K[$N425U07R(1S_@"9D921E_8)L0ZKJOH"<6
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M7=$GOK3%1<D4EBGFZXR^,%"0BNH%GL%AIRXI*'N:@<DC%@VN[TQ+XY8B,(?
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MS:,-D.5\8VXGBG<ALD\(#\XN,(ZE2P,S)HCAPF: 8;ZL:&',RV*95E51;DZ
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MAH#XWVED/F/VS>(5)#0#6X2Q 7X3Y'PZ49LF^4-4KTNX&D@DM/.98?60<M<
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MZ9O=!)Y^'=&DN1^1Q0CI[1@N(HM9TM<Q8*FSF"A]'=%V$#-AJ[3<B R^NTE
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MD&XR3V@)E]66M)U'_ 2VI!^%2V[[ZPB?P-:68W#)D@[TB)_X%C3.DECTF)]
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MKEPG.5YC?"525>HYN!?+S>^)>J+7HY)5:[(:6TBA1FJ<HP\@*1NID5=<N_G
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M%18TK2ECO;3FCR+!5[Y,K\/[A_SK3Y&NPJP\*=G\,:O^FAU)>'@+,DKA##V
M-P2C%%+.ZW$>P)47QBFDG\%=@R^;NPU?<.D%BR2WN%YN\RP/8L5%)"K,.VVR
MO'%A;F>3Y38+N[@PV[+)<IM;75R8+=ED*=^#ZFPKD@Q)1)CG8"G*.94\/H9Y
MG>^S.6NLBJ5*,)C*&,38HL',Q2!&^5S 9NDH-DZ=[Z>(Y_CI3DQ_P?GP/37-
M"3-F)'Z:B"-;'2N59D@SGT6JZLV=!%DHIRG.C6^0(AX_B 7S$2S%8URJ!,]?
M<!;Z86,>H]!8CLG%H#$/GW]+KH*T.D.$4['K!7CXOH/ R!Z& CS&0)JS3&]R
M58*C,*O.8"_Q&/F#39S'^!C0&=F#39S'V!6V9(MM_I"DZD#^GU]P2G23&(^Q
MTJ Q+OU(C-/8E)DQ)!*71;XCPFE,&A0NRWM'A.58N*SP'1'*=PI]DSKO$W""
M;Z,<I]CJXG$A 4,Y3E'6Q>-""89R?./-A1(,Y2C?7>WLJF@:SJ,]:,MCGE1V
MXQS:@[:T\Z%?D+DIL_T%I]@VB=&.@@&-:4V'8FS'QK2V0S':)Q4R:_>.$"?T
M=A'G&7DM=*;EWRK.,Q(7>9Z&=]N\J&&0J$,229Q+W5$K_Y1$;B(*>ZEF.N9N
M7C'1C;U4\XR5YK39E;ICGL2.7C*1F$F[XAE+([UFHDV3=D4::]K<0R<O3<KF
M+SACNUV8-!ZTQBG3ZH-<.'.[79@66?4YH3IJ=O+R/0[_WK9SU59#9R!LCCHX
MX6P5X_R"L[J;Q#BA*7>-Y:]SE>+M"\[[;A=FCLS VVS"M$]'G7'E2S(%RT#*
MC)+\1FN'R4"IC)+DXY2'1;[NN[Q7#NP+SA)O%B0?)8S(P$U,@CS&Z%N2B^PJ
M>%&VU=]R<<IVLR"/,=(B,K$+@R#C,;+0"21(^LZD,>PJ%64RU<&SZ_M3D82S
M>KA)G!9NX:>.1X1ZH+>P$#]UE-%<EO8J-VAR;_;UYY/<LHD3$8M-*#=X.#^Z
M19)R1&V8,",Q2]*/4W'J0.6M3%9!I(.&B8F3 OI1LR+$/,5) >$8*JZQF_4-
M>[^(LSS=J@.+B\=D&^>27^*,Y\XZ"$?2'2?.<^ZL@_-X]G8-.,NYIR;.8]O'
M#.F0IR8VX]PN=O0%YS#'0FQ&KXL$,AHLQ&9,EFEX'\9!I'Z[>[A ZF(79C-&
M>F20P-B%68[9V5:<R55[N2G^$;S\EL2YRC/P+Q'(+15._#U2(\O1M?@ TIZ1
M&EG&0?VUY[HQ6R)WY$(6/2S'7(<7)]GVTD,]OE6Y[B\XB7:[&?7H--::Z0I]
M#?*NM6;V434C?+/4M=;,,*IFA*<"N]::V4/5C##K7M=:,R.HFA%FU"V6(,UU
M39S*&D@0/RE:&]#BZS%.5*UIS<;VUDO*W8)2)*:0[!)GIG97,@ND1^]PBFH/
M+5R@G@<K4;)\A<RX[&J%V(Q9%XAQ1=8+\01B7*RU0L0K]\ZF-K_L)W=3T(PK
MNZ,:-N%G VLD!JYJ.((MKS3N"KPJL$9>X:B&Y<CJP!JYB*L:-F"+%Z=RD8I7
MX5,0*7R.7*4OR6?\AI <N<I D@NDRR95UM$[G.\7R; 9F=^"?)N&^8MZWZ20
M.+*/CAA;,(X,I"O&!4SK8*>$XLA!>)P&[=IT+=;BL?CN4!#OSI,;YV%UU3$/
MF([4PZ"#"\PRY9>$Y$@PR%.$=<WY'@=E!4.Q5N\H*HJ/DY[:I;E#<^0.6FGF
MT!PYA$Z:S0Y-#PVG*+5+D[Z(W03;*+],XGO)M!^+-X&[S\[+S>]A$A5W39;I
MUV=IOOKD44@HR ;J,58KZ=S<PQ4&XC):*ZDKBM.418'9YE/,.YSM5"M .Y:%
M/?!XX3N<X=0FRQN6@;=89%G#,G 7LRSILF&%96 Q9EG:):-K6J>.^SN<]=0H
MR&E6]0 92(M)D!Z0NER>9:)YBU84_=PDZ8\@74M@.)FIDP(&(V8#:"(H#@KX
M ,RJJN^729:U;53QB?.7NFMA-)9&J%8"XJ"%$=1?DV3](XRB12R?(7D0WZO/
MGN6?%%HK17%2Q&EL+8"MY,5-$2? J0Q !<U*8'HBK$:M!F&E*WT1CB"L_*0G
MPH!!-A9=Q%=ILA*9JA,FI#)UQO1,/(LH>7HL]V@XK:JW,DXA: >.,Z_Z*YL7
M<&>68U7&*=1;7/J;*'"Z\YR>+*= 'L)RYS1]6=:PW,E+3Y93$"Z?BE0[\?V
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M6'7; ,-"##0R+&%85OVA##EY&9BDXUZ[:\@@7=H13N\_83<<0G>/)$%'N$C
M!.IG[QP[DYEE@B:+]5_C0-VL;O*B'>$2!7Z:^,;#$+*=,;EI8@?9GO?I")<_
M&*N3W\B[N,%.RN:34@N8#)9":Z[$(USU8-J>^$7.>)?9&>4T/;TAE]G9ZR0]
M<>"\+MG(CG#9!Q\]_"85@NM+3[DE<?,PLTHE=H0+2G@KF\<XU\!Q&0I_9:3
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M*?^_?=@.)PSU5D8ZYK[ /^!4H_[*"(%K8[#^ /<!)R4U"E*.I 40IAE&04I
MN=@=B?N $Y=V&I*.0-=@3#DZ#?D8C(E&NR$E$=VJH%QNF@W4C;@O'B_*>LPQ
MH!1EL)B@8#Z!I>BA7(NG)"V6^#863!"P&(-QT8/!:[Y!C Y,$R95YD&% 6<2
M';8F' >MZ7!1UK1F9CI<?H>M"1^P V-V6[(/.,<HEN(40&TH<&DV2#& TGZE
M\0&G'=6UYS 27?/A>JUMS\Y\N$;KVG.8TEWSX;*L:T_X(J^;K*/)H/L!9Q[5
M2W"(_QX$G)$42'"!T*IC^0$G)658YM, P[X^\RGA:8!A7Z-[,AR>3%V3FHP)
M'W"R4(LHOQ!K@;(OVT"4,RC[8JX7Y1=^ZG78#I=]E8?2_(*P"\W. + T<VB.
MW$ GS28@Z^28$@].KPE$V(1>&X0C4=B)< 3A2!,:$3;A=!W>/^3+S?=,%&5,
M%19'KM"79!-<&DB.A&$@R1B2(UWH2[((/+EW+.Z(;)+T1Y"NL\LP%A>Y>"RF
MD@-EP/(L@K!OWFWU(04GH+3)4L)*[X,X_(^T+HE/F])>\A^+>'V5BDP^SHI_
M+C?5&?H@NI&_*3_OMMZMX=R5T_0P5Q?MLB"U/Z;CU)F3=_:V'(?S=4[?&:'C
MBKKCJU6Z%6M=4L$/.+NG190R&JR@,,NRB!*#4L414_$@XBQ\%KOWI^=)*L+[
MN+1R]7*;!G$F'V5E2!;_BLH 7?][6];".Q%R71"WP4_E#<S3#M0G=6P<QHV8
M&QZJSS?I1LQ'#]0G)9,]G!LQ^SU0GY3?< R0*G=@QFR19?JLJF!A+FR3)895
M6M.<'L0I6X>MJ4>D9SI.R*II36QZ)UW^!YQE=="8VN<]P\W\C4E1 )WA9JK5
M;DR]*O4,-Y.;=F/J=>!;$B?=(P:[+^(X=ZI%E#K^C:#,2[U!E#,H\X*-1:GG
MC1&4>;G&HFSG5.N]'$[!ZJB"[1QK@<2)6%U5S &DF1?851#.P:L@7%_$_R^,
MU[MK7Q]PKE5-<\(PU!L/.8.N.:7QY2?)Y4;E'[_(LFT@Y50]=$4@<+)4DQSI
M6!CA0")AE&,+!U((DQSI-#?"@>3!)$>XR%K@0-I@DB.\:;XSJTF'U6"!+ $*
ML7@(#(#@;*58B .0HGA7/\)POE*C((N1T0,RK/@F0;Z #"S (,CB$:T'Y$ (
M-((L'M)Z0 Z40"-(^9B.@OA;\-BD+?Z ,Y?VFE)._%1L1)J*L@KA:1(_BS0/
M[R)1_IB%27RMOE$H.)@&N"J9"5!,$)R5< ':KG)Q)=*5.DUQKUZ>X#RD3@K8
MC"0$B'.-NBG@ O#F(9![4?64$VL%"W,++,9FM/I@,*\PB/$"L]SF61[$:\E+
M%2),+"RRS,:H!PO3"YLL*:RG(%Q7K]-VYY5P<D^]!.W(Z"%@:J&78 C!1"<T
M$I3<NS3H(LZVJ:*:RGH31^@VI@^?CN&F=;_7F-+P\%FMQU%0)J1JC@?@))=
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M  3R$BS$$PCD(U"(,K16#V*]578-ZPD6Q5C;[_%P-E0/-93AYP46\Q</-2S
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M?F-!H!;3C&,&3DPS3H07T\XU:TX3DJV8,@8'QWR;B&:\F#2FEB,VF.E7YD3
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M>GID#78?]9?0;</ZBR.^]:]42%;-^EN=K57M/%GA<2.+PN.5MY[TF2W*V&Q
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M#M_ [)N?+NHBLRT%;TOK5?&[3MBT[V@X)R[8N%<OF^W'D%M>X"$@[S0T^_-
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MX \QHFN^9<!PYCS!)LP>8*KAY@8,==Z7B<_UOP/&3>_+Z-2_ P",RA[3@FH
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M[<VQ$S_%8!#MITUN\AZ$!2BZQ,G8 BJ=-RD,JX,Y;O@2AB&WG\[U+L]O&'0
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M_T#D?_0S].__'U!+ 0(4 Q0    ( '2J#%W174EV20<  + :   /
M      "  0    !E>&AI8FET,S$M,2YH=&U02P$"% ,4    " !TJ@Q=!XK0
M_ED'  "G&@  #P              @ %V!P  97AH:6)I=#,Q+3(N:'1M4$L!
M A0#%     @ =*H,7111SRW3 P  ' H   \              ( !_ X  &5X
M:&EB:70S,BTQ+FAT;5!+ 0(4 Q0    ( '2J#%VWX1;GWP,  "\*   /
M          "  ?P2  !E>&AI8FET,S(M,BYH=&U02P$"% ,4    " !TJ@Q=
MSF)>FU0T 0 ,H!$ "P              @ $(%P  9F]R;3$P<2YH=&U02P$"
M% ,4    " !TJ@Q=&W]@)/\<  !%:@$ $0              @ &%2P$ ;61C
M>"TR,#(V,#8S,"YX<V102P$"% ,4    " !TJ@Q=4H&]4N4+   /I0  %0
M            @ &S: $ ;61C>"TR,#(V,#8S,%]C86PN>&UL4$L! A0#%
M  @ =*H,7=!:OQ8U+P  42D# !4              ( !RW0! &UD8W@M,C R
M-C V,S!?9&5F+GAM;%!+ 0(4 Q0    ( '2J#%VIDA5W#3 ! !"T$0 5
M          "  3.D 0!M9&-X+3(P,C8P-C,P7VQA8BYX;6Q02P$"% ,4
M" !TJ@Q=]H]]^HQ+  !63@4 %0              @ %SU ( ;61C>"TR,#(V
B,#8S,%]P<F4N>&UL4$L%!@     *  H > (  #(@ P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>form10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mdcx="http://www.medicuspharma.com/20260630"
  xmlns:srt="http://fasb.org/srt/2026"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mdcx-20260630.xsd" xlink:type="simple"/>
    <context id="C_20260101to20260630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20251231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20260630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20251231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20250630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20250630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20260101to20260131_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mdcx:RbxCapitalLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="C_20231018to20231018_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mdcx:RbxCapitalLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-18</startDate>
            <endDate>2023-10-18</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mdcx:RbxCapitalLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mdcx:RbxCapitalLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20250401to20250630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mdcx:RbxCapitalLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mdcx:RbxCapitalLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20250630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mdcx:RbxCapitalLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_20260401to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mdcx:RbxCapitalLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260401to20260630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ClinicalManufacturingAndRegulatoryActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:SkinjectIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250401to20250630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ClinicalManufacturingAndRegulatoryActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:SkinjectIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ClinicalManufacturingAndRegulatoryActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:SkinjectIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ClinicalManufacturingAndRegulatoryActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:SkinjectIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ProfessionalServicesAndIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:SkinjectIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ProfessionalServicesAndIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:SkinjectIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250401to20250630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ProfessionalServicesAndIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:SkinjectIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20260401to20260630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ProfessionalServicesAndIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:SkinjectIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ClinicalManufacturingAndRegulatoryActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:TeverelixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ClinicalManufacturingAndRegulatoryActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:TeverelixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250401to20250630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ClinicalManufacturingAndRegulatoryActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:TeverelixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20260401to20260630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ClinicalManufacturingAndRegulatoryActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:TeverelixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ProfessionalServicesAndIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:TeverelixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ProfessionalServicesAndIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:TeverelixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250401to20250630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ProfessionalServicesAndIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:TeverelixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20260401to20260630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mdcx:ProfessionalServicesAndIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mdcx:TeverelixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250401to20250630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20260401to20260630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260630_usgaapDebtInstrumentAxis_mdcxNoteBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_mdcxBusinessCombinationConsiderationTransferredEquityInterestTypeAxis_usgaapCommonStockMember_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdcx:AntevLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdcx:ContingentConsiderationPhasesOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mdcx:BusinessCombinationConsiderationTransferredEquityInterestTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdcx:AntevLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdcx:ContingentConsiderationPhasesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_mdcxBusinessCombinationConsiderationTransferredEquityInterestTypeAxis_usgaapCommonStockMember_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdcx:AntevLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdcx:ContingentConsiderationPhasesTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mdcx:BusinessCombinationConsiderationTransferredEquityInterestTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdcx:AntevLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdcx:ContingentConsiderationPhasesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_srtRangeAxis_srtMaximumMember_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdcx:AntevLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdcx:ContingentConsiderationPhasesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdcx:AntevLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdcx:ContingentConsiderationPhasesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_srtRangeAxis_srtMaximumMember_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdcx:AntevLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdcx:ContingentConsiderationPhasesFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdcx:AntevLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mdcx:ContingentConsiderationPhasesFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mdcx:AntevLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20260101to20260331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_20241231_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SharesIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20250101to20250331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20250331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SharesIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_20251231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SharesIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_20260101to20260331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SharesIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_20260331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_20260331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_20260331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_20260331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_20260331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_20260331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SharesIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20241231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20250331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_20250331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_20250331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_20250331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_20250331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SharesIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260401to20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SharesIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_20250630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SharesIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20250401to20250630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SharesIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20260630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SharesIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
        </entity>
        <period>
            <instant>2026-08-10</instant>
        </period>
    </context>
    <context id="C_20250901to20250917_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mdcx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-17</endDate>
        </period>
    </context>
    <context id="C_20250917_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mdcx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-17</instant>
        </period>
    </context>
    <context id="C_20260101to20260331_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:DebentureContinuityOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="C_20260630_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:DebentureContinuityOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mdcx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20251231_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:DebentureContinuityOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20260501to20260527_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mdcx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-01</startDate>
            <endDate>2026-05-27</endDate>
        </period>
    </context>
    <context id="C_20260501to20260527_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-01</startDate>
            <endDate>2026-05-27</endDate>
        </period>
    </context>
    <context id="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-27</instant>
        </period>
    </context>
    <context id="C_20260501to20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-01</startDate>
            <endDate>2026-05-27</endDate>
        </period>
    </context>
    <context id="C_20260501to20260527_usgaapDebtInstrumentAxis_mdcxNoteBMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-01</startDate>
            <endDate>2026-05-27</endDate>
        </period>
    </context>
    <context id="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteBMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-27</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapDebtInstrumentAxis_mdcxNoteBMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260630_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapDebtInstrumentAxis_mdcxNoteBMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260331_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:DebentureContinuityOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="C_20260401to20260630_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:DebentureContinuityOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-27</instant>
        </period>
    </context>
    <context id="C_20260527_srtRangeAxis_srtMaximumMember_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mdcx:SecuredPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-27</instant>
        </period>
    </context>
    <context id="C_20260501to20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mdcx:NoteAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-01</startDate>
            <endDate>2026-05-27</endDate>
        </period>
    </context>
    <context id="C_20250101to20251231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20260630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20240101to20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20260330to20260330_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mdcx:IndividualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-30</startDate>
            <endDate>2026-03-30</endDate>
        </period>
    </context>
    <context id="C_20260601to20260603_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mdcx:IndividualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-01</startDate>
            <endDate>2026-06-03</endDate>
        </period>
    </context>
    <context id="C_20250310to20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mdcx:RegulationAOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-10</startDate>
            <endDate>2025-03-10</endDate>
        </period>
    </context>
    <context id="C_20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mdcx:RegulationAOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-10</instant>
        </period>
    </context>
    <context id="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_mdcxMeasurementInputValuationDateSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mdcx:RegulationAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">mdcx:MeasurementInputValuationDateSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-10</instant>
        </period>
    </context>
    <context id="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mdcx:RegulationAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-10</instant>
        </period>
    </context>
    <context id="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mdcx:RegulationAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-10</instant>
        </period>
    </context>
    <context id="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mdcx:RegulationAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-10</instant>
        </period>
    </context>
    <context id="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mdcx:RegulationAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-10</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mdcx:RegulationAOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20250210to20250210_usgaapSubsidiarySaleOfStockAxis_mdcxStandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mdcx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-10</startDate>
            <endDate>2025-02-10</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantsIssuedAsPartOfIpoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:WarrantsIssuedAsPartOfIpoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxRegulationAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:RegulationAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantWithExpiryDateJune302030WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:WarrantWithExpiryDateJune302030WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantsIssuedAsPartOfIpoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:WarrantsIssuedAsPartOfIpoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapStatementEquityComponentsAxis_mdcxRegulationAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:RegulationAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantWithExpiryDateJune302030WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:WarrantWithExpiryDateJune302030WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxSeriesCAndDWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SeriesCAndDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260630_usgaapStatementEquityComponentsAxis_mdcxSeriesCAndDWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mdcx:SeriesCAndDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_mdcxStandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mdcx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260630_usgaapFinancialInstrumentAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapFinancialInstrumentAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">mdcx:RegulationAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-10</instant>
        </period>
    </context>
    <context id="C_20250101to20251231_usgaapFinancialInstrumentAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_20251231_usgaapFinancialInstrumentAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20251229_usgaapSubsidiarySaleOfStockAxis_mdcxAtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mdcx:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-29</instant>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_mdcxAtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mdcx:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mdcx:RegulationAOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260630_usgaapSubsidiarySaleOfStockAxis_mdcxStandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mdcx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mdcxStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mdcx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20260101to20260630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mdcxDebenturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mdcx:DebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mdcxStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mdcx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20250101to20250630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mdcxDebenturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mdcx:DebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_20260701to20260731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001997296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-07-31</endDate>
        </period>
    </context>
    <unit id="Percent">
        <measure>pure</measure>
    </unit>
    <unit id="Percentage">
        <measure>mdcx:Percentage</measure>
    </unit>
    <unit id="Segment">
        <measure>mdcx:Segment</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USD_PER_SHARE">
        <measure>mdcx:USD_PER_SHARE</measure>
    </unit>
    <unit id="USD_Per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Year">
        <measure>mdcx:Year</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="C_20260101to20260630" id="F20250325062249593_0">0001997296</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="C_20260101to20260630" id="F20250325062249593_1">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_20260101to20260630" id="F20250325062249593_2">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_20260101to20260630"
      id="Fdei_CurrentFiscalYearEndDate20260509003700566">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220623095332635">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220623112859151">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260322150144982">2026-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260322150212142">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220623095400766">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260810151922184">001-42408</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260509004231725">MEDICUS PHARMA LTD.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220623095428081">A6</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220623095437970">98-1778211</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220623095455172">300 Conshohocken State Rd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260509004320494">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220623095509997">W. Conshohocken</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220623095521671">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220623095535888">19428</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220623095546673">610</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220623095555746">636-0184</dei:LocalPhoneNumber>
    <dei:Security12gTitle
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20220623095613676">Common shares, no par value</dei:Security12gTitle>
    <dei:TradingSymbol
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20230318022908173">MDCX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20250325151346309">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12gTitle
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapWarrantMember"
      id="Fxbrl_20260511105600664">Warrants</dei:Security12gTitle>
    <dei:TradingSymbol
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapWarrantMember"
      id="Fxbrl_20260511103901103">MDCXW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_usgaapWarrantMember"
      id="Fxbrl_20260511103912746">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220623113244591">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220623095718179">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220623095732300">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220623095745301">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220623095754631">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220623113153809">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="C_20260101to20260630"
      id="Fxbrl_20220623095809952">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_20260810"
      decimals="INF"
      id="Fxbrl_20260810192557303"
      unitRef="Share">63180610</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250324185207196"
      unitRef="USD">15174128</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250324185220671"
      unitRef="USD">8705218</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250324185211363"
      unitRef="USD">1807461</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250324185228349"
      unitRef="USD">1086121</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:DeferredCostsCurrent
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20260321102225490_xbrl_20250324185211363"
      unitRef="USD">0</us-gaap:DeferredCostsCurrent>
    <us-gaap:DeferredCostsCurrent
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20260321102225490_xbrl_20250324185228349"
      unitRef="USD">99305</us-gaap:DeferredCostsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250324185213621"
      unitRef="USD">16981589</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250324185230475"
      unitRef="USD">9890644</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20260812112738426_xbrl_20260321102225490_xbrl_20250324185211363"
      unitRef="USD">10017412</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20260812112738426_xbrl_20260321102225490_xbrl_20250324185228349"
      unitRef="USD">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250324185215866"
      unitRef="USD">117184</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250324185232983"
      unitRef="USD">170733</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250324185217711"
      unitRef="USD">27116185</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250324185235659"
      unitRef="USD">10061377</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250324185546605"
      unitRef="USD">6734310</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250324185621737"
      unitRef="USD">3435297</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250324185548578"
      unitRef="USD">308007</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250324185623692"
      unitRef="USD">995290</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <mdcx:RelatedPartyPayableCurrent
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250325140138511"
      unitRef="USD">161846</mdcx:RelatedPartyPayableCurrent>
    <mdcx:RelatedPartyPayableCurrent
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250325140141152"
      unitRef="USD">116476</mdcx:RelatedPartyPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250324185833660"
      unitRef="USD">137330</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250324185632506"
      unitRef="USD">145456</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:SecuredDebtCurrent
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20260812113042661_xbrl_20250324185833660"
      unitRef="USD">3500000</us-gaap:SecuredDebtCurrent>
    <us-gaap:SecuredDebtCurrent
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20260812113042661_xbrl_20250324185632506"
      unitRef="USD">5245543</us-gaap:SecuredDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250324185556041"
      unitRef="USD">10841493</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250324185635725"
      unitRef="USD">9938062</us-gaap:LiabilitiesCurrent>
    <us-gaap:SecuredLongTermDebt
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20260810095620851_xbrl_20250325140138511"
      unitRef="USD">17982542</us-gaap:SecuredLongTermDebt>
    <us-gaap:SecuredLongTermDebt
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20260810095620851_xbrl_20250325140141152"
      unitRef="USD">0</us-gaap:SecuredLongTermDebt>
    <us-gaap:LongTermLoansPayable
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20260321102232034_xbrl_20250324185211363"
      unitRef="USD">17114</us-gaap:LongTermLoansPayable>
    <us-gaap:LongTermLoansPayable
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20260321102232034_xbrl_20250324185228349"
      unitRef="USD">25865</us-gaap:LongTermLoansPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250324185558941"
      unitRef="USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250324185638603"
      unitRef="USD">60139</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250324185601168"
      unitRef="USD">28841149</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250324185643822"
      unitRef="USD">10024066</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20260630"
      id="Fxbrl_20260810094937290"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20251231"
      id="Fxbrl_20260810094942483"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250325175853688"
      unitRef="USD_Per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250324194312776"
      unitRef="USD_Per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250324195143853"
      unitRef="Share">60168044</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250324195131376"
      unitRef="Share">60168044</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250324195110360"
      unitRef="Share">60168044</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250325153820533"
      unitRef="Share">25176303</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250325153757310"
      unitRef="Share">25176303</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250325153750820"
      unitRef="Share">25176303</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockValue
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250324185603778"
      unitRef="USD">74298513</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250324185645813"
      unitRef="USD">57076175</us-gaap:CommonStockValue>
    <mdcx:CommonSharesToBeIssued
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20260321102237428_xbrl_20250324185211363"
      unitRef="USD">0</mdcx:CommonSharesToBeIssued>
    <mdcx:CommonSharesToBeIssued
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20260321102237428_xbrl_20250324185228349"
      unitRef="USD">313934</mdcx:CommonSharesToBeIssued>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250324185606115"
      unitRef="USD">8884707</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250324185648279"
      unitRef="USD">6879575</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20260321102239953_xbrl_20250324185211363"
      unitRef="USD">61095</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20260321102239953_xbrl_20250324185228349"
      unitRef="USD">10880</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250324185608476"
      unitRef="USD">-85007966</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250324185657379"
      unitRef="USD">-64348118</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20260321102243202_xbrl_20250324185211363"
      unitRef="USD">-1763651</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20260321102243202_xbrl_20250324185228349"
      unitRef="USD">-67554</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20260321102246836_xbrl_20250324185211363"
      unitRef="USD">38687</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20260321102246836_xbrl_20250324185228349"
      unitRef="USD">104865</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250324185610766"
      unitRef="USD">-1724964</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250324185659593"
      unitRef="USD">37311</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250324185613231"
      unitRef="USD">27116185</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250324185702202"
      unitRef="USD">10061377</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260321104758134_xbrl_20250808233309120"
      unitRef="USD">6571097</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260321104758134_xbrl_20250808233317465"
      unitRef="USD">4576524</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810101807932"
      unitRef="USD">12463781</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810101810031"
      unitRef="USD">7696584</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260321104758137_xbrl_20250808233332815"
      unitRef="USD">4907692</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260321104758137_xbrl_20250808233340505"
      unitRef="USD">1439564</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810101814690"
      unitRef="USD">7612085</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810101816498"
      unitRef="USD">3445778</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260321104758139_xbrl_20250808233347755"
      unitRef="USD">11478789</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260321104758139_xbrl_20250808233357158"
      unitRef="USD">6016088</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810101820769"
      unitRef="USD">20075866</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810101822204"
      unitRef="USD">11142362</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260321104758140_xbrl_20250808233405500"
      unitRef="USD">-11478789</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260321104758140_xbrl_20250808233409898"
      unitRef="USD">-6016088</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810101831139"
      unitRef="USD">-20075866</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810101833313"
      unitRef="USD">-11142362</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260509005722018_xbrl_20260321104758148_xbrl_20250808233430989"
      unitRef="USD">0</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260509005722018_xbrl_20260321104758148_xbrl_20250808233437947"
      unitRef="USD">40004</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810101839161"
      unitRef="USD">0</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810101841731"
      unitRef="USD">63870</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpense
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260509005723514_xbrl_20260321104758148_xbrl_20250808233430989"
      unitRef="USD">205638</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260509005723514_xbrl_20260321104758148_xbrl_20250808233437947"
      unitRef="USD">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810101846864"
      unitRef="USD">523789</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810101849602"
      unitRef="USD">0</us-gaap:InterestExpense>
    <mdcx:GainLossOnSettlements
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260509005725117_xbrl_20260321104758148_xbrl_20250808233430989"
      unitRef="USD">0</mdcx:GainLossOnSettlements>
    <mdcx:GainLossOnSettlements
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260509005725117_xbrl_20260321104758148_xbrl_20250808233437947"
      unitRef="USD">0</mdcx:GainLossOnSettlements>
    <mdcx:GainLossOnSettlements
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810101854475"
      unitRef="USD">-127083</mdcx:GainLossOnSettlements>
    <mdcx:GainLossOnSettlements
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810101857403"
      unitRef="USD">0</mdcx:GainLossOnSettlements>
    <mdcx:ChangeInFairValueOfDebentures
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260810102250180_xbrl_20260509005725117_xbrl_20260321104758148_xbrl_20250808233430989"
      unitRef="USD">0</mdcx:ChangeInFairValueOfDebentures>
    <mdcx:ChangeInFairValueOfDebentures
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260810102250180_xbrl_20260509005725117_xbrl_20260321104758148_xbrl_20250808233437947"
      unitRef="USD">-200000</mdcx:ChangeInFairValueOfDebentures>
    <mdcx:ChangeInFairValueOfDebentures
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810102250180_xbrl_20260810101854475"
      unitRef="USD">0</mdcx:ChangeInFairValueOfDebentures>
    <mdcx:ChangeInFairValueOfDebentures
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810102250180_xbrl_20260810101857403"
      unitRef="USD">-200000</mdcx:ChangeInFairValueOfDebentures>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260321104758148_xbrl_20250808233430989"
      unitRef="USD">-205638</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260321104758148_xbrl_20250808233437947"
      unitRef="USD">-159996</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810101906321"
      unitRef="USD">-650872</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810101909713"
      unitRef="USD">-136130</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260321104819527_xbrl_20251114150504281"
      unitRef="USD">-11684427</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260321104819527_xbrl_20251105161449089_xbrl_20250808233357158"
      unitRef="USD">-6176084</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810101914674"
      unitRef="USD">-20726738</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810101917011"
      unitRef="USD">-11278492</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260321104758151_xbrl_20251105161451073_xbrl_20250808233347755"
      unitRef="USD">255177</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260810101935010"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810101937186"
      unitRef="USD">50928</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810101941218"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260810101949188"
      unitRef="USD">-11429250</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260810101951874"
      unitRef="USD">-6176084</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321104837020_xbrl_20251105161452905_xbrl_20250808233347755"
      unitRef="USD">-20675810</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260321104837020_xbrl_20251105161452905_xbrl_20250808233357158"
      unitRef="USD">-11278492</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260321104758153_xbrl_20251105162318707_xbrl_20251105161452905_xbrl_20250808233347755"
      unitRef="USD">-11617705</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260321104758153_xbrl_20251105162318707_xbrl_20251105161452905_xbrl_20250808233357158"
      unitRef="USD">-6176084</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810101956771"
      unitRef="USD">-20659848</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810101959210"
      unitRef="USD">-11278492</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260321104758154_xbrl_20251105162320777_xbrl_20251105161452905_xbrl_20250808233347755"
      unitRef="USD">-66722</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260321104758154_xbrl_20251105162320777_xbrl_20251105161452905_xbrl_20250808233357158"
      unitRef="USD">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810102004458"
      unitRef="USD">-66890</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810102006776"
      unitRef="USD">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260321104758156_xbrl_20251105162323034_xbrl_20251105161452905_xbrl_20250808233347755"
      unitRef="USD">-11438822</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260321104758156_xbrl_20251105162323034_xbrl_20251105161452905_xbrl_20250808233357158"
      unitRef="USD">-6176084</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810102012212"
      unitRef="USD">-20676523</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810102014931"
      unitRef="USD">-11278492</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260321104758157_xbrl_20251105162325523_xbrl_20251105161452905_xbrl_20250808233347755"
      unitRef="USD">3572</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260321104758157_xbrl_20251105162325523_xbrl_20251105161452905_xbrl_20250808233357158"
      unitRef="USD">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810102020219"
      unitRef="USD">713</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810102028394"
      unitRef="USD">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20260401to20260630"
      decimals="2"
      id="Fxbrl_20260321190555378"
      unitRef="USD_Per_Share">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20260401to20260630"
      decimals="2"
      id="Fxbrl_20260321104758160_xbrl_20250808233500804"
      unitRef="USD_Per_Share">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20250401to20250630"
      decimals="2"
      id="Fxbrl_20260321215446573"
      unitRef="USD_Per_Share">-0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20250401to20250630"
      decimals="2"
      id="Fxbrl_20260321215440862"
      unitRef="USD_Per_Share">-0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20260101to20260630"
      decimals="2"
      id="Fxbrl_s_20260810102038529"
      unitRef="USD_Per_Share">-0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20260101to20260630"
      decimals="2"
      id="Fxbrl_20260810102038529"
      unitRef="USD_Per_Share">-0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20250101to20250630"
      decimals="2"
      id="Fxbrl_s_20260810102042460"
      unitRef="USD_Per_Share">-0.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20250101to20250630"
      decimals="2"
      id="Fxbrl_20260810102042460"
      unitRef="USD_Per_Share">-0.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260321190632072"
      unitRef="Share">55055225</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260321104758162_xbrl_20250808233514249"
      unitRef="Share">55055225</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260321190643627"
      unitRef="Share">14284261</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260321104758162_xbrl_20250808233518944"
      unitRef="Share">14284261</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_s_20260810102048145"
      unitRef="Share">47566945</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810102048146"
      unitRef="Share">47566945</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_s_20260810102050362"
      unitRef="Share">13853305</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810102050362"
      unitRef="Share">13853305</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20251231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20260321120838609_xbrl_20250325144928519"
      unitRef="Share">25176303</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20251231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260321120838609_xbrl_20250325144956857"
      unitRef="USD">57076175</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20251231_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="INF"
      id="Fxbrl_20260321120838609_xbrl_20251106045621903"
      unitRef="Share">205980</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20251231_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260321124601612"
      unitRef="USD">313934</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20251231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260321120838609_xbrl_20250325145111663"
      unitRef="USD">6879575</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20251231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260321120838609_xbrl_20250325145117272"
      unitRef="USD">-64348118</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20251231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260321124608991"
      unitRef="USD">10880</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20251231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260321124625180"
      unitRef="USD">104865</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20260321120838609_xbrl_20250325145121928"
      unitRef="USD">37311</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <mdcx:StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20260321121109065_xbrl_20250503161758184_xbrl_20250503134537353_xbrl_20250325144928519"
      unitRef="Share">5336780</mdcx:StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260321121109065_xbrl_20250503161758184_xbrl_20250503134537353_xbrl_20250325144956857"
      unitRef="USD">4229823</mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260321121109065_xbrl_20251106045713574"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260321121109065_xbrl_20250503161758184_xbrl_20250503134537353_xbrl_20250325145111663"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260321121109065_xbrl_20250503161758184_xbrl_20250503134537353_xbrl_20250325145117272"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260321121109065_xbrl_20251106045954378"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260321121109065_xbrl_20251106045957744"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts
      contextRef="C_20260101to20260331"
      decimals="0"
      id="Fxbrl_20260321121109065_xbrl_20250503161758184_xbrl_20250503134537353_xbrl_20250325145121928"
      unitRef="USD">4229823</mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts>
    <mdcx:StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20260321124124958_xbrl_20250325144928519"
      unitRef="Share">9482380</mdcx:StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260321124124958_xbrl_20250325144956857"
      unitRef="USD">5808013</mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260321124124958_xbrl_20260321124030010"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260321124124958_xbrl_20250325145111663"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260321124124958_xbrl_20250325145117272"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260321124124958_xbrl_20260321124004517"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260321124124958_xbrl_20260321124008252"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost
      contextRef="C_20260101to20260331"
      decimals="0"
      id="Fxbrl_20260321124124958_xbrl_20250325145121928"
      unitRef="USD">5808013</mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260321125311378"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260321125314259"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20250325151831513_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145111663"
      unitRef="USD">599306</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260321125316410"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260321125318666"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260321125321097"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20260101to20260331"
      decimals="0"
      id="Fxbrl_20250325151831513_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145121928"
      unitRef="USD">599306</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260321125420345"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260321125425147"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260321125428162"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260321121442929_xbrl_20251106050849745_xbrl_20251106050116126"
      unitRef="USD">-9042143</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260321125431787"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260321121442929_xbrl_20251106050849745_xbrl_20251106050100818"
      unitRef="USD">-168</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20260101to20260331"
      decimals="0"
      id="Fxbrl_20260321121442929_xbrl_20251106050849745_xbrl_20250325151300282_xbrl_20250325151118378_xbrl_20250325145121928"
      unitRef="USD">-9042311</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260321121508234_xbrl_20251106054755749"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20251106045811216"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145111663"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145117272"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20251106050023393"
      unitRef="USD">-201390</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="C_20260101to20260331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20251106050032310"
      unitRef="USD">-2859</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="C_20260101to20260331"
      decimals="0"
      id="Fxbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145121928"
      unitRef="USD">-204249</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192029694"
      unitRef="Share">39995463</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20260331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192035816"
      unitRef="USD">67114012</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20260331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050516320"
      unitRef="Share">205980</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20260331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050456969"
      unitRef="USD">313934</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20260331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192041478"
      unitRef="USD">7478881</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20260331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192047365"
      unitRef="USD">-73390261</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20260331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050501329"
      unitRef="USD">-190510</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20260331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050504953"
      unitRef="USD">101838</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20260331"
      decimals="0"
      id="Fxbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192053814"
      unitRef="USD">1427894</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <mdcx:StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20260810113640894_xbrl_20260321124124958_xbrl_20250325144928519"
      unitRef="Share">18766601</mdcx:StockIssuedDuringPeriodSharesConnectionWithAtTheMarketOfferingNetOfIssuanceCosts>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260810113640894_xbrl_20260321124124958_xbrl_20250325144956857"
      unitRef="USD">6492497</mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260810113640894_xbrl_20260321124124958_xbrl_20260321124030010"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260810113640894_xbrl_20260321124124958_xbrl_20250325145111663"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260810113640894_xbrl_20260321124124958_xbrl_20250325145117272"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260810113640894_xbrl_20260321124124958_xbrl_20260321124004517"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260810113640894_xbrl_20260321124124958_xbrl_20260321124008252"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260810113640894_xbrl_20260321124124958_xbrl_20250325145121928"
      unitRef="USD">6492497</mdcx:StockIssuedDuringPeriodValueConnectionWithAtTheMarketOfferingNetOfIssuanceCost>
    <mdcx:StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260810120415332_xbrl_20260810113640894_xbrl_20260321124124958_xbrl_20250325144928519"
      unitRef="Share">1200000</mdcx:StockIssuedDuringPeriodSharesNoncashCompensationServicesRendered>
    <mdcx:StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260810120415332_xbrl_20260810113640894_xbrl_20260321124124958_xbrl_20250325144956857"
      unitRef="USD">378070</mdcx:StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered>
    <mdcx:StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260810120415332_xbrl_20260810113640894_xbrl_20260321124124958_xbrl_20260321124030010"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered>
    <mdcx:StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260810120415332_xbrl_20260810113640894_xbrl_20260321124124958_xbrl_20250325145111663"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered>
    <mdcx:StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260810120415332_xbrl_20260810113640894_xbrl_20260321124124958_xbrl_20250325145117272"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered>
    <mdcx:StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260810120415332_xbrl_20260810113640894_xbrl_20260321124124958_xbrl_20260321124004517"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered>
    <mdcx:StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260810120415332_xbrl_20260810113640894_xbrl_20260321124124958_xbrl_20260321124008252"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered>
    <mdcx:StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260810120415332_xbrl_20260810113640894_xbrl_20260321124124958_xbrl_20250325145121928"
      unitRef="USD">378070</mdcx:StockIssuedDuringPeriodValueNoncashCompensationForServicesRendered>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260810114458150_xbrl_20260321120838609_xbrl_20250325144928519"
      unitRef="Share">205980</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260810114458150_xbrl_20260321120838609_xbrl_20250325144956857"
      unitRef="USD">313934</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260810114458150_xbrl_20260321120838609_xbrl_20251106045621903"
      unitRef="Share">-205980</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260810114458150_xbrl_20260321124601612"
      unitRef="USD">-313934</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260810114458150_xbrl_20260321120838609_xbrl_20250325145111663"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260810114458150_xbrl_20260321120838609_xbrl_20250325145117272"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260810114458150_xbrl_20260321124608991"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260810114458150_xbrl_20260321124625180"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260810114458150_xbrl_20260321120838609_xbrl_20250325145121928"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260810113723460_xbrl_20260321125311378"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260810113723460_xbrl_20260321125314259"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260810113723460_xbrl_20250325151831513_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145111663"
      unitRef="USD">1405826</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260810113723460_xbrl_20260321125316410"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260810113723460_xbrl_20260321125318666"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260810113723460_xbrl_20260321125321097"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260810113723460_xbrl_20250325151831513_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145121928"
      unitRef="USD">1405826</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260810114127151_xbrl_20260321125420345"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260810114127151_xbrl_20260321125425147"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260810114127151_xbrl_20260321125428162"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260810114127151_xbrl_20260321121442929_xbrl_20251106050849745_xbrl_20251106050116126"
      unitRef="USD">-11617705</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260810114127151_xbrl_20260321125431787"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260810114127151_xbrl_20260321121442929_xbrl_20251106050849745_xbrl_20251106050100818"
      unitRef="USD">-66722</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260810114127151_xbrl_20260321121442929_xbrl_20251106050849745_xbrl_20250325151300282_xbrl_20250325151118378_xbrl_20250325145121928"
      unitRef="USD">-11684427</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260810114039868_xbrl_20260321121508234_xbrl_20251106054755749"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260810114039868_xbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20251106045811216"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260810114039868_xbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145111663"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260810114039868_xbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145117272"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260810114039868_xbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20251106050023393"
      unitRef="USD">251605</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="C_20260401to20260630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260810114039868_xbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20251106050032310"
      unitRef="USD">3572</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260810114039868_xbrl_20260321121508234_xbrl_20251106054640966_xbrl_20251106050725954_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145121928"
      unitRef="USD">255177</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20260810114640487_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192029694"
      unitRef="Share">60168044</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20260630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260810114640487_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192035816"
      unitRef="USD">74298513</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260810114640487_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050516320"
      unitRef="Share">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20260630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260810114640487_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050456969"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20260630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260810114640487_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192041478"
      unitRef="USD">8884707</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20260630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260810114640487_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192047365"
      unitRef="USD">-85007966</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20260630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260810114640487_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050501329"
      unitRef="USD">61095</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20260630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260810114640487_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050504953"
      unitRef="USD">38687</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20260810114640487_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192053814"
      unitRef="USD">-1724964</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20250325144928519"
      unitRef="Share">11816721</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20250325144956857"
      unitRef="USD">30518195</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="INF"
      id="Fxbrl_20251106045621903"
      unitRef="Share">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260321124030010"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20250325145111663"
      unitRef="USD">1520412</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20250325145117272"
      unitRef="USD">-28903903</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260321124004517"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20241231_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260321124008252"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20241231"
      decimals="0"
      id="Fxbrl_20250325145121928"
      unitRef="USD">3134704</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <mdcx:IssuanceCostsInConnectionWithRegulationA
      contextRef="C_20250101to20250331"
      decimals="0"
      id="Fxbrl_20260321130439346"
      unitRef="USD">483020</mdcx:IssuanceCostsInConnectionWithRegulationA>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20260321153117197"
      unitRef="Share">1490000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260321153042823"
      unitRef="USD">2076507</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260321121049666_xbrl_20251106045701376"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260321121049666_xbrl_20250503134537353_xbrl_20250325145111663"
      unitRef="USD">1612474</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260321121049666_xbrl_20250503134537353_xbrl_20250325145117272"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260321121049666_xbrl_20251106045934567"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260321121049666_xbrl_20251106045941896"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20250101to20250331"
      decimals="0"
      id="Fxbrl_20260321121049666_xbrl_20250503134537353_xbrl_20250325145121928"
      unitRef="USD">3688981</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mdcx:StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20260509011751740_xbrl_20260321121109065_xbrl_20250503161758184_xbrl_20250503134537353_xbrl_20250325144928519"
      unitRef="Share">105840</mdcx:StockIssuedDuringPeriodSharesConnectionWithSepaOfferingCosts>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260509011751740_xbrl_20260321121109065_xbrl_20250503161758184_xbrl_20250503134537353_xbrl_20250325144956857"
      unitRef="USD">300000</mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260509011751740_xbrl_20260321121109065_xbrl_20251106045713574"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260509011751740_xbrl_20260321121109065_xbrl_20250503161758184_xbrl_20250503134537353_xbrl_20250325145111663"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260509011751740_xbrl_20260321121109065_xbrl_20250503161758184_xbrl_20250503134537353_xbrl_20250325145117272"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260509011751740_xbrl_20260321121109065_xbrl_20251106045954378"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260509011751740_xbrl_20260321121109065_xbrl_20251106045957744"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts
      contextRef="C_20250101to20250331"
      decimals="0"
      id="Fxbrl_20260509011751740_xbrl_20260321121109065_xbrl_20250503161758184_xbrl_20250503134537353_xbrl_20250325145121928"
      unitRef="USD">300000</mdcx:StockIssuedDuringPeriodValueConnectionWithSepaOfferingCosts>
    <mdcx:StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325144928519"
      unitRef="Share">5000</mdcx:StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants>
    <mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325144956857"
      unitRef="USD">14000</mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants>
    <mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260321121249955_xbrl_20251106050608804_xbrl_20251106045740351"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants>
    <mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325145111663"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants>
    <mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325145117272"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants>
    <mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260321121249955_xbrl_20251106050608804_xbrl_20251106050011572"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants>
    <mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260321121249955_xbrl_20251106050608804_xbrl_20251106050014802"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants>
    <mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants
      contextRef="C_20250101to20250331"
      decimals="0"
      id="Fxbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325145121928"
      unitRef="USD">-14000</mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260321120741328_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325144956857"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260321120741328_xbrl_20251106045811216"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260321120741328_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145111663"
      unitRef="USD">112277</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260321120741328_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145117272"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260321120741328_xbrl_20251106050023393"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260321120741328_xbrl_20251106050032310"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20250101to20250331"
      decimals="0"
      id="Fxbrl_20260321120741328_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145121928"
      unitRef="USD">112277</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260321120759983_xbrl_20250325151300282_xbrl_20250325151118378_xbrl_20250325144956857"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260321120759983_xbrl_20251106045822777"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260321120759983_xbrl_20250325151300282_xbrl_20250325151118378_xbrl_20250325145111663"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260321120759983_xbrl_20250325151300282_xbrl_20250325151118378_xbrl_20250325145117272"
      unitRef="USD">-5102408</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260321120759983_xbrl_20251106050116126"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20250101to20250331_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260321120759983_xbrl_20251106050100818"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20250101to20250331"
      decimals="0"
      id="Fxbrl_20260321120759983_xbrl_20250325151300282_xbrl_20250325151118378_xbrl_20250325145121928"
      unitRef="USD">-5102408</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192035816"
      unitRef="Share">13417561</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20250331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050516320"
      unitRef="USD">32908702</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20250331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050456969"
      unitRef="Share">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20250331_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192041478"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20250331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192047365"
      unitRef="USD">3245163</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20250331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050501329"
      unitRef="USD">-34006311</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20250331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050504953"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20250331"
      decimals="0"
      id="Fxbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192053814"
      unitRef="USD">2147554</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <mdcx:IssuanceCostsInConnectionWithEquityFinancing
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260810120551437"
      unitRef="USD">809606</mdcx:IssuanceCostsInConnectionWithEquityFinancing>
    <mdcx:StockIssuedDuringPeriodSharesConnectionWithEquityFinancing
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260810114904191_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325144928519"
      unitRef="Share">2260000</mdcx:StockIssuedDuringPeriodSharesConnectionWithEquityFinancing>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithEquityFinancing
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260810114904191_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325144956857"
      unitRef="USD">3961899</mdcx:StockIssuedDuringPeriodValueConnectionWithEquityFinancing>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithEquityFinancing
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260810114904191_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20251106045740351"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithEquityFinancing>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithEquityFinancing
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260810114904191_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325145111663"
      unitRef="USD">2234495</mdcx:StockIssuedDuringPeriodValueConnectionWithEquityFinancing>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithEquityFinancing
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260810114904191_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325145117272"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithEquityFinancing>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithEquityFinancing
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260810114904191_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20251106050011572"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithEquityFinancing>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithEquityFinancing
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260810114904191_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20251106050014802"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueConnectionWithEquityFinancing>
    <mdcx:StockIssuedDuringPeriodValueConnectionWithEquityFinancing
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260810114904191_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325145121928"
      unitRef="USD">6196394</mdcx:StockIssuedDuringPeriodValueConnectionWithEquityFinancing>
    <mdcx:StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20260810113942846_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325144928519"
      unitRef="Share">258705</mdcx:StockIssuedDuringPeriodSharesUponExerciseOfStockWarrants>
    <mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260810113942846_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325144956857"
      unitRef="USD">963398</mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants>
    <mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260810113942846_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20251106045740351"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants>
    <mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260810113942846_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325145111663"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants>
    <mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260810113942846_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325145117272"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants>
    <mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260810113942846_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20251106050011572"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants>
    <mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260810113942846_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20251106050014802"
      unitRef="USD">0</mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants>
    <mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260810113942846_xbrl_20260321121249955_xbrl_20251106050608804_xbrl_20250503161759897_xbrl_20250503134537353_xbrl_20250325145121928"
      unitRef="USD">963398</mdcx:StockIssuedDuringPeriodValueUponExerciseOfStockWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260810113917847_xbrl_20260321120741328_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325144956857"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260810113917847_xbrl_20260321120741328_xbrl_20251106045811216"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260810113917847_xbrl_20260321120741328_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145111663"
      unitRef="USD">117448</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260810113917847_xbrl_20260321120741328_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145117272"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260810113917847_xbrl_20260321120741328_xbrl_20251106050023393"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260810113917847_xbrl_20260321120741328_xbrl_20251106050032310"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260810113917847_xbrl_20260321120741328_xbrl_20250325151258473_xbrl_20250325151118378_xbrl_20250325145121928"
      unitRef="USD">117448</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260810113848230_xbrl_20260321120759983_xbrl_20250325151300282_xbrl_20250325151118378_xbrl_20250325144956857"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260810113848230_xbrl_20260321120759983_xbrl_20251106045822777"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260810113848230_xbrl_20260321120759983_xbrl_20250325151300282_xbrl_20250325151118378_xbrl_20250325145111663"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260810113848230_xbrl_20260321120759983_xbrl_20250325151300282_xbrl_20250325151118378_xbrl_20250325145117272"
      unitRef="USD">-6176084</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260810113848230_xbrl_20260321120759983_xbrl_20251106050116126"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20250401to20250630_usgaapStatementEquityComponentsAxis_usgaapNoncontrollingInterestMember"
      decimals="0"
      id="Fxbrl_20260810113848230_xbrl_20260321120759983_xbrl_20251106050100818"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260810113848230_xbrl_20260321120759983_xbrl_20250325151300282_xbrl_20250325151118378_xbrl_20250325145121928"
      unitRef="USD">-6176084</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260810113755227_xbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192035816"
      unitRef="Share">15936266</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20250630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20260810113755227_xbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050516320"
      unitRef="USD">37833999</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20250630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260810113755227_xbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050456969"
      unitRef="Share">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20250630_usgaapStatementEquityComponentsAxis_mdcxSharesIssuedMember"
      decimals="0"
      id="Fxbrl_20260810113755227_xbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192041478"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20250630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20260810113755227_xbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192047365"
      unitRef="USD">5597106</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20250630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20260810113755227_xbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050501329"
      unitRef="USD">-40182395</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20250630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fxbrl_20260810113755227_xbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251106050504953"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_20250630"
      decimals="0"
      id="Fxbrl_20260810113755227_xbrl_20260509011805398_xbrl_20260321121514349_xbrl_20251106051038336_xbrl_20251105192053814"
      unitRef="USD">3248710</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321111840933_xbrl_20250325115322380"
      unitRef="USD">-20726738</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260321111840933_xbrl_20250325115328019"
      unitRef="USD">-11278492</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321111737911_xbrl_20250325130311306"
      unitRef="USD">2005132</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260321111737911_xbrl_20250325130455375"
      unitRef="USD">229725</us-gaap:ShareBasedCompensation>
    <us-gaap:PaidInKindInterest
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321111737920_xbrl_20250809010611002_xbrl_20250325130317063"
      unitRef="USD">480594</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260321111737920_xbrl_20250809010611002_xbrl_20250325130501370"
      unitRef="USD">0</us-gaap:PaidInKindInterest>
    <mdcx:IncreaseDecreaseInOperatingLeaseRightofuseAssets
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321111737912_xbrl_20250325130317063"
      unitRef="USD">53549</mdcx:IncreaseDecreaseInOperatingLeaseRightofuseAssets>
    <mdcx:IncreaseDecreaseInOperatingLeaseRightofuseAssets
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260321111737912_xbrl_20250325130501370"
      unitRef="USD">47572</mdcx:IncreaseDecreaseInOperatingLeaseRightofuseAssets>
    <mdcx:GainLossOnSettlements
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321111737922_xbrl_20251105165758290_xbrl_20250325130311306"
      unitRef="USD">-127083</mdcx:GainLossOnSettlements>
    <mdcx:GainLossOnSettlements
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260321111737922_xbrl_20251105165758290_xbrl_20250325130455375"
      unitRef="USD">0</mdcx:GainLossOnSettlements>
    <mdcx:ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810105602017_xbrl_20260321111737922_xbrl_20251105165758290_xbrl_20250325130311306"
      unitRef="USD">0</mdcx:ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes>
    <mdcx:ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810105602017_xbrl_20260321111737922_xbrl_20251105165758290_xbrl_20250325130455375"
      unitRef="USD">200000</mdcx:ChangeInFairValueOfDebenturesAndSecuredPromissoryNotes>
    <mdcx:CostsToIssueDebenturesAndSecuredPromissoryNotes
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810105604189_xbrl_20260321111737922_xbrl_20251105165758290_xbrl_20250325130311306"
      unitRef="USD">0</mdcx:CostsToIssueDebenturesAndSecuredPromissoryNotes>
    <mdcx:CostsToIssueDebenturesAndSecuredPromissoryNotes
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810105604189_xbrl_20260321111737922_xbrl_20251105165758290_xbrl_20250325130455375"
      unitRef="USD">111725</mdcx:CostsToIssueDebenturesAndSecuredPromissoryNotes>
    <mdcx:IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810105606137_xbrl_20260321111737922_xbrl_20251105165758290_xbrl_20250325130311306"
      unitRef="USD">378070</mdcx:IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered>
    <mdcx:IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810105606137_xbrl_20260321111737922_xbrl_20251105165758290_xbrl_20250325130455375"
      unitRef="USD">0</mdcx:IssuanceOfCommonSharesConnectionWithNonCashCompensationForServicesRendered>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321111737926_xbrl_20250325115752505"
      unitRef="USD">707316</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260321111737926_xbrl_20250325115849101"
      unitRef="USD">113201</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321111737929_xbrl_20250325115755346"
      unitRef="USD">3147801</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260321111737929_xbrl_20250325115851240"
      unitRef="USD">404670</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321111737931_xbrl_20250325115757810"
      unitRef="USD">-680071</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260321111737931_xbrl_20250325115859128"
      unitRef="USD">1065475</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321111737933_xbrl_20250325115800060"
      unitRef="USD">-76605</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260321111737933_xbrl_20250325115901950"
      unitRef="USD">-56113</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321111737935_xbrl_20250325115803074"
      unitRef="USD">45370</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260321111737935_xbrl_20250325115857197"
      unitRef="USD">-21186</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321111737937_xbrl_20250325115805768"
      unitRef="USD">-15953129</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260321111737937_xbrl_20250325115904539"
      unitRef="USD">-9409825</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321113859805_xbrl_20260321112041265_xbrl_20251105165804188_xbrl_20250325130311306"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260321113859805_xbrl_20260321112041265_xbrl_20251105165804188_xbrl_20250325130455375"
      unitRef="USD">9790015</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810111159411_xbrl_20260321113859805_xbrl_20260321112041265_xbrl_20251105165804188_xbrl_20250325130311306"
      unitRef="USD">22000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810111159411_xbrl_20260321113859805_xbrl_20260321112041265_xbrl_20251105165804188_xbrl_20250325130455375"
      unitRef="USD">4500000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810111201315_xbrl_20260321113859805_xbrl_20260321112041265_xbrl_20251105165804188_xbrl_20250325130311306"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810111201315_xbrl_20260321113859805_xbrl_20260321112041265_xbrl_20251105165804188_xbrl_20250325130455375"
      unitRef="USD">977398</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260810111203246_xbrl_20260321113859805_xbrl_20260321112041265_xbrl_20251105165804188_xbrl_20250325130311306"
      unitRef="USD">615000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260810111203246_xbrl_20260321113859805_xbrl_20260321112041265_xbrl_20251105165804188_xbrl_20250325130455375"
      unitRef="USD">54582</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260509015909416_xbrl_20260321112129228_xbrl_20251105183204922_xbrl_20251105165804188_xbrl_20250325130311306"
      unitRef="USD">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260509015909416_xbrl_20260321112129228_xbrl_20251105183204922_xbrl_20251105165804188_xbrl_20250325130455375"
      unitRef="USD">297783</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321112059420_xbrl_20251105165808130_xbrl_20250325130311306"
      unitRef="USD">5532613</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260321112059420_xbrl_20251105165808130_xbrl_20250325130455375"
      unitRef="USD">0</us-gaap:RepaymentsOfDebt>
    <mdcx:ProceedsFromIssuanceOfSharesUnderSettlements
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321112129228_xbrl_20251105183204922_xbrl_20251105165804188_xbrl_20250325130311306"
      unitRef="USD">4102740</mdcx:ProceedsFromIssuanceOfSharesUnderSettlements>
    <mdcx:ProceedsFromIssuanceOfSharesUnderSettlements
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260321112129228_xbrl_20251105183204922_xbrl_20251105165804188_xbrl_20250325130455375"
      unitRef="USD">0</mdcx:ProceedsFromIssuanceOfSharesUnderSettlements>
    <mdcx:ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260509015831576_xbrl_20260321112129228_xbrl_20251105183204922_xbrl_20251105165804188_xbrl_20250325130311306"
      unitRef="USD">12399815</mdcx:ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts>
    <mdcx:ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260509015831576_xbrl_20260321112129228_xbrl_20251105183204922_xbrl_20251105165804188_xbrl_20250325130455375"
      unitRef="USD">0</mdcx:ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingNetOfIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321111737953_xbrl_20250325115820829"
      unitRef="USD">32354942</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260321111737953_xbrl_20250325115921653"
      unitRef="USD">14915048</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321111737961_xbrl_20251105165823133_xbrl_20250325130311306"
      unitRef="USD">84509</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260321111737961_xbrl_20251105165823133_xbrl_20250325130455375"
      unitRef="USD">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321112144595_xbrl_20251105165823133_xbrl_20250325130311306"
      unitRef="USD">16486322</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260321112144595_xbrl_20251105165823133_xbrl_20250325130455375"
      unitRef="USD">5505223</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20260321112149025_xbrl_20250325115828192"
      unitRef="USD">8705218</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20241231"
      decimals="0"
      id="Fxbrl_20260321112149025_xbrl_20250325115927259"
      unitRef="USD">4164323</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20260321112202767_xbrl_20250325115830759"
      unitRef="USD">25191540</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20250630"
      decimals="0"
      id="Fxbrl_20260321112202767_xbrl_20250325115931676"
      unitRef="USD">9669546</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321113925782_xbrl_20260321112224885_xbrl_20251107154602864"
      unitRef="USD">330626</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260321113925782_xbrl_20260321112224885_xbrl_20251107154609823"
      unitRef="USD">0</us-gaap:InterestPaidNet>
    <mdcx:DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321112336068_xbrl_20251105190829309_xbrl_20250326124516894"
      unitRef="USD">0</mdcx:DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement>
    <mdcx:DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260321112336068_xbrl_20251105190829309_xbrl_20250326124531877"
      unitRef="USD">300000</mdcx:DeferredIssuanceCostsOnIssuedSharesRelatedToSepaAgreement>
    <mdcx:IssuanceCostsIncludedInAccountsPayable
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321112303177_xbrl_20250326124516894"
      unitRef="USD">0</mdcx:IssuanceCostsIncludedInAccountsPayable>
    <mdcx:IssuanceCostsIncludedInAccountsPayable
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260321112303177_xbrl_20250326124531877"
      unitRef="USD">271618</mdcx:IssuanceCostsIncludedInAccountsPayable>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20250323190950558">
    &lt;p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1. Description of business&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Medicus Pharma Ltd. (the "Company"), formerly Interactive Capital Partners Corporation, is a clinical stage, multi-strategy, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company is a public limited company originally incorporated pursuant to the provisions of the &lt;i&gt;Business Corporations Act&lt;/i&gt; (Ontario) on April 30, 2008, as a private company named Interactive Capital Partners Corporation, with nominal assets and liabilities. The Company's registered office is located at 100 King Street West, Suite 3400, One First Canadian Place, Toronto, Ontario, Canada, and its head office is located at 300 Conshohocken State Rd., Suite 200, W. Conshohocken, PA.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
  </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20250323220925857">
    &lt;p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2. Summary of significant accounting policies &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

      &lt;div&gt;
        &lt;p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Basis of presentation and consolidation&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The accompanying unaudited condensed consolidated financial statements included herein have been prepared in conformity with generally accepted accounting principles in the United States ("GAAP") and under the rules and regulations of the United States Securities and Exchange Commission ("SEC") for interim reporting. The accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, that are necessary to present fairly the Company's financial position, results of operations, and cash flows. The condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosures of the Company normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC's rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto for the year ended December 31, 2025, included in the Company's Annual Report on Form 10-K, as amended, originally filed with the SEC on March 25, 2026 (the "2025 Annual Report"). These condensed consolidated financial statements include the financial statements of the Company and its subsidiaries, SkinJect, Inc., Medicus Pharma Inc., Antev Limited ("Antev") and MDCX Holdings, LLC. All intercompany balances and transactions have been eliminated on consolidation. Non-controlling interest in the consolidated financial statements represents the portion of Antev not 100% owned by the Company. The functional currency of the Company and its three wholly-owned subsidiaries, SkinJect, Inc., Medicus Pharma Inc. and MDCX Holdings, LLC. is the United States dollar (USD). The functional currency of the Company's other subsidiary, Antev is Pound Sterling (GBP).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;


      &lt;p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Foreign operations remeasurement and translation&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions, and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates, are generally recognized in the condensed consolidated statements of operations and comprehensive loss. The results and financial position of foreign operation which has functional currency different from presentation currency are translated into the presentation currency as follows: assets and liabilities are translated at the closing rate at the date of that statement of financial position, income and expenses are translated at average exchange rates, and all resulting translated exchange differences are recognized in a separate component of other comprehensive loss within the condensed consolidated statement of changes in shareholders equity.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


      &lt;div&gt;
        &lt;div&gt;
          &lt;p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Use of estimates&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The preparation of these condensed consolidated financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements, and the reported amounts of income and expenses during the reporting period. Such estimates include the valuation of stock-based awards, the incremental borrowing rate used to discount the Company's operating lease liabilities, fair value of the Company's debentures and secured promissory notes and warrants, and valuation allowance on deferred tax assets, all of which are management's best estimates. Estimates are based on historical experience, where applicable, and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. By their nature, these estimates are subject to measurement uncertainty and the effect on the financial statements of changes in estimates in future years could be significant. Management believes that the estimates utilized in preparing the financial statements are reasonable, however, actual results could differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;

    &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
    &lt;div&gt;&lt;/div&gt;

      &lt;div&gt;
        &lt;div&gt;
          &lt;p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Operating segments&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating segments are identified as components of an entity about which separate discrete financial information is available for evaluation by the chief operating decision-maker ("CODM") in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;


      &lt;p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Recently issued accounting pronouncements &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In November 2024, the FASB issued ASU 2024-03 "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures" to provide greater transparency about the components of specific expense categories in the income statements. The effective dates of ASU 2024-03 were subsequently clarified by ASU 2025-01. ASU 2025-01 is effective for our annual period beginning January 1, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting the amendment on the Company's financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;There were no other significant updates to the recently issued accounting standards which may be applicable to the Company. Although there are several other new accounting pronouncements issued or proposed by the FASB, the Company does not believe any of those accounting pronouncements have had or will have a material impact on its financial position or operating results.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <mdcx:BasisOfPresentationAndConsolidationPolicyTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20250323221121886">
      &lt;div&gt;
        &lt;p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Basis of presentation and consolidation&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The accompanying unaudited condensed consolidated financial statements included herein have been prepared in conformity with generally accepted accounting principles in the United States ("GAAP") and under the rules and regulations of the United States Securities and Exchange Commission ("SEC") for interim reporting. The accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, that are necessary to present fairly the Company's financial position, results of operations, and cash flows. The condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosures of the Company normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC's rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto for the year ended December 31, 2025, included in the Company's Annual Report on Form 10-K, as amended, originally filed with the SEC on March 25, 2026 (the "2025 Annual Report"). These condensed consolidated financial statements include the financial statements of the Company and its subsidiaries, SkinJect, Inc., Medicus Pharma Inc., Antev Limited ("Antev") and MDCX Holdings, LLC. All intercompany balances and transactions have been eliminated on consolidation. Non-controlling interest in the consolidated financial statements represents the portion of Antev not 100% owned by the Company. The functional currency of the Company and its three wholly-owned subsidiaries, SkinJect, Inc., Medicus Pharma Inc. and MDCX Holdings, LLC. is the United States dollar (USD). The functional currency of the Company's other subsidiary, Antev is Pound Sterling (GBP).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    </mdcx:BasisOfPresentationAndConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260321123839001">
      &lt;p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Foreign operations remeasurement and translation&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions, and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates, are generally recognized in the condensed consolidated statements of operations and comprehensive loss. The results and financial position of foreign operation which has functional currency different from presentation currency are translated into the presentation currency as follows: assets and liabilities are translated at the closing rate at the date of that statement of financial position, income and expenses are translated at average exchange rates, and all resulting translated exchange differences are recognized in a separate component of other comprehensive loss within the condensed consolidated statement of changes in shareholders equity.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    </us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_20260101to20260630"
      id="Fxbrl_20250323221204705">
      &lt;div&gt;
        &lt;div&gt;
          &lt;p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Use of estimates&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The preparation of these condensed consolidated financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements, and the reported amounts of income and expenses during the reporting period. Such estimates include the valuation of stock-based awards, the incremental borrowing rate used to discount the Company's operating lease liabilities, fair value of the Company's debentures and secured promissory notes and warrants, and valuation allowance on deferred tax assets, all of which are management's best estimates. Estimates are based on historical experience, where applicable, and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. By their nature, these estimates are subject to measurement uncertainty and the effect on the financial statements of changes in estimates in future years could be significant. Management believes that the estimates utilized in preparing the financial statements are reasonable, however, actual results could differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    </us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20250323221856028">
      &lt;div&gt;
        &lt;div&gt;
          &lt;p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Operating segments&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/div&gt;
        &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating segments are identified as components of an entity about which separate discrete financial information is available for evaluation by the chief operating decision-maker ("CODM") in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    </us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260509005724318"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20250323221934096">
      &lt;p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Recently issued accounting pronouncements &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In November 2024, the FASB issued ASU 2024-03 "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures" to provide greater transparency about the components of specific expense categories in the income statements. The effective dates of ASU 2024-03 were subsequently clarified by ASU 2025-01. ASU 2025-01 is effective for our annual period beginning January 1, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting the amendment on the Company's financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;There were no other significant updates to the recently issued accounting standards which may be applicable to the Company. Although there are several other new accounting pronouncements issued or proposed by the FASB, the Company does not believe any of those accounting pronouncements have had or will have a material impact on its financial position or operating results.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260321100201840">
    &lt;div&gt;
      &lt;p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;3.&lt;/strong&gt;&#160;&lt;strong&gt;Balance sheet components&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Prepaid expenses include the following:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

        &lt;table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31, 2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Insurance&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;109,405&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;345,084&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Contract research organizations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;390,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;410,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Professional services&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;330,400&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;300,033&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Prepaid services&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;977,656&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;31,004&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;1,807,461&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:1%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;1,086,121&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Accrued expenses and other current liabilities include the following:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

        &lt;table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31, 2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Accrued legal fees&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;110,976&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;352,864&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;195,082&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;300,181&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Accrued other&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,949&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;342,245&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;308,007&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:1%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;995,290&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

    &lt;/div&gt;
  </us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <mdcx:ScheduleOfPrepaidExpensesTableTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260321100214534">
        &lt;table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31, 2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Insurance&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;109,405&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;345,084&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Contract research organizations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;390,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;410,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Professional services&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;330,400&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;300,033&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Prepaid services&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;977,656&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;31,004&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;1,807,461&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:1%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;1,086,121&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </mdcx:ScheduleOfPrepaidExpensesTableTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250323225637621"
      unitRef="USD">109405</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250323225919745"
      unitRef="USD">345084</us-gaap:PrepaidInsurance>
    <mdcx:PrepaidContractResearch
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250323225802395"
      unitRef="USD">390000</mdcx:PrepaidContractResearch>
    <mdcx:PrepaidContractResearch
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250323225934485"
      unitRef="USD">410000</mdcx:PrepaidContractResearch>
    <mdcx:PrepaidProfessionalServices
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250323225820626"
      unitRef="USD">330400</mdcx:PrepaidProfessionalServices>
    <mdcx:PrepaidProfessionalServices
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250323225941575"
      unitRef="USD">300033</mdcx:PrepaidProfessionalServices>
    <mdcx:PrepaidServices
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250323225833496"
      unitRef="USD">977656</mdcx:PrepaidServices>
    <mdcx:PrepaidServices
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250323230008285"
      unitRef="USD">31004</mdcx:PrepaidServices>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250323225900903"
      unitRef="USD">1807461</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20260810183443310"
      unitRef="USD">1086121</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20250323225619934">
        &lt;table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31, 2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap;border-top:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Accrued legal fees&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;110,976&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;352,864&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;195,082&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;300,181&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Accrued other&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,949&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;342,245&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;308,007&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:1%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;995,290&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:1.5pt solid #000000;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250323230109336"
      unitRef="USD">110976</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250323230126130"
      unitRef="USD">352864</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250323230147827"
      unitRef="USD">195082</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250323230259340"
      unitRef="USD">300181</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250323230240468"
      unitRef="USD">1949</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250323230316942"
      unitRef="USD">342245</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250323230225428"
      unitRef="USD">308007</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250323230326696"
      unitRef="USD">995290</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260509010341744">
    &lt;div&gt;
      &lt;p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;4. Leases&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of June 30, 2026, the Company had one operating lease for its corporate office that commenced in 2024, for which the Company recorded a right-of-use asset and lease liability as of the commencement date. The Company's lease does not contain a purchase option. Where the Company's lease contains an option to extend the lease term, the extended lease term is only included in the measurement of the lease when it is reasonably certain to remain in the lease beyond the non-cancellable term. The Company's lease also contains variable lease costs, which pertain to common area maintenance and other operating charges, that are expensed as incurred.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Balance sheet information related to the Company's lease is presented below:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

        &lt;table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Six Months Ended &lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Year Ended &lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;December 31,2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Operating lease&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;117,184&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;170,733&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating lease liabilities - current&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;137,330&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;145,456&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating lease liabilities - non-current&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;60,139&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other information related to leases is presented below:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

        &lt;table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="4" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Six months ended June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td colspan="1" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease cost&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating lease cost&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;61,889&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;61,889&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other information&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating cash flows used in operating leases&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(76,952&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(70,080&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;)&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Remaining lease term (in years)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Discount rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of June 30, 2026, the annual future minimum lease payments of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="width:50%;border-collapse:collapse;font-size:10pt;border-color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="color:#231f20"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="color:#231f20"&gt;74,348&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="color:#231f20"&gt;74,348&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="color:#231f20"&gt;Total future minimum lease payments, undiscounted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;148,696&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Present value discount&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(11,366&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total lease liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;137,330&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

    &lt;/div&gt;
  </us-gaap:LesseeOperatingLeasesTextBlock>
    <mdcx:LesseeOperatingLeasesDisclosureTableTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20250323230512381">
        &lt;table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Six Months Ended &lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Year Ended &lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;December 31,2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Operating lease&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;117,184&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;170,733&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating lease liabilities - current&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;137,330&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;145,456&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating lease liabilities - non-current&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;60,139&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </mdcx:LesseeOperatingLeasesDisclosureTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20260321100722615"
      unitRef="USD">117184</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250323231135654"
      unitRef="USD">170733</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20260321100728265"
      unitRef="USD">137330</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250323231148017"
      unitRef="USD">145456</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20260321100734695"
      unitRef="USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20250323231214952"
      unitRef="USD">60139</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20250323230540980">
        &lt;table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="4" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Six months ended June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td colspan="1" style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease cost&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating lease cost&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;61,889&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;61,889&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other information&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating cash flows used in operating leases&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(76,952&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(70,080&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;)&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Remaining lease term (in years)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Discount rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321100521993"
      unitRef="USD">61889</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20250323231231585"
      unitRef="USD">61889</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260321100533032"
      unitRef="USD">76952</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20250323231246011"
      unitRef="USD">70080</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="C_20260630" id="Fxbrl_20260321100538623">P1Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="C_20250630" id="Fxbrl_20250323231302002">P1Y11M1D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_20260630"
      decimals="2"
      id="Fxbrl_20260321100546455"
      unitRef="Percent">0.10</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_20250630"
      decimals="2"
      id="Fxbrl_20250323231338153"
      unitRef="Percent">0.10</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20250323230555241">
        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="width:50%;border-collapse:collapse;font-size:10pt;border-color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="color:#231f20"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="color:#231f20"&gt;74,348&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="color:#231f20"&gt;74,348&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="color:#231f20"&gt;Total future minimum lease payments, undiscounted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;148,696&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Present value discount&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(11,366&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total lease liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;137,330&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250323231412976"
      unitRef="USD">74348</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250323232600160"
      unitRef="USD">74348</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250323232614195"
      unitRef="USD">148696</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250323232634471"
      unitRef="USD">11366</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250323232646916"
      unitRef="USD">137330</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260509013512151">
    &lt;div&gt;
      &lt;p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;5. Share capital&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;i&gt;Authorized&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has authorized an unlimited number of common shares participating, voting and without nominal or par value. Each holder of common shares is entitled to one vote for each share owned on all matters voted upon by shareholders.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;i&gt;Regulation A Offering&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On March 10, 2025, the Company closed a Tier II Regulation A offering for gross proceeds of $4,172,000. The Company issued 1,490,000 units at a price of $2.80 per unit. Each unit consisted of one common share of the Company and one warrant to purchase one common share of the Company (each a "Regulation A Warrant"). The Regulation A Warrants have an exercise price of $2.80 per share and will expire 5 years from the date of issuance on March 10, 2030. The Company incurred total issuance costs of $483,020, including legal fees and placement fees directly related to the issuance. The issuance costs incurred were recognized as a reduction in equity and allocated based on the relative fair values of the Regulation A Warrants and common shares on a standalone basis. The fair value of the common shares was based on the Company's share price on the day of issuance of $3.40 and the fair value of the Regulation A Warrants was $2.63 per warrant. The Regulation A Warrants were recognized in additional paid-in capital as they met the criteria for equity classification.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company's Regulation A Warrants are not actively traded and are therefore classified as Level 3 within the fair value hierarchy. The fair value of these warrants is estimated using a Black-Scholes option pricing model. The valuation incorporates significant unobservable inputs and management judgment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of June 30, 2026, 133,800 of the 1,490,000 Regulation A Warrants have been exercised for cash for proceeds to the Company of $374,640. No Regulation A Warrants were exercised during the six months ended June 30, 2026.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The fair value of the Regulation A Warrants were estimated using the Black-Scholes model with the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="width:50%;border-collapse:collapse;font-size:10pt;border-color:#000000;margin-left:auto;margin-right:auto"&gt;

              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Issue Date&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;March 10,&lt;br/&gt;2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Valuation date share price&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercise price&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2.80&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.98%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected warrant life&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.00 years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected volatility&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;97.81%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrant activity as below:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Number of &lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;common share &lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;warrants &lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;outstanding&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Weighted&lt;br/&gt;average exercise&lt;br/&gt;price $&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Weighted average&lt;br/&gt;remaining life&lt;br/&gt;(years)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Outstanding as at December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:10%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7,281,795&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:10%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2.70&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:10%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.90&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrants granted&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrants exercised&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:10%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:10%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:10%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Total Warrants outstanding as at June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:10%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;7,281,795&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:10%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2.70&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:10%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;4.41&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

      &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;The number of warrants outstanding as at the six months ended June 30, 2026:&lt;/p&gt;
      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;

        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt"&gt;

              &lt;tr&gt;
                &lt;td style="width:20%;vertical-align:top;border-bottom:0.75pt solid #000000;text-align:center;padding-left:5pt;padding-right:5pt;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td colspan="4" style="padding-right:5pt;padding-left:5pt;vertical-align:top;border-bottom:0.75pt solid #000000;text-align:center;width:80%;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Warrants outstanding&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;border-bottom:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;border-bottom:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Expiry date&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Exercise price&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Number outstanding&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;vertical-align:top;border-bottom:0.75pt solid #000000;text-align:right;padding-left:5pt;padding-right:5pt;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Number&lt;br/&gt;exercisable &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrants issued as part of the IPO&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;November 15, 2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$ 4.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;985,595&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;vertical-align:top;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:right;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;985,595&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Regulation A Warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;March 10, 2030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$ 2.80&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;16,200&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;vertical-align:top;text-align:right;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;16,200&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30, 2030 Warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 2, 2030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;background-color:#e6efff;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$ 3.10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;background-color:#e6efff;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,260,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;vertical-align:top;background-color:#e6efff;text-align:right;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,260,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Series C and D Warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 5, 2031&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$ 2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,020,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;vertical-align:top;text-align:right;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,020,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;i&gt;Standby Equity Purchase Agreement &lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On February 10, 2025, the Company also announced that it had entered into a standby equity purchase agreement (the "SEPA") with YA II PN, Ltd. ("Yorkville"). Pursuant to the SEPA and subject to the satisfaction of certain conditions, Yorkville has committed to purchase the Company's common shares in increments up to an aggregate gross sales price of $15,000,000 during the 36 months following the date of the SEPA (such shares, the "Shares"). The Shares will be sold at the Company's option pursuant to the SEPA at 97% of the Market Price (as defined pursuant to the SEPA) and purchases are subject to certain limitations set forth in the SEPA. For the six months ended June 30, 2026, the Company issued 5,336,780 common shares pursuant to the SEPA at market prices for gross proceeds of $4,229,823 and net proceeds of&#160; $4,102,740. During the six months ended June 30, 2026, $3,223,980 of the gross proceeds received under the SEPA were held back to partially repay the Company's Yorkville debenture and related interest obligations. As at June 30, 2026 the Company has $2,489,206 available to exercise in relation to the SEPA.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On December 29, 2025, the Company entered into an equity distribution agreement (the "ATM Agreement") with Maxim Group LLC and Yorkville Securities LLC ("Yorkville Securities" and together with Maxim Group LLC, the "Agents") to create an at-the-market equity program (the "ATM"). Under the ATM Agreement, the Company may offer and sell its common shares from time to time through the Agents. The Company agreed to pay the Agents a commission equal to 3% of the gross sales from the sales of the shares pursuant to the ATM Agreement. For the six months ended June 30, 2026, the Company has issued 28,248,981 common shares as part of the program. The gross proceeds from the issuance were $12,868,181.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;/div&gt;
  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_20250310to20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember"
      decimals="0"
      id="F20260321072134998_15"
      unitRef="USD">4172000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_20250310to20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember"
      decimals="INF"
      id="F20260321072134999_16"
      unitRef="Share">1490000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember"
      decimals="2"
      id="F20260321072134999_17"
      unitRef="USD_Per_Share">2.8</us-gaap:SharesIssuedPricePerShare>
    <mdcx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20250310to20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember"
      decimals="2"
      id="F20260321072135000_18"
      unitRef="USD_Per_Share">2.8</mdcx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardWarrantsGrantsInPeriodWeightedAverageExercisePrice>
    <mdcx:StockPurchaseWarrantsTerm
      contextRef="C_20250310to20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember"
      id="Fxbrl_20260323102539545">P5Y</mdcx:StockPurchaseWarrantsTerm>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20250310to20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember"
      decimals="0"
      id="F20260321072135000_20"
      unitRef="USD">483020</us-gaap:PaymentsOfStockIssuanceCosts>
    <mdcx:FairValuePerShare
      contextRef="C_20250310to20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember"
      decimals="2"
      id="F20260321072135001_21"
      unitRef="USD_Per_Share">3.4</mdcx:FairValuePerShare>
    <mdcx:FairValuePerWarrant
      contextRef="C_20250310to20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember"
      decimals="2"
      id="F20260321072135001_22"
      unitRef="USD_Per_Share">2.63</mdcx:FairValuePerWarrant>
    <mdcx:NumberOfWarrantsExercised
      contextRef="C_20260630_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember"
      decimals="INF"
      id="F20260321072135005_33"
      unitRef="Share">133800</mdcx:NumberOfWarrantsExercised>
    <mdcx:NumberOfCommonShareWarrantsOutstandingGrantsInPeriod
      contextRef="C_20250310to20250310_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember"
      decimals="INF"
      id="F20260321072135005_34"
      unitRef="Share">1490000</mdcx:NumberOfCommonShareWarrantsOutstandingGrantsInPeriod>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_mdcxRegulationAOfferingMember"
      decimals="0"
      id="Fxbrl_20260809151738991"
      unitRef="USD">374640</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_20260101to20260630"
      id="F20260321072135028_76">
        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="width:50%;border-collapse:collapse;font-size:10pt;border-color:#000000;margin-left:auto;margin-right:auto"&gt;

              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Issue Date&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;March 10,&lt;br/&gt;2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Valuation date share price&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercise price&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2.80&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.98%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected warrant life&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.00 years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected volatility&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;97.81%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_mdcxMeasurementInputValuationDateSharePriceMember"
      decimals="2"
      id="F20260321072135002_24"
      unitRef="USD_PER_SHARE">3.4</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExercisePriceMember"
      decimals="2"
      id="F20260321072135003_26"
      unitRef="USD_PER_SHARE">2.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember"
      decimals="2"
      id="F20260321072135003_28"
      unitRef="Percentage">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="F20260321072135004_30"
      unitRef="Percentage">0.0398</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember"
      decimals="0"
      id="F20260321072135037_99"
      unitRef="Year">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_20250310_usgaapFinancialInstrumentAxis_mdcxRegulationAWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember"
      decimals="2"
      id="F20260321072135005_32"
      unitRef="Percentage">97.81</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <mdcx:ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260809151418948">
        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Number of &lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;common share &lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;warrants &lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;outstanding&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Weighted&lt;br/&gt;average exercise&lt;br/&gt;price $&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Weighted average&lt;br/&gt;remaining life&lt;br/&gt;(years)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Outstanding as at December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:10%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7,281,795&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:10%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2.70&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:10%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.90&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrants granted&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrants exercised&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:10%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:10%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:10%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Total Warrants outstanding as at June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:10%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;7,281,795&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:10%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2.70&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:10%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;4.41&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </mdcx:ScheduleOfWarrantsContinuityOutstandingAndExercisableTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20251231_usgaapFinancialInstrumentAxis_usgaapWarrantMember"
      decimals="INF"
      id="Fxbrl_20260321163632269_20260321072135029_78"
      unitRef="Share">7281795</us-gaap:ClassOfWarrantOrRightOutstanding>
    <mdcx:WeightedAverageExercisePriceOfWarrant
      contextRef="C_20251231_usgaapFinancialInstrumentAxis_usgaapWarrantMember"
      decimals="2"
      id="Fxbrl_20260321163632269_20260321072135030_81"
      unitRef="USD_Per_Share">2.7</mdcx:WeightedAverageExercisePriceOfWarrant>
    <mdcx:WeightedAverageRemainingContractualTermOfWarrant
      contextRef="C_20250101to20251231_usgaapFinancialInstrumentAxis_usgaapWarrantMember"
      id="Fxbrl_20260321163632269_20260321072135030_80">P4Y10M24D</mdcx:WeightedAverageRemainingContractualTermOfWarrant>
    <mdcx:NumberOfCommonShareWarrantsOutstandingGrantsInPeriod
      contextRef="C_20260101to20260630_usgaapFinancialInstrumentAxis_usgaapWarrantMember"
      decimals="INF"
      id="F20260321072135031_84"
      unitRef="Share">0</mdcx:NumberOfCommonShareWarrantsOutstandingGrantsInPeriod>
    <mdcx:WeightedAverageExercisePriceWarrantGranted
      contextRef="C_20260101to20260630_usgaapFinancialInstrumentAxis_usgaapWarrantMember"
      decimals="0"
      id="F20260321072135034_92"
      unitRef="USD_Per_Share">0</mdcx:WeightedAverageExercisePriceWarrantGranted>
    <mdcx:NumberOfCommonShareWarrantsOutstandingExerciseInPeriod
      contextRef="C_20260101to20260630_usgaapFinancialInstrumentAxis_usgaapWarrantMember"
      decimals="INF"
      id="Fxbrl_20260321164432396_20260321072135032_86"
      unitRef="Share">0</mdcx:NumberOfCommonShareWarrantsOutstandingExerciseInPeriod>
    <mdcx:WeightedAverageExercisePriceWarrantExercise
      contextRef="C_20260101to20260630_usgaapFinancialInstrumentAxis_usgaapWarrantMember"
      decimals="0"
      id="Fxbrl_20260321164432396_20260321072135035_94"
      unitRef="USD_Per_Share">0</mdcx:WeightedAverageExercisePriceWarrantExercise>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20260630_usgaapFinancialInstrumentAxis_usgaapWarrantMember"
      decimals="INF"
      id="F20260321072135031_83"
      unitRef="Share">7281795</us-gaap:ClassOfWarrantOrRightOutstanding>
    <mdcx:WeightedAverageExercisePriceOfWarrant
      contextRef="C_20260630_usgaapFinancialInstrumentAxis_usgaapWarrantMember"
      decimals="2"
      id="Fxbrl_20260509013754603"
      unitRef="USD_Per_Share">2.7</mdcx:WeightedAverageExercisePriceOfWarrant>
    <mdcx:WeightedAverageRemainingContractualTermOfWarrant
      contextRef="C_20260101to20260630_usgaapFinancialInstrumentAxis_usgaapWarrantMember"
      id="Fxbrl_20260509013801382">P4Y4M28D</mdcx:WeightedAverageRemainingContractualTermOfWarrant>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="C_20260101to20260630"
      id="F20260321072135011_50">
        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt"&gt;

              &lt;tr&gt;
                &lt;td style="width:20%;vertical-align:top;border-bottom:0.75pt solid #000000;text-align:center;padding-left:5pt;padding-right:5pt;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td colspan="4" style="padding-right:5pt;padding-left:5pt;vertical-align:top;border-bottom:0.75pt solid #000000;text-align:center;width:80%;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Warrants outstanding&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;border-bottom:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;border-bottom:0.75pt solid #000000;white-space:nowrap;vertical-align:top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Expiry date&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Exercise price&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Number outstanding&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;vertical-align:top;border-bottom:0.75pt solid #000000;text-align:right;padding-left:5pt;padding-right:5pt;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Number&lt;br/&gt;exercisable &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrants issued as part of the IPO&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;November 15, 2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$ 4.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;985,595&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;vertical-align:top;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:right;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;985,595&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Regulation A Warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;March 10, 2030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$ 2.80&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;16,200&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;vertical-align:top;text-align:right;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;16,200&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 30, 2030 Warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 2, 2030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;background-color:#e6efff;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$ 3.10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;background-color:#e6efff;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,260,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;vertical-align:top;background-color:#e6efff;text-align:right;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,260,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Series C and D Warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;width:20%;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;June 5, 2031&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$ 2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,020,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="width:20%;vertical-align:top;text-align:right;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,020,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <mdcx:ClassOfWarrantOrRightExpiryDate
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantsIssuedAsPartOfIpoMember"
      id="F20260321072135012_51">November 15, 2029</mdcx:ClassOfWarrantOrRightExpiryDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantsIssuedAsPartOfIpoMember"
      decimals="2"
      id="F20260321072135013_55"
      unitRef="USD_Per_Share">4.64</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantsIssuedAsPartOfIpoMember"
      decimals="INF"
      id="F20260321072135013_54"
      unitRef="Share">985595</us-gaap:ClassOfWarrantOrRightOutstanding>
    <mdcx:ClassOfWarrantOrRightExercisable
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantsIssuedAsPartOfIpoMember"
      decimals="INF"
      id="Fxbrl_20260324062626887"
      unitRef="Share">985595</mdcx:ClassOfWarrantOrRightExercisable>
    <mdcx:ClassOfWarrantOrRightExpiryDate
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxRegulationAWarrantsMember"
      id="F20260321072135012_52">March 10, 2030</mdcx:ClassOfWarrantOrRightExpiryDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20260630_usgaapStatementEquityComponentsAxis_mdcxRegulationAWarrantsMember"
      decimals="2"
      id="F20260321072135014_57"
      unitRef="USD_Per_Share">2.8</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20260630_usgaapStatementEquityComponentsAxis_mdcxRegulationAWarrantsMember"
      decimals="INF"
      id="F20260321072135014_56"
      unitRef="Share">16200</us-gaap:ClassOfWarrantOrRightOutstanding>
    <mdcx:ClassOfWarrantOrRightExercisable
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxRegulationAWarrantsMember"
      decimals="INF"
      id="Fxbrl_20260324062633517"
      unitRef="Share">16200</mdcx:ClassOfWarrantOrRightExercisable>
    <mdcx:ClassOfWarrantOrRightExpiryDate
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantWithExpiryDateJune302030WarrantsMember"
      id="F20260321072135013_53">June 2, 2030</mdcx:ClassOfWarrantOrRightExpiryDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantWithExpiryDateJune302030WarrantsMember"
      decimals="2"
      id="F20260321072135015_59"
      unitRef="USD_Per_Share">3.1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantWithExpiryDateJune302030WarrantsMember"
      decimals="INF"
      id="F20260321072135014_58"
      unitRef="Share">2260000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <mdcx:ClassOfWarrantOrRightExercisable
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxWarrantWithExpiryDateJune302030WarrantsMember"
      decimals="INF"
      id="Fxbrl_20260324062639233"
      unitRef="Share">2260000</mdcx:ClassOfWarrantOrRightExercisable>
    <mdcx:ClassOfWarrantOrRightExpiryDate
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxSeriesCAndDWarrantsMember"
      id="F20260321072135015_60">June 5, 2031</mdcx:ClassOfWarrantOrRightExpiryDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20260630_usgaapStatementEquityComponentsAxis_mdcxSeriesCAndDWarrantsMember"
      decimals="2"
      id="Fxbrl_20251105153503197_20260321072135015_59"
      unitRef="USD_Per_Share">2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20260630_usgaapStatementEquityComponentsAxis_mdcxSeriesCAndDWarrantsMember"
      decimals="INF"
      id="Fxbrl_20251105153503197_20260321072135014_58"
      unitRef="Share">4020000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <mdcx:ClassOfWarrantOrRightExercisable
      contextRef="C_20260101to20260630_usgaapStatementEquityComponentsAxis_mdcxSeriesCAndDWarrantsMember"
      decimals="INF"
      id="Fxbrl_20260324062645731"
      unitRef="Share">4020000</mdcx:ClassOfWarrantOrRightExercisable>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20250210to20250210_usgaapSubsidiarySaleOfStockAxis_mdcxStandbyEquityPurchaseAgreementMember"
      decimals="0"
      id="F20260321072135009_44"
      unitRef="USD">15000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mdcx:SharePriceAsPercentageOfMarketPrice
      contextRef="C_20250210to20250210_usgaapSubsidiarySaleOfStockAxis_mdcxStandbyEquityPurchaseAgreementMember"
      decimals="2"
      id="F20260321072135010_45"
      unitRef="Percent">0.97</mdcx:SharePriceAsPercentageOfMarketPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_mdcxStandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="F20260321072135026_71"
      unitRef="Share">5336780</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_mdcxStandbyEquityPurchaseAgreementMember"
      decimals="0"
      id="F20260321072135026_70"
      unitRef="USD">4229823</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_mdcxStandbyEquityPurchaseAgreementMember"
      decimals="0"
      id="F20260321072135026_69"
      unitRef="USD">4102740</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mdcx:ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures
      contextRef="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_mdcxStandbyEquityPurchaseAgreementMember"
      decimals="0"
      id="Fxbrl_20260809154820152"
      unitRef="USD">3223980</mdcx:ProceedsFromShareIssuanceUsedToRepayOutstandingDebentures>
    <mdcx:AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement
      contextRef="C_20260630_usgaapSubsidiarySaleOfStockAxis_mdcxStandbyEquityPurchaseAgreementMember"
      decimals="0"
      id="Fxbrl_20260809155228524"
      unitRef="USD">2489206</mdcx:AmountAvailableToExerciseInRelationToStandbyEquityPurchaseAgreement>
    <mdcx:EquityDistributionAgreementCommissionRate
      contextRef="C_20251229_usgaapSubsidiarySaleOfStockAxis_mdcxAtmAgreementMember"
      decimals="2"
      id="Fxbrl_20260321182936616"
      unitRef="Percent">0.03</mdcx:EquityDistributionAgreementCommissionRate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_mdcxAtmAgreementMember"
      decimals="INF"
      id="Fxbrl_20260509014444569"
      unitRef="Share">28248981</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20260101to20260630_usgaapSubsidiarySaleOfStockAxis_mdcxAtmAgreementMember"
      decimals="0"
      id="Fxbrl_20260509014515926"
      unitRef="USD">12868181</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260509021028221">
    &lt;div&gt;
      &lt;p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;6.&lt;/strong&gt;&#160;&lt;strong&gt;Stock-based compensation &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;At June 30, 2026, the Company had in place a stock option plan for employee, non-employee directors, and consultants of the Company (the "Plan"). The Plan provides both for the direct award or sale of shares and for the grant of options to purchase shares. Under the plan, the total number of shares available for options cannot exceed 10% of the Company's issued and outstanding common shares at the time of any grant. The Company is authorized to issue options to employees, non-employee directors and consultants under the plan.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On March 30, 2026, the Company issued 975,000 stock options to directors, officers, and employees of the Company. The options are exercisable at $0.50 per share, expire five years from the grant date, and vest quarterly over a one-year period. On June 3, 2026, the Company issued an additional 2,075,000 stock options to directors, officers, and employees of the Company. The options are exercisable at $0.36 per share, expire five years from the grant date, and vest quarterly over a one-year period. During the three months ended June 30, 2026, the Company accelerated the vesting of all options outstanding except the 2,075,000 options that were granted on June 3, 2026.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table summarizes option transactions for the Plan:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

        &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-size:10pt;width:100%;border-color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;options&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;average&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;exercise price&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;average&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;remaining&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;contractual life&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;(years)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Aggregate&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;intrinsic value&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(230, 239, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Outstanding at December 31, 2024&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1,185,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1.47&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;4.18&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1.18&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;100,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2.60&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;5.00&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(230, 239, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Outstanding at June 30, 2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1,285,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1.56&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;3.79&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1.43&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Exercisable at June 30, 2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;980,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1.25&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;4.01&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1.74&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(230, 239, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Unvested at June 30, 2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;305,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2.56&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;4.44&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(230, 239, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Outstanding at December 31, 2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2,505,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2.05&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2.75&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:20pt;padding-right:5pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;3,050,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;0.40&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;4.87&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(230, 239, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:20pt;padding-right:5pt;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(45,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1.79&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Outstanding at June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;5,510,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1.14&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;4.32&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(230, 239, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Exercisable at June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;3,435,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1.62&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;3.94&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Unvested at June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2,075,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;0.36&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;4.93&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

      &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;p style="margin:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of June 30, 2026, there were $419,075 of unrecognized stock-based compensation cost related to share options outstanding, which is expected to be recognized over a weighted-average period of 0.93 years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The weighted average grant date fair value of awards for options granted during the six months ended June 30, 2026, was $0.24. The fair value of options granted was estimated using the Black-Scholes option pricing model, resulting in the following weighted average assumptions for the options granted:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="width:90%;border-collapse:collapse;font-size:10pt;border-color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;June 30, 2026&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;Weighted-average&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercise price&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share price&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.37&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.13%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Estimated life (in years)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected volatility&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;76.33%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;For the three and six months ended June 30, 2026, stock-based compensation expense was $1,405,826 and $2,005,133, respectively. For the three and six months ended June 30, 2025, stock-based compensation expense was $117,448 and $585,442, respectively. Stock-based compensation expense has been reported in the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss within the line items &#x2018;general and administrative&#x2019; expenses&lt;/span&gt;&lt;/span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;/div&gt;
  </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <mdcx:LimitOfOptionsAsPercentageOfSharesOutstanding
      contextRef="C_20260101to20260630"
      decimals="2"
      id="Fxbrl_20250325182814380"
      unitRef="Percent">0.10</mdcx:LimitOfOptionsAsPercentageOfSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20260330to20260330_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember"
      decimals="0"
      id="Fxbrl_20260509022608290"
      unitRef="Share">975000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20260330to20260330_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember"
      decimals="2"
      id="Fxbrl_20260509022617981"
      unitRef="USD_Per_Share">0.5</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_20260330to20260330_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember"
      id="Fxbrl_20260509022622751">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20260330to20260330_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember"
      id="Fxbrl_20260509022627134">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20260601to20260603_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember"
      decimals="0"
      id="Fxbrl_20260809160528164"
      unitRef="Share">2075000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20260601to20260603_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember"
      decimals="2"
      id="Fxbrl_20260809160554428"
      unitRef="USD_Per_Share">0.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_20260601to20260603_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember"
      id="Fxbrl_20260809160601051">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20260601to20260603_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember"
      id="Fxbrl_20260809160608532">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20260601to20260603_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxIndividualsMember"
      decimals="0"
      id="Fxbrl_20260809160619082"
      unitRef="Share">2075000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260509015400849">
        &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-size:10pt;width:100%;border-color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;options&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;average&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;exercise price&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;average&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;remaining&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;contractual life&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;(years)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Aggregate&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;intrinsic value&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(230, 239, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Outstanding at December 31, 2024&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1,185,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1.47&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;4.18&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1.18&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;100,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2.60&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;5.00&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(230, 239, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Outstanding at June 30, 2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1,285,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1.56&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;3.79&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1.43&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Exercisable at June 30, 2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;980,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1.25&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;4.01&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1.74&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(230, 239, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Unvested at June 30, 2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;305,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2.56&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;4.44&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(230, 239, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Outstanding at December 31, 2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2,505,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2.05&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2.75&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:20pt;padding-right:5pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;3,050,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;0.40&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;4.87&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(230, 239, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:20pt;padding-right:5pt;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(45,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1.79&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Outstanding at June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;5,510,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1.14&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;4.32&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(230, 239, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Exercisable at June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;3,435,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1.62&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;3.94&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(219, 229, 241)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(219, 229, 241)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
              &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;padding-left:5pt;padding-right:5pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Unvested at June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2,075,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;0.36&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;4.93&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:10%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;-&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20241231"
      decimals="0"
      id="Fxbrl_20260509021349807_xbrl_20260509014944168_xbrl_20250324181236791_xbrl_20250324180521687_12"
      unitRef="Share">1185000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20241231"
      decimals="2"
      id="Fxbrl_20260509021349807_xbrl_20260509014944168_xbrl_20250324181236791_xbrl_20250324180521687_15"
      unitRef="USD_Per_Share">1.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20240101to20241231"
      id="Fxbrl_20260509021349807_xbrl_20260509014944168_xbrl_20250324181437312">P4Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_20241231"
      decimals="2"
      id="Fxbrl_20260509021349807_xbrl_20260509014944168_xbrl_20250324181236791_xbrl_20250324180521687_111"
      unitRef="USD">1.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260809160005135_xbrl_20260509015013472_xbrl_20250811142538631"
      unitRef="Share">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20250101to20250630"
      decimals="2"
      id="Fxbrl_20260809160005135_xbrl_20260509015013472_xbrl_20250811142601463"
      unitRef="USD_Per_Share">2.6</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <mdcx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted
      contextRef="C_20250101to20250630"
      id="Fxbrl_20260809160005135_xbrl_20260509015013472_xbrl_20250811142608728">P5Y</mdcx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20250630"
      decimals="0"
      id="Fxbrl_20260509021353733_xbrl_20260509014944168_xbrl_20250324181236791_xbrl_20250324180521687_12"
      unitRef="Share">1285000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20250630"
      decimals="2"
      id="Fxbrl_20260509021353733_xbrl_20260509014944168_xbrl_20250324181236791_xbrl_20250324180521687_15"
      unitRef="USD_Per_Share">1.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20250101to20250630"
      id="Fxbrl_20260509021353733_xbrl_20260509014944168_xbrl_20250324181437312">P3Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_20250630"
      decimals="2"
      id="Fxbrl_20260509021353733_xbrl_20260509014944168_xbrl_20250324181236791_xbrl_20250324180521687_111"
      unitRef="USD">1.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20250630"
      decimals="0"
      id="Fxbrl_20260509021407501_xbrl_20260509015056344_xbrl_20250324180521687_72"
      unitRef="Share">980000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_20250630"
      decimals="2"
      id="Fxbrl_20260509021407501_xbrl_20260509015056344_xbrl_20250324180521687_75"
      unitRef="USD_Per_Share">1.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_20250101to20250630"
      id="Fxbrl_20260509021407501_xbrl_20260509015056344_xbrl_20250324180521687_78">P4Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_20250630"
      decimals="2"
      id="Fxbrl_20260509021407501_xbrl_20260509015056344_xbrl_20250324180521687_711"
      unitRef="USD">1.74</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_20250630"
      decimals="INF"
      id="Fxbrl_20260509021414469_xbrl_20260509015104079_xbrl_20250324180521687_82"
      unitRef="Share">305000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_20250630"
      decimals="2"
      id="Fxbrl_20260509021414469_xbrl_20260509015104079_xbrl_20250325103832992"
      unitRef="USD_Per_Share">2.56</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_20250101to20250630"
      id="Fxbrl_20260509021414469_xbrl_20260509015104079_xbrl_20250325105103101">P4Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_20250630"
      decimals="0"
      id="Fxbrl_20260509021414469_xbrl_20260509015104079_xbrl_20250325105245212"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20260509014944168_xbrl_20250324181236791_xbrl_20250324180521687_12"
      unitRef="Share">2505000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20251231"
      decimals="2"
      id="Fxbrl_20260509014944168_xbrl_20250324181236791_xbrl_20250324180521687_15"
      unitRef="USD_Per_Share">2.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20250101to20251231"
      id="Fxbrl_20260509014944168_xbrl_20250324181437312">P2Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20260509014944168_xbrl_20250324181236791_xbrl_20250324180521687_111"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260509015013472_xbrl_20250811142538631"
      unitRef="Share">3050000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20260101to20260630"
      decimals="2"
      id="Fxbrl_20260509015013472_xbrl_20250811142601463"
      unitRef="USD_Per_Share">0.4</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <mdcx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260509015013472_xbrl_20250811142608728">P4Y10M13D</mdcx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20251105132756851"
      unitRef="Share">45000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_20260101to20260630"
      decimals="2"
      id="Fxbrl_20251105132812260"
      unitRef="USD_Per_Share">1.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20260509015049128_xbrl_20250324182436535_xbrl_20250324181236791_xbrl_20250324180521687_12"
      unitRef="Share">5510000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20260630"
      decimals="2"
      id="Fxbrl_20260509015049128_xbrl_20250324182436535_xbrl_20250324181236791_xbrl_20250324180521687_15"
      unitRef="USD_Per_Share">1.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260509015049128_xbrl_20250324182436535_xbrl_20250324181437312">P4Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20260509015049128_xbrl_20250324182436535_xbrl_20250324181236791_xbrl_20250324180521687_111"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20260509015056344_xbrl_20250324180521687_72"
      unitRef="Share">3435000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_20260630"
      decimals="2"
      id="Fxbrl_20260509015056344_xbrl_20250324180521687_75"
      unitRef="USD_Per_Share">1.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260509015056344_xbrl_20250324180521687_78">P3Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20260509015056344_xbrl_20250324180521687_711"
      unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_20260630"
      decimals="INF"
      id="Fxbrl_20260509015104079_xbrl_20250324180521687_82"
      unitRef="Share">2075000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_20260630"
      decimals="2"
      id="Fxbrl_20260509015104079_xbrl_20250325103832992"
      unitRef="USD_Per_Share">0.36</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260509015104079_xbrl_20250325105103101">P4Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20260509015104079_xbrl_20250325105245212"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20250324203254745"
      unitRef="USD">419075</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_20260101to20260630"
      id="Fxbrl_20250325135300051">P0Y11M4D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20260101to20260630"
      decimals="2"
      id="Fxbrl_20250809015123536"
      unitRef="USD_Per_Share">0.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260810163956578">
        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="width:90%;border-collapse:collapse;font-size:10pt;border-color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;June 30, 2026&lt;/strong&gt;&lt;br/&gt;&lt;strong&gt;Weighted-average&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercise price&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Share price&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.37&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4.13%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Estimated life (in years)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected volatility&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;76.33%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_20260630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="2"
      id="Fxbrl_20260509015239492_xbrl_20250809064019026"
      unitRef="USD_Per_Share">0.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharePrice
      contextRef="C_20260630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="2"
      id="Fxbrl_20260509015239492_xbrl_20250809064050283"
      unitRef="USD_Per_Share">0.37</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20260101to20260630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="2"
      id="Fxbrl_20260509015239493_xbrl_20250809064053729"
      unitRef="Percent">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20260101to20260630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20250809064056897"
      unitRef="Percent">0.0413</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20260101to20260630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      id="Fxbrl_20250809064112019">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20260101to20260630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20260509015239494_xbrl_20250809064109086"
      unitRef="Percent">0.7633</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260812123047230"
      unitRef="USD">1405826</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260812123101326"
      unitRef="USD">2005133</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260812123120147"
      unitRef="USD">117448</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260812123126205"
      unitRef="USD">585442</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260509023016958">
    &lt;div&gt;
      &lt;div&gt;
        &lt;p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;7.&lt;/strong&gt;&#160;&lt;strong&gt;Related party transactions&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On October 18, 2023, the Company signed an agreement with RBx Capital, LP ("RBx"), a family office controlled by the Company's Executive Chairman and CEO, that provides for certain managerial positions to be filled from within RBx. RBx is responsible for the payment and provision of all wages, bonuses, and benefits for these positions. In January 2026, reimbursable salaries paid to RBx pursuant to this agreement were increased to $125,000 per month from $100,000 per month. Reimbursable salaries paid to RBx were $750,000 and $600,000 during the six months ended June 30, 2026 and 2025, respectively. Additional expenses of $455,486 and $64,046 were incurred by RBx on behalf of the Company during the three months ended June 30, 2026 and 2025, respectively. Additional expenses of $898,983 and $104,911 were incurred by RBx on behalf of the Company during the six months ended June 30, 2026 and 2025, respectively.&#160;The total amount of accounts payable to RBx was $161,846 and $121,273 as of June 30, 2026 and 2025, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="C_20260101to20260131_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember"
      decimals="0"
      id="Fxbrl_20250324001152653"
      unitRef="USD">125000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="C_20231018to20231018_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember"
      decimals="0"
      id="Fxbrl_20250324001225834"
      unitRef="USD">100000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="C_20260101to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember"
      decimals="0"
      id="Fxbrl_20250324001249676"
      unitRef="USD">750000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="C_20250101to20250630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember"
      decimals="0"
      id="Fxbrl_20250324001253364"
      unitRef="USD">600000</us-gaap:SalariesWagesAndOfficersCompensation>
    <mdcx:RelatedPartyTransactionAdditionalExpenses
      contextRef="C_20260401to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember"
      decimals="0"
      id="Fxbrl_20260812123840354"
      unitRef="USD">455486</mdcx:RelatedPartyTransactionAdditionalExpenses>
    <mdcx:RelatedPartyTransactionAdditionalExpenses
      contextRef="C_20250401to20250630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember"
      decimals="0"
      id="Fxbrl_20250324001337661"
      unitRef="USD">64046</mdcx:RelatedPartyTransactionAdditionalExpenses>
    <mdcx:RelatedPartyTransactionAdditionalExpenses
      contextRef="C_20260101to20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember"
      decimals="0"
      id="Fxbrl_20260812123553899"
      unitRef="USD">898983</mdcx:RelatedPartyTransactionAdditionalExpenses>
    <mdcx:RelatedPartyTransactionAdditionalExpenses
      contextRef="C_20250101to20250630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember"
      decimals="0"
      id="Fxbrl_20260812123609030"
      unitRef="USD">104911</mdcx:RelatedPartyTransactionAdditionalExpenses>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="C_20260630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember"
      decimals="0"
      id="Fxbrl_20250324001421995"
      unitRef="USD">161846</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="C_20250630_usgaapRelatedPartyTransactionsByRelatedPartyAxis_mdcxRbxCapitalLPMember"
      decimals="0"
      id="Fxbrl_20250324001437196"
      unitRef="USD">121273</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260321105359264">
    &lt;p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;8.&lt;/strong&gt;&#160;&lt;strong&gt;Fair value measurements&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The accounting guidance for fair value establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="margin-left:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 1: Observable inputs such as quoted prices in active markets;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="margin-left:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly; and&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="margin-left:36pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 3: Unobservable inputs in which there is little or no market data, or which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company's cash and cash equivalents and restricted cash are classified as Level 1. The fair value of the Company's cash and cash equivalents is determined based on market pricing that is both objective and publicly available. As of June 30, 2026 and December 31, 2025, the fair value of the Company's cash and cash equivalents and restricted cash were $25,191,540 and $8,705,218, respectively. As of June 30, 2026 and December 31, 2025, the Company's cash equivalents are invested in money market funds.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;div&gt;&lt;/div&gt;
    &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;

        &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;width:100%;border-color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt"&gt;

              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;
                  &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Level 1&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Level 2&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Level 3&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Total&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;
                &lt;td style="padding-right:5.4pt;padding-left:16.2pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;Current assets:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="padding-right:5.4pt;padding-left:27pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;Money market funds&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;13,573,269&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;13,573,269&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;
                &lt;td style="padding-right:5.4pt;padding-left:52.2pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;13,573,269&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;13,573,269&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:bottom;text-align:right;width:10%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);text-align:center;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;December 31, 2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Level 1&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Level 2&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Level 3&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Total&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:2%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;
                &lt;td style="padding-right:5.4pt;padding-left:16.2pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;Current assets:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="padding-right:5.4pt;padding-left:27pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;8,705,218&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;8,705,218&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;
                &lt;td style="padding-right:5.4pt;padding-left:52.2pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;8,705,218&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;8,705,218&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

    &lt;/div&gt;
    &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company did not reclassify any investments between levels in the fair value hierarchy during the periods presented.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The carrying value of the Company's secured promissory notes described in Note 12 below approximates the fair value since the financial instrument is short-term with a maturity date of November 27, 2027. As of June 30, 2026 and December 31, 2025, the carrying amounts of the Company's other financial instruments, which include cash and cash equivalents and restricted cash, accounts payable and accrued expenses approximate fair values because of their short-term maturities.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
  </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_20260630"
      decimals="0"
      id="Fxbrl_20260321111218190"
      unitRef="USD">25191540</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_20251231"
      decimals="0"
      id="Fxbrl_20260321111227246"
      unitRef="USD">8705218</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260809161332878">
        &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;width:100%;border-color:rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt"&gt;

              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;
                  &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="margin-top:0pt;margin-bottom:0pt"&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Level 1&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Level 2&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Level 3&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Total&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:center;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;
                &lt;td style="padding-right:5.4pt;padding-left:16.2pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;Current assets:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="padding-right:5.4pt;padding-left:27pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;Money market funds&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;13,573,269&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;13,573,269&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;
                &lt;td style="padding-right:5.4pt;padding-left:52.2pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;13,573,269&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;13,573,269&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:bottom;text-align:right;width:10%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);text-align:center;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;December 31, 2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;border-bottom:0.75pt solid rgb(0, 0, 0);white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Level 1&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Level 2&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Level 3&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;white-space:nowrap;text-align:center;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="white-space:normal;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong style="margin-top:0pt;margin-bottom:0pt"&gt;Total&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:2%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;
                &lt;td style="padding-right:5.4pt;padding-left:16.2pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;Current assets:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:1%;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:10%;text-align:right;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;width:2%;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="padding-right:5.4pt;padding-left:27pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;8,705,218&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;8,705,218&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid rgb(0, 0, 0);width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;
                &lt;td style="padding-right:5.4pt;padding-left:52.2pt;vertical-align:bottom;text-indent:-10.8pt;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;8,705,218&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:10%;text-align:right;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;8,705,218&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:2.25pt double rgb(0, 0, 0);width:2%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(230, 239, 255)"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_20260630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fxbrl_20260321112324586_20260321050257311_4"
      unitRef="USD">13573269</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_20260630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fxbrl_20260321112324586_20260321050257311_5"
      unitRef="USD">0</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_20260630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fxbrl_20260321112324586_20260321050257311_6"
      unitRef="USD">0</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_20260630_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fxbrl_20260321112324586_20260321050257312_7"
      unitRef="USD">13573269</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_20260630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"
      decimals="0"
      id="F20260321050257311_4"
      unitRef="USD">13573269</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_20260630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"
      decimals="0"
      id="F20260321050257311_5"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_20260630_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"
      decimals="0"
      id="F20260321050257311_6"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_20260630_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"
      decimals="0"
      id="F20260321050257312_7"
      unitRef="USD">13573269</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20251231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fxbrl_20260321112327479_20260321050257311_4"
      unitRef="USD">8705218</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20251231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fxbrl_20260321112327479_20260321050257311_5"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20251231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fxbrl_20260321112327479_20260321050257311_6"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20251231_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fxbrl_20260321112327479_20260321050257312_7"
      unitRef="USD">8705218</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_20251231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel1Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"
      decimals="0"
      id="F20260321050257312_12"
      unitRef="USD">8705218</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_20251231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"
      decimals="0"
      id="F20260321050257312_13"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_20251231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel3Member_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"
      decimals="0"
      id="F20260321050257313_14"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_20251231_usgaapFairValueByMeasurementFrequencyAxis_usgaapFairValueMeasurementsRecurringMember"
      decimals="0"
      id="F20260321050257313_15"
      unitRef="USD">8705218</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260321102720325">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div&gt;
          &lt;p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;9.&lt;/strong&gt;&#160;&lt;strong&gt;Commitments and contingencies&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;i&gt;Commitments&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;div&gt;
            &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As part of the acquisition of Antev, the Company may be required to make future payments contingent on the achievement of specified milestones. These potential payments represent a commitment and may result in future cash outflows. As these milestones conditions are not considered probable, the Company has not recognized liability related to the contingent consideration.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
            &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Pursuant to the terms of the Antev acquisition, the Company acquired 98.60% ownership in Antev, including all the assets and its In-Process Research and Development (IPR&amp;amp;D) &#x2013; Teverelix. There was additional contingent consideration based on the following development milestones of the IPR&amp;amp;D:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

              &lt;table border="0" style="border-collapse:collapse" width="100%"&gt;

                  &lt;tr style="background-color:rgb(230, 239, 255)"&gt;
                    &lt;td style="vertical-align:top;padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Phases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Contingent Consideration agreed for Antev shares acquired through issue of shares&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Contingent Consideration agreed for Antev shares acquired by cash payment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(i) Advanced Prostate Cancer - Phase 2 success or registration&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$2.00 per common share issued&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$1.47 per Antev share (pro rata interest in $5,333,200)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(230, 239, 255)"&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(ii)Acute Urinary Retention Prevention - Phase 2 success or registration&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$7.50 per common share issued&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$5.52 per Antev share (pro rata interest in $19,999,500)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(iii) FDA NDA approval - Hormone therapy for prostate cancer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Up to $20,000,000 (subject to pro rata reduction)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$5.52 per Antev share (pro rata interest in $20,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(230, 239, 255)"&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(iv) FDA NDA approval &#x2013; AUR prevention&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Up to $20,000,000 (subject to pro rata reduction)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$5.52 per Antev share (pro rata interest in $20,000,000)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;

          &lt;/div&gt;
          &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of June 30, 2026, the Company had no other long-term commitments.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;i&gt;Contingencies &lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
          &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In the ordinary course of business, from time to time, the Company may be involved in various claims related to operations, rights, commercial, employment or other claims. Although such matters cannot be predicted with certainty, management does not consider the Company's exposure to such claims to be material to these consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember"
      decimals="4"
      id="Fxbrl_20260812173234560"
      unitRef="Percent">0.986</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260812152017209">
              &lt;table border="0" style="border-collapse:collapse" width="100%"&gt;

                  &lt;tr style="background-color:rgb(230, 239, 255)"&gt;
                    &lt;td style="vertical-align:top;padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Phases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Contingent Consideration agreed for Antev shares acquired through issue of shares&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Contingent Consideration agreed for Antev shares acquired by cash payment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(i) Advanced Prostate Cancer - Phase 2 success or registration&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$2.00 per common share issued&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$1.47 per Antev share (pro rata interest in $5,333,200)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(230, 239, 255)"&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(ii)Acute Urinary Retention Prevention - Phase 2 success or registration&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$7.50 per common share issued&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$5.52 per Antev share (pro rata interest in $19,999,500)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(iii) FDA NDA approval - Hormone therapy for prostate cancer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Up to $20,000,000 (subject to pro rata reduction)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$5.52 per Antev share (pro rata interest in $20,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(230, 239, 255)"&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:33%;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(iv) FDA NDA approval &#x2013; AUR prevention&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:32%;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Up to $20,000,000 (subject to pro rata reduction)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                    &lt;td style="padding-left:3pt;padding-right:3pt;width:30%;background-color:rgb(230, 239, 255)"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;$5.52 per Antev share (pro rata interest in $20,000,000)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            </us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="C_20260630_mdcxBusinessCombinationConsiderationTransferredEquityInterestTypeAxis_usgaapCommonStockMember_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesOneMember"
      decimals="2"
      id="Fxbrl_20260812151036268"
      unitRef="USD_Per_Share">2</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesOneMember"
      decimals="2"
      id="Fxbrl_20260812151114782"
      unitRef="USD_Per_Share">1.47</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_20260630_mdcxBusinessCombinationConsiderationTransferredEquityInterestTypeAxis_usgaapCommonStockMember_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesOneMember"
      decimals="0"
      id="Fxbrl_20260812151133117"
      unitRef="USD">5333200</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="C_20260630_mdcxBusinessCombinationConsiderationTransferredEquityInterestTypeAxis_usgaapCommonStockMember_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesTwoMember"
      decimals="2"
      id="Fxbrl_20260812151240084"
      unitRef="USD_Per_Share">7.5</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesTwoMember"
      decimals="2"
      id="Fxbrl_20260812151306717"
      unitRef="USD_Per_Share">5.52</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesTwoMember"
      decimals="0"
      id="Fxbrl_20260812151323991"
      unitRef="USD">19999500</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_20260630_srtRangeAxis_srtMaximumMember_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesThreeMember"
      decimals="0"
      id="Fxbrl_20260812151342260"
      unitRef="USD">20000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesThreeMember"
      decimals="2"
      id="Fxbrl_20260812151537933"
      unitRef="USD_Per_Share">5.52</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesThreeMember"
      decimals="0"
      id="Fxbrl_20260812151558038"
      unitRef="USD">20000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_20260630_srtRangeAxis_srtMaximumMember_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesFourMember"
      decimals="0"
      id="Fxbrl_20260812151629135"
      unitRef="USD">20000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesFourMember"
      decimals="2"
      id="Fxbrl_20260812151703255"
      unitRef="USD_Per_Share">5.52</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_20260630_usgaapBusinessAcquisitionAxis_mdcxAntevLimitedMember_usgaapContingentConsiderationByTypeAxis_mdcxContingentConsiderationPhasesFourMember"
      decimals="0"
      id="Fxbrl_20260812151735397"
      unitRef="USD">20000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260509025046115">
    &lt;div&gt;
      &lt;div&gt;
        &lt;p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;10.&lt;/strong&gt;&#160;&lt;strong&gt;Segment reporting&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the CODM in deciding how to allocate resources to an individual segment and in assessing performance. The Company manages the business activities on a consolidated basis and operates as&#160;one reportable segment that constitutes all of the consolidated entity, which is the business of advancing the clinical development program of the Company&#x2019;s product, while opportunistically identifying, evaluating, and acquiring accretive assets, properties or businesses. The Company&#x2019;s CODM is its Chief Executive Officer. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM uses consolidated net loss to measure segment loss, allocate resources and assess performance. The significant segment expense categories (general and administrative and research and development) are consistent with those presented on the face of the statements of operations and comprehensive loss. Other segment items are interest (income) expenses which are consistent with those presented on the face of the statements of operations and comprehensive loss. Additionally, the CODM reviews cash forecast models to determine where the Company will invest in planned research and development activities.&#160;As the Company&#x2019;s operations are comprised of a single reporting segment, the segment assets are reflected on the accompanying condensed consolidated balance sheet as Total Assets. Segment asset information is not used by the CODM to allocate resources.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;div&gt;
          &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company's single reporting segment. A reconciliation to consolidated operating expenses as the Company&#x2019;s single segment operating loss for the three and six months ended June 30, 2026 and 2025 is included in the table below:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

            &lt;table cellpadding="0" cellspacing="0" style="font-size:10pt;border-collapse:collapse;width:100%;border-color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="4" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Three Months Ended June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="4" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Six Months Ended June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Research and development expenses:&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;SkinJect&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-left:10pt;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Clinical, manufacturing and regulatory activities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,268,747&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,011,362&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;2,011,288&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;2,453,931&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-left:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Professional services and intellectual property&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;96,653&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;71,561&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;145,227&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;116,678&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Teverelix&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-left:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Clinical, manufacturing and regulatory activities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;2,927,793&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;3,850,023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-left:10pt;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Professional services and intellectual property&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;46,169&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;78,341&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Salaries and benefits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;568,329&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;356,641&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,527,207&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;875,169&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Total research and development expenses&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;4,907,692&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;1,439,564&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;7,612,085&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;3,445,778&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Total general and administrative expenses&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;6,571,097&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;4,576,524&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;12,463,781&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;7,696,584&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Total operating expenses&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;11,478,789&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;6,016,088&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;20,075,866&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;11,142,362&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Other income (expense):&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Finance income&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;40,004&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;63,870&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Interest income (expense)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(205,638&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(523,789&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Loss on SEPA settlements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(127,083&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Change in fair value of debentures&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(200,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(200,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Total other income (expense)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;(205,638&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;(159,996&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;(650,872&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;(136,130&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Net loss for the period&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;(11,684,427&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;(6,176,084&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;(20,726,738&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;(11,278,492&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260812173738166"
      unitRef="Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260812165504668">
            &lt;table cellpadding="0" cellspacing="0" style="font-size:10pt;border-collapse:collapse;width:100%;border-color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="4" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Three Months Ended June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="4" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Six Months Ended June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Research and development expenses:&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;SkinJect&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-left:10pt;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Clinical, manufacturing and regulatory activities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,268,747&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,011,362&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;2,011,288&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;2,453,931&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-left:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Professional services and intellectual property&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;96,653&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;71,561&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;145,227&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;116,678&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Teverelix&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-left:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Clinical, manufacturing and regulatory activities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;2,927,793&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;3,850,023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;padding-left:10pt;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Professional services and intellectual property&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;46,169&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;78,341&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Salaries and benefits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;568,329&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;356,641&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,527,207&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;875,169&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Total research and development expenses&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;4,907,692&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;1,439,564&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;7,612,085&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;3,445,778&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Total general and administrative expenses&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;6,571,097&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;4,576,524&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;12,463,781&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;7,696,584&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Total operating expenses&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;11,478,789&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;6,016,088&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;20,075,866&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;11,142,362&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Other income (expense):&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Finance income&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;40,004&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;63,870&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Interest income (expense)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(205,638&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(523,789&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Loss on SEPA settlements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(127,083&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Change in fair value of debentures&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(200,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(200,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Total other income (expense)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;(205,638&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;(159,996&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;(650,872&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;(136,130&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;Net loss for the period&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;(11,684,427&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;(6,176,084&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;(20,726,738&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:10%;text-align:right;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;(11,278,492&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_20260401to20260630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember"
      decimals="0"
      id="Fxbrl_20260812163638895"
      unitRef="USD">1268747</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_20250401to20250630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember"
      decimals="0"
      id="Fxbrl_20260812163817879"
      unitRef="USD">1011362</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_20260101to20260630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember"
      decimals="0"
      id="Fxbrl_20260812163821574"
      unitRef="USD">2011288</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_20250101to20250630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember"
      decimals="0"
      id="Fxbrl_20260812163826824"
      unitRef="USD">2453931</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_20260401to20260630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember"
      decimals="0"
      id="Fxbrl_20260812164137234_xbrl_20260812163638895"
      unitRef="USD">96653</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_20250401to20250630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember"
      decimals="0"
      id="Fxbrl_20260812164137234_xbrl_20260812163817879"
      unitRef="USD">71561</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_20260101to20260630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember"
      decimals="0"
      id="Fxbrl_20260812164137234_xbrl_20260812163821574"
      unitRef="USD">145227</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_20250101to20250630_deiLegalEntityAxis_mdcxSkinjectIncMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember"
      decimals="0"
      id="Fxbrl_20260812164137234_xbrl_20260812163826824"
      unitRef="USD">116678</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_20260401to20260630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember"
      decimals="0"
      id="Fxbrl_20260812164139513_xbrl_20260812163638895"
      unitRef="USD">2927793</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_20250401to20250630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember"
      decimals="0"
      id="Fxbrl_20260812164139513_xbrl_20260812163817879"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_20260101to20260630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember"
      decimals="0"
      id="Fxbrl_20260812164139513_xbrl_20260812163821574"
      unitRef="USD">3850023</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_20250101to20250630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxClinicalManufacturingAndRegulatoryActivitiesMember"
      decimals="0"
      id="Fxbrl_20260812164139513_xbrl_20260812163826824"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_20260401to20260630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember"
      decimals="0"
      id="Fxbrl_20260812164141327_xbrl_20260812163638895"
      unitRef="USD">46169</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_20250401to20250630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember"
      decimals="0"
      id="Fxbrl_20260812164141327_xbrl_20260812163817879"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_20260101to20260630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember"
      decimals="0"
      id="Fxbrl_20260812164141327_xbrl_20260812163821574"
      unitRef="USD">78341</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="C_20250101to20250630_deiLegalEntityAxis_mdcxTeverelixMember_usgaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mdcxProfessionalServicesAndIntellectualPropertyMember"
      decimals="0"
      id="Fxbrl_20260812164141327_xbrl_20260812163826824"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:LaborAndRelatedExpense
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260812164145506_xbrl_20260812163638895"
      unitRef="USD">568329</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260812164145506_xbrl_20260812163817879"
      unitRef="USD">356641</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260812164145506_xbrl_20260812163821574"
      unitRef="USD">1527207</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260812164145506_xbrl_20260812163826824"
      unitRef="USD">875169</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260812164147650_xbrl_20260812163638895"
      unitRef="USD">4907692</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260812164147650_xbrl_20260812163817879"
      unitRef="USD">1439564</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260812164147650_xbrl_20260812163821574"
      unitRef="USD">7612085</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260812164147650_xbrl_20260812163826824"
      unitRef="USD">3445778</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260812164149201_xbrl_20260812163638895"
      unitRef="USD">6571097</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260812164149201_xbrl_20260812163817879"
      unitRef="USD">4576524</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260812164149201_xbrl_20260812163821574"
      unitRef="USD">12463781</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260812164149201_xbrl_20260812163826824"
      unitRef="USD">7696584</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260812164150832_xbrl_20260812163638895"
      unitRef="USD">11478789</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260812164150832_xbrl_20260812163817879"
      unitRef="USD">6016088</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260812164150832_xbrl_20260812163821574"
      unitRef="USD">20075866</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260812164150832_xbrl_20260812163826824"
      unitRef="USD">11142362</us-gaap:OperatingExpenses>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260812164152960_xbrl_20260812163638895"
      unitRef="USD">0</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260812164152960_xbrl_20260812163817879"
      unitRef="USD">40004</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260812164152960_xbrl_20260812163821574"
      unitRef="USD">0</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260812164152960_xbrl_20260812163826824"
      unitRef="USD">63870</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpense
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260812164155160_xbrl_20260812163638895"
      unitRef="USD">205638</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260812164155160_xbrl_20260812163817879"
      unitRef="USD">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260812164155160_xbrl_20260812163821574"
      unitRef="USD">523789</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260812164155160_xbrl_20260812163826824"
      unitRef="USD">0</us-gaap:InterestExpense>
    <mdcx:GainLossOnSettlements
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260812164158430_xbrl_20260812163638895"
      unitRef="USD">0</mdcx:GainLossOnSettlements>
    <mdcx:GainLossOnSettlements
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260812164158430_xbrl_20260812163817879"
      unitRef="USD">0</mdcx:GainLossOnSettlements>
    <mdcx:GainLossOnSettlements
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260812164158430_xbrl_20260812163821574"
      unitRef="USD">-127083</mdcx:GainLossOnSettlements>
    <mdcx:GainLossOnSettlements
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260812164158430_xbrl_20260812163826824"
      unitRef="USD">0</mdcx:GainLossOnSettlements>
    <mdcx:ChangeInFairValueOfDebentures
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260812164202863_xbrl_20260812163817879"
      unitRef="USD">0</mdcx:ChangeInFairValueOfDebentures>
    <mdcx:ChangeInFairValueOfDebentures
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260812164202863_xbrl_20260812163821574"
      unitRef="USD">-200000</mdcx:ChangeInFairValueOfDebentures>
    <mdcx:ChangeInFairValueOfDebentures
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260812164202863_xbrl_20260812163826824"
      unitRef="USD">-200000</mdcx:ChangeInFairValueOfDebentures>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260812164205057_xbrl_20260812163638895"
      unitRef="USD">-205638</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260812164205057_xbrl_20260812163817879"
      unitRef="USD">-159996</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260812164205057_xbrl_20260812163821574"
      unitRef="USD">-650872</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260812164205057_xbrl_20260812163826824"
      unitRef="USD">-136130</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260812164206802_xbrl_20260812163638895"
      unitRef="USD">-11684427</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260812164206802_xbrl_20260812163817879"
      unitRef="USD">-6176084</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260812164206802_xbrl_20260812163821574"
      unitRef="USD">-20726738</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260812164206802_xbrl_20260812163826824"
      unitRef="USD">-11278492</us-gaap:ProfitLoss>
    <us-gaap:LongTermDebtTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260810114655501">
    &lt;div&gt;
      &lt;p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;11. Debentures and Secured Promissory Notes&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On September 17, 2025, the Company entered into a securities purchase agreement with Yorkville to issue a debenture with the principal amount of $8,000,000 issued at a discount of $633,707 for proceeds of approximately $7,366,293. Interest accrued on the outstanding principal amount of the debenture at an annual rate of 8%, subject to a potential increase to 18% per annum upon the occurrence of certain events of default. The debenture had a maturity date of September 17, 2026, and was to be repaid using proceeds from the SEPA; however, on May 27, 2026, the Company used part of the proceeds from the issuance of the Secured Promissory Notes (as defined herein) to repay and extinguish the outstanding balance and accrued interest owing on the debenture.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The debenture was initially recorded at fair value, based on the discounted proceeds. Subsequently, the Company accounted for the debenture at amortized cost using the effective interest rate method, resulting in accretion expense of $374,712 for the six months ended June 30, 2026. The effective interest rate calculated was 32.75% as of June 30, 2026. On May 27, 2026, the Company repaid the outstanding principal balance of $2,343,778 related to the Yorkville debenture, together with accrued interest of $135,664, using proceeds received from the issuance of the Secured Promissory Notes.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On May 27, 2026, the Company entered into a Note Purchase Agreement with Streeterville Capital, LLC ("Streeterville"), pursuant to which the Company issued two secured promissory notes with aggregate principal amounts of $22,864,225. The first promissory note ("Note A") was issued with a face value of $12,864,225 and a purchase price of $12,000,000, resulting in an issue discount of $864,225. The second promissory note ("Note B") was issued with a principal amount of $10,000,000. Note A bears interest at 8.75% per annum compounded daily and Note B bears interest at 5.0% per annum compounded daily. Both promissory notes mature on November 27, 2027.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;/div&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span id="page_21"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;The Secured Promissory Notes are secured by a first-ranking security interest over substantially all assets of the Company. Guarantees are provided by the Company's subsidiaries.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The Company evaluated the transaction under ASC 470-50, Debt Modifications and Extinguishments, and determined that the issuance of the Streeterville promissory notes and repayment of the Yorkville debenture should be accounted for as an extinguishment of debt. Accordingly, the carrying amount of the Yorkville debenture was derecognized upon settlement, and the newly issued promissory notes were recognized as new debt instruments.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The Company initially recorded the Note A and Note B ("promissory notes") at fair value based on the proceeds received, net of directly attributable debt issuance costs. Subsequently, the Company accounts for the promissory notes at amortized cost using the effective interest method. Debt issuance costs are amortized over the contractual life of the respective promissory notes. The&#160;Company&#160;incurred $615,000 in debt issuance cost related to the promissory notes.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The Note A permits the lender to require monthly redemptions beginning on the seventh month following the issuance, subject to the terms of the agreement. Beginning on the seventh month following the issuance date,&#160;the lender has the right to require monthly redemptions of up to $500,000 per month plus make-whole interest calculated as if the redeemed amount had remained outstanding until maturity. If the Company fails to satisfy a redemption notice within the required period, the outstanding balance is increased by 20% of the applicable redemption amount. In addition, beginning on the sixth month following the issuance date, both Note A and Note B permit the lender to require limited redemptions of up to 5% of the cumulative daily dollar trading volume during specified redemption windows when the Company's common shares trade at least 15% above the defined Minimum Price per the agreement. Such limited redemptions are payable at 110% of the applicable redemption amount.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Both Note A and Note B contain customary trigger event and event of default provisions, including payment defaults, insolvency events, delisting determinations and specified corporate transactions.&#160;&#160;Upon the occurrence of such trigger events, the lender may increase the outstanding balance by 5% for certain minor trigger events or 15% for certain major trigger events, as more fully described in Note A and Note B, subject to contractual limitations. Following an event of default, the lender may accelerate repayment and default interest may accrue at a rate of up to 18% per annum, subject to applicable law.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;As at June 30, 2026, the Company was in compliance with the terms and covenants of both notes.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In connection with Note B, $10,000,000 of the proceeds were deposited into a restricted deposit account maintained pursuant to a Deposit Account Control Agreement. The lender has control rights over the account upon the occurrence of specified trigger events and may direct the disposition of funds in the account. Under certain circumstances, amounts outstanding under Note B may be exchanged into additional Note A borrowings. Specifically, for each $2.0 million of Note A principal repaid, up to $1.0 million of the outstanding Note B balance may be exchanged into a new Note A advance, subject to the conditions set out in the financing agreements.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company evaluated the embedded features contained within the promissory notes and concluded that certain features would require bifurcation under ASC 815; however, the fair value of such features was determined to be de minimis. Accordingly, no embedded derivative liability was recorded as of June 30, 2026.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Debenture issued on September 17, 2025:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net balance as at December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,245,543&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Repayment of new debenture&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(3,180,084&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest accretion&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;374,712&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest payment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;border-bottom:0.75pt solid #000000;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(96,393&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;border-bottom:0.75pt solid #000000;width:2%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Ending balance as of March 31, 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;border-bottom:2.25pt double #000000;width:1%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;border-bottom:2.25pt double #000000;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,343,778&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;border-bottom:2.25pt double #000000;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Repayment of Yorkville debenture&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(2,343,778&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Ending balance as of June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;border-bottom:2.25pt double #000000;width:1%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;border-bottom:2.25pt double #000000;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;border-bottom:2.25pt double #000000;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

      &lt;div&gt;

          &lt;div&gt;
            &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
            &lt;table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Note A issued on May 27, 2026:&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Proceeds of Note A&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,864,225&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Discount on debt&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(864,225&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Debt issuance costs&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(349,091&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest accretion&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;79,257&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Ending balance&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;border-bottom:2.25pt double #000000;width:1%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;border-bottom:2.25pt double #000000;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,730,166&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;border-bottom:2.25pt double #000000;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Note B issued on May 27, 2026:&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Proceeds of Note B&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Debt issuance costs&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(265,909&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest accretion&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;18,286&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Ending balance&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,752,376&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;

      &lt;/div&gt;
      &lt;p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman', Times, serif"&gt;&#160;&lt;/p&gt;
      &lt;div&gt;&lt;/div&gt;
      &lt;div style="margin-top:0pt;margin-bottom:0pt"&gt;
        &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;As of June 30, 2026, accrued interest of $81,426 related to the promissory notes was included in accounts payable on the condensed consolidated balance sheet, with the corresponding amount recognized in interest expense in the condensed consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="C_20250901to20250917_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember"
      decimals="0"
      id="F20260321061347344_8"
      unitRef="USD">8000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <mdcx:DebtIssuanceDiscount
      contextRef="C_20250917_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fxbrl_20260321160743159"
      unitRef="USD">633707</mdcx:DebtIssuanceDiscount>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_20250901to20250917_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fxbrl_20260321160819556"
      unitRef="USD">7366293</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_20250917_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember"
      decimals="2"
      id="F20260321061347344_10"
      unitRef="Percent">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="C_20250901to20250917_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember"
      decimals="2"
      id="F20260321061347345_11"
      unitRef="Percent">0.18</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_20250901to20250917_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember"
      id="F20260321061347345_12">2026-09-17</us-gaap:DebtInstrumentMaturityDate>
    <mdcx:ConvertibleDebtAccretionExpense
      contextRef="C_20260101to20260630_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember"
      decimals="0"
      id="F20260321061347347_23"
      unitRef="USD">374712</mdcx:ConvertibleDebtAccretionExpense>
    <mdcx:EffectiveInterestRateOnDebt
      contextRef="C_20260101to20260630_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember"
      decimals="4"
      id="Fxbrl_20260321161504817"
      unitRef="Percent">0.3275</mdcx:EffectiveInterestRateOnDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_20260501to20260527_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fxbrl_20260810103130553"
      unitRef="USD">2343778</us-gaap:RepaymentsOfDebt>
    <mdcx:AccruedInterestRepaid
      contextRef="C_20260501to20260527_usgaapTypeOfArrangementAxis_mdcxSecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fxbrl_20260810103316307"
      unitRef="USD">135664</mdcx:AccruedInterestRepaid>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="C_20260501to20260527_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="0"
      id="Fxbrl_20260810110719057"
      unitRef="USD">22864225</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="0"
      id="Fxbrl_20260810110742939"
      unitRef="USD">12864225</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="C_20260501to20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="0"
      id="Fxbrl_20260810110804602"
      unitRef="USD">12000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="0"
      id="Fxbrl_20260810110852840"
      unitRef="USD">864225</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="C_20260501to20260527_usgaapDebtInstrumentAxis_mdcxNoteBMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="0"
      id="Fxbrl_20260810110825087"
      unitRef="USD">10000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="4"
      id="Fxbrl_20260810111030162"
      unitRef="Percent">0.0875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteBMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="3"
      id="Fxbrl_20260810111022825"
      unitRef="Percent">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_20260501to20260527_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      id="Fxbrl_20260810111132411">2027-11-27</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_20260501to20260527_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="0"
      id="Fxbrl_20260810111602099"
      unitRef="USD">615000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <mdcx:DebtInstrumentRedemptionLimitAmount
      contextRef="C_20260527_srtRangeAxis_srtMaximumMember_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="0"
      id="Fxbrl_20260812143050726"
      unitRef="USD">500000</mdcx:DebtInstrumentRedemptionLimitAmount>
    <mdcx:DebtDefaultBalanceIncreasePercentage
      contextRef="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="2"
      id="Fxbrl_20260812154444764"
      unitRef="Percent">0.20</mdcx:DebtDefaultBalanceIncreasePercentage>
    <mdcx:DebtInstrumentVolumeBasedRedemptionPercentageLimit
      contextRef="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="2"
      id="Fxbrl_20260812154510515"
      unitRef="Percent">0.05</mdcx:DebtInstrumentVolumeBasedRedemptionPercentageLimit>
    <mdcx:DebtInstrumentCovenantSharePriceThresholdPercentage
      contextRef="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="2"
      id="Fxbrl_20260812154749211"
      unitRef="Percent">0.15</mdcx:DebtInstrumentCovenantSharePriceThresholdPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="C_20260501to20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="2"
      id="Fxbrl_20260812154846305"
      unitRef="Percent">1.10</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault
      contextRef="C_20260501to20260527_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      id="Fxbrl_20260812114904600">Upon the occurrence of such trigger events, the lender may increase the outstanding balance by 5% for certain minor trigger events or 15% for certain major trigger events, as more fully described in Note A and Note B, subject to contractual limitations. Following an event of default, the lender may accelerate repayment and default interest may accrue at a rate of up to 18% per annum, subject to applicable law.</us-gaap:DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteBMember"
      decimals="0"
      id="Fxbrl_20260812142123073"
      unitRef="USD">10000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <mdcx:DebtInstrumentExchangeThresholdAmount
      contextRef="C_20260501to20260527_usgaapDebtInstrumentAxis_mdcxNoteAMember"
      decimals="-5"
      id="Fxbrl_20260812155856621"
      unitRef="USD">2000000</mdcx:DebtInstrumentExchangeThresholdAmount>
    <mdcx:DebtInstrumentMaximumExchangeLimitAmount
      contextRef="C_20260527_usgaapDebtInstrumentAxis_mdcxNoteBMember"
      decimals="-5"
      id="Fxbrl_20260812155825869"
      unitRef="USD">1000000</mdcx:DebtInstrumentMaximumExchangeLimitAmount>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260810174201949">
        &lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000"&gt;

              &lt;tr&gt;
                &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Debenture issued on September 17, 2025:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net balance as at December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,245,543&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Repayment of new debenture&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(3,180,084&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest accretion&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;374,712&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest payment&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;border-bottom:0.75pt solid #000000;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(96,393&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;border-bottom:0.75pt solid #000000;width:2%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Ending balance as of March 31, 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;border-bottom:2.25pt double #000000;width:1%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:right;border-bottom:2.25pt double #000000;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,343,778&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;text-align:left;border-bottom:2.25pt double #000000;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Repayment of Yorkville debenture&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(2,343,778&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Ending balance as of June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;border-bottom:2.25pt double #000000;width:1%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;border-bottom:2.25pt double #000000;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;border-bottom:2.25pt double #000000;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtCurrent
      contextRef="C_20251231_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember"
      decimals="0"
      id="Fxbrl_20260509022016774"
      unitRef="USD">5245543</us-gaap:DebtCurrent>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_20260101to20260331_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember"
      decimals="0"
      id="F20260321061347346_19"
      unitRef="USD">3180084</us-gaap:RepaymentsOfDebt>
    <mdcx:ConvertibleDebtAccretionExpense
      contextRef="C_20260101to20260331_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember"
      decimals="0"
      id="F20260321061347347_20"
      unitRef="USD">374712</mdcx:ConvertibleDebtAccretionExpense>
    <mdcx:RepaymentsOfInterest
      contextRef="C_20260101to20260331_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember"
      decimals="0"
      id="F20260321061347347_21"
      unitRef="USD">96393</mdcx:RepaymentsOfInterest>
    <us-gaap:DebtCurrent
      contextRef="C_20260331_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember"
      decimals="0"
      id="Fxbrl_20260810144141928"
      unitRef="USD">2343778</us-gaap:DebtCurrent>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_20260401to20260630_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember"
      decimals="0"
      id="Fxbrl_20260810144324362"
      unitRef="USD">2343778</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtCurrent
      contextRef="C_20260630_usgaapLongtermDebtTypeAxis_mdcxDebentureContinuityOneMember"
      decimals="0"
      id="F20260321061347347_22"
      unitRef="USD">0</us-gaap:DebtCurrent>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260810174251326">
          &lt;div&gt;
            &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
            &lt;table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Note A issued on May 27, 2026:&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Proceeds of Note A&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,864,225&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Discount on debt&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(864,225&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Debt issuance costs&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(349,091&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest accretion&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;79,257&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Ending balance&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;border-bottom:2.25pt double #000000;width:1%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;border-bottom:2.25pt double #000000;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;11,730,166&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;border-bottom:2.25pt double #000000;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;white-space:nowrap;padding-left:5pt;padding-right:5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Note B issued on May 27, 2026:&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;border-bottom:0.75pt solid #000000;white-space:nowrap"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Proceeds of Note B&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Debt issuance costs&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(265,909&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest accretion&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;18,286&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="padding-right:5pt;padding-left:5pt;vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Ending balance&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:1%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:right;width:12%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,752,376&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:left;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        </us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="C_20260101to20260630_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="0"
      id="Fxbrl_20260810115824309"
      unitRef="USD">12864225</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_20260630_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="0"
      id="Fxbrl_20260810115904324"
      unitRef="USD">864225</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_20260101to20260630_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="0"
      id="Fxbrl_20260810115933474"
      unitRef="USD">349091</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="C_20260101to20260630_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="0"
      id="Fxbrl_20260810115955476"
      unitRef="USD">79257</us-gaap:InterestExpenseDebt>
    <us-gaap:NotesPayable
      contextRef="C_20260630_usgaapDebtInstrumentAxis_mdcxNoteAMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="0"
      id="Fxbrl_20260810120017545"
      unitRef="USD">11730166</us-gaap:NotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="C_20260101to20260630_usgaapDebtInstrumentAxis_mdcxNoteBMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="0"
      id="Fxbrl_20260810115850550"
      unitRef="USD">10000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_20260101to20260630_usgaapDebtInstrumentAxis_mdcxNoteBMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="0"
      id="Fxbrl_20260810115924469"
      unitRef="USD">265909</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="C_20260101to20260630_usgaapDebtInstrumentAxis_mdcxNoteBMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="0"
      id="Fxbrl_20260810120007773"
      unitRef="USD">18286</us-gaap:InterestExpenseDebt>
    <us-gaap:NotesPayable
      contextRef="C_20260630_usgaapDebtInstrumentAxis_mdcxNoteBMember_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="0"
      id="Fxbrl_20260810120033798"
      unitRef="USD">9752376</us-gaap:NotesPayable>
    <us-gaap:InterestPayableCurrent
      contextRef="C_20260630_usgaapLongtermDebtTypeAxis_mdcxSecuredPromissoryNotesMember"
      decimals="0"
      id="Fxbrl_20260810113217371"
      unitRef="USD">81426</us-gaap:InterestPayableCurrent>
    <us-gaap:RestrictedAssetsDisclosureTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260810014026005">
    &lt;div&gt;
      &lt;p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;12. Restricted Cash&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of June 30, 2026, cash of US$10.0 million was held in a restricted deposit account maintained by a subsidiary of the Company pursuant to the Deposit Account Control Agreement entered into in connection with the Note B financing. The funds are subject to a first-ranking security interest in favour of the lender and are not available for general corporate purposes except in accordance with the financing arrangements. Accordingly, the balance has been presented as restricted cash in the condensed interim consolidated statement of financial position.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;/div&gt;
  </us-gaap:RestrictedAssetsDisclosureTextBlock>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_20260630_usgaapDebtInstrumentAxis_mdcxNoteBMember"
      decimals="-5"
      id="Fxbrl_20260810014041940"
      unitRef="USD">10000000</us-gaap:RestrictedCashCurrent>
    <mdcx:LiquidityTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260509031047316">
    &lt;div&gt;
      &lt;p style="text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;13. Liquidity and Going Concern&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. In addition to the ATM, SEPA and Debenture (as defined herein), management believes that the Company has access to additional capital resources through public and/or private equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, it is possible that the Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. Further, the terms of any financing may adversely affect the holdings or the rights of the Company's shareholders. If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays or entirely prevent the Company's continued efforts to progress its research and development program, pursue product portfolio expansion or commercialize its current or future products, each of which is critical to the realization of the Company's business plan and its future operations. This uncertainty, along with the Company's history of losses, indicates that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. The financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company is subject to risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company's research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;/div&gt;
  </mdcx:LiquidityTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260812123257109">
    &lt;div&gt;
      &lt;p style="margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;14.&lt;/strong&gt;&#160;&lt;strong&gt;Loss per share&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

        &lt;table cellpadding="0" cellspacing="0" style="font-size:10pt;border-collapse:collapse;width:100%;border-color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Three Months Ended June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Six Months Ended June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Net loss attributable to shareholders&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(11,617,705&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(6,176,084&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(20,659,848&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(11,278,492&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Weighted average number of common shares outstanding &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;55,055,225&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14,284,261&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;47,566,945&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;13,853,305&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Basic and diluted net loss per share attributable to shareholders&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.21&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.43&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.43&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.81&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

      &lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;The Company's potentially dilutive securities as of June 30, 2026 and 2025, include stock options, warrants, and debentures. The Company excluded the potential ordinary shares outstanding at each period end from the computation of diluted net loss per share attributable to ordinary shareholders for the period ended June 30, 2026 and 2025 because including them would have had an anti-dilutive effect.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="text-align:justify;margin-top:10pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;/div&gt;

      &lt;div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-size:10pt;border-collapse:collapse;width:100%;border-color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="4" style="vertical-align:bottom;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;For the Period Ended&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30, 2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Stock options&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,510,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,285,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:12%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7,281,795&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:12%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,596,795&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Debentures&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:12%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:12%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:12%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;12,791,795&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:12%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;10,881,795&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;

    &lt;p style="text-align:justify;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
  </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260812123321374">
        &lt;table cellpadding="0" cellspacing="0" style="font-size:10pt;border-collapse:collapse;width:100%;border-color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Three Months Ended June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Six Months Ended June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td colspan="1" style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Net loss attributable to shareholders&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(11,617,705&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(6,176,084&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(20,659,848&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(11,278,492&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Weighted average number of common shares outstanding &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;55,055,225&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;14,284,261&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;47,566,945&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;13,853,305&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Basic and diluted net loss per share attributable to shareholders&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.21&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.43&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.43&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:10%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(0.81&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260812123408401"
      unitRef="USD">-11617705</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260812123424680"
      unitRef="USD">-6176084</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260812123436467"
      unitRef="USD">-20659848</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260812123614310"
      unitRef="USD">-11278492</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20260401to20260630"
      decimals="0"
      id="Fxbrl_20260812123636698_xbrl_20260812123408401"
      unitRef="Share">55055225</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20250401to20250630"
      decimals="0"
      id="Fxbrl_20260812123636698_xbrl_20260812123424680"
      unitRef="Share">14284261</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260812123636698_xbrl_20260812123436467"
      unitRef="Share">47566945</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260812123636698_xbrl_20260812123614310"
      unitRef="Share">13853305</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20260401to20260630"
      decimals="2"
      id="Fxbrl_20260812124007459"
      unitRef="USD_Per_Share">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20260401to20260630"
      decimals="2"
      id="Fxbrl_20260812123639038_xbrl_20260812123408401"
      unitRef="USD_Per_Share">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20250401to20250630"
      decimals="2"
      id="Fxbrl_20260812124022429"
      unitRef="USD_Per_Share">-0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20250401to20250630"
      decimals="2"
      id="Fxbrl_20260812123639038_xbrl_20260812123424680"
      unitRef="USD_Per_Share">-0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20260101to20260630"
      decimals="2"
      id="Fxbrl_20260812124050854"
      unitRef="USD_Per_Share">-0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20260101to20260630"
      decimals="2"
      id="Fxbrl_20260812123639038_xbrl_20260812123436467"
      unitRef="USD_Per_Share">-0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20250101to20250630"
      decimals="2"
      id="Fxbrl_20260812124058038"
      unitRef="USD_Per_Share">-0.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20250101to20250630"
      decimals="2"
      id="Fxbrl_20260812123639038_xbrl_20260812123614310"
      unitRef="USD_Per_Share">-0.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260812123332775">
      &lt;div&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" style="font-size:10pt;border-collapse:collapse;width:100%;border-color:#000000"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="4" style="vertical-align:bottom;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;For the Period Ended&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30, 2026&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30, 2025&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Stock options&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,510,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:12%;text-align:right;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,285,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:12%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;7,281,795&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:12%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,596,795&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Debentures&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:12%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:12%;text-align:right;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left;border-bottom:0.75pt solid #000000;background-color:#e6efff"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:12%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;12,791,795&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:12%;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;10,881,795&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
                  &lt;td style="vertical-align:bottom;width:2%;text-align:left"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20260101to20260630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mdcxStockOptionsMember"
      decimals="0"
      id="Fxbrl_20260812123410224"
      unitRef="Share">5510000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20250101to20250630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mdcxStockOptionsMember"
      decimals="0"
      id="Fxbrl_20260812123540584"
      unitRef="Share">1285000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20260101to20260630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember"
      decimals="0"
      id="Fxbrl_20260812123457576"
      unitRef="Share">7281795</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20250101to20250630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember"
      decimals="0"
      id="Fxbrl_20260812123557337"
      unitRef="Share">4596795</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20260101to20260630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mdcxDebenturesMember"
      decimals="0"
      id="Fxbrl_20260812123532496"
      unitRef="Share">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20250101to20250630_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mdcxDebenturesMember"
      decimals="0"
      id="Fxbrl_20260812123600848"
      unitRef="Share">5000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20260101to20260630"
      decimals="0"
      id="Fxbrl_20260812123505336"
      unitRef="Share">12791795</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20250101to20250630"
      decimals="0"
      id="Fxbrl_20260812123604792"
      unitRef="Share">10881795</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_20260101to20260630"
      id="Fxbrl_20260810014241249">
    &lt;div&gt;
      &lt;p style="margin-left:17pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;15.&lt;/strong&gt;&#160;&lt;strong&gt;Subsequent events&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;div&gt;
        &lt;p style="margin-top:10pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Subsequent to the period ended June 30, 2026, the Company completed sales under its ATM pursuant to which it issued 2,812,566 common shares for gross proceeds of approximately $840,471 or approximately $815,257 after incurring commissions payable to the Agents.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20260701to20260731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="0"
      id="Fxbrl_20260321152020250"
      unitRef="Share">2812566</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20260701to20260731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="0"
      id="Fxbrl_20260321143243804"
      unitRef="USD">840471</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mdcx:ProceedsFromCommonSharesNetOfCommissionsPayableToAgents
      contextRef="C_20260701to20260731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember"
      decimals="0"
      id="Fxbrl_20260321152044696"
      unitRef="USD">815257</mdcx:ProceedsFromCommonSharesNetOfCommissionsPayableToAgents>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
